Understanding and preventing visual loss in commotio retinae by Blanch, Richard James
 
 
I 
 
UNDERSTANDING AND PREVENTING VISUAL LOSS IN COMMOTIO RETINAE 
By 
RICHARD JAMES BLANCH 
A thesis submitted to the University of Birmingham for the degree of DOCTOR OF PHILOSOPHY 
 
 
 
 
 
 
 
 
 
 
 
 
       School of Clinical and Experimental Medicine 
       College of Medical and Dental Sciences 
       University of Birmingham 
       August 2013  
 
 
 
 
 
 
 
 
 
University of Birmingham Research Archive 
 
e-theses repository 
 
 
This unpublished thesis/dissertation is copyright of the author and/or third 
parties. The intellectual property rights of the author or third parties in respect 
of this work are as defined by The Copyright Designs and Patents Act 1988 or 
as modified by any successor legislation.   
 
Any use made of information contained in this thesis/dissertation must be in 
accordance with that legislation and must be properly acknowledged.  Further 
distribution or reproduction in any format is prohibited without the permission 
of the copyright holder.  
 
 
 
 
 
II 
 
Abstract 
Commotio retinae describes retinal opacification following trauma and affected 16% of British 
soldiers suffering major trauma.  The macula was affected in 55% of soldiers and 31% of civilian 
cases, permanently reducing vision to less than 6/9 in 26% of cases, associated with photoreceptor 
degeneration. 
In an experimental rat model, commotio retinae was more readily induced by high velocity ballistic 
injury (20m/s) than low velocity weight drop (2-7m/s). In rats, after experimentally induced 
commotio retinae, photoreceptors died by a combination of necrosis (central to the impact site) and 
apoptosis (peripheral to it), demonstrated by morphological changes on electron micrographs and 
TUNEL staining.  Photoreceptor death after commotio retinae was associated with reduced ERG a-
wave amplitude.  Apoptosis occurred through the intrinsic pathway, mediated by caspase 9 but not 
involving any of the classical executioner caspases (3, 6 and 7).  Inhibition of caspase 9 reduced 
photoreceptor death and improved retinal function, assessed by a-wave amplitude. 
Clinical studies suggested a protective effect of female gender after commotio retinae, but 
progesterone treatment increased photoreceptor death after ballistic injury in the experimental 
model. 
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1.  Introduction 
The eye is a complex and delicate organ on which we rely for vision.  Our perceptions, our thoughts, 
our social and occupational interactions are all overwhelmingly visual in nature.  Loss of vision is a 
tragedy that impairs all aspects of our lives, particularly traumatic loss of vision, which is usually 
sudden, unexpected and commonly affects the young. 
1.1. Structure and Function of the Eye 
A brief overview of ocular anatomy and physiology is provided, for a detailed description the reader 
is referred elsewhere (Snell, Lemp, and Grunther 1998), (Forrester, Dick, McMenamin, and Lee 2003), 
(Elkington, Frank, and Greaney 1999).  
Figure 1.1.1. An illustrative cross-sectional diagram of a human eye. 
 
The eye (or globe) is suspended in the bony orbit by connective tissue and muscle attachments.  In 
addition to the globe, extra-ocular muscles and connective tissue, the orbit contains nerves, blood 
vessels, orbital fat and the lacrimal gland.  Anteriorly the orbit is covered by the eyelids, which 
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contain part of the lacrimal drainage apparatus.  The anterior segment of the eye (anterior to the 
lens) is covered by cornea and contains aqueous.   The posterior segment (posterior to the lens) is 
covered anteriorly by translucent conjunctiva.  Beneath the conjunctiva is vascular episclera and 
Tenon’s capsule.  Tenon’s capsule covers the globe from the optic nerve to the limbus (junction of 
cornea and sclera and is reflected back to envelop the extra-ocular muscles from their insertions 
onto sclera.  The sclera is the tough collagenous outer coat of the globe.  Inside the sclera is the 
choroid containing the choriocapillaris, which provides a rich blood supply, from which oxygen and 
nutrients diffuse to the outer retina (Figure 1.1.3).   
Light enters the eye through the clear optical media (tear film, cornea, aqueous in the anterior 
segment, lens, vitreous) and is focussed on the retina.  The tear film/cornea provide the main 
contribution to refractive power (approx 43 dioptres) and the lens provides a smaller, but modifiable 
component (approx 15 dioptres).  The lens is suspended from the ciliary body by zonules.  In younger 
people, contraction of the ciliary muscle changes lens shape allowing light emanating from objects at 
variable distances to be focussed on the retina.  The 95% confidence interval for the axial length of 
the eye has been reported as 21.87 – 25.47  in a mixed white and Africian-Carrribean population and 
20.78 - 24.42 in an Indian population (Oliveira et al. 2007), (Nangia et al. 2010).  The average axial 
length of the human lens is 4mm (17% of the total) (Nangia et al. 2010). 
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Figure 1.1.2. A fundus photograph showing the features most prominent on fundoscopy of a normal 
human eye.  The optic disc is the point of exit from the eye for retinal ganglion cell axons.  Posterior 
to the disc (after the lamina cribosa), axons are myelinated in the optic nerve.  In their intra-ocular 
course they are usually unmyelinated.  The fovea is the avascular central region of the macula 
responsible for detailed colour vision and contains only cone photoreceptors. 
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Figure 1.1.3. A. Diagram illustrating the retinal cell types (Berry et al. 2008).  B. Low power electron 
micrograph of the primate retina demonstrating the layered arrangement: CC, choriocapillaris; RPE, 
retinal pigment epithelium; OS, outer segments; INS, inner segments; ONL, outer nuclear layer with 
rod and cone cell nuclei; OPL, outer plexiform layer; INL, inner nuclear layer with bipolar, Müller and 
amacrine cell nuclei; IPL, inner plexiform layer; GCL, ganglion cell layer with ganglion cell nuclei; NFL, 
nerve fibre layer; V, retinal vessel; OLM, outer limiting membrane; CP, cone pedicle/outer segment; 
ILM, internal limiting membrane.  Original magnification x930” (Forrester, Dick, McMenamin, and Lee 
2003).   
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Light passes through the retina from top to bottom as seen in Figure 1.1.3., and is detected by the 
photoreceptor outer segments (OS).  In the OPL photoreceptors synapse with bipolar cells, whose 
nuclei are present in the INL.  Bipolar cells synapse with the ganglion cell dendrites in the IPL and 
visual information is transmitted to the brain by the ganglion cell axons which run in the retinal nerve 
fibre layer (RNFL).   Müller cells are radial glia that span the retina from the OLM, formed by their 
foot processes to the inner limiting membrane (ILM), their basement membrane.  
Photoreceptors are sustained by the retinal pigment epithelium (RPE), which recycles and 
regenerates the light sensitive pigments.  The two classes of photoreceptor are distinguished by the 
shape of their OS: rods contain the pigment rhodopsin, are most light sensitive and function under 
scotopic (dark) conditions; cones function under photopic (light) conditions and in different species 
contain a variety of cone opsins (light-sensitive pigments), which are maximally sensitive to different 
wavelengths of light, giving rise to colour vision.   
In the human eye, there are three classes of cone sensitive to short (S), medium (M) and long (L) 
wavelengths, giving rise to trichromatic colour vision.  The M and L cones are maximally 
concentrated at the fovea, whereas rods dominate the periphery; 95% of photoreceptors are rods.  
The photoreceptor OS containing the opsin pigments consist of membraneous discs that are 
constantly replenished.  Discs are shed from the photoreceptor OS and are phagocytosed by the RPE.  
The human retina is described as holangiotic, i.e.the blood supply to the inner retina comes from a 
retinal circulation.  The retinal blood vessels supply a capillary plexus in the GCL and another 
extending from the IPL to the OPL.  The outer retina derives its blood supply from the 
choriocapillaris.  In contrast, a merangiotic retina (e.g. in the rabbit) derives most of its blood supply 
from the choriocapillaris.  The retinal blood vessels and the RPE (with its basement membrane, called 
Bruch’s membrane) have tight junctions that prevent the passage of cells and larger molecules.  This 
arrangement is referred to as the blood-retinal barrier (BRB). 
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Vitreous gel fills the posterior segment of the eye and is composed of water, collagen and 
glycosaminoglycans (mostly hyaluronic acid) with very few cells.  The vitreous body is strongly 
attached to the retina posteriorly at the optic disc and anteriorly the vitreous base attaches to the 
ora serrata, where the most posterior of the zonular fibres, insert into the anterior hyaloid face 
(anterior face of the vitreous) instead of the lens (Bernal, Parel, and Manns 2006).  Weaker 
attachments of the vitreous occur over retinal blood vessels and are responsible for retinal tears 
when the vitreous pulls off the retina in trauma or senile degeneration of the vitreous.  The area of 
vitreous adjacent to the ILM is the lamina rara and is formed of collagen fibres running parallel to the 
retina and is 0.03 -0.06µm thick – this shows no species variations (Sebag 1992). 
Visual function is usually assessed using a Snellen chart with different letter sizes from which visual 
acuity (VA) is measured as the smallest line of letters that the patient can read and specified as a 
fraction, the denominator of which is the distance at which the letters could be read by a patient 
with normal vision and the numerator the distance at which the chart is read, for example 6/6 
represents normal vision and 6/120 is the level below which a patient can be registered as Severely 
Sight Impaired in the UK. 
1.2. Ocular Trauma 
Parts of the work in this section have been published in a review article in the Journal of the Royal 
Army Medical Corps (Blanch and Scott 2010); the paper is presented in Appendix 1. 
Ocular trauma can affect people from all walks of life and the consequent visual loss can cause loss of 
career, major lifestyle changes and disfigurement.  The Beaver Dam Eye Study reported a 19.8% 
lifetime prevalence of ocular trauma in a large civilian population in the USA (Wong, Klein, and Klein 
2000).  It is most common in young male manual workers, such as farmers and factory workers 
(Wong, Klein, and Klein 2000).   
The military population are at particular risk of ocular trauma.  British armed forces involved in 
combat operations in Iraq on operation TELIC from March 2003 to May 2011 and in Helmand 
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province, Afghanistan, on operation HERRICK since May 2006 have faced threats throughout the 
spectrum of conflict, from armoured manoeuvre warfare to counter-insurgency.  British military 
ophthalmologists have not been routinely deployed in support of operations since the end of the first 
Operation TELIC in May 2003.  Eye injuries requiring the input of an ophthalmologist in theatre are 
evacuated back to the UK and assessed and treated in the Royal Centre for Defence Medicine 
(RCDM) in Birmingham; a small number are sent locally to coalition partners’ medical facilities in 
theatre and to US facilities in Germany for Ophthalmology input before Birmingham.   
Historically the number of eye injuries as a proportion of those wounded in action varied from 0.5% 
in the American civil war to 13% in US forces in the first Gulf war with 70-80% of these due to blast 
(Blanch and Scott 2010), (Wong, Seet, and Ang 1997).   
In modern warfare, most casualties are civilian.  There are no widely accepted figures for civilian 
injuries in the current conflict in Iraq, however, the Congressional Research Service reviewed a 
variety of estimates ranging from 34,832 (Apr 2005 to Jun 2006 – the “Associated Press”) to 601,027 
individuals (May 2003 to Jun 2006) (Fischer 2008), (Burnham, Lafta, Doocy, and Roberts 2006).  In 
terrorist bombings in civilian settings the proportion of eye injuries is reported to be up to 20.7% 
(Odhiambo, Guthua, Macigo, and Ahama 2002), though Arnold et al found it to vary from 1% to 6% 
depending on environment (Arnold, Halpern, Tsai, and Smithline 2004). The causes of injury are 
primary fragments from the ordnance casing and secondary fragments of glass, cement and mortar 
that may cause minimal damage to clothes or skin, but significant morbidity if they hit the eye (Carley 
and Mackway-Jones 1997) , (Mallonee et al. 1996) , (Thach et al. 2000). 
Eye injuries are classified using the Birmingham Eye Trauma Terminology System (Pieramici et al. 
1997) (Figure 1.2.): 
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Figure 1.2. Birmingham Trauma Terminology System (Pieramici et al. 1997) 
In the closed globe category, a blunt object striking the eye causes anteroposterior shortening and 
equatorial expansion – so that the lens-iris diaphragm is displaced posteriorly, while the peripheral 
structures are expanding outwards, which can tear ocular tissues such as those at the iridocorneal 
angle.  Retinal stretching and shearing can cause retinal injuries such as dialyses, tears and commotio 
retinae. 
1.2.1. Blast Injuries 
In peacetime, unilateral eye injuries are typical, but ocular war injuries are bilateral in 15%-37% of 
cases (Weichel et al. 2008), (Belkin 1983).  Though the eyes occupy just 0.1% of the total and 0.27% 
of the anterior surface of the body, soldiers’ use of body armour makes explosions more survivable 
but leaves the face and eyes relatively exposed.  
Blast injury is usually divided into 4 categories: Primary blast injury (PBI) is caused by the wave of 
blast overpressure (‘blast wave’).  Secondary blast injury is caused by fragments driven by the blast 
wind, which is movement of air due to the pressure differentials.  Tertiary blast injury is caused by 
the effects of this blast wind, including displacement of the victim against other surfaces and 
structural collapse.  Quaternary blast injury is due to mechanisms other than those above such as 
burns and toxic inhalation (DePalma, Burris, Champion, and Hodgson 2005). 
Eye Injury 
Closed globe 
Contusion Lamellar Laceration 
Open globe 
Laceration 
Penetrating Perforating Intraocular foreign body 
Rupture 
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The blast wave responsible for PBI is a shockwave caused by the sudden expansion of explosive 
products, which are greatly compressed and heated.  The shockwave travels at the local speed of 
sound.  The high pressure generated by the explosion means that the shockwave travels at 
hypersonic speeds with respect to undisturbed air.  The impact of the blast wave on the body 
generates internal shockwaves and the different material speeds of sound mean that they propogate 
at different speeds through different tissues.  This differing response causes shearing and tearing at 
tissue interfaces such as in the lung alveoli and the bowels (Cullis 2001).  The eyes are less 
susceptible to a PBI than the air filled organs such as the lungs, bowel and ears (Sharpnack, Johnson, 
and Phillips 1991).  However, the eye consists of tissues with differing densities and elastic 
properties, such as the photoreceptors-RPE interface, which is vulnerable to shearing injury as in 
commotio retinae and the vitreo-retinal interface, which is vulnerable to tearing. 
In clinical practice it is difficult to separate the effects of primary, secondary and tertiary blast.  The 
pattern of injury of 23 cases of suspected ocular PBI reported in the literature is summarised in Table 
1.2.1.  The most commonly reported injury is commotio retinae.  The posterior segment is more 
affected than the anterior segment in 57% of cases, even though the blast wave traversed the 
anterior segment first, suggesting that it is more vulnerable to blast effects. 
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Injury Number Percentage 
Chorioretinal lesions (commotio retinae, 
choroidal rupture, macular lesions, retinal 
detachment) 
13 35% 
Iris and papillary lesions (hyphaema, 
iridodialysis, iris rupture) 
9 24% 
Traumatic optic neuropathy 4 11% 
Lens opacities 4 11% 
Vitreous haemorrhage 3 8% 
Extraocular muscle paralysis 2 5% 
Conjunctival haemorrhage 1 3% 
Orbital blow out fracture 1 3% 
Table 1.2.1. Distribution of PBI reported in the literature (Beiran and Miller 1992), (Bellows 1947), 
(Blanch and Scott 2008), (Campbell 1941), (Chalioulias, Sim, and Scott 2007), (Zuckerman 1941). 
1.3. Commotio Retinae 
1.3.1. Clinical Picture 
Commotio retinae describes grey-white opacification of the neuroretina and may affect the macula, 
reducing vision.  It was first described by Berlin in 1873 and is also known as Berlin’s oedema (Berlin 
1873).  The signs variably resolve over days to months. Visual loss may be transient  or permanent 
(Eagling 1974), (Hart and Frank 1975), with recovery taking up to 6 months and leaving occasional 
RPE mottling (Eagling 1974), (Liem, Keunen, and van Norren 1995). 
Large studies in UK Eye Casualty Departments have found that commotio retinae occurs in 0.4% of all 
eye injuries (Jones et al. 1986), (Vernon 1983).  Such closed globe injuries are also a problem in the 
military.  US sources report 21,965 soldiers wounded in action in the Iraq conflict from October 2001 
– September 2006, of whom 13% had ocular and adnexal injuries requiring evacuation.  In a US series 
of 432 globe injuries from this conflict, 54% were closed, 14.8% suffering commotio retinae of which 
73% had macular involvement (Weichel et al. 2008).   
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There are few published data on the prognosis of commotio retinae.  Hart and Frank. (1975) reported 
a series of 19 eyes with no abnormalities apparent on Fundus Fluorescein Angiography (FFA) and 
variable reduction in vision (Hart and Frank 1975).  All recovered to a VA equal to that in the fellow 
eye by 3-4 months, bar one that remained at 6/12 with a paracentral scotoma at one month.  Eagling 
(1974) followed a series of 108 posterior segment civilian closed globe injuries with hyphaema for 6 
months.  Of these, 30 had macular involvement including commotio retinae and choroidal rupture 
(Eagling 1974). The most common cause was assault.  Anterior segment damage was reported in 
approximately 2/3 of cases and classified as “moderate” (lens opacity, multiple iris sphincter tears or 
90-180° angle recession) or “severe” (cataract, lens malposition, iridodialysis or >180° angle 
recession).  “Most” cases recovered within 2 weeks of injury, though, in some, improvement 
continued for up to 6 months.  Twelve patients had permanent macular damage: 5 of whom had final 
VA in the affected eye of 6/6-6/12, 5 were of 6/18, 1 was 6/60 and 1 was left with no perception of 
light caused by a coincident optic nerve avulsion.  Areas of absolute scotoma on central visual field 
testing did not recover, whereas areas of relative scotoma showed some recovery.  An unspecified 
number of patients had peripheral commotio retinae only. 
The optical coherence tomography (OCT) features of commotio retinae are disruption at the level of 
photoreceptor OS in all cases (Meyer, Rodrigues, and Mennel 2003), (Oh et al. 2011), (Sony, 
Venkatesh, Gadaginamath, and Garg 2006), (Souza-Santos et al. 2012).  Souza-Santos et al. (2012) 
reported OCT findings on 11 patients, 5 of whom had disruption in the region of the photoreceptor 
inner segments (IS) and hyper-reflectivity of the ONL and other retinal layers; in these patients the 
ONL degenerated with associated visual loss (Souza-Santos et al. 2012).  It is likely that the ONL 
hyper-reflectivity is predictive of ONL degeneration, as IS disruption has been reported to resolve 
without adverse long-term sequalae (Park et al. 2011). 
There is one paper, in Portuguese, looking at the characteristics of commotio with full field 
electroretinography (ERG)  and a case report in English (Knighton and Blankenship 1980), (Noia Lda et 
al. 2006) that both show a reduction in amplitude of the major components with full recovery within 
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2 weeks.  Other reports of isolated cases with concomitant macular holes provide multi-focal ERG 
data on commotio retinae (Lai, Yip, Wong, and Lam 2005).  The effects of commotio on pattern ERG 
have not been reported.   
The BRB is assessed by FFA and indocyanine green angiography (ICG), which assess the retinal and 
choroidal circulations respectively.  A series of 21 patients with FFA and ICG found fluorescein 
leakage in 9 eyes and a ‘salt and pepper’ fundus appearance in one, which the authors felt indicated 
a more severe injury (though they did not specify VA in these cases).   In some cases early increases 
in choriocapillaris permeability developed into occlusion by day 4.  All eyes with abnormal FFA had 
some abnormality of ICG (delayed filling/hypofluorescence).  The authors speculated that in severe 
commotio retinae occlusion of the choriocapillaris leads to outer retinal ischaemia within days after 
injury and impaired recovery (Kohno, Miki, and Hayashi 1998). 
1.3.2. Summary 
In clinical studies of commotio retinae many patients recover completely, but an unknown 
proportion are left with reduced vision or paracentral scotomas.  These patients have early ONL 
hyper-reflectivity on OCT and/or choroidal leakage with subsequent ONL degeneration and/or 
choroidal occlusion.    There are no treatments available to improve the outcomes for those patients 
who suffer permanent loss of vision. 
1.4. Retinal Injury in Experimental Models 
Parts of the work in this section have been published as a “Perspectives” piece in Investigative 
Ophthalmology and Visual Science (Blanch et al. 2012b), the paper is presented in Appendix 2. 
1.4.1. Comparative Anatomy of the Eye 
The eyes of different mammals vary in size, refractive properties, retinal vasculature and visual 
photopigments.  The cellular composition and thickness of the retina is conserved across mammals 
e.g. 0.24mm in the mouse eye compared to 0.249mm in the human eye (Glickstein and Millodot 
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1970), (Remtulla and Hallett 1985), (Alamouti and Funk 2003).  The photoreceptors show particular 
variation in photopigments and in size.  Rods all contain rhodopsin, which has 87% sequence 
homology between human, bovine, ovine, galline and murine DNA (Nathans 1992).  Rod size varies 
with animal size and diurnal or nocturnal behaviours, whilst the proportion of cones and their 
function is highly variable between species.  No mammals except primates have a macula. 
The rabbit retina is merangiotic; humans, primates, pigs and murine rodents have holangiotic 
retinae.   The arrangement of capillaries in mouse, pig and primate retinae is similar to humans, with 
capillary plexi in the ganglion cell/nerve fibre layer and bracketing  the inner nuclear layer at its 
sclerad and vitread aspects (Simoens, De Schaepdrijver, and Lauwers 1992),(Snodderly and Weinhaus 
1990),(Cuthbertson and Mandel 1986).  The rat retina has been reported to have two only planes of 
capillary plexi – in the ganglion cell layer and the outer plexiform layer (Bhutto and Amemiya 1995), 
(Ninomiya and Kuno 2001); however, given the similarities in retinal vasculature between mouse, 
primate and porcine retinae, it is likely that more detailed studies would reveal a similar arrangement 
in rats. 
1.4.1.1. Mice 
The mouse eye has an average axial length of 3.4mm and 60% of this is taken up by the lens.  The 
distance from the posterior lens surface to the retina is 0.56mm (Remtulla and Hallett 1985).  There 
is some disagreement on the refractive status of the mouse eye, but existing evidence suggests that 
it is either emetropic (image focussed on the retina) or slightly myopic (image focussed in front of the 
retina) (Remtulla and Hallett 1985), (Glickstein and Millodot 1970).  The average density of rods in 
mice is 437,000 /mm2, with an outer segment diameter of 2µm, giving approximately 6.4 million rods 
per retina (Jeon, Strettoi, and Masland 1998).  3% of mouse photoreceptors are cones, which are 
distributed throughout the retina.  The majority of cones co-express short (S - blue/UV) and medium 
(M - green) wavelength opsin pigments, with greater S opsin expression overall (Applebury et al. 
2000).  M opsin expression increases in a ventral to dorsal gradient and S opsin increases in a dorsal 
to ventral gradient (Applebury et al. 2000). 
Figure 1.4.1.3. 
Labelled cross section of an adult 
rabbit eye. Scale bar= 1mm 
Figure 1.4.1.2 
Labelled cross section of the eye of an 
adult Wistar rat. Scale bar= 1mm 
Figure 1.4.1.4. 
Labelled cross section of the eye of an adult 
large white pig. Scale bar= 1mm 
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The vitreous body contains primarily type II collagen and hyaluronic acid.  Collagen fibres of 15-20nm 
in diameter connect the vitreous cortex to the internal limiting membrane of the posterior retina and 
more strongly to the peripheral retina and lens zonules.  The fibres are a similar size but are less 
frequent than in larger species, such as humans (Rhodes 1982), (Rhodes 1983), (Rhodes 1985). 
1.4.1.2. Rats 
The rat eye (Figure 1.4.1.2.) has an axial length of 6.29- 6.31mm, 8 times larger by volume than the 
mouse eye (Remtulla and Hallett 1985), (Hughes 1979).  The lens accounts for 60% of axial length at 
3.71mm (Hughes 1979).  Existing evidence suggests that the rat eye is emmetropic, with a 0.3mm 
pupil giving a 30D depth of field (Hughes 1977).  Rod densities are 400,000-500,000 /mm2 and rod 
outer segment diameter is around 2µm (unpublished data – Blanch, RJ).  Rats have two classes of 
cone, M and S, though M cones are most frequent (Szel and Rohlich 1992).  They constitute only 1% 
of photoreceptors and are distributed throughout the retina, being denser dorsally (Szel and Rohlich 
1992). 
The vitreous base attachment spans the ora serrata, and has fewer collagen fibres than in larger 
species such as rabbits and humans (Rhodes 1983).  It is hypothesised that smaller eyes require less 
glycoconjugate to maintain structural integrity.   
Albino rats are commonly used for research purposes, but albinism is associated with multiple neuro-
retinal abnormalities, including non-pigmented retinal pigment epithelium and abnormal decussation 
of retinal ganglion cell (RGC) axons at the optic chiasm (Prusky, Harker, Douglas, and Whishaw 2002).  
The visual function of albino rats is abnormal, the RPE is abnormal and exposure of albino rats to 
excessive ambient light results in photoreceptor apoptosis.  Pigmented rats are therefore more 
suitable for visual system research. 
1.4.1.3. Rabbits 
The rabbit eye (Figure 1.4.1.3.) is large in relation to body size.  It has an axial length of 16-19mm, 
slightly smaller than the human eye.  The average lens thickness is 7.6mm, more similar to rat than 
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human dimensions.  Different to the human eye, rabbit retina has: (1) RPE that is irregular in size and 
arrangement (human has a regular hexagonal configuration); (2) longer and thinner rods and cones; 
(3) myelinated nerve fibres in the retina, forming nasal and temporal crescents about the optic disc.  
The retinal arteries and veins supply only the retina below the myelinated fibres; the remainder of 
the retina is avascular (merangiotic) (Gwon 2008). 
The peak density of rods is 300,000 /mm2 (Famiglietti and Sharpe 1995).  Rabbits do not have a 
macula but have cones concentrated in a “visual streak” (Famiglietti and Sharpe 1995).  
Approximately 5% of photoreceptors are cones in two classes – S and M (Famiglietti and Sharpe 
1995), (De Monasterio 1978).  The S cones are not collocated with medium wavelength cones 
(Famiglietti and Sharpe 1995), so dichromatic colour vision with colour opponency is limited (De 
Monasterio 1978).    
Rabbit vitreous contains hyaluronic acid and collagen.  The collagen fibres are thinner and less 
frequent than in humans (7nm vs 10-25nm), but attach the vitreous base to the ILM of the peripheral 
retina and the pars plana, spanning the ora serrata (similar to the arrangement in humans) (Sebag 
and Yee 2007), (Matsumoto, Blanks, and Ryan 1984). 
1.4.1.4. Pigs 
The porcine eye (Figure 1.4.1.4.) has an axial length of 22–23.9mm and a lens thickness of 6.75–
7.4mm (Fatehee et al. 2011), (Sanchez, Martin, Ussa, and Fernandez-Bueno 2011), (Koopmans et al. 
2004), (Wong, Koopmans, Terwee, and Kooijman 2007).  The peak density of rods is 113,000 /mm2 
(Gerke, Hao, and Wong 1995).  Pigs do not have a macula but, like rabbits, their cones are 
concentrated in a “visual streak,” which contains capillaries but no arterioles or venules.  Cones 
constitute approximately 20% of photoreceptors and have two visual pigments sensitive to short 
(blue) and medium (green) wavelength light (Simoens, De Schaepdrijver, and Lauwers 1992), 
(Hendrickson and Hicks 2002).    
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The vitreous base is most firmly attached to the pars plana.  The attachment is widest temporally, 
where it is confined to the pars plana, which is also widest temporally, as in the human eye.  Nasally, 
a thinner attachment spans the ora serrata to attach to pars plana and retina (Weidenthal and 
Schepens 1966).  The concentrations of both hyaluronic acid and collagen are half that of the human 
vitreous (Sebag and Yee 2007). 
1.4.1.5. Primates 
Primate species have a great variation in eye size and structure.  Diurnal rhesus monkeys have a peak 
rod density of 180,000 /mm2 and a larger cell size, whilst smaller nocturnal primates have higher 
peak rod densities and correspondingly smaller rod photoreceptors.  For example, peak rod density is 
325,000 /mm2 in the owl monkey and 450,000 /mm2 in the bushbaby (Wikler and Rakic 1990).  The 
majority of primates possess  a macula and fovea and all have rod dominant retinae.  Old World 
monkeys and great apes have three classes of cone with trichromatic colour vision and a fovea 
centralis (Jacobs 1998).  New World monkeys are highly polymorphic, though all – except the owl 
monkey – have a fovea with a high cone concentration (Jacobs 2008), (Dyer et al. 2009).  Inheritance 
of photopigment genes in New World monkeys (except the trichomatic Howler monkey (Jacobs 
1998)) is by two genes on the X chromosome, so females may have variants of trichromatic vision, 
whereas males have only dichromatic vision (Jacobs 2008).  The nocturnal owl monkey lacks a fovea 
centralis and has only one class of cone, giving monochromatic vision (Hamasaki 1967), (Dyer et al. 
2009). 
The rhesus monkey has vitreal constituents in the same concentrations as the human (though 
hyaluronic acid is half the molecular weight of human), whereas the owl monkey has a higher 
concentration of hyaluronic acid and no collagen (Sebag and Yee 2007).  The cynomalous monkey has 
an internal limiting membrane whose thickness varies in the same way as in the human – being 
thinner at the fovea – and also shows vitreous syneresis (age related liquefaction) in a similar fashion 
to humans (Matsumoto, Blanks, and Ryan 1984).  The vitreous body of the rhesus monkey has 
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collagenous attachments to the pars plana, though this circumferential band of attachment is only 
one sixth the antero-posterior thickness found in the human (Lutjen-Drecoll et al. 2010). 
1.4.2. Neuroretinal Cell Death 
Necrosis is uncontrolled and causes inflammation as inflammatory cells phagocytose the cellular 
remains.  Cells undergo necrosis when an insult damages their structural integrity, as in trauma, gross 
ischaemia and excitoxicity.  Apoptosis ensues after stress or injury and as part of normal 
development or tissue functions, e.g. T cell death in the adult thymus.  Apoptosis can be precipitated 
by DNA damage causing activation of p53, withdrawal of growth factors, stimulation by neighbouring 
cells, activation of Fas receptor by T cells and traumatic damage of a lesser severity than induces 
necrosis.  Different stimuli cause apoptosis through different routes and different cell types have 
different mechanisms (Pradelli, Beneteau, and Ricci 2010). 
1.4.2.1. Morphological classifications of cell death 
There is no binary distinction between apoptosis and necrosis though, rather both lie at opposite 
ends of a spectrum.  Programmed cell death in development may not display features of apoptosis 
and necrosis may be regulated by cell death signalling pathways (Nicotera, Leist, and Manzo 1999), 
(Galluzzi et al. 2012).  Cell death may be mediated by number of different overlapping molecular 
signalling pathways, giving rise to a variety of morphological features that may be termed apoptotic, 
necrotic or neither.   
Apoptosis is characterised by cell and nuclear shrinkage, chromatin condensations (typically at the 
nuclear periphery), nuclear blebbing and cytoplasmic blebbing with the formation of apoptotic 
bodies in the presence of intact cellular organelles such as mitochondria and endoplasmic reticulum 
and enclosed by an intact plasma membrane (Elmore 2007).  Necrotic cell death had a more diverse 
morphology, but is characterised by cellular swelling and swelling of organelles.  The nucleus 
disintegrates late in the cell death process, but there may be chromatin condensation or karyolysis 
(chomatin dissolution).  Due to leakage of cellular contents, local inflammation occurs with  
Extrinsic 
DNA fragmentation, 
membrane blebbing, ,.__ 
cell death 
! 
Intrinsic 
/ Smac/DIABLO 
Figure 1.4.2. An outline of the main pathways of caspase dependent apoptosis (Berry et al. 2008). Sortillin 
complexes with the p75 neurotrophin receptor (NTR) to facilitate apoptosis in the extrinsic pathway. 
Neurotrophin receptor interacting melanoma-associated antigen homolog (NRAGE) is a p75 Intracellular 
binding partner that facilitates apoptosis through caspase 8 and c-Jun N-terminal kinase (JNK). 
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inflammatory cell infiltration.  Necrosis may be autophagic, when cytoplasmic vacuoles filled with 
cellular contents are formed, or non-lysosomal, when there is no vacuolation (Ziegler and Groscurth 
2004). 
1.4.2.2. Molecular classifications of cell death 
Factors that precipitate and prevent apoptosis are constitutively expressed and present in the 
cytosol.  Most are present in inactive form and there is usually a balance between the pro- and anti-
apoptotic factors.  Stimulation of apoptosis often inhibits the function of inhibitors of apoptosis 
(IAPs) or upregulates or activates pro-apoptotic factors.  The main route for apoptosis is through the 
caspase enzymes (Figure 1.4.3.2.1.), so called because they have cysteine in their active site and 
cleave target molecules at aspartate residues.  Caspases can be activated by cleavage from pro-
enzymes, oligomerisation and the formation of an apoptosome. 
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1.4.2.3. Mitochondria and the intrinsic pathway 
Apoptosis may occur through either intrinsic or extrinsic pathways.  Mitochondria are central to the 
cell death pathways: 
1) They provide energy through oxidative phosphorylation, without which cells die. 
2) They initiate apoptosis by releasing proapoptotic proteins. 
3) They generate reactive oxygen species and nitric oxide. 
4) They regulate the intrinsic pathway to apoptosis by controlling the redox state of cytochrome 
C. 
5) They contribute to cellular calcium homeostasis. 
Permeabilisation of mitochrondria leads to cell death through release of cytochrome C, apoptosis 
inducing factor (AIF) and endonuclease G among others as well as decreased ATP production, all of 
which may be terminal events.  Permeabilisation is controlled by Bcl-2 family proteins, being 
dependent on the presence of either one of Bak and Bax.  The other Bcl-2 family members are either 
anti-apoptotic (inhibiting Bak, Bax and other pro-apoptotic Bcl-2 proteins) or proapoptotic (activating 
Bak and Bax or inhibiting the anti-apoptotic Bcl-2 family members).  Bak and Bax are normally 
present in inactive form in the cytosol, but during apoptosis they translocate to the mitochondria and 
undergo conformational changes and oligomerisation, inserting into the mitochondrial plasma 
membrane to increase permeability either by acting as channels themselves or destabilising the lipid 
bilayer (Borutaite 2010).   Bcl-2 family members are additionally present in the endoplasmic 
reticulum, where they influence calcium homeostasis (Borutaite 2010). 
The state of membrane lipids also influences mitochondrial outer membrane permiabilisation 
(MOMP).  For example, reactive oxygen species peroxidate cardiolipin in the inner and to a lesser 
extent outer membranes affecting membrane interactions with Bax and Bak (Borutaite 2010).  
Mitochondrial membrane permeability is also increased (and mitochondrial ATP production 
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decreased) by the opening of non-specific channels in response to elevated intracellular calcium, 
called mitochondrial permeability transition pores (MPTP), which are permeable to small molecules 
and electrolytes.  MPTP therefore allows water and electrolytes to move whilst trapping proteins, 
which causes swelling and ultimately rupture of mitochondria (Borutaite 2010). 
MOMP releases cytochrome C, apoptosis activating factor 1 (Apaf-1), second mitochondrial-derived 
activator of caspases (smac/DIABLO) and serine protease high temperature requirement protein 2 
(HtrA2/Omi) into the cytoplasm.  In the cytosol, oxidised cytochrome C complexes with apaf-1 to 
form an apoptosome that binds and activates pro-caspase 9, which initiates the intrinsic pathway to 
apoptosis and activates downstream mediators and executioner caspases.  The intrinsic pathway is 
activated by stimuli such as DNA damage, viral infection and growth factor deprivation and regulated 
by Bcl-2 proteins.  Several IAP provide additional regulation and can even prevent apoptosis in the 
presence of activated executioner caspases.   
smac/DIABLO and HtrA2 inhibit endogenous IAPs, promoting caspase activation (Borutaite 2010).  
Mitochondrial release of AIF and endonuclease G , which translocate to the nucleus causing caspase-
independent cell death (Susin et al. 1999), is dependent on caspase activity (Arnoult et al. 2003).  In 
addition to releasing cytochrome C, mitochondria also control its redox state – oxidisation being 
necessary for its pro-apoptotic activity (Borutaite 2010).  Prevention of MOMP by knockout of Bcl-2 
family proteins makes cells resistant to a wide variety of death stimuli (Pradelli, Beneteau, and Ricci 
2010). 
1.4.2.4. The extrinsic and other pathways 
The extrinsic system is activated by cell surface receptors such as the Fas receptor, which activates 
Fas-associated death domain protein (FADD) which activates caspase 8.  Caspase 8 and 9 are initiator 
caspases.  Executioner caspases act downsteam of the initiator casapses and  directly trigger cell 
death.  The executioner caspases are 3, 6 and 7 and their targets include enzymes involved in cell 
cycle control, DNA repair, cytoskeletal assembly and other caspases, which creates feedback loops.  
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Caspase 2 has structural similarities to the initiator caspases, but substrate specificities similar to the 
executioner caspases.  The exact role of caspase 2 is unclear though it may allow a mitochondria-
independent intrinsic pathway (Troy and Ribe 2008). 
In some cells during extrinsic apoptosis, caspase 8 directly activates caspase 3, whilst in others it 
mediates BH3-interacting domain death agonist (BID) cleavage to truncated-BID (tBID), which 
induces MOMP.   
Troy et al. (1997) showed that caspase 2 is necessary for apoptosis caused by growth factor 
withdrawal but not oxidative stress in PC12 (rat pheochromocytoma) cells and Troy et al. (1996) 
showed IL-1β (activated by caspase 1) was necessary for apoptosis induced by copper/zinc 
superoxide dismutase downregulation but not by withdrawal of trophic factor support (though both 
were caspase-dependent).  Thus, in the same cell line different stimuli result in apoptosis mediated 
by different caspases (Troy et al. 1996), (Troy, Stefanis, Greene, and Shelanski 1997). 
Calpains are calcium-activated non-lysosomal (cytosolic) cysteine proteases that are implicated in 
apoptosis and necrosis.  There a number of calpain-family proteins, of which µ- and m-calpain 
(calpain 1 and 2) are the best characterised.  In apoptosis and necrosis, calpains cleave structural 
proteins including non-erythrocytic α2 spectrin into fragments of specific size distinct from those 
produced by caspase activity (Zhang et al. 2009b). 
Receptor interacting protein kinase 1 (RIP1) is recruited by the death domain of the Fas receptor to 
form part of a death-inducing signaling complex (DISC) that regulates caspase-8, as part of the 
extrinsic apoptosic pathway (Galluzzi et al. 2012).  In addition, RIP1 is ubiquitinated by cellular 
inhibitors of apoptosis to activate transcription factor (nuclear factor) NF-κβ and increase cell 
susceptibility to extrinsic apoptosis.  However, RIP1 is also implicated in necroptic cell death 
precipitated by caspase inhibition, when its inhibition prevented necrosis (Trichonas et al. 2010). 
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1.4.3. Retinal Response to Closed Globe Injury 
1.4.3.1. Commotio Retinae 
Commotio retinae has been induced in pigs, rabbits, cats and rhesus and owl monkeys, by a 
projectile fired from either a modified air pistol or a catapult (Blight and Hart 1977), (Hart, Blight, 
Cooper, and Papakostopoulos 1975), (Blight and Hart 1978), (Gregor and Ryan 1982a), (Hui et al. 
1993), (Bunt-Milam, Black, and Bensinger 1986), (Kohno et al. 1983), (Sipperley, Quigley, and Gass 
1978).  The energies and impact sites are summarised in Table 1.4.2.1.  The report of Hui et al (1993; 
Table 1.4.2.1.) is unusual in reporting a very high impact energy.  However, Scott et al. showed that a 
high velocity impact of a low weight projectile created more injury than a low velocity impact from a 
heavy projectile, despite similar kinetic energy (Scott, Lloyd, Benedict, and Meredith 2000).  
The main finding in animal studies of commotio retinae is traumatic disruption of the photoreceptor 
OS (Hart, Blight, Cooper, and Papakostopoulos 1975), (Blight and Hart 1977), (Blight and Hart 1978), 
(Bunt-Milam, Black, and Bensinger 1986), (Kohno et al. 1983), (Sipperley, Quigley, and Gass 1978), 
consistent with optical coherence tomography findings in humans and reversible loss of cone 
pigment on fundus reflection densitometry (Meyer, Rodrigues, and Mennel 2003), (Liem, Keunen, 
and van Norren 1995), (Sony, Venkatesh, Gadaginamath, and Garg 2006).  The RPE phagocytoses the 
OS and becomes a multilayered disorganised structure, that, in some cases, directly apposes the 
photoreceptor IS (Sipperley, Quigley, and Gass 1978).  Outer retinal damage explains the clinical 
finding of reduced vision. 
The evidence about BRB disruption in commotio retinae from porcine, feline and lapine studies 
conflicts with the human data.  A normal fluorescein angiogram has been reported (Sipperley, 
Quigley, and Gass 1978), (Pulido and Blair 1987), (Hart and Frank 1975), but disruption of the BRB, at 
the level of the RPE has been shown with horseradish peroxidase and lanthanum (Gregor and Ryan 
1982a), (Bunt-Milam, Black, and Bensinger 1986), (Hui et al. 1993).  In a rabbit model, fluorescein 
angiography demonstrated an intact BRB but leakage from choroidal vessels using intrachoroidal 
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indocyanine green (Miki, Kitashoji, and Kohno 1992).  This is consistent with some clinical findings in 
humans (Kohno, Miki, and Hayashi 1998), but the relevance may be limited because of the 
merangiotic rabbit retina.  Intracellular oedema of Müller cell processes and axons in the RNFL and 
photoreceptors has been documented (Kohno et al. 1983), (Blight and Hart 1977), (Blight and Hart 
1978), (Hart, Blight, Cooper, and Papakostopoulos 1975), (Dean Hart and Blight 1978), but no 
extracellular oedema, which would be expected with BRB disruption.  The axonal oedema resolves 
within 4 hr and the glial oedema in 2-3 d (Hart and Blight 1979b).  Axonal and glial oedema are 
probably responsible for the white retinal appearance seen on clinical examination. 
Regeneration of photoreceptor OS begins at 1 week and continues for at least 2 months (Blight and 
Hart 1977), (Blight and Hart 1978), (Bunt-Milam, Black, and Bensinger 1986).  This may explain the 
course of visual recovery.  Photoreceptors die by necrosis and apoptosis detected by nuclear changes 
and TUNEL staining (Sipperley, Quigley, and Gass 1978), (An, Zhang, and Zhang 2004).  Argyrophilia 
has been reported in unspecified retinal cells in a rabbit model (Antelava 1969).  Argyrophillia is an 
early sign of compromised neurons that may later die by either apoptotic or necrotic routes (Gallyas, 
Zoltay, and Dames 1992), (Gallyas, Hsu, and Buzsaki 1993).  The intrinsic and extrinsic mechanisms of 
cell death or regeneration have not been reported in these (Table 1.4.2.1.) models. 
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Group Animal Impact Site Energy Velocity Weight Injuries Reported 
Blight and Hart 
(Blight and Hart 
1977), (Hart, 
Blight, Cooper, 
and 
Papakostopoulos 
1975), (Blight 
and Hart 1978), 
(Hart and Blight 
1979a) 
10-30kg 
store pigs 
Nasal sclera 
over ora 
serrate 
0.49-
0.78J 
50-
64m/s 
0.38g Retinal breaks, choroidal 
rupture and RPE disruption 
at lower energy.  Commotio 
retinae at >0.68J. 
Gregor and Ryan 
(Gregor and 
Ryan 1982a) 
11-27kg 
domestic 
pig 
Lateral 
sclera over 
pars plana 
0.32J 33m/s 0.57g Commotio retinae, vitreous 
haemorrhage, no retinal 
breaks/dialyses. 
Latanza et al 
(Latanza et al. 
1988) 
Rabbit Lateral 
sclera over 
retina 
0.57J 46.8m/s 0.52g Retinal holes, commotio 
retinae, choroidal and 
vitreous haemorrhage. 
Cox (Cox 1980) Rabbit Lateral 
sclera over 
retina 
0.9-1.62J 58.8 – 
79m/s 
0.52g Gross retinal damage with 
tears and necrosis and 
choroidal and vitreous 
haemorrhage with 
commotio retinae at lower 
energy.  Globe rupture at 
higher energy. 
Blight and Hart 
(Hart and Blight 
1979a) 
10-30kg 
store pigs 
Nasal sclera 
over ora 
serrata 
1.9J 100m/s 0.38g Complete absence of 
neuroretina at impact site.  
Choroidal rupture, dispersed 
RPE, ciliary epithelial 
detachment. 
Sipperley et al 
(Sipperley, 
Quigley, and 
Gass 1978) 
Owl 
monkeys 
Central 
cornea 
0.39-
1.05J 
47m/s 0.35-
0.95g 
Commotio retinae only. 
Bunt-Milam et al 
(Bunt-Milam, 
Black, and 
Bensinger 1986)   
Cat Central 
cornea 
0.44J 50m/s 0.35g Commotio retinae, variable 
hyphaema. 
Blight and Hart 
(Hart and Blight 
1979a) 
10-30kg 
store pigs 
Central 
cornea 
0.49-1.9J 50-
100m/s 
0.38g No injury at lower energy.  
Dialysis in 50% at higher 
energy. 
Gregor and Ryan 
(Gregor and 
Ryan 1982a) 
30kg 
domestic 
pig 
Paracentral 
cornea 
1.25J 52.3m/s 0.95g Commotio retinae, RPE 
disruption, RPE and retinal 
detachment. 
Hui et al (Hui et 
al. 1993) 
Rabbit Central 
cornea 
2.87J 18.9m/s 16g Commotio retinae only. 
Table 1.4.2.1.  Animal models of retinal injury induced by blunt ocular trauma.  Bold figures are 
estimated or calculated from the material in the published paper; n/a = not available 
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Multiple mechanisms of injury are used in animal studies of commotio retinae.  Some studies report 
central corneal trauma, whilst others report lateral scleral injury (Table 1.4.2.1.).  Clinically, direct 
scleral injury is associated with chorioretinitis sclopetaria in which the retina is severely disrupted 
and retinal haemorrhages, holes and detachments are present that ultimately scar, but do not 
detach (Hart, Natsikos, Raistrick, and Doran 1980).  The features of injury seen by electron 
microscopy are similar in both central corneal and scleral impact models and are consistent with 
those of commotio retinae.  It is likely that chorioretinitis sclopetaria occurs with higher energy 
impacts only. 
1.4.3.2. Retinal Tears and Dialyses 
Deformation of the globe along the sagittal axis (long axis) during blunt trauma causes disinsertion of 
the retina at the ora serata (a retinal dialysis) and retinal tears.  Delori et al. (1969) injured 
enucleated pig eyes embedded in gelatin with projectile impacts to the central cornea of 0.345g 
travelling at 62.3m/s and reduced axial length from 20.7 to 12.2 mm (41%) (Delori, Pomerantzeff, 
and Cox 1969).  They did not report lens size, but speculated that during injury, the corneal 
endothelium would be in contact with the lens.  Taking pig axial lens length as 6.75mm (Koopmans et 
al. 2004), there would be approximately 3.5mm between the retina and posterior surface of the lens 
at the point of greatest compression.  This is less than the 3.9mm anterior chamber depth and 
corneolenticular contact is certain (Sanchez, Martin, Ussa, and Fernandez-Bueno 2011).  With a 
lateral scleral impact in pigs, given that in coronal section the lens lies centrally instead of anteriorly 
in both axial and sagittal sections, the retina will impact the lens with a 40% deformation.    
Weidenthal and Schepens (1966) supported the theory that retinal tears and dialyses are caused by 
deformation of the globe.  They injured enucleated pig eyes with a central corneal ball bearing 
impact (0.76J) and supported the area between the ciliary body and equator by placing the eyes in a 
rigid plaster mould, which protected the nasal ora serrata from injury compared to the same injury 
within the orbit or using a flexible gelatin support (Weidenthal and Schepens 1966). 
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1.4.3.3. Blast injury 
There is indirect evidence that ocular PBI is possible from the observed degeneration of RGC axons in 
the optic tracts following exposure of rats to a simulated blast in a “shock tube” and RGC apoptosis 
detected by terminal deoxynucleotidyl transferase-mediated dUTP nick end labelling (TUNEL) after 
exposure of rabbits’ eyes to firecrackers (Petras, Bauman, and Elsayed 1997), (Chen et al. 2003).  
However, neither experiment controlled for tertiary blast injury.  In a model of air blast in dogs, 
orbital blow out fractures were demonstrated, almost certainly due to tertiary blast effects 
(Richmond, Pratt, and White 1962). 
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1.4.4. Retinal Response to Open Globe Injury 
Injury Animal Cells affected Response studied Technical details 
Incisonal retinal injury 
(Turner, Blair, and 
Chappell 1986) 
Rat/mouse Cells of all retinal 
layers near the 
wound 
Cell death Incision through sclera, choroid and 
retina, <1mm in length, closed with 
sutures. 
Optic nerve crush 
(Berkelaar et al. 1994) 
Rat/mouse RGC RGC apoptosis and 
axonal regeneration 
Proximal injuries (0.5mm from globe) 
cause more aggressive cell death than 
distal (>8mm). Optic nerve transection 
(Berkelaar et al. 1994) 
Rat/mouse RGC RGC apoptosis 
Retinal detachment 
(Fisher, Lewis, Linberg, 
and Verardo 2005), 
(Fontainhas and 
Townes-Anderson 
2011), (Lewis et al. 
2010), (Zadro-
Lamoureux et al. 
2009), (Kayama et al. 
2011), (Lewis et al. 
2009) 
Pig/cat/rat
/mouse 
Photoreceptors Apoptosis, 
programmed 
necrosis, 
“deconstruction” 
Detachment is created by subretinal 
injection of balanced salt solution (BSS) 
or hyaluronic acid (prevents 
reattachment) with/without 
vitrectomy and lensectomy. The 
cannula is introduced into the vitreous 
through a small pars plana/peripheral 
retinal sclerotomy and into the 
subretinal space.  
Bipolar, horizontal 
cells, RGC 
Remodelling, 
neurite outgrowth 
Müller cells, 
astrocytes 
Gliosis 
Rabbit Photoreceptors, 
glia 
Aggressive cell 
death, gliosis 
Intravenous sodium 
iodate (Burgi, Schaffner, 
and Seiler 2001) 
Pig/rabbit/
rat/mouse 
RPE Cell death and tissue 
regeneration 
>10mg/kg is toxic in rats 
Intraperitoneal N-
methyl-N-nitrosourea  
(Wan et al. 2008), 
(Harada et al. 2011) 
Photoreceptors >15mg/kg is toxic in mice, 60mg/kg 
obliterates the outer nuclear layer 
Intravitreal N methyl-D-
asparate (Ohta, Ito, and 
Tanaka 2008) 
RGC, amacrine 
cells 
Dose dependent loss of RGC but wide 
variation in dosing 
Phototoxicity  
(Organisciak and 
Vaughan 2010) 
Rat/mouse Photoreceptors, 
RPE 
Apoptosis Exposure to toxic light levels for 
minutes – days.  Hours of exposure 
causes rod apoptosis; days causes RGC 
apoptosis. 
Mechanical RPE 
debridement (Leonard 
et al. 1997), (Hayashi et 
al. 1999), (Valentino et 
al. 1995), (Kiilgaard et 
al. 2007) 
Primate/ 
pig/cat/ 
rabbit 
RPE Tissue regeneration 
and scarring 
A vitrectomy is performed through a 
pars plana incision and a retinal 
detachment created by subretinal BSS 
injection to expose RPE. Mechanical 
debridement is by abrasion with a 
silicone brush or tubing or tearing with 
forceps.  Hydraulic RPE 
debridement (Leonard 
et al. 1997) 
Table 1.4.3.2. Animal models used to study retinal injury responses. 
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1.4.4.1. Proliferative Vitreoretinopathy 
In open globe injuries with vitreous loss that is managed conservatively, there is a high risk of 
developing intraocular fibrosis termed proliferative vitreoretinopathy (PVR).  PVR is the endpoint of a 
number of disease processes and occurs most commonly after retinal detachment and surgical 
repair.  A number of models of retinal injury have been designed to study PVR.  In vivo models of PVR 
have been reviewed elsewhere (Agrawal et al. 2007).  
 Of the 27 existing models of PVR, four are primarily induced by posterior segment trauma and the 
rest by intravitreal injection of growth factors and/or cells including cultured fibroblasts and RPE cells 
(Agrawal et al. 2007), (Gregor and Ryan 1982b).  In PVR after retinal injury, degeneration of 
photoreceptors and other retinal cells precedes scar formation (Topping, Abrams, and Machemer 
1979), though inflammation and photoreceptor damage are associated with the retinal detachment 
(Gregor and Ryan 1982c).  Most animal models of open globe retinal injury with time points longer 
than a few days are at high risk of PVR from posterior segment penetration with vitreous loss.  In 
pigs, entering the posterior segment through the pars plana, abscising vitreous, injecting autologous 
blood and closing the wound with sutures causes PVR, with tractional retinal detachment by 2 weeks 
(Gregor and Ryan 1982b), (Gregor and Ryan 1983a).  In the rhesus monkey, intracapsular lens 
extraction with reinjection of homogenised lens causes PVR, with fibrous ingrowth by 3 weeks 
(Cleary, Jarus, and Ryan 1980).  PVR is avoided by vitrectomy at 1 or 14 d, though vitrectomy must be 
complete (Cleary and Ryan 1981), (Gregor and Ryan 1983b).  In rabbits inhibiting matrix 
metalloproteinases 2, 3 and 9 and x-ray irradiation all prevent PVR (Chakravarthy, Maguire, and 
Archer 1986), (Chakravarthy et al. 1989), (Ozerdem et al. 2000), (Ozerdem et al. 2001).   
In the rabbit, pars plana incision, intravitreal injection of autologous blood and vitreous lens 
admixture, and cryopexy, causes PVR (Westra et al. 1995), (Cleary and Ryan 1979).   In the mouse, 
transcorneal excision of the lens and vitreous and peripheral retinal breaks causes PVR, with 
multilayered (RPE derived) fibroblasts expressing collagen VI as early as 1 week after injury (Saika et 
al. 2004).  In the rat, serial limbal penetrations with a 27 guage needle has been documented to 
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create PVR (Bignami and Dahl 1979), though it is likely that there was  undocumented intraocular 
injury, as in the rat an isolated limbal penetration would initially enter the anterior chamber. 
1.4.4.2. Retinal Ganglion Cell Death and Axonal Regeneration 
Optic nerve injury causes RGC axotomy, which is a closed globe injury.  However, it is studied in the 
context of various surgical interventions – i.e. open globe injury – to manipulate retinal cell death 
and regeneration and many of the underlying molecular mechanisms are conserved throughout the 
CNS and retina. 
Traumatic optic nerve injury is rarely recognised in civilians (Lee et al. 2010), but is damaged in up to 
20% of military ocular trauma (Weichel et al. 2008), and traumatic optic neuropathy will often cause 
profound and intractable visual loss.  The optic nerve represents a simple and readily accessible CNS 
tract to model the CNS response to injury.  The response of RGC to axotomy caused by optic nerve 
injury has been extensively studied and reviewed (Cui, Yin, and Benowitz 2009), (Berry et al. 2008), 
(Benowitz and Yin 2010), (Chaum 2003).  Intraorbital axotomy causes RGC to display transitory 
sprouting of proximal axon stumps, followed by apoptotic death in 90% by 14 d (Berkelaar et al. 
1994).  To restore or improve vision in patients with traumatic optic neuropathy, cell death must be 
prevented and RGC axonal regeneration promoted. 
In murine models, optic nerve axotomy is caused without central retinal artery damage.  In rats optic 
nerve transection causes a more aggressive pattern of RGC death than optic nerve crush, with 
differing transcriptional responses and susceptibility to the neuroprotective effects of neurotrophins 
(Agudo et al. 2008), (Parrilla-Reverter et al. 2009).  Similarly, transection at greater distances from 
the eye result in more delayed and less extensive RGC death with a neuroprotective effect of brain 
derived neurotrophic factor (BDNF) demonstrable in distal injury only (Berkelaar et al. 1994), (Zhi et 
al. 2005).  Therapeutic interventions to limit RGC loss and promote axonal regeneration such as 
neurotrophins, siRNA, shRNA and viral vectors encoding therapeutic molecules can be most easily 
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delivered by intravitreal injection, though viral transfection with retrograde axonal transport via the 
cut optic nerve stump has been reported (Kugler et al. 1999). 
1.4.4.2.1. RGC Apoptosis 
Apoptotic RGC death after axotomy is primarily caspase-dependent.  Transient broad spectrum 
caspase inhibition by AAV-transduced p35 expression sustains RGC survival when p35 is no longer 
expressed (Kugler et al. 1999).  In rats, z-DEVD-cmk inhibits activated executioner caspase 3 in the 
cytoplasm of apoptotic RGCs, rescuing up to 22% that would otherwise die (Kermer, Klocker, Labes, 
and Bahr 1998), (Kermer et al. 1999).  The repulsive guidance molecule RGMa opposes caspase 3 
dependent apoptotic cell death, by binding to its transmembrane receptor neogenin, and treatment 
with intravitreal RGMa rescues 26% of RGC (Koeberle et al. 2010).  However, Kermer et al. (1999) did 
not use a cell marker for RGC, so activated caspase 3 in the RGC layer could be in glia and z-DEVD-
cmk is not a completely specific caspase 3 inhibitor, so off-target effects are possible.   
In contrast, after optic nerve crush and optic nerve transection in rats, Ahmed et al. (2011) found no 
activated caspase 3 in RGC or glia in the RGC layer, but specific localization of activated caspase 2 
(both an initiator and an executioner) in RGC and cells of the inner nuclear layer (Ahmed et al. 2011), 
(Lamkanfi et al. 2002).  In addition siRNA mediated knockdown of caspase 2 mRNA prevented cell 
death in almost 100% of RGC.  Caspase 2 therefore seems to be necessary for axotomy-induced RGC 
death.  Comparable efficacy of RGC rescue is achieved by AAV vector induced Bcl-XL overexpression, 
emphasing the importance of mitochondrial permeabilisation in axotomy-induced RGC cell death 
(Malik, Shevtsova, Bahr, and Kugler 2005). 
Upstream of the caspase pathways, a number of neurotrophic factors protect RGC from apoptosis 
after optic nerve injury in rats including BDNF, ciliary neurotrophic factor (CNTF), glial cell derived 
neurotrophic factor (GDNF), neurturin, neurotrophin-4 (NT-4), erythropoietin and inosine (Koeberle 
and Ball 1998), (Koeberle and Ball 2002), (Peinado-Ramon, Salvador, Villegas-Perez, and Vidal-Sanz 
1996), (Hou et al. 2004).  BDNF is temporarily neuroprotective for RGC after optic nerve transection 
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in rats (Mo et al. 2002), and acts through both the PI-3-kinase/Akt/mTOR (phosphatidylinositol 3-
kinase/protein kinase B/mammalian Target Of Rapamycin) and the MEK/ERK (mitogen activated 
protein kinase/extracellular signal related kinase) tyrosine related kinase B (TrkB) receptor pathways 
(Klocker et al. 2000).  The decrease in neuroprotective effect of BDκ is correlated with 
downregulation of its TrkB receptor and reversed by TrkB gene transfer by AAV vector (Cheng et al. 
2002).  CNTF is also RGC neuroprotective acting through the JAK/STAT (Janus kinase/signal 
tranducers and activators of transcription), MEK/ERK and the PI-3 kinase/Akt/mTOR pathways.  
Lentiviral CNTF gene transfer sustains RGC for up to 21 d (Park et al. 2004), (van Adel et al. 2003).  
Erythropoeitin is also RGC neuroprotective acting through the PI-3-kinase/pAkt/mTOR pathway 
(Weishaupt et al. 2004). 
1.4.4.2.2. Axonal Regeneration 
Many neurotrophic factors are axogenic as well as neuroprotective, however, the pro-regenerative 
mechanisms are distinct from the pro-survival (Ahmed et al. 2010).  Glia have a prominent 
paradoxical role in either supporting or blocking axon regeneration. Activated glia in the retina and 
optic nerve produce multiple pro-regenerative neurotrophic factors (Ahmed et al. 2010), (Muller, 
Hauk, and Fischer 2007).  However, reactive astrocytes in the optic nerve interact with invading 
fibroblasts to produce a glial scar, which contains proteoglycans that inhibit axon regeneration (Silver 
and Miller 2004).  Nogo, a myelin-derived and Müller glial protein, and other myelin-derived 
inhibitors inhibit axon growth, acting through the Nogo-66 receptors to modulate GTPase Rho A and 
its downstream effector Rho-associated, coiled-coil containing protein kinase 1 (ROCK), and/or 
intracellular calcium levels (Sandvig et al. 2004), (Schwab 2010), (Wang, Chan, Taylor, and Chan 
2008).  Transfection with a dominant negative Nogo receptor enhances RGC axon regeneration, but 
only when combined with an activated growth state (Fischer, He, and Benowitz 2004). 
PTEN (phosphatase and tensin homolog), SOCS3 (suppressor of cytokine signalling) and TSC1 
(tuberous sclerosis complex 1) negatively regulate the mTOR pathway, and their deletion or 
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conditional knockout stimulates, while administration of the mTOR inhibitor rapamycin reduces RGC 
survival and axon regeneration (Park et al. 2008), (Smith et al. 2009). 
1.4.4.2.3. Inflammation 
RGC death is reduced and axonal regeneration induced after optic nerve injury by a number of 
inflammatory stimuli, including lens injury, intravitreal injection of zymosan (macrophage activating 
and chemoattractant) and intravitreal peripheral nerve grafting (Leon et al. 2000), (Cui, Yin, and 
Benowitz 2009), (Berry, Carlile, and Hunter 1996), (Berry et al. 1999), (Berry et al. 2008), though not 
by retinal injury alone (Fischer, Pavlidis, and Thanos 2000).  Peripheral nerve grafts protect other 
retinal cells as well, preventing retinal die-back around the edge of transcleral incisions, whereas 
tendon and nerve sheath implants, which also cause inflammation, do not (Turner, Blair, and 
Chappell 1986).  Peripheral nerve grafts secrete gp130 cytokines (such as CTNF and leukaemia 
inhibitory factor (LIF)), which may contribute to the neurotrophic effects (Turner, Blair, and Chappell 
1986), (Jo, Wang, and Benowitz 1999), (Lorber, Berry, and Logan 2008).  In rats, lens injury and 
intravitreal zymosan injection induce retinal astrocytes and Müller cells to release CNTF, which acts 
through the JAK/STAT3 pathway to promote axon regeneration (Muller, Hauk, and Fischer 2007), and 
Müller cell-derived factors may be essential for zymosan-induced axonal regeneration (Ahmed et al. 
2010).  The neurotrophic effects of intravitreally implanted peripheral nerve and lens tissue are 
enhanced by activated macrophages (Lorber, Berry, and Logan 2008). 
Macrophages have multiple phenotypes with a variety of functions.  “M2” type macrophages are 
pro-regenerative, whilst the “M1” type are neurotoxic in spinal cord organotypic cultures (Kigerl et 
al. 2009).  Neurotoxic M1 macrophages may explain the apparently contradictory results of Thanos 
et al. (1993) who found increased RGC survival in rats after intravitreal macrophage inhibitory factor 
injections and decreased survival with macrophage stimulating factor in the optic nerve transection 
model (Thanos, Mey, and Wild 1993).  Macrophages release the calcium binding protein 
oncomodulin, which acts through intracellular mammalian sterile 20-like kinase-3b (Mst3b), requiring 
high levels of cAMP to promote RGC survival and axon regeneration (Yin et al. 2006), (Lorber, Howe, 
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Benowitz, and Irwin 2009).  The underlying mechanisms of RGC axonal regeneration in the peripheral 
nerve graft and lens injury models remain controversial. 
The JAK/STAT, MEK/ERK and the PI3-kinase/Akt/mTOR intracellular signalling pathways are all 
important mediators of RGC neuroprotection.  Though inhibition of these pathways abolishes the 
neuroprotective effects of different neurotrophins after optic nerve crush, their inhibition can also be 
neuroprotective and pro-regenerative (Park et al. 2004), an effect dependent on activated 
macrophages for the JAK/STAT and PI-3 kinase/Akt/mTOR pathways and independent of them for 
the MEK/ERK pathway (Luo et al. 2007). 
1.4.4.3. Photoreceptor Cell Death and Retinal Remodelling 
Animal models of open globe injury, used to study retinal cell death and tissue regeneration, damage 
the retina by incision, excision or abrasion and photoreceptor death also occurs in other – non-
trauma – models (Table 1.4.3.2.).   
Death of non-RGC retinal components has been little studied in models of trauma.  Photoreceptor 
apoptosis occurs in closed globe injury and cells of all retinal layers die adjacent to penetrating 
wounds (Table 1.4.3.2.) (Sipperley, Quigley, and Gass 1978), (Turner, Blair, and Chappell 1986).  In 
rats, fibroblast growth factor receptor (FGFR1) is upregulated in photoreceptors and fibroblast 
growth factor 2 (FGF-2), CNTF and pigment epithelium-derived factor (PEDF) are released within 
hours of penetrating injury and retinal detachment (Ozaki, Radeke, and Anderson 2000), (Penn et al. 
2006), (Wen et al. 1995).  FGF-2 and CNTF reduce photoreceptor apoptosis in other models of 
photoreceptor degeneration (Chaum 2003). 
1.4.4.3.1. Retinal Detachment 
Retinal detachment induced by subretinal hyaluronic acid infusion models the outer retinal damage 
and ischemia components of the injury response (Table 1.4.3.2.).  Reattachment can be achieved by 
vitrectomy and fluid-gas exchange (Fisher, Lewis, Linberg, and Verardo 2005). 
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Photoreceptor OS are disrupted by detachment and in most models 20% die after 3 d, rising to 50% 
with longstanding detachment. In the rabbit retina, all photoreceptors die, as do cells of the inner 
retina (Fisher, Lewis, Linberg, and Verardo 2005).  After retinal detachment in rats, 60% of 
photoreceptors die by apoptosis, the remainder by programmed necrosis dependent on RIP kinases 
(Trichonas et al. 2010).  Caspase 3 and 9 activity are increased by retinal detachment and intrinsic 
pathway inhibition by AAV-transduced X-linked inhibitor of apoptosis (XIAP) over-expression or heat 
shock protein (HSP70) downregulation of the mTOR pathway partially protects photoreceptors after 
detachment.  Extrinsic pathway inhibition by Fas receptor or TNF-α blockade or TNF-α knockout and 
caspase-independant pathway knockdown by apoptosis inducing factor-deficiency also protect 
photoreceptors from detachment-induced apoptosis (Zadro-Lamoureux et al. 2009), (Kayama et al. 
2011), (Besirli, Chinskey, Zheng, and Zacks 2010), (Hisatomi et al. 2008), (Nakazawa et al. 2011), 
(Zacks et al. 2003).  Thus all regulated cell death pathways are implicated, but complete 
photoreceptor protection has not yet been achieved in any study. 
Retinal remodelling is a significant component of the response to detachment.   Photoreceptor OS 
shorten within days (deconstruction) and mitochondria redistribute from the IS to the cell body 
(Fisher, Lewis, Linberg, and Verardo 2005).  Rods show RhoA-dependent retraction of their axons 
from the outer plexiform layer (OPL) but maintain outer segment protein synthesis (Fontainhas and 
Townes-Anderson 2011).  Cone synapses remain in the OPL but, by 7 d after detachment, cone-
specific protein expression is undetectable by immunohistochemistry (Fisher, Lewis, Linberg, and 
Verardo 2005).  Rod bipolar cells remodel leaving fewer dendrites, some innervating retracted rod 
synapses in the outer nuclear layer (Fisher, Lewis, Linberg, and Verardo 2005). 
After retinal detachment, horizontal cells and RGC extend neurites throughout the retina and into 
the subretinal space (Fisher, Lewis, Linberg, and Verardo 2005).  RPE cells proliferate and migrate in 
the subretinal space or onto the inner retinal surface (Fisher, Lewis, Linberg, and Verardo 2005).  
Müller cells proliferate, positively regulated by the mTOR pathway, and upregulate intermediate 
filament proteins, including GFAP, vimentin, nestin and synemin, extend thickened processes and 
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migrate through the retina, into the subretinal space, along the epiretinal surface and (after 
reattachment) into the vitreous to form gliotic scars (Lewis et al. 2010), (Lewis et al. 2009), (Luna et 
al. 2010).  Astrocytes also proliferate and, along with Müller and RPE cells and RGC and horizontal 
cell neurites are found in epiretinal membranes after reattachment (Fisher, Lewis, Linberg, and 
Verardo 2005).  
Retinal function after reattachment is reduced by altered synaptic connectivity, photoreceptor 
apoptosis and imperfect outer segment regeneration (especially cones), and is further impaired by 
subretinal scarring (Fisher, Lewis, Linberg, and Verardo 2005). 
1.4.4.3.2. Phototoxicity 
Light damage is commonly used to induce photoreceptor apoptosis and model retinal degenerative 
diseases and caspases 1, 3, 7, 8, and 9 and calpain have been implicated in light damage models.  In 
some models, caspase 3 inhibition protects against light damage; in others activated caspase 3 is not 
found at all.  DNA fragmentation occurs within hours of exposure and so may to be a direct effect of 
reactive oxygen species created by photopigment bleaching.  Neuronal nitric oxide (NO) synthase 
inhibition reduces photoreceptor apoptosis after phototoxicity (NO has been reported to inhibit 
caspases by S-nitrosylation and to activate caspase 9), though without improving photoreceptor 
function, and NO increases neuronal necrosis in the rat brain (Organisciak and Vaughan 2010). 
In an adult albino zebrafish model of light damage, prior application of CNTF prevents apoptosis of 
photoreceptors through a MAPK/ERK (mitogen activated protein kinase/extracellular signal regulated 
kinase) pathway and stimulates neuronal progenitor cell proliferation through a STAT3 dependent 
pathway (Kassen et al. 2009). 
Faktorovich et al. (1992) studied the effects of intravitreal FGF-2 and PBS injections in albino rats 
subjected to either cyclic light or 1-2 weeks constant light exposure and then observed for up to 10 d, 
which is the turnover time of a rod outer segment in the rat (Faktorovich et al. 1992), (Lim, 
Umapathy, Baharuddin, and Zubaidah 2011).  They found that intravitreal and subretinal FGF-2 and 
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subretinal (though not intravitreal) PBS injections protected photoreceptors from light induced cell 
death and resulted in greater regeneration of photoreceptor IS and OS, suggesting that either injury 
or inflammation induced neurotrophin release. 
The intimate functional and structural relationship between photoreceptors and RPE links death and 
dysfunction of one to death and dysfunction of the other.  The phototoxicity model highlights the 
relationship between the photoreceptors and RPE.  The wavelength of maximal sensitivity to light 
damage in rods corresponds to the peak in the absorption spectrum of rhodopsin.  Retinaldehyde 
(the light sensitive component) is present in both rod rhodopsin and in RPE cells in bis-retinaldehyde-
phophatidylethanolamine (A2E), which is generated in the cycling and regeneration of visual 
pigments through the RPE.  The absorption spectrum of A2E is slightly different from rhodopsin and 
preferentially absorbs higher energy blue light, increasing the likelihood of RPE damage, particularly 
after photoreceptor outer segment damage from a first light exposure with subsequent phagocytosis 
of damaged discs by the RPE and generation of A2E.  In addition, there is a delayed effect with RPE 
damage and apoptosis occurring 5-10 hr after a broad spectrum light injury.  RPE damage is more 
pronounced in rats reared in darkness than cyclic light (which induces greater concentrations of 
rhodopsin in rods).  The mechanism of RPE damage is hypothesised to be oxidative stress on the RPE 
from light damaged rod outer segment discs (Organisciak and Vaughan 2010). 
1.4.4.3.3. Chemotoxicity  
Intraperitoneal N-methyl-N-nitrosourea  induces photoreceptor apoptosis because 7-
methyldeoxyguanosine DNA adducts form in the nuclei of photoreceptors (Ogino et al. 1993).  
Caspase 2, 3, 7, 8 and 9 are described as not active in some reports but active in others, with 
neuroprotective effects demonstrated by caspase 3 inhibitor Ac-DEVD-CHO (Doonan, Donovan, and 
Cotter 2003), (Yoshizawa et al. 1999), (Yoshizawa et al. 2000). 
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1.4.4.3.4. Retinitis Pigmentosa 
Retinitis pigmentosa is an inherited retinal degeneration in which photoreceptors are progressively 
lost.  The Royal College of Surgeons (RCS) rat is a well-known retinitis pigmentosa model, in which 
caspase 1 and 2 staining colocate in a small proportion of TUNEL +ve cells and in which apoptosis, 
(quantified by the proportion of TUNEL +ve cells), is reduced by caspase 1 inhibition (Katai et al. 
1999).   
Calpain inhibition by the highly specific calpastatin peptide (CAST) reduces photoreceptor apoptosis 
in retinal explants and rd1 mice  (another model of retinitis pigmentosa) (Paquet-Durand et al. 2010).    
Conversely, the non-specific calpain inhibitor CX295 decreases cell death over the short term and 
increases cell death over the long term in retinal explants (Paquet-Durand et al. 2010).  Calpain 
activates caspase 9 (intrinsic pathway) and caspase 3 may be the executioner (Sharma and Rohrer 
2004).  However, as caspase 3 inhibition is less effective than calpain inhibition in the 661W cone cell 
line, other pathways may be involved (Sharma and Rohrer 2004). 
1.4.4.3.5. Photoreceptor Death In Vitro 
In the cone photoreceptor cell line 661W, after growth factor deprivation caspase 3, 9 and 12 and m-
calpain are activated and inhibition of caspase and calpain pathways in isolation reduces, but does 
not prevent, apoptosis (Gomez-Vicente, Donovan, and Cotter 2005).   
After apoptosis induction by anti-human FAS ligand and UV irradiation, broad spectrum caspase 
inhibitors DEVD-CHO (inhibits caspase-3, -7, -1 and -4),  zVAD-fmk (inhibits caspases-3, -6, -8, -1, -2 
and -4) and BD-fmk (inhibits all caspases) do not reduce apoptosis as assessed by annexin-V-FITC 
binding to externalised phosphatidylserine, and western blotting shows an absence of activated 
caspase 3 (Carmody and Cotter 2000).  These results have been confirmed in vivo in albino Balb-c 
mice after light injury and N-methyl-N-nitrosourea (MNU) injection and in C3H/HEN  rd mice 
(Doonan, Donovan, and Cotter 2003), (Donovan, Carmody, and Cotter 2001), along with an absence 
of activated caspase 2, 7, 8, 9 and cytochrome C release. 
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1.4.4.4. Retinal Tissue Regeneration and Gliosis 
The adult zebrafish (Danio rerio) regenerates axons and neural tissue.  A peripheral retinal 
population of stem cells at the ciliary margin, known as the circumferential germinal zone, 
continually generates new cells of all retinal layers except rods, which are generated from a separate 
stem cell population in the outer nuclear layer (Otteson and Hitchcock 2003).  The mechanisms of 
RGC and photoreceptor replacement after injury have been extensively studied at the genetic and 
cellular levels in models of trauma such as excision of retina as well as light injury, chemotoxicity, 
heat injury and transgenic models of degeneration (Stenkamp 2007), (Morris, Scholz, and Fadool 
2008), (Becker and Becker 2008).  The Müller cells dedifferentiate to form multi-potent progenitor 
cells that can migrate through the retina to replenish different cell populations including rod and 
cone photoreceptors and RGC (Stenkamp 2007), (Morris, Scholz, and Fadool 2008), (Becker and 
Becker 2008).  In embryonic chick and rat, excised retina regenerates from the RPE and members of 
the FGF family and insulin are important in this process (Park and Hollenberg 1993), (Klassen, 
Sakaguchi, and Young 2004). 
The adult mammalian retina has a low regenerative potential.  After incisional injury to the rat inner 
retinal surface, there is limited RGC axon regeneration in the nerve fibre layer (McConnell and Berry 
1982).  Implanted hippocampus-derived stem cells incorporate into the host retina at the site of 
injury and show evidence of neural and glial differentiation and synapse formation (Nishida et al. 
2000).   
After chemical injury to the mouse and rat retina, a small number of Müller glia migrate through the 
retina and enter the cell cycle, expressing the progenitor cell markers nestin, proliferating cell 
nuclear antigen (PCNA), Pax6, glial fibrillary acidic protein (GFAP) and the glial marker, glutamine 
synthetase (Ooto et al. 2004), (Wan et al. 2008), (Karl et al. 2008).  Pax6 is a transcription factor 
found in embryonic progenitors and is a phenotypic marker for Müller cell-derived progenitor cells in 
zebrafish (Fischer and Bongini 2010), (Bernardos, Barthel, Meyers, and Raymond 2007), (Thummel et 
al. 2008).   
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Dedifferentiation occurs through cyclin D1 and D3 related pathways and is positively regulated by the 
Notch and Wnt (wingless-type MMTV integration site family) 3a/β-catenin protein signalling 
pathways (Wan et al. 2008), (Karl et al. 2008), (Das et al. 2006), (Osakada et al. 2007).  In mice, reelin 
is upregulated in the GCL, INL and ONL after incisional retinal injury and may attract and direct stem 
cells to the injury-site; a similar role is reported in embryonic development (Pulido, Sugaya, 
Comstock, and Sugaya 2007).  N-Methyl-N-nitrosourea induced photoreceptor degeneration 
stimulates glial progenitors to generate photoreceptors. This effect is enhanced by exogenous BDNF 
acting through the TrkB receptor (Wan et al. 2008), (Harada et al. 2011).   
After intravitreal N-methyl-D-aspartate-induced excitotoxicity of the inner retina, Müller cells show 
spontaneous photoreceptor and bipolar cell neogenesis, the latter being enhanced by intravitreal 
retinoic acid and, under the influence of epidermal growth factor (EGF) or FGF-1 combined with 
insulin, generate amacrine cells (Karl et al. 2008), (Ooto et al. 2004).  The proliferation of retinal glial 
progenitor cells may be opposed by transforming growth factor β (TGFβ) (Close, Gumuscu, and Reh 
2005).  There is limited evidence for a similar pattern of proliferation in explants taken from 
cynomolous monkeys (Osakada et al. 2007). 
In a rabbit model, incisional retinal injury without RPE injury stimulates retinal glia to express PCNA, 
send processes into the vitreous and along the inner limiting membrane and form a scar (Miller, 
Miller, Patterson, and Ryan 1986), (Cullinane et al. 2002).  Incisional retinal injury in the rat 
upregulates cell cycle-related transcription factors c-fos and jun-B in the INL and to a lesser extent 
the GCL, within 30 min, probably associated with a reactive Müller gliosis (Ohki et al. 1995), (Yoshida 
et al. 1995).    GFAP is upregulated within 3 d of retinal detachment caused by retinal tearing with a 
needle, associated with growth of glial processes into the subretinal  space and expression of the 
apoptotic genes: Bax, Caspase 3, Ctsl, Litaf, Tnfrsf21, Mx3, Apobec1, Vdac1, A2m and Spinc2 
(Vazquez-Chona, Song, and Geisert, Jr. 2004).  This transcriptional response to injury is generic across 
the CNS (Vazquez-Chona et al. 2005). 
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Thus, after injury, mammalian glia form scars and block regenerating axons, whereas zebrafish glia 
regenerate lost retinal tissue by neurogenesis.  When stimulated by the application of endogenous 
neurotrophins, mammalian glia have a limited potential to regenerate lost tissue in the same manner 
as zebrafish, though not yet to the same extent. 
1.4.4.4.1. RPE Regeneration 
RPE is injured with and without excising the overlying neuroretina (Hayashi et al. 1999), by hydraulic 
RPE debridement, abrasion with a silicone brush and tubing and grasping it with forceps (Table 
1.4.3.2.) (Lopez et al. 1995), (Leonard et al. 1997), (Hayashi et al. 1999), (Del Priore et al. 1995), 
(Valentino et al. 1995).  In primates, pigs, rabbits and cats, in order to induce a model of RPE damage, 
with an intact neuroretina, the RPE  is injured beneath a retinal detachment that is first created by 
subretinal balanced salt solution injection (Del Priore et al. 1995), (Kiilgaard et al. 2007), (Lopez et al. 
1995), (Leonard et al. 1997), (Valentino et al. 1995).  Hydraulic RPE debridement leaves Bruch’s 
membrane intact; however, grasping the RPE with forceps and mechanical debridement with silicone 
tubing results in areas of damage to Bruch’s membrane with concomitant damage to the 
choriocapillaris (Leonard et al. 1997), (Valentino et al. 1995). 
After denudement, RPE cells surrounding the area of bare Bruch’s membrane lose their polygonal 
shape and apical basal polarity, become hypopigmented, flattened, enlarged and fusiform (Heriot 
and Machemer 1992), (Oganesian et al. 1997), migrate to cover the defect and remain 
hypopigmented, even after 9 months (Valentino et al. 1995).  RPE multilayering, with or without 
neuroretinal retinal folds and tubuloacinus formation, has been reported and in some areas the RPE 
is replaced by fibroblast-like cells (Leonard et al. 1997), (Oganesian et al. 1997).  RPE cells proliferate 
after intravitreal FGF-2 injection (Kimizuka, Yamada, and Tamai 1997). 
Raising a retinal detachment shears photoreceptor OS.  The presence of regenerated or autografted 
RPE permits photoreceptor outer segment regeneration (Zhang et al. 2009a), though there is still loss 
of photoreceptor nuclei (Lopez et al. 1995), particularly cones (Del Priore et al. 1995).  Where Bruch’s 
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membrane and choriocapillaris are damaged, the RPE does not resurface the defect and the outer 
retina degenerates (Leonard et al. 1997), (Valentino et al. 1995).  However, the RPE resurfaces an 
intact Bruch’s membrane, whether or not the neuroretina overlies the defect (Hayashi et al. 1999), 
(Ozaki et al. 1997), but only forms a pigmented monolayer when the neuroretina is present (Ozaki et 
al. 1997).  When RPE resurfacing is prevented by subretinal mitomycin C, both the outer retina and 
choriocapillaris degenerate (Del Priore et al. 1996). 
Excision of rabbit retina and RPE (leaving Bruch’s membrane intact) and laser photocoagulation in 
primates stimulates local cellular proliferation, as identified by 3H methylthymidine autoradiography, 
with complete resurfacing of Bruch’s membrane by 4 d (Heriot and Machemer 1992), (Smiddy et al. 
1986), (Ozaki et al. 1997).  In pigs, after isolated RPE removal, there is peripheral RPE proliferation 
identified by 5-bromo-2’-deoxyuridine incorporation, but not proliferation at the lesion site (Kiilgaard 
et al. 2007).  Peripheral RPE cells have a higher proliferative capacity in vitro than central cells and 
proliferation is enhanced by subretinal amniotic membrane grafting (Kiilgaard et al. 2007).  
Peripheral RPE cells also proliferate remote from a laser-induced RPE lesion (von Leithner, Ciurtin, 
and Jeffery 2010).  A small (10-15 cells/eye) peripheral population of dividing RPE cells exists in 
mature pigmented and albino rats, which could function as a pool of peripheral progenitor cells (Al-
Hussaini et al. 2008). 
1.4.5. Comparison of Models 
Experimental models of human diseases are usually best performed in animals whose anatomy most 
closely approaches that of humans for the area of interest.  The choice of species is also based on 
availability and a body of previous work that allows comparison, although the use of cats, dogs, 
primates and equidæ require special justification due to public concern (National Centre for the 
Replacement Refinement and Reduction of Animals in Research ).  The optimal species and models 
for different ocular injuries are summarised in Table 1.4.4. 
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Rabbits have a merangiotic retina, which confounds any comparison with human injuries when blood 
supply and vascular responses of the inner retina may be relevant.  In commotio retinae, the long 
thin rabbit photoreceptor OS may affect their vulnerability to shearing forces.  The structure of the 
rabbit vitreous body is similar to humans and rabbits may be a good model for studies of vitreous. 
Mice and rats have a similar retinal cellular and vascular structure to humans. Their small size, ease 
of husbandry and genetic manipulation and a ready availability of antibodies for molecular studies 
renders them very attractive for models of ocular trauma.  However, the commonly used albino rats 
have marked neuroretinal and functional visual abnormalities, which renders them less suitable for 
studies of RPE, photoreceptors and in vivo functional/behavioural testing than pigmented rats.  The 
rodent eye has a different gross structure to that of humans, with a very large lens, making them less 
suitable for biomechanical trauma studies.  Larger animals such as pigs and primates have ocular 
anatomy comparable to humans and few experimental disadvantages.  Their use is limited by capital 
costs, husbandry and political/ethical objections. 
Closed globe injury is achieved by moderate (20-50m/s) velocity impact, most commonly to sclera 
rather than central cornea.  For such injuries the rabbit is the smallest model reported.  A mouse or 
rat model would be ideal, but has not been reported, thus at present, porcine and primate models 
have precedence.   
Rats and mice are suitable for open globe injury modelling.  A relative advantage of larger animals is 
the ease of surgical access to intraocular structures.  In cases where macular and foveal architecture 
are studied, primate models are the only choice, though, as rodents possess cones distributed 
throughout the retina (rather than concentrated at a fovea), cone responses to injury may be more 
effectively studied in these smaller animals. 
RGC death and axonal regeneration are most commonly studied in murine models.  Optic nerve 
transection causes the most aggressive RGC death; however, optic nerve crush has a greater 
potential for RGC axonal regeneration.  Axonal regeneration is stimulated by a number of surgical 
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manipulations including lens injury, intravitreal peripheral nerve grafting, recruitment of activated 
macrophages by intravitreal zymosan and intravitreal neurotrophic factors.  However, the 
combination of activated macrophages with other stimulatory factors, such as in lens injury and 
intravitreal peripheral nerve grafting, results in the most marked RGC axon regeneration. 
Surgical open globe injuries are most commonly trans-scleral, which causes neurotrophin release and 
has a significant risk of complications such as PVR.  Smaller wounds and an approach through the 
pars plana or even the anterior chamber reduce these problems and allow more precise retinal 
injuries to be created, for example injuring the retina without damaging the RPE.  In models where 
prolonged survival is required, it is important either to avoid vitreous loss, or manage it appropriately 
to reduce the risk of PVR.   
Research area Animal  Model Pros  Cons 
Cell death and 
regeneration in closed 
globe injury 
Pig High velocity (20-
60m/s) contusion 
Similar ocular 
dimensions to 
humans and same 
cellular structure 
and vasculature.  
Capital costs 
and husbandry. 
Axotomy-induced RGC 
death and axonal 
regeneration 
Mouse/Rat Optic nerve crush 
+/- lens injury or 
intravitreal 
peripheral nerve 
grafting  
Availability of 
specific inhibitors, 
antibodies and 
transgenic mice.  
Low capital costs 
and ease of 
husbandry. 
None. 
Neuroretinal cell death 
and regeneration in 
open globe injury 
Mouse/Rat Retinal excision 
through a pars 
plana approach 
Availability of 
specific inhibitors, 
antibodies and 
transgenic mice.  
Low capital costs 
and ease of 
husbandry. 
Technically 
challenging 
surgery in mice. 
RPE repair and 
regeneration 
Rabbit RPE excision 
through a pars 
plana approach, 
under an induced 
retinal 
detachment +/- 
preservation of 
the overlying 
neuroretina 
Similar anatomy of 
the RPE and outer 
retina and ocular 
dimensions to 
humans. 
None. 
Table 1.4.4. – Choice of species and models for ocular trauma research 
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1.5. Assessment of Retinal Function 
A detailed reference text on electrophysiological assessment of retinal function is “Principles and 
Practice of Clinical Electrophysiology of Vision” by Heckenlively and Arden (2nd Ed. MIT Press, 
Cambridge MA, USA. 2006).   
Light hyperpolarises photoreceptors, reducing neurotransmitter release and thus changing the 
polarisation of second order neurons (ON-centre and OFF-centre bipolar cells), ultimately generating 
an action potential in RGC axons in the optic nerve - a process termed visual phototransduction.  The 
electrical activity of the retina is measured as small changes in voltage – the electrical potential 
difference – between the ocular surface and surrounding skin.  In electroretinography, a minimum of 
three electrodes are placed: (1), on the front of the eye; (2), behind the eye and; (3), away from the 
eye.  Voltage is measured between electrodes 1 and 2 and the system grounded to electrode 3.   
Electrode 1 can be placed anywhere from the central cornea to the inferior conjunctival fornix and in 
human studies is usually a thin, low impedance, silver/nylon wire termed a Dawson, Trick, and 
Litzkow (DTL) electrode; other electrodes include gold foils placed in the inferior fornix, gold rings 
held in contact with the cornea and electrodes embedded in contact lenses.  Electrical connection 
with the eye relies on the presence of an ionic fluid to couple the electrode with the cornea.  In 
humans the tear film is usually sufficient; in animal research, where the electrode is placed centrally 
on the exposed cornea, a dilute solution of methylcellulose is usually applied and a contact lens used 
to cover the cornea/DTL fibres, preventing evaporation. The volume of fluid present has a significant 
effect, in that too low a volume does not allow coupling, whereas too high a volume increases 
impedance by grossly increasing the electrode area (so the effective electrode becomes a large pool 
of fluid in contact with the whole ocular surface).  Impedance is a measure of the opposition to 
variable current flow and incorporates both resistance (magnitude of the opposition to the passage 
of electric current) and the phase shift - the extent to which current and voltage differ in timing, due 
for instance to the storage of electrical charge in the system (capacitance). 
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Electrode 2 is usually a skin electrode placed close behind the lateral canthus and may be either skin 
surface, connected by coupling gel, or a needle electrode inserted subdermally.  The relative position 
of electrodes 1 and 2 has a critical effect on the voltage recorded. 
In humans, electrode 3 is usually placed on centre of the forehead and in rodents, at the base of the 
tail. 
1.5.1. The Electroretinogram (ERG) 
A typical rat ERG (shown in Figure 1.5.1) is recorded from three electrodes – as describe above – 
after a short duration flash of light.  The corneal voltage so recorded is a summed response of 
positive and negative component potentials originating from all retinal layers.  However, different 
specific components of the waveform primarily reflect the activity of specific retinal cells. 
 
Figure 1.5.1. Typical rat ERG.  The first negative deflection from baseline is the a-wave (circled).  The 
b-wave amplitude is measured from the base of the a-wave (dotted lines).  After the a-wave, on the 
rising edge of the b-wave, are high frequency, low amplitude, oscillatory potentials (stars), the 
precise cellular origins of which are unclear. 
The first electrical response of the retina to incident light is photoreceptor hyperpolarisation, which 
is reflected as the negative (with respect to the cornea) a-wave.  Approximately the first 70% of the 
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a-wave is generated by photoreceptors and the subsequent 30% by post-receptoral/downstream 
activation (e.g. OFF bipolar cells).  However, the a-wave is usually curtailed by the onset of the 
positive b-wave.  The b-wave is generated by the activity of second order neurons such as ON bipolar 
cells in the inner nuclear layer with a smaller contribution from Müller cells.  The leading edge of the 
a-wave shows low voltage high frequency oscillations termed oscillatory potentials.  These are more 
prominent in the rat (Figure 1.5.1.) than in humans.  They are post-receptoral with the early 
components originating in the inner retina, though their exact retinal origins remain controversial. 
The negative a-wave therefore reflects photoreceptor function and under scotopic (dark-adapted) 
conditions in humans and rats is dominated by rods, whilst under photopic (light-adapted) 
conditions, cones dominate.  The other way in which cone function can be isolated is by a 30Hz 
flicker stimulus, which exceeds the temporal resolution of the rods.  To ensure reproducible 
recordings, the extent of dark or light adaptation must be controlled – for scotopic ERG, rodents 
usually reach maximal dark adaptation in 40 min.   
Photoreceptor function is assessed by measuring a-wave magnitude – baseline to trough – though 
such an assessment may be confounded by the b-wave, since conditions affecting b-wave latency 
may spuriously change a-wave magnitude.  Alternatively, the leading edge of the a-wave may be 
modelled to predict the final amplitude that would be seen were the ERG “electronegative” (lacking a 
post-receptoral response) or, more simply, the gradient of the a-wave’s leading edge may be 
measured.  Similarly, b-wave amplitude measured from the base of the a-wave to the peak of the b-
wave measures mostly ON bipolar cell function, but is dependent on the magnitude of the 
photoreceptor response because: (1), being measured from the base of the a-wave, it incorporates 
this response and; (2), second order bipolar cells only generate electrical potentials in response to 
photoreceptor activity. 
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1.6. Aims and Hypotheses 
1.6.1. Summary Rationale 
Commotio retinae occurs after blast injury in the military or assaults in civilians.  Ocular PBI may or 
may not exist; however, of those cases in which it is suspected clinically, commotio retinae is the 
most common manifestation. 
Ocular trauma is common and retinal injury is the most common cause of post-traumatic loss of 
vision.  Blunt ocular trauma causes commotio retinae, however the prognosis and outcomes are 
poorly defined.  The cell death pathways activated in commotio retinae have not been previously 
studied.  There are no pharmacological interventions currently available in the clinical setting that 
improve outcome after commotio retinae or retinal injury in general.   
In commotio retinae there is damage to photoreceptor OS and some evidence of photoreceptor cell 
death.  In other models of photoreceptor cell death caspase-dependent apoptosis (involving a variety 
of different caspases) and caspase-independent programmed necrosis have been demonstrated.  In 
particular caspase 3 and 7 are the executioner caspases that have thus far been implicated in these 
models (though not consistently). 
1.6.2. Hypotheses 
I.  Commotio retinae is common in deployed British military personnel. 
II. After macular commotio retinae, one third of patients suffer permanent visual impairment. 
III. Permanent visual impairment after commotio retinae is associated with loss of 
photoreceptors. 
IV. Commotio retinae may be modelled experimentally by blunt ocular trauma or PBI to the eye. 
V. Photoreceptor cell death in commotio retinae is by a combination of caspase-dependent 
apoptosis and caspase-independent necrosis. 
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VI. Photoreceptor cell death is prevented by interference with the caspase-dependent cell death 
signalling pathway. 
VII. A reduction in photoreceptor cell death is associated with preservation of the ERG. 
These hypotheses are stated as valid at commencement of the PhD; the work of Souza-Santos et al. 
(2012) has added evidence to support hypothesis III. 
1.6.3. Aims 
I. Identify the extent to which commotio retinae affects deployed British military personnel. 
II. Characterise visual outcomes after commotio retinae in humans. 
III. Identify patients with visual loss after commotio retinae and define the cause.  
IV. Develop an experimental model of commotio retinae. 
V. Characterise the ultrastructural features of the model. 
VI. Characterise the electroretinographic features of the model. 
VII. Characterise the cell death signalling pathways in the model. 
VIII. Evaluate translational neuroprotective therapies in the model. 
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2. Materials and Methods 
2.1. Development of a Rat Ocular Trauma Model 
2.1.1. Animals  
All animal studies were conducted in accordance with Home Office guidelines adhering to the UK 
Animals (Scientific Procedures) Act 1986 and were licensed by the Home Office.  Rats strains used 
were Wistar, Sprague Dawley and Lister hooded (Charles River, Margate, UK).  All rats were female 
and kept on a 12 hr light dark cycle with a day time luminance of 80 lux and fed and watered ad 
libitum.  Unless otherwise stated, rats weighed 170-200g at commencement of each experiment.  
Rats were weighed, anaesthetised and placed in a head holder (Figure 6.4.1.) for surgery. 
2.1.2. Anaesthesia 
For terminal and some recovery ERG experiments, anaesthesia was induced by intraperitoneal 
injection of ketamine/medetomidine combination at a dose 0.06mg medetomidine + 14.4mg 
ketamine for a 200mg rat.  Oxygen supplementation was given during ERG recording.  Animals were 
killed by perfusion with fixative under terminal anaesthesia. 
Unless otherwise stated, in recovery experiments, the anaesthetic was an inhalational 
isofluorane/oxygen combination titrated to achieve appropriate plane of anaesthesia.  The default 
concentrations of isofluorane in oxygen were 5% into a sealed box for induction of anaesthesia, 2% 
for ERG recording, 2.5-3% for surgery at a flow rate of 1l delivered through a small tube over the 
nose and mouth with a separate scavenging tube to remove waste anaesthetic gases. 
Schedule 1 killing by overdose of anaesthetic used intraperitoneal pentobarbital after gaseous 
induction with isofluorane. 
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2.1.3. Surgery 
For improved access to the eye, a lateral canthotomy was performed.  The skin and ocular surface 
were prepared with 5% povidone iodine in water, without shaving the incision site.  The lateral 
canthus was divided using scissors to a depth of approximately 5mm.  For access to the lateral sclera, 
a 6.0 vicryl suture was placed in a horizontally orientated subcuticular mattress configuration (Figure 
2.1.3.) and used to retract the wound edges whilst the eye was injured and then tied at the end to 
close the wound.  For access to the inferior sclera, a temporary traction suture was placed in the 
lower lid.  A limbal traction suture was used to rotate the eye. 
Figure 2.1.3. A representative diagram of a left lateral canthotomy.  The suture is shown in blue with 
a dotted lining indicating that it is subcuticular.  Black dotted lines indicate cut skin edges. 
 
 
 
 
 
 
2.1.4. Electroretinography 
2.1.4.1. Recording 
ERG were recorded using a standard system specifically designed for small animals incorporating a 
mini-Ganzfeld stimultor (HMsERG – Ocuscience, Kansas City, MO USA) and interpreted using 
ERGView (Ocuscience).  Animals were dark-adapted overnight and prepared for ERG under dim red 
light (>630nm) before recording scotopic flash ERG.  Photopic flash ERG were recorded with 
background illumination of 30,000mcd/m2 during and for 10 min before recording.  To dark-adapt, 
Palpebral 
aperture Cornea 
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the animals were placed in a cage covered with a combination of volatile organic compound-free 
black paint (Artifolk, Portsmouth, UK) and Rosco supergel medium red filter (blocks <630nm; 
Enlightened Lighting Ltd, Bath, UK).  The electrodes used for recording were DTL fibre (Unimed 
Electrode Supplies, Farnham, UK) corneal electrodes connected to a DTL mini-grabber (Unimed) 
covered by pressure-moulded Aclar (Agar scientific, Stansted, UK) contact lenses and coupled by 
0.3% hydroxypropylmethylcellulose eye drops (Tesco, Cheshunt, UK).  The DTL grabber was 
positioned at the lateral canthus and the thread placed across the centre of the cornea before being 
trimmed to only that length in contact with the eye, and then the contact lens, moistened with 
hydroxypropylmethylcellulose was applied over the top.  Subcutaneous needle electrodes (Unimed) 
were used for reference – inserted anteriorly at the base of the pinna towards the eye – and ground 
– inserted anteriorly at the midline dorsal aspect of the base of the tail. 
2.1.4.2. Analysis 
To assess retinal function, the major components of the ERG (a- and b-waves) were observed, 
quantified and compared between injured and control eyes.  ERG interpretation and quantification 
used ERGView (Ocuscience) software. 
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2.2. Processing of Tissues 
2.2.1. Protocols 
2.2.1.1. Reagents 
Unless otherwise stated, chemical and reagents came from Sigma (Poole, UK ) 
Reagent Target/Purpose Species Supplier 
(location) 
Catalogue 
No. 
Batch 
No. 
Dilution Used 
Phosphate 
buffered 
saline (PBS)  
Diluent n/a Scientific 
Laboratory 
Supplies 
(Nottingham, UK) 
BR014G Multiple 1 tab/100ml 
dH2O 
Mountant Fluorescent mounting 
medium with DAPI 
n/a Vector 
Laboratories 
(Peterborough, 
UK) 
H-1200 Multiple n/a 
VectaMount permanent 
mounting medium 
n/a Vector H-5000 Multiple n/a 
1y 
Antibodies 
 
Activated caspase 2 
(P35) 
Rabbit Abcam 
(Cambridge, UK) 
AB2251-
100 
10873 1/100 for IHC 
Activated caspase 3 
(P17/P19) 
Rabbit Cell Signalling 
(New England 
Biolabs, Hitchin, 
UK) 
9661S 18 1/100 for IHC 
1/1000 for 
western blotting 
Activated caspase 6 
(P18) 
Rabbit Cell Signalling 9761s Lot 1 1/100 for IHC 
1/1000 for 
western blotting 
Activated caspase 6 
(P10) 
Goat Santa Cruz sc-22177  1/50 for IHC 
Activated caspase 7 
(p20) 
Rabbit Cell Signalling 9491S Not 
known 
1/100 for IHC 
1/1000 for 
western blotting 
Caspase 8 (P20) Rabbit Santa Cruz (Santa 
Cruz, CA, USA) 
sc-7890 B1203 1/100 for IHC 
1/500 for 
western blotting 
Caspase 9 (P35) Rabbit Santa Cruz Sc-8355 G2203 1/100 for IHC 
Caspase 9  Rabbit Cell Signalling 9507S  1/1000 for 
western blotting 
ED1 (CD68) Mouse ABD Serotec 
(Kidlington, UK) 
MCA341G
A 
 1/200 for IHC 
OX42 (CD11b) Mouse ABD Serotec MCA275B  1/200 for IHC 
RIP3 Rabbit Abcam Ab56164  1/200 for IHC 
Phospho-Akt Rabbit Cell Signalling 9271s Lot 12 1/200 for IHC (in 
ADB made with 
TBS) 
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Phospho-MToR Rabbit Cell Signalling 5536s Lot 1 1/200 for IHC (in 
ABD made with 
TBS) 
Alexa fluor 488 
(495/519nm) anti-rabbit 
IgG 
Goat Invitrogen 
(Paisley, UK) 
A11034 461250 1/400 for IHC 
2y 
Antibodies 
Texas red  (595/615nm) 
anti-mouse IgG 
Mouse Invitrogen T6390 Not 
known 
1/400 for IHC 
FragEL™ DNA 
Fragmentation Detection 
Kit, Fluorescent - TdT 
Enzyme containing:  
Proteinase K 
5X TdT equilibration 
buffer 
Fluorescein-FragEL™ 
labeling reaction mix  
TdT enzyme 
n/a Merck (Feltham, 
UK) 
QIA39 D000943
41 
1/20 enzyme/ 
reaction mix 
TUNEL DNAase 1  (Vial 3 in the 
“Papain Dissociation 
System”) 
n/a Worthington 
Biochemical 
(Lakewood, NJ, 
USA) 
LK003150 Not 
known 
Add 0.5ml to give 
1µg/µl 
Gluteraldehyde – 25% 
EM grade 
n/a Taab 
(Aldermaston, 
UK) 
G003 Multiple 4/25 to give 4% 
in 0.1M PB 
Electron 
Microscopy 
Osmium tetroxide – 4% n/a Electron 
Microscopy 
Sciences 
(Hatfield, PA, 
USA) 
19150 0901522 1/4 in 0.1M PB 
Durcopan ACM 
Embedding Kit 
n/a Electron 
Microscopy 
Sciences 
14040 1348248 
3260713
3 
10g of “ A” 
10g of “B” 
0.3g of “C” 
0.3g of “D” 
Uranyl Acetate n/a Unknown Unknown Unknow
n 
1% in 70% 
ethanol 
Polyvinyl formal n/a Unknown Unknown Unknow
n 
0.5% in 
chloroform 
Protease inhibitor 
cocktail 
n/a Sigma P8340  5µl/ml 
Western 
Blotting 
2x Laemmli buffer n/a Sigma S3401  Various 
Protogel n/a Geneflow 
(Lichfield, UK) 
A2-0072  Various 
NNN´N´-
Tetramethylethylenedia
mine (TEMED) Electran 
n/a VWR 
(Lutterworth, UK) 
443083G  Various 
Sodium Dodecyl 
Sulphate (SDS) 20% Soln  
n/a Fisher Scientific 
(Loughborough, 
UK) 
BP1311  Various 
Ammonium persulphate n/a Sigma A3678  Various 
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(APS) 
Protein assay 
components A, B and S 
n/a Bio-Rad (Hemel 
Hempstead, UK) 
A 500-
0113 
B 500-
0114 
S 500-0115 
 A* = 600µl of A + 
12µl of S 
bVAD-fmk n/a MP Biomedicals 
(Solon, OH, USA) 
FK-014 VM154 Dissolve 1mg in 
149μl DMSO to 
give 10mM 
Streptavidin coated 
Dynabeads - MyOne T1  
n/a Invitrogen 65601 1126902
60 
 
ECL Western Blotting 
Detection Reagents 
n/a GE Life Sciences 
(Little Chalfont, 
UK) 
RPN2109  1.5ml soln. 1 
mixed with 1.5ml 
soln. 2 
Protease Inhibitor 
Cocktail 
n/a Sigma P8340  1/200 
ELISA Progesterone Human 
ELISA Kit 
Rabbit Abcam ab108670   
 
0.1M Phosphate buffer (PB)1 was made by adding 7.84g Na2HPO4 and 5.38g NaH2PO4 to 1l dH2O and 
titrating to pH 7.3 using HCl or NaOH.  Reynolds lead citrate was made by boiling 100ml of dH2O, 
letting it cool in an airtight container (to remove carbonate), then adding 1.33g lead nitrate and 1.76g 
sodium citrate to 30ml of this degased water.  Tris buffered saline (TBS)2 at a concentration of 20mM 
                                                            
1 Phosphate buffer is subject to the following dissociation reactions: 
1) H3PO4  H+ + H2PO4- pKa 2.12 
2) H2PO4-  H+ + HPO42- pKa 6.8 to 7.2 dependant on ionic strength of solution – “true” pKa is 7.21 
3) HPO22-  H+ + PO43- pKa 12.32 
Monobasic and disbasic sodium phosphate dissociate as follows: Na2HPO4  2Na+ + HPO42- 
NaH2PO4  Na+ + H2PO4- 
At physiological pH H2PO4
- and HPO4
2- are the main ionic components (the first and third equations are pushed 
to the right and left respectively). [HPO4
2-] is determined by Na2HPO4 and [H2PO4
-] by NaH2PO4. 
According to the Henderson-Hasselbalch equation: 
pH = pKa + log ([base]/[acid]) 
7.3 = 7.21 + log([Na2HPO4]/[NaH2PO4]) 
[Na2HPO4]/[NaH2PO4] = 1.23 
For 0.1M solution 0.1 = [Na2HPO4] + [NaH2PO4] 
This solves to give: 
[Na2HPO4] = 0.0552M 
[NaH2PO4] = 0.0448M 
Molecular weight of Na2HPO4 is 141.958/M so 7.84g are required 
Molecular weight of NaH2PO4 is 119.976g g/M so 5.38g are required 
2 Tris base -  tris(hydroxymethyl)aminomethane,  
Tris HCl - (HOCH2)3CNH2.HCl 
Molecular weight 121.14 g/mol without HCl, 157.6 with HCl, pKa of 8.06 
For 20mM pH = 7.6 
[tris acid] = 14.8mM or 2.33g 
[tris base] = 5.2mM or 0.630g 
NaCl molecular weight 58.44g 
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tris, 140mM NaCl, pH 7.6 was made by adding 0.63g tris base, 2.33g tris HCl and 8.18g NaCl to 1l 
dH20 and titrating to pH 7.6.  Tris-buffered saline with Tween (10mM tris, 150mM NaCl, 0.05% 
Tween; TBST) was made by adding 0.218g of tris base, 1.29g of tris HCl, 8.77g NaCl and 500μl Tween 
20 to 1l of MilliQ water and adjusting to pH 7.4.  Tris 1.5M pH 8.8 was made by adding 36.2g of tris 
HCl and 154g tris base to 1l of MilliQ water.  Tris 0.5M pH 6.8 was made by adding 74.7g of tris HCl 
and 3.16g of tris base to 1l MilliQ water.  Western blotting lysis buffer was made by adding 1.12g KCl, 
1.19g HEPES and 0.1g CHAPS to 100ml MilliQ water and adjusting the pH to 7.4 (150mM KCl, 50mM 
HEPES, 0.1% CHAPS).  MgSO4 at 100mM in TBS (diluted at 1/100 to get 1mM) was made by adding 
1.20g MgSO4 to 100ml TBS. Antibody diluting buffer (ADB) was made by adding 0.2g bovine serum 
albumin (BSA)  and 10µl Triton X-100 to 10ml 1x PBS.  To make 1% osmium tetroxide, 2ml 4% OsO4, 
2ml 0.2M PB and 2ml dH2O were mixed.  Western blot running buffer was made by mixing 3.03g tris 
base, 14.4g glycine and 5ml 20% SDS with 1l of milliQ water.  Western blotting transfer buffer was 
made by mixing 3.03g tris base, 14.4g glycine, 1ml 20% SDS and 200ml methanol with 1l milliQ water.  
Western blot stripping buffer was made by adding 7.5g of glycine to 1l of milliQ water and then 
adjusting to pH 2.9. 
2.2.1.2. Electron Microscopy 
2.2.1.2.1. Embedding  
After perfusion with 4% gluteraldehyde, the eyes were removed and the cornea penetrated before 
leaving them in fixative for at least 24 hr.  A section of lesioned retina and underlying sclera 
measuring less than 2x2mm was dissected out by first removing the cornea, iris and then lens under 
a dissecting microscope and then cutting the fixed retina with Vannas scissors.  Equivalent sections 
were combined for processing to save time and reagents.  The sections were washed in 0.1M PB for 
at least 30 min and then fixed in 1% osmium tetroxide buffered in 0.1M PB for 45 min.  The osmium 
tetroxide was washed off with 3 x 10 min washes in 0.1M PB and the specimens were dehydrated in 
solutions with ascending concentrations of 50%, 70%, 90%, 100% and 100% ethanol with dH2O for 10 
min each.  After 50% ethanol, the specimens were stained in 1% uranyl acetate in 70% ethanol for 45 
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min. After dehydration the absolute ethanol was replaced with propylene oxide by 2 x 10 min 
washes.  The dehydrated specimens were transferred to resin (Durcopan) and left to infiltrate for 24 
hr.  The specimens were set in resin blocks with tissue orientated to give a section perpendicular to 
the retinal surface.  The tissue was supported with fragments of pre-polymerised resin as necessary 
and then polymerised in a 56°C oven for >24 hr. 
2.2.1.2.2. Sectioning 
Glass knives were made using an LKB (Stockholm, Sweden) type 7801A knife-maker.  A drop of 
distilled water placed on the scored glass extended the cutting edge (Slabe, Rasmussen, and Tandler 
1990).  Excess resin was trimmed from the block with a jeweller’s saw and razor blades.  Semithin 
sections were cut at 1µm using glass knives on a Reichert-Jung “ultracut” ultramicrotome (Reichert-
Jung, Vienna, Austria), stained with toludine blue and used to locate the area to be cut for electron 
microscopy.  The blocks were trimmed down with razor blades to square sections 0.5x0.5mm.  
Ultrathin gold sections (70-90nm) were cut with a glass or diamond knife, floated in distilled water 
and mounted on formvar-coated 50 mesh copper grids (Agar Scientfic, Stansted, UK). 
2.2.1.2.3. Staining 
After immersion in 30% uranyl acetate in ethanol for 7 min, sections were washed x3 in dH2O and 
then stained in Reynold’s lead citrate for 7 min and washed x1 in 50mM NaOH and x2 in dH2O. 
2.2.1.2.4. Microscopy 
Ultrathin sections were examined on a Jeol 1200EX (JEOL [UK] Ltd., Welwyn Garden City, UK) 
transmission electron microscope fitted with a LaB6 filament  at an operating voltage of 80 keV. 
2.2.1.3. Cryosections 
2.2.1.3.1. Embedding  
After perfusion fixation, the eyes were enucleated, penetrated through the cornea, post-fixed in 4% 
paraformaldehyde for at least 24 hr and cryoprotected by immersion in 10%, 20% and 30% sucrose in 
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PBS for 24 hr each.  The cornea, iris, lens and vitreous were removed and a strip cut from the 
remaining retinal/scleral cup spanning ciliary body to ciliary body through the optic disc and 
encompassing the lesion site (approximately 4mm wide), placed on its side in a block of OCT and 
frozen to -80°C for storage.  This process ensured: (1) cutting of only sections that included lesioned 
retinal tissue and; (2), the retina was embedded in direct contact with OCT. 
2.2.1.3.2. Sectioning  
OCT blocks were fixed in a cryostat (Bright instruments, Huntingdon,UK) and sections cut at 15µm 
and mounted onto SuperfrostTM (Fisher) coated glass microscope slides.  The slides were dried 
overnight at 37°C and then frozen to -80°C for storage. 
2.2.1.4. Retinal Whole Mounts 
Animals were killed by overdose of anaesthetic.  The eyes were enucleated and the cornea, iris and 
lens removed before 15-60 min immersion fixation in 4% paraformaldehyde.  Retinae were 
separated from the sclera by cutting through the optic disc, placed onto Superfrost slides and cut 
into 4 leaves joined at the optic disc before 5 min drying and mounting with DAPI mountant. 
2.2.1.5. Western Blotting 
Animals were killed by overdose of anaesthetic.  The eyes were enucleated and the cornea, iris, lens 
and vitreous removed.  Retinae were separated from the sclera by cutting through the optic disc, 
placed in cryotubes and snap frozen in liquid nitrogen for later processing. 
Retinae from each injury/treatment group were pooled and homogenised on ice at 1000rpm rising to 
3000rpm over 2 min in 200µl western blotting lysis buffer supplemented with 5μl protease inhibitor 
cocktail per 1ml for every 6 retinae.  The homogenate was stood on ice for 30 min and then 
centrifuged at 13,000g at 4°C for 10 min.  The supernatant was collected, aliquoted and frozen at -
80°C for later analysis. 
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For Western blotting, protein solution was mixed with an equal volume of 2x Laemmli buffer heated 
to 90°C for 5 min and loaded onto the gel. 
To make an 8% resolving gel, a combination of 1.83ml Protogel, 1.65ml 1.5M Tris pH 8.8, 3.12ml 
MilliQ water, 66µl 10% SDS, 23.1µl 10% APS and 9.9µl TEMED (added last) was pipetted into a 1mm 
cassette, topped with ethanol to remove air bubbles and left to set for 15 min.  To make a 12% 
resolving gel, a combination of 3.592ml Protogel and 1.358ml MilliQ water was mixed with the other 
ingredients. Stacking gel is a combination of 0.4ml Protogel, 1.85ml 0.5M Tris pH 6.8, 0.75ml MilliQ 
water, 30µl 10% SDS, 15µl 10% APS and 7.5µl TEMED (added last) pipetted on top of the resolving gel 
with a 10 or 12 well comb inserted and left to set for 15 min. 
The gel was placed in a XCell SureLock blot module (Invitrogen) with running buffer and samples 
were loaded in wells to give a total protein of 80µg/lane with 3 lanes per treatment group.  Gels 
were run for 2 hr at the default settings on the PowerEase 500 power supply (Invitrogen; 125V, 
35mA) or until the blue marker in the buffer and/or the ladder neared the bottom. 
To blot, the gel was removed, washed in transfer buffer for 15 min and placed under a Immobilon 
polyvinylidene difluoride membrane that had been activated in pure methanol for 1 min, washed in 
transfer buffer and run at the default settings on the power pack (25V, 125mA) for 2 hr in the 
Western blot module in transfer buffer. 
After blotting, the membrane was washed x3 in TBST for 10 min each and then blocked in 5% dried 
skimmed milk (Marvel) in TBST for 1 hr at room temperature (RT).  Primary antibody in 5% 
Marvel/TBST was applied overnight at 4°C.  The membrane was washed x3 in TBST, secondary 
antibody in 5% Marvel/TBST was applied for 1 hr at RT and then washed off as before.  The 
membrane was immersed in ECL solution for 1 min and either exposed to photographic film or read 
on a digital imaging system (ChemiDocTM MP System, Bio-Rad, Hemel Hempstead, UK).  Membranes 
were stored in TBST at 4°C. 
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2.2.1.5.1. Protein Assay 
To measure the concentration of protein in the lysate, stock solutions of 2mg/ml, 1.5mg/ml, 1mg/ml 
and 0.5mg/ml BSA were prepared along with serial dilutions (1 in 5, 1 in 8, 1 in 10, 1 in 20 and 1 in 
100) of the lysate in western blotting lysis buffer in quantities of  at least 6µl.  A 5µl quantity of each 
sample was placed in a 96 well plate with 20µl of A* and 160µl of reagent B from the Bio-rad protein 
assay. 
Plates were then kept in the dark for 20 min and read on a Victor X3 spectrophotometer (Perkin 
Elmer, Waltham, MA USA) at 750nm. 
2.2.1.5.2. Caspase Pull-down Assay 
To capture active caspases, 5μl of 1mM bVAD-fmk dissolved in 10% DMSO in PBS was injected 
intravitreally to both eyes of 3 animals.  Retinae were removed as for Western blotting and 
homogenised on ice in CHAPS buffer (150mM KCl, 50mM HEPES, 0.1% CHAPS pH 8.5) supplemented 
with protease inhibitor cocktail.  Samples were incubated on ice for 10 min, then centrifuged at 
13,000g for 10 min and the supernatant collected.  PBS/0.1% Tween-20 at pH 8.5 was used to wash 
2mg of streptavidin-coated Dynabeads x3, which were combined with 200μl of the PBS/Tween and 
the supernatant (except for 20μl, which was retained - retain 1).  The beads and protein were gently 
rotated overnight at 4°C.  The beads were washed x4 in PBS/Tween and the supernatant retained 
(retain 2).  After washing, the beads were mixed with 60μl of 2x Laemmli buffer and incubated at 
90°C for 5 min.  The Laemmli buffer was removed and loaded onto a 12% gel (20μl per lane) and run 
as a Western blot.   
A solution of 10% DMSO in PBS was used as a vehicle because 100% was found to be retinotoxic – 
causing visibly oedematous and friable retina 24 hr after injection.  Streptavidin-coated Dynabeads 
bind 400pM of peptide-bound biotin/mg of beads and 800pM (from the 2mg beads used) of biotin-
bound bVAD is equivalent to 133pM/eye in the study (6 eyes of 3 animals contribute to the 
supernatant).  A solution of 5μl of 1mM bVAD-fmk is 5000pM – i.e. 37.6x more biotin was injected 
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per eye than could be captured by the beads.   PBS/Tween at pH 8.5 and 150mM KCL was used, as 
high pH and salt concentrations increase the specificity of the streptavidin-biotin interaction. 
Although there is no published data on the speed at which bVAD-fmk penetrates to the ONL after 
intravitreal injection, it is likely to take several hours.  The caspase-bVAD-fmk complexes are rapidly 
cleared and 5 hr after they are formed is the latest time point at which they can be easily detected 
(personal communication – Carol Troy, Columbia University, NY, USA).  Therefore, for pull-down 
assay of initiator caspases, injection of bVAD-fmk was at 2 hr pre-injury and animals were killed at 5 
hr post-injury.  
2.2.1.6. Staining for Light Microscopy 
2.2.1.6.1. Toludine Blue 
Semithin resin-embedded sections were covered with Toludine blue stain and heated over a naked 
flame until vapour was seen to rise.  The stain was washed off in dH2O and the sections were left to 
dry. 
2.2.1.6.2. H&E 
Cryosections were rehydrated in dH2O for 10-20 s, covered with Mayer’s haematoxylin for 30 sec, 
washed in dH2O, covered with eosin for 20 sec and washed in dH2O before mounting using hard set 
mounting medium. 
Semithin resin-embedded sections were either: (1), covered with Mayer’s haematoxlin and heated 
on a 150°C surface until the stain boiled, washed in dH2O and the process repeated with Eosin or; (2), 
de-plasticised in a saturated solution of NaOH in absolute ethanol for 5 min, washed x2 in absolute 
ethanol, rehydrated in 90%, 70% and 50% ethanol and then PBS for 5 min each and stained in the 
same way as cryosections. 
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2.2.1.6.3. Immunohistochemistry 
The initial protocol was as follows: Frozen sections were left to thaw/dry for 30 min at RT and then 
fixed in absolute ethanol for 1 min, washed x2 in PBS for 5 min each, encircled with a hydrophobic 
marker, permiabilised in 0.1% Triton X-100 in PBS for 20 min at RT, washed x2 in PBS for 5 min each 
and then left to block in ADB, containing 0.5% BSA and 0.5% Tween-20 in PBS, for 30 min at RT.  
Blocking buffer was removed and primary antibody in ADB added and left overnight at 4°C in a 
humidified chamber.  Slides were washed x3 in PBS for 5 min each and secondary antibody in ADB 
added and left to incubate for 1 hr at RT.  Slides were washed x3 in PBS for 5 min each and then 
mounted in DAPI mounting medium and stored at 4°C in the dark. 
The initial protocol was found to give unacceptably high levels of background staining and so was 
modified as follows: after drying for 30 min and encircling with a hydrophobic marker, sections were 
rehydrated in PBS for 5 min followed by 0.1% Triton-X in PBS for 15 min, blocking in the modified 
ADB described in Section 2.2.1.1. with the addition of 15% relevant normal serum (to match the 
secondary source animal, usually goat).  Primary antibody in ADB was added and left overnight at 4°C 
in a humidified chamber.  Slides were washed x2 in 0.1% Triton X-100 in PBS and x1 in PBS for 5 min 
each and incubated for 1 hr at RT with secondary antibody in ADB  with the addition of 1.5% relevant 
normal serum.  Slides were washed x2 in 0.1% Triton X-100 in PBS for 5 min each, then PBS for 5 min 
and then mounted as before. 
2.2.1.6.4. TUNEL 
The FragEL™ DNA Fragmentation Detection Kit, Fluorescent - TdT Enzyme was used.  Reagents were 
kept on ice on the bench during use, except for the TdT enzyme, which was  kept at -20°C.  
Specimens were encircled with a hydrophobic slide marker and then immersed in TBS for 5 min at 
RT.  Specimens were permeabilised in 0.1% Triton X in PBS for 15 min and then washed x2 in TBS for 
5 min each.  The recommended permeabilisation step involving proteinase K was omitted because it 
was found to result in, (1), digestion of the specimen, which often fell off the slide, even when this 
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step was reduced to 2 min and, (2), a high rate of false TUNEL positive in control tissue.  A 100µl 
solution of 1x equilibration buffer (5x TdT Equilibration Buffer diluted 1:5 with dH2O) was added to 
the specimen and left for 10 min then replaced with 57µl Fluorescein-FragEL™ TdT Labeling Reaction 
Mix mixed with 3 µl of the TdT Enzyme before covering in Parafilm and incubating for 1.5 hr at 37°C 
in a humidified chamber.  The reaction was terminated by 3x 1 min washes in TBS and the sections 
were mounted on slides in DAPI mounting medium and stored at 4°C in the dark. 
To generate a positive control, 1µg/µl of DNAase 1 in 1mM MgSO4 in TBS was added and the slides 
incubated for 20 min at RT before the equilibration step. 
2.3. Statistics 
2.3.1. Theory 
In general, data that are normally distributed can be analysed with parametric statistical tests, data 
that are not normally distributed or lack an underlying numeric structure (e.g. ordinal data) should be 
analysed with non-parametric tests.  For relatively straightforward statistical analyses such as 
comparing means, this is a simple distinction; with 2 normal independent series of measurements, a 
Student’s t-test can be used and with 2 ordinal or heavily skewed independent series, a Mann 
Whitney U test can be used. 
Many of the analyses reported in this text are on repeated measures with multiple possible factors 
influencing the dependent variable and under these circumstances; more complex statistical 
modelling techniques are required.  Analysis of variance (ANOVA) uses linear regression to predict 
one (dependent) variable on the basis of one or more predictor variables and tests the null 
hypothesis that there is no difference in the distribution of the dependent variable in groups 
clustered by the predictors.  It assumes that the scores for each condition (one state of a predictor 
variable e.g. stimulus intensity = 300mcd/m2 in an ERG data series) are normally distributed about 
the mean for that condition and (for standard ANOVA) that the variances are the same for each 
condition.  The main weakness of ANOVA from the point of view of this text is that subjects with 
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missing data are excluded, so, in a repeated measures ANOVA used to analyse multiple ERG data 
points (with, e.g. 64 observations per rat – 2 eyes, 2 time points, 16 stimulus intensities), a single 
missing observation would mean exclusion of all of that subject’s data. Generalised estimating 
equations are used to estimate the parameters of a generalised linear model, which is a more flexible 
version of ordinary linear regression and makes fewer assumptions about the variance and normality 
of the response variables.  Generalised estimating equations incorporate datasets with missing data.  
The main choices to make when specifying the statistical model used are: (1), the choice of 
correlation matrix; (2), the choice of probability distribution; and, (3), the link function. The 
correlation matrix choice is between: (1), independent – assumes no correlation between clustered 
responses, e.g. if the a-wave at one stimulus intensity is of lower magnitude than the average, this 
does not affect the likelihood of other a-waves in the same subject being below average; (2), 
exchangeable – assumes any two responses within a cluster have the same correlation (ANOVA 
makes this assumption), e.g. a-waves at 300 and 3000mcd/m2 have the same correlation as a-waves 
at 30 and 10,000mcd/m2; (3), autoregressive (AR1) – assumes that the correlation between points is 
raised to a power corresponding to their separation (i.e. the correlation between adjacent 
measurements is R, measurements separated by 1 R2, by 2 R3 and so on), e.g. in a scotopic ERG series 
with stimulus intensity increasing in half log unit steps, if the correlation between a-waves at 300 and 
1000mcd/m2 is R, then the correlation between a-waves at 300 and 3000mcd/m2 is R2; (4), 
unstructured – makes no assumptions about the correlations; (5), M-dependant – which is a mixture 
of unstructured and independent with the cut-off between the two at a pre-specified degree of 
separation.  The probability distribution that provides the best fit for the data may be specified as 
normal or gamma for numeric data.  The link function may be linear or logistic depending on whether 
the factors directly predict the dependent variable or whether the response is logarithmic.    
2.3.2. Analyses 
All statistical analyses were performed in SPSS (v16-v21; IBM, Armonk, NY USA).  The analyses used 
are specified in the relevant results sections.  Where general (ANOVA) and generalised (generalised 
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estimating equations) linear models were used, model fit was assessed by plotting raw and 
standardised (Pearson) residuals and using the standard goodness of fit tests within SPSS.  For 
generalised estimating equations, a model using an autoregressive correlation matrix and the gamma 
distribution with log link function provided the best fit for both ERG and cell count data.  Models 
were initially specified to include all possible factors and factorial interactions and analysis was 
performed iteratively, removing non-significant interactions from the model one at a time, starting 
with the highest order. 
Power calculations were performed in G*power (v. 3.1.4, Kiel University, Germany) and power 
calculations for ANOVA were taken to approximate the result that would be obtained were a 
simulation run to calculate the true power of the intended analysis with generalised estimating 
equations. 
  
 
 
67 
 
3. Retrospective Study of Ocular Trauma in Deployed British Forces 
The work in this section has been published in Eye (Blanch, Bindra, Jacks, and Scott 2011), the full 
paper is presented in Appendix 3.  The relevant sections are reproduced here. 
3.1.  Background 
The patterns of ocular injury and visual outcomes have not previously been described for British 
military personnel deployed in Iraq and Afghanistan.  This information is important for the planning 
of ophthalmic care to and ophthalmic research within the British Armed Forces. 
3.2. Hypotheses 
I. Visual outcomes from British military injuries conform to standard civilian ocular trauma 
score (OTS) predictions. 
II. Blast is the major cause of injury in deployed British military personnel. 
III. Retinal injury is the main cause of visual loss in deployed British military personnel. 
IV. Commotio retinae is a major cause of morbidity in deployed British military personnel. 
3.3. Aims 
I. To present injury and outcome data on all ocular trauma occurring in British armed forces in 
Iraq and Afghanistan between 19 Jul ’04 and 2 May ’08.   
II. To validate the dataset by relating OTS to visual outcomes and by comparing outcomes with 
previous reports. 
III. To identify the main causes of visual loss in deployed British military personnel. 
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3.4. Materials and Methods 
This study was registered as an audit with University Hospitals Birmingham NHS Trust and was a 
retrospective, non-comparative interventional case series. 
The study included all cases of ocular trauma occurring in British military personnel who survived 
injuries (ocular or otherwise) severe enough to merit admission to hospital on return to the UK 
between 19 Jul 04 to 2 May 08.  Cases were identified using the UK Joint Theatre Trauma Registry 
(JTTR) held in RCDM.  In addition, cases that were not included in that database were identified by 
searching clinic letters for the keywords, “Iraq,” “Afghanistan,” “TELIC,” “HERRICK,” and, “Blast.”  
Patients who were treated in theatre by non-ophthalmologists and returned to duty were not 
included. 
Data was extracted from the patients’ paper medical records and recorded on a Microsoft Excel 
spreadsheet for analysis.  Where available, data were collected on: demography, time and place of 
injury, actions at time of injury, personal protective equipment, all ocular and other injuries 
sustained with initial examination findings, initial, best and final VA, all operative interventions, 
medical interventions relevant to ocular management (ocular medications and systemic antibiotics) 
and functional and occupational outcomes. 
Injuries were categorised as open or closed, in line with the Birmingham Eye Trauma Terminology 
(Pieramici et al. 1997), as illustrated in Figure 1.2.  To facilitate comparison with other studies that 
included only “severe” ocular injuries (Thach et al. 2008), (Mader et al. 2006), subconjunctival 
haemorrhage, corneal abrasion or superficial foreign bodies were not counted as significant injuries 
but placed in a minor injuries category.  When describing open injuries, it was not possible to 
distinguish between rupture and perforating injuries, as in these cases the eye was severely 
disrupted and there were probable elements of both injury mechanisms present.  Adnexal injuries 
occurring in conjunction with globe injury were counted as one injury.  None occurred in isolation. 
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Initial VA may have been recorded in theatre by non-Ophthalmologists, on arrival in the UK on 
Ophthalmology assessment or may not have been recordable until after definitive treatment due to 
unconsciousness.  Outcomes are reported by final VA either at 6-12 months post-surgery or at 
discharge from follow-up.  Final VA is a useful measure in these patients because patients are 
followed up until full recovery and are rarely discharged or transferred to another centre before they 
are functionally stable and permanent occupational recommendations have been made.   
For the purposes of analysis, Snellen VA measurements were converted to logMAR including those 
with acuity less than 1/60, as previously reported (Schulze-Bonsel et al. 2006).  Severity was 
calculated retrospectively using the OTS (Kuhn et al. 2002), to grade eye injuries from 1 (most severe) 
to 5 (least severe). 
The statistical analysis is descriptive, with average values given as either the median in those cases 
where the data are not numeric or do not appear to follow the normal distribution or the mean in 
other cases.  Spearman’s rank was used to calculate the correlation of final VA with Ocular Trauma 
Score. 
3.5. Results 
A total of 630 British soldiers survived major trauma from 19 Jul 04 to 2 May 08. Of these, 63 (10%) 
suffered ocular injuries affecting 82 eyes with 19 of these bilateral (30.2%). The ocular injuries were 
classed as significant in 58 eyes of 48 individuals, constituting 7.6% of major trauma. Over the same 
time period, 7447 UK soldiers were wounded in action (WIA) with 492 ocular injuries (6.6%). Because 
all major injuries were aeromedically evacuated from theatre, we calculated that 48 (0.64%) of those 
WIA suffered significant ocular injuries. 
Only one soldier had a history of ambylopia in the affected eye. Two injuries occurred in women – 
one minor and one closed – and 54.5% were to the left eye and 44.5% to the right.  The mean age at 
time of injury was 26.5 years (range 18-53) and 52% occurred in Iraq on operation TELIC and 48% in 
Afghanistan on operation HERRICK. 
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The aetiology was explosive blast in 54/63 patients (86%), closed globe contusion in 6/63 (9.5%) 
cases, disease non-battle injury (DNBI) in 3, a motor vehicle collision in 1, a non-combat related 
aircraft incident in 1 and an electrical burn in 1.  Among the significant injuries, 40/48 (83%) were 
caused by explosive blast. 
Mean follow up was 245 d for closed globe injuries and 220 d for open.  The first recorded VA was at 
a mean of 7.8 d after closed globe injury for injuries and 3.6 d after open globe injury. Mean time to 
arrival in the UK was 2.63 d (median 1) after all injuries and 2.52 d after open globe injuries (median 
1). 
Figure 3.5. Injuries classified by the Birmingham Eye Trauma Terminology System.   An additional 24 
minor cases are not shown here (subconjunctival haemorrhage, corneal abrasion, superficial foreign 
body). 
 
The distribution of cases in this cohort is shown in Figure 3.5.  Of the 58 severely injured, 22 (38% of 
eyes) had associated adnexal damage e.g. lid lacerations, burns or orbital fractures.  Facial or orbital 
fractures occurred in 17 of 48 patients (35%).  Penetrating or closed brain injury with structural 
abnormality on imaging occurred in 9 patients (19%); known cases of mild traumatic brain 
injury/post-concussive syndrome were not included.  Isolated ocular trauma occurred in 9 individuals 
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(19%), of which 1 was minor. A further 7 cases (2 minor) were associated with soft tissue 
fragmentation injuries, which required no treatment. 
 There were 21 open globe injuries (Figure 3.5.) of which 11 were associated with an intraocular 
foreign body (IOFB) – 1 of these penetrated the anterior segment only, 1 was intralenticular and 4 
penetrated the eye posterior to the equator. Lens damage occurred in 6/11 (54.5%) of IOFB and 2 
(18.2%) were recorded to have associated retinal detachments. 
 For open globe injuries, mean time to primary repair was 1.9 d (range 0-5) and there were an 
average of 1.57 operations per eye.  Of the 9 ruptured globes, 7 (77.8%) were ultimately enucleated 
or eviscerated (5 as a primary procedure); the final VA in the two remaining eyes that ruptured were 
hand movements (HM) and no light perception (NLP). 
Intravitreal antibiotics were given at the time of primary repair (with vitrectomy) in 5/13 eyes 
repaired.  All open globe injuries received broad spectrum systemic antibiotics before evacuation.  
There were no cases of endophthalmitis and 2 cases (of 12 open globes repaired) of proliferative 
vitreoretinopathy (PVR), which caused the only two cases of retinal re-detachment.   
The distribution of closed injuries is summarised in Table 3.5.1.  Surgery was required in 10/37 cases 
with an average of 1.2 operations per eye.  There were 9 cases of commotio retinae (16% of 
significant injuries), of which 5 (55% of commotio) affected the macula.  In macular and extramacular 
cases, the median presenting VA were 3/60 and 6/21 and the median final VA were 6/9 and 6/7.5 
respectively.  However, both initial and final VA were affected by multiple other pathologies as 
detailed in Table 3.5.1. 
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Lids Laceration 5 
Burn causing scarring 2 
Cornea  Superficial foreign body 9 
Abrasion 6 
Partial thickness laceration 4 
Blunt trauma causing oedema 2 
All burns 6 
With limbal ischaemia 3 
Subconjunctival haemorrhage 4 
Iris Iritis 4 
Sphincter damage/traumatic mydriasis 12 
Iridocorneal angle recession 2 
Hyphaema 9 
Cataract 7 
Posterior segment Vitreous haemorrhage 8 
Commotio retinae/sclopetaria 11 
Retinal tear 1 
Choroidal rupture 4 
Traumatic optic neuropathy 4 
Orbit Blow out/other fracture 11 
All foreign bodies 4 
Foreign body with intracranial penetration 1 
Muscle damage 1 
Table 3.5.1. – Closed globe injuries.  Eyes with minor injuries only excluded.  A total of 37 eyes. 
 There were 34 eyes with initial VA≤6/60, 18 eyes had final VA<6/60 and 17 eyes had a final VA of 
1/60 or worse, of which 6 (3 patients) were bilateral.  The causes were rupture/extensive disruption 
(9 eyes), corneal scar (2 eyes), PVR (2 eyes), traumatic optic neuropathy (1 eye), subfoveal choroidal 
rupture (1 eye), IOFB impacted fovea (1 eye) and retinal burns from hot IOFB (1 eye). 
The correlation of final VA with the OTS for all cases is shown in Table 3.5.2.  The median OTS for 
closed-globe injuries was 4, with a median final VA of 0.2 (6/10).  The median OTS for IOFB was 2.5, 
with a median final VA of 1.45 (6/169); this improved to a median final VA of 0.25 (6/11) when the 
two eviscerated eyes were excluded. 
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Table 3.5.2.  Correlation of final VA with OTS.  Total number 65 eyes on which OTS could be 
calculated.  Spearman’s rank correlation coefficient = -0.730 (df=63, 2 tailed, tied rank corrected) 
p<0.0001.  For 15 open globe injuries on which OTS could be calculated Spearman’s rank correlation 
coefficient = -0.137, p>0.05 (df=13, 2 tailed, tied rank corrected).  OTS = Ocular Trauma Score; NLP = 
No Light Perception; LP = Light Perception; HM = Hand Movements; CF = Counting Fingers 
Eye protection was recorded as worn in only 7/63 patients.  Of these, one had an IOFB injury with hot 
metal, ultimately requiring evisceration, and one had a closed globe injury with an orbital foreign 
body (vision recovered to 6/18), the remainder were minor injuries.  Of those not recorded as 
wearing eye protection, 11/56 had a final VA of HM or worse (including enucleation/evisceration). 
3.6. Discussion 
This is a complete report of all United Kingdom military ocular injuries from Iraq and Afghanistan, as 
there is a single point of treatment delivery and follow-up that allows comprehensive data to be 
collected.  This allows long-term outcomes to be recorded, unlike other reports of military trauma. 
Military is much more severe than civilian ocular trauma, with an initial VA of 6/60 recorded in 71% 
compared with 27% among civilians (Kuhn et al. 2002) and is associated with severe polytrauma in 
75% (source United Kingdom JTTR), which is rare in the civilian setting.  Most military patients are 
male (98%) compared with 80% of civilians and high energy explosive blast causes 83% of injuries 
compared with 3% in civilians (Weichel et al. 2008).  Despite these differences, the dataset recorded 
broadly conforms to OTS predictions, although, as in other reports of military trauma (Weichel et al. 
2008), comorbidities often delayed or hampered assessment of initial VA, which may have made the 
scoring system less reliable particularly for the more severely injured open globe injury patients.   
No. Points OTS NLP LP/HM CF -<6/60 6/60 -<6/12 ≥6/12 
0-44 1 83% 17%    
45-65 2 33% 17% 17% 17% 17% 
66-80 3 7.1% 14% 14% 21% 43% 
81-91 4    30% 70% 
>92 5    6.9% 93% 
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The total number of ocular casualties is much lower than that reported in the United States military 
(Colyer et al. 2008), (Mader et al. 2006), (Thach et al. 2008), (Weichel et al. 2008), reflecting 
differences in the overall number of casualties between the British and the United States Armed 
Forces.  It is difficult to compare the proportion of eye trauma between different reports, as there 
are subtle differences in how the data are presented. In our series, 6.6% of WIA suffered ocular 
injuries, though only 0.64% suffered significant ocular injuries.  This is in line with historical data 
(Wong, Seet, and Ang 1997), but much less than the 4.9% of WIA suffering ‘severe’ ocular injury 
reported by Thach et al. (Thach et al. 2008). Mader et al. reported 10% of surgical admissions with 
‘severe’ eye injuries, similar to the 7.6% of major trauma in our series (Mader et al. 2006).  Though 
both studies defined ‘severe’ differently, they were broadly similar to our definition of significant 
injury. 
We report a high proportion of blast injuries (86%) compared to 70–80% in previous reports (Wong, 
Seet, and Ang 1997), but this is not representative of the United Kingdom JTTR as a whole, which in 
the same period recorded 57% blast injuries (source United Kingdom JTTR).  It is possible that other 
causes of major trauma (gunshot wound, motor vehicle incidents, and DNBI) are less likely to involve 
the eyes compared with improvised explosive devices targeted at the face.  The enforced use of 
safety devices in theatre, such as seatbelts and eye protection, may reduce the incidence of eye 
injuries from other causes and, when exposed to blast, the eye is vulnerable to small, low energy 
fragments that would cause only minor skin damage. 
All soldiers were issued with polycarbonate spectacles and goggles for eye protection (Eye Safety 
Systems, Sun Valley, ID, USA), but a low proportion were documented as wearing them at the time of 
injury.  We do not have data on the proportion of soldiers using eye protection in theatre and so 
cannot assess any protective benefits of eye protection.  A recent study found a modest reduction in 
eye injury rates from 26% to 17% in those with and without eye protection respectively (Thomas et 
al. 2009). 
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Of the 17 eyes with final VA 1/60 or worse, 9 were grossly disrupted and so completely 
unsalvageable, 2 developed PVR and 3 had primary retinal damage.  Retinal pathology therefore 
caused 5/8 potentially salvageable cases with a poor outcome.  In general though, the outcome for 
non-ruptured/perforated open globe trauma was excellent.   
Commotio retinae occurred in 16% of cases with significant injury.  Of the closed globe injures, those 
with the potential to cause a permanent reduction in VA are commotio retinae, sclopetaria retinae, 
choroidal rupture, retinal tear and traumatic optic neuropathy, though the outcomes after closed 
globe injuries were excellent.   
3.7. Conclusions 
I. The visual outcomes after British military ocular trauma broadly conform to civilian OTS 
predictions and are in line with previous US military reports. 
II. Blast is the most common cause of ocular trauma and injures the eye more than other body 
regions. 
III. The main vision threatening injuries in British military trauma are open globe retinal injuries. 
IV. Commotio retinae is more common in military than in civilian trauma, but did not cause 
significant visual loss in this series.   
Blast causing retinal injury is the main cause of ocular morbidity in deployed British soldiers and 
there are no pharmacological interventions that are available to modulate the disease process, 
therefore identifying blast-related retinal injury as an important subject for further study. 
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4. Ocular Primary Blast Injury in a Porcine Model 
4.1.  Rationale 
Blast is the most common cause of ocular trauma in deployed British military personnel (see Section 
3).  Secondary and tertiary blast injury cause penetrating and blunt ocular trauma, whereas PBI is an 
injury mechanism unique to blast.  We have reported cases of commotio retinae after suspected PBI 
(Blanch and Scott 2008), (Chalioulias, Sim, and Scott 2007), and commotio retinae is the most 
common manifestation reported in the literature, though the existence of ocular PBI is disputed 
(Abbotts, Harrison, and Cooper 2007).  The most commonly reported electron micrographic 
appearances of commotio retinae in animal studies are disruption of photoreceptor OS (Hart, Blight, 
Cooper, and Papakostopoulos 1975), (Blight and Hart 1977), (Blight and Hart 1978), (Bunt-Milam, 
Black, and Bensinger 1986), (Kohno et al. 1983), (Sipperley, Quigley, and Gass 1978), and swelling of 
Müller cell processes (Kohno et al. 1983), (Blight and Hart 1977), (Blight and Hart 1978), (Hart, Blight, 
Cooper, and Papakostopoulos 1975), (Dean Hart and Blight 1978).  In this study, the retinal effects of 
primary blast exposure were evaluated in a porcine model of PBI at the Defence Science and 
Technology Laboratory (DSTL) Porton Down. 
4.2. Hypotheses 
I. Ocular PBI occurs with clinically relevant blast exposure 
II. Ocular PBI causes causes commotio retinae. 
4.3.  Aim 
To investigate whether ocular PBI occurred with clinically relevant blast doses in pigs by looking for 
evidence of commotio retinae and traumatic optic neuropathy. 
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4.4.  Materials and Methods 
4.4.1. Animal Model 
A prospective, controlled animal study was conducted by the research team at DSTL on 3 large 
terminally anaesthetised white pigs (DSTL).  Two animals were subjected to a standardised primary 
blast wave delivered to the right hand side, sufficient to cause reproducible, lethal blast lung as 
previously described (Garner et al. 2009).  Secondary and tertiary blast were minimised by protecting 
the animals with a KevlarTM blanket to stop fragments and mass movement of air and by strapping 
the animal to a trolley to prevent them being thrown against another surface. 
Animals were anaesthetised and prepared as previously described (Garner et al. 2009), except that a 
liver snare was placed to cause uncontrolled haemorrhage.  After blast a controlled haemorrhage 
was simulated by removal of 30% blood volume and then uncontrolled haemorrhage was created by 
pulling the liver snare to lacerate the liver.  One animal became acidotic after surgery and was 
sacrificed without blast injury using an overdose of intravenous phenobarbitone and was used as the 
control.  Of the two animals subjected to blast, case 1 survived for 55 min and case 2 for 3.5 hr.  Due 
to the constraints of Home Office licensing and the primary use to which the model was put, 
pharmacological mydriasis was not possible and so fundoscopy was conducted with a direct 
ophthalmoscope through an undilated pupil. 
4.4.2. Pathology 
Post mortem globes were fixed by intravitreal injection of 4% gluteraldehyde in PBS within min of 
death followed by enucleation including the optic nerve up to the optic canal, via an inferior 
approach. Specimens were then immersed in 4% gluteraldehyde in PBS for >24 hr.  Globes were cut 
into three segments: segment 1 was processed for light microscopy, segment 2 for electron 
microscopy and segment 3 was retained in the gluteraldehyde solution. 
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4.4.2.1. Light Microscopy 
Sean James (Walsgrave Hospital, Coventry, UK) processed specimens for light microscopy.  After 
automated processing though to paraffin wax, 3µm sections were cut and mounted onto Superfrost 
plus slides and incubated overnight in a 56°C oven.  Sections were rehydrated in graded isopropyl 
alcohols to water and stained with haematoxylin and eosin (H&E) to examine nuclei and retinal 
structure using Harris’s haematoxylin (Leica Microsystems, Milton Keynes, UK) and 1% aqueous eosin 
(Surgipath, UK).  Vitreo-retinal attachments were defined by exposure to freshly prepared 1% 
periodic acid for 10 min, washing in distilled water, incubating at RT for 10 min in Schiff’s reagent 
(PAS; VWR), immersing in cold running tap water for 10 min to develop the stain then 
counterstaining in Mayer’s haematoxylin for 1 min and blued in Scott’s tap water. 
GFAP (Clone 6F2, Dako, Cambridge) immunohistochemistry using 3, 3'-diaminobenzidine (DAB) for 
light microscopy was carried out as previously described (Snead et al. 2004). 
4.4.2.2. Electron Microscopy 
Processing for electron microscopy was performed by technicians at Queens Medical Centre 
(Nottingham, UK).  Specimens were embedded in agar, trimmed to a 2x2mm square, washed in PBS 
and excess agar removed.  Samples were post-fixed in 1% aqueous osmium tetroxide for 2 hr, 
washed in water and dehydrated in ascending concentrations of ethanol (40%, 70%, 90%, X3 100%), 
then two changes of 100% acetone, all with gentle agitation.  TAAB Embedding Resin of medium 
hardness was prepared and a 50% solution in acetone used for initial infiltration for 30 min followed 
by 100% resin mixture for 3 hr at 37°C and  -400mbar vacuum using a TAAB embedding oven.  
Samples were embedded in fresh resin mixture using TAAB type G silicone flat embedding moulds 
before polymerisation overnight (15 hr) at 65°C and -400mbar vacuum using a TAAB embedding 
oven.  Sections for light microscopy were cut at 0.5µm using glass knives on a Leica EM UC6 
ultramicrotome and stained with 1% Toluidine Blue in 1% borax.  Virtual microscopy images of the 
stained 0.5µm sections were recorded using a NanoZoomer scanner (Hamamatsu Photonics, Welwyn 
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Garden City, UK).  Sections were cut at 80nm using a diamond knife on the EM UC6 before mounting 
onto copper 200HH grids (Guilder, UK) and staining with saturated uranyl acetate in 50% ethanol, 
followed by Reynold’s lead citrate, both for 5 min, then washed in distilled water and viewed under a 
JEOL 1010 electron microscope at 100KV. Digital images were recorded using an integrated SIS 
Megaview III camera and iTEM software (Olympus-SIS, Münster, Germany) 
4.5.  Results 
After blast injury and haemorrhage, the 2 injured animals became hypoxic and acidotic, 
demonstrated by blood gas analysis. It is unclear why the control animal became acidotic without 
blast or haemorrhage.  Both animals subjected to blast had post-mortem blast-lung, visible as 
haemorrhage on post-mortem examination (case 1, 75% R caudal lobe, 10% L caudal lobe; case 2, 
70% R caudal lobe, 5% L caudal lobe).   
Direct ophthalmoscopy was normal.   
There was no macroscopic evidence of commotio retinae and no structural changes in any eyes on 
light microscopy with H&E or PAS or GFAP labelling.  On electron microscopy, there was artefactual 
separation of the retina and RPE with consequent damage to photoreceptor OS, but no changes 
consistent with commotio retinae.  Photoreceptor OS were preserved (Figure 4.5.) in all eyes with no 
loose disc material.  There was no swelling of Müller cell processes. 
4.6. Discussion 
The effects of isolated PBI on solid organs have not been reported elsewhere.  A recent report of a 
mouse model did not control for tertiary blast injury (Hines-Beard et al. 2012).  Ocular PBI is relevant 
to military ophthalmology, but also to wider considerations of the effects of blast exposure on the 
brain (Mac Donald et al. 2011). 
  
Figure 4.5. Transmission electron micrographic images of pig retina. Right eyes are shown, as these were clos-
est to the blast. Right- control (uninjured) tissue, preserved photoreceptor outer segments (arrowed). Left-
case 2, preserved photoreceptor outer segments (arrowed). 
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4.6.1. Study Findings 
Commotio retinae, defined as macroscopic post-traumatic retinal whitening, did not occur in this 
study.  Immediately after injury, the electron micrographic appearance of photoreceptor OS in 
commotio retinae is gross disruption with free disc material, neither of which were seen and, 
additionally, there was no Müller cell oedema, which is the next most frequently reported 
observation,  so there were no ultrastructural features of commotio retinae either. 
The optic nerve is often used to study CNS injury responses (Berry et al. 2008).  There were no 
structural changes in the nerve fibre layer on electron microscopy or gross structural changes in the 
optic nerve on light microscopy.  That GFAP was not upregulated is of limited significance as its gene 
is upregulated as a late response to injury and upregulation so quickly after injury has not been 
previously described (Vazquez-Chona, Song, and Geisert, Jr. 2004).  Longer follow up would give a 
greater expectation of immunohistochemical changes, if injury occurs. 
With only 2 cases (4 eyes) negative findings do not rule out ocular PBI.  However, the blast dose 
administered caused reproducible lethal blast lung in pigs and we did not detect any evidence of 
ocular PBI in either the retina or optic nerve (Garner et al. 2009).  Assuming that each eye was 
independently injured, the 95% confidence interval for the proportion of animals that could develop 
commotio retinae after exposure to blast is 0–55% (modified Wald method).     
That the experimental animals developed severe blast lung demonstrates that they are susceptible to 
blast effects.  We cannot exclude that porcine eyes have a particular resistance to blast effects, 
though their dimensions and structure are similar to human eyes so there is no anatomical reason to 
believe that this should be the case. 
Both injured animals had severe blast lung.  Therefore, if ocular PBI is possible, it requires a higher 
blast dose than pulmonary PBI.  This is unsurprising, as PBI requires energy transfer at the interface 
between tissues of different densities and densities vary less in the eye than in the hollow organs.  
The blast wave decays rapidly with increasing distance from the explosion, so PBI requires closer 
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proximity than secondary and tertiary mechanisms.  Secondary and tertiary blast effects cause 
commotio retinae by blunt trauma and it is therefore difficult clinically to separate commotio retinae 
caused by PBI from other mechanisms.  To suffer ocular primary blast injury, a patient would usually 
have to be exposed to a blast dose at least sufficient to cause severe blast lung and would also 
therefore likely be close enough to the blast to suffer tertiary and secondary blast effects to the eyes.  
Thus ocular PBI is unlikely to be a major mechanism of wounding in surviving patients and it is likely 
that the 86% of military eye injuries caused by blast that were identified in Section 3 resulted from 
secondary and tertiary mechanisms. 
4.6.2. Methodological Considerations 
The artefactual separation of the neurosensory retina from the RPE was unfortunate given that the 
photoreceptor OS is the main area of interest.  Better tissue preservation could be achieved through 
perfusion fixation.   
Glutaraldehyde (CH2(CH2CHO)2) cross links proteins much more effectively and rapidly than 
formaldehyde.  Primarily the two terminal aldehyde groups cross link lysine є-amino groups, but it 
reacts with other amino acids and with lipids, carbohydrates and nucleic acids.  Because of this and 
because of its larger molecular size, it penetrates tissues more slowly than formaldehyde at 
approximately 500µm/3 hr (Bozzola and Russell 1999).  The mammalian retina is approximately 
240µm thick and thus after immersion of the eye cup or intravitreal injection of gluteraldehyde, 
photoreceptor-RPE junction fixation would take 1.5 hr (Hughes 1979).  No part of the photoreceptors 
is more than 50µm from either the outer retinal capillary plexus or the choriocapillaris, so perfusion 
fixation would take 18 min.  However, photoreceptor OS are largely membrane lipids, which are not 
strongly fixed by gluteraldehyde. 
Osmium tetroxide (OsO4) is a non-polar molecule that diffuses rapidly through lipid cell membranes 
and reacts with and stabilises membrane lipids, staining  and providing contrast thus making 
photoreceptor OS visible under the electron microscope.   Osmium preserves membrane structures 
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by oxidising unsaturated fatty acids and reacts with and stabilises proteins (Bozzola and Russell 
1999).  Glutaraldehyde followed by osmium tetroxide is the standard protocol for fixation of a wide 
range of tissues (Bozzola and Russell 1999). 
Electron microscopy requires the selection of a very small piece of tissue for analysis and without 
clinical or macroscopic pathological abnormalities as a guide, it is possible that retina with occult 
pathology was not sampled.  Pathological findings should be interpreted in the light of clinical 
findings and so for future studies, dilated fundoscopy is essential and electroretinography desirable.   
Clinical examination, electroretinography, perfusion fixation and longer time points would be difficult 
within the context of the model at DSTL Porton Down because of the other uses to which the models 
are put, the large size of pigs used in the model and the fact that recovery experiments have not yet 
received ethical approval.  In addition, the cost of these blast injury models is prohibitive (approx. 
£10,000 per animal).  The initial negative findings were not encouraging with respect to overcoming 
these difficulties in order to obtain a useful animal model of ocular blast injury.   
The study indicated that a blunt trauma model would be a more clinically relevant way to model 
commotio retinae and suggested refinements to the laboratory techniques relevant to Chapter 5 
onwards, which are summarised in the conclusions below. 
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4.7. Conclusions 
I. PBI is unlikely to be a major ocular wounding mechanism. 
II. The porcine blast model at DSTL Porton Down is unsuitable for ocular research. 
II. Retinal injury can be more reliably induced by blunt ocular trauma rather than blast.  
III. Clinical examination is essential to guide selection of tissue for pathology and aid 
interpretation of results, so an animal model dedicated to ocular studies is required. 
IV. Perfusion fixation is necessary for studies of photoreceptor morphology, so rodents are a 
more suitable species than pigs in which to model commotio retinae. 
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5. Characterising Commotio Retinae 
The work in this chapter has been published in Ophthalmology, the paper is presented in Appendix 4. 
5.1.  Rationale 
Commotio retinae is a common military and civilian retinal injury, that can affect the macula with 
consequent loss of vision.  The proportion of patients in which the macula is affected, the probability 
and extent of recovery and the probability of complications are all unknown. 
5.2. Hypotheses 
I. After macular commotio retinae, one third of patients suffer permanent visual impairment. 
II. Permanent visual impairment after commotio retinae is associated with loss of 
photoreceptors. 
5.3.  Aims 
I. To describe the proportion of patients with commotio retinae in whom the macula is 
affected. 
II. To describe the level of permanent visual loss in macular commotio retinae. 
III. To describe the time course and extent of recovery of vision. 
IV. To identify any factors which predict visual loss or recovery. 
V. To describe complications and their frequency. 
5.4.  Materials and Methods 
The study protocol was approved by the Birmingham East North and Solihull Research Ethics 
Committee.  The NHS Research Ethics Committee application form is presented in Appendix 5. 
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This was a retrospective non-interventional case series.    
We included all patients presenting to the Birmingham Midland Eye Centre Eye Casualty from 1st 
October 2007 to 23rd February 2011 who were given a diagnosis of either commotio retinae or 
sclopetaria retinae.  There were no exclusion criteria.  A total of 1262 cases with ocular trauma were 
identified by searching the Birmingham & Midland Eye Centre Eye Casualty clinical database for the 
Accident and Emergency diagnostic codes: 02104B/L/R – contusion bilateral/left/right eye; the 10th 
revision of the international statistical classification of diseases and related health problems (ICD-10) 
diagnostic codes: contusion – S001 or S051, other retinal disorders – H35, H358 or H359; the free 
text entries: assault, commotio, ecchymosis.  Clinical records were examined to identify patients 
diagnosed with commotio retinae, defined as retinal whitening after ocular trauma or sclopetaria 
retinae defined as full thickness chorioretinal disruption associated with haemorrhages and retinal 
holes.  Age, gender, VA, injury mechanism, clinical findings of extent of commotio retinae and 
associated features and the extent of recovery and complications on follow up were recorded.  For 
the purposes of analysis, Snellen VA measurements were converted to the logarithm of the minimum 
angle of resolution (logMAR), including those with acuity of < 1/60 (Schulze-Bonsel et al. 2006). 
Duration of follow-up was variable, with patients who completely recovered being discharged at that 
point.  Follow-up for >3 months was considered adequate to determine final VA where it was 
reduced after injury.  VA <6/9 was considered reduced and cases with follow-up <3 months and VA 
worse than 6/9 were excluded from analyses of visual outcomes. 
Data were not normally distributed.  Descriptive statistics used median values +/- interquartile range 
(IQR) and the range of extreme (highest and lowest) values; VA between groups were compared 
using Wilcoxon signed rank test and proportions were compared using Fisher’s exact test.  Linear 
regression was used to assess the effects of age, gender and initial VA in the injured eye on final VA, 
interaction between initial VA in the injured eye and gender was examined using analysis of variance 
(type III sum of squares) and model fit assessed with diagnostic plots. 
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Figure 5.5.1. Fundus and OCTimages of the left eye of a 14 year old boy who was hit in the left eye by a 
soccer ball. At 3 days after injury his visual acuity was 20/80 right eye and he had an inferior altitudinal 
field defect corresponding to an area of commotio retinae; visual function was unchanged at 4 months 
follow up. (a and c), fundus images at 3 days (a) and 10 days (c) after injury. Vitreous hemorrhage 
obscures the view at 3 days; however, retinal pallor is still seen. By 10 days an area of retinal atrophy 
has developed superior to and involving the fovea, revealing the choroidal vasculature. (b), on OCT at 3 
days, the inner retina is swollen and the outer retina disrupted, with thinning of the outer nuclear layer 
and photoreceptor outer segments. (c-d), on OCT at 10 days, the ONL and external limiting membrane 
are absent in the affected areas, leaving the outer plexiform layer (OPL) directly apposed to the retinal 
pigment epithelium, which is thinned. 
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Figure 5.5.2. Humphrey visual field and OCT of a 34 
+1
.: :+. · , year old competitive squash player who suffered blunt 
:: : ::::: trauma to his left eye from the edge of his opponent's 
· : : ::: : :: : : .· ''''''·'<·::.!}:,:·"''''·''·' squash racquet 18 months previously. Presenting 
· · · · · · · · visual acuity was 20/20 right eye, 20/40 left eye with 
pinhole; examination showed a microscopic hyphaema 
and commotio retinae affecting the fovea, nasal 
macula and peripapillary area. Eighteen months after 
b~PLL the injury he re-presented complaining that he lost the 
~ONL squash ball in upper left field. VA was 20/32 OS: (a), 
~~';~s left eye Humphrey visual field 24:2, mean deviation 
'RPE -2.18 dB p < 5%, pattern standard deviation 6.05 dB, p 
<0.5%. An absolute scotoma is present 
superotemporal to fixation; (b), left eye Humphrey 
visual field 10:2 mean deviation -6.97, p<1%, pattern 
standard deviation 12.06, p<1%; (c), an OCT image of 
the left eye, showing the loss of the external limiting 
membrane and outer nuclear layer, leaving the outer 
plexiform layer (OPL) directly apposed to the retinal 
pigment epithelium; (d), an OCT image of the left eye, 
showing the same features as Figure 1c next to the 
fovea. 
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Figure 5.5.3. A scatter plot showing final VA (y axis) against initial VA in the injured eye (x axis) with 
males (blue dots) and females (red dots) shown separately. Lines denoting model predicted means 
obtained from fitting a linear regression with main effects of initial VA and gender and an 
interaction term between them to explain final visual acuity are overlaid with dashed lines 
indicating corresponding 95% confidence intervals. A positive correlation exists between initial and 
final VA in males (r = 0.53, 95% Cl [0.24, 0.74]), but not in females (r = -0.18, 95% Cl [-0.82, 0.66]). 
LogMAR = logarithm of the minimum angle of resolution. 
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5.5. Results 
5.5.1. Macular Commotio Retinae 
Macular commotio retinae was diagnosed in 53 patients (31% of all commotio retinae), of which 40 
were injured by assaults, 4 by footballs, 2 by tennis balls, 1 by a squash racquet and the rest by 
accidents at home.  There was adequate follow-up to determine final VA in 34 patients (19 were 
excluded).  The median presenting VA was 6/12 (IQR 6/9-6/60) and the median time after injury to 
presentation was 12 hr (IQR 6-24).  25 (74%) of patients recovered to 6/9 or better, 9 (26%) patients 
remained worse than 6/9 (range 6/10-counting fingers); the overall median visual recovery was 
logMAR 0.18 (equivalent to approximately one Snellen line).  The median VA in the uninjured eye 
was 6/6 (IQR 6/6-6/6) and was significantly better than the final VA (paired samples Wilcoxon signed 
rank test, median difference=0.18, p=0.002).  Of those patients presenting with a VA <6/9, the 
median visual recovery was logMAR 0.52 (equivalent to approximately 3 Snellen lines).  Of those 
patients with a final VA <6/9, one developed a macular hole, one had macular choroidal folds 
secondary to hypotony from a ciliary cleft; and the remainder had retinal atrophy (example shown in 
Figure 5.5.1.).  Two patients developed symptomatic paracentral scotomas, despite VA of 6/6 and 
6/9 (Figure 5.5.2.).  The median age was 28 years (IQR 21-36) and 45 patients were male.  Regression 
analysis suggested a model including main effects of initial VA in the injured eye, gender and a term 
to model their interaction provided a reasonable fit to the data, with little explanatory value to 
keeping age in the model as either a main effect or as an interaction term (model shown in Figure 
5.5.3.; p=0.24 for gender, p=0.1 for initial VA, p=0.033 for gender*initial VA). 
5.5.2. Extramacular Commotio Retinae 
Extramacular commotio retinae was diagnosed in 117 patients (69% of all commotio).  The median 
age was 23 years (IQR 17-33), 99 patients were male, 93 were injured during assaults, 10 playing 
football, 6 accidents in the home and 1 occupational injury, a military explosive blast injury.  There 
was adequate follow up to determine final VA in 58 patients (59 were excluded); the median 
 
 
90 
 
presenting VA was 6/9 (IQR 6/6-6/12, range 6/4-3/60) and the median time after injury to 
presentation was 20 hr (IQR 8-24).  Of 9 patients with presenting VA < 6/12, the median time post-
injury of assessment was 15 hr (IQR 6-24) and the causes of reduced vision recorded in the notes 
were hyphaema (2), amblyopia (1) and corneal abrasion (1); no apparent cause was recorded in 5 
patients.  Three patients had final VA <6/9: 6/12, 6/12 and 6/18, with follow-up of 5, 24 and 31 
months, respectively. Of these, the patient with a final VA 6/18 had a past history of amblyopia with 
no change from pre-injury VA and one had an extramacular choroidal rupture. Thus, a total of 2 
patients (3%) had a significant VA reduction, of whom one had a significant additional injury.  The 
median extent of visual recovery was logMAR 0.076.  Median final VA was 6/6 (IQR 6/5-6/9).  The 
median VA in the uninjured eye was 6/6 (IQR 6/6-6/9) and was not significantly different from the 
final VA (paired samples Wilcoxon signed rank test, median difference=0, p=0.124).  There was one 
case of extramacular sclopetaria retinae.  The 3 most common retinal locations of commotio, in 
order of frequency were; infero-temporal (37%), temporal (17%), supero-temporal (17%), <5% of 
cases were in a nasal location. 
5.5.3. Associated Injuries 
Anterior and posterior segment injuries occurred with similar frequencies in the two groups.  Overall, 
hyphaema occurred in 24 patients and retinal tears in 3, 1 of whom also had a retinal dialysis.  Orbital 
fractures were more likely to occur in patients with macular commotio, with 13 fractures (12 
involving the floor, one the medial wall) in the macular group and 12 fractures (all involving the floor) 
in the extramacular group (p=0.02, Fisher’s exact test, 2 tailed).  Fractures of the inferior and lateral 
orbital rim occurred in two patients with extramacular commotio. 
5.6. Discussion 
This is the first report of the prognosis and retinal location of macular and extramacular commotio 
retinae.  These data represent a complete capture of all ocular trauma presenting to Birmingham 
Midland Eye Centre from 1st October 2007 to 23rd February 2011.   
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In civilian practice macular commotio represents 31% of all cases , compared with 73% in the military 
(Weichel et al. 2008).  After macular injury, 26% of patients were left visually impaired on the basis of 
VA ≤6/9.  The true proportion with some visual impairment is higher because: (1), a deterioration 
from 6/4 to 6/9 will be significant to many patients and; (2), additional patients may be visually 
impaired by symptomatic paracentral visual field defects despite a normal VA. 
The absence of an effect on prognosis of advancing age in our data is unsurprising, as most patients 
were under 30 and very few are over 40 years old.  There is a positive correlation between initial and 
final VA – on average, the worse the presenting VA, the worse the final VA – and an interaction of 
gender with this correlation meaning that for poorer initial VA, females tend to have better final VA 
than males.  However, with adequate follow-up data on only 7 females, this result requires 
confirmation.  A protective effect of female gender in CNS trauma has been postulated and is 
thought to be mediated by progesterone (Roof and Hall 2000). 
After extramacular injury, 2 patients (5%) suffered a long-term, but mildly, reduced VA, which may 
represent occult macular injury or previously undiagnosed visual impairment in the affected eye.  
Despite a highly variable presenting VA after extramacular commotio, the visual prognosis is 
generally excellent with visual recovery to the same level as the fellow eye in the vast majority of 
patients.  In the acute setting after injury, reduced vision without other apparent causes may be due 
to occult macular injury or be non-organic or factitious 
The association of macular commotio with orbital floor fractures is consistent with its presumed 
contrecoup mechanism of injury causing retropulsion and increased intraorbital pressure (Berlin 
1873), as opposed to extramacular commotio, which occurs mostly in an infero-temporal to temporal 
location that is occasionally associated with orbital rim fractures, consistent with direct trauma to the 
sclera overlying the injured retina (Blight and Hart 1977). 
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5.7. Conclusions 
I. Civilian commotio retinae affects the macula in 31% of cases. 
II. At least 26% of patients with macular commotio retinae remain permanently visually 
impaired. 
III. Patients with impaired vision have loss of the ONL, seen on OCT, indicating photoreceptor 
death.  
IV. Extramacular commotio retinae is most often caused by direct scleral trauma. 
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6. Developing a Model of Blunt Ocular Trauma 
Parts of the work in this section have been published in Investigative Ophthalmology and Visual 
Science (Blanch et al. 2012a), the paper is presented in Appendix 6. 
6.1.  Rationale 
Our understanding of the mechanisms underlying retinal damage such as that seen after blast injury 
in soldiers or other blunt ocular trauma in civilians, is incomplete.  There are no treatment options 
available to patients with visual loss from commotio retinae.  These considerations identify a need 
for research into commotio retinae and the development of translational treatments using a suitable 
animal model.  As previously described, rats are the most appropriate species to use, since: 
• the anatomy of the rat and human retinae is similar 
• antibodies for rat immunohistochemical studies are readily availabile 
• alternative species have higher costs and maintenance  
• the relatively large size of the rat eye facilitates in vivo manipulations and investigations 
Ideally an animal model should demonstrate the same clinical and ultrastructural features of human 
commotio retinae, assessed by fundus examination and photography and electroretinography.  
Ultrastructural changes of photoreceptor outer segment disruption will be assessed with electron 
microscopy.  Photoreceptor apoptosis will be assessed by ultrastructural features, TUNEL staining, 
and immunohistochemistry. 
Previous animal studies have used modified airguns and catapults to deliver a high velocity (20-
50m/s) weight to the eye, but control and calibration of the energy delivered using these methods is 
imprecise.  For example, with a modified airgun measurement of the breach pressure before 
discharge is difficult and so assuring reproducibility is also problematic; with a catapult 
standardisation of the impact is also difficult. 
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The kinetic energy levels used to create commotio retinae in large animals vary from 0.49-2.87J, e.g. 
in the pig, 0.49J is sufficient, suggesting that a lower energy will be required in the rat. 
6.2. Hypotheses 
I. In the rat commotio retinae is induced by blunt ocular trauma. 
II. The energy level required to create commotio retinae reproducibly is < 0.5J. 
III. Photoreceptor apoptosis occurs after commotio retinae. 
6.3. Aims 
I. To create a rat model of commotio retinae 
II. To assess the type of cell death (apoptotic versus necrotic) that occurs in commotio retinae. 
6.4. Materials and Methods 
The simplest and most reproducible way of delivering an impact of known energy is by weight drop.  
Therefore, a weight drop apparatus was manufactured to attach to a standard rat head holder 
(Figure 6.4.1.).  To calculate the weight and height required to deliver a defined energy impact, the 
following formula was used: 
PE  = m*g*h 
Where: PE = gravitation potential energy in Newton metres (Nm) or Joules (J); m  = mass in kg; g = 
gravity in m/s2; h = height in m. The maximum practical height was 0.5m and the expected maximum 
kinetic energy to be delivered was 0.5J.  The weight that would be required to generate a potential 
energy of 0.5J was 100g, derived from: 
 0.5 = m*9.8*0.5 
  
Figure 6.4.2. 
Three weights used with the apparatus 
shown in figure 6.4.1. (i)- 22.6g weight, 
6mm impact tip, (ii)- 31.3g weight, 6mm 
impact tip, (iii)- adjustable weight with 
3mm impact tip. 1 section weighs 5.85g, 2 
11.3g, 3 17.6g and 4 23.0g. 
Tip-*. Restraining cord 
attached to end to allow controlled 
excursion and ease of release and 
retrieval - * *. 
* 
ii * 
Figure 6.4.1. 
The head holder 
and tubing used to 
deliver an impact 
to rat eyes by 
weight drop. The 
rat was held in 
place by the two 
ear bars and 
incisor clamp. The 
lower end of the 
tubing was aligned 
with the desired 
impact point on th 
eye and a weight 
dropped from the 
top of the tube. 
The tube was SOcm 
long. A small hole 
in the side released 
the weight from a 
height of 41cm. 
The internal 
diameter of the 
tube was 6mm. 
** 
** 
** 
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A weight of 100g intuitively seemed excessive for a rat eye, and 0.5J was taken as an upper limit, so 
smaller weights were chosen (Figure 6.4.2.).  A 22.6g weight gives a kinetic energy of 0.111J and 
31.3g a kinetic energy of 0.154J.  To allow an increased energy to be investigated without increasing 
the weight, a catapult latex (Match System superpower catapult latex, Middy Tackle International, 
Heanor, UK) was placed over the tip of the tube (Figure 6.4.1) and used to propel the weight 
downwards – 7cm of catapult latex was tensioned by being stretched by an additional 7cm.  The 
increased velocity was calculated as follows: 
 
 
 
The drop-tube was held parallel to the ground and the weight fired.  The height (h) was 19cm.  The 
distance travelled (x) was measured.  The results are shown below in Table 6.4. 
 
22.6g weight 
distance travelled 
(cm) 
31.3g weight 
distance travelled 
(cm) 
Mean 132.25 98.25 
Standard deviation 
(n-1) 42.72 29.35 
Mode 180 and 90 140 and 70 
Mean velocity (m/s) 6.71 4.99 
Mean KE (J) 0.51 0.39 
PE of 50cm drop (J) 0.11 0.153 
Mean total KE after 
40cm drop + 
catapult latex (J) 0.62 0.543 
Calculated velocity 
after 40cm drop + 
catapult latex (m/s) 7.41 5.89 
Table 6.4. Horizontal distance travelled after the weight was released for 20 iterations with 
calculated velocity and kinetic energy (KE). PE = gravitational potential energy.3 
                                                            
3 To calculate the KE and PE given in the table, the time taken to fall 19cm was 0.197s, calculated by the 
formula: 
d  = vi*t + 0.5*a*t2 
 
Copper tubing (Fig. 6.4.1.) 
orientated horizontally 
Weight 
fired using 
catapult 
latex  
h 
x 
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The distribution of velocities in Table 6.4 was bimodal because the weight drop apparatus was not 
designed to be enhanced by the catapult band and so, if the weight was held slightly off-axis when 
fired, friction slowed it down.  Logically the additional KE from the latex should have been the same 
whatever size of weight was used, so the lighter weight should have had a lower total KE than the 
heavier weight (lower PE).  That it did not was attributable to the poor reproducibility achieved using 
the catapult latex.  However, this apparatus allowed a higher velocity to be achieved easily.  Had it 
become necessary to use such velocities of weight-drop in the final model, a higher weight drop tube 
would have been necessary. 
6.5. Weight Drop Method 
6.5.1. Cadaveric Study of Blunt Ocular Trauma 
6.5.1.1. Hypothesis 
Ocular injury in rats using the weight drop method rarely causes globe rupture. 
6.5.1.2. Aim 
To test the whether the weight drop can be used in rats without globe rupture. 
  
                                                                                                                                                                                          
Where  vi = initial velocity (0m/s), d = distance in m (19 cm), a = acceleration (9.8m/s2), t = time in s 
Velocity was then calculated by:   
v = x/t 
Where  x = horizontal distance travelled. 
PE = m*g*h  
KE = 0.5*m*v2 
Where m = mass in kg,  g = gravity (9.8m/s2), h = height in m 
KE was calculated for the experimental data in Table 6.4.  PE was calculated for the weight drop (0.11J for 22.6g 
and 0.153J for 31.3g).  The two were summed to get total KE for the weight drop + catapult band and then v 
was calculated from KE by working backwards through the equations. 
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6.5.1.3. Materials and Methods 
Three male Wistar rats of weight 170-200g were used.  One was killed by cervical dislocation.  One 
was killed by overdose of anaesthetic and one was killed by exposure to progressively increasing 
concentrations of CO2.  One eye of each animal was exposed to a 31.3g weight drop from 50cm using 
the apparatus described in Figure 6.4.1. to deliver a KE of 0.153J.  One eye of each animal was 
exposed to the same weight delivered using the catapult latex giving an approximate KE of 0.54J. 
6.5.1.4. Results 
Globe rupture did not occur in any injured eyes.   
6.5.1.5. Conclusions 
The apparatus delivered a weight drop injury without causing globe rupture and could therefore be 
used for future studies.  
6.5.2. Terminal Study of Blunt Ocular Trauma 
6.5.2.1. Hypotheses 
I. Ocular injury in rats using the weight drop method induces commotio retinae without 
causing globe rupture. 
II. Central corneal injury induces a contre-coup commotio retinae. 
6.5.2.2. Aims 
I. To test the potential of the weight drop system to induce commotio retinae in rats without 
causing globe rupture. 
II. To demonstrate photoreceptor OS disruption in commotio retinae after central corneal 
weight drop injury. 
  
 
 
99 
 
6.5.2.3. Materials and Methods 
Two female Wistar rats were used under terminal anaesthesia.  In each animal, the right central 
cornea was impacted by a 31.3g weight (0.153J) and the left by a 22.6g (0.111J) weight – both with 
6mm tips from 50cm – using the apparatus described in Figure 6.4.1. 
Retinae were examined before and after injury by indirect fundoscopy, using tropicamide (Queen 
Elizabeth Hospital, Birmingham, UK) to dilate the pupils, and the sclera was marked at the sight of 
any identified abnormality with a permanent marker pen after dissecting off the conjunctiva and 
drying the scleral surface with a swab.  Animals were killed 1 hr after death and retinae were 
processed for electron microscopy.  Peripheral retinal areas that appeared macroscopically uninjured 
were used as control tissue. 
Figure 6.5.2. 
A, Band D: transmission electron micrographs of rat retina (gold sections) showing the ultrastructural ef-
fects of weight drop 1 hr after injury. C: Toludine blue stained 111m semithin section of rat retina. 
A- #2 LE 
22.6g weight drop. Shows RPE to ONL. Pre-
served photoreceptor OS sectioned tangentially 
give an apparent ovoid shape. Artefactual retinal 
detachment (arrows). 
C- #2 RE 
31.3g weight drop. Disorganised area of retina 
without recognisable retinal architecture. Mag-
nification xlO 
B- #3 LE 
22.6g weight drop. Shows photoreceptor OS and 
RPE. Tissue architecture is normal 
D- #3 RE 
31.3g weight drop. Area of /lcontrol" retina from 
RPE to ON L. There is disruption of the photore-
ceptor OS with a tissue defect(*). Such a tissue 
defect is unlikely to have developed within 1 hr 
of injury, given the absence of any inflammatory 
cells. Partially formed ovoid OS are seen (arrow), 
which differs from previous reports of commotio 
retinae where the OS were completely disrupted. 
This is therefore likely to be artefactual damage 
occurring during tissue processing. 
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6.5.2.4. Results 
Indirect fundoscopy revealed subtle retinal changes that may or may not have been consistent with 
the appearance of commotio retinae, but electron microscopic assessment did not show any injury 
consistent with commotio retinae in any eye (Table 6.5.2.4.). 
Rat # 
- eye 
Weight 
dropped 
(g) 
Fundoscopy  Gross Pathology Electron Microscopy (See 
Figure 6.5.2.) 
2 – 
LE 
22.6 Query retinal pallor 
inferotemporally – sclera 
marked at site; difficult to 
assess retinal pallor in an 
albino rat. 
Poor fixation – post-mortem 
(artefactual) retinal 
detachments; marked area 
taken for EM. 
Poor tissue architecture 
3 – 
LE  
22.6 Small vitreous 
haemorrhage at disc; 
query retinal pallor 
inferotemporally – sclera 
marked at site. 
Well preserved retina 
looked normal.  Retinal 
vasculature still visible in 
parts (inadequate PBS 
washout).  Marked area 
taken for EM.  Temporal 
retina taken as control. 
Normal retinal structure 
2 – 
RE 
31.3 Vitreous haemorrhage; 2 
large choroidal 
haemorrhages 
Poor fixation – artefactual 
retinal detachments in 
addition to choroidal 
haemorrhages.  Marked 
area taken for EM. 
No recognisable retinal 
architecture 
3 – 
RE   
31.3 Larger vitreous 
haemorrhage than 2nd rat 
Normal retina.  Marked area 
taken for EM.  Temporal 
retina taken as control. 
Control area shows 
artefactual disruption of 
photoreceptor OS.  
Marked area shows 
normal retinal 
architecture (not shown).   
Table 6.5.2.4. 
6.5.2.5. Discussion/Conclusions 
This was a terminal study and showed that the weight drop protocol can be used in recovery 
experiments with a low risk of globe rupture. 
Commotio retinae was not induced by central corneal impact in this experimental model despite 
being seen clinically after both central corneal and direct scleral impact.  Direct scleral impact is likely 
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to create a more reproducible injury to the underlying retina than the indirect contre-coup type 
injury generated by central corneal impact. 
Since this protocol did not induce commotio and a previous studies used 6mm ball bearings on larger 
animals with bigger eyes such as the pig, it was concluded that the 6mm tip was inappropriately large 
in relation to the rat eye and so 3mm impact tips were developed for subsequent studies (Figure 
6.4.2.). 
6.5.3. Recovery Study Of Blunt Ocular Trauma 
6.5.3.1. Hypotheses 
I. Commotio retinae is reproducibly created by direct scleral impact. 
II. A 3mm tip that gives a small impact area produces uniform and reproducible retinal injury. 
6.5.3.2. Materials and Methods 
Four female Wistar rats of weight 170-200g were used under recovery anaesthesia.  Rats were killed 
1 d after bilateral weight-drop injury and the eyes processed for electron microscopy.  The  11.26g, 
17.61g and 23.02g “iii” weights from Figure 6.4.2. were dropped from a height of 50cm using the 
apparatus described in Figure 6.4.1. to impact a 3mm tip onto the inferior sclera with KE of 0.055J, 
0.086J and 0.113J respectively.  The limbal traction suture was tied off to mark the clock hour of the 
injury site. 
Rat #1 was injured by the 23.02g weight dropped onto the left eye and a 17.61g weight to the right 
eye, which ruptured.  This animal was terminally anaesthetised and killed by perfusion with fixative 
for electron microscopy.  The first and third rats were poorly perfused so fixation was by immersion.  
6.5.3.3. Results 
The results are presented in Table 6.5.3.3.  In #1 LE (one eye of one animal only – Figure 6.5.3.3. and 
Table 6.5.3.3.) changes consistent with commotio retinae were seen by electron microscopy  
Figure 6.5.3.1. 
Scanned images of recorded findings on indirect fundoscopy after weight drop impacted the inferior 
retina. The abnormal areas in the inferior retinae were small and corresponded to the size and shape of 
A -#2 
Examination 1 day after injury. Left 
eye (L) 11.26g weight drop, right eye 
(R) 17.61g weight drop. Whitening 
(pallor) was difficult to assess in 
albino rats. The retinal appearance 
was subtly altered but suggestive of 
commotio retinae. 
B- #3 
Examination immediately 
after injury. LE 23.02g weight 
drop, RE 23.02g weight drop. 
Figure 6.5.3.2. 
RE Whitening with intra-
__... retinal haemorrhage LE Query 
whitening? ~ Vitreous 
haemorrhage 
Small area of preretinal 
haemorrhage and some 
whitening 
LE 
Area of choroidal 
effusion/haemorrhage 
Vitreous haemorrhage with 
whitening underneath 
RE 
Whitened retina 
Macroscopic pathology of fixed globes photographed down dissecting microscope. 
A- #1 RE 
Whole eye showing limbal rupture running from 12 to 6 
o'clock position (arrowed) 
B- #2 RE 
Eye cup after removal of cornea, lens 
and iris diaphragm. Vitreous 
haemorrhage overlying impact site on 
inferior retina (arrowed). 
Figure 6.5.3.3. 
Transmission electron micrographs of rat retina (gold sections) showing the effects of weight drop. 
A- #1 LE 
23.02g weight drop 1 hour before death. IS to OS. 
There is disruption of outer segments with some 
preservation of structure in the disrupted area 
(*). The rest of the retina (not shown) was 
normal. 
C- #3 LE 
23.02g weight drop 1 day before death. Promi-
nent linear striations running across the retina are 
folds in the section. Less prominent striations 
running parallel to the retinal layers are knife 
marks. Normal retina. 
B #2 RE 
17.61g weight drop 1 day before death. Normal 
retina. Black marks (e.g. arrow) are artefact from 
osmium tetroxide staining. 
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(photoreceptor outer segment disruption).  Unfortunately this animal was killed immediately after 
injury, due to contralateral globe rupture, so any  secondary changes that could have developed in 
response to OS disruption, such as inflammatory cell infiltration, did not occur.  As a result, it was not 
possible to determine whether the changes seen were processing artefact or were present in vivo.  
The retina looked normal on fundoscopy, which suggested that the changes were artefactual, as 
commotio retinae should be seen clinically as retinal pallor. 
Rat # - 
eye 
Weight 
dropped 
(g) 
Fundoscopy (see Figure 6.5.3.1.) Gross Pathology (see 
Figure 6.5.3.2.) 
Electron Microscopy 
(see Figure 6.5.3.3.) 
1 - LE  23.02 No injury seen Normal retina OS disrupted 
1 - RE  17.61 Rupture Limbal globe rupture Not processed 
2 - LE  11.26 Day 1 – no injury seen 
Day 2 –inferior retinal pallor; overlying 
vitreous haemorrhage 
Inferior vitreous 
haemorrhage – 
otherwise normal retina 
Normal retina 
2 - RE  17.61 Day 1 – preretinal haemorrhage 
inferiorly 
Day 2 – inferior pallor; superior 
whitening and intraretinal haemorrhage  
Vitreous haemorrhage 
inferiorly and superiorly 
(contre-coup) 
Normal retina 
3 - LE  23.02 Day 1 – inferior choroidal effusion, 
haemorrhage and retinal pallor  
Day 2 – inferior vitreous haemorrhage  
Inferior vitreous 
haemorrhage – 
otherwise normal retina 
Normal retina 
(samples processed 
together) 
3 - RE  23.02 Day 1 – inferior choroidal effusion, 
haemorrhage and retinal pallor  
Day 2 – inferior retinal haemorrhage  
Artefactual retinal 
detachment away from 
injury site 
4 - LE  23.02 Day 1 - Inferior pallor and vitreous 
haemorrhage 
Day 2 – no change 
Inferior vitreous 
haemorrhage; normal 
retina 
4 - RE  23.02 Day 1 - Inferior pallor  
Day 2 – no change 
Normal retina 
Table 6.5.3.3. 
6.5.3.4. Discussion 
On fundoscopy, the abnormal areas (rats #2-4 - Figure 6.5.3.3. and Table 6.5.3.3.) were small 
(corresponding to the 3mm impact tip).  With a limited injury, the area of abnormality may easily 
have been missed when selecting tissue for electron microscopy.  In addition, the globe that 
ruptured was impacted by the light weight.  With a small impact tip, a slightly off axis impact is likely 
 
 
106 
 
to have resulted in trauma by the sharp edge of the tip with an increased risk of globe rupture.  A 
larger impact tip was therefore deemed less likely to cause globe rupture. 
The abnormal retina (rats #2-4 – Figure 6.5.3.1. and Table 6.5.3.3.) seen on fundoscopy was very 
anterior and difficult to visualise by fundoscopy.  A significant portion of the injured area may 
therefore have been ciliary body (anterior to the ora serrata) rather than retina.  With an inferior 
approach, this was the most posterior that the impact could be delivered. 
The naturally pale and translucent appearance of the albino fundus makes fundus examination and 
the detection of clinical signs difficult.  In addition, albino rats display a variety of neuroretinal 
abnormalities that could affect their predisposition and response to the changes of commotio retinae 
(see Section 1.4.1.2.). 
6.5.3.5. Conclusions 
The clinical changes seen with this protocol were subtle.  A relatively low energy impact was used in 
this experiment, so it was concluded that increasing the delivered energy may result in a more 
obvious injury. 
6.5.4. Recovery Study of Higher Energy Blunt Ocular Trauma 
6.5.4.1. Hypotheses 
I. Higher (>0.113J) energy weight drop induces a more reproducible injury. 
II. Lateral scleral impact injures more posterior retina than inferior scleral impact. 
III. Commotio retinae is easier to visualise by fundoscopy in pigmented rats than albino rats and 
more similar to the clinical condition in humans. 
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6.5.4.2. Aim 
To induce commotio retinae in pigmented rats by weight drop injury to the lateral sclera with KE 
>0.113J. 
6.5.4.3. Materials and Methods 
Four female Lister hooded rats of weight 170-200g were used under recovery anaesthesia.  The “ii” 
weight  from Figure 6.4.2. (6mm tip) was dropped from a height of 50cm onto the lateral sclera using 
the apparatus described in Figure 6.4.1., with (0.54J) or without (0.154J) a catapult latex to increase 
velocity (see Section 6.4.).  Access to the lateral sclera was facilitated by a lateral cathotomy and the 
limbal traction suture was tied off to mark the clock hour of the impact site.  Rats were killed 24 hr 
after bilateral weight-drop injury and tissues processed for electron microscopy. 
When rat #4 RE was injured with the weight and catapult latex, the globe ruptured.  This animal was 
killed by perfusion with 4% glutaraldehyde immediately after injury.  Rat #3 RE sustained a posterior 
rupture that was unrecognised at the time and so this was killed with rats #1 and 2 after 24 hr. 
6.5.4.4. Results 
The results are presented in Table 6.5.4.3.  Rat #2 RE (Figure 6.5.4.3. and Table 6.5.4.3.) had 
ultrastructural changes consistent with commotio retinae at the lesion site and opposite (contre-
coup).  The disrupted ILM of the contre-coup injury (Figure 6.5.4.3. D) suggests that this was caused 
by the lens impacting the retina.  Unfortunately the KE required to cause these changes caused globe 
rupture in rats #3 and #4.  No changes consistent with commotio retinae were seen with the lower 
energy level impacts. 
Figure 6.5.4.1. 
Fundoscopic images taken through the indirect ophthalmoscope 1 dafter injury. 
A- #1 RE 
Normal appearance of peripheral retina at lesion 
site. Indented retina is seen at bottom of image. 
Figure 6.5.4.2. 
B- #2 LE 
Normal appearance of retina temporal to optic 
disc (seen top left). 
Macroscopic retinal pathology photographed down dissecting microscope. 
A#1 RE 
Artefactual retinal detachment (arrowed) down 
right from lesion site(*). Note dark choroid and 
RPE in the Lister Hooded rats, which was not 
seen in albino rats. 
B- #4 LE 
Vitreous haemorrhage (arrowed) overlying 
lesion site (surrounding area of retinal pallor). 
Figure 6.5.4.3. 
Histological appearance of rat retina 1 d after weight drop. 
A- #1 LE 
Toludine blue lightly stained section of a perile-
sional area in rat retina. Section thickness 111m. 
Magnification x40. 31.3g weight drop. Retinal 
detachment may be due to processing artefact-
there are pigmented cells collecting in subretinal 
space (arowed), but no inflammatory cells or 
proteinaceous material present. 
C #2 RE 
Transmission electron micrograph of rat 
retina (gold section). RPE to OS. 31.3g + 
catapult latex. Disrupted photoreceptor 
OS at lesion site (arrows top and bottom 
of disrupted area). These changes are 
similar to those previously reported 
(Blight and Hart 1977). 
D- #2 RE 
B- #2 LE 
Toludine blue section of normal rat retina at 
lesion site. Section thickness SOOnm. Magnifica-
tion x40. 31.3g weight drop. 
Transmission electron micrographs of rat retina opposite lesion 
site (gold sections). 31.3g +catapult latex. Disrupted 
photoreceptor outer segments (arrowed- top left) correspond to 
areas of disrupted ILM (bottom left- arrowed). Relatively intact 
outer segments (top right) correspond to intact ILM (bottom R). 
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Rat # - 
eye 
Weight 
dropped 
(g) 
Fundoscopy (see 
Figure 6.5.4.1) 
Gross Pathology (see Figure 
6.5.4.2.) 
Electron Microscopy (see Figure 
6.5.4.3.) 
1 - RE  31.3 No injury seen Perilesional RD  Area of perilesional RD shows 
pigment in subretinal space. 
1 -LE  31.3 No injury seen Some areas of RD Normal retina – samples 
processed together.   2 - LE  31.3 No injury seen Normal retina 
3 - LE 31.3 No injury seen Normal retina 
4 - LE 31.3 No injury seen 
(killed on day 1) 
Vitreous haemorrhage 
opposite lesion site.  
(processed separately).  
Perilesional RD.  
Artefactual RD – stretched OS 
2 - RE 31.3 + 
latex 
No injury seen Normal retina Lesion site: - OS disrupted 
Opposite: areas of intact and 
disrupted ILM corresponding to 
intact and disrupted OS 
3 - RE  31.3 + 
latex 
Dense vitreous 
haemorrhage 
Posterior rupture – lens 
outside of eye 
Not processed 
4 - RE 31.3 + 
latex 
Rupture (killed 
on day 1) 
Posterior rupture ILM and OS disrupted 
Table 6.5.4.3.  
6.5.4.5. Discussion/Conclusions 
Changes consistent with commotio retinae were only observed in eyes that had been impacted by 
the heaviest weight whose velocity had been increased using a catapult latex and that protocol 
ruptured 2/3 eyes so injured.  Therefore to create commotio retinae reproducibly in future 
experiments, without causing globe rupture, it was concluded that a lower weight should be used 
with the catapult latex.   
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6.5.5. Recovery Study of Low Weight, High Energy Blunt Ocular Trauma 
6.5.5.1. Hypothesis 
Commotio retinae without globe rupture is induced by a 22.6g weight + catapult latex (estimated KE  
0.62J, Section 6.4.). 
6.5.5.2. Aim 
To induce commotio retinae without globe rupture by weight drop with catapult latex using an 
impact energy of 0.62J. 
6.5.5.3. Materials and Methods 
Three male Sprague-Dawley rats of weights 289g, 265g and 269g were used.  Rats were killed 3 d 
after bilateral weight-drop injury using the apparatus described in Figure 6.4.1. and the eyes 
processed for electron microscopy.  The “i” weight shown in Figure 6.4.2. (6mm tip) was dropped 
from a height of 50cm onto the lateral sclera using a catapult latex to increase velocity (see Section 
6.4.). 
Figure 6.5.5.1. 
Fundoscopic images taken through the indirect ophthalmoscope. 
A- #2 RE 
Day 1. Optic disc and temporal retina. The pale 
band from 11 o'clock to 3 o'clock (arrowed) is 
from the scleral indenter used to visualise the 
anterior retina. 
C- #2 RE 
Day 4. Peripheral retina at lesion site. 
A small patch of altered light reflex and 
subtle pallor was seen (arrowed). 
B- #2 RE 
Day 4. Retina around the optic disc. Pale ap-
pearance is normal for albino rats. 
Figure 6.5.5.2. 
Light microscopic images of retina stained with toludine blue showing histological appearance after 
injury by weight drop+ catapult latex. Section thickness liJ.m. Magnification x40. Letters refer to speci-
mens listed in Table 6.5.5.5. 
Absent OS, RPE response and an inflammatory cell 
(arrowed) among the OS remnants. 
Figure 6.5.5.3. 
Normal retina. 
a1 
Artefactual retinal detachment. This is processing 
artefact because there is no proteinaceous or cellular 
material in the subretinal space except for the 
fragmented photoreceptor outer segments (arrowed). 
Electron micrographic appearance of specimen a6 (Table 6.5.5.5.) shown in Figure 6.5.5.2. Absent OS with 
an inflammatory cell (arrowed). 
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6.5.5.4. Results 
The results are shown in Table 6.5.5.5.  One area of one specimen (a6 - Table 6.5.5.5. and Figures 
6.5.5.2. and 6.5.5.3.) showed ultrastructural changes consistent with commotio retinae, in that 
absent OS and inflammatory cells in the subretinal space suggested previous OS damage. 
Rat # - 
eye 
Weight 
dropped (g) 
Fundoscopy (see Figure 6.5.5.1.) Toludine blue (see Figure 
6.5.5.2.) 
Electron Microscopy 
(see Figure 6.5.5.3.) 
1 - LE  22.6 + latex Vitreous haemorrhage and subtle 
underlying retinal pallor 
Samples processed 
together. 
a1 - shows artefactual 
RD. 
a2-5 - specimens showed 
normal retina 
a6 - specimen showed a 
section of abnormal OS 
associated with an RPE 
response 
Samples processed 
together. 
a6 - absent and 
disrupted OS with 
an RPE response 
1 - RE 22.6 + latex Subtle temporal retinal pallor 
2 - LE  22.6 + latex Hyphaema with poor fundus view 
2 - RE  22.6 + latex Query subtle temporal retinal 
pallor 
3 - LE  22.6 + latex Dense vitreous haemorrhage 
3 - RE  22.6 + latex Temporal retinal haemorrhage + 
pallor 
Table 6.5.5.5.  Note: Specimens were labelled a1-6 because eyes were pooled for processing. 
6.5.5.5. Discussion/Conclusions 
This weight drop apparatus with catapult latex delivered a variable energy impact with a moderately 
heavy weight moving slowly (up to 7 m/s – see Section 6.4.) that was difficult to standardise.  Only 
with impact speeds >5m/s were any changes consistent with commotio retinae observed in the 
experiments so far.  Published studies have used higher speed (20-50 m/s) impacts with lower 
weights (0.38 – 16g) than can be accommodated using the weight drop apparatus developed here.  
Reproducible injury is more likely to be created by replicating these higher velocity impact protocols. 
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6.6. Ballistic Injury 
6.6.1. Hypothesis 
Commotio retinae is more reproducibly created by a ballistic high speed (20-50m/s) low weight (≤1g) 
impact than by using the weight drop apparatus. 
6.6.2. Aim 
To cause commotio retinae in the retina underlying the site of impact of a 0.5-1g pellet delivered at 
20-50m/s to the scleral surface of a rat eye. 
6.6.3. Materials and Methods 
A compressed air system was designed to deliver a high velocity projectile to the rat eye, using this 
ballistic injury to induce commotio retinae. 
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6.6.3.1. Device Components 
 
 
 
 
 
 
 
Figure 6.6.3.1. Diagram of the pneumatic components of the experimental apparatus shown in Figure 
6.6.3.2.  The numbered components are: 
1.  VQ20 2 port solenoid valve,24Vdc M5 8mm (RS components, Birmingham, UK) 
2. Pneumatic in line non-return valve 8mm (RS components) 
3. Pressure gauge,40mm dia 0-10bar R1/8 (RS components) 
4. 1/8in BSP Norgren air reservoir,0.5l. M/163/50 (RS components) 
5. Mini MIG CO2 regulator (Welding Equipment and Cutting Services, Sheffield, UK) 
6. 0.22 inch barrel blank (cut to 300mm and machined to fit G1/4 female connector; Sandwell 
Field Sports, Sandwell, UK) 
Black 8mm standard PU tubing,30m (RS components) is shown as black lines joining the components 
and was connected to the components using the hydraulic fittings: push-in branch tee 
adaptor,1/8inx8mm (RS components); male parallel straight adaptor,G1/4x8mm (RS components); 
female BSPP sleeve fitting,G1/4xG3/8 (RS components); female BSPP sleeve fitting,G1/4xG1/2 (RS 
components).  A 24V/0.5A direct current power supply unit (RS components) and a Flex Switch 
(Maplin, UK VJ83E) were used to power and control the solenoid-actuated valve. 
Reservoir (4) 
Solenoid 
Valve (1) 
CO
2  cylinder 
CO2 
regulator (5) 
Barrel (6) 
Pressure 
gauge (3) 
Non-return 
valve (2) 
Figure 6.6.3.2 
The head holder and ballistic injury apparatus used to deliver a low weight/high velocity projectile to rat 
eyes using compressed air. Opening the regulator on the C0 2 cylinder pressurises the system, monitored 
by the pressure guage. The barrel is loaded by unscrewing it from the push-fit adapter next to the valve. 
The electrical switch opens the solenoid actuated valve, propelling a projectile down the barrel. 
Figure 6.6.5.2. 
Head 
holder 
C0 2 
regula-
Screenshot showing the sound waveform recorded when the ballistic injury apparatus above was used to 
fire a BB into a metal plate. The waveform was used to calculate velocity. 
1.640 ms 1.650 ms 
liiliiliiliilliiiilliiiil 
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All parts are specified to withstand pressures of ≥6 bar.  The VQ20 solenoid valve has a specified 
response time <5ms, an effective cross-sectional area of 9mm2 and a flow rate of 491Nl/min.  A 
muzzle velocity of 50m/s after linear acceleration would take the projectile 12ms to leave the barrel 
from valve opening (0.3m distance/25m/s average speed).  Thus a response time of 5ms was deemed 
acceptable because the valve would go from fully closed to fully open in less than half the time it 
would take for the projectile to leave the barrel at 50m/s and a faster response time was unrealistic 
within the equipment budget.  With a projectile travelling at 50m/s the flow rate of gas down the 
barrel would be 0.07l/min (2.38x10-5m2 cross sectional area x 50m/s x 60s) which is well below the 
maximum flow rate of the valve. 
6.6.3.2. Energy calculations 
A lower range estimate of projectile KE of 0.2J was derived from considering a 1g projectile (m=1g) 
travelling at 20m/s using the formula given in Section 6.4.  To calculate the force required to 
generate a projectile KE of 0.2J: 
Change in KE = Work Done =  force * distance 
Change in KE = 0.2J and distance = 0.3m (the length of the barrel), so force = 0.666N.  The barrel has 
a diameter of 5.5mm (0.22 inches) giving a cross sectional area of 2.38*10-5m2 (area = πr2).  To 
calculate the chamber pressure required: 
Force = Pressure * Area 
Thus pressure = 28011pa=0.28bar and internal chamber pressure before firing = 0.28bar above 
atmospheric pressure.  Doing the same calculations for a 1J (1g, 45m/s) pellet yields an internal 
pressure difference of five times as much, thus a total chamber pressure of 2.4bar.  Note that the 
energy of the projectile is related to chamber pressure and independent of the pellet weight.  So a 
0.5g pellet fired by 2.4bar has an energy of 1J and a velocity of 63m/s. 
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6.6.3.3. Methods 
The head of an anaesthetised rat was fixed in a head-holder frame (as shown in Figure 6.6.3.2.), the 
inferior sclera exposed and the eye rotated superiorly with a limbal traction suture.  The system was 
pressurised with CO2 and a projectile fired against exposed sclera from a distance of 0.5 cm.   
6.6.4. Cadaveric Study of Ballistic Ocular Injury 
6.6.4.1. Aim 
To determine the maximum chamber pressure that can be used to fire a projectile against a rat eye 
with minimal risk of globe rupture. 
6.6.4.2. Materials and Methods 
Thirteen female Wistar rat cadavers (140 – 420g) were used immediately after death to minimise any 
post-mortem drop in intraocular pressure.  The ballistic injury apparatus described in Section 6.6.3. 
was used to deliver different weighted projectiles at high velocity to the lateral sclera.  If rupture did 
not occur, the chamber pressure was increased and the eye injured again.  Four weights of projectile 
were used: a commercially available 0.91g lead pellet (rsmsports, ebay.co.uk); a commercially 
available 0.5g alloy and plastic pellet (pointed tip reduced to a smooth dome; Keens Guns and Tackle, 
Bridgend, UK); a plastic 0.16g pellet custom-made in our laboratories; a 0.095g plastic BB (ball 
bearing; reduced in size from 6mm to fit the 0.22 inch barrel; Park Lane Gifts, amazon.co.uk).  At the 
low pressures used, all stock ammunition tended to stick in the barrel and so needed to be trimmed 
down to a less tight fit. 
6.6.4.3. Results 
The results are presented in Table 6.6.4.3.  Chamber pressures below 0.15 bar rarely caused globe 
rupture. 
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Animal History 
Projectile 
weight (g) 
Eye 
Chamber 
pressure 
(bar) 
Expected 
velocity (m/s) 
Globe injury 
1 
405g rat with IUGR 
anaethetised for 3 hr and killed 
by overdose of intravenous 
 
0.91 
RE 1 39.6 Rupture 
LE 
0.5 28.0 Intact globe 
0.75 34.3 Rupture 
2 
300g rat anaesthetised for 3 
hr, subjected to intermittent 
hypoxia/hypercapnia and killed 
by intravenous urethane 
overdose 
0.91 
RE 0.6 30.7 Rupture 
LE 
0.5 28.0 Intact 
0.6 30.7 Intact 
0.8 35.4 Rupture 
3 
380g IUGR rat treated similarly 
to #1 
0.91 
RE 0.6 30.7 Rupture 
LE 0.5 28.0 Rupture 
4 
370g IUGR rat treated similarly 
to #1 
0.91 
RE 0.5 28.0 Rupture 
LE 0.4 25.1 Rupture 
5 300g rat treated similarly to #2 0.91 
RE 0.4 25.1 Rupture 
LE 0.3 21.7 Rupture 
6 
370g IUGR rat treated similarly 
to #1 
0.91 
RE 0.3 21.7 Rupture 
LE 0.25 19.8 Rupture 
7 140g rat treated similarly to #1 0.5 
RE 0.2 23.9 Rupture 
LE 0.1 16.9 Rupture 
8 
397g IUGR rat treated similarly 
to #1 
0.095 
RE 
0.1 38.8 Intact 
0.2 54.8 Intact 
0.4 77.5 Intact 
0.8 109.7 Rupture 
LE 0.4 77.5 Rupture 
9 
375g IUGR rat treated similarly 
to #1 
0.16 
RE 0.3 51.7 Rupture 
LE 0.15 36.6 Rupture 
10 150g rat treated similarly to #1 0.095 
RE 0.2 54.8 Rupture 
LE 0.15 47.5 Rupture 
11 305g rat treated similarly to #2 0.095 
RE 
0.1 38.8 Intact 
0.15 47.5 Rupture 
LE 
0.1 38.8 Intact 
0.15 47.5 Intact 
0.2 54.8 Rupture 
12 
275g IUGR rat treated similarly 
to #1 
0.095 
RE 
0.1 38.8 Intact 
0.15 47.5 Rupture 
LE 
0.1 38.8 Intact 
0.15 47.5 Rupture 
13 
420g IUGR rat treated similarly 
to #1 
0.095 
RE 
0.125 43.3 Intact 
0.15 47.5 Rupture 
LE 
0.125 43.3 Intact 
0.15 47.5 Rupture 
Table 6.6.4.3. Pressures causing rupture are shown in red. Expected velocity was calculated as 
described in Section 6.6.3.3. IUGR = intrauterine growth retardation 
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6.6.4.4. Discussion/Conclusions 
The maximum chamber pressure tolerated for firing the projectile without causing globe rupture was 
0.1-0.125 bar was.  Because previous studies used projectile velocities of 20-50m/s to induce 
commotio retinae, the maximum velocity possible (achieved using the lowest weight) was preferred, 
so a 0.095g BB was used for future studies. 
6.6.5. Measuring the Velocity of Projectiles Delivered by the Ballistic Injury Apparatus 
6.6.5.1. Rationale 
To assure reproducibility and ease of reporting of the injury protocol it is necessary to know the 
range of projectile velocities produced by the compressed air device. 
6.6.5.2. Aim 
To determine the mean muzzle velocity and its variation when a 0.095g BB is fired with a chamber 
pressure of 0.125 bar. 
6.6.5.3. Materials and Methods 
Bullet velocity was measured using a PC soundcard as has been previously reported (Courtney and 
Edwards 2006).  Briefly, a Dell Studio XPS (Dell Corporation Ltd, Berkshire, UK) laptop was used to 
record the sound of the compressed air device being fired using MAGIX Music Editor 3 (MAGIX AG, 
Reno, NV USA) at a metal plate at known distance from the muzzle.  The waveform was then viewed 
(see Figure 6.6.5.2.) and the time between air leaving the barrel and the BB impact with the metal 
plate recorded at ranges of 1cm, 10.5cm, 22cm, 31.5cm and 42cm from the muzzle for 10 iterations 
at each distance.  Mean velocity at each range was calculated as distance/time. 
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6.6.5.4. Results 
The results are shown in Table 6.6.5.3. and Figure 6.6.5.  Velocity at 1cm from the muzzle was 20.2 ± 
1.08m/s and velocity decays with time after injury.  Assuming linear deceleration, the rate of decay is 
0.19m/s for every cm travelled, thus 20.2m/s approximates muzzle velocity. 
Distance (cm) Time to impact (ms) Mean velocity ± standard error (m/s) 
1 30.7 20.2* ± 1.08 
10.5 35.7 19.0 ± 2.24 
22 44.8 14.9 ± 0.80 
31 51.9 14.2 ± 0.66 
42 61.9 13.1 ± 0.63 
Table 6.6.5.3. Mean BB velocity at different distances from target. * Velocity at 1cm was taken as 
muzzle velocity and, assuming linear acceleration, was calculated as twice the mean velocity at which 
the BB travelled through the barrel. 
Figure 6.6.5. Mean velocity at different distances from target ± SEM. 
 
6.6.5.5. Discussion/Conclusions 
The standard error of the mean velocity at each distance is small indicating that kinetic energy 
delivered to the eye by the compressed air delivery system is reproducible.  The impact velocity with 
a 0.095g BB and a chamber pressure of 0.125 bar was 20m/s with a KE on impact of 0.019J. 
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6.6.6. Electron Microscopic Terminal Study of Ballistic Ocular Injury  
6.6.6.1. Rationale 
The experiments reported in Section 6.5. showed that, in rats, low velocity weight drop injury did not 
induce commotio retinae reproducibly and previous experimental studies of commotio retinae used 
high velocity (20-50m/s) projectiles.  Further studies demonstrated that, in rats, ballistic injury with a 
0.095g BB travelling at 20m/s did not cause globe rupture.  This ballistic injury protocol was therefore 
used to induce commotio retinae. 
6.6.6.2. Hypothesis 
Ballistic injury from a 0.095g BB impacting the scleral surface at 20m/s reproducibly induces 
commotio retinae in the rat eye. 
6.6.6.3. Aim 
To cause commotio retinae by delivering a BB of 0.095g at 20m/s to the scleral surface of rat eyes 
without causing globe rupture. 
6.6.6.4. Materials and Methods 
Four female Lister Hooded rats of weight 170-200g were used under terminal anaesthesia.  A 0.095g 
BB was fired at the lateral sclera of both eyes at 20m/s using the ballistic injury apparatus described 
in Section 6.6.3.  The eye was rotated with a limbal traction suture, which was then tied off to mark 
the clock hour of the impact site.  Indirect fundoscopy was performed to look for commotio retinae 
immediately after injury.  Rats were killed 2 hr after injury and retinae were processed for electron 
microscopy.  Uninjured inferior sclera was used as normal control tissue. 
6.6.6.5. Results 
Fundoscopy revealed retinal pallor underlying the impact site in all eyes and variable vitreous 
haemorrhage immediately after injury (Figure 6.6.6.1).  Retinal pallor was also obvious under the 
dissecting microscope (Figure 6.6.6.2.).  Electron microscopy of resin-embedded retinal sections  
Figure 6.6.6.1. 
Fundoscopic images taken through the indirect ophthalmoscope. 
A 
Normal appearance of retina before injury. Note 
the darker red/pink appearance and RPE texture 
visible through the retina. 
Figure 6.6.6.2. 
B 
Vitreous haemorrhage with underlying white area 
of retina 
Macroscopic pathology of eyes photographed down dissecting microscope. 
A 
The eye shown in Figure 6.6.6.l.B. 
Vitreous/pre-retinal haemorrhage surrounded 
by an area of retinal pallor (commotio retinae-
arrowed) 
B 
Eye cup has been cut in two. The left hand sec-
tion shows a spot vitreous haemorhage overly-
ing retina with a normal appearance. The right 
hand section shows areas of retinal pallor 
(commotio retinae- arrowed) 
Figure 6.6.6.3. 
Transmission electron micrographic appearance of rat outer retina (gold sections) 2 hrs after ballistic 
injury. (A) Normal control area of retina. (B) Disrupted photoreceptor inner and outer segments and 
external limiting membrane. 
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showed photoreceptor OS and IS disruption all 8 eyes and external limiting membrane (ELM) 
disruption in 3 eyes (Figure 6.6.6.3.).   There were occasional apoptotic nuclei in the ONL (Figure 
6.6.7.4.A) 
6.6.6.6. Conclusions 
The ballistic injury protocol induced a retinal injury with the clinical and ultrastructural features of 
commotio retinae, without globe rupture and was therefore used in subsequent recovery studies.   
As 98% of rat photoreceptors are rods and the ONL contains exclusively photoreceptors, apoptotic 
ONL nuclei are those of photoreceptors and are likely to be of rods.  The evidence for photoreceptor 
apoptosis is discussed in the next section. 
6.6.7. Electron Microscopic Recovery Study of High Velocity Ocular Injury  
6.6.7.1. Rationale 
Ballistic trauma, as described in Section 6.6.6, caused an injury that looked clinically and 
ultrastructurally like commotio retinae.  This study set out to demonstrate a cellular response of the 
photoreceptors to injury.  If injury-induced photoreceptor death occurs, morphological features of 
cell death should be visible in these cells by 2 d. 
Additionally, after macular commotio retinae in humans, 26% of cases stabilise with a visual acuity 
<6/9 and persistent, visually debilitating, paracentral scotomas are not uncommon, with visual 
impairment caused by photoreceptor degeneration(Blanch et al. 2013),(Souza-Santos et al. 2012).  If 
photoreceptor apoptosis occurs, that would suggest that regulated apoptotic signalling mediates cell 
death in a proportion of photoreceptors, implying that antiapoptotic neuroprotective therapies have 
a potential role in the treatment of commotio retinae.  It was therefore deemed important to look 
for evidence of apoptosis. 
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6.6.7.2. Hypotheses 
I. Ballistic retinal injury causes commotio retinae characterised by damage to photoreceptor 
OS with associated infiltration of inflammatory cells. 
II. Photoreceptor apoptosis occurs after ballistic retinal injury. 
6.6.7.3. Aim 
To cause commotio retinae and characterise the cellular response 2 d later. 
6.6.7.4. Materials and Methods 
Four anaesthetised female Lister-hooded rats received bilateral ballistic ocular injury (as described in 
Section 6.6.6.), except that injury was made to the inferior sclera, which, (1), afforded better surgical 
access than the lateral sclera and, (2), allowed comparison with the uninjured inferior retinal control 
tissue described in Section 6.6.6.  Indirect fundoscopy was performed immediately and then 2 d after 
injury to look for commotio retinae.  Animals were killed 2 d later and samples were processed for 
electron microscopy. 
6.6.7.5. Results 
Fundoscopy 2 d after injury revealed inferior retinal pallor in all eyes in which the inferior retina 
could be visualised (7/8) and vitreous haemorrhage in 5 eyes (Figure 6.6.7.1.).  Retinal pallor was also 
visible under the dissecting microscope (Figure 6.6.7.2.).  Light microscopy of semi-thin sections 
stained with toluidine blue and H&E revealed sub-retinal and intra-retinal haemorrhage in 2 eyes, 
gross disorganisation of retinal structure at the centre of the impact site in 3 eyes and abnormal or 
poorly staining nuclei at the centre of the impact site in all eyes (Figure 6.6.7.3.).  Transmission 
electron micrographs demonstrated necrotic photoreceptor nuclei, oedema and histiocyte 
infiltration central to the impact site and apoptotic nuclei peripheral to it (Figure 6.6.7.4.). 
  
Figure 6.6.7.1. 
Fundoscopic images taken through the indirect ophthalmoscope. 
A 
Normal appearance of retina before injury. 
Note the darker red/pink appearance and 
RPE texture visible through the retina. 
c 
Vitreous haemorrhage (arrowed) and pale retina 
(yellow dotted circle). 
D 
B 
Vitreous haemorrhage (arrowed) and 
surrounding pale retina. 
Vitreous haemorrhage originating along blood 
vessel, raised and pale area of retina (arrowed). 
Figure 6.6.7.2. 
Macroscopic pathology photographed down dissecting microscope. 
A 
Vitreous haemorrhage overlying an area of 
raised and whitened retina (arrowed) wth 
surrounding subtle retinal pallor (arrowheads). 
B 
Vitreous haemorrhage overlying an area of 
raised and whitened retina (arrowed). 
Figure 6.6.7.3. 
111m thick semi-thin resin embedded sections of rat retina 2 days after high velocity impact. 
A2 
H&E stained section. Magnification X40· lnflamm_a- Toludine blue stained section from same eye as A. 
tory cells among OS remnants (arrow) -note vanable Magnification x4o. Inflammatory cells among OS 
t(hickness of)OS. Few vitreal erythrocytes remnants (arrow), shallow retinal detachment 
arrowhead . ( h d) arrow ea . 
H&E stained section. Magnification x20. Disorganised Same H&E stained section from same eye as B. 
/remodelled retina at lesion site with haemorrhage, Magnification x40. Perilesional area with poorly 
oedema and inflammatory cells stained nuclei in the ONL and inflammatory cells 
amongst the OS (arrow). 
C2 H&E stained section. Magnification x40. Perilesional 
Toludine blue stained section from the same eye as 
C. Magnification x20. Subretinal haemorrhage 
(arrow) with disrorganised/remodelled retina. 
area showing disrupted OS with a shallow retinal de-
tachmnent arrowhead) and an abrupt demarkation 
with loss of nuclear staining in the ONL (arrow). 
Figure 6.6.7.4. A-G. Transmission electron micrographs of rat outer retina. A. ONL 2 hrs after ballistic 
injury; blebbed, apoptotic, photoreceptor nucleus (arrowed). B-G. 2 days after ballistic injury. B. Close to 
the impact site, macrophage removing disrupted photoreceptor OS and IS (arrowed) and non-specific cell 
death with condensed and fragmented photoreceptor nuclei in the ON L- yelow boxed area shown at 
higher magnification in C. D. Close to the impact site, necrotic photoreceptor nucleus in an oedematous 
ONL with ruptured cell membranes (arrowed). E-H. Apoptotic photoreceptor nuclei further away from the 
impact site: E. Nuclear blebbing (arrowed); F. Nuclear blebbing (arrowed) with invasion of the 
photoreceptor cytoplasm by MUller cell processes (arrowhead); G. Condensed photoreceptor nucleus with 
chromatin aggregates at the periphery of the nucleus, typical of apoptosis; H. Chromatin aggregates 
(arrowhead) dispersed throughout the condensed photoreceptor nucleus (rather than peripherally), 
however the intact mitochodrion (arrowed) is suggestive of apoptosis. I. Apoptotic photoreceptor cell body 
with nuclear blebbing (arrowed) and a cytoplasmic apoptotic body (arrowhead). J. Apoptotic photoreceptor 
cell body with nuclear blebbing (arrowed) and a preserved mitochondrion (arrowhead). K. ONL at the edge 
of an area of necrosis towards the centre of the impact site with an abrupt demarcation between relatively 
normal nuclei on the left (arrowhead) and karyolytic nuclei (arrow) on the right. 
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6.6.7.6. Discussion 
The morphological features of apoptosis are cell and nuclear shrinkage, chromatin condensations 
(typically at the nuclear periphery) and nuclear blebbing and cytoplasmic blebbing with the 
formation of apoptotic bodies, all occurring in the presence of intact cellular organelles such as 
mitochondria and enclosed by an intact plasma membrane (Elmore 2007), all of which were been 
demonstrated peripheral to the impact site. 
Necrotic cell death is characterised by cellular swelling and karyolysis which caused the loss of 
haematoxylin staining in the ONL demonstrated at the centre of the impact site in Figure 6.6.7.3.A, 
B2 and C and the loss of uranyl acetate nuclear staining demonstrated in Figure 6.6.7.4.K. 
6.6.7.7. Conclusions 
I. After commotio retinae, an inflammatory reaction with histiocyte infiltration occurred. 
II. At the centre of the impact site, photoreceptors died by necrosis. 
III. Peripheral to the impact site, photoreceptors died by apoptosis.  
6.6.8. Assessing the Reduction in Photoreceptor Numbers After Ballistic Ocular Injury  
6.6.8.1. Rationale 
In humans, photoreceptors degenerate after commotio retinae, causing permanent visual loss 
(Chapter 5) and current studies in the rat ballistic injury model have shown photoreceptor apoptosis 
2 d after injury.  Both in humans and in the experimental model, injury-related changes are most 
prominent in the outer retinal layers.  The proportion of cells that die in the different retinal layers 
and the variation in cell death with distance from the impact site is not known. 
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6.6.8.2. Hypothesis 
I. Photoreceptors die after commotio retinae. 
II. Cells in the inner retinal layers are relatively spared after commotio retinae. 
6.6.8.3. Aim 
To cause an outer retinal injury as in Section 6.6.6. and evaluate  the extent and distribution of cell 
death 2 weeks later. 
6.6.8.4. Materials and Methods 
Four anaesthetised female Lister Hooded rats (200g) received a bilateral ballistic ocular injury (as 
described in Section 6.6.7.) and were killed 2 weeks later. Indirect fundoscopy was performed 
immediately and then 2 weeks after injury to look for commotio retinae.  Retinae were processed as 
for electron microscopy.   A strip of inferior retina including the optic disc and ciliary body and 
running radially through the centre of the lesion site was dissected out for embedding.  Five control 
strips of retina including the optic disc and ciliary body were taken from the uninjured inferior retinal 
tissue from Section 6.6.6.   Resin embedded sections were stained with Toludine blue and images 
captured at 40x magnification (0.25x0.3mm field of view) from the ONL of 5 different areas of each 
section as shown in Figure 6.6.8.1.  ONL (photoreceptor) nuclei per 40x field were counted by an 
observer blind to the injury condition using the user-defined manual counting facility in ImagePro 
(Media Cybernetics, Bethesda, MD, USA). 
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Figure 6.6.8.1. – A diagram (not to scale) showing the positioning of the 5 photographs on a radial 
cross section of retina running from optic disc to ciliary body through the lesion site. 
6.6.8.5. Results 
Fundoscopy immediately after injury confirmed the development of commotio retinae at the impact 
site.  Six of 8 eyes injured had an area of central vitreous haemorrhage overlying the lesion site and 
one of the eyes (with vitreous haemorrhage) had a central area with the appearance of sclopetaria 
retinae.  At 2 weeks after injury, fundoscopy of all eyes showed a large area of retinal and RPE 
atrophy of the same size (Figure 6.6.8.2.).  There was variable resolution of the vitreous 
haemorrhages by 2 weeks.  The appearances on dissection were the same as those on fundoscopy.   
Toludine blue stained sections showed a reproducible injury with progressive loss of the ONL 
approaching the centre of the lesion site, but relative preservation of the INL and GCL and 
hypopigmentation and irregularity of the underlying RPE.  At the centre of the impact site all 
neuroretinal layers were absent (Figure 6.6.8.3.-4.). 
Ciliary body 
Optic disc 
5 
4 
3 
2 
1 
Figure 6.6.8.2. 
Fundoscopy and gross pathologiy of rat retinae 2 weeks after ballistic injury. 
A 
Fundoscopic image. Area of retinal atrophy 
with choroidal structure visible (circled with 
white dotted line). 
Figure 6.6.8.3. 
B 
Gross pathology showing half of retinal cup in-
cluding lesion site. Area of retinal atrophy 
(circled with white dotted line). 
A. Composite image of a toludine blue-stained resin section of rat retina 2 weeks after ballistic injury. The 
ONL is lost with relative preservation of the INLand GCL approaching the lesion site. Where some 
photoreceptor nuclei remain, the OS are shortened and, closer to the injury site, the ONL is directly 
opposed to the RPE. At the impact site there is loss of all retinal layers and obliteration of the underlying 
choriocapillaris. B. Higher magnification cut-out of A showing the point at which the ONL disappears. 
retinal layers 
B 
Thinning 
of OS 
INL still present, Thinning 
no underlying of NL 
ONL ~ 
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Figure 6.6.8.4. - Percentage of surviving nuclei in the different retinal layers plotted against distance 
from the lesion site. Cell counts are shown as percentages of the mean value for uninjured control 
tissue in the same retinal area (normalised).  ONL survival is lowest, with the INL and GCL relatively 
spared. Standard error is shown at those distances where more than 2 measurements were taken. 
6.6.8.6. Discussion 
Central to the impact site, where photoreceptors die by necrosis (as demonstrated in Section 6.6.7.), 
there is complete loss of the ONL indicating complete loss of photoreceptors and extensive loss of 
the inner retinal layers.  The reduction in cell counts compared to uninjured control tissue is similar in 
the INL and GCL, but much greater in the ONL, indicating that the injury predominantly caused 
photoreceptor death with relative sparing of the inner retinal layers. 
Peripheral to the impact site, where photoreceptors die by apoptosis, the proportion of cells dying is 
lower and decreases with increasing distance from the impact site, but photoreceptors are still 
predominantly affected in comparison to cells of the INL and GCL.  Therefore any attempt to improve 
visual outcomes by preventing apoptosis should focus on preventing photoreceptor death. 
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6.6.8.7. Conclusions 
There is photoreceptor death around the lesion site and death of all retinal cells at the lesion site.  
The proportion of photoreceptors dying declines at increasing distance from the lesion site, with 
relative sparing of the inner retinal layers. 
6.6.9. Assessing the Total Reduction in Photoreceptor Numbers After Ballistic Ocular Injury 
6.6.9.1. Rationale 
Cell death predominantly affects photoreceptors after ballistic ocular injury as demonstrated in 
Section 6.6.8.  To give an indication of the severity of injury, the magnitude of potential functional 
impairment and potential benefits of neuroprotective treatment and to complete characterisation of 
the model, the total proportion of photoreceptor death needed to be determined. 
6.6.9.2. Aim 
To determine the total proportion of photoreceptor death after ballistic ocular injury. 
6.6.9.3. Materials and Methods 
Eight anaesthetised female Lister Hooded rats had unilateral ballistic ocular injury (as described in 
Section 6.6.7.) and were killed 2 weeks later and retinae processed for retinal whole mounts.  Images 
of retinal whole mounts were captured at x40 magnification using a Zeiss epifluorescent microscope 
(Carl Zeiss, Hertfordshire, UK) equipped with a Axiocam HRc camera (Carl Zeiss) running the 
Axiovision software (Zeiss). Because of the poor axial resolution of the light microscope, which is 
greater than ONL thickness, cell counting was repeated using images captured at x63 magnification 
and ONL thickness measured as the axial distance between the farthest two points in which the ONL 
was visible, using a confocal laser scanning microscope (Carl Zeiss) running the LSM 510 software 
version 3.2 (Carl Zeiss). Images were captured from 3 different areas (at 1/6, 3/6 and 5/6 of the 
radius as shown in Figure 6.6.9.1.) of each quadrant (total = 12 counts per eye) in the middle of the 
ONL, to account for variation in photoreceptor numbers in the different areas and DAPI-stained 
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nuclei quantified using the built-in particle counting facilities in ImagePro and expressed as mean 
normalised photoreceptor density per high power field (0.143x0.143mm on confocal images). 
Figure 6.6.9.1. Illustrative diagram showing location on retinal whole mounts of images for cell 
counts at 1/6, 3/6 and 5/6 of the radius of each quadrant (total = 12 counts per eye). 
 
 
 
 
 
 
 
 
 
6.6.9.4. Results 
ONL cell counting on epifluorescent images of retinal whole mounts showed that 18.4 ±4.6% 
photoreceptors had died.  Similarly, ONL cell counting on confocal images showed that 18.3±4.1% 
photoreceptors had died.  Adjusting confocal cell counts to take account of ONL thickness by 
multiplying cell count by ONL thickness, showed that 18.6±10.3% photoreceptors had died. 
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Figure 6.6.9.2. Mean number of surviving photoreceptors in injured and control eyes measured by 
cell counts on confocal images.  p=0.004 for main effect of injury and  p=0.005 for the 2-way 
interaction retinal position*injury (repeated measure ANOVA) 
 
6.6.9.5. Discussion/Conclusions 
After commotio retinae induced by ballistic ocular injury, 18% of photoreceptors die, indicating that 
visual function assessed by ERG should be reduced by at least this amount and setting 18% as the 
limit on the proportion of photoreceptors that could benefit from neuroprotective therapies. 
6.6.10. Immunohistochemical Study of Ballistic Ocular Trauma 
6.6.10.1. Rationale 
After commotio retinae induced in rats by ballistic ocular injury, 18% of photoreceptors die by a 
combination of apoptosis and necrosis, with relative sparing of the inner retinal layers.  Electron 
micrographs allowed assessment of cell death only in small, discrete areas of retina, which may not 
represent gross changes. TUNEL staining of retinal sections allows assessment of the mechanisms of 
cell death in a wider area of retina more easily.   
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It was noted on electron micrographs that histiocytic inflammatory cells infiltrated the retina after 
injury.  Immunohistochemical staining would allow more precise identification of these cells to 
characterise the inflammatory response. 
6.6.10.2. Hypotheses 
I. Apoptosis is rare at the centre of the impact site, but more common in a penumbral zone at 
the periphery. 
II. After ballistic ocular injury, macrophages infiltrate the retina. 
6.6.10.3. Aim 
I. To characterise the distribution of photoreceptor apoptosis in the whole retina after ballistic 
ocular trauma by TUNEL staining. 
II. To identify infiltrating inflammatory cells in the retina after ballistic ocular trauma. 
6.6.10.4. Materials and Methods 
Four anaesthetised female Lister Hooded rats had unilateral, right ballistic ocular injury (as described 
in Section 6.6.7.) and were killed 2 d later.  Eyes were processed for immunohistochemistry.  The left 
eyes acted as controls.  TUNEL staining and immunohistochemical staining for ED1 (CD68) and OX42 
(CD11b) were performed. 
6.6.10.5. Results 
The results of immunohistochemistical analysis are presented in Figure 6.6.10.  Examination of the 
necrotic central zone of the impact site revealed gross positive TUNEL staining in the ONL with very 
high levels of background fluorescence.  Peripheral to the lesion site there were scattered TUNEL 
positive nuclei, decreasing in frequency with increasing distance from the impact site.  Control tissue 
was TUNEL negative.  There were many ED1 positive cells invading through the full thickness of the  
  
Figure 6.6.10. 
A-B. TUNEL -ve intact control retina. A. TUNEL staining in green. B. combined image with DAPI stained 
nuclei in blue. C-F. Injured rat retina 2 days after injury with DAPI-stained nuclei in blue. C. Whole 
injured area of retina; at the centre of the impact site (arrowhead), there is diffuse TUNEL positivity. The 
frequency of TUNEL positive nuclei reduces in frequency with increasing distance. D-F. Higher 
magnification cut-out from Cat the periphery of the lesion site showing DAPI stained nuclei (D), TUNEL 
stained nuclei (arrowed; E), and combined image (F). 
G-J. EDl and OX42 staining showing negative OX42 (Santa Cruz, polyclonal) staining in red (G), green EDl 
positive macrophages arrowed (H), blue DAPI stained nuclei (I) and combined image (J). K-L. Negative 
OX42 (Serotec monoclonal) staining in green (K) and combined image with DAPI stained nuclei in blue (L). 
Note that absent fluorescence on the red channel excludes autofluorescent inflammatory cells as a cause 
for positive staining on the green channel. 
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injured area of retina only, but present in greatest numbers in the region of the photoreceptor OS 
and outer nuclear layer.  No OX42 positive cells were present in injured or control tissue. 
6.6.10.6. Discussion 
In the centre of the impact site, there was diffuse photoreceptor nuclear and cytoplasmic TUNEL 
staining, probably because direct cellular injury caused necrotic death (van Lookeren and Gill 1996).  
However, away from the impact site, the presence of specific TUNEL-positive photoreceptor cell 
nuclei in the ONL indicated apoptosis of these cells, confirming the electron micrographic findings. 
ED1 (rat homologue of human CD68) is a transmembrane glycoprotein expressed by activated 
macrophages (though may also be expressed by activated microglia), whereas OX42 (rat homologue 
of human CD11b) is expressed on microglia (at any stage of activation) and neutrophils – and may be 
expressed on macrophages (Streit 2005), (Lloyd, Phillips, Cooper, and Dunbar 2008).  In addition, all 
the inflammatory cells seen in electron micrographs were histiocytic (Section 6.6.7.).  These three 
features – ED1 positive, OX42 negative with a histiocytic morphology suggest that these cells are 
macrophages. 
The distribution of macrophages in the region of photoreceptor OS and throughout the retina 
suggests that they are both clearing damaged outer segments and debris from dying cells. 
6.6.10.7. Conclusions 
I. After ballistic ocular trauma, TUNEL positive photoreceptors are present in retinal areas 
peripheral to the impact site. 
II. Macrophages infiltrate the retina after ballistic ocular trauma, being most frequent in the 
region of the photoreceptor outer segments. 
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6.7. General Discussion 
The ocular injury induced in rats by weight drop was inconsistent.  The energy threshold for induction 
of commotio retinae was close to that at which globe rupture occurred in 50% of animals (approx 
0.62J).  This was because low velocity injury did not cause commotio retinae, consistent with the 
body of literature in which commotio retinae has been created using high velocity impact (see 
Section 1.4.3.1.).  In contrast, a lower energy injury with a 0.095g BB travelling at 20m/s (0.019J) 
reproducibly created central sclopetaria retinae at the impact site and surrounding commotio 
retinae, indicating that velocity rather than impact energy determined the development of commotio 
retinae, consistent with the work of Scott et al. (2000), who showed that a high velocity impact of a 
light projectile created more injury than a low velocity impact from a heavy projectile despite similar 
kinetic energy ((reference not available)).   
After the closed globe ballistic injury there was a relative preservation of the inner retinal layers and 
most cell death occurred in the ONL so that approximately 18% of photoreceptors across the retina 
died by a combination of necrosis and apoptosis after ballistic retinal injury. 
In the current studies photoreceptor apoptosis was assessed by TUNEL staining.  During apoptosis, 
DNA is cleaved into fragments, which are detected by the TUNEL assay.  The terminal 
deoxynucleotidyl transferase enzyme attaches fluorescein labelled deoxynucleotides to the cut ends 
of DNA fragments, thereby labelling the nuclei of apoptotic cells.  False positive TUNEL can occur for 
a number of reasons including over-incubation with proteinase K and sectioning artefact.  The 
frequency of false positive TUNEL staining is reported to be up to 30% with 15µm section widths, up 
to 69% with 5µm widths and 100% was observed with 1µm resin sections from the above 
experiments (Sloop et al. 1999).  For this reason, TUNEL is an unreliable indicator of apoptosis and 
morphological nuclear changes assessed by transmission electron microscopy are the gold standard. 
Central to the impact site there was gross retinal disruption and photoreceptor necrosis, 
demonstrated by grossly swollen cell bodies, ruptured cell and nuclear membranes and diffuse 
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TUNEL staining.  Further away from the impact site, photoreceptors died by a combination of 
apoptosis and necrosis.  Apoptosis was demonstrated by specific nuclear TUNEL staining, nuclear 
shrinkage with chomatin condensation and nuclear and cytoplasmic blebbing with invasion of the 
photoreceptor cytoplasm by adjacent cells, all in the presence of intact cellular organelles.   
Cell death represents a spectrum between apoptosis and necrosis, with significant overlap.  The 
present studies showed individual photoreceptors that had features of necrosis and others that 
showed features of apoptosis, though it is likely that many undergo a mixed form of cell death.  
Whilst necrosis is an unregulated form of cell death, apoptosis is controlled by specific cell death 
signalling pathways (see Section 1.4.2.), as is the mixed form of cell death (necroptosis) and these 
pathways can be experimentally suppressed to preserve cell viability (Ahmed et al. 2011), (Trichonas 
et al. 2010).  Thus, these results imply that, after ballistic retinal injury, death of a proportion of 
photoreceptors is mediated by one or more regulated signalling pathways, suggesting a potential for 
successful neuroprotective therapies, for example by caspase inhibition. 
In human studies, mild commotio retinae associated with photoreceptor recovery is characterised by 
outer segment disruption, whereas severe commotio retinae is associated with photoreceptor inner 
and outer segment disruption observed by OCT (Souza-Santos et al. 2012).  Inner segment disruption 
was also present in our model, but has not been reported in other (mild, recovering) animal models 
of commotio retinae.  The RPE and photoreceptor outer and inner segments appear as 3 bands on 
spectral domain OCT.  The thinner line above them may represent the ELM or the myoid portion of 
the cone inner segments (Gloesmann et al. 2003).  Loss of this line on OCT may be a marker of severe 
photoreceptor damage in commotio retinae and age related macular degeneration (Souza-Santos et 
al. 2012), (Oishi et al. 2010).  If it represents cone inner segments, it may be that disruption of these 
mitochondria rich structures (seen in our model) is a lethal injury to photoreceptors, whilst outer 
segment disruption is less likely to cause photoreceptor death. 
The rat lens accounts for 60% of axial length (Blanch et al. 2012b).  With such a small vitreous cavity, 
it is likely that the lens impacted the retina during injury in our experiments with potential crushing 
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of the retina.  This is also the case in larger animals in which ocular dimensions are close to humans, 
though with the larger lens this crushing may be more prominent in the rat (Blanch et al. 2012b).  
Importantly, the ballistic injury model developed reproducibly displayed the clinical and 
ultrastructural features of commotio retinae seen in previous human and animal studies and – similar 
to the human condition – results in photoreceptor death. 
6.8. Conclusion 
Current studies have developed an animal model of ballistic closed globe injury that induces a retinal 
response mirroring the outer retinal changes that occur after severe commotio retinae in humans, 
making it the first murine rodent model of blunt ocular trauma.  The results suggest that outer retinal 
atrophy occurs as a result of photoreceptor apoptosis and necrosis due to a terminal injury to 
photoreceptor inner segments.  The observed photoreceptor apoptosis is translationally relevant 
because it demonstrates that there is the potential to prevent photoreceptor death and improve 
visual outcomes by using anti-apoptotic neuroprotective therapies.  This model provides an 
opportunity for both mechanistic and translational therapeutic studies, which are described in 
subsequent sections. 
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7. Electroretinographic Assessment of Blunt Ocular Trauma 
Parts of the work in this section have been published in Investigative Ophthalmology and Visual 
Science (Blanch et al. 2012a), the paper is presented in Appendix 6. 
7.1. Rationale 
Photoreceptor death after ballistic retinal injury must affect retinal function.  To be able to assess the 
efficacy of neuroprotective therapies, an objective measure of retinal function is required.   
7.2. Hypothesis 
Ballistic retinal injury reduces a-wave amplitude without affecting the b/a wave ratio. 
7.3. Aims 
I. To develop a method of recording reproducible ERG in rats, after ballistic retinal injury. 
II. To assess the functional effects of ballistic retinal injury using ERG. 
7.4. Developing ERG methodology 
7.4.1. Aim 
To develop a method of recording reproducible ERG in rats, after ballistic retinal injury. 
7.4.2. Materials and Methods 
One 570g male Sprague-Dawley rat was anaesthetised with intraperitoneal ketamine/medetomidine.  
Core temperature was maintained using a water heating system, to minimise electrical interference 
with the ERG signal that could occur using an electrical heating pad.  The water heating system 
consisted of: an in-line thermostatically controlled heater, made from: a Protronic Nova water heater 
(Firstcall Photographic, Taunton, UK) sealed inside a 400x60mm cylindrical acrylic tank (Specialtech, 
Haverfordwest, UK); a second acrylic tank as a reservoir; a Phobya 12v watercooling pump 
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(Specialtech) to circulate water; a Phobya in-line G1/4” thermometer (Computers & Components 
(Central) Ltd, Redditch, UK)  to monitor temperature; a Koolance HD-60 3.5" Hard Drive Wateblock 
(Specialtech) on which the rat was positioned during recording; with all parts connected by 8mm 
polyurethane tubing (RS Components).  The apparatus was set to 38°C to maintain a constant body 
temperature in the physiological range. 
Light flashes of standard intensity (3000mcd/m2) were delivered and ERG recorded using a 
commercially available rodent ERG system (HMsERG). 
7.4.3. Results/DIscussion 
The traces recorded from both eyes had high amplitude noise, with no recognisable ERG waveform, 
examples of which are shown below in Figure 7.4.3.1. 
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Figure 7.4.3.1. A. ERG trace obtained with inadequate earthing of apparatus causing 50Hz noise from 
mains electricity. B. Poor ERG trace obtained before optimisation of electrode placement with high 
amplitude noise. 
The following modifications were made to improve recording: 
• All metal components of the heating and recording apparatus were earthed. 
• ERG were recorded in a Faraday cage. 
These modifications allowed clean and reproducible traces to be obtained.  Corneal DTL fibre 
electrodes and metal loop electrodes with hydroxypropylmethylcellulose, hyaluronate (Optive – 
Allergan, Marlow, UK) and PBS coupling medium, with and without aclar contact lens coverage were 
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all tried.  The cleanest traces were obtained with metal loop corneal 
electrodes/hydroxypropylmethylcellulose and with DTL fibre 
electrodes/hydroxypropylmethylcellulose/aclar contact lenses.  Some eye movements occur under 
anaesthesia and the animal moves with breathing and during advancement of the rat into the 
Ganzfeld stimulator, making corneal loop electrodes prone to change position.  DTL fibres were 
therefore the best option for corneal electrodes.  An example of the traces obtained with this 
recording protocol is shown in Figure 1.5.1. and repeated below in Figure 7.4.3.2. 
 
Figure 7.4.3.2. Normal rat ERG obtained after optimisation of recording protocol. 
7.4.4. Conclusions 
Clean and clear rat ERG were obtained using the optimised recording protocol, which was deemed 
suitable to use in subsequent studies to assess, (1), the reproducibility of ERG recording in the rat 
and, (2), the functional effects of the ballistic injury model. 
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7.5. ERG assessment of blunt ocular trauma 
7.5.1. Hypotheses 
I. The optimised ERG recording protocol described in Section 7.4. reproducibly assesses rat 
retinal function. 
II. Ballistic retinal injury reduces a-wave amplitude without affecting the b/a wave ratio. 
7.5.2. Aim 
To characterise the ERG features of ballistic retinal injury. 
7.5.3. Materials and Methods 
Eight female Lister-hooded rats were injured under recovery anaesthesia (see Section 6.6.7.) and ERG 
recorded from both eyes at 2, 7 and 14 d after ballistic injury under general anaesthesia with 
intraperitoneal ketamine/medetomidine.  Scotopic flash ERG were recorded at -2.5, 0 and +0.5 log 
units with respect to standard flash and photopic flash ERG at 0 and +0.5 log units as described in 
Table 7.5.3.  Animals were killed by overdose of anaesthetic at 2 weeks and tissues were used for the 
investigations described in Section 6.6.9.   
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Stage of testing 
Light exposure (log 
units with respect 
to standard flash) 
Light 
exposure 
(mcd.s/m2) 
Number of 
flashes 
averaged 
Interval 
between 
flashes (sec) 
Time 
elapsed 
(sec) 
Dark adaptation       
  
Low intensity flash 2.5 10 10 2 12 
Delay       2 14 
Standard flash 0 3000 4 10 54 
Delay       30 84 
High intensity flash 0.5 10000 4 20 164 
Background (BG) light adaptation 
(remains on for testing) 
1 30000   600 
764 
Standard flash + BG 0 + BG 3000 + BG 32 2 828 
Delay + BG 1 30000   2 830 
High intensity flash + BG 0.5 + BG 10000 + BG 32 2 894 
Table 7.5.3. ERG recording protocol. 
7.5.4. Results 
There were 2 anaesthetic deaths, 1 immediately on injection of anaesthetic and 1 during ERG 
recording.  These animals were replaced (so n=10 animals with 2 excluded). 
The raw a-wave amplitude dataset was heavily right-skewed (Appendix 7, p27-30).  The raw residuals 
after modelling with generalised estimating equations, fail both the Shipiro-Wilk and the 
Kolmogorov-Smirnov tests for normality (p<0.001 for both; Appendix 7). The Pearson residuals fail 
the Shapiro –Wilk (p=0.044) but not the Kolmogorov-Smirnov (p=0.2) tests.  The variance of the 
residuals increases with their means (Appendix 7 p31).  All of these features are consistent with the 
gamma distribution, which was used to model the data instead of the normal distribution. 
The amplitude and latency of all components were intensity dependent, though only amplitude was 
injury dependent.  Scotopic a-wave amplitude was significantly reduced by injury (Figure 7.5.4.1., 
p<0.001) and there was a borderline significant 3-way interaction between time, injury and stimulus 
intensity (p=0.056, see Appendix 7).  Since b-wave onset can obscure the a-wave, the gradient of the 
a-wave’s linear portion (leading edge) was measured, giving a similar trend as that observed for  
Figure 7.5.4.1. Quantification of the relevant components of the ERG at 2, 7 and 14 days after ballistic injury 
displayed as mean amplitude+/- standard error of the mean (SEM) at increasing stimulus intensity. A. Scotopic 
(dark-apapted) a-wave amplitude is significantly reduced by injury at all time points and stimulus intensities. B. 
Test of model effects from generalised estimating equations modelling scotopic a wave-amplitude. The term 
modelling the 3-way interaction flashintensity*timepoint*lnjured was borderline significant at p=0.056 and so was 
excluded from the model. C. Photopic (light-adapted) b-wave amplitude is similarly reduced. C. Scotopic a/b-wave 
ratio at increasing stimulus intensity. There is no significant difference between injured and control eyes. 
a/b-wave ratio is displayed, as b/a wave ratio tends to infinity with small a waves. 
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amplitude, except that the 3-way interaction between time, injury and stimulus intensity was 
significant (p=0.021; see Appendix 8).  There was no significant effect of injury on the scotopic b-/a-
wave ratio (Figure 7.5.4.1.; Appendix 9).  Photopic a-waves were frequently undetectable in injured 
and control eyes, so b-wave amplitude was analysed and was shown to be significantly reduced by 
injury (Figure 3.5.2.3.1.; p<0.001; Appendix 10), consistent with commotio retinae affecting both 
cones and rods equally.   
7.6. Discussion 
The a-wave is routinely used to measure photoreceptor function.  The b-wave is generated by the 
activity of second order neurons.  The b-wave is therefore dependent on photoreceptor activation 
and synaptic transmission in addition to inner retinal function. ERG of the injured eyes showed a 
significant reduction in a- wave amplitude compared to the control eyes without any change in 
implicit time. The b-/a-wave ratio is a measure of how much of the variation in b-wave amplitude is 
attributable to variation in the magnitude of photoreceptor, compared to second order neuron, 
activation.  The b/a wave ratio was normal and similar between injured and control eyes, indicating 
that the variation in b-wave amplitude is caused by variation in the magnitude of the photoreceptor 
response.  The reductions in ERG amplitude occurred under both scotopic and photopic conditions 
consistent with damage primarily to the photoreceptor layer and affecting both rods and cones.  
Rods make up 99% of rat photoreceptors (Szel and Rohlich 1992) and, in our model, scotopic a-wave 
amplitude (which reflects rod function) was reduced by > 50% (Figure 5), although only 18% of 
photoreceptors died (Section 6.6.9.).  The degree of ERG reduction was therefore disproportionate to 
the amount of histological photoreceptor death, suggesting reduced function in the surviving 
photoreceptors and may be explained by either outer segment damage beyond the zone of cell 
death that would not be expected to have recovered completely by 14 d or other photoreceptor 
remodelling, similar to that seen after retinal detachment (Fisher, Lewis, Linberg, and Verardo 2005).  
Additionally, the photoreceptor component (leading edge) of the a-wave is sensitive to extracellular 
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Ca2+ and K+ levels (Vinberg, Strandman, and Koskelainen 2009), which may be affected by altered 
Müller glial function or local structural changes. 
The effect of time in all the analyses is seen in 3 ways: (1), there is a change in a-wave amplitude over 
time in both the injured and control eyes (p=0.001 for scotopic a-wave amplitude); (2), there is a 2-
way interaction between time and flash intensity, i.e. the greater the stimulus intensity, the greater 
the effect of time (p=0.021 for scotopic a-wave amplitude); (3), there is a borderline significant 3-way 
interaction between time, injury and stimulus intensity, i.e. the difference in the response of the 
injured and control eyes to increasing stimulus intensity varies with time in that the effect of injury 
on this relationship is greater at 14 than at 2 d after injury (see “Estimated Marginal Means 
timepoint* flashintensity* Injured” in Appendix 7, p16).  Similarly, there is a statistically significant 2-
way interaction between stimulus intensity and injury because the effect of injury is greater at high 
stimulus intensities. 
Anaesthetic deaths whilst recording ERG may have been due to hypoxia, exacerbated by a flexed 
neck position as the animal overhangs the edge of the warming plate.  To address this, the animals 
were given oxygen supplementation and the head supported to prevent neck flexion in subsequent 
experiments.  Future experiments used inhalational anaesthetic to reduce the risk of anaesthetic 
death. 
7.7. Conclusion 
ERG assessment of the ballistic injury model generated results that were consistent with the retinal 
pathology observed in Section 6.6. and which were internally consistent in injured and in control eyes 
with reproducibility evidenced by the tight error bars (Figure 7.5.4.1.).   
Ballistic ocular injury causing commotio retinae consistently reduced a-wave amplitude without 
affecting b/a ratio indicating that the observed reduction in b wave amplitude was related to a 
reduction in function of photoreceptors rather than second order neurons.  ERG a-wave amplitude 
can therefore be used to assess functional outcomes after ballistic ocular injury. 
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8. Mechanisms of cell death following blunt ocular trauma 
Parts of the work in this section have been prepared for submission to Cell Death and Differentiation, 
the manuscript is presented in Appendix 11. 
8.1. Rationale 
The rat ballistic injury model of commotio retinae shares clinical and ultrastructural features with the 
human condition and the current studies have revealed photoreceptor apoptosis reducing visual 
function, measured using ERG a-wave amplitude.  The observation of photoreceptor apoptosis 
suggests that regulated apoptotic signalling mediates photoreceptor death and that antiapoptotic 
neuroprotective therapies have a potential role in the treatment of commotio retinae.  Subsequent 
studies examined apoptotic signalling in order to generate potential translational neuroprotective 
therapies. 
8.2. Hypotheses 
I. In experimental commotio retinae, photoreceptor apoptosis is caspase-dependent. 
II. Caspase-dependent apoptosis in experimental commotio retinae occurs through the intrinsic 
pathway. 
III. Interfering with caspase function after induction of experimental commotio retinae prevents 
photoreceptor apoptosis and improves retinal function assessed by ERG. 
8.3. Aims 
I. To assess which caspase-dependent cell death pathways are active after blunt ocular trauma. 
II. To assess the neuroprotective effects of interfering with caspase function after induction of 
commotio retinae in an experimental model. 
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8.4. Western Blotting Study of Ballistic Ocular Injury  
8.4.1. Hypothesis 
The retinal levels of activated caspase 9 and 3 will be increased in a time-dependent manner after 
ballistic ocular injury (initially caspase 9 then the executioner caspase 3). 
8.4.2. Aim 
To study which caspase-dependent cell death pathways are active after ballistic ocular injury. 
8.4.3. Materials and Methods 
At 5, 24 and 48 hr post-injury and in an uninjured control group 3 Lister-hooded rats were killed and 
both retinae removed and processed for Western blotting.  Blots were probed with antibodies to 
caspases 3, 6 (Cell Signalling), 7, 8 and 9 (Cell Signalling) and to α-tubulin (loading control). 
8.4.4. Results 
8.4.4.1. Initiator Caspases 
Western blotting results are presented in Figure 8.4.1.  Retinal levels of both activated caspase 8 and 
9 were increased after injury.  The retinal levels of activated caspase 9 increased by 5 hr and 
decreased to basal levels by 24 hr after ballistic injury (p=0.018, 1-way ANOVA).  The retinal levels of 
activated caspase 8 p16/18 fragments increased by 5 hr and did not show a significant decrease at 24 
hr or 48 hr (p=0.041, 1-way ANOVA). The retinal levels of activated caspase 8 p10 fragment increased 
by 48 hr compared to the levels at 5 and 24 hr (p=0.004, 1-way ANOVA).  The changes in levels of 
caspase 9 were qualitatively larger than those of caspase 8.  Full length caspase 9 was also increased 
at 48 hr with respect to all other time points (p<0.001, one way ANOVA); full length caspase 8 was 
not detected. 
  
Figure 8.4.1. A-B. Retinal levels of full length (49kDa) and cleaved (35-39kDa) caspase 9 after injury 
assessed by Western blotting showing increased cleaved form at 5 hrs and increased full length form at 
48 hrs. *p=0.018, **p<0.001 from Tukey post-hoc tests. C-D. Retinal levels of full length (55kDa) and 
cleaved (16/18 and 10kDa) caspase 8 after injury assessed by Western blotting showing increased p18 
fragment at 5 hrs compared to 5 and 24 hrs. Full length caspase 8 was not detected. *p=0.031, Tukey 
post-hoc tests. 
A 
35000 
Ul 
-~ 30000 
:::l 
jij 25000 
!:; 
:e 20000 
~ 
-~ 15000 
Ill 
1: 
-~ 10000 
-g 5000 
"' 
"" 0 
B 60 kDA 
35-39 kDA 
SO kDA 
I 
1 
• cont ro l 
* ** 
+ 
-
-
t 
-
-:It= -
5hrs 24hrs 48hrs 
c 
Ul 
:!::: 
25000 
§ 20000 
~ 
~ 
:5 15000 
D 35-39kDA~ 
• 49 kDA > 
·"5; 10000 
1: 
~ 
~ 5000 
1: 
"' 
"" 0 
1 
1 
control 
D 55 kDA 
18 kDA 
a-tubulin SO kDA 
* 
r--+--
+ T 
1 
0 18 kDA 
5hrs 24hrs 48hrs 
Figure 8.4.2. 
A-B. Retinal levels of full length (p33-35) and cleaved (p18) caspase-6 after injury assessed by western 
blotting showing an increase in levels of p18 up to 48 hours. Note that the level of p18 falls near the 
lower limit of detection for this assay. (*=0.009) C-D. Retinal levels of full length (32kDA), and cleaved 
(p17) caspase 3 after injury were unchanged, the pll fragment was not detected. E-F. Retinal levels of 
full length caspase 7 (p35) were unchanged after injury, the cleaved form (p20) was not detected. 
A 
33-35 kDA 
18 kDA 
50 kDA 
B 30000 
"' ·1§ 25000 
:::l 
> ~ 20000 
:.0 
~ 15000 
.<!" 
·o;; 
fii 10000 
-~ 
"0 5000 c: 
"' a:l 
0 
contro l 5 hr 24 hr 
F 
35 kDA 
20 kDA 
50 kDA 
E 
16000 
"' 
·"E 14000 
:I 
c:- 12000 
ro 
-~ 10000 
-e 
~ 8000 
> 
.... 
·;;; 6000 c 
Q) 
.... 4000 
·= 
"0 
c 2000 ro 
Ill 
0 
control 5 hr 24 hr 
c 
Full 32 kDA 
Cleaved 17 kDA 
caspase 6 
a-tubulin 11 kDA 
50 kDA 
D 
12000 
"' ·1§ 10000 
018 kDA ;_ 
• 35 kDA ~ 8000 
:e 
"' 6000 
.<!" 
·o;; 
c: 4000 w 
48 hr .S 
-o 
c: 2000 
"' a:l 
0 
Full 
Cleaved 
a-tubulin 
• 35 kDA 
48 hr 
control 5 hr 24 hr 48 hr 
Full 
Cleaved 
Cleaved 
a-tubulin 
o 17 kDa 
• 32 KDA 
 
 
159 
 
8.4.4.2. Executioner Caspases 
Western blotting results are presented in Figure 8.4.2.  Retinal levels of the full length (p32) and 
cleaved (p17) caspase 3 were detectable by western blotting, but were unchanged over the 48 hr 
after injury (p=0.519, 0.536 respectively; one way ANOVA), whilst the p11 fragment was 
undetectable (Figure 4C-D).  Similarly, western blots detected full length caspase 7 in the retina (p35) 
that remained unchanged in the 48 hr after injury (p=0.317; one way ANOVA), whilst the p20 cleaved 
fragment was not detectable (Figure 4E-F).  However, western blots showed that retinal levels of 
cleaved caspase-6 (p18),  increased up to 48 hr after injury (p=0.009; one way ANOVA), but the levels 
of full length caspase-6 (p33-35) were not significantly altered (p=0.059; one way ANOVA) (Figure 4A-
B). 
8.4.5. Discussion 
Western blotting was performed to investigate the expression and processing of initiator caspases in 
the retina.  Compared to uninjured retinae, levels of cleaved caspase-9 were increased by 5 hr and 
decreased to basal levels by 24 hr after ballistic injury.  Caspase-9 is an initiator caspase, and as such 
usually activates downstream executioner caspases (such as caspase-3, -6, and -7) to bring about 
apoptosis (Galluzzi, Blomgren, and Kroemer 2009).  Western blotting, was used to investigate which 
executioner caspases were cleaved after ballistic injury and showed that the only active executioner 
caspase in the retina after ballistic injury is caspase-6. 
Subsequent experiments were needed for precise retinal localisation of these caspases and to 
confirm catalytic activity. 
8.4.6. Conclusions 
Retinal levels of cleaved caspases 6, 8 and 9 are increased after ballistic ocular injury. 
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8.5. Immunohistochemical study of high velocity retinal injury  
8.5.1. Hypothesis 
Cleaved caspases 6, 8 and 9 immunolocalise to photoreceptors after ballistic ocular injury. 
8.5.2. Aim 
To confirm the precise retinal locations of cleaved caspases within the retina. 
8.5.3. Materials and Methods 
Two groups of 4 female Lister-hooded rats had unilateral, right ballistic ocular injury under recovery 
anaesthesia  (see Section 6.6.7.) and were killed 5 and 24 hr later.  The left eyes were controls.  
Samples were processed for immunohistochemistry.  
Immunohistochemical staining was performed for caspases 3, 6 (Cell Signalling and Santa Cruz), 7, 8 
and 9 (Santa Cruz), cone arrestin, ED1 (CD68) and OX42 (CD11b). 
8.5.4. Results 
Caspase 9 staining was increased in the region of photoreceptor inner segments around the impact 
site 5 hr after injury and in photoreceptor cell bodies 48 hr after injury (Figure 8.5.1.).  Caspase 8 was 
not detected in the ONL (data not shown).   
Cleaved caspase 6 was detected in all photoreceptors 48 hr after injury (Figure 8.5.2.A-D) and in 
cones (co-staining with cone arrestin; Figure 8.5.2.E-H) around the impact site.  Co-staining with ED1 
and OX42 confirmed that the observed caspase immunolocalisation was not in inflammatory cells.  
Cleaved caspases 3 and 7 were not detected in the ONL.  
8.5.5. Discussion 
Compared to uninjured control retinae, caspase-9 levels were increased in photoreceptor inner 
segments of injured animals at 5 hr after injury and in photoreceptor cell bodies at 48 hr, indicating  
Figure 8.5.1. 
Immunohistochemical staining of rat outer retinal layers after injury (DAPI-stained nuclei shown in blue, 
501J.m scale bar). A-B. Caspase-9 (arrows) in photoreceptor inner segments, seen between the DAPI 
stained outer nuclear layer (ONL) and the autofluorescent outer segments (OS) at 5 hours after injury 
(A), but not in uninjured control retina (B). C-F. Increased caspase-9 levels in photoreceptor cell bodies 
(arrows) at 2 days in injured (C, blue and green channels in D-E, respectively) but not uninjured control 
retina (F). 
Figure 8.5.2. 
A-D. Activated caspase-6 (Cell Signalling, rabbit; arrow) in photoreceptor cell body (green) at 2 days 
after injury (A, blue and green channels in B-C, respectively), but not in uninjured control tissue (D). In-
flammatory cells are stained red by EDl. E-J- DAPI-stained nuclei shown in blue, cone arrestin in red and 
activated caspase-6 (Santa Cruz, goat) in green E. 2 days after injury activated caspase-6 colocalised 
with cone arrestin and so was present in cones in the outer nuclear layer (ONL). F-G. Red and green 
channels of E. H. Uninjured control retina with cone arrestin staining cones green (example cell body ar-
rowed), but no caspase-6 staining (red). 1-J. Red and green channels of H. 
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that cleaved active caspase-9 was present in photoreceptors 5 hr after injury, consistent with its 
function as an initiator and full length caspase-9 was upregulated by 48 hr, correlating with 
photoreceptor apoptosis. 
Despite being advertised as specific for the cleaved form, the antibodies against caspase 9 may have 
limited ability to distinguish between cleaved and full length enzyme, evidenced by the fact that on 
western blotting, levels of cleaved enzyme are increased at 5 hr and full length enzyme at 48 hr, yet 
the same antibody immunohistochemically detected increased levels of caspase 9 at 5 and 48 hr 
after injury.  An alternative explanation is that cleaved caspase 9 immunolocalised in photoreceptor 
cell bodies 48 hr after injury, but that cells with active caspase 9 represented too few of the total 
number of retinal cells for increased cleaved caspase 9 levels to be detected by western blotting.  It is 
therefore not possible from these data be certain that photoreceptors expressed the 
transcriptionally upregulated full-length caspase 9.  However, the immunolocalisation of cleaved 
caspase 9 to the mitochondria-rich outer segments 5 hr after injury is consistent with activation 
linked to MOMP and the immunolocalisation of caspase 9 to the cell body 48 hr after injury is 
consistent with synthesis there, suggesting that the antibody detected both cleaved and full length 
caspase 9, though possibly with different affinities for the 2 forms. 
Of the 3 executioner caspases (3, 6 and 7), only cleaved caspase 6 was immunolocalised in 
photoreceptors and increased in the retina assessed by western blotting.  Thus the only active 
executioner caspase present in photoreceptors after ballistic injury is caspase-6 and therefore we 
hypothesised that caspase-6 executes the apoptotic programme in photoreceptors after initiation by 
caspase-9.. 
8.5.6. Conclusion 
There is cleaved caspase 6 and 9 in photoreceptors after ballistic ocular trauma.  This suggests that 
cell death could be prevented by caspase 6 and 9  inhibition. 
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8.6. Demonstration of Catalytically Active Caspase 9 in Photoreceptor Apoptosis 
8.6.1. Rationale 
Cleaved caspase 9 levels increased in the retina 5 hr after ballistic injury and immunolocalised to 
photoreceptors.   
Valine-Alanine-Aspartate-fluoromethyl ketone (VAD-fmk) is a pan-caspase inhibitor that covalently 
binds and, in its biotinlyated form (bVAD-fmk),  isolates caspases-1, -2, -3, -8 and -9 through 
interaction with immobilised streptavidin (Tu et al. 2006), (Moulin and Arrigo 2008).  Because binding 
is initiated by the catalytic activity of the caspase, bVAD-fmk isolates only catalytically active enzyme. 
8.6.2. Hypothesis 
I. Caspase 9 is catalytically active within the first 5 hr after ballistic ocular injury. 
II. Caspase 6 is catalytically active 48 hr after ballistic injury. 
8.6.3. Aim 
I. To demonstrate catalytically active caspase 9 in the retina within the first 5 hr after ballistic 
ocular injury. 
II. To demonstrate catalytically active caspase 6 in the retina 48 hr after ballistic ocular injury. 
8.6.4. Materials and Methods 
In 2 groups of 6 animals, bVAD-fmk was injected intravitreally into both eyes, 3 of which were 
bilaterally ballistically injured.  To capture the active initiator caspase 9 (group 1), injuries were 
induced 2 hr after injection and all animals were killed 5 hr after injury.  To capture the active 
executioner caspase 6 (group 2), injuries were induced 43 hr before injection and all animals were 
killed 5 hr after injection and retinae processed for caspase pull-down assay.  The blot for group 1 
was probed with an antibody to caspase 9 (Cell Signalling) and the blot for group 2 with an antibody 
to caspase 6 (Cell Signalling). 
Figure 8.6. 
Caspase capture assay. A-B. Pull-down 5 hr after ballistic injury, probed for caspase 9 (Cell Signalling) and 
showing increased levels of catalytically active caspase 9 in the injured compared to the control retinae 
(p=0.028). B-C. Pull-down 48 hr after injury probed for caspase 6 (Cell Signalling) and showing increased 
levels of catalytically active caspase 6 in the injured compared to the control retinae (p=0.003). Note the 
faint band, that required a long (10 min) exposure time. 
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8.6.5. Results 
8.6.5.1. Caspase 9 Capture 
Higher levels of active caspase-9 were isolated from injured than from uninjured retinae (Figure 8.6.; 
p=0.028, 2 sample t-test). 
8.6.5.2. Caspase 6 Capture 
Higher levels of active caspase-9 were isolated from injured than from uninjured retinae (Figure 8.6.; 
p=0.003, 2 sample t-test;). 
8.6.6. Discussion 
bVAD-fmk was used to isolate active caspase 9 within the first 5 hr after ballistic ocular injury, which 
is the first demonstration of catalytically active caspase 9 after eye injury.   
8.6.7. Conclusion 
Caspase 9 was catalytically active within 5 hr after ballistic ocular injury. 
8.7. Demonstration of the Role of Caspase 9 in Photoreceptor Apoptosis 
8.7.1. Rationale 
Caspase 9 was active in photoreceptors within 5 hr of injury.  It is therefore likely that caspase 9 
initiates apoptosis in a proportion of photoreceptors after ballistic ocular injury. 
8.7.2. Hypothesis 
Caspase 9 inhibition decreases cell death and preserves retinal function after ballistic ocular injury. 
8.7.3. Aim 
To assess the importance of caspase 9 as a mediator of cell death in photoreceptors after ballistic 
ocular injury. 
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8.7.4. Materials and Methods 
Eight rats were subjected to bilateral ballistic ocular injury.  The highly specific caspase-9 inhibitor, X-
linked inhibitor of apoptosis (IAP)-baculoviral IAP repeat 3 domain (XBIR3), linked to a cell 
transduction peptide Penetratin 1 (Pen1; PolyPeptide Laboratories,Torrance, CA USA) (Eckelman et 
al. 2006) was prepared as previously described (kindly supplied by Carol Troy, Columbia University, 
USA) (Sun et al. 2000), and 5µl of 5µM solution was delivered by unilateral intravitreal injection to 
inhibit caspase-9 in 8 rats (n=8 eyes).  Contralateral eyes were given control treatment with Pen1 
alone.  Scotopic and photopic ERG series with stimuli ranging from -2.5 to + 1 log units with respect 
to a standard flash were recorded at 7 and 14 d after injury as shown in Table 8.7.4.  Animals were 
killed at 14 d and eyes prepared as for immunohistochemistry.  Sections were taken through the 
optic disc (and centre of the impact site) and 600, 1200 and 1800μm either side for H&E staining and 
quantification of cell death. 
H&E stained slides were scanned on a Mirax slide scanner (Zeiss) and the ONL manually segmented 
using the magnetic lasso tool in Adobe Photoshop by an observer blind to treatment allocation 
(Figure 8.6.1.).  To measure average ONL thickness without incorporating cryosection fragmentation 
artefact, the outer nuclear layer was then converted to 8 bit grayscale and thresholded to level 160 
in ImageJ (http://rsbweb.nih.gov/ij).  Pixels above threshold were counted using the automatic pixel 
counting function of ImageJ and total section length was measured using the segmented line tool.  
Average ONL thickness (in pixels) was calculated as number of above threshold ONL pixels divided by 
the length of the section (Figure 8.7.1.). 
Figure 8.7.1. A. Cut-out outer nuclear layer from B. B 
whole H&E stained rat retinal section with illustrative 
line showing the measurement of section length. 
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Stage of testing 
Light exposure (log 
units with respect 
to standard flash) 
Light 
exposure 
(mcd.s/m2) 
Number of 
flashes 
averaged 
Interval 
between 
flashes (sec) 
Time 
elapsed 
(sec) 
Dark adaptation           
Scotopic Flash -2.5 10 10 2 20 
Delay       2 22 
Scotopic Flash -2 30 4 5 42 
Delay       5 47 
Scotopic Flash -1.5 100 4 10 87 
Delay       10 97 
Scotopic Flash -1 300 4 10 137 
Delay       10 147 
Scotopic Flash -0.5 1000 4 10 187 
Delay       10 197 
Scotopic Flash 0 3000 4 10 237 
Delay       10 247 
Scotopic Flash 0.5 10000 4 15 307 
Delay       15 322 
Scotopic Flash 1 25000 4 20 402 
Background (BG) light adaptation 
(remains on for testing) 
1 30000   600 1002 
Photopic Flash (+ BG) -2.5 10 10 0.5 1007 
Delay + BG  1  30000   0.5 1007.5 
Photopic Flash (+ BG) -2 30 10 0.5 1012.5 
Delay + BG  1  30000   0.5 1013 
Photopic Flash (+ BG) -1.5 100 10 0.5 1018 
Delay + BG  1  30000   0.5 1018.5 
Photopic Flash (+ BG) -1 300 10 0.5 1023.5 
Delay + BG  1  30000   0.5 1024 
Photopic Flash (+ BG) -0.5 1000 10 0.5 1029 
Delay + BG  1  30000   0.5 1029.5 
Photopic Flash (+ BG) 0 3000 10 0.5 1034.5 
Delay + BG  1  30000   0.5 1035 
Photopic Flash (+ BG) 0.5 10000 10 0.5 1040 
Delay + BG  1  30000   0.5 1040.5 
Photopic Flash (+ BG) 1 25000 10 0.5 1045.5 
Table 8.7.4. Scotopic and photopic ERG recording protocol 
8.7.5. Results 
8.7.5.1. Structural Neuroprotection 
Caspase-9 inhibition reduced photoreceptor death, demonstrated by preserved outer nuclear layer 
(ONL) thickness on retinal sections (Figure 8.6.2.A-B).  The effect of treatment on ONL thickness was 
modelled using generalised estimating equations (Appendix 12) showing: (1), a non-significant effect  
Figure 8.7.2. A. Outer nuclear layer (ONL) thickness as a function of distance from the impact site. B. Test of model 
effects after analysis of ONL thickness including treatment, distance from the impact site and a term to model their 
interaction. C Scotopic a-wave amplitude as a function of stimulus intensity. D. Test of model effects after analysis 
of scotopic a-wave amplitude including time after injury (timepointdays), stimulus intensity (flashintensitymcd), 
Penl-XBIR3 compared to Penl alone (TreatedXBIR3vspen) and terms to model all 2 and 3 way interactions. E. 
Photopic b-wave amplitude as a function of stimulus intensity. F. Test of model effects after analysis of photopic 
b-wave amplitude including time after injury, stimulus intensity, treatment and terms to model all 2- and 3-way 
interactions. Caspase-9 inhibition by Penl-XBIR3 increases scotopic a- and photopic b-wave amplitudes with an 
effect that is more pronounced at higher stimulus intensities and at 14 as opposed to 7 days after injury. 
Caspase-9 inhibition also increased ONL thickness peripheral but not central to the impact site. 
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of caspase-9 inhibition across all distances from the impact site (p=0.29); (2), a highly significant 
effect of distance from the centre of the impact site, i.e. the outer nuclear layer was thinner towards 
the centre of the impact site (p<0.001), as we have previously reported (Blanch et al. 2012a); (3), a 
significantly thicker ONL peripheral, but not central, to the impact site in caspase-9-suppressed than 
in Pen1-treated eyes (p=0.019 for the 2-way interaction distance*caspase-9 inhibition). 
8.7.5.2. Functional Neuroprotection 
Compared to eyes injected with intravitreal Pen1 alone, caspase-9 inhibition improved rod and cone 
function, assessed by scotopic a-and photopic b-wave amplitude respectively, and this benefit 
increased with time after injury (Figure 8.6.2.C-F).  The effect of treatment on scotopic a-wave 
amplitude was modelled using generalised estimating equations (Figure 8.6.2.D and Appendix 13) 
showing: (1), a borderline significant increase in a-wave amplitude after caspase-9 inhibition across 
all stimulus intensities and time points (p=0.070); (2), a positive effect of caspase-9 inhibition on a-
wave amplitude that increases with stimulus intensity (p<0.001 for 2-way interaction caspase-9 
inhibition*stimulus intensity); (3), a significant difference in the effect of caspase-9 inhibition 
between the 2 time points with a more pronounced positive effect (with smaller error bars) at 14 
than at 7 d (p<0.001 for the 3-way interaction caspase-9 inhibition*stimulus intensity*time).  
Photopic b-wave analysis showed similar effects (Figure 8.6.2.E-F; Appendix 14). 
8.7.6. Discussion 
Use of peptide pharmacological inhibitors (like VAD-fmk) to study caspase activity is common.  
However, overlap in cleavage motifs means that these inhibitors are non-specific.  XBIR3 –the BIR3 
domain of XIAP – is a highly specific inhibitor of caspase-9 (Srinivasula et al. 2001) and so the 
observed neuroprotective effects of caspase-9 inhibition are unlikely to be XBIR3 off-target effects 
(Akpan et al. 2011). 
As 98% of rat photoreceptors are rods and the ONL contains exclusively photoreceptors, ONL 
thickness reflects rod survival (Blanch et al. 2012b).  Caspase-9 inhibition after blunt ocular trauma 
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most affected ONL thickness peripheral to the impact site, where the highest proportion of apoptotic 
cells are found, as opposed to central to the impact site, where most cell death is necrotic and 
therefore less susceptible to modulation by altered caspase activity (Blanch et al. 2012a).  Consistent 
with caspase-9’s function as an initiator caspase, the spike in retinal levels of activated caspase-9 was 
recorded 5 hr after injury and was followed by compensatory upregulation of full length caspase-9 by 
48 hr.  The western blotting, immunohistochemical and survival data therefore demonstrate that 
caspase-9 initiates rod and cone apoptosis in a proportion of photoreceptors after blunt ocular 
trauma causing commotio retinae. 
The a-wave is the first negative deflection on the ERG, caused by photoreceptor hyperpolarisation, 
and its amplitude is routinely measured to assess photoreceptor function.  Commotio retinae 
reduces photoreceptor function (assessed by a-wave amplitude) out of proportion to the extent of 
photoreceptor death (Blanch et al. 2012a).  Scotopic a-wave amplitude in rats reflects rod function 
and was increased by caspase-9 inhibition, indicating that the increased survival seen on ONL 
thickness measurements was accompanied by increased rod function.   
Photopic ERG are recorded under conditions of light adaptation, which bleaches rod photoreceptors 
and ensures that the ERG response is cone-mediated.  In rats, the photopic a-waves are small and 
often undetectable after injury (Blanch et al. 2012a).  The b-wave is the first positive deflection, 
immediately following the a-wave and is generated by the activity of second order neurons (such as 
ON bipolar cells in the inner nuclear layer).  The b-wave is therefore dependent on photoreceptor 
activation and synaptic transmission in addition to inner retinal function.  In addition, the b-wave is 
measured from the base of the a-wave and thus incorporates both responses.  The b- to a-wave ratio 
is a measure of how much of the variation in b-wave amplitude is due to variation in the magnitude 
of photoreceptor activation compared to the function of second order neurons.  In rats, the b- to a-
wave ratio is unaffected by commotio retinae (Blanch et al. 2012a), indicating that any variation in b-
wave amplitude is due to variation in the magnitude of the photoreceptor response.  The observed 
changes in photopic b-wave amplitude therefore reflect cone photoreceptor function, which was 
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increased by caspase-9 inhibition, indicating that caspase-9 also initiates cone apoptosis after blunt 
ocular trauma. 
The most commonly reported ultrastructural feature of acute commotio retinae is photoreceptor 
outer segment disruption (Blight and Hart 1977), (Souza-Santos et al. 2012).  In mild cases of 
commotio retinae there is visual recovery, correlated with outer segment regeneration over weeks 
to months (Blight and Hart 1977), (Souza-Santos et al. 2012).  The effect of caspase-9 inhibition on 
cone and rod function was greater at 14 than at 7 d, consistent with functional regeneration of 
damaged outer segments of photoreceptors rescued from apoptosis by caspase-9 inhibition. 
demonstrating that caspase-9 mediates photoreceptor apoptosis after ballistic injury.  indicating that 
caspase-9 mediates both rod and cone apoptosis after ballistic injury and its inhibition is functionally 
neuroprotective 
This study clearly shows that after high velocity blunt ocular trauma causing retinal injury, inhibition 
of caspase 9 function with Pen1-XBIR3 delivered intravitreally, (1), reduces photoreceptor death over 
2 weeks and, (2), improves photoreceptor function, as assessed by ERG a-wave amplitude.   
P values are not significant for an overall effect of treatment but only for interactions with other 
factors.  In the analysis of ONL thickness, this is because the sections through the centre of the 
impact site feature predominantly necrotic cells, which will not survive as a result of caspase 9 
inhibition.  If the zone of apoptotic cells is viewed as a peripheral ring of potentially salvageable cells 
around the necrotic zone at the impact site, the sections through the centre cut radially through this 
ring and have a minority of salvageable cells.  The sections through the peripherally of the impact site 
have few necrotic cells, but cut tangentially through this ring of salvageable cells.  So a 
neuroprotective effect of sufficient magnitude to achieve statistical significance is only seen in the 
peripheral sections and this is reflected as an interaction between the effects of distance from the 
impact site and treatment.  Similarly for the ERG data, the a-wave is low amplitude or absent at low 
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stimulus intensities, so an effect of treatment is only apparent at higher stimulus intensities and this 
is reflected as an interaction between the effects of stimulus intensity and treatment. 
8.7.7. Conclusions 
Caspase 9 initiates rod and cone apoptosis after ballistic ocular injury. 
8.8. Demonstration of the Role of Caspase 6 in Photoreceptor Apoptosis 
8.8.1. Hypothesis 
Caspase 6 inhibition decreases cell death and preserves retinal function after ballistic ocular injury. 
8.8.2. Aim 
To assess the importance of caspase 6 as a mediator of cell death in photoreceptors after ballistic 
ocular injury. 
8.8.3. Materials and Methods 
Eight rats were subjected to bilateral ballistic ocular injury.  Inhibition of caspase-6 activity used a 
caspase-6 (Cys163Ala) dominant negative (C6DN) protein linked to Pen1 (kindly supplied by Carol 
Troy, Columbia University, USA).  The C6DN construct was a gift from G. S. Salvesen, Sanford-
Burnham Institute, La Jolla, CA and C6DN was purified as previously described (Denault and Salvesen 
2003), and 5µl of 5mM solution was delivered by unilateral intravitreal injection in 8 rats (n=8 eyes).  
Contralateral eyes were given control treatment with Pen1 alone.  Scotopic and photopic ERG series 
with stimuli ranging from -2.5 to + 1 log units with respect to a standard flash in half log unit steps 
were recorded at 7 and 14 d after injury as shown in Table 8.7.4. and animals killed at 14 d and eyes 
prepared as for immunohistochemistry.  ONL thickness was measured as described in Section 8.6.3. 
  
Figure 8.8. A. Outer nuclear layer thickness as a function of distance from the impact site. B. Test of model 
effects after analysis of ONL thickness including treatment and distance from the impact site, with 
non-significant terms removed (before removal, p=0.345 for normalisedslidenumber*TreatedCasp6DNvspen 
and p=0.689 for TreatedCasp6DNvspen). C. Scotopic a-wave amplitude as a function of stimulus intensity. D. 
Test of model effects after analysis of scotopic a-wave amplitude including time after injury (timepointdays), 
stimulus intensity (flashintensitymcd), Pen1-C6DN compared to Penl alone (TreatedCasp6DNvspen) and terms 
to model all 2- and 3-way interactions. E. Photopic b-wave amplitude as a function of stimulus intensity. F. Test 
of model effects after analysis of photopic b-wave amplitude including time after injury, stimulus intensity, 
treatment and terms to model significant interactions only. Caspase-6 inhibition using Pen1-C6DN had no 
effect on ONL thickness, but reduced scotopic a- and photopic b-wave amplitudes with an effect that was more 
pronounced at higher stimulus intensities. 
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8.8.4. Results 
8.8.4.1. Structural Assessment 
The effect of caspase-6 inhibition on ONL thickness was modelled using generalised estimating 
equations (Appendix 15) and did not show any significant differences compared to control eyes  in 
main effects or interaction terms (Figure 8.7.A-B), indicating that caspase-6 inhibition did not reduce 
rod death after ballistic injury.   
8.8.4.2. Functional Assessment 
Caspase-6 inhibition reduced rod and cone photoreceptor function, assessed by scotopic a- and 
photopic b-wave amplitude (Figure 8.7.C-F).  The effect of caspase-6 inhibition on scotopic a-wave 
amplitude was modelled using generalised estimating equations (Figure 8.7.D; Appendix 16) and 
showed: (1), a non-significant effect of caspase-6 inhibition across all stimulus intensities and time-
points (p=0.791); (2), a negative effect of caspase-6 inhibition on a-wave amplitude that increases 
with stimulus intensity (p<0.001 for the 2-way interaction caspase-6 inhibition*stimulus intensity); 
(3), a significant difference in the effect of caspase-6 inhibition between the 2 time points, with a 
greater negative effect at 14 than at 7 d (p<0.001 for the 3-way interaction caspase-6 
inhibition*stimulus intensity*time).  Photopic ERG assessment of cone function showed similar 
effects, except that there was no significant difference between 7 and 14 d (Figure 8.7.E-F; Appendix 
17). 
8.8.5. Discussion 
The unexpected failure of caspase 6 inhibition to affect photoreceptor death may represent a 
significant negative or an underpowered study.  In general post-hoc power calculations are not 
helpful in determining whether an observed non-significant effect reflects the absence of a 
population effect or a lack of power because the estimate of effect size derived from the (non-
significant) data is necessarily imprecise.  The use of confidence intervals is more appropriate in this 
context in defining the range of effect size consistent with the data.  However, the interpretation of 
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confidence intervals for interaction terms derived from repeated measures data such as this is not 
clear.  Looking at the error bars in Figure 8.7.F, the data seems to be consistent with a positive effect 
of similar magnitude to that presented after caspase 9 inhibition in Section 8.7.  However, the finding 
of a statistically significant detrimental effect on retinal function would suggest that insufficient 
power is an unlikely explanation for these findings. 
Of the three executioner caspases (-3, -6 and -7), only caspase-6 activity was increased after ballistic 
injury.  Caspase-6 was active in both rods and cones after injury, but does not seem to serve as an 
executioner in this model.  Although caspase-6 inhibition did not affect ONL thickness, it did reduce 
both scotopic and photopic ERG amplitudes, indicating that caspase-6 inhibition is detrimental to 
retinal function after blunt ocular trauma.  Caspase-6 has been implicated in cell death after 
ischaemic stroke (Akpan et al. 2011), in axonal degeneration in vitro and after optic nerve crush 
(Nikolaev, McLaughlin, O'Leary, and Tessier-Lavigne 2009), (Monnier et al. 2011), and in cleavage of 
microtubules and cytoskeletal proteins in Alzheimer’s disease (Guo et al. 2004), (Klaiman, Petzke, 
Hammond, and Leblanc 2008).  That ONL thickness was not affected, suggests that the observed 
functional effects do not relate to caspase-6’s role in cell death.  It may be that caspase-6’s role in 
microtubule processing is required for photoreceptor outer segment survival or regeneration after 
commotio retinae. 
The role of caspase 6 in apoptosis is incompletely understood and caspase 6 activation does not 
necessarily induce cell death (Klaiman, Champagne, and LeBlanc 2009).  It is also possible that in the 
ballistic injury model, caspase 6 has a role in preventing necroptotic cell death through RIP cleavage 
and that inhibiting caspase 6 in the current study increased the number of cells undergoing a necrotic 
form of cell death (van Raam, Ehrnhoefer, Hayden, and Salvesen 2013).  If decreased RIP cleavage 
caused necroptotic cell death after caspase 6 treatment, then future studies using the RIP1 inhibitor 
necrostatin in addition to caspase 6 inhibition or in isolation would be expected to demonstrate 
neuroprotective effects. 
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8.8.6. Conclusions 
Caspase 6 does not mediate rod or cone apoptosis after ballistic ocular injury and caspase 6 
inhibition is detrimental to retinal function. 
8.9. General Discussion/Conclusions 
The experiments described in this section indicate that rod and cone apoptosis after blunt ocular 
trauma occur through the intrinsic pathway, initiated by caspase-9.  Despite the presence of 
catalytically active caspase-6 in rods and cones after injury, its inhibition using a highly specific 
inhibitor did not prevent photoreceptor apoptosis but instead was detrimental to retinal function. In 
contrast, active caspase trapping assays revealed that caspase-9 is an early mediator of 
photoreceptor death and its inhibition reduced photoreceptor death and preserved visual function in 
both rods and cones, inducing structural and functional neuroprotection that was sustained at 2 
weeks post-injury. 
bVAD-fmk was used to isolate active caspase-9 within the first 5 hr after trauma, which is the first 
demonstration of catalytically active caspase-9 after eye injury.  Caspase-6 was also isolated by this 
method 48 hr after ballistic injury, which is the first report of catalytically active caspase-6 isolation 
using bVAD-fmk.  Activated caspase-6 levels detected by Western blotting and bVAD-fmk increased 
up to 48 hr after injury, but were near the lower limits of detection of the assays, suggesting that 
although caspase-6 is active after ballistic injury, it is present in only a small number of 
photoreceptors. 
The high levels of cleaved caspase 9 observed 5 hr after injury are consistent with its function as an 
initiator caspase.  For caspase 9 inhibition to be a translational therapy for eye injury, there would 
need to be a time window after injury in which initiation of treatment retained therapeutic benefit.  
There would also need to be a sustained benefit after discontinuing treatment.  Future studies 
should therefore investigate how delayed administration of and duration of treatment with XBIR3 
affect its neuroprotective benefits. 
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Caspase 2 shares substrate specificities with the executioner caspases (Troy and Ribe 2008), thus 
further investigations should examine the role of caspase 2 as a potential, novel, executioner caspase 
in the ballistic injury model.  The role of caspase 6 in the ballistic ocular injury model is still unclear 
and further work should include an assessment of the effects of caspase 9 inhibition on caspase 6 
activation and investigation of the RIP necroptotic cell death pathway and its interaction with 
caspase 6. 
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9. The neuroprotective Effect of Progesterone After High Velocity Injury 
Parts of the work in this section have been prepared for submission to PLOS One, a draft manuscript 
is presented in Appendix 18. 
9.1. Study of Progesterone-induced Neuroprotection 
9.1.1. Rationale 
9.1.1.1. Progesterone in Traumatic Brain Injury 
Female rats have better functional outcomes and develop less cerebral oedema after traumatic brain 
injury than male rats, and this effect is more pronounced in pseudo-pregnant rats, which have high 
circulating progesterone and low oestrogen (Attella, Nattinville, and Stein 1987), (Roof, Duvdevani, 
and Stein 1993).   In contrast, female gender in humans is associated with a worse outcome after 
traumatic brain injury (TBI) (Farace and Alves 2000).  Nonetheless, the beneficial effects of female 
gender in animal studies of CNS trauma have been attributed to the higher levels of circulating 
progesterone compared to male rats and, in humans, phase II trials of progesterone treatment after 
traumatic brain injury have shown promising results (Xiao et al. 2008). 
9.1.1.2. Mechanisms of progesterone-induced neuroprotection  
Progesterone has transcriptional, translational and post-translational effects which limit lipid 
peroxidation, oxidative stress, inflammatory cytokine release, excitotoxicity and apoptosis.  
9.1.1.2.1. Intracellular signaling  
The progesterone receptor is a nuclear transcription factor associated with progesterone response 
elements in the promoter region of neurotrophin genes such as BDNF, upregulation of which 
mediates progesterone-induced neuroprotection (Jodhka et al. 2009) (Kaur et al. 2007) (Singh and Su 
2013b).  In addition, progesterone binding to the neuronal progesterone receptor membrane 
component-1 (PGRMC1) releases BDNF (Singh and Su 2013b) (Singh and Su 2013a).  Membrane 
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receptor binding activates a number of intracellular signalling pathways including MAPK/ERK and PI-
3-kinase/Akt/mTOR (Singh and Su 2013b) (Singh and Su 2013a), and inhibition of these pathways 
blocks progesterone’s neuroprotective effects (Kaur et al. 2007).  Progesterone upregulates anti-
apoptotic Bcl-2 expression and activates Akt to phosphorylate pro-apoptotic Bad, inactivating it.  Akt 
also phosphorylates forkhead transcription factor (FKHR), which inhibits Fas pathway activation 
(Zhao, Sapolsky, and Steinberg 2006) (Sugawara et al. 2004).  Progesterone has some conflicting 
effects on cell death pathways though, upregulating uterine caspase 3 expression in pregnancy 
(when caspase 3 has functional, non-apoptotic effects), indirectly downregulating anti-apoptotic 
factors including NF-κB and complexing with the NFκB p65 subunit to prevent its action (Pettus, 
Wright, Stein, and Hoffman 2005), (Jeyasuria et al. 2009). 
9.1.1.2.2. Anti-oxidant  
Lipid peroxidation disrupts plasma membranes and contributes to blood-brain barrier breakdown 
after TBI.  Progesterone reduces lipid peroxidation and free radical production and enhances free 
radical scavenging systems (Stein 2008a), (Roof, Hoffman, and Stein 1997), (Subramanian, 
Pusphendran, Tarachand, and Devasagayam 1993).  Clinical evidence showing that the lipid 
peroxidation marker, F (2)-isoprostane is higher in male than female cerebral spinal fluid after TBI 
supports the membrane-stabilising effects progesterone (Bayir et al. 2004) (Stein 2007).   
9.1.1.2.3. Anti-inflammatory  
Progesterone downregulates synthesis and inhibits release of inflammatory factors and cytokines 
such as IL-1β, TNFα, complement factors C3, 5, macrophage-inducing factor-1, CDs 24 and 74 and 
iNOS reducing cerebral oedema and improving functional outcomes in TBI models (Pettus, Wright, 
Stein, and Hoffman 2005), (Djebaili et al. 2005), (Nilsen and Brinton 2002a), (Drew and Chavis 2000) 
(Gibson et al. 2005).  Progesterone also reduces astrocytosis, gliosis and microglial activation after 
TBI (Garcia-Estrada, Luquin, Fernandez, and Garcia-Segura 1999) (Garcia-Estrada et al. 1993).  
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9.1.1.2.4.  Progesterone metabolites   
Progesterone metabolites may mediate neuroprotection.  Progesterone is broken down to 
dihydroprogesterone  (DHP) by 5α-reductase and then to 3α, 5α-tetrahydroprogesterone (THP).   
THP administration reduced oedema and apoptosis and improved functional outcomes  after 
experimental TBI (Djebaili et al. 2005), (Djebaili, Hoffman, and Stein 2004), (He et al. 2004). THP binds 
to the GABA receptor, potentiating chloride conductance and counteracting glutamate-induced 
excitotoxicity.  THP also inhibits MPTP opening and upregulates BDNF (Sayeed et al. 2009), (Wang et 
al. 2008) (Nin et al. 2011).   
The synthetic progestin medroxyprogesterone acetate has not been found to be neuroprotective in 
excitotoxic models, actually reducing BDNF levels, and administration of the 5α-reductase inhibitor 
finasteride blocked progesterone’s neuroprotective effects (Jodhka et al. 2009), (Nilsen and Brinton 
2002b), (Ciriza, Carrero, Frye, and Garcia-Segura 2006).   
9.1.1.3. Progesterone in Photoreceptor Death 
Results from preclinical studies of progesterone in photoreceptor cell death models are variable.  In 
Sprague-Dawley rats exposed to 2700 lux for 24 hr, progesterone was not neuroprotective when 
given IP at a dose of 60mg/kg daily in benzyl alcohol whereas, the synthetic progestin Norgestrel was 
neuroprotective when given IP to both Balb/c mice exposed to 5000 lux for 2 hr and rd10 retinal 
degeneration mice (Kaldi and Berta 2004), (Doonan, O'Driscoll, Kenna, and Cotter 2011).  The efficacy 
of Norgestrel conflicts with previous work suggesting that metabolites are responsible for the 
neuroprotective effect (Ciriza, Carrero, Frye, and Garcia-Segura 2006) and there were more TUNEL-
positive cells in the Norgestrel-treated animals 14 d after injury (Doonan, O'Driscoll, Kenna, and 
Cotter 2011), suggesting that apoptosis had been delayed rather than prevented.  One other pre-
clinical study in phototoxicity models did not show a beneficial effect of progesterone, but instead 
showed that ovariectomy (which lowers serum progesterone) was neuroprotective (O'Steen 1977). 
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Another study using rd1 mice (a retinitis pigmentosa model) showed reduced photoreceptor death 
with progesterone treatment (Sánchez-Vallejo et al. 2012). 
The investigations reported in Chapter 5 have identified a possible protective effect of female gender 
after commotio retinae, suggesting that progesterone should be considered as a potential 
neuroprotective therapy after retinal injury. 
There are limited pharmacokinetic data on progesterone in rats, reporting a half-life from 0.5 to 10 
hr (Gangrade, Boudinot, and Price 1992), (Petroff and Mizinga 2003).  Therapeutic dosing range of 
progesterone in rats has not been reported, though peak plasma progesterone concentrations in 
pregnant mice range from 45.5 - 81.9ng/ml (McCormack and Greenwald 1974), (Virgo and Bellward 
1974) and these values were taken as the upper limit of the physiological range. 
Progesterone therefore has a track record of being a successful neuroprotective agent in pre-clinical 
and clinical studies of traumatic brain injury and there is some evidence for a gender difference in 
visual outcomes after commotio retinae, implying that progesterone may affect recovery after eye 
injury.  In addition progesterone has been reported to be neuroprotective in some (though not all) 
other experimental models of photoreceptor death and there is rat data that allows calculation of a 
dosing regimen for the current study. 
9.1.2. Hypothesis 
I. Progesterone reduces photoreceptor death after ballistic retinal injury. 
II. Progesterone preserves retinal function after ballistic retinal injury assessed by ERG a-wave 
amplitude. 
9.1.3. Aim 
To test the neuroprotective efficacy of progesterone after ballistic retinal injury using structural and 
functional outcome measures. 
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9.1.4. Materials and Methods 
9.1.4.1. Dosage calculations 
Progesterone was administered in ethyl oleate vehicle, as an 8mg/kg IP loading dose immediately 
after injury and then by continuous subcutaneous infusion of 100µg/h/kg from a primed osmotic 
minipump (Charles River) for the duration of the study.  Using data from Gangrade et al. (1992) this 
would be expected to give a steady state plasma concentration of 36.4ng/ml (infusion rate = steady 
state concentration x clearance; clearance = 2.75l/kg/hr) or 263ng/ml using data from Petroff et al. 
(2003; clearance = 0.38l/kg/hr).   
9.1.4.2. Experimental Protocol 
The right eyes of 16 anaesthetised  male Lister-hooded rats (170-200g) was injured by ballistic 
trauma (as described in Section 6.6.7.).  Eight rats were treated with progesterone as above and 8 
with ethyl oleate vehicle.  Scotopic ERG only were recorded under inhalational anaesthesia at 
stimulus intensities ranging from -2.5 to +1 log units with respect to standard flash at 7 and 14 d after 
injury, as shown in Table 8.7.4.  Animals were killed 14 d after injury and the right eyes processed as 
described in Section 8.7.4. for measurement of ONL thickness.   
9.1.4.3. Enzyme-linked Immunosorbant Assay (ELISA) 
Blood samples were taken from the tail vein at 2 hr after progesterone injection and from the jugular 
vein at the time of perfusion fixation (at 14 d) for measurement of serum progesterone 
concentration.  
Blood was centrifuged for 5 min at 10,000 rpm and the serum removed and frozen to -80°c for 
storage.  Uninjured eyes were removed after perfusion fixation and frozen to -80°c for storage.  To 
extract retinal progesterone, eyes were thawed and the retinae removed, weighed and homogenised 
in 200µl of methanol, left to stand for 20 min and then centrifuged at 13,000g for 10 min.  The 
supernatent was removed and kept and the pellet resuspended in 200µl methanol and then mixed 
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by gentle rotation for 30 min before centrifuging at 13,000g for 10 min.  The supernatent was 
removed and combined with the earlier supernatent before being dried in a vacuum centrifuge at 
37°c.  Two retinae from an uninjured male Wistar rat were used as positive control by being 
combined then processed in the same way except that 2µl of 2µg/ml progesterone in water was 
added to the methanol before homogenisation.  After drying, the extracted solutes were 
resuspended in 40µl of dH2O, which should have given a measured progesterone concentration of 
50ng/ml in the positive control. 
Serum and retinal progesterone concentration was measured by competitive ELISA according to the 
manufacturer’s instructions.  Briefly, 20µl of diluted serum at 1/4 and 1/10 dilutions was loaded into 
the wells, 200µl of progesterone-HRP conjugate added to each well and the plate incubated for 1 hr 
at 37°C before adding 100µl of tetramethylbenzidine/H2O2 substrate, incubating for 15 min and 
stopping the reaction by adding 100µl 0.15M sulphuric acid.  Absorbance was measured at 450nm.  
In addition to the standard solutions supplied by the manufacturer, 1 ng/ml, 10ng/ml, 100ng/ml and 
1000ng/ml standards were created by serial dilution of progesterone dissolved in DMSO at 10mg/ml. 
Processing of tissues and image analysis for measurement of ONL thickness was performed by a 
BMedSci student, Ellie McCance. 
9.1.5. Results 
9.1.5.1. Structural Assessment 
The effects of treatment with progesterone on ONL thickness were analysed using generalised 
estimating equations (Appendix 19).  The ONL thickness in the injured eyes was significantly reduced 
in animals treated with progesterone compared to the vehicle-treated control animals (p=0.002; 
Figure 9.1.1.A-B), an effect that was greater further away from the impact site (p=0.051; Figure 
9.1.1.A-B). 
Figure 9.1.1. Effect of progesterone treatment on outcomes after ballistic ocular trauma in rat assessed by 
ONL thickness 14 days after injury (A-B) and ERG a-wave amplitude at 7 and 14 days after injury (C-D). 
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Figure 9.1.2. A. a-wave amplitude in the injured eyes only plotted against stimulus intensity. B. a-wave 
amplitude in the uninjured eyes only plotted againsts stimulus intensity. C. Test of model effects after 
analysis of a-wave amplitude using generalised estimating equations to construct a fully factorial model 
including time after injury (timepointdays), stimulus intensity (flashintensitymcd), treatment with 
progesterone compared to vehicle (TreatedProgesteronevsControl), injured or uninjured eye (Eye) and 
terms to model all 2-,3- and 4-way interactions 
a-wave amplitude increased with increasing stimulus intensity (p<0.001 for flashintensitymcd) and was 
lower in injured than in uninjured eyes (p=0.001 for Eye; data not shown on graph). 
On average, treatment with progesterone decreased a-wave amplitude at higher stimulus intensities 
more than at lower intensities (p<0.001 for the 2-way interaction flashintensitymcd * 
TreatedProgesteronevsControl; see parts A and B), i.e. the lines of the graph are further separated with 
increasing stimulus intensity. Treatment with progesterone had a different effect at 7 compared to 14 
days (p=0.001 for the 3-way interaction timepointdays * flashintensitymcd * 
TreatedProgesteronevsControl, see parts A and B), increasing a-wave amplitude compared to controls at 
7 days, whilst decreasing it at 14 days. 
On average, the negative effect of progesterone was greater in uninjured than in injured eyes (p=0.018 
for the 3-way interaction flashintensitymcd * TreatedProgesteronevsControl * Eye; see part B). i.e. the 
effect of progesterone on a wave amplitude seen in this Figure was not related to the observed 
photoreceptor death caused by injury (see Figure 9.1.1.). 
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9.1.5.2. Functional Assessment 
ERG data are presented in Figures 9.1.2.  The effects of treatment with progesterone on the ERG 
were analysed using generalised estimating equations (Appendix 19).  Combining data from both 7 
and 14 d, progesterone reduced a-wave amplitude compared to vehicle-treated controls (p<0.001 for 
flashintensitymcd * TreatedProgesteronevsControl).  However, progesterone increased a-wave 
amplitude at 7 d, whilst reducing it at 14 d after injury (p=0.001 for timepointdays * 
flashintensitymcd * TreatedProgesteronevsControl).  These changes in a-wave amplitude caused by 
progesterone were greater in the uninjured left eyes than the injured right eyes (Figure 9.1.2.). 
9.1.5.3. Serum ELISA 
The serum progesterone concentration at 14 d in the progesterone-treated group was 6.04ng/ml.  
This result allowed clearance to be calculated: infusion rate = steady state concentration x clearance, 
infusion rate = 100µg/kg/hr, so clearance = 16.667l/kg/hr, assuming that steady state had been 
reached, i.e. half-life was <2.8 d, as time taken to reach steady state is 5 half-lives.  The serum 
progesterone in control animals was 2.1ng/ml. 
 
Figure 9.1.4. Mean serum progesterone concentrations after ballistic injury ± standard error of the 
mean. 
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9.1.5.4. Retinal ELISA 
No progesterone was detected in either the treated or untreated retinae.  Progesterone at an 
average of 42.6ng/ml was detected in the positive control samples, giving an efficiency of recovery of 
85.2%.   
9.1.6. Discussion 
Treatment with progesterone increased photoreceptor death after ballistic injury and depressed a-
wave amplitude in both the injured and uninjured eyes. However, the serum progesterone levels at 
14 d after injury were significantly lower than the intended 50-100ng/ml.  There are 2 possible 
explanations for this observation of unexpectedly low circulating progesterone: (1), the clearance of 
progesterone from the rat plasma was much higher than has previously been reported or, (2), the 
osmotic minipumps did not deliver progesterone at the intended rate of 5µl/hr (or at all).   
Methanol extraction failed to detect any progesterone in any of the retinal tissue samples, which 
could be because retinal levels were very low, or because extraction failed.  The lower limit of 
sensitivity of the ELISA assay is 0.2ng/ml, which would be expected to detect retinal levels 5x lower 
than serum levels in control animals (20µg retinal weight resuspended in 40µl dH2O compared to 
2.1ng/ml in control animals) and 15x lower than serum levels in progesterone-treated animals, 
suggesting that extraction failed.  The positive control showed that supplementing the retina with 
aqueous progesterone allowed good recovery of added progesterone, indicating that extraction did 
not fail because of either adherence to the tubes used for drying or because of trapping in 
precipitated lipid.  Though methanol extraction of faecal progesterone has been previously reported 
(Korndorfer, Meirelles, Bueno, and Abdalla 1998), it is likely that retinal extraction failed because 
methanol (a polar solute) failed to solubilise progesterone from the retinal lipid components.  It is 
concluded that any future attempt should use ether extraction, which is more commonly reported 
but also more hazardous due to the risk of ether combustion. 
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To aid interpretation of the results, it was decided that the pharmacokinetics of progesterone in 200g 
male Lister-hooded rats was required. 
9.2. Pharmacokinetic Study of Progesterone 
9.2.1. Rationale 
It was unclear whether the lower-than-intended 14 d serum progesterone data presented in Section 
9.1. occurred because the clearance of progesterone in the rat was higher than previously reported 
or because the osmotic minipumps did not function correctly, so a study was designed to measure 
the pharmacokinetics of progesterone in the rat. 
9.2.2. Hypothesis 
The clearance of progesterone in approx. 200g male Lister-hooded rats is 16.6l/kg/hr. 
9.2.3. Aim 
To determine the pharmacokinetics of progesterone in 200g male Lister-hooded rats. 
9.2.4. Methods 
Three 215-200g male Lister-hooded rats were given IP injections of 8mg/kg progesterone in ethyl 
oleate vehicle.  Blood samples were taken from the tail veins at 2, 6, 24 and 72 hr after injection, 
centrifuged for 5 min at 10,000 rpm and the serum removed and frozen to -80°C for storage.  Serum 
progesterone concentration was measured by competitive ELISA according to the manufacturer’s 
instructions (see Section 9.1.4.3.). 
9.2.5. ELISA Results 
The serum progesterone measured 2 hr after injection was 67.1ng/ml and at 6 hr it was 25.9ng/ml.  
The half-life derived from these measurements is 2.91 hr.  Working the levels back from a 2 hr level 
of 67.1ng/ml gives an initial serum progesterone concentration of 108ng/ml.  Initial concentration = 
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dose/volume of distribution and, with a dose of 8mg/kg, the volume of distribution = 74.1l/kg.  The 
elimination rate constant, ke = ln2/half life = 0.238/hr and clearance = volume of distribution x ke, so 
clearance = 17.6l/kg/hr.   
 
Figure 9.2. Serum progesterone against time after IP injection ± SEM. 
9.2.6. Discussion 
The calculated half-life of progesterone in the current experiment was 2.91 hr and the calculated 
clearance was 17.6l/kg/hr, which is similar to the figure of 16.667l calculated from the ELISA data 
obtained in samples from animals with osmotic minipumps implanted (Section 9.1.5.3.), indicating 
that the osmotic minipumps delivered the intended dose.   
9.2.7. Conclusions 
I. The clearance of progesterone in approx. 200g male Lister-hooded rats is 17l/kg/hr. 
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II. The osmotic minipumps used in Section 9.1. functioned correctly and delivered the intended 
dose of progesterone. 
9.3. General Discussion 
9.3.1. Pharmacokinetics 
In this experiment, after a single bolus IP injection, progesterone was delivered by continuous 
subcutaneous infusion.  The dose for the bolus injection was derived from previous studies in which 
8mg/kg bolus doses were used successfully to treat traumatic brain injury (Goss, Hoffman, and Stein 
2003).  The rate of progesterone infusion of 100µg/kg/hr was derived from data suggesting that, in 
rats, the half-life of progesterone is 0.6-10.5 hr and the volume of distribution is 2.75-5.62l 
(Gangrade, Boudinot, and Price 1992), (Petroff and Mizinga 2003), which would have caused plasma 
levels of 36.4-236ng/ml.  The half-life in the current study was 2.91 hr (in the range previously 
reported); however, the volume of distribution was 74l/kg, which is considerably higher than has 
been reported in rats and mice (Gangrade, Boudinot, and Price 1992), (Petroff and Mizinga 2003), 
(Wong, Ray, and Kendall 2012). 
On data from the current study (clearance = 17l/kg/hr), an infusion rate of 850µg/kg/hr or 
20.4mg/kg/d would be required to maintain plasma progesterone at 50ng/ml, which is significantly 
higher than has been administered in most studies of the neuroprotective effects of progesterone 
(which administer intermittent doses of 4-16mg/kg/d after the initial bolus) (Goss, Hoffman, and 
Stein 2003).  Were the commonly used intermittent dosing regimen of 0, 6, 24, 48. 72, 96 and 120 hr 
after injury administered to 200g Lister-hooded rats, plasma progesterone levels would be at 
baseline from 18-24, 36-48, 59-72, 73-96 and 107-120 hr after injury (Goss, Hoffman, and Stein 
2003).  Male Sprague-Dawley rats weighing approx. 300g are commonly used for traumatic brain 
injury studies and – though we do not have data on their pharmacokinetics – it seems unlikely that 
Sprague-Dawley rats would have radically different pharmacokinetics than the Lister-hooded rats 
used in the current studies. 
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Three days of daily dosing progesterone after traumatic brain injury is less effective than 5 at 
improving functional outcomes and reducing lesion size, suggesting that intermittent therapeutic 
serum levels of progesterone do not preclude a therapeutic effect (Shear, Galani, Hoffman, and Stein 
2002).  Cutler et al. (2005) found that tapering progesterone dosing over 2 d reduced levels of 
inflammatory markers, apoptotic markers and behavioural tests for anxiety compared to an abrupt 
withdrawal after a daily dosing regimen continued for the same length of time, thus either, (1), the 
beneficial effects of progesterone in the brain do not directly relate to its persistence in the plasma 
which would contradict the mouse data of Wong et al. (2012) that brain progesterone levels drop 
below plasma levels approx. 2hr post-dosing, or (2), in the tapered dose group the beneficial effect 
was seen because levels became sub-therapeutic after 5 d whereas in the abrupt withdrawal group, 
therapeutic levels continued for 7 d and this prolonged dosing was damaging (Cutler, Pettus, 
Hoffman, and Stein 2005). 
9.3.2. The Effect of Progesterone on Functional and Structural Outcomes After Ballistic Ocular 
Trauma 
9.3.2.1. Structural effects 
Progesterone treatment significantly reduced ONL thickness after injury compared to vehicle-treated 
controls, an apparently detrimental effect.  As 98% of rat photoreceptors are rods and the ONL 
contains photoreceptor somata only, ONL thickness reflects rod survival (Blanch et al. 2012b).  After 
traumatic brain injury, progesterone treatment reduces oedema and lesion size (Stein 2008b).  It is 
possible that a reduction in ONL thickness could occur because of reduced oedema; however, (1), the 
ONL thickness measurement assessed only haematoxylin-stained nuclei, thus excluding any oedema 
and, (2), the ONL is not oedematous 14 d after ballistic injury (Blanch et al. 2012a).  Thus, it is likely 
that the reduction in ONL thickness occurred because treatment with progesterone increased the 
number of photoreceptors that died after ballistic injury.   
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With a half-life of 2.9 hr, serum progesterone levels would have peaked at near to 100ng/ml and 
reached steady-state at 6ng/ml 11.6-14.5 hr after injury, which could be considered an abrupt 
withdrawal of treatment.  After traumatic brain injury, abrupt withdrawal of progesterone treatment 
increases the expression of cell death markers and worsens outcome compared to tapered 
withdrawal; however, both treatment regimens are still beneficial compared to placebo (Cutler, 
Pettus, Hoffman, and Stein 2005), (Stein 2008b).  Thus, abrupt withdrawal is unlikely to explain the 
increase in cell death observed in the current study.   
Too short a duration of therapeutic plasma levels might explain the observed increase in 
photoreceptor death.  A mechanism for increased cell death could be that brief inhibition of 
programmed cell death pathways causes cells to undergo less regulated and more inflammatory 
necrotic cell death, with bystander damage to healthy cells.   
Another possibility is that progesterone treatment increased the animals’ core temperature (Forman, 
Chapman, and Steptoe 1987), increasing the metabolic demands of photoreceptors, a cell type with a 
high requirement for energy and oxygen that lack a functional reserve in terms of excess oxygen 
supply under normal conditions (Linsenmeier and Padnick-Silver 2000). 
9.3.2.2. Functional effects 
The a-wave is the first negative deflection on ERG after a light stimulus and is commonly used to 
assess photoreceptor function.  Progesterone treatment significantly reduced ERG a-wave amplitude 
in both injured and uninjured eyes.  An effect of sex steroids on the ERG has been previously 
reported (Brule et al. 2007); however, an effect of progesterone on the ERG in the uninjured eye 
makes it difficult to assess the functional effects of treatment with respect to injury.  Considering 
data from both eyes, progesterone reduced a-wave amplitude differently in the injured and 
uninjured eyes, but the reduction was greater in the uninjured eyes.  An interaction between 
progesterone treatment and injury is possible, for example injury could cause paracrine changes that 
prime the retina to decrease a-wave amplitude less in response to progesterone treatment than 
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uninjured retina.  It is also possible that changes in core temperature could have caused that 
observed ERG effects of progesterone, as ERG amplitude is dependent on temperature (Heckenlively 
and Arden 2006) and temperature, though controlled, was not specifically measured during the 
experiments. 
The current studies of the neuroprotective effects of progesterone used a non-standard dosing 
regimen and found treatment to be detrimental to retinal structure and function.  Repeating the 
study using a previously reported intermittent regimen would clarify whether the detrimental effect 
is specific to the current dosing regimen (Stein 2008b).  However, a significant detrimental effect 
after administration of low dose treatment is not encouraging with respect to the translational 
potential of progesterone in ocular injury and is consistent with past studies that did not find that 
progesterone reduced photoreceptor death (Doonan, O'Driscoll, Kenna, and Cotter 2011), (Kaldi and 
Berta 2004) (O'Steen 1977).  
9.4. Conclusions 
I. Progesterone clearance in 200g male Lister-hooded rats is 17l/kg/hr and the half-life is 2.91 
hr. 
II. Progesterone treatment administered as a high dose bolus followed by a low-dose infusion 
to maintain serum levels 3x baseline increased rod death and reduced rod function 14 d after injury. 
III. Progesterone is not a translatable treatment for ballistic ocular injury, due to the potential 
for a detrimental effect with low dose treatment. 
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10. Summary 
Commotio retinae is a closed globe retinal injury caused by blunt ocular trauma characterised by 
retinal whitening and loss of vision when the macula is affected. 
In retrospective clinical studies, commotio retinae affected 16% of British soldiers with an eye injury 
and 0.4% of civilians with an eye injury (Jones et al. 1986).  Macular commotio retinae constituted 
31% of civilian cases 55-73% of military cases (Weichel et al. 2008) and was associated with reduced 
visual acuity.  In 26% of patients vision remained ≤6/9, though the proportion with some visual 
impairment was higher because: (1), a deterioration from 6/4 to 6/9 would be significant to many 
patients and; (2), paracentral visual field defects may not affect VA.  Commotio retinae is 
predominantly an injury to photoreceptors and permanent visual impairment was associated with 
photoreceptor degeneration. 
In order to investigate the mechanisms of photoreceptor degeneration after commotio retinae, an 
experimental model was developed.  In rats, high velocity ocular impact by a light weight induced 
commotio retinae more readily than low velocity impact by a relatively heavy weight despite lower 
delivered kinetic energy. 
In an experimental rat model of commotio retinae induced by ballistic ocular injury, photoreceptors 
died by a combination of necrosis and apoptosis.  Visual function, assessed by ERG a-wave amplitude, 
was reduced out of proportion to the extent of photoreceptor death.  Apoptosis was mediated by 
active caspase 9 present in photoreceptors 5 hr after injury and inhibiting caspase 9 by intravitreal 
injection of Pen1-XBIR3 reduced photoreceptor death and improved retinal function. 
Of the 3 executioner caspases (3, 6 and 7), only caspase 6’s activity was increased in the retina after 
commotio retinae.  Despite immunolocalisation of active caspase 6 in photoreceptors 48 hr after 
injury, caspase 6 inhibition by intravitreal injection of Pen1-C6DN did not prevent photoreceptor 
death and was detrimental to retinal function, suggesting that caspase 6 does not mediate apoptosis 
in this model. 
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Because clinical studies suggested a possible protective effect of female gender in commotio retinae, 
progesterone was assessed in the rat ballistic injury model as a potential neuroprotective treatment.  
However, progesterone treatment significantly increased photoreceptor death.  This surprising result 
may be explained by the observation that the clearance of progesterone from the rat plasma was 
significantly higher than previous reports (Gangrade, Boudinot, and Price 1992), which meant that 
plasma levels after treatment were lower than intended.  Nonetheless, increased cell death after 
progesterone administration (whether subtherapeutic dosing or not) is discouraging with respect to 
the potential for progesterone to be a translatable treatment for ocular injury. 
 
 
 
 
 
 
 
  
 
 
198 
 
References 
Abbotts, R., S. E. Harrison, and G. L. Cooper. 2007. "Primary blast injuries to the eye: a review of the 
evidence." J R Army Med Corps 153:119-123. 
Agrawal, R. N., S. He, C. Spee, J. Z. Cui, S. J. Ryan, and D. R. Hinton. 2007. "In vivo models of 
proliferative vitreoretinopathy." Nat Protoc 2:67-77. 
Agudo, M., M. C. Perez-Marin, U. Lonngren, P. Sobrado, A. Conesa, I. Canovas, M. Salinas-Navarro, J. 
Miralles-Imperial, F. Hallbook, and M. Vidal-Sanz. 2008. "Time course profiling of the retinal 
transcriptome after optic nerve transection and optic nerve crush." Mol Vis 14:1050-1063. 
Ahmed, Z., H. Kalinski, M. Berry, M. Almasieh, H. Ashush, N. Slager, A. Brafman, I. Spivak, N. Prasad, I. 
Mett, E. Shalom, E. Alpert, A. Di Polo, E. Feinstein, and A. Logan. 2011. "Ocular 
Neuroprotection by siRNA Targeting Caspase-2." Cell Death Dis 2:e173. 
Ahmed, Z., M. Aslam, B. Lorber, E. L. Suggate, M. Berry, and A. Logan. 2010. "Optic nerve and vitreal 
inflammation are both RGC neuroprotective but only the latter is RGC axogenic." Neurobiol 
Dis 37:441-454. 
Akpan, N., E. Serrano-Saiz, B. E. Zacharia, M. L. Otten, A. F. Ducruet, S. J. Snipas, W. Liu, J. Velloza, G. 
Cohen, S. A. Sosunov, 2. nd. Frey WH, G. S. Salvesen, E. S. Connolly, Jr., and C. M. Troy. 2011. 
"Intranasal delivery of caspase-9 inhibitor reduces caspase-6-dependent axon/neuron loss 
and improves neurological function after stroke." J Neurosci 31:8894-904 LID - 10.1523/JN. 
Alamouti, B. and J. Funk. 2003. "Retinal thickness decreases with age: an OCT study." Br J Ophthalmol 
87:899-901. 
Al-Hussaini, H., J. H. Kam, A. Vugler, M. Semo, and G. Jeffery. 2008. "Mature retinal pigment 
epithelium cells are retained in the cell cycle and proliferate in vivo." Mol Vis 14:1784-1791. 
An, M. X., X. F. Zhang, and J. S. Zhang. 2004. "(Oxidative damage and photoreceptor cell apoptosis in 
contusion injury of the rabbit retina) (Chinese)." Zhonghua yan ke za zhi (Chin J Ophthalmol) 
40:118. 
Antelava, J. N. 1969. "Morpho-histological evidence of the clinical picture of the retina in eye 
contusion." Ophthalmologica 158 Suppl:329-331. 
Applebury, M. L., M. P. Antoch, L. C. Baxter, L. L. Chun, J. D. Falk, F. Farhangfar, K. Kage, M. G. 
Krzystolik, L. A. Lyass, and J. T. Robbins. 2000. "The murine cone photoreceptor: a single cone 
type expresses both S and M opsins with retinal spatial patterning." Neuron 27:513-523. 
Arnold, J.L., P. Halpern, M.C. Tsai, and H. Smithline. 2004. "Mass casualty terrorist bombings: a 
comparison of outcomes by bombing type." Ann Emerg Med 43:263-273. 
Arnoult, D., B. Gaume, M. Karbowski, J. C. Sharpe, F. Cecconi, and R. J. Youle. 2003. "Mitochondrial 
release of AIF and EndoG requires caspase activation downstream of Bax/Bak-mediated 
permeabilization." EMBO J 22:4385-4399. 
Attella, M. J., A. Nattinville, and D. G. Stein. 1987. "Hormonal state affects recovery from frontal 
cortex lesions in adult female rats." Behav Neural Biol 48:352-367. 
 
 
199 
 
Bayir, H., D. W. Marion, A. M. Puccio, S. R. Wisniewski, K. L. Janesko, R. S. Clark, and P. M. Kochanek. 
2004. "Marked gender effect on lipid peroxidation after severe traumatic brain injury in adult 
patients." J Neurotrauma 21:1-8. 
Becker, C. G. and T. Becker. 2008. "Adult zebrafish as a model for successful central nervous system 
regeneration." Restor Neurol Neurosci 26:71-80. 
Beiran, I. and B. Miller. 1992. "Pure ocular blast injury." Am J Ophthalmol 114:504-505. 
Belkin, M. 1983. "Ocular injuries in the Yom Kippur war." J Ocul Ther Surg 2:40-49. 
Bellows, J. G. 1947. "Observations on 300 consecutive cases of ocular war injuries." Am J Ophthalmol 
30:309-323. 
Benowitz, L. I. and Y. Yin. 2010. "Optic nerve regeneration." Arch Ophthalmol 128:1059-1064. 
Berkelaar, M., D. B. Clarke, Y. C. Wang, G. M. Bray, and A. J. Aguayo. 1994. "Axotomy results in 
delayed death and apoptosis of retinal ganglion cells in adult rats." J Neurosci 14:4368-4374. 
Berlin, R. 1873. "Zur sogenannten commotio retinae." Klin Monatsbl Augenheilkd 1:42-78. 
Bernal, A., J. M. Parel, and F. Manns. 2006. "Evidence for posterior zonular fiber attachment on the 
anterior hyaloid membrane." Invest Ophthalmol Vis Sci 47:4708-4713. 
Bernardos, R. L., L. K. Barthel, J. R. Meyers, and P. A. Raymond. 2007. "Late-stage neuronal 
progenitors in the retina are radial Muller glia that function as retinal stem cells." J Neurosci 
27:7028-7040. 
Berry, M., J. Carlile, A. Hunter, W. Tsang, P. Rosenstiel, and J. Sievers. 1999. "Optic nerve 
regeneration after intravitreal peripheral nerve implants: trajectories of axons regrowing 
through the optic chiasm into the optic tracts." J Neurocytol 28:721-741. 
Berry, M., J. Carlile, and A. Hunter. 1996. "Peripheral nerve explants grafted into the vitreous body of 
the eye promote the regeneration of retinal ganglion cell axons severed in the optic nerve." J 
Neurocytol 25:147-170. 
Berry, M., Z. Ahmed, B. Lorber, M. Douglas, and A. Logan. 2008. "Regeneration of axons in the visual 
system." Restor Neurol Neurosci 26:147-174. 
Besirli, C. G., N. D. Chinskey, Q. D. Zheng, and D. N. Zacks. 2010. "Inhibition of retinal detachment-
induced apoptosis in photoreceptors by a small peptide inhibitor of the fas receptor." Invest 
Ophthalmol Vis Sci 51:2177-2184. 
Bhutto, I. A. and T. Amemiya. 1995. "Corrosion cast demonstration of retinal vasculature of normal 
Wistar-Kyoto rats." Acta Anat (Basel) 153:290-300. 
Bignami, A. and D. Dahl. 1979. "The radial glia of Muller in the rat retina and their response to injury. 
An immunofluorescence study with antibodies to the glial fibrillary acidic (GFA) protein." Exp 
Eye Res 28:63-69. 
Blanch, R. J., M.S. Bindra, A.S. Jacks, and R.A.H. Scott. 2011. "Ophthalmic Injuries in British Armed 
Forces in Iraq and Afghanistan." Eye 25:218-223. 
Blanch, R. J., P. A. Good, P. Shah, J. R. B. Bishop, A. Logan, and R. A. H. Scott. 2013. "Visual outcomes 
after blunt ocular trauma." Ophthalmol 120:1588-1591. 
 
 
200 
 
Blanch, R. J., Z. Ahmed, A. Sik, D. R. Snead, P. A. Good, J. O'Neill, M. Berry, R. A. Scott, and A. Logan. 
2012a. "Neuroretinal cell death in a murine model of closed globe injury; pathological and 
functional characterisation." Invest Ophthalmol Vis Sci 53:7220-7226. 
Blanch, R. J., Z. Ahmed, M. Berry, R. A. H. Scott, and A. Logan. 2012b. "Animal Models of Retinal 
Injury." Invest Ophthalmol Vis Sci 53:2913-2920. 
Blanch, R. J. and R. A. Scott. 2008. "Primary blast injury of the eye." J R Army Med Corps 154:76. 
Blanch, R. J. and R.A.H. Scott. 2010. "Military Ocular Injury: Presentation, Assessment and 
Management." J R Army Med Corps 155:279-284. 
Blight, R. and J. C. Hart. 1977. "Structural changes in the outer retinal layers following blunt 
mechanical non-perforating trauma to the globe: an experimental study." Br J Ophthalmol 
61:573. 
—1978. "Histological changes in the internal retinal layers produced by concussive injuries to the 
globe. An experimental study." Trans Ophthalmol Soc UK 98:270-277. 
Borutaite, V. 2010. "Mitochondria as decision-makers in cell death." Environ Mol Mutagen 51:406-16 
LID - 10.1002/em.. 
Bozzola, J.J. and L.D. Russell. 1999. Electron Microscopy: Jones and Barlett Publishers, Inc. 
Brule, J., M. P. Lavoie, C. Casanova, P. Lachapelle, and M. Hebert. 2007. "Evidence of a possible 
impact of the menstrual cycle on the reproducibility of scotopic ERGs in women." Doc 
Ophthalmol 114:125-134. 
Bunt-Milam, A. H., R. A. Black, and R. E. Bensinger. 1986. "Breakdown of the outer blood-retinal 
barrier in experimental commotio retinae." Exp Eye Res 43:397-412. 
Burgi, H., T. H. Schaffner, and J. P. Seiler. 2001. "The toxicology of iodate: a review of the literature." 
Thyroid 11:449-456. 
Burnham, G., R. Lafta, F. Doocy, and L. Roberts. 2006. "Mortality after the 2003 invasion of Iraq: a 
cross-sectional cluster sample survey." Lancet 368:1421-1428. 
Campbell, D. R. 1941. "Ophthalmic Casualties resulting from Air Raids." Br Med J 1:966. 
Carley, S. D. and K. Mackway-Jones. 1997. "The casualty profile from the Manchester bombing 1996: 
a proposal for the construction and dissemination of casualty profiles from major incidents." 
J Accid Emerg Med 14:76-80. 
Carmody, R. J. and T. G. Cotter. 2000. "Oxidative stress induces caspase-independent retinal 
apoptosis in vitro." Cell Death Differ 7:282-291. 
Chakravarthy, U., C. J. Maguire, and D. B. Archer. 1986. "Experimental posterior perforating ocular 
injury: a controlled study of the gross effects of localised gamma irradiation." Br J 
Ophthalmol 70:561-569. 
Chakravarthy, U., J. H. Biggart, T. A. Gardiner, D. B. Archer, and C. J. Maguire. 1989. "Focal irradiation 
of perforating eye injuries." Curr Eye Res 8:1241-1250. 
Chalioulias, K., K. T. Sim, and R. Scott. 2007. "Retinal sequelae of primary ocular blast injuries." J R 
Army Med Corps 153:124-125. 
 
 
201 
 
Chaum, E. 2003. "Retinal neuroprotection by growth factors: a mechanistic perspective." J Cell 
Biochem 88:57-75. 
Chen, S., Z. Huang, L. Wang, T. Jiang, B. Wu, and G. Sun. 2003. "Study on retinal ganglion cell 
apoptosis after explosive injury of eyeballs in rabbits." Yan Ke Xue Bao (Eye Science) 19:187. 
Cheng, L., P. Sapieha, P. Kittlerova, W. W. Hauswirth, and A. Di Polo. 2002. "TrkB gene transfer 
protects retinal ganglion cells from axotomy-induced death in vivo." J Neurosci 22:3977-
3986. 
Ciriza, I., P. Carrero, C. A. Frye, and L. M. Garcia-Segura. 2006. "Reduced metabolites mediate 
neuroprotective effects of progesterone in the adult rat hippocampus. The synthetic 
progestin medroxyprogesterone acetate (Provera) is not neuroprotective." J Neurobiol 
66:916-928. 
Cleary, P. E., G. Jarus, and S. J. Ryan. 1980. "Experimental posterior penetrating eye injury in the 
rhesus monkey: vitreous-lens admixture." Br J Ophthalmol 64:801-808. 
Cleary, P. E. and S. J. Ryan. 1979. "Experimental posterior penetrating eye injury in the rabbit. I. 
Method of production and natural history." Br J Ophthalmol 63:306-311. 
—1981. "Vitrectomy in penetrating eye injury: results of a controlled trial of vitrectomy in an 
experimental posterior penetrating eye injury in the rhesus monkey." Arch Ophthalmol 
99:287-292. 
Close, J. L., B. Gumuscu, and T. A. Reh. 2005. "Retinal neurons regulate proliferation of postnatal 
progenitors and Muller glia in the rat retina via TGF beta signaling." Development 132:3015-
3026. 
Colyer, M. H., D. W. Chun, K. S. Bower, J. S.B. Dick, and E. D. Weichel. 2008. "Perforating Globe 
Injuries during Operation Iraqi Freedom." Ophthalmol 115:2087-2093. 
Courtney, M. and B. Edwards. 2006. "Measuring Bullet Velocity with a PC Soundcard." Arxiv preprint 
physics/0601102 2011. 
Cox, M. S. 1980. "Retinal breaks caused by blunt nonperforating trauma at the point of impact." 
Trans Am Ophthalmol Soc 78:414-466. 
Cui, Q., Y. Yin, and L. I. Benowitz. 2009. "The role of macrophages in optic nerve regeneration." 
Neurosci 158:1039-1048. 
Cullinane, A. B., P. O'Callaghan, K. McDermott, C. Keohane, and P. E. Cleary. 2002. "Effects of 
autologous platelet concentrate and serum on retinal wound healing in an animal model." 
Graefes Arch Clin Exp Ophthalmol 240:35-41. 
Cullis, I. G. 2001. "Blast waves and how they interact with structures." J R Army Med Corps 147:16-26. 
Cuthbertson, R. A. and T. E. Mandel. 1986. "Anatomy of the mouse retina. Endothelial cell-pericyte 
ratio and capillary distribution." Invest Ophthalmol Vis Sci 27:1659-1664. 
Cutler, S. M., E. H. Pettus, S. W. Hoffman, and D. G. Stein. 2005. "Tapered progesterone withdrawal 
enhances behavioral and molecular recovery after traumatic brain injury." Exp Neurol 
195:423-429. 
 
 
202 
 
Das, A. V., K. B. Mallya, X. Zhao, F. Ahmad, S. Bhattacharya, W. B. Thoreson, G. V. Hegde, and I. 
Ahmad. 2006. "Neural stem cell properties of Muller glia in the mammalian retina: regulation 
by Notch and Wnt signaling." Dev Biol 299:283-302. 
De Monasterio, F. M. 1978. "Spectral interactions in horizontal and ganglion cells of the isolated and 
arterially-perfused rabbit retina." Brain Res 150:239-258. 
Dean Hart, J. C. and R. Blight. 1978. "Changes occuring in the nerve fibre layer of pigs' retinae 
following concussive injuries to the globe." Bull Soc Ophtalmol Fr 78:69-70. 
Del Priore, L. V., H. J. Kaplan, R. Hornbeck, Z. Jones, and M. Swinn. 1996. "Retinal pigment epithelial 
debridement as a model for the pathogenesis and treatment of macular degeneration." Am J 
Ophthalmol 122:629-643. 
Del Priore, L. V., R. Hornbeck, H. J. Kaplan, Z. Jones, T. L. Valentino, J. Mosinger-Ogilvie, and M. Swinn. 
1995. "Debridement of the pig retinal pigment epithelium in vivo." Arch Ophthalmol 
113:939-944. 
Delori, F., O. Pomerantzeff, and M. S. Cox. 1969. "Deformation of the globe under high-speed impact: 
it relation to contusion injuries." Invest Ophthalmol 8:290-301. 
Denault, J. B. and G. S. Salvesen. 2003. "Expression, purification, and characterization of caspases." 
Curr Protoc Protein Sci Chapter 21:Unit 21.13 LID-10.1002/0471140864.p. 
DePalma, R. G., D. G. Burris, H. R. Champion, and M. J. Hodgson. 2005. "Blast injuries." New Eng J 
Med 352:1335. 
Djebaili, M., Q. Guo, E. H. Pettus, S. W. Hoffman, and D. G. Stein. 2005. "The neurosteroids 
progesterone and allopregnanolone reduce cell death, gliosis, and functional deficits after 
traumatic brain injury in rats." J Neurotrauma 22:106-118. 
Djebaili, M., S. W. Hoffman, and D. G. Stein. 2004. "Allopregnanolone and progesterone decrease cell 
death and cognitive deficits after a contusion of the rat pre-frontal cortex." Neuroscience 
123:349-359. 
Donovan, M., R. J. Carmody, and T. G. Cotter. 2001. "Light-induced photoreceptor apoptosis in vivo 
requires neuronal nitric-oxide synthase and guanylate cyclase activity and is caspase-3-
independent." J Biol Chem 276:23000-23008. 
Doonan, F., C. O'Driscoll, P. Kenna, and T. G. Cotter. 2011. "Enhancing survival of photoreceptor cells 
in vivo using the synthetic progestin Norgestrel." J Neurochem 118:915-27 LID - 10.1111/j.1. 
Doonan, F., M. Donovan, and T. G. Cotter. 2003. "Caspase-independent photoreceptor apoptosis in 
mouse models of retinal degeneration." J Neurosci 23:5723-5731. 
Drew, P. D. and J. A. Chavis. 2000. "Female sex steroids: effects upon microglial cell activation." J 
Neuroimmunol 111:77-85. 
Dyer, M. A., R. Martins, F. ilho M. da Silva, J. A. Muniz, L. C. Silveira, C. L. Cepko, and B. L. Finlay. 2009. 
"Developmental sources of conservation and variation in the evolution of the primate eye." 
Proc Natl Acad Sci U S A 106:8963-8968. 
Eagling, E. M. 1974. "Ocular damage after blunt trauma to the eye. Its relationship to the nature of 
the injury." Br J Ophthalmol 58:126-140. 
 
 
203 
 
Eckelman, B. P., G. S. Salvesen, and F. L. Scott. 2006. "Human inhibitor of apoptosis proteins: why 
XIAP is the black sheep of the family." EMBO Rep 7:988-994. 
Elkington, A. R., H. J. Frank, and M. J. Greaney. 1999. Clinical Optics. Oxford, UK: Blackwell Science 
Ltd. 
Elmore, S. 2007. "Apoptosis: a review of programmed cell death." Toxicol Pathol 35:495-516. 
Faktorovich, E. G., R. H. Steinberg, D. Yasumura, M. T. Matthes, and M. M. LaVail. 1992. "Basic 
fibroblast growth factor and local injury protect photoreceptors from light damage in the 
rat." J Neurosci 12:3554-3567. 
Famiglietti, E. V. and S. J. Sharpe. 1995. "Regional topography of rod and immunocytochemically 
characterized "blue" and "green" cone photoreceptors in rabbit retina." Vis Neurosci 
12:1151-1175. 
Farace, E. and W. M. Alves. 2000. "Do women fare worse: a metaanalysis of gender differences in 
traumatic brain injury outcome." J Neurosurg 93:539-545. 
Fatehee, N., P. K. Yu, W. H. Morgan, S. J. Cringle, and D. Y. Yu. 2011. "Correlating morphometric 
parameters of the porcine optic nerve head in spectral domain optical coherence 
tomography with histological sections." Br J Ophthalmol 95:585-589. 
Fischer, A. J. and R. Bongini. 2010. "Turning Muller glia into neural progenitors in the retina." Mol 
Neurobiol 42:199-209. 
Fischer, D., M. Pavlidis, and S. Thanos. 2000. "Cataractogenic lens injury prevents traumatic ganglion 
cell death and promotes axonal regeneration both in vivo and in culture." Invest Ophthalmol 
Vis Sci 41:3943-3954. 
Fischer, D., Z. He, and L. I. Benowitz. 2004. "Counteracting the Nogo receptor enhances optic nerve 
regeneration if retinal ganglion cells are in an active growth state." J Neurosci 24:1646-1651. 
Fischer, H. 2008. "Iraqi civilian death estimates." Congressional Research Service. 
Fisher, S. K., G. P. Lewis, K. A. Linberg, and M. R. Verardo. 2005. "Cellular remodeling in mammalian 
retina: results from studies of experimental retinal detachment." Prog Retin Eye Res 24:395-
431. 
Fontainhas, A. M. and E. Townes-Anderson. 2011. "RhoA inactivation prevents photoreceptor axon 
retraction in an in vitro model of acute retinal detachment." Invest Ophthalmol Vis Sci 
52:579-587. 
Forman, R. G., M. C. Chapman, and P. C. Steptoe. 1987. "The effect of endogenous progesterone on 
basal body temperature in stimulated ovarian cycles." Hum Reprod 2:631-634. 
Forrester, J. V., A. D. Dick, P. McMenamin, and W. R. Lee. 2003. The Eye: Basic Sciences in Practice. 
Philadelphia, PA, USA: W.B. Saunders. 
Galluzzi, L, I. Vitale, J. M. Abrams, . S. Alnemri, E. H. Baehrecke, M. V. Blagosklonny, T. M. Dawson, V. 
L. Dawson, W. S. El-Deiry, S. Fulda, E. Gottlieb, D. R. Green, M. O. Hengartner, O. Kepp, R. A. 
Knight, S. Kumar, and S. A.  Lipton. 2012. "Molecular definitions of cell death subroutines: 
recommendations of the Nomenclature Committee on Cell Death 2012." 19:107-120. 
 
 
204 
 
Galluzzi, L., K. Blomgren, and G. Kroemer. 2009. "Mitochondrial membrane permeabilization in 
neuronal injury." Nat Rev Neurosci 10:481-94 LID - 10.1038/nrn. 
Gallyas, F., G. Zoltay, and W. Dames. 1992. "Formation of "dark" (argyrophilic) neurons of various 
origin proceeds with a common mechanism of biophysical nature (a novel hypothesis)." Acta 
Neuropathol 83:504-509. 
Gallyas, F., M. Hsu, and G. Buzsaki. 1993. "Four modified silver methods for thick sections of 
formaldehyde-fixed mammalian central nervous tissue: 'dark' neurons, perikarya of all 
neurons, microglial cells and capillaries." J Neurosci Methods 50:159-164. 
Gangrade, N. K., F. D. Boudinot, and J. C. Price. 1992. "Pharmacokinetics of progesterone in 
ovariectomized rats after single dose intravenous administration." Biopharm Drug Dispos 
13:703-709. 
Garcia-Estrada, J., J. A. Del Rio, S. Luquin, E. Soriano, and L. M. Garcia-Segura. 1993. "Gonadal 
hormones down-regulate reactive gliosis and astrocyte proliferation after a penetrating brain 
injury." Brain Res 628:271-278. 
Garcia-Estrada, J., S. Luquin, A. M. Fernandez, and L. M. Garcia-Segura. 1999. 
"Dehydroepiandrosterone, pregnenolone and sex steroids down-regulate reactive astroglia 
in the male rat brain after a penetrating brain injury." Int J Dev Neurosci 17:145-151. 
Garner, J. P., S. Watts, C. Parry, J. Bird, and E. Kirkman. 2009. "Development of a Large Animal Model 
for Investigating Resuscitation After Blast and Hemorrhage." World J Surg 33:2194-2202. 
Gerke, C. G., Y. Hao, and F. Wong. 1995. "Topography of rods and cones in the retina of the domestic 
pig." Hong Kong Med J 1:302-308. 
Gibson, C. L., D. Constantin, M. J. Prior, P. M. Bath, and S. P. Murphy. 2005. "Progesterone suppresses 
the inflammatory response and nitric oxide synthase-2 expression following cerebral 
ischemia." Exp Neurol 193:522-530. 
Glickstein, M. and M. Millodot. 1970. "Retinoscopy and eye size." Science 168:605. 
Gloesmann, M., B. Hermann, C. Schubert, H. Sattmann, P. K. Ahnelt, and W. Drexler. 2003. "Histologic 
correlation of pig retina radial stratification with ultrahigh-resolution optical coherence 
tomography." Invest Ophthalmol Vis Sci 44:1696. 
Gomez-Vicente, V., M. Donovan, and T. G. Cotter. 2005. "Multiple death pathways in retina-derived 
661W cells following growth factor deprivation: crosstalk between caspases and calpains." 
Cell Death Differ 12:796-804. 
Goss, C. W., S. W. Hoffman, and D. G. Stein. 2003. "Behavioral effects and anatomic correlates after 
brain injury: a progesterone dose-response study." Pharmacol Biochem Behav 76:231-242. 
Gregor, Z. and S. J. Ryan. 1982a. "Blood-retinal barrier after blunt trauma to the eye." Graefe's Arch 
Clin Exp Ophthalmol 219:205-208. 
—1982b. "Combined posterior contusion and penetrating injury in the pig eye. I. A natural history 
study." Br J Ophthalmol 66:793-798. 
—1982c. "Combined posterior contusion and penetrating injury in the pig eye. II. Histological 
features." Br J Ophthalmol 66:799-804. 
 
 
205 
 
—1983a. "Combined posterior contusion and penetrating injury in the pig eye. III. A controlled 
treatment trial of vitrectomy." Br J Ophthalmol 67:282-285. 
—1983b. "Complete and core vitrectomies in the treatment of experimental posterior penetrating 
eye injury in the rhesus monkey. II. Histologic features." Arch Ophthalmol 101:446-450. 
Guo, H., S. Albrecht, M. Bourdeau, T. Petzke, C. Bergeron, and A. C. LeBlanc. 2004. "Active caspase-6 
and caspase-6-cleaved tau in neuropil threads, neuritic plaques, and neurofibrillary tangles of 
Alzheimer's disease." Am J Pathol 165:523-531. 
Gwon, A. 2008. "The Rabbit in Cataract/IOL Surgery." Pp. 184-201 in Animal models in eye research 
edited by P. Tsonis. San Diego, CA: Academic Press. 
Hamasaki, D. I. 1967. "An anatomical and electrophysiological study of the retina of the owl monkey, 
Aotes trivirgatus." J Comp Neurol 130:163-174. 
Harada, C., X. Guo, K. Namekata, A. Kimura, K. Nakamura, K. Tanaka, L. F. Parada, and T. Harada. 
2011. "Glia- and neuron-specific functions of TrkB signalling during retinal degeneration and 
regeneration." Nat Commun 2:189. 
Hart, J. C., R. Blight, R. Cooper, and D. Papakostopoulos. 1975. "Electrophysiological and pathological 
investigation of concussional injury. An Experimental study." Trans Ophthalmol Soc UK 
95:326. 
Hart, J. C., V. E. Natsikos, E. R. Raistrick, and R. M. Doran. 1980. "Chorioretinitis sclopetaria." Trans 
Ophthalmol Soc UK 100:276. 
Hart, J. C. and H. J. Frank. 1975. "Retinal opacification after blunt non-perforating concussional 
injuries to the globe. A clinical and retinal fluorescein angiographic study." Trans Ophthalmol 
Soc U K 95:94-100. 
Hart, J. C. and R. Blight. 1979a. "Early changes in peripheral retina following concussive ocular 
injuries: an experimental study." J R Soc Med 72:180-184. 
Hart, JCD and R. Blight. 1979b. "Commotio retinae. To the editor." Arch Ophthalmol 97:1738. 
Hayashi, A., A. B. Majji, S. Fujioka, H. C. Kim, I. Fukushima, and E. de Juan, Jr. 1999. "Surgically 
induced degeneration and regeneration of the choriocapillaris in rabbit." Graefes Arch Clin 
Exp Ophthalmol 237:668-677. 
He, J., C. O. Evans, S. W. Hoffman, N. M. Oyesiku, and D. G. Stein. 2004. "Progesterone and 
allopregnanolone reduce inflammatory cytokines after traumatic brain injury." Exp Neurol 
189:404-412. 
Heckenlively, J. R. and G. B. Arden. 2006. "Principles and Practice of Clinical Electrophysiology of 
Vision.". 
Hendrickson, A. and D. Hicks. 2002. "Distribution and density of medium- and short-wavelength 
selective cones in the domestic pig retina." Exp Eye Res 74:435-444. 
Heriot, W. J. and R. Machemer. 1992. "Pigment epithelial repair." Graefes Arch Clin Exp Ophthalmol 
230:91-100. 
 
 
206 
 
Hines-Beard, J., J. Marchetta, S. Gordon, E. Chaum, E. E. Geisert, and T. S. Rex. 2012. "A mouse model 
of ocular blast injury that induces closed globe anterior and posterior pole damage." Exp Eye 
Res 99:63-70 LID - 10.1016/j.e. 
Hisatomi, T., T. Nakazawa, K. Noda, L. Almulki, S. Miyahara, S. Nakao, Y. Ito, H. She, R. Kohno, N. 
Michaud, and others. 2008. "HIV protease inhibitors provide neuroprotection through 
inhibition of mitochondrial apoptosis in mice." J Clin Invest 118:2025. 
Hou, B., S. W. You, M. M. Wu, F. Kuang, H. L. Liu, X. Y. Jiao, and G. Ju. 2004. "Neuroprotective effect 
of inosine on axotomized retinal ganglion cells in adult rats." Invest Ophthalmol Vis Sci 
45:662-667. 
Hughes, A. 1977. "The refractive state of the rat eye." Vision Res 17:927-939. 
—1979. "A schematic eye for the rat." Vision Res 19:569-588. 
Hui, Y. N., Y. Q. Wu, Q. S. Xiao, B. Kirchhof, and K. Heimann. 1993. "Repair of outer blood-retinal 
barrier after severe ocular blunt trauma in rabbits." Graefes Arch Clin Exp Ophthalmol 
231:365-369. 
Jacobs, G. H. 1998. "Photopigments and seeing--lessons from natural experiments: the Proctor 
lecture." Invest Ophthalmol Vis Sci 39:2204-2216. 
—2008. "Primate color vision: a comparative perspective." Vis Neurosci 25:619-633. 
Jeon, C. J., E. Strettoi, and R. H. Masland. 1998. "The major cell populations of the mouse retina." J 
Neurosci 18:8936-8946. 
Jeyasuria, P., J. Wetzel, M. Bradley, K Subedi, and J. C. Condon. 2009. "Progesterone-regulated 
caspase-3 action in the mouse may play a role in uterine quiescence during pregnancy 
through fragmentation of uterine myocyte contractile proteins." Biol Reprod 80:928-934. 
Jo, S. A., E. Wang, and L. I. Benowitz. 1999. "Ciliary neurotrophic factor is an axogenesis factor for 
retinal ganglion cells." Neuroscience 89:579-591. 
Jodhka, P. K., P. Kaur, W. Underwood, J. P. Lydon, and M. Singh. 2009. "The differences in 
neuroprotective efficacy of progesterone and medroxyprogesterone acetate correlate with 
their effects on brain-derived neurotrophic factor expression." Endocrinology 150:3162-8 LID 
- 10.1210/en.2. 
Jones, N. P., J. M. Hayward, P. T. Khaw, C. M. Claoue, and A. R. Elkington. 1986. "Function of an 
ophthalmic "accident and emergency" department: results of a six month survey." Br Med J 
292:188-190. 
Kaldi, I. and A. Berta. 2004. "Progesterone administration fails to protect albino male rats against 
photostress-induced retinal degeneration." Eur J Ophthalmol 14:306-314. 
Karl, M. O., S. Hayes, B. R. Nelson, K. Tan, B. Buckingham, and T. A. Reh. 2008. "Stimulation of neural 
regeneration in the mouse retina." Proc Natl Acad Sci U S A 105:19508-19513. 
Kassen, S. C., R. Thummel, L. A. Campochiaro, M. J. Harding, N. A. Bennett, and D. R. Hyde. 2009. 
"CNTF induces photoreceptor neuroprotection and Muller glial cell proliferation through two 
different signaling pathways in the adult zebrafish retina." Exp Eye Res 88:1051-1064. 
 
 
207 
 
Katai, N., T. Kikuchi, H. Shibuki, S. Kuroiwa, J. A. T. Kurokawa, and N. Yoshimura. 1999. "Caspaselike 
Proteases activated in apoptotic photoreceptors of Royal College of Surgeons rats." Invest 
Ophthalmol Vis Sci 40:1802-1807. 
Kaur, P., P. K. Jodhka, W. A. Underwood, C. A. Bowles, N. C. de Fiebre, C. M. de Fiebre, and M. Singh. 
2007. "Progesterone increases brain-derived neuroptrophic factor expression and protects 
against glutamate toxicity in a mitogen-activated protein kinase- and phosphoinositide-3 
kinase-dependent manner in cerebral cortical explants." J Neurosci Res 85:2441-2449. 
Kayama, M., T. Nakazawa, A. Thanos, Y. Morizane, Y. Murakami, S. Theodoropoulou, T. Abe, D. 
Vavvas, and J. W. Miller. 2011. "Heat shock protein 70 (HSP70) is critical for the 
photoreceptor stress response after retinal detachment via modulating anti-apoptotic Akt 
kinase." Am J Pathol 178:1080-1091. 
Kermer, P., N. Klocker, M. Labes, and M. Bahr. 1998. "Inhibition of CPP32-like proteases rescues 
axotomized retinal ganglion cells from secondary cell death in vivo." J Neurosci 18:4656-
4662. 
Kermer, P., N. Klocker, M. Labes, S. Thomsen, A. Srinivasan, and M. Bahr. 1999. "Activation of 
caspase-3 in axotomized rat retinal ganglion cells in vivo." FEBS Lett 453:361-364. 
Kigerl, K. A., J. C. Gensel, D. P. Ankeny, J. K. Alexander, D. J. Donnelly, and P. G. Popovich. 2009. 
"Identification of two distinct macrophage subsets with divergent effects causing either 
neurotoxicity or regeneration in the injured mouse spinal cord." J Neurosci 29:13435-13444. 
Kiilgaard, J. F., J. U. Prause, M. Prause, E. Scherfig, M. H. Nissen, and M. la Cour. 2007. "Subretinal 
posterior pole injury induces selective proliferation of RPE cells in the periphery in in vivo 
studies in pigs." Invest Ophthalmol Vis Sci 48:355-360. 
Kimizuka, Y., T. Yamada, and M. Tamai. 1997. "Quantitative study on regenerated retinal pigment 
epithelium and the effects of growth factor." Curr Eye Res 16:1081-1087. 
Klaiman, G., N. Champagne, and A. C. LeBlanc. 2009. "Self-activation of Caspase-6 in vitro and in vivo: 
Caspase-6 activation does not induce cell death in HEK293T cells." Biochim Biophys Acta 
1793:592-601 LID - 10.1016/j.. 
Klaiman, G., T. L. Petzke, J. Hammond, and A. C. Leblanc. 2008. "Targets of caspase-6 activity in 
human neurons and Alzheimer disease." Mol Cell Proteomics 7:1541-55 LID - 10.1074/mcp. 
Klassen, H., D. S. Sakaguchi, and M. J. Young. 2004. "Stem cells and retinal repair." Prog Ret Eye Res 
23:149-181. 
Klocker, N., P. Kermer, J. H. Weishaupt, M. Labes, R. Ankerhold, and M. Bahr. 2000. "Brain-derived 
neurotrophic factor-mediated neuroprotection of adult rat retinal ganglion cells in vivo does 
not exclusively depend on phosphatidyl-inositol-3'-kinase/protein kinase B signaling." J 
Neurosci 20:6962-6967. 
Knighton, R. W. and G. W. Blankenship. 1980. "Electrophysiological evaluation of eyes with opaque 
media." Int Ophthalmol Clin 20:1-19. 
Koeberle, P. D., A. Tura, N. G. Tassew, L. C. Schlichter, and P. P. Monnier. 2010. "The repulsive 
guidance molecule, RGMa, promotes retinal ganglion cell survival in vitro and in vivo." 
Neuroscience 169:495-504. 
 
 
208 
 
Koeberle, P. D. and A. K. Ball. 1998. "Effects of GDNF on retinal ganglion cell survival following 
axotomy." Vision Res 38:1505-1515. 
—2002. "Neurturin enhances the survival of axotomized retinal ganglion cells in vivo: combined 
effects with glial cell line-derived neurotrophic factor and brain-derived neurotrophic factor." 
Neuroscience 110:555-567. 
Kohno, T., T. Ishibashi, H. Inomata, H. Ikui, and Y. Taniguchi. 1983. "Experimental macular edema of 
commotio retinae: preliminary report." Jpn J Ophthalmol 27:149. 
Kohno, T., T. Miki, and K. Hayashi. 1998. "Choroidopathy after blunt trauma to the eye: a fluorescein 
and indocyanine green angiographic study." Am J Ophthalmol 126:248-260. 
Koopmans, S. A., T. Terwee, H. J. Haitjema, H. Deuring, S. Aarle, and A. C. Kooijman. 2004. "Relation 
between injected volume and optical parameters in refilled isolated porcine lenses." 
Ophthalmic Physiol Opt 24:572-579. 
Korndorfer, C. N., C. F. Meirelles, I. C. S. Bueno, and A. L. Abdalla. 1998. "Evaluation of extraction 
methods for progesterone determination in rabbit (Oryctolagus cuniculus) feces by 
radioimmunoassay." Braz. J. Vet. Res. Anim. Sci. 35:115-119. 
Kugler, S., N. Klocker, P. Kermer, S. Isenmann, and M. Bahr. 1999. "Transduction of axotomized 
retinal ganglion cells by adenoviral vector administration at the optic nerve stump: an in vivo 
model system for the inhibition of neuronal apoptotic cell death." Gene Ther 6:1759-1767. 
Kuhn, F., R. Maisiak, L. Mann, V. Mester, R. Morris, and C. D. Witherspoon. 2002. "The Ocular Trauma 
Score (OTS)." Ophthalmol Clin N Am 15:163-165. 
Lai, T. Y., W. W. Yip, V. W. Wong, and D. S. Lam. 2005. "Multifocal electroretinogram and optical 
coherence tomography of commotio retinae and traumatic macular hole." Eye 19:219-221. 
Lamkanfi, M., W. Declercq, M. Kalai, X. Saelens, and P. Vandenabeele. 2002. "Alice in caspase land. A 
phylogenetic analysis of caspases from worm to man." Cell Death Differ 9:358-361. 
Latanza, L., D. V. Alfaro, R. Bockman, T. Iwamoto, M. H. Heinemann, and S. Chang. 1988. 
"Leukotrienes levels in the aqueous humor following experimental ocular trauma." Retina 
8:199-204. 
Lee, V., R. L. Ford, W. Xing, C. Bunce, and B. Foot. 2010. "Surveillance of traumatic optic neuropathy 
in the UK." Eye 24:240-250. 
Leon, S., Y. Yin, J. Nguyen, N. Irwin, and L. I. Benowitz. 2000. "Lens injury stimulates axon 
regeneration in the mature rat optic nerve." J Neurosci 20:4615-4626. 
Leonard, D. S., X. G. Zhang, G. Panozzo, I. K. Sugino, and M. A. Zarbin. 1997. "Clinicopathologic 
correlation of localized retinal pigment epithelium debridement." Invest Ophthalmol Vis Sci 
38:1094-1109. 
Lewis, G. P., E. A. Chapin, G. Luna, K. A. Linberg, and S. K. Fisher. 2010. "The fate of Muller’s glia 
following experimental retinal detachment: nuclear migration, cell division, and subretinal 
glial scar formation." Mol Vis 16:1361. 
Lewis, G. P., E. A. Chapin, J. Byun, G. Luna, D. Sherris, and S. K. Fisher. 2009. "Muller cell reactivity and 
photoreceptor cell death are reduced after experimental retinal detachment using an 
inhibitor of the Akt/mTOR pathway." Invest Ophthalmol Vis Sci 50:4429-4435. 
 
 
209 
 
Liem, A. T., J. E. Keunen, and D. van Norren. 1995. "Reversible cone photoreceptor injury in 
commotio retinae of the macula." Retina 15:58-61. 
Lim, M. N., T. Umapathy, P. J. Baharuddin, and Z. Zubaidah. 2011. "Characterization and safety 
assessment of bioengineered limbal epithelium." Med J Malaysia 66:335-341. 
Linsenmeier, R. A. and L. Padnick-Silver. 2000. "Metabolic dependence of photoreceptors on the 
choroid in the normal and detached retina." Invest Ophthalmol Vis Sci 41:3117-3123. 
Lloyd, C. M., A. R. Phillips, G. J. Cooper, and P. R. Dunbar. 2008. "Double immunofluorescent labeling 
using sequential application of two rat primary antibodies." J Immunol Methods 334:70-71. 
Lopez, P. F., Q. Yan, L. Kohen, N. A. Rao, C. Spee, J. Black, and A. Oganesian. 1995. "Retinal pigment 
epithelial wound healing in vivo." Arch Ophthalmol 113:1437-1446. 
Lorber, B., M. Berry, and A. Logan. 2008. "Different factors promote axonal regeneration of adult rat 
retinal ganglion cells after lens injury and intravitreal peripheral nerve grafting." J Neurosci 
Res 86:894-903. 
Lorber, B., M. L. Howe, L. I. Benowitz, and N. Irwin. 2009. "Mst3b, an Ste20-like kinase, regulates 
axon regeneration in mature CNS and PNS pathways." Nat Neurosci 12:1407-1414. 
Luna, G., G. P. Lewis, C. D. Banna, O. Skalli, and S. K. Fisher. 2010. "Expression profiles of nestin and 
synemin in reactive astrocytes and Muller cells following retinal injury: a comparison with 
glial fibrillar acidic protein and vimentin." Mol Vis 16:2511. 
Luo, J. M., L. P. Cen, X. M. Zhang, S. W. Chiang, Y. Huang, D. Lin, Y. M. Fan, N. van Rooijen, D. S. Lam, 
C. P. Pang, and Q. Cui. 2007. "PI3K/akt, JAK/STAT and MEK/ERK pathway inhibition protects 
retinal ganglion cells via different mechanisms after optic nerve injury." Eur J Neurosci 
26:828-842. 
Lutjen-Drecoll, E., P. L. Kaufman, R. Wasielewski, L. Ting-Li, and M. A. Croft. 2010. "Morphology and 
accommodative function of the vitreous zonule in human and monkey eyes." Invest 
Ophthalmol Vis Sci 51:1554-1564. 
Mac Donald, C. L., A. M. Johnson, D. Cooper, E. C. Nelson, N. J. Werner, J. S. Shimony, A. Z. Snyder, M. 
E. Raichle, J. R. Witherow, R. Fang, S. F. Flaherty, and D. L. Brody. 2011. "Detection of blast-
related traumatic brain injury in U.S. military personnel." N Engl J Med 364:2091-2100. 
Mader, T. H., R. D. Carroll, C. S. Slade, R. K. George, J. P. Ritchey, and S. P. Neville. 2006. "Ocular war 
injuries of the Iraqi Insurgency,January-September 2004." Ophthalmol 113:97-104. 
Malik, J. M., Z. Shevtsova, M. Bahr, and S. Kugler. 2005. "Long-term in vivo inhibition of CNS 
neurodegeneration by Bcl-XL gene transfer." Mol Ther 11:373-381. 
Mallonee, S., S. Shariat, G. Stennies, R. Waxweiler, D. Hogan, and F. Jordan. 1996. "Physical injuries 
and fatalities resulting from the Oklahoma City bombing." J Am Med Assoc 276:382-387. 
Matsumoto, B., J. C. Blanks, and S. J. Ryan. 1984. "Topographic variations in the rabbit and primate 
internal limiting membrane." Invest Ophthalmol Vis Sci 25:71-82. 
McConnell, P. and M. Berry. 1982. "Regeneration of ganglion cell axons in the adult mouse retina." 
Brain Res 241:362-365. 
 
 
210 
 
McCormack, J. T. and G. S. Greenwald. 1974. "Progesterone and oestradiol-17beta concentrations in 
the peripheral plasma during pregnancy in the mouse." J Endocrinol 62:101-107. 
Meyer, C. H., E. B. Rodrigues, and S. Mennel. 2003. "Acute commotio retinae determined by cross-
sectional optical coherence tomography." Eur J Ophthalmol 13:816-818. 
Miki, T., K. Kitashoji, and T. Kohno. 1992. "Intrachoroidal dye leakage in indocyanine green fundus 
angiography after experimental commotio retinae." Eur J Ophthalmol 2:79-82. 
Miller, B., H. Miller, R. Patterson, and S. J. Ryan. 1986. "Retinal wound healing. Cellular activity at the 
vitreoretinal interface." Arch Ophthalmol 104:281-285. 
Mo, X., A. Yokoyama, T. Oshitari, H. Negishi, M. Dezawa, A. Mizota, and E. Adachi-Usami. 2002. 
"Rescue of axotomized retinal ganglion cells by BDNF gene electroporation in adult rats." 
Invest Ophthalmol Vis Sci 43:2401-2405. 
Monnier, P. P., P. M. D'Onofrio, M. Magharious, A. C. Hollander, N. Tassew, K. Szydlowska, M. 
Tymianski, and P. D. Koeberle. 2011. "Involvement of caspase-6 and caspase-8 in neuronal 
apoptosis and the regenerative failure of injured retinal ganglion cells." J Neurosci 31:10494-
10505. 
Morris, A. C., T. Scholz, and J. M. Fadool. 2008. "Rod progenitor cells in the mature zebrafish retina." 
Adv Exp Med Biol 613:361-368. 
Moulin, M. and A. P. Arrigo. 2008. "Caspases activation in hyperthermia-induced stimulation of TRAIL 
apoptosis." Cell Stress Chaperones 13:313-26 LID - 10.1007/s12. 
Muller, A., T. G. Hauk, and D. Fischer. 2007. "Astrocyte-derived CNTF switches mature RGCs to a 
regenerative state following inflammatory stimulation." Brain 130:3308-3320. 
Nakazawa, T., M. Kayama, M. Ryu, H. Kunikata, R. Watanabe, M. Yasuda, J. Kinugawa, D. Vavvas, and 
J. W. Miller. 2011. "Tumor necrosis factor-alpha mediates photoreceptor death in a rodent 
model of retinal detachment." Invest Ophthalmol Vis Sci 52:1384-1391. 
Nangia, V., J. B. Jonas, A. Sinha, A. Matin, M. Kulkarni, and S. Panda-Jonas. 2010. "Ocular axial length 
and its associations in an adult population of central rural India: the Central India Eye and 
Medical Study." Ophthalmology 117:1360-1366. 
Nathans, J. 1992. "Rhodopsin: structure, function, and genetics." Biochemistry 31:4923-4931. 
National Centre for the Replacement Refinement and Reduction of Animals in Research. . "Species 
Selection." 2011. 
Nicotera, P., M. Leist, and L. Manzo. 1999. "Neuronal cell death: a demise with different shapes." 
Trends Pharmacol Sci 20:46-51. 
Nikolaev, A., T. McLaughlin, D. D. O'Leary, and M. Tessier-Lavigne. 2009. "APP binds DR6 to trigger 
axon pruning and neuron death via distinct caspases." Nature 457:981-9 LID - 10.1038/natu. 
Nilsen, J. and R. D. Brinton. 2002a. "Impact of progestins on estradiol potentiation of the glutamate 
calcium response." Neuroreport 13:825-830. 
—2002b. "Impact of progestins on estrogen-induced neuroprotection: synergy by progesterone and 
19-norprogesterone and antagonism by medroxyprogesterone acetate." Endocrinology 
143:205-212. 
 
 
211 
 
Nin, M. S., L. A. Martinez, F. Pibiri, M. Nelson, and G. Pinna. 2011. "Neurosteroids reduce social 
isolation-induced behavioral deficits: a proposed link with neurosteroid-mediated 
upregulation of BDNF expression." Front Endocrinol (Lausanne) 2:73 LID-
10.3389/fendo.2011.0. 
Ninomiya, H. and H. Kuno. 2001. "Microvasculature of the rat eye: scanning electron microscopy of 
vascular corrosion casts." Vet Ophthalmol 4:55-59. 
Nishida, A., M. Takahashi, H. Tanihara, I. Nakano, J. B. Takahashi, A. Mizoguchi, C. Ide, and Y. Honda. 
2000. "Incorporation and differentiation of hippocampus-derived neural stem cells 
transplanted in injured adult rat retina." Invest Ophthalmol Vis Sci 41:4268-4274. 
Noia Lda, C., A. Berezovsky, D. Freitas, P. Y. Sacai, and S. R. Salomao. 2006. "[Clinical and 
electroretinographic profile of commotio retinae.]." Arq Bras Oftalmol 69:895-906. 
Odhiambo, W.A., S.W. Guthua, F.G. Macigo, and M.K. Ahama. 2002. "Maxillofacial injuries caused by 
terrorist bomb attack in Nairobi, Kenya." Int J Oral Maxillofac Surg 31:374-377. 
Oganesian, A., E. Bueno, Q. Yan, C. Spee, J. Black, N. A. Rao, and P. F. Lopez. 1997. "Scanning and 
transmission electron microscopic findings during RPE wound healing in vivo." Int 
Ophthalmol 21:165-175. 
Ogino, H., M. Ito, K. Matsumoto, S. Yagyu, H. Tsuda, I. Hirono, C. P. Wild, and R. Montesano. 1993. 
"Retinal degeneration induced by N-methyl-N-nitrosourea and detection of 7-
methyldeoxyguanosine in the rat retina." Toxicol Pathol 21:21-25. 
Oh, J., J. H. Jung, S. W. Moon, S. J. Song, H. G. Yu, and H. Y. Cho. 2011. "Commotio retinae with 
spectral-domain optical coherence tomography." Retina 31:2044-2049. 
Ohki, K., K. Yoshida, A. Yamakawa, T. Harada, H. Matsuda, and J. Imaki. 1995. "jun-B gene expression 
in rat retinal cells following focal retinal injury." Curr Eye Res 14:1021-1024. 
Ohta, K., A. Ito, and H. Tanaka. 2008. "Neuronal stem/progenitor cells in the vertebrate eye." Dev 
Growth Differ 50:253-259. 
Oishi, A., M. Hata, M. Shimozono, M. Mandai, A. Nishida, and Y. Kurimoto. 2010. "The significance of 
external limiting membrane status for visual acuity in age-related macular degeneration." Am 
J Ophthalmol 150:27-32.e1. 
Oliveira, C., N. Harizman, C. A. Girkin, A. Xie, C. Tello, J. M. Liebmann, and R. Ritch. 2007. "Axial length 
and optic disc size in normal eyes." Br J Ophthalmol 91:37. 
Ooto, S., T. Akagi, R. Kageyama, J. Akita, M. Mandai, Y. Honda, and M. Takahashi. 2004. "Potential for 
neural regeneration after neurotoxic injury in the adult mammalian retina." Proc Natl Acad 
Sci USA 101:13654-13659. 
Organisciak, D. T. and D. K. Vaughan. 2010. "Retinal light damage: mechanisms and protection." Prog 
Retin Eye Res 29:113-134. 
Osakada, F., S. Ooto, T. Akagi, M. Mandai, A. Akaike, and M. Takahashi. 2007. "Wnt signaling 
promotes regeneration in the retina of adult mammals." J Neurosci 27:4210-4219. 
O'Steen, W. K. 1977. "Ovarian steroid effects on light-induced retinal photoreceptor damage." Exp 
Eye Res 25:361-369. 
 
 
212 
 
Otteson, D. C. and P. F. Hitchcock. 2003. "Stem cells in the teleost retina: persistent neurogenesis and 
injury-induced regeneration." Vision Res 43:927-936. 
Ozaki, S., M. J. Radeke, and D. H. Anderson. 2000. "Rapid upregulation of fibroblast growth factor 
receptor 1 (flg) by rat photoreceptor cells after injury." Invest Ophthalmol Vis Sci 41:568-579. 
Ozaki, S., M. Kita, T. Yamana, A. Negi, and Y. Honda. 1997. "Influence of the sensory retina on healing 
of the rabbit retinal pigment epithelium." Curr Eye Res 16:349-358. 
Ozerdem, U., B. Mach-Hofacre, K. Keefe, T. Pham, K. Soules, K. Appelt, and W. R. Freeman. 2001. 
"The effect of prinomastat (AG3340), a synthetic inhibitor of matrix metalloproteinases, on 
posttraumatic proliferative vitreoretinopathy." Ophthalmic Res 33:20-23. 
Ozerdem, U., B. Mach-Hofacre, L. Cheng, S. Chaidhawangul, K. Keefe, C. D. McDermott, G. Bergeron-
Lynn, K. Appelt, and W. R. Freeman. 2000. "The effect of prinomastat (AG3340), a potent 
inhibitor of matrix metalloproteinases, on a subacute model of proliferative 
vitreoretinopathy." Curr Eye Res 20:447-453. 
Paquet-Durand, F., D. Sanges, J. McCall, J. Silva, T. van Veen, V. Marigo, and P. Ekstrom. 2010. 
"Photoreceptor rescue and toxicity induced by different calpain inhibitors." J Neurochem 
115:930-940. 
Park, C. M. and M. J. Hollenberg. 1993. "Growth factor-induced retinal regeneration in vivo." Int Rev 
Cytol 146:49-74. 
Park, J. Y., W. H. Nam, S. H. Kim, S. Y. Jang, Y. H. Ohn, and T. K. Park. 2011. "Evaluation of the central 
macula in commotio retinae not associated with other types of traumatic retinopathy." 
Korean J Ophthalmol 25:262-267. 
Park, K., J. M. Luo, S. Hisheh, A. R. Harvey, and Q. Cui. 2004. "Cellular mechanisms associated with 
spontaneous and ciliary neurotrophic factor-cAMP-induced survival and axonal regeneration 
of adult retinal ganglion cells." J Neurosci 24:10806-10815. 
Park, K. K., K. Liu, Y. Hu, P. D. Smith, C. Wang, B. Cai, B. Xu, L. Connolly, I. Kramvis, M. Sahin, and Z. 
He. 2008. "Promoting axon regeneration in the adult CNS by modulation of the PTEN/mTOR 
pathway." Science 322:963-966. 
Parrilla-Reverter, G., M. Agudo, P. Sobrado-Calvo, M. Salinas-Navarro, M. P. Villegas-Perez, and M. 
Vidal-Sanz. 2009. "Effects of different neurotrophic factors on the survival of retinal ganglion 
cells after a complete intraorbital nerve crush injury: a quantitative in vivo study." Exp Eye 
Res 89:32-41. 
Peinado-Ramon, P., M. Salvador, M. P. Villegas-Perez, and M. Vidal-Sanz. 1996. "Effects of axotomy 
and intraocular administration of NT-4, NT-3, and brain-derived neurotrophic factor on the 
survival of adult rat retinal ganglion cells. A quantitative in vivo study." Invest Ophthalmol Vis 
Sci 37:489-500. 
Penn, J. S., G. W. McCollum, J. M. Barnett, X. Q. Werdich, K. A. Koepke, and V. S. Rajaratnam. 2006. 
"Angiostatic effect of penetrating ocular injury: role of pigment epithelium-derived factor." 
Invest Ophthalmol Vis Sci 47:405-414. 
Petras, J. M., R. A. Bauman, and N. M. Elsayed. 1997. "Visual system degeneration induced by blast 
overpressure." Toxicol 121:41-49. 
 
 
213 
 
Petroff, B. K. and K. M. Mizinga. 2003. "Pharmacokinetics of ovarian steroids in Sprague-Dawley rats 
after acute exposure to 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD)." Reprod Biol 3:131-141. 
Pettus, E. H., D. W. Wright, D. G. Stein, and S. W. Hoffman. 2005. "Progesterone treatment inhibits 
the inflammatory agents that accompany traumatic brain injury." Brain Res 1049:112-119. 
Pieramici, D. J., P. Sternberg, Jr., S. r. Aaberg TM, W. Z. Bridges, Jr., A. Capone, Jr., J. A. Cardillo, E. de 
Juan, Jr., F. Kuhn, T. A. Meredith, W. F. Mieler, T. W. Olsen, P. Rubsamen, and T. Stout. 1997. 
"A system for classifying mechanical injuries of the eye (globe). The Ocular Trauma 
Classification Group." Am J Ophthalmol 123:820-831. 
Pradelli, L. A., M. Beneteau, and J. E. Ricci. 2010. "Mitochondrial control of caspase-dependent and -
independent cell death." Cell Mol Life Sci 67:1589-1597. 
Prusky, G. T., K. T. Harker, R. M. Douglas, and I. Q. Whishaw. 2002. "Variation in visual acuity within 
pigmented, and between pigmented and albino rat strains." Behav Brain Res 136:339-348. 
Pulido, J. S., I. Sugaya, J. Comstock, and K. Sugaya. 2007. "Reelin expression is upregulated following 
ocular tissue injury." Graefes Arch Clin Exp Ophthalmol 245:889-893. 
Pulido, J. S. and N. P. Blair. 1987. "The blood-retinal barrier in Berlin's edema." Retina 7:233-236. 
Remtulla, S. and P. E. Hallett. 1985. "A schematic eye for the mouse, and comparisons with the rat." 
Vision Res 25:21-31. 
Rhodes, R. H. 1982. "An ultrastructural study of the complex carbohydrates of the mouse posterior 
vitreoretinal juncture." Invest Ophthalmol Vis Sci 22:460-477. 
—1983. "A comparative study of vitreous-body and zonular glycoconjugates that bind to the lectin 
from Ulex europaeus." Histochemistry 78:349-360. 
—1985. "An ultrastructural study of complex carbohydrates in the posterior chamber and vitreous 
base of the mouse." Histochem J 17:291-312. 
Richmond, D. R., D. E. Pratt, and C. S. White. 1962. "Orbital 'Blow-Out' Fractures in Dogs Produced by 
Air Blast. Formal Progress Report to Defence Atomic Support Agency 1316." Lovelace 
Foundation for Medical Education and Research, Albuquerque, N. Mex., Washington DC. 
Roof, R. L., R. Duvdevani, and D. G. Stein. 1993. "Gender influences outcome of brain injury: 
progesterone plays a protective role." Brain Res 607:333-336. 
Roof, R. L., S. W. Hoffman, and D. G. Stein. 1997. "Progesterone protects against lipid peroxidation 
following traumatic brain injury in rats." Mol Chem Neuropathol 31:1-11. 
Roof, R. L. and E. D. Hall. 2000. "Gender differences in acute CNS trauma and stroke: neuroprotective 
effects of estrogen and progesterone." J Neurotrauma 17:367-388. 
Sánchez-Vallejo, V., I. Almansa, R. López-Pedrajas, F. J. Romero, and M.  Miranda. 2012. "The effect 
of progesterone on retinitis pigmentosa." The International Society for Eye Research, Berlin. 
Saika, S., S. Kono-Saika, T. Tanaka, O. Yamanaka, Y. Ohnishi, M. Sato, Y. Muragaki, A. Ooshima, J. Yoo, 
K. C. Flanders, and A. B. Roberts. 2004. "Smad3 is required for dedifferentiation of retinal 
pigment epithelium following retinal detachment in mice." Lab Invest 84:1245-1258. 
 
 
214 
 
Sanchez, I., R. Martin, F. Ussa, and I. Fernandez-Bueno. 2011. "The parameters of the porcine 
eyeball." Graefes Arch Clin Exp Ophthalmol 249:475-482. 
Sandvig, A., M. Berry, L. B. Barrett, A. Butt, and A. Logan. 2004. "Myelin-, reactive glia-, and scar-
derived CNS axon growth inhibitors: expression, receptor signaling, and correlation with axon 
regeneration." Glia 46:225-251. 
Sayeed, I., S. Parvez, B. Wali, D. Siemen, and D. G. Stein. 2009. "Direct inhibition of the mitochondrial 
permeability transition pore: a possible mechanism for better neuroprotective effects of 
allopregnanolone over progesterone." Brain Res 1263:165-73 LID - 10.1016/j.b. 
Schulze-Bonsel, K., N. Feltgen, H. Burau, L. Hansen, and M. Bach. 2006. "Visual acuities "hand 
motion" and "counting fingers" can be quantified with the freiburg visual acuity test." Invest 
Ophthalmol Vis Sci 47:1236-1240. 
Schwab, M. E. 2010. "Functions of Nogo proteins and their receptors in the nervous system." Nat Rev 
Neurosci 11:799-811. 
Scott, W. R., W. C. Lloyd, J. V. Benedict, and R. Meredith. 2000. "Ocular injuries due to projectile 
impacts." Annu Proc Assoc Adv Automot Med 44:205-217. 
Sebag, J. 1992. "Anatomy and pathology of the vitreo-retinal interface." Eye 6:541-552. 
Sebag, J. and K.M.P. Yee. 2007. "Vitreous: From Biochemistry to Clinical Relevance." Pp. Chap 16; 13 
and 22 in Duane's Foundations of Clinical Ophthalmology, vol. 1 edited by W. Tasman and E. 
Jaeger. Philadelphia, PA: Lippincott Williams & Wilkins. 
Sharma, A. K. and B. Rohrer. 2004. "Calcium-induced calpain mediates apoptosis via caspase-3 in a 
mouse photoreceptor cell line." J Biol Chem 279:35564-35572. 
Sharpnack, D. D., A. J. Johnson, and Y. Y. Phillips. 1991. "The pathology of primary blast injury." 
Pp. 272-294 in Conventional Warfare--Ballistic, Blast and Burn Injuries edited by R. Zajtchuk, 
P. Jenkins, R. Bellamy, and C. Quick. Washington, DC: Office of the Surgeon General at TMM 
publications. 
Shear, D. A., R. Galani, S. W. Hoffman, and D. G. Stein. 2002. "Progesterone protects against necrotic 
damage and behavioral abnormalities caused by traumatic brain injury." Exp Neurol 178:59-
67. 
Silver, J. and J. H. Miller. 2004. "Regeneration beyond the glial scar." Nat Rev Neurosci 5:146-156. 
Simoens, P., L. De Schaepdrijver, and H. Lauwers. 1992. "Morphologic and clinical study of the retinal 
circulation in the miniature pig. A: Morphology of the retinal microvasculature." Exp Eye Res 
54:965-973. 
Singh, M. and C. Su. 2013a. "Progesterone and neuroprotection." Horm Behav 63:284-290. 
—2013b. "Progesterone, brain-derived neurotrophic factor and neuroprotection." Neuroscience 
239:84-91 LID - 10.1016/j.n. 
Sipperley, J. O., H. A. Quigley, and J. D.M. Gass. 1978. "Traumatic retinopathy in primates: the 
explanation of commotio retinae." Arch Ophthalmol 96:2267. 
Slabe, T. J., S. T. Rasmussen, and B. Tandler. 1990. "A simple method for improving glass knives." J 
Electron Microsc Tech 15:316-317. 
 
 
215 
 
Sloop, G. D., J. C. Roa, A. G. Delgado, J. T. Balart, 3. rd. Hines MO, and J. M. Hill. 1999. "Histologic 
sectioning produces TUNEL reactivity. A potential cause of false-positive staining." Arch 
Pathol Lab Med 123:529-532. 
Smiddy, W. E., S. L. Fine, H. A. Quigley, G. Dunkelberger, R. M. Hohman, and E. M. Addicks. 1986. 
"Cell proliferation after laser photocoagulation in primate retina. An autoradiographic 
study." Arch Ophthalmol 104:1065-1069. 
Smith, P. D., F. Sun, K. K. Park, B. Cai, C. Wang, K. Kuwako, I. Martinez-Carrasco, L. Connolly, and Z. 
He. 2009. "SOCS3 deletion promotes optic nerve regeneration in vivo." Neuron 64:617-623. 
Snead, D. R., N. Cullen, S. James, A. V. Poulson, A. H. Morris, A. Lukaris, J. D. Scott, A. J. Richards, and 
M. P. Snead. 2004. "Hyperconvolution of the inner limiting membrane in 
vitreomaculopathies." Graefes Arch Clin Exp Ophthalmol 242:853-862. 
Snell, R. S., M. A. Lemp, and I. Grunther. 1998. Clinical anatomy of the eye. Oxford, UK: Blackwell 
Science. 
Snodderly, D. M. and R. S. Weinhaus. 1990. "Retinal vasculature of the fovea of the squirrel monkey, 
Saimiri sciureus: three-dimensional architecture, visual screening, and relationships to the 
neuronal layers." J Comp Neurol 297:145-163. 
Sony, P., P. Venkatesh, S. Gadaginamath, and S. P. Garg. 2006. "Optical coherence tomography 
findings in commotio retina." Clin Exp Ophthalmol 34:621. 
Souza-Santos, F., D. Lavinsky, N. S. Moraes, A. R. Castro, J. A. Cardillo, and M. E. Farah. 2012. 
"Spectral-domain optical coherence tomography in patients with commotio retinae." Retina 
32:711-718. 
Srinivasula, S. M., R. Hegde, A. Saleh, P. Datta, E. Shiozaki, J. Chai, R. A. Lee, P. D. Robbins, T. 
Fernandes-Alnemri, Y. Shi, and E. S. Alnemri. 2001. "A conserved XIAP-interaction motif in 
caspase-9 and Smac/DIABLO regulates caspase activity and apoptosis." Nature 410:112-116. 
Stein, D. G. 2007. "Sex differences in brain damage and recovery of function: experimental and 
clinical findings." Prog Brain Res 161:339-351. 
—2008a. "Progesterone exerts neuroprotective effects after brain injury." Brain Res Rev 57:386-397. 
—2008b. "Progesterone exerts neuroprotective effects after brain injury." Brain Res Rev 57:386-397. 
Stenkamp, D. L. 2007. "Neurogenesis in the fish retina." Int Rev Cytol 259:173-224. 
Streit. 2005. Microglia, Edited by H. Kettenmann and B. R. Ransom. New York: Oxford University 
Press. 
Subramanian, M., C. K. Pusphendran, U. Tarachand, and T. P. Devasagayam. 1993. "Gestation confers 
temporary resistance to peroxidation in the maternal rat brain." Neurosci Lett 155:151-154. 
Sugawara, T., M. Fujimura, N. Noshita, G. W. Kim, A. Saito, T. Hayashi, P. Narasimhan, C. M. Maier, 
and P. H. Chan. 2004. "Neuronal death/survival signaling pathways in cerebral ischemia." 
NeuroRx 1:17-25. 
Sun, C., M. Cai, R. P. Meadows, N. Xu, A. H. Gunasekera, J. Herrmann, J. C. Wu, and S. W. Fesik. 2000. 
"NMR structure and mutagenesis of the third Bir domain of the inhibitor of apoptosis protein 
XIAP." J Biol Chem 275:33777-33781. 
 
 
216 
 
Susin, S. A., H. K. Lorenzo, N. Zamzami, I. Marzo, B. E. Snow, G. M. Brothers, J. Mangion, E. Jacotot, P. 
Costantini, M. Loeffler, N. Larochette, D. R. Goodlett, R. Aebersold, D. P. Siderovski, J. M. 
Penninger, and G. Kroemer. 1999. "Molecular characterization of mitochondrial apoptosis-
inducing factor." Nature 397:441-446. 
Szel, A. and P. Rohlich. 1992. "Two cone types of rat retina detected by anti-visual pigment 
antibodies." Exp Eye Res 55:47-52. 
Thach, A. B., A. J. Johnson, R. B. Carroll, A. Huchun, D. J. Ainbinder, R. D. Stutzman, S. M. Blaydon, S. 
L. Demartelaere, T. H. Mader, C. S. Slade, R. K. George, J. P. Ritchey, S. D. Barnes, and L. A. 
Fannin. 2008. "Severe eye injuries in the war in Iraq, 2003-2005." Ophthalmol 115:377-382. 
Thach, A. B., T. P. Ward, R. D. Hollifield, K. Cockerham, R. Birdsong, and K. K. Kramer. 2000. "Eye 
injuries in a terrorist bombing: Dhahran, Saudi Arabia, June 25, 1996." Ophthalmology 
107:844-847. 
Thanos, S., J. Mey, and M. Wild. 1993. "Treatment of the adult retina with microglia-suppressing 
factors retards axotomy-induced neuronal degradation and enhances axonal regeneration in 
vivo and in vitro." J Neurosci 13:455-466. 
Thomas, R., J. G. McManus, A. Johnson, P. Mayer, C. Wade, and J. B. Holcomb. 2009. "Ocular injury 
reduction from ocular protection use in current combat operations." J Trauma 66:S99-103. 
Thummel, R., S. C. Kassen, J. M. Enright, C. M. Nelson, J. E. Montgomery, and D. R. Hyde. 2008. 
"Characterization of Muller glia and neuronal progenitors during adult zebrafish retinal 
regeneration." Exp Eye Res 87:433-444. 
Topping, T. M., G. W. Abrams, and R. Machemer. 1979. "Experimental double-perforating injury of 
the posterior segment in rabbit eyes: the natural history of intraocular proliferation." Arch 
Ophthalmol 97:735-742. 
Trichonas, G., Y. Murakami, A. Thanos, Y. Morizane, M. Kayama, C. M. Debouck, T. Hisatomi, J. W. 
Miller, and D. G. Vavvas. 2010. "Receptor interacting protein kinases mediate retinal 
detachment-induced photoreceptor necrosis and compensate for inhibition of apoptosis." 
Proc Natl Acad Sci U S A 107:21695-21700. 
Troy, C. M., L. Stefanis, A. Prochiantz, L. A. Greene, and M. L. Shelanski. 1996. "The contrasting roles 
of ICE family proteases and interleukin-1beta in apoptosis induced by trophic factor 
withdrawal and by copper/zinc superoxide dismutase down-regulation." Proc Natl Acad Sci U 
S A 93:5635-5640. 
Troy, C. M., L. Stefanis, L. A. Greene, and M. L. Shelanski. 1997. "Nedd2 is required for apoptosis after 
trophic factor withdrawal, but not superoxide dismutase (SOD1) downregulation, in 
sympathetic neurons and PC12 cells." J Neurosci 17:1911-1918. 
Troy, C. M. and E. M. Ribe. 2008. "Caspase-2: vestigial remnant or master regulator?" Sci Signal 1. 
Tu, S., G. P. McStay, L. M. Boucher, T. Mak, H. M. Beere, and D. R. Green. 2006. "In situ trapping of 
activated initiator caspases reveals a role for caspase-2 in heat shock-induced apoptosis." 
Nat Cell Biol 8:72-77. 
Turner, J. E., J. R. Blair, and E. T. Chappell. 1986. "Peripheral nerve implantation into a penetrating 
lesion of the eye: stimulation of the damaged retina." Brain Res 376:246-254. 
 
 
217 
 
Valentino, T. L., H. J. Kaplan, L. V. Del Priore, S. R. Fang, A. Berger, and M. S. Silverman. 1995. "Retinal 
pigment epithelial repopulation in monkeys after submacular surgery." Arch Ophthalmol 
113:932-938. 
van Adel, B. A., C. Kostic, N. Deglon, A. K. Ball, and Y. Arsenijevic. 2003. "Delivery of ciliary 
neurotrophic factor via lentiviral-mediated transfer protects axotomized retinal ganglion cells 
for an extended period of time." Hum Gene Ther 14:103-115. 
van Lookeren, C. ampagne M. and R. Gill. 1996. "Ultrastructural morphological changes are not 
characteristic of apoptotic cell death following focal cerebral ischaemia in the rat." Neurosci 
Lett 213:111-114. 
van Raam, B. J., D. E. Ehrnhoefer, M. R. Hayden, and G. S. Salvesen. 2013. "Intrinsic cleavage of 
receptor-interacting protein kinase-1 by caspase-6." Cell Death Differ 20:86-96 LID - 
10.1038/cdd. 
Vazquez-Chona, F., B. K. Song, and E. E. Geisert, Jr. 2004. "Temporal changes in gene expression after 
injury in the rat retina." Invest Ophthalmol Vis Sci 45:2737-2746. 
Vazquez-Chona, F. R., A. N. Khan, C. K. Chan, A. N. Moore, P. K. Dash, M. R. Hernandez, L. Lu, E. J. 
Chesler, K. F. Manly, R. W. Williams, and E. E. Geisert, Jr. 2005. "Genetic networks controlling 
retinal injury." Mol Vis 11:958-970. 
Vernon, S. A. 1983. "Analysis of all new cases seen in a busy regional centre ophthalmic casualty 
department during 24-week period." J R Soc Med 76:279-282. 
Vinberg, F. J., S. Strandman, and A. Koskelainen. 2009. "Origin of the fast negative ERG component 
from isolated aspartate-treated mouse retina." J Vis 9:9.1-17. 
Virgo, B. B. and G. D. Bellward. 1974. "Serum progesterone levels in the pregnant and postpartum 
laboratory mouse." Endocrinology 95:1486-1490. 
von Leithner, P. L., C. Ciurtin, and G. Jeffery. 2010. "Microscopic mammalian retinal pigment 
epithelium lesions induce widespread proliferation with differences in magnitude between 
center and periphery." Mol Vis 16:570-581. 
Wan, J., H. Zheng, Z. L. Chen, H. L. Xiao, Z. J. Shen, and G. M. Zhou. 2008. "Preferential regeneration 
of photoreceptor from Muller glia after retinal degeneration in adult rat." Vision Res 48:223-
234. 
Wang, J., C. K. Chan, J. S. Taylor, and S. O. Chan. 2008. "Localization of Nogo and its receptor in the 
optic pathway of mouse embryos." J Neurosci Res 86:1721-1733. 
Wang, J. M., L. Liu, R. W. Irwin, S. Chen, and R. D. Brinton. 2008. "Regenerative potential of 
allopregnanolone." Brain Res Rev 57:398-409. 
Weichel, E. D., M. H. Colyer, S. E. Ludlow, K. S. Bower, and A. S. Eiseman. 2008. "Combat ocular 
trauma visual outcomes during operations Iraqi and Enduring Freedom." Ophthalmol 
115:2235-2245. 
Weidenthal, D. T. and C. L. Schepens. 1966. "Peripheral fundus changes associated with ocular 
contusion." Am J Ophthalmol 62:465-477. 
 
 
218 
 
Weishaupt, J. H., G. Rohde, E. Polking, A. L. Siren, H. Ehrenreich, and M. Bahr. 2004. "Effect of 
erythropoietin axotomy-induced apoptosis in rat retinal ganglion cells." Invest Ophthalmol 
Vis Sci 45:1514-1522. 
Wen, R., Y. Song, T. Cheng, M. T. Matthes, D. Yasumura, M. M. LaVail, and R. H. Steinberg. 1995. 
"Injury-induced upregulation of bFGF and CNTF mRNAS in the rat retina." J Neurosci 15:7377-
7385. 
Westra, I., S. G. Robbins, D. J. Wilson, J. E. Robertson, L. M. O'Rourke, C. E. Hart, and J. T. Rosenbaum. 
1995. "Time course of growth factor staining in a rabbit model of traumatic tractional retinal 
detachment." Graefes Arch Clin Exp Ophthalmol 233:573-581. 
Wikler, K. C. and P. Rakic. 1990. "Distribution of photoreceptor subtypes in the retina of diurnal and 
nocturnal primates." J Neurosci 10:3390-3401. 
Wong, K. H., S. A. Koopmans, T. Terwee, and A. C. Kooijman. 2007. "Changes in spherical aberration 
after lens refilling with a silicone oil." Invest Ophthalmol Vis Sci 48:1261-1267. 
Wong, R., D. Ray, and D. A. Kendall. 2012. "Progesterone pharmacokinetics in the mouse: 
implications for potential stroke therapy." J Pharm Pharmacol 64:1614-20 LID - 10.1111/j.2. 
Wong, T. Y., B. E. Klein, and R. Klein. 2000. "The prevalence and 5-year incidence of ocular trauma. 
The Beaver Dam Eye Study." Ophthalmol 107:2196. 
Wong, T. Y., M. B. Seet, and C. L. Ang. 1997. "Eye injuries in twentieth century warfare: a historical 
perspective." Surv Ophthalmol 41:433-459. 
Xiao, G., J. Wei, W. Yan, W. Wang, and Z. Lu. 2008. "Improved outcomes from the administration of 
progesterone for patients with acute severe traumatic brain injury: a randomized controlled 
trial." Crit Care 12:R61 LID-10.1186/cc6887 [doi]. 
Yin, Y., M. T. Henzl, B. Lorber, T. Nakazawa, T. T. Thomas, F. Jiang, R. Langer, and L. I. Benowitz. 2006. 
"Oncomodulin is a macrophage-derived signal for axon regeneration in retinal ganglion 
cells." Nat Neurosci 9:843-852. 
Yoshida, K., Y. Muraki, K. Ohki, T. Harada, T. Ohashi, H. Matsuda, and J. Imaki. 1995. "C-fos gene 
expression in rat retinal cells after focal retinal injury." Invest Ophthalmol Vis Sci 36:251-254. 
Yoshizawa, K., H. Nambu, J. Yang, Y. Oishi, H. Senzaki, N. Shikata, H. Miki, and A. Tsubura. 1999. 
"Mechanisms of photoreceptor cell apoptosis induced by N-methyl-N-nitrosourea in 
Sprague-Dawley rats." Lab Invest 79:1359-1367. 
Yoshizawa, K., J. Yang, H. Senzaki, Y. Uemura, Y. Kiyozuka, N. Shikata, Y. Oishi, H. Miki, and A. 
Tsubura. 2000. "Caspase-3 inhibitor rescues N -methyl- N -nitrosourea-induced retinal 
degeneration in Sprague-Dawley rats." Exp Eye Res 71:629-635. 
Zacks, D. N., V. Hanninen, M. Pantcheva, E. Ezra, C. Grosskreutz, and J. W. Miller. 2003. "Caspase 
activation in an experimental model of retinal detachment." Invest Ophthalmol Vis Sci 
44:1262-1267. 
Zadro-Lamoureux, L. A., D. N. Zacks, A. N. Baker, Q. D. Zheng, W. W. Hauswirth, and C. Tsilfidis. 2009. 
"XIAP effects on retinal detachment-induced photoreceptor apoptosis [corrected]." Invest 
Ophthalmol Vis Sci 50:1448-1453. 
 
 
219 
 
Zhang, T., Y. Hu, Y. Li, J. Wu, L. Zhao, C. Wang, Y. Liu, Z. Yin, and Z. Ma. 2009a. "Photoreceptors repair 
by autologous transplantation of retinal pigment epithelium and partial-thickness choroid 
graft in rabbits." Invest Ophthalmol Vis Sci 50:2982-2988. 
Zhang, Z., S. F. Larner, M. C. Liu, W. Zheng, R. L. Hayes, and K. K. Wang. 2009b. "Multiple alphaII-
spectrin breakdown products distinguish calpain and caspase dominated necrotic and 
apoptotic cell death pathways." Apoptosis 14:1289-1298. 
Zhao, H., R. M. Sapolsky, and G. K. Steinberg. 2006. "Phosphoinositide-3-kinase/akt survival signal 
pathways are implicated in neuronal survival after stroke." Mol Neurobiol 34:249-270. 
Zhi, Y., Q. Lu, C. W. Zhang, H. K. Yip, K. F. So, and Q. Cui. 2005. "Different optic nerve injury sites 
result in different responses of retinal ganglion cells to brain-derived neurotrophic factor but 
not neurotrophin-4/5." Brain Res 1047:224-232. 
Ziegler, U. and P. Groscurth. 2004. "Morphological features of cell death." News Physiol Sci 19:124-
128. 
Zuckerman, S. 1941. "Ocular injuries resulting from the war." Trans Ophthal  Soc U K 61:45-60. 
 
 APPENDIX 1 
  
Appendix 1, p1
Appendix 1, p2
Appendix 1, p3
Appendix 1, p4
Appendix 1, p5
Appendix 1, p6
284 JR Army Med Corps 155(4): 279-284
Appendix 1, p7
 APPENDIX 2 
  
Appendix 2, p1
Appendix 2, p2
Appendix 2, p3
Appendix 2, p4
Appendix 2, p5
Appendix 2, p6
Appendix 2, p7
Appendix 2, p8
Appendix 2, p9
 APPENDIX 3  
  
Appendix 3, p1
Appendix 3, p2
Appendix 3, p3
Appendix 3, p4
Appendix 3, p5
Appendix 3, p6
Appendix 3, p7
 APPENDIX 4  
  
Appendix 4, p1
Appendix 4, p2
Appendix 4, p3
Appendix 4, p4
4Appendix 4, p5
 APPENDIX 5  
  
Appendix 5, p1
??????????????????????????????????????????????????????
? ???????????????????
???????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????
?????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????
????????????????????????????????????????????????????????????????????????????????????????????????????????????
?
????????????????????????????????????????????????? ???????????????????
???????????????????????????????????????????????????????
?????????????????????????????
???? ???
????????????????????????????????????????????
?
????????????????????????????????????????????????????????????????????????????
?
???????????????????????????????????????????????????????
??????????????????????????????????????????????????????????
?????????????????????????????????????????????????????????????????????????????????????????????
???????????????????????????????????????????????
??????????????????????????????????????????????????????????????????????????????????????????????????????????????????
???????????
?????????????????????????????????????????
????????? ????????????????????????????????????????????????????????????????????????????????????????????????????????
?????
?????????????????????
??????????????????
????????????
?????????????????????????????????????????????
?
??? ????????????????????????????????? ??????????????????????????????????????????????????????????
????????????????? ????????? ???
??? ?????????????????????????????????????????????????????????????????????????????????????????? ????????? ???
??? ????????????????????????????????????????????????????????????????????????????????????????
???????????? ????????? ???
??? ?????????????????????????????????????????????????????????????????????????????????????????????????????
????????????????? ????????? ???
?????????????????????????????????????????????????????????????????????????????????????????
?????????
??????????
? ????
??????????????????
NHS REC Form Reference:
10/H1206/87
IRAS Version 3.1
Date: 15/11/2010 60615/165861/1/3501
Appendix 5, p2
????????????????????????????????????????????????????????????????????????
????????
?????????
? ????
?????????????????
????????????????????????????????????
??? ???????????????????????????????????????
?????????????????????????????????????????
??????????????????????????????????????
??????????????????????????
????????????????????????????????????????????????????????????????????????
? ????????????????????????
???????????????????????????????????????????
???? ???????????????????????????????????????????????????????????????????????????????????????????????????
????????? ???
??? ???????????????????????????????????????????????????????????
????????? ???
?????????????????????????????????????????????????????????????????????????????????????????????????????????????????
????????? ???
???????????????????????????????????????????????????????????????????? ????????????????????????????????????????????????
??????????????????????????????????????????????????????????????????????
????????????????????????????????????????????????????????????
?
????????? ???
??????????????????????????????????????????????????????????????????????????????????????????????????????????????? ??????
???????????????????????????????????????????????????????????????????????????????
????????? ???
???????????????????????????????????????????????????????????????????????????????????????????????????????????????????????
???????????????????????????????????????????????????????????????????? ?????
?
????????? ???
???????????????????????????????????????????????????????????????????????????????????????
????????? ???
?????????????????????????????????????????????????? ?????????????????????????????????
NHS REC Form Reference:
10/H1206/87
IRAS Version 3.1
Date: 15/11/2010 60615/165861/1/3502
Appendix 5, p3
????????? ???
?????????????????????????????????????????????????????????????????????????????????????????????????????????
????????? ???
???? ???????????????????????????????????????????????????????????????????????????????????????????????????????????????????
??????????????????????????????????????????????????????????????
?
????????? ???
NHS REC Form Reference:
10/H1206/87
IRAS Version 3.1
Date: 15/11/2010 60615/165861/1/3503
Appendix 5, p4
Appendix 5, p5
Appendix 5, p6
Appendix 5, p7
Appendix 5, p8
Appendix 5, p9
Appendix 5, p10
Date: 15/11/2010 60615/165861/1/35010
Appendix 5, p11
Appendix 5, p12
Appendix 5, p13
Appendix 5, p14
Appendix 5, p15
Appendix 5, p16
Appendix 5, p17
Date: 15/11/2010 60615/165861/1/35017
Appendix 5, p18
???????????????????????????????????????
??????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????
????????????????????????????????????????????????????????????????????????????????????? ??????????????????????????????? ?????????
?????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????
???????????????????????????????????????????????
?
?
????????????? ???????????????????????????????????
?????? ?
???????????????? ????????????? ??????????????????????????????????
???????????????
?????????????? ???????????
????????? ??????????
????????? ???????
?????? ?
????? ??
????????????
???????? ?????????
??????? ??????
NHS REC Form Reference:
10/H1206/87
IRAS Version 3.1
Date: 15/11/2010 60615/165861/1/35018
Appendix 5, p19
?????????????????????
??????????????????????????????????????
?? ??????????????????????????????????????????????????????????????????????????????????????????????????????????????????????
????
?
?? ????????????????????????????????????????????????????????????????????????????????????????????????????????
??????????????????????????????????????????????
?
?? ??????????????????????????????????????????????????????????????????????????????????????????????????????????????
?????????????????????????????????????????????????????????????????????????
?
?? ???????????????????????????????????????????????????????????????????????????????????????????????????????????
???????????????????????????????????????????????????????????????????????? ??????????????????????????
?
?? ??????????????????????????????????????????????????????????????????????????????????????????????????????????????
????????
?
?? ??????????????????????????????????????????????????????????????????????????????????????????????????????????
??????????????????????????????????????????????????????????????????????????????????????????????????????????????????????
??????????????????????????????????????????????????????????????????????????????????????????????????????????????
????????????????????????????????????????????????????????????????????????????????????????????????????????????????
???????????????????????????? ?????????????????????????????????????????????????????????????????????????????????
?????????????????
?
?? ????????????????????????????????????????????????????????????????????????????????????????????????????????????
??????????
?
?? ????????????????????????????????????????????????????????????????????????????????????????????????????????????
??????????????????????????????????????????????????????????????????????????????????????????????????????????
?????
?
?? ??????????????????????????????????????????????????????????????????????????????????????????????????????
????????????????????????????????????????????????????????????????????????????????????????????
??? ???????????????????????????????????????????????????????????????????????????????????????????????????????????????????
?????????????????????????????????????????????????????????????????????????????????????????????????????????
??????????????????????????????????????????????? ?
?
??? ?????????????????????????????????????????????????????????????????????????????????????????????????????????????
?????????????????????????????????????????????????????????????????????????????????????????????????????????????????
????????????????????????????????????????????????????????????????????????????????????????????????????????????
?
? ?????????????????????????????????????????????????????????????????????????????????????????????????????
?????????????????????????????????????????????????????????????????????????????????????????
???????????????????????????????????????????????????????????????
? ???????????????????????????????????????????????????????????????????????????????????????????????????????
???????????????????????????????????????????????????????????????????????????????????????????????
???????????
? ??????????????????????????????????????????????????????????????????????
? ??????????????????????????????????????????????????????????????????????????????????????????????????????
????????????????????????????????????????????????????????????????????????
???????????????????????????????????????????????????????????
?????????????????????????????????????????????????????????????????????????????????????????????????????????????????????
????????????? ??????????????????????????????????????????????????????????????????????????
???????????????????
????????
???????????????????
NHS REC Form Reference:
10/H1206/87
IRAS Version 3.1
Date: 15/11/2010 60615/165861/1/35019
Appendix 5, p20
?
?
?????????????????????????????????????????????????????????????????????????????????
?
?
?
????????
????????????????????????????
?????
??????????????????????????????????????????????????????????????????????????
?????????? ?????????????????????????????
?????????????????????????????????????????????????????????????????????????????????????????????????????????????????
????????????????????????????????????????????????????????????????????????????????????????????????????????????????
???????????
??????????????? ?????????????????????????????? ?????
????????????? ????????????? ??????????????????????????????????
?????? ????????????????????????????
?????????? ??????????????????????????????????????????????????????
???????????? ??????????????
?????? ?????????? ????????????
NHS REC Form Reference:
10/H1206/87
IRAS Version 3.1
Date: 15/11/2010 60615/165861/1/35020
Appendix 5, p21
????????????????????????????????????????????????
?
??????????????????????????????????????????????????????????????????????????????????????????????????????????????????????
???????????????????????????????????
????????????????
?? ????????????????????????????????????????????????????????????????????????????????????????????????????????????
??????????????????????????
?? ???????????????????????????????????????????????????????????????????????????????????????????????????????????????
????????????????????????
?? ?????????????????????????????????????????????????????????????????????????????????????????????????????????
??????????????????????????????????????????????????????????????????????????????????????????????????????????
??????????
?? ????????????????????????????????????????????????????????????????????????????????????????????????????????????
?????????????????????????????????????
?? ????????????????????????????????????????????????????????????????????????????????????????????????????????????
????????????????????????????????????????
?? ???????????????????????????????????????????????????????????????????????????????????????????????????????
?????????????????????????????????????????
?? ?????????????????????????????????????????????????????????????????????????????????????????????????????????????
???????????????????????????????????????????????????????????????????????????????????????????????????????????????
????????????????????????????????????????????????????????????????????????????????????????????????????????????
??????????????? ?
?????????? ??????????????????????????????????????????????????????
???????????? ????????????????
????? ??????????????????????????????????????????????????????????????????????
?????????????? ????????????? ??????????????????????????????????
?????? ????????????
NHS REC Form Reference:
10/H1206/87
IRAS Version 3.1
Date: 15/11/2010 60615/165861/1/35021
Appendix 5, p22
????????????????????????????????????????????????????????????
?
?
???????????????????????????????????????????????????????????????????????????????
?
?
?
????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????
????????????????????????????????????????????????????????????????????????????????
????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????
??????????????????????????????????????????????????????????
????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????
?????????????????????????????????????????????????????????????????????????????????????????????????????????????????????
????????????????????????????
?????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????
?????????????????????????????????????????????????????????????????????????????????????????????????????????????????????
????????????????????????????????????
??????????????? ?????????????????? ???????
????????????? ?????????????????????????????????
?????? ???????? ??????????????
NHS REC Form Reference:
10/H1206/87
IRAS Version 3.1
Date: 15/11/2010 60615/165861/1/35022
Appendix 5, p23
NHS REC Form Reference:
10/H1206/87
IRAS Version 3.1
Date: 15/11/2010 60615/165861/1/35023
Appendix 5, p24
 APPENDIX 6  
  
Appendix 6, p1
Retina
Neuroretinal Cell Death in a Murine Model of Closed Globe
Injury: Pathological and Functional Characterization
Richard J. Blanch,1,2 Zubair Ahmed,1 Attila Sik,1 David R. J. Snead,3 Peter A. Good,4
Jenna O’Neill,1 Martin Berry,1 Robert A. H. Scott,2,4,5 and Ann Logan1,5
PURPOSE. Blunt ocular trauma causes severe retinal injury with
death of neuroretinal tissue, scarring, and permanent visual
loss. The mechanisms of cell death are not known, and there
are no therapeutic interventions that improve visual outcome.
We aimed to study the extent, distribution, and functional
consequences of cell death by developing and characterizing a
rat model of retinal injury caused by blunt ocular trauma.
METHODS. The eyes of anesthetized adult rats were injured by
either weight drop or low-velocity ballistic trauma and assessed
by clinical examination, electroretinography, light microscopy,
electron microscopy, and TUNEL. Projectile velocity was
measured and standardized.
RESULTS. Weight drop did not cause reproducible retinal injury,
and the energy threshold for retinal injury was similar to that
for rupture. Low-velocity ballistic trauma to the inferior sclera
created a reproducible retinal injury, with central sclopetaria
retinae, retinal necrosis, and surrounding commotio retinae
with speciﬁc photoreceptor cell death and sparing of cells in
the other retinal layers. The extent of photoreceptor cell death
declined and necrosis progressed to apoptosis with increasing
distance from the impact site.
CONCLUSIONS. This is the only murine model of closed globe
injury and the only model of retinal trauma with speciﬁc
photoreceptor cell death. The clinical appearance mirrors that
in severe retinal injury after blunt ocular trauma in humans,
and the ultrastructural features are consistent with human and
animal studies of commotio retinae. After ocular trauma,
photoreceptor apoptosis may be prevented and visual out-
comes improved by blocking of the cell death pathways.
(Invest Ophthalmol Vis Sci. 2012;53:7220–7226) DOI:
10.1167/iovs.12-9887
Ocular trauma affects 20% of Americans during theirlifetime, and 0.6% to 1% of these suffer retinal injury.1–3
Personnel in war zones are at much higher risk, and up to 13%
of soldiers wounded in action sustain an ocular injury, of
whom 50% to 60% have retinal injuries.4,5 Retinal trauma
occurs with penetrating and perforating globe injuries,
ruptures, and contusion-type closed globe injuries including
those caused by blast.6,7
Retinal injury caused by blunt trauma is characterized
clinically as commotio retinae (Berlin’s edema) or the more
severe sclopetaria retinae.8,9 Commotio retinae describes gray-
white opaciﬁcation of the neuroretina caused by blunt ocular
trauma and covers a spectrum of injury from self-limiting to
severe with permanent visual loss.10,11 Commotio retinae has
been modeled in pigs, rabbits, cats, and rhesus and owl
monkeys, demonstrating traumatic disruption of the photore-
ceptor outer segments,12–14 which is also seen on optical
coherence tomography (OCT) and fundus reﬂection densitom-
etry in humans.11,15 The outer segments are phagocytosed by
retinal pigment epithelium (RPE) cells. The RPE becomes a
multilayered disorganized structure, sometimes directly op-
posed to the inner segments.14 Though photoreceptor cell
death has been noted in animal models, the focus of previous
studies was disruption and subsequent recovery of photore-
ceptor outer segments; the extent, distribution, and type of
cell death have not been reported.14,16 After severe blunt
ocular trauma in humans, commotio retinae features disruption
of the inner–outer segment junction and progresses to outer
retinal atrophy with degeneration of photoreceptors.17
Rats are an ideal species in which to model ocular trauma
due to the similarities of their retina with that of humans, the
ready availability of antibodies for immunohistochemical
studies, the low capital costs, and the ease of husbandry and
surgical interventions.12 Previous animal studies of commotio
retinae used modiﬁed air guns or a catapult to deliver high-
velocity (20-50 m/s) projectiles to the eye,12 but such methods
cannot precisely control and calibrate the energy delivered. For
the pig, 0.49 J is sufﬁcient to cause commotio retinae, and thus
we hypothesized that a lower energy would be required in the
smaller, more delicate rat eye.12
We report a rat model of retinal injury induced by low-
energy blunt ocular trauma, which features commotio retinae
and sclopetaria retinae with speciﬁc photoreceptor cell death.
This correlates well with reported loss of the outer nuclear
layer (ONL) observed by OCT in patients with long-term visual
loss after commotio retinae.17
MATERIALS AND METHODS
Animal Care and Procedures
Animal procedures were evaluated and licensed by the UK Home Ofﬁce,
approved by the University of Birmingham’s Biomedical Ethics Review
Sub-Committee, and conducted in accordance with the ARVO Statement
From the 1Neurotrauma and Neurodegeneration Section, Clinical
and Experimental Medicine, University of Birmingham, Birmingham,
United Kingdom; the 2Academic Department of Military Surgery and
Trauma, Royal Centre for Defence Medicine, Birmingham, United
Kingdom; the 3University Hospitals Coventry and Warwickshire NHS
Trust, Coventry, United Kingdom; and the 4Birmingham and Midland Eye
Centre, Birmingham, United Kingdom.
5These authors are joint senior authors.
Supported by the Ministry of Defence, United Kingdom; the
Drummond Foundation, United Kingdom; and the Sir Ian Fraser
Foundation, Blind Veterans UK.
Submitted for publication March 20, 2012; revised July 28,
2012; accepted September 11, 2012.
Disclosure: R.J. Blanch, None; Z. Ahmed, None; A. Sik, None;
D.R.J. Snead, None; P.A. Good, None; J. O’Neill, None; M. Berry,
None; R.A.H. Scott, None; A. Logan, None
Corresponding author: Richard J. Blanch, Molecular Neurosci-
ence Research Group, IBR West (2nd Floor), Medical School,
University of Birmingham, Edgbaston, Birmingham B15 2TT, United
Kingdom; rjb017@bham.ac.uk.
Investigative Ophthalmology & Visual Science, October 2012, Vol. 53, No. 11
7220 Copyright 2012 The Association for Research in Vision and Ophthalmology, Inc.
Appendix 6, p2
for the Use of Animals in Ophthalmic and Vision Research. Female rats
weighing 170 to 200 g were purchased from Charles River Laboratories
(Margate, UK), kept on a 12-hour light/dark cycle with a daytime
luminance of 80 lux, and fed andwatered ad libitum (as in all our previous
studies of central nervous system injury18). Wistar rats were used for
studies of weight drop and Lister hooded rats for studies of ballistic injury,
except where otherwise stated. All injuries were induced under general
anesthesia with inhaled isoﬂuorane in oxygen. For electron microscopy
(EM) and terminal deoxynucleotidyl transferase-mediated dUTP nick-end
labeling (TUNEL), animals were killed by perfusion with ﬁxative under
terminal anesthesia with intraperitoneal ketamine/medetomidine. Elec-
troretinograms (ERG) were recorded under general anesthesia with
intraperitoneal ketamine/medetomidine, and animals were killed by
intraperitoneal overdose of pentobarbitone for retinal whole mounts.
Weight Drop Injury
Weights were dropped from a height of 50 cm onto the lateral sclera. Six
groups of rats were injured by weight drop (2–6 eyes of 2–4 rats per
group). Weights of 22.6 g (0.111 J) and 31.3 g (0.154 J) with 6 mm ﬂat
tips were dropped onto the central cornea, and rats were killed at 2
hours after injury. Weights of 17.6 g (0.086 J) and 23.0 g (0.113 J) with 3
mm ﬂat tips and 22.6 and 31.3 g with 6 mm ﬂat tips were dropped onto
the lateral sclera, and animals were killed at 2 days after injury. To
increase the energy of the weight drop method, a 7 cm doubled section
of catapult latex (Match System superpower catapult latex; Middy Tackle
International, Heanor, UK), stretched by 7 cm, was used to propel a 22.6
g/6 mm tip weight downward; animals were killed at 2 days after injury.
Additional Lister hooded ratswere injuredwith a 31.3 gweight/6mm tip
plus catapult latex. The catapult latex gave a measured impact energy of
0.6 J for both 22.6 and 31.3 g weights due to inefﬁciencies in the system.
Velocitywas calculated for weight drop as gravitational potential energy;
the additional energy of the catapult latex was calculated by distance
traveled when ﬁred horizontally from a known height.
Ballistic Injury
Injury was created by ﬁring a dome-headed (air gun pellet) or spherical
(ball bearing) weight down a 5.5 3 300 mm steel barrel using
compressed air held in a 500 mL reservoir with pressure monitoring,
released by a solenoid-actuated valve (response time <5 ms, ﬂow
coefﬁcient [Cv] 491 NL/min; SMC Pneumatics, Milton Keynes, UK).
Projectiles were plastic ball bearings (0.095 g), plastic 0.22-caliber
pellets (0.5 g), and metal 0.22-caliber air gun pellets (0.91 g). Projectile
velocity was measured using a PC sound card.19 Brieﬂy, a Dell Studio
XPS (Dell Corporation Ltd., Berkshire, UK) laptop was used to record
the sound of the compressed air device being ﬁred using MAGIX Music
Editor 3 (MAGIX AG, Reno, NV) at a metal plate at known distance
from the muzzle. The resultant waveform was then viewed and the
time between air ﬁrst leaving the barrel and the impact with the metal
plate recorded at 1, 10.5, 22, 31.5, and 42 cm for 10 iterations at each
distance. Mean velocity was calculated at the different time points.
Wistar rats (n¼ 13 rats, 26 eyes) were used for cadaveric studies to
determine the risk of rupture. Female Lister hooded rats were used to
study the effects of a 0.095 g projectile delivered at 20 m/s to the
sclera: (1) bilaterally for EM studies before killing at 2 hours (lateral
scleral impact; n ¼ 4 animals), 2 days (inferior scleral impact; n ¼ 4
animals), and 14 days (inferior scleral impact; n ¼ 4 animals) after
injury; (2) unilaterally to inferior sclera for TUNEL and immunohisto-
chemical studies before killing at 2 days (n ¼ 4 animals); and (3)
unilaterally to inferior sclera for ERG studies and retinal whole mounts
before killing at 2 weeks (n ¼ 8 animals).
In Vivo Imaging
Animals were examined immediately after injury, at 2 days, and at 14
days by indirect ophthalmoscopy.
Electroretinography
ERG were recorded (HMsERG; Ocuscience, Kansas City, MO) at 2, 7,
and 14 days after ballistic injury and interpreted using ERGView
(Ocuscience). Animals were dark adapted overnight and prepared for
ERG under dim red light (>630 nm). Scotopic ﬂash ERG were recorded
at 2.5, 0, and þ0.5 log units with respect to standard ﬂash and
photopic ﬂash ERG with background illumination of 30,000 mcd/m2 at
0 and þ0.5 log units, using DTL ﬁber (Unimed Electrode Supplies,
Farnham, UK) corneal electrodes with pressure-molded Aclar (Agar
Scientiﬁc, Stansted, UK) contact lenses and needle skin electrodes
(Unimed).
Electron Microscopy
The primary tissue ﬁxative was 4% gluteraldehyde in 0.1 M phosphate
buffer (PB; pH 7.3) as used in previous studies of commotio
retinae.13,14 Eyes were removed and the cornea incised before 24
hours postﬁxation in the primary ﬁxative at room temperature. A
section of injured retina was dissected out, washed in 0.1 M PB,
postﬁxed in 1% osmium tetroxide in 0.1 M PB for 45 minutes, washed
in PB, dehydrated in ascending concentrations of ethanol, and
immersed in propylene oxide before inﬁltrating in resin (Durcupan;
Electron Microscopy Sciences, Hatﬁeld, PA) for 24 hours and
polymerizing at 568C for 24 hours. Semithin sections (1 lm thick)
were cut using glass knives on an "ultracut" ultramicrotome (Reichert-
Jung, Vienna, Austria). Sections were stained with toludine blue.
Ultrathin gold sections (70–90 nm) were cut with a glass or diamond
knife, ﬂoated on distilled water, mounted on formvar-coated 50-mesh
copper grids, stained with uranyl acetate and lead citrate, and
examined on a JEOL 1200 EX transmission electron microscope (JEOL
[UK] Ltd., Welwyn Garden City, UK) ﬁtted with a LaB6 ﬁlament at an
operating voltage of 80 keV.
TUNEL and Immunohistochemistry
The tissue ﬁxative was 4% paraformaldehyde (PFA) in phosphate-
buffered saline. Eyes were removed, and the cornea was incised before
24 hours postﬁxation at 48C. Specimens were cryoprotected in
ascending concentrations of sucrose in phosphate-buffered saline
(PBS) at 48C; the anterior segments were removed, and the retinal cup
was embedded in OCT and stored at808C. Sections 15 lm thick were
cut using a cryostat (Bright Instruments, Huntingdon, UK) and adhered
onto SuperfrostTM (Fisher, Loughborough, UK)-coated glass micro-
scope slides. TUNEL FragEL DNA Fragmentation Detection Kit (Merck,
Nottingham, UK) was used per manufacturer’s instructions, except
that proteinase K was omitted and replaced by 15 minutes in Triton X-
100 0.1% in PBS. Immunohistochemistry was performed using primary
antibodies to ED1 (1/400, monoclonal; ABD Serotec, Kidlington, UK)
and OX42 (1/400, monoclonal; ABD Serotec; and 1/100, polyclonal;
Santa Cruz Biotechnology, Inc., Heidelberg, Germany) with Texas red
anti-mouse and Alexa Fluor 488 anti-rabbit IgG (both 1/400; Invitrogen,
Grand Island, NY) secondary antibodies.
Retinal Whole Mounts and Counting of
Photoreceptors
Anterior segments and vitreous were removed; eye cups were ﬁxed in
4% PFA in PBS, and the neuroretina was dissected from the RPE except
when it was adherent, in which case the RPE was dissected from the
choroid. Retinae were permeabilized in 0.1% Triton X-100/4 0,6-
diamidino-2-phenylindole (DAPI) in PBS for 2 hours and mounted with
DAPI mountant for cell counting. Images were captured at 633
magniﬁcation using a confocal laser scanning microscope (Zeiss,
Hertfordshire, UK) running the LSM 510 software version 3.2 (Zeiss).
Images were captured from three different areas (at 1/6, 3/6, and 5/6 of
the radius) of each quadrant (total¼12 counts per eye) in the middle of
the outer nuclear layer, to account for variation of photoreceptor
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numbers in the different areas, and quantiﬁed using the built-in particle
counting facilities in ImagePro (Media Cybernetics, Bethesda, MD).
Mean photoreceptor density per high-power ﬁeld (0.1463 0.146 mm)
was expressed as a percentage of the mean value for uninjured control
tissue.
Semithin (1 lm) toludine blue–stained retinal sections were cut 2
weeks after injury from the optic disc to the ciliary body through the
center of the impact site; control tissue was taken from the (uninjured)
inferior retina of animals killed at 2 hours after impact to the lateral
sclera. Images were captured at 403magniﬁcation (0.2530.3 mm ﬁeld
of view) from ﬁve different areas of each section and quantiﬁed by a
blinded observer using the user-deﬁned manual counting facility in
ImagePro. For display, counts were normalized as percentages of the
mean value for uninjured control tissue in the same retinal area.
Statistical Analysis
Cell count and ERG data were normally distributed and analyzed with
parametric tests in SPSS 19 (IBM, Armonk, NY). Means 6 standard
error were calculated for all samples. Electrophysiological data were
analyzed using either three-way (time, intensity, injury) repeated
measures ANOVA or generalized estimating equations for sets missing
data (type III sum of squares). Nonsigniﬁcant interactions were
removed from the models, and normality was assessed using residual
plots.
RESULTS
Weight Drop Did Not Create a Reproducible Retinal
Injury
Two hours after impact to the central cornea, no injury was
seen by clinical examination or light or electron microscopy.
After direct scleral impact, retinal pathology was clinically
occult, as the clinical examination and macroscopic appear-
ances were normal. Photoreceptor outer segment disruption
was induced in two of nine eyes to which 0.6 J was delivered;
and, at this energy level, globe rupture occurred in two of nine
eyes (Fig. 1).
Ballistic Trauma Created a Reproducible Retinal
Injury
In cadaveric studies, a chamber pressure of ‡0.15 bar caused
rupture in >50% of eyes. Weights of 0.91, 0.50, 0.16 (air gun
pellets), and 0.095 g (ball bearing) were tested; 0.095 g was
chosen to give the highest-velocity injury, 20 m/s at chamber
pressure of 0.125 bar.
Immediately after injury, there was retinal pallor underlying
the injury site in all eyes and variable vitreous hemorrhage. The
pallor resolved over the next 2 weeks to leave an area of retinal
atrophy revealing the choroidal vasculature.
Light and electron microscopy of resin-embedded retinal
sections at 2 hours after injury showed disruption of
photoreceptor outer and inner segments in all eight eyes and
disruption of the external limiting membrane (ELM) in three
eyes (Fig. 2).
Speciﬁc Photoreceptor Death Developed after
Ballistic Blunt Ocular Trauma
By 2 weeks after ballistic injury, a large area of retinal and RPE
atrophy developed. There was progressive loss of the ONL
approaching the center of the impact site but relative
preservation of the inner nuclear and ganglion cell layers,
with hypopigmentation and irregularity of the underlying RPE
(Figs. 3A, 3B). At the center of the impact site, all neuroretinal
layers were absent.
The proportion of photoreceptors surviving increased at
increasing distances from the center of the impact site,
demonstrated by ONL cell counts on toludine blue–stained
resin sections of the retina radially from the optic disc to the
ciliary body, through the center of the lesion site (Fig. 3C).
FIGURE 1. Electron micrographs of rat outer retina. (A) Two days after
22.6 g (0.6 J) weight drop to lateral sclera; absent photoreceptor inner
segments (IS) and outer segments (OS) with RPE response (arrowed),
disrupted external limiting membrane (ELM), and a macrophage
(arrowhead). (B) Immediately after 31.3 g (0.6 J) weight drop to
lateral sclera. Disrupted photoreceptor outer segments (OS; arrowed
above and below).
FIGURE 2. Electron micrographs of rat outer retina. (A) Normal control
retina. (B) Disrupted photoreceptor inner (IS) and outer segments (OS)
and external limiting membrane (ELM) 2 hours after ballistic injury.
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ONL cell counting on retinal whole mounts conﬁrmed that
18.4 6 4.6% of photoreceptors had died.
Photoreceptors Died by Necrosis and Apoptosis
By 2 hours after injury, there were occasional apoptotic nuclei
in the ONL with chromatin condensation and nuclear blebbing
(Fig. 4A). Two days after injury, in the center of the impact site,
there was inﬁltration of macrophages (histiocytic, ED1-
positive, OX42-negative; Figs. 4B, 4I–K, Supplementary Mate-
rial and Supplementary Figs. S1C–H, http://www.iovs.org/
lookup/suppl/doi:10.1167/iovs.12-9887/-/DCSupplemental),20
edema, and necrotic nuclei in the ONL (Figs. 4B–E). In the
perilesional area there was disruption of outer segments with
inﬂammatory cell inﬁltration. There were fewer necrotic
photoreceptor nuclei at increasing distances from the lesion
site but more apoptotic photoreceptor nuclei (Figs. 4E–H; see
Supplementary Material and Supplementary Figs. S1A, S1B
http://www.iovs.org/lookup/suppl/doi:10.1167/iovs.12-9887/
-/DCSupplemental). Centrally in the impact site, many cells
with diffuse nuclear and cytoplasmic TUNEL staining were
observed (Fig. 4L), probably because direct cellular injury
caused necrotic death.21 However, in areas away from the
impact site, the presence of speciﬁc TUNEL-positive photore-
ceptor cell nuclei conﬁrmed apoptosis of these cells (Figs. 4L–
O).
Electrophysiological Assessment of Ballistic Injury
To assess retinal function, scotopic and photopic ﬂash ERG
series were recorded and the major components (a- and b-
waves) observed. The a- and b-wave amplitudes were
quantiﬁed and compared between injured and control eyes
at 2, 7, and 14 days postinjury. The magnitude and latency of all
components were intensity dependent, though only amplitude
was injury dependent. ANOVA was used to compare scotopic
(dark adapted) a-wave amplitudes. Scotopic a-wave amplitude
was signiﬁcantly reduced by injury (Fig. 5A; 1 df, F¼ 59.7, P <
0.001, g¼0.895), and there was no signiﬁcant change between
the three time points (2 df, F ¼ 2.706, P ¼ 0.129, g ¼ 0.279).
Since b-wave onset can obscure the a-wave, gradient of the a-
wave’s linear portion (leading edge) was measured, giving a
trend similar to that observed for amplitude (1 df, F¼40.9, P <
0.001, g¼ 0.854). Scotopic b-wave amplitude was signiﬁcantly
reduced by injury (2 df, F¼39.9, P < 0.001, g¼0.851), though
there was no signiﬁcant effect on the scotopic b-/a-wave ratio
(see Supplementary Material and Supplementary Fig. S2,
http://www.iovs.org/lookup/suppl/doi:10.1167/iovs.12-9887/
-/DCSupplemental; 1 df, F ¼ 4.917, P ¼ 0.062, g ¼ 0.413).
Photopic a-waves were frequently undetectable in injured and
control eyes, and some data points were missing. Generalized
estimating equations were therefore used to analyze photopic
b-wave amplitudes, which were signiﬁcantly reduced by injury
(Fig. 5B; unstructured correlation matrix, 1 df, P < 0.001),
consistent with the outer retinal injury affecting both cones
and rods equally.
DISCUSSION
This is the ﬁrst murine model of closed globe injury to show
that low-velocity ballistic trauma creates reproducible commo-
tio retinae, with pathological features that mirror the clinical
and OCT ﬁndings in humans after severe blunt ocular
trauma.17 At the impact site, there was necrosis of photore-
ceptors, and centrally there was death of all retinal cells
FIGURE 3. Light micrograph of rat retina 2 weeks after ballistic injury. (A) Outer nuclear layer (ONL) around the optic disc (asterisk) is normal.
Approaching the impact site it thins (arrowed) and then disappears, leaving the inner retina relatively intact. (B) Line graph showing normalized
retinal cell counts at distance from the impact site 6 standard error of the mean. ONL survival is lowest, with the inner nuclear layer (INL) and
ganglion cell layer (GCL) relatively spared. (C) Higher-power cutout of (A) showing thinning and loss of the ONL.
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(sclopetaria retinae). Away from the impact site, photoreceptor
death occurred by a combination of apoptosis and necrosis.
Preservation of the inner retinal layers, together with speciﬁc
photoreceptor cell death, mirrored human OCT ﬁndings. The
reason this injury predominantly affects photoreceptors is
unclear, but we suggest that shearing forces at the neuroretina–
RPE junction during globe deformation make them particularly
vulnerable.
The spectrum of cell death ranges between apoptosis and
necrosis, with signiﬁcant overlap. We have shown cells that are
clearly necrotic (Figs. 4C, 4D) and cells that exhibit features
consistent with apoptosis (Figs. 4E–H, 4L–O; see Supplemen-
tary Material and Supplementary Figs. S1A, S1B, http://www.
iovs .org/ lookup/suppl/doi :10.1167/ iovs .12 -9887/ - /
DCSupplemental), though it is likely that many photoreceptors
undergo a mixed form of cell death. While necrosis is an
unregulated form of cell death, apoptosis is mediated by
speciﬁc cell death signaling pathways, as is the mixed form of
cell death, termed necroptosis, and these pathways can be
modulated to increase cell survival.18,22 Thus, our results imply
that in a proportion of photoreceptors after ballistic retinal
injury, cell death is mediated by apoptotic or necroptotic
FIGURE 4. (A–G) Electron micrographs of rat outer retina. (A) Outer nuclear layer (ONL) 2 hours after ballistic injury; blebbed (apoptotic)
photoreceptor nucleus arrowed. (B–G) Two days after ballistic injury. (B) Close to the impact site, macrophage removing disrupted photoreceptor
outer and inner segments (arrowed) and nonspeciﬁc cell death with condensed and fragmented photoreceptor nuclei in the ONL, shown at higher
magniﬁcation in (C). (D) Close to the impact site, necrotic photoreceptor nucleus in an edematous ONL with ruptured cell membranes (arrowed).
(E–H) Apoptotic photoreceptor nuclei farther away from the impact site. (E) Nuclear blebbing (arrowed); (F) nuclear blebbing (arrowed) with
invasion of the photoreceptor cytoplasm by Mu¨ller cell processes (arrowhead); (G) a condensed photoreceptor nucleus with chromatin
condensation at the periphery of the nucleus, typical of apoptosis; (H) chromatin aggregates (arrowhead) dispersed throughout the condensed
photoreceptor nucleus (rather than peripherally), but the intact mitochodrion (arrowed) is suggestive of apoptosis. (I–K) ED1 staining showing
DAPI-stained nuclei (I), red ED1-positive macrophages (arrowed) in the inner nuclear layer (INL) and ONL (J), and combined image (K). (L) TUNEL
staining. The frequency of TUNEL-positive cells is highest in the ONL centrally to the impact site (arrowhead), reducing in frequency with
increasing distance. (M–O) High-power cutout of (L): DAPI-stained nuclei (M), apoptotic photoreceptor nuclei (arrowed, N), combined image (O).
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regulated signaling pathways, with a potential for successful
neuroprotective therapies.
In human studies, mild commotio retinae associated with
photoreceptor recovery is characterized by outer segment
disruption, whereas severe commotio retinae is associated
with photoreceptor inner and outer segment disruption
observed by OCT.17 Inner segment disruption was also present
in our model, but has not been reported in other (mild,
recovering) animal models of commotio retinae. The RPE and
photoreceptor outer and inner segments appear as three bands
on spectral-domain OCT. The thinner line above them may
represent the ELM or the myoid portion of the cone inner
segments.23 Loss of this line on OCT may be a marker of severe
photoreceptor damage in commotio retinae and age-related
macular degeneration.17,24 If it represents cone inner seg-
ments, we speculate that disruption of these mitochondria-rich
structures (seen in our model) is a lethal injury to photore-
ceptors, while outer segment disruption is less likely to cause
photoreceptor death.
In our hands, the severity of weight drop–induced retinal
injuries was inconsistent in rats. The energy threshold for
inducing commotio retinae is close to that causing rupture
(approximately 0.6 J). That low-velocity injury does not usually
cause commotio retinae is consistent with the body of
literature on commotio retinae induced by high-velocity
impact.12 In contrast, a lower-energy injury with a 0.095 g
pellet traveling at 20 m/s (0.019 J) reproducibly created central
sclopetaria retinae at the impact site and surrounding
commotio retinae. High-velocity impact of a low-weight
projectile creates more injury than low-velocity impact by a
heavy projectile, despite similar kinetic energies25; and the
curved proﬁle of ball bearings used for ballistic trauma in this
study resulted in a higher area-normalized impact energy
(lower with a larger projectile), which is a better predictor of
corneoscleral stress and vitreous pressure than impact energy
alone.26 The ultrastructural features of our ballistic retinal
injury model are consistent with other studies of commotio
retinae, showing disruption of photoreceptor outer segments.
The rat lens accounts for 60% of axial length.27 With such a
small vitreous cavity, it is likely that the lens impacted the
retina during injury in our experiments with potential crushing
of the retina. This is also the case in larger animals in which
ocular dimensions are similar to those in humans,12 though
with the larger lens this crushing will be more extensive in the
rat.
The a-wave is the initial negative deﬂection caused by
photoreceptor activation (rods in scotopic series, cones in
photopic series) and is routinely used to measure photorecep-
tor function. The b-wave is the ﬁrst positive deﬂection,
immediately following the a-wave, and is generated by the
activity of second-order neurons (such as ON bipolar cells in
the inner nuclear layer). The b-wave is therefore dependent on
photoreceptor activation and synaptic transmission in addition
to inner retinal function. The ERG in the injured eyes showed a
signiﬁcant reduction in a- and b-wave amplitude compared to
the control eyes without any change in implicit time. The b-/a-
wave ratio is a measure of how much of the variation in b-wave
amplitude is explained by variation in the magnitude of
photoreceptor activation compared to the function of sec-
ond-order neurons; this ratio was normal and similar between
injured and control eyes. These reductions in ERG amplitude
occurred under both scotopic and photopic conditions and
would be consistent with damage primarily to the photore-
ceptor layer.
Rods make up 99% of rat photoreceptors28 and, in our
model, scotopic a-wave amplitude (which reﬂects rod func-
tion) was reduced by >50% (Fig. 5), although only 18% of
photoreceptors died. The degree of ERG reduction was
therefore disproportionate to the amount of histological
photoreceptor death. Either outer segment damage or photo-
receptor remodeling (similar to that seen after retinal
detachment29) could reduce the a-wave. Additionally, the
photoreceptor component (leading edge) of the a-wave is
sensitive to extracellular Ca2þ and Kþ levels,30 which may be
affected either by altered Mu¨ller glial function or by local
structural changes.
In conclusion, we report an animal model of the outer
retinal changes that occur after severe commotio retinae in
humans, which is the ﬁrst murine rodent model of blunt ocular
trauma. Our results suggest that outer retinal atrophy occurs as
a result of photoreceptor apoptosis and necrosis due to a
terminal injury to photoreceptor inner segments. The ob-
served photoreceptor apoptosis is translationally relevant
because there is the potential to prevent neuronal death and
improve visual outcomes with use of antiapoptotic neuropro-
tective therapies. This model provides an opportunity for both
mechanistic and translational therapeutic studies.
Acknowledgments
We thank Peter Nightingale (Queen Elizabeth Hospital, Birming-
ham, UK) for statistical advice and Theresa Morris and Katharine
Grifﬁths (University of Birmingham) for technical support.
FIGURE 5. Quantiﬁcation of the relevant components of the ERG at 2,
7, and 14 days after injury displayed as amplitude 6 standard error of
the mean (SEM) at increasing stimulus intensity. (A) Scotopic (dark
adapted) a-wave amplitude was signiﬁcantly reduced by injury at all
time points and stimulus intensities (*P < 0.001), and (B) photopic
(light adapted) b-wave amplitude was similarly reduced.
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GET
  FILE='C:\Users\Public\Documents\PhD\ERG\Results\T-CEM423-6\scotopic data T.sav'.
DATASET NAME DataSet1 WINDOW=FRONT.
EXAMINE VARIABLES=awaveamplitudev
  /PLOT BOXPLOT STEMLEAF NPPLOT
  /COMPARE GROUPS
  /STATISTICS DESCRIPTIVES
  /CINTERVAL 95
  /MISSING LISTWISE
  /NOTOTAL.
* Generalized Estimating Equations.
GENLIN awaveamplitudev BY timepoint flashintensitymcd Injured (ORDER=ASCENDING)
  /MODEL timepoint flashintensitymcd Injured timepoint*flashintensitymcd timepoint*Injured f
 DISTRIBUTION=GAMMA LINK=LOG
  /CRITERIA METHOD=FISHER(1) SCALE=MLE MAXITERATIONS=100 MAXSTEPHALVING=5 PCONVERGE=1E-006(A
  /REPEATED SUBJECT=animal WITHINSUBJECT=Injured*timepoint*flashintensitymcd SORT=YES CORRTY
(ABSOLUTE) UPDATECORR=1
  /MISSING CLASSMISSING=EXCLUDE
  /PRINT CPS DESCRIPTIVES MODELINFO FIT SUMMARY.
Generalized Linear Models
[DataSet1] C:\Users\Public\Documents\PhD\ERG\Results\T-CEM423-6\scotopic 
data T.sav
Warnings
One or more cases were found with dependent variable data values that are less than 
or equal to zero. These values are invalid for the gamma probability distribution, and 
the cases are not used in the analysis.
Model Information
Dependent Variable
Probability Distribution
Link Function
Subject Effect 1
Within-Subject Effect 1
2
3
Working Correlation Matrix Structure
awaveamplitudev
Gamma
Log
animal
Injured
timepoint
flashintensitymcd
AR(1)
Case Processing Summary
N Percent
Included
Excluded
Total
134 88.2%
18 11.8%
152 100.0%
Page 1
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Correlated Data Summary
Number of Levels Subject Effect animal
Within-Subject Effect Injured
timepoint
flashintensitymcd
Number of Subjects
Number of Measurements 
per Subject
Minimum
Maximum
Correlation Matrix Dimension
8
2
3
3
8
13
18
18
Categorical Variable Information
N Percent
Factor timepoint 2
7
14
Total
flashintensitymcd 10
3000
10000
Total
Injured 0
1
Total
47 35.1%
42 31.3%
45 33.6%
134 100.0%
38 28.4%
48 35.8%
48 35.8%
134 100.0%
69 51.5%
65 48.5%
134 100.0%
Continuous Variable Information
N Minimum Maximum Mean
Dependent Variable awaveamplitudev 134 1.6 440.5 128.900
Continuous Variable Information
Std. Deviation
Dependent Variable awaveamplitudev 117.9479
Page 2
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Goodness of Fita
Value
Quasi Likelihood under 
Independence Model 
Criterion (QIC)b
Corrected Quasi 
Likelihood under 
Independence Model 
Criterion (QICC)b
59.414
61.584
Dependent Variable: 
awaveamplitudev
 Model: (Intercept), timepoint, 
flashintensitymcd, Injured, timepoint * 
flashintensitymcd, timepoint * Injured, 
flashintensitymcd * Injured, timepoint * 
flashintensitymcd * Injured
Information criteria are in small-is-better form.a.
Computed using the full log quasi-likelihood function.b.
Tests of Model Effects
Source
Type III
Wald Chi-
Square df Sig.
(Intercept)
timepoint
flashintensitymcd
Injured
timepoint * 
flashintensitymcd
timepoint * Injured
flashintensitymcd * Injured
timepoint * 
flashintensitymcd * Injured
4435.076 1 .000
12.739 2 .002
466.775 2 .000
114.068 1 .000
10.396 4 .034
2.246 2 .325
9.226 2 .010
9.195 4 .056
Dependent Variable: awaveamplitudev
 Model: (Intercept), timepoint, flashintensitymcd, Injured, timepoint * 
flashintensitymcd, timepoint * Injured, flashintensitymcd * Injured, 
timepoint * flashintensitymcd * Injured
* Generalized Estimating Equations.
GENLIN awaveamplitudev BY timepoint flashintensitymcd Injured (ORDER=ASCENDING)
  /MODEL timepoint flashintensitymcd Injured timepoint*flashintensitymcd timepoint*Injured f
 DISTRIBUTION=GAMMA LINK=LOG
  /CRITERIA METHOD=FISHER(1) SCALE=MLE MAXITERATIONS=100 MAXSTEPHALVING=5 PCONVERGE=1E-006(A
012 ANALYSISTYPE=3(WALD) CILEVEL=95 LIKELIHOOD=FULL
  /REPEATED SUBJECT=animal WITHINSUBJECT=Injured*timepoint*flashintensitymcd SORT=YES CORRTY
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(1) ADJUSTCORR=YES COVB=ROBUST MAXITERATIONS=100 PCONVERGE=1e-006(ABSOLUTE) UPDATECORR=1
  /MISSING CLASSMISSING=EXCLUDE
  /PRINT CPS DESCRIPTIVES MODELINFO FIT SUMMARY.
Generalized Linear Models
[DataSet1] C:\Users\Public\Documents\PhD\ERG\Results\T-CEM423-6\scotopic 
data T.sav
Warnings
One or more cases were found with dependent variable data values that are less than 
or equal to zero. These values are invalid for the gamma probability distribution, and 
the cases are not used in the analysis.
Model Information
Dependent Variable
Probability Distribution
Link Function
Subject Effect 1
Within-Subject Effect 1
2
3
Working Correlation Matrix Structure
awaveamplitudev
Gamma
Log
animal
Injured
timepoint
flashintensitymcd
AR(1)
Case Processing Summary
N Percent
Included
Excluded
Total
134 88.2%
18 11.8%
152 100.0%
Correlated Data Summary
Number of Levels Subject Effect animal
Within-Subject Effect Injured
timepoint
flashintensitymcd
Number of Subjects
Number of Measurements 
per Subject
Minimum
Maximum
Correlation Matrix Dimension
8
2
3
3
8
13
18
18
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Categorical Variable Information
N Percent
Factor timepoint 2
7
14
Total
flashintensitymcd 10
3000
10000
Total
Injured 0
1
Total
47 35.1%
42 31.3%
45 33.6%
134 100.0%
38 28.4%
48 35.8%
48 35.8%
134 100.0%
69 51.5%
65 48.5%
134 100.0%
Continuous Variable Information
N Minimum Maximum Mean
Dependent Variable awaveamplitudev 134 1.6 440.5 128.900
Continuous Variable Information
Std. Deviation
Dependent Variable awaveamplitudev 117.9479
Goodness of Fita
Value
Quasi Likelihood under 
Independence Model 
Criterion (QIC)b
Corrected Quasi 
Likelihood under 
Independence Model 
Criterion (QICC)b
58.126
54.352
Dependent Variable: 
awaveamplitudev
 Model: (Intercept), timepoint, 
flashintensitymcd, Injured, timepoint * 
flashintensitymcd, timepoint * Injured, 
flashintensitymcd * Injured
Information criteria are in small-is-better form.a.
Computed using the full log quasi-likelihood function.b.
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Tests of Model Effects
Source
Type III
Wald Chi-
Square df Sig.
(Intercept)
timepoint
flashintensitymcd
Injured
timepoint * 
flashintensitymcd
timepoint * Injured
flashintensitymcd * Injured
4675.918 1 .000
11.620 2 .003
466.202 2 .000
73.306 1 .000
11.029 4 .026
2.581 2 .275
15.387 2 .000
Dependent Variable: awaveamplitudev
 Model: (Intercept), timepoint, flashintensitymcd, Injured, timepoint * 
flashintensitymcd, timepoint * Injured, flashintensitymcd * Injured
* Generalized Estimating Equations.
GENLIN awaveamplitudev BY timepoint flashintensitymcd Injured (ORDER=ASCENDING)
  /MODEL timepoint flashintensitymcd Injured timepoint*flashintensitymcd flashintensitymcd*I
 DISTRIBUTION=GAMMA LINK=LOG
  /CRITERIA METHOD=FISHER(1) SCALE=MLE MAXITERATIONS=100 MAXSTEPHALVING=5 PCONVERGE=1E-006
(ABSOLUTE) SINGULAR=1E-012 ANALYSISTYPE=3(WALD) CILEVEL=95 LIKELIHOOD=FULL
  /EMMEANS TABLES=timepoint*flashintensitymcd*Injured SCALE=ORIGINAL
  /REPEATED SUBJECT=animal WITHINSUBJECT=Injured*timepoint*flashintensitymcd SORT=YES CORRTY
(1) ADJUSTCORR=YES COVB=ROBUST MAXITERATIONS=100 PCONVERGE=1e-006(ABSOLUTE) UPDATECORR=1
  /MISSING CLASSMISSING=EXCLUDE
  /PRINT CPS DESCRIPTIVES MODELINFO FIT SUMMARY WORKINGCORR
  /SAVE RESID PEARSONRESID.
Generalized Linear Models
[DataSet1] C:\Users\Public\Documents\PhD\ERG\Results\T-CEM423-6\scotopic 
data T.sav
Warnings
One or more cases were found with dependent variable data values that are less than 
or equal to zero. These values are invalid for the gamma probability distribution, and 
the cases are not used in the analysis.
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Model Information
Dependent Variable
Probability Distribution
Link Function
Subject Effect 1
Within-Subject Effect 1
2
3
Working Correlation Matrix Structure
awaveamplitudev
Gamma
Log
animal
Injured
timepoint
flashintensitymcd
AR(1)
Case Processing Summary
N Percent
Included
Excluded
Total
134 88.2%
18 11.8%
152 100.0%
Correlated Data Summary
Number of Levels Subject Effect animal
Within-Subject Effect Injured
timepoint
flashintensitymcd
Number of Subjects
Number of Measurements 
per Subject
Minimum
Maximum
Correlation Matrix Dimension
8
2
3
3
8
13
18
18
Categorical Variable Information
N Percent
Factor timepoint 2
7
14
Total
flashintensitymcd 10
3000
10000
Total
Injured 0
1
Total
47 35.1%
42 31.3%
45 33.6%
134 100.0%
38 28.4%
48 35.8%
48 35.8%
134 100.0%
69 51.5%
65 48.5%
134 100.0%
Continuous Variable Information
N Minimum Maximum Mean
Dependent Variable awaveamplitudev 134 1.6 440.5 128.900
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Continuous Variable Information
Std. Deviation
Dependent Variable awaveamplitudev 117.9479
Goodness of Fita
Value
Quasi Likelihood under 
Independence Model 
Criterion (QIC)b
Corrected Quasi 
Likelihood under 
Independence Model 
Criterion (QICC)b
53.508
50.798
Dependent Variable: 
awaveamplitudev
 Model: (Intercept), timepoint, 
flashintensitymcd, Injured, timepoint * 
flashintensitymcd, flashintensitymcd * 
Injured
Information criteria are in small-is-better form.a.
Computed using the full log quasi-likelihood function.b.
Tests of Model Effects
Source
Type III
Wald Chi-
Square df Sig.
(Intercept)
timepoint
flashintensitymcd
Injured
timepoint * 
flashintensitymcd
flashintensitymcd * Injured
4569.188 1 .000
13.094 2 .001
443.504 2 .000
58.947 1 .000
11.561 4 .021
14.143 2 .001
Dependent Variable: awaveamplitudev
 Model: (Intercept), timepoint, flashintensitymcd, Injured, timepoint * 
flashintensitymcd, flashintensitymcd * Injured
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Working Correlation Matrixa
Measurement
Measurement
[ Injured = 0 ]* 
[ timepoint = 2 
]* [ 
flashintensity
mcd = 10 ]
[ Injured = 0 ]* 
[ timepoint = 2 
]* [ 
flashintensity
mcd = 3000 ]
[ Injured = 0 ]* 
[ timepoint = 2 
]* [ 
flashintensity
mcd = 10000 ]
[ Injured = 0 ]* 
[ timepoint = 7 
]* [ 
flashintensity
mcd = 10 ]
[ Injured = 0 ]* [ timepoint 
= 2 ]* [ flashintensitymcd = 
10 ]
[ Injured = 0 ]* [ timepoint 
= 2 ]* [ flashintensitymcd = 
3000 ]
[ Injured = 0 ]* [ timepoint 
= 2 ]* [ flashintensitymcd = 
10000 ]
[ Injured = 0 ]* [ timepoint 
= 7 ]* [ flashintensitymcd = 
10 ]
[ Injured = 0 ]* [ timepoint 
= 7 ]* [ flashintensitymcd = 
3000 ]
[ Injured = 0 ]* [ timepoint 
= 7 ]* [ flashintensitymcd = 
10000 ]
[ Injured = 0 ]* [ timepoint 
= 14 ]* [ flashintensitymcd 
= 10 ]
[ Injured = 0 ]* [ timepoint 
= 14 ]* [ flashintensitymcd 
= 3000 ]
[ Injured = 0 ]* [ timepoint 
= 14 ]* [ flashintensitymcd 
= 10000 ]
[ Injured = 1 ]* [ timepoint 
= 2 ]* [ flashintensitymcd = 
10 ]
[ Injured = 1 ]* [ timepoint 
= 2 ]* [ flashintensitymcd = 
3000 ]
[ Injured = 1 ]* [ timepoint 
= 2 ]* [ flashintensitymcd = 
10000 ]
[ Injured = 1 ]* [ timepoint 
= 7 ]* [ flashintensitymcd = 
10 ]
[ Injured = 1 ]* [ timepoint 
= 7 ]* [ flashintensitymcd = 
3000 ]
1.000 .479 .229 .110
.479 1.000 .479 .229
.229 .479 1.000 .479
.110 .229 .479 1.000
.053 .110 .229 .479
.025 .053 .110 .229
.012 .025 .053 .110
.006 .012 .025 .053
.003 .006 .012 .025
.001 .003 .006 .012
.001 .001 .003 .006
.000 .001 .001 .003
.000 .000 .001 .001
.000 .000 .000 .001
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Working Correlation Matrixa
Measurement
Measurement
[ Injured = 0 ]* 
[ timepoint = 7 
]* [ 
flashintensity
mcd = 3000 ]
[ Injured = 0 ]* 
[ timepoint = 7 
]* [ 
flashintensity
mcd = 10000 ]
[ Injured = 0 ]* 
[ timepoint = 
14 ]* [ 
flashintensity
mcd = 10 ]
[ Injured = 0 ]* 
[ timepoint = 
14 ]* [ 
flashintensity
mcd = 3000 ]
[ Injured = 0 ]* [ timepoint 
= 2 ]* [ flashintensitymcd = 
10 ]
[ Injured = 0 ]* [ timepoint 
= 2 ]* [ flashintensitymcd = 
3000 ]
[ Injured = 0 ]* [ timepoint 
= 2 ]* [ flashintensitymcd = 
10000 ]
[ Injured = 0 ]* [ timepoint 
= 7 ]* [ flashintensitymcd = 
10 ]
[ Injured = 0 ]* [ timepoint 
= 7 ]* [ flashintensitymcd = 
3000 ]
[ Injured = 0 ]* [ timepoint 
= 7 ]* [ flashintensitymcd = 
10000 ]
[ Injured = 0 ]* [ timepoint 
= 14 ]* [ flashintensitymcd 
= 10 ]
[ Injured = 0 ]* [ timepoint 
= 14 ]* [ flashintensitymcd 
= 3000 ]
[ Injured = 0 ]* [ timepoint 
= 14 ]* [ flashintensitymcd 
= 10000 ]
[ Injured = 1 ]* [ timepoint 
= 2 ]* [ flashintensitymcd = 
10 ]
[ Injured = 1 ]* [ timepoint 
= 2 ]* [ flashintensitymcd = 
3000 ]
[ Injured = 1 ]* [ timepoint 
= 2 ]* [ flashintensitymcd = 
10000 ]
[ Injured = 1 ]* [ timepoint 
= 7 ]* [ flashintensitymcd = 
10 ]
[ Injured = 1 ]* [ timepoint 
= 7 ]* [ flashintensitymcd = 
3000 ]
.053 .025 .012 .006
.110 .053 .025 .012
.229 .110 .053 .025
.479 .229 .110 .053
1.000 .479 .229 .110
.479 1.000 .479 .229
.229 .479 1.000 .479
.110 .229 .479 1.000
.053 .110 .229 .479
.025 .053 .110 .229
.012 .025 .053 .110
.006 .012 .025 .053
.003 .006 .012 .025
.001 .003 .006 .012
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Working Correlation Matrixa
Measurement
Measurement
[ Injured = 0 ]* 
[ timepoint = 
14 ]* [ 
flashintensity
mcd = 10000 ]
[ Injured = 1 ]* 
[ timepoint = 2 
]* [ 
flashintensity
mcd = 10 ]
[ Injured = 1 ]* 
[ timepoint = 2 
]* [ 
flashintensity
mcd = 3000 ]
[ Injured = 1 ]* 
[ timepoint = 2 
]* [ 
flashintensity
mcd = 10000 ]
[ Injured = 0 ]* [ timepoint 
= 2 ]* [ flashintensitymcd = 
10 ]
[ Injured = 0 ]* [ timepoint 
= 2 ]* [ flashintensitymcd = 
3000 ]
[ Injured = 0 ]* [ timepoint 
= 2 ]* [ flashintensitymcd = 
10000 ]
[ Injured = 0 ]* [ timepoint 
= 7 ]* [ flashintensitymcd = 
10 ]
[ Injured = 0 ]* [ timepoint 
= 7 ]* [ flashintensitymcd = 
3000 ]
[ Injured = 0 ]* [ timepoint 
= 7 ]* [ flashintensitymcd = 
10000 ]
[ Injured = 0 ]* [ timepoint 
= 14 ]* [ flashintensitymcd 
= 10 ]
[ Injured = 0 ]* [ timepoint 
= 14 ]* [ flashintensitymcd 
= 3000 ]
[ Injured = 0 ]* [ timepoint 
= 14 ]* [ flashintensitymcd 
= 10000 ]
[ Injured = 1 ]* [ timepoint 
= 2 ]* [ flashintensitymcd = 
10 ]
[ Injured = 1 ]* [ timepoint 
= 2 ]* [ flashintensitymcd = 
3000 ]
[ Injured = 1 ]* [ timepoint 
= 2 ]* [ flashintensitymcd = 
10000 ]
[ Injured = 1 ]* [ timepoint 
= 7 ]* [ flashintensitymcd = 
10 ]
[ Injured = 1 ]* [ timepoint 
= 7 ]* [ flashintensitymcd = 
3000 ]
.003 .001 .001 .000
.006 .003 .001 .001
.012 .006 .003 .001
.025 .012 .006 .003
.053 .025 .012 .006
.110 .053 .025 .012
.229 .110 .053 .025
.479 .229 .110 .053
1.000 .479 .229 .110
.479 1.000 .479 .229
.229 .479 1.000 .479
.110 .229 .479 1.000
.053 .110 .229 .479
.025 .053 .110 .229
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Working Correlation Matrixa
Measurement
Measurement
[ Injured = 1 ]* 
[ timepoint = 7 
]* [ 
flashintensity
mcd = 10 ]
[ Injured = 1 ]* 
[ timepoint = 7 
]* [ 
flashintensity
mcd = 3000 ]
[ Injured = 1 ]* 
[ timepoint = 7 
]* [ 
flashintensity
mcd = 10000 ]
[ Injured = 1 ]* 
[ timepoint = 
14 ]* [ 
flashintensity
mcd = 10 ]
[ Injured = 0 ]* [ timepoint 
= 2 ]* [ flashintensitymcd = 
10 ]
[ Injured = 0 ]* [ timepoint 
= 2 ]* [ flashintensitymcd = 
3000 ]
[ Injured = 0 ]* [ timepoint 
= 2 ]* [ flashintensitymcd = 
10000 ]
[ Injured = 0 ]* [ timepoint 
= 7 ]* [ flashintensitymcd = 
10 ]
[ Injured = 0 ]* [ timepoint 
= 7 ]* [ flashintensitymcd = 
3000 ]
[ Injured = 0 ]* [ timepoint 
= 7 ]* [ flashintensitymcd = 
10000 ]
[ Injured = 0 ]* [ timepoint 
= 14 ]* [ flashintensitymcd 
= 10 ]
[ Injured = 0 ]* [ timepoint 
= 14 ]* [ flashintensitymcd 
= 3000 ]
[ Injured = 0 ]* [ timepoint 
= 14 ]* [ flashintensitymcd 
= 10000 ]
[ Injured = 1 ]* [ timepoint 
= 2 ]* [ flashintensitymcd = 
10 ]
[ Injured = 1 ]* [ timepoint 
= 2 ]* [ flashintensitymcd = 
3000 ]
[ Injured = 1 ]* [ timepoint 
= 2 ]* [ flashintensitymcd = 
10000 ]
[ Injured = 1 ]* [ timepoint 
= 7 ]* [ flashintensitymcd = 
10 ]
[ Injured = 1 ]* [ timepoint 
= 7 ]* [ flashintensitymcd = 
3000 ]
.000 .000 .000 .000
.000 .000 .000 .000
.001 .000 .000 .000
.001 .001 .000 .000
.003 .001 .001 .000
.006 .003 .001 .001
.012 .006 .003 .001
.025 .012 .006 .003
.053 .025 .012 .006
.110 .053 .025 .012
.229 .110 .053 .025
.479 .229 .110 .053
1.000 .479 .229 .110
.479 1.000 .479 .229
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Working Correlation Matrixa
Measurement
Measurement
[ Injured = 1 ]* 
[ timepoint = 
14 ]* [ 
flashintensity
mcd = 3000 ]
[ Injured = 1 ]* 
[ timepoint = 
14 ]* [ 
flashintensity
mcd = 10000 ]
[ Injured = 0 ]* [ timepoint 
= 2 ]* [ flashintensitymcd = 
10 ]
[ Injured = 0 ]* [ timepoint 
= 2 ]* [ flashintensitymcd = 
3000 ]
[ Injured = 0 ]* [ timepoint 
= 2 ]* [ flashintensitymcd = 
10000 ]
[ Injured = 0 ]* [ timepoint 
= 7 ]* [ flashintensitymcd = 
10 ]
[ Injured = 0 ]* [ timepoint 
= 7 ]* [ flashintensitymcd = 
3000 ]
[ Injured = 0 ]* [ timepoint 
= 7 ]* [ flashintensitymcd = 
10000 ]
[ Injured = 0 ]* [ timepoint 
= 14 ]* [ flashintensitymcd 
= 10 ]
[ Injured = 0 ]* [ timepoint 
= 14 ]* [ flashintensitymcd 
= 3000 ]
[ Injured = 0 ]* [ timepoint 
= 14 ]* [ flashintensitymcd 
= 10000 ]
[ Injured = 1 ]* [ timepoint 
= 2 ]* [ flashintensitymcd = 
10 ]
[ Injured = 1 ]* [ timepoint 
= 2 ]* [ flashintensitymcd = 
3000 ]
[ Injured = 1 ]* [ timepoint 
= 2 ]* [ flashintensitymcd = 
10000 ]
[ Injured = 1 ]* [ timepoint 
= 7 ]* [ flashintensitymcd = 
10 ]
[ Injured = 1 ]* [ timepoint 
= 7 ]* [ flashintensitymcd = 
3000 ]
.000 .000
.000 .000
.000 .000
.000 .000
.000 .000
.000 .000
.001 .000
.001 .001
.003 .001
.006 .003
.012 .006
.025 .012
.053 .025
.110 .053
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Working Correlation Matrixa
Measurement
Measurement
[ Injured = 0 ]* 
[ timepoint = 2 
]* [ 
flashintensity
mcd = 10 ]
[ Injured = 0 ]* 
[ timepoint = 2 
]* [ 
flashintensity
mcd = 3000 ]
[ Injured = 0 ]* 
[ timepoint = 2 
]* [ 
flashintensity
mcd = 10000 ]
[ Injured = 0 ]* 
[ timepoint = 7 
]* [ 
flashintensity
mcd = 10 ]
[ Injured = 1 ]* [ timepoint 
= 7 ]* [ flashintensitymcd = 
10000 ]
[ Injured = 1 ]* [ timepoint 
= 14 ]* [ flashintensitymcd 
= 10 ]
[ Injured = 1 ]* [ timepoint 
= 14 ]* [ flashintensitymcd 
= 3000 ]
[ Injured = 1 ]* [ timepoint 
= 14 ]* [ flashintensitymcd 
= 10000 ]
.000 .000 .000 .000
.000 .000 .000 .000
.000 .000 .000 .000
.000 .000 .000 .000
Working Correlation Matrixa
Measurement
Measurement
[ Injured = 0 ]* 
[ timepoint = 7 
]* [ 
flashintensity
mcd = 3000 ]
[ Injured = 0 ]* 
[ timepoint = 7 
]* [ 
flashintensity
mcd = 10000 ]
[ Injured = 0 ]* 
[ timepoint = 
14 ]* [ 
flashintensity
mcd = 10 ]
[ Injured = 0 ]* 
[ timepoint = 
14 ]* [ 
flashintensity
mcd = 3000 ]
[ Injured = 1 ]* [ timepoint 
= 7 ]* [ flashintensitymcd = 
10000 ]
[ Injured = 1 ]* [ timepoint 
= 14 ]* [ flashintensitymcd 
= 10 ]
[ Injured = 1 ]* [ timepoint 
= 14 ]* [ flashintensitymcd 
= 3000 ]
[ Injured = 1 ]* [ timepoint 
= 14 ]* [ flashintensitymcd 
= 10000 ]
.001 .001 .003 .006
.000 .001 .001 .003
.000 .000 .001 .001
.000 .000 .000 .001
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Working Correlation Matrixa
Measurement
Measurement
[ Injured = 0 ]* 
[ timepoint = 
14 ]* [ 
flashintensity
mcd = 10000 ]
[ Injured = 1 ]* 
[ timepoint = 2 
]* [ 
flashintensity
mcd = 10 ]
[ Injured = 1 ]* 
[ timepoint = 2 
]* [ 
flashintensity
mcd = 3000 ]
[ Injured = 1 ]* 
[ timepoint = 2 
]* [ 
flashintensity
mcd = 10000 ]
[ Injured = 1 ]* [ timepoint 
= 7 ]* [ flashintensitymcd = 
10000 ]
[ Injured = 1 ]* [ timepoint 
= 14 ]* [ flashintensitymcd 
= 10 ]
[ Injured = 1 ]* [ timepoint 
= 14 ]* [ flashintensitymcd 
= 3000 ]
[ Injured = 1 ]* [ timepoint 
= 14 ]* [ flashintensitymcd 
= 10000 ]
.012 .025 .053 .110
.006 .012 .025 .053
.003 .006 .012 .025
.001 .003 .006 .012
Working Correlation Matrixa
Measurement
Measurement
[ Injured = 1 ]* 
[ timepoint = 7 
]* [ 
flashintensity
mcd = 10 ]
[ Injured = 1 ]* 
[ timepoint = 7 
]* [ 
flashintensity
mcd = 3000 ]
[ Injured = 1 ]* 
[ timepoint = 7 
]* [ 
flashintensity
mcd = 10000 ]
[ Injured = 1 ]* 
[ timepoint = 
14 ]* [ 
flashintensity
mcd = 10 ]
[ Injured = 1 ]* [ timepoint 
= 7 ]* [ flashintensitymcd = 
10000 ]
[ Injured = 1 ]* [ timepoint 
= 14 ]* [ flashintensitymcd 
= 10 ]
[ Injured = 1 ]* [ timepoint 
= 14 ]* [ flashintensitymcd 
= 3000 ]
[ Injured = 1 ]* [ timepoint 
= 14 ]* [ flashintensitymcd 
= 10000 ]
.229 .479 1.000 .479
.110 .229 .479 1.000
.053 .110 .229 .479
.025 .053 .110 .229
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Working Correlation Matrixa
Measurement
Measurement
[ Injured = 1 ]* 
[ timepoint = 
14 ]* [ 
flashintensity
mcd = 3000 ]
[ Injured = 1 ]* 
[ timepoint = 
14 ]* [ 
flashintensity
mcd = 10000 ]
[ Injured = 1 ]* [ timepoint 
= 7 ]* [ flashintensitymcd = 
10000 ]
[ Injured = 1 ]* [ timepoint 
= 14 ]* [ flashintensitymcd 
= 10 ]
[ Injured = 1 ]* [ timepoint 
= 14 ]* [ flashintensitymcd 
= 3000 ]
[ Injured = 1 ]* [ timepoint 
= 14 ]* [ flashintensitymcd 
= 10000 ]
.229 .110
.479 .229
1.000 .479
.479 1.000
Dependent Variable: awaveamplitudev
 Model: (Intercept), timepoint, flashintensitymcd, Injured, timepoint * flashintensitymcd, flashintensitymcd * 
Injured
The AR(1) working correlation matrix structure is computed assuming the measurements are equally 
spaced for all subjects.
a.
Estimated Marginal Means: timepoint* flashintensitymcd* Injured
Estimates
timepoint flashintensitymcd Injured Mean Std. Error
95% Wald Confidence Interval
Lower Upper
2 10 0
1
3000 0
1
10000 0
1
7 10 0
1
3000 0
1
10000 0
1
14 10 0
1
3000 0
1
10000 0
1
15.494 1.5642 12.713 18.884
8.205 .9912 6.476 10.397
176.086 26.6687 130.860 236.942
62.891 8.0637 48.916 80.859
224.350 26.8911 177.378 283.761
83.104 8.9128 67.349 102.544
16.761 3.0466 11.738 23.935
8.876 2.0411 5.656 13.930
240.090 30.5745 187.058 308.156
85.750 14.7053 61.272 120.007
280.907 32.1364 224.483 351.514
104.054 16.8664 75.733 142.966
19.160 2.7818 14.415 25.467
10.147 1.8597 7.085 14.532
281.935 17.8812 248.979 319.252
100.696 13.9219 76.794 132.037
321.952 25.6459 275.414 376.353
119.257 18.5496 87.920 161.764
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EXAMINE VARIABLES=Residual PearsonResidual
  /PLOT BOXPLOT HISTOGRAM NPPLOT
  /COMPARE GROUPS
  /STATISTICS DESCRIPTIVES
  /CINTERVAL 95
  /MISSING LISTWISE
  /NOTOTAL.
Explore
[DataSet1] C:\Users\Public\Documents\PhD\ERG\Results\T-CEM423-6\scotopic 
data T.sav
Case Processing Summary
Cases
Valid Missing Total
N Percent N Percent N Percent
Raw Residual
Pearson Residual
134 88.2% 18 11.8% 152 100.0%
134 88.2% 18 11.8% 152 100.0%
Descriptives
Statistic Std. Error
Raw Residual Mean
95% Confidence Interval 
for Mean
Lower Bound
Upper Bound
5% Trimmed Mean
Median
Variance
Std. Deviation
Minimum
Maximum
Range
Interquartile Range
Skewness
Kurtosis
Pearson Residual Mean
95% Confidence Interval 
for Mean
Lower Bound
Upper Bound
5% Trimmed Mean
Median
Variance
Std. Deviation
Minimum
Maximum
Range
.83261 4.998476
-9.05418
10.71940
.64777
-.48135
3347.958
57.861543
-168.752
157.243
325.994
44.021
.157 .209
1.199 .416
.01414 .036701
-.05845
.08673
-.00164
-.01573
.180
.424844
-.842
1.319
2.161
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Descriptives
Statistic Std. Error
Interquartile Range
Skewness
Kurtosis
.560
.478 .209
.219 .416
Tests of Normality
Kolmogorov-Smirnova Shapiro-Wilk
Statistic df Sig. Statistic df Sig.
Raw Residual
Pearson Residual
.152 134 .000 .938 134 .000
.048 134 .200* .980 134 .044
This is a lower bound of the true significance.*.
Lilliefors Significance Correctiona.
Raw Residual
Raw Residual
100.000.000-100.000-200.000
Fr
eq
ue
nc
y
40
30
20
10
0
Histogram
Mean = .833
Std. Dev. = 57.862
N = 134
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Observed Value
2001000-100-200
Ex
pe
ct
ed
 N
or
m
al
2
0
-2
-4
Normal Q-Q Plot of Raw Residual
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Observed Value
2001000-100-200
D
ev
 fr
om
 N
or
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Pearson Residual
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Observed Value
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Observed Value
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Pearson Residual
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113
87
EXAMINE VARIABLES=awaveamplitudev
  /PLOT BOXPLOT HISTOGRAM NPPLOT
  /COMPARE GROUPS
  /STATISTICS DESCRIPTIVES
  /CINTERVAL 95
  /MISSING LISTWISE
  /NOTOTAL.
Explore
[DataSet1] C:\Users\Public\Documents\PhD\ERG\Results\T-CEM423-6\scotopic 
data T.sav
Case Processing Summary
Cases
Valid Missing Total
N Percent N Percent N Percent
awaveamplitudev 144 94.7% 8 5.3% 152 100.0%
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Descriptives
Statistic Std. Error
awaveamplitudev Mean
95% Confidence Interval 
for Mean
Lower Bound
Upper Bound
5% Trimmed Mean
Median
Variance
Std. Deviation
Minimum
Maximum
Range
Interquartile Range
Skewness
Kurtosis
119.949 9.8672
100.444
139.453
111.256
76.250
14020.079
118.4064
.0
440.5
440.5
192.0
.883 .202
-.332 .401
Tests of Normality
Kolmogorov-Smirnova Shapiro-Wilk
Statistic df Sig. Statistic df Sig.
awaveamplitudev .162 144 .000 .870 144 .000
Lilliefors Significance Correctiona.
awaveamplitudev
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awaveamplitudev
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Observed Value
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Observed Value
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awaveamplitudev
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* Chart Builder.
GGRAPH
  /GRAPHDATASET NAME="graphdataset" VARIABLES=MeanPredicted MEAN(Residual)[name="MEAN_Residu
  /GRAPHSPEC SOURCE=INLINE.
BEGIN GPL
  SOURCE: s=userSource(id("graphdataset"))
  DATA: MeanPredicted=col(source(s), name("MeanPredicted"))
  DATA: MEAN_Residual=col(source(s), name("MEAN_Residual"))
  GUIDE: axis(dim(1), label("Predicted Value of Mean of Response"))
  GUIDE: axis(dim(2), label("Mean Raw Residual"))
  ELEMENT: point(position(MeanPredicted*MEAN_Residual))
END GPL.
* Chart Builder.
GGRAPH
  /GRAPHDATASET NAME="graphdataset" VARIABLES=MeanPredicted_1 Residual_2 MISSING=LISTWISE RE
  /GRAPHSPEC SOURCE=INLINE.
BEGIN GPL
  SOURCE: s=userSource(id("graphdataset"))
  DATA: MeanPredicted_1=col(source(s), name("MeanPredicted_1"))
  DATA: Residual_2=col(source(s), name("Residual_2"))
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  GUIDE: axis(dim(1), label("Predicted Value of Mean of Response"))
  GUIDE: axis(dim(2), label("Raw Residual"))
  ELEMENT: point(position(MeanPredicted_1*Residual_2))
END GPL.
GGraph
[DataSet1] C:\Users\Public\Documents\PhD\ERG\Results\T-CEM423-6\scotopic 
data T.sav
Predicted Value of Mean of Response
400.0300.0200.0100.0.0
R
aw
 R
es
id
ua
l
200.000
100.000
.000
-100.000
-200.000
* Chart Builder.
GGRAPH
  /GRAPHDATASET NAME="graphdataset" VARIABLES=MeanPredicted_1 PearsonResidual_2 MISSING=LIST
  /GRAPHSPEC SOURCE=INLINE.
BEGIN GPL
  SOURCE: s=userSource(id("graphdataset"))
  DATA: MeanPredicted_1=col(source(s), name("MeanPredicted_1"))
  DATA: PearsonResidual_2=col(source(s), name("PearsonResidual_2"))
  GUIDE: axis(dim(1), label("Predicted Value of Mean of Response"))
  GUIDE: axis(dim(2), label("Pearson Residual"))
  ELEMENT: point(position(MeanPredicted_1*PearsonResidual_2))
END GPL.
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GGraph
[DataSet1] C:\Users\Public\Documents\PhD\ERG\Results\T-CEM423-6\scotopic 
data T.sav
Predicted Value of Mean of Response
400.0300.0200.0100.0.0
Pe
ar
so
n 
R
es
id
ua
l
1.500
1.000
.500
.000
-.500
-1.000
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 APPENDIX 8  
  
Appendix 8, p1
DATASET ACTIVATE DataSet5.
* Generalized Estimating Equations.
GENLIN awaveslopevms BY timepoint flashintensitymcd Injured (ORDER=DATA)
  /MODEL timepoint flashintensitymcd Injured timepoint*flashintensitymcd flashintensitymcd*I
 DISTRIBUTION=GAMMA LINK=LOG
  /CRITERIA METHOD=FISHER(1) SCALE=MLE MAXITERATIONS=100 MAXSTEPHALVING=5 PCONVERGE=1E-006
(ABSOLUTE) SINGULAR=1E-012 ANALYSISTYPE=3(WALD) CILEVEL=95 LIKELIHOOD=FULL
  /EMMEANS TABLES=timepoint*flashintensitymcd*Injured SCALE=ORIGINAL
  /REPEATED SUBJECT=animal WITHINSUBJECT=Injured*timepoint*flashintensitymcd SORT=YES CORRTY
(1) ADJUSTCORR=YES COVB=ROBUST MAXITERATIONS=100 PCONVERGE=1e-006(ABSOLUTE) UPDATECORR=1
  /MISSING CLASSMISSING=EXCLUDE
  /PRINT CPS DESCRIPTIVES MODELINFO FIT SUMMARY WORKINGCORR.
* Generalized Estimating Equations.
GENLIN awaveslopevms BY timepoint flashintensitymcd Injured (ORDER=DATA)
  /MODEL timepoint flashintensitymcd Injured timepoint*flashintensitymcd timepoint*Injured f
 DISTRIBUTION=GAMMA LINK=LOG
  /CRITERIA METHOD=FISHER(1) SCALE=MLE MAXITERATIONS=100 MAXSTEPHALVING=5 PCONVERGE=1E-006(A
  /EMMEANS TABLES=timepoint*flashintensitymcd*Injured SCALE=ORIGINAL
  /REPEATED SUBJECT=animal WITHINSUBJECT=Injured*timepoint*flashintensitymcd SORT=YES CORRTY
(ABSOLUTE) UPDATECORR=1
  /MISSING CLASSMISSING=EXCLUDE
  /PRINT CPS DESCRIPTIVES MODELINFO FIT SUMMARY WORKINGCORR.
Generalized Linear Models
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Notes
Output Created
Comments
Input Data
Active Dataset
Filter
Weight
Split File
N of Rows in Working 
Data File
Missing Value Handling Definition of Missing
Cases Used
Weight Handling
Syntax
02-MAY-2013 09:59:00
C:
\Users\Public\Documents\PhD\ERG\
Results\T-CEM423-6\scotopic data 
T.sav
DataSet5
<none>
<none>
<none>
152
User-defined missing values for 
factor, subject and within-subject 
variables are treated as missing.
Statistics are based on cases with 
valid data for all variables in the 
model.
not applicable
GENLIN awaveslopevms BY 
timepoint flashintensitymcd Injured 
(ORDER=DATA)
   /MODEL timepoint 
flashintensitymcd Injured 
timepoint*flashintensitymcd
timepoint*Injured
flashintensitymcd*Injured
timepoint*flashintensitymcd*Injured
INTERCEPT=YES
  DISTRIBUTION=GAMMA 
LINK=LOG
   /CRITERIA METHOD=FISHER(1) 
SCALE=MLE
MAXITERATIONS=100
MAXSTEPHALVING=5
PCONVERGE=1E-006(ABSOLUTE)
SINGULAR=1E-012
ANALYSISTYPE=3(WALD)
CILEVEL=95 LIKELIHOOD=FULL
   /EMMEANS 
TABLES=timepoint*flashintensitymc
d*Injured SCALE=ORIGINAL
   /REPEATED SUBJECT=animal 
WITHINSUBJECT=Injured*timepoint
*flashintensitymcd SORT=YES 
CORRTYPE=AR(1)
ADJUSTCORR=YES
COVB=ROBUST
MAXITERATIONS=100
PCONVERGE=1e-006(ABSOLUTE)
UPDATECORR=1
   /MISSING 
CLASSMISSING=EXCLUDE
   /PRINT CPS DESCRIPTIVES ...
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Notes
Resources Processor Time
Elapsed Time
00:00:00.11
00:00:00.14
[DataSet5] C:\Users\Public\Documents\PhD\ERG\Results\T-CEM423-6\scotopic d
ata T.sav
Warnings
One or more cases were found with dependent variable data values that are less than 
or equal to zero. These values are invalid for the gamma probability distribution, and 
the cases are not used in the analysis.
Model Information
Dependent Variable
Probability Distribution
Link Function
Subject Effect 1
Within-Subject Effect 1
2
3
Working Correlation Matrix Structure
awaveslopevms
Gamma
Log
animal
Injured
timepoint
flashintensitymcd
AR(1)
Case Processing Summary
N Percent
Included
Excluded
Total
142 93.4%
10 6.6%
152 100.0%
Correlated Data Summary
Number of Levels Subject Effect animal
Within-Subject Effect Injured
timepoint
flashintensitymcd
Number of Subjects
Number of Measurements 
per Subject
Minimum
Maximum
Correlation Matrix Dimension
8
2
3
3
8
17
18
18
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Categorical Variable Information
N Percent
Factor timepoint 2
7
14
Total
flashintensitymcd 10
3000
10000
Total
Injured 1
0
Total
48 33.8%
46 32.4%
48 33.8%
142 100.0%
46 32.4%
48 33.8%
48 33.8%
142 100.0%
70 49.3%
72 50.7%
142 100.0%
Continuous Variable Information
N Minimum Maximum Mean
Dependent Variable awaveslopevms 142 .019 93.300 19.45224
Continuous Variable Information
Std. Deviation
Dependent Variable awaveslopevms 21.003468
Goodness of Fita
Value
Quasi Likelihood under 
Independence Model 
Criterion (QIC)b
Corrected Quasi 
Likelihood under 
Independence Model 
Criterion (QICC)b
87.520
92.409
Dependent Variable: awaveslopevms
 Model: (Intercept), timepoint, 
flashintensitymcd, Injured, timepoint * 
flashintensitymcd, timepoint * Injured, 
flashintensitymcd * Injured, timepoint * 
flashintensitymcd * Injured
Information criteria are in small-is-better form.a.
Computed using the full log quasi-likelihood function.b.
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Tests of Model Effects
Source
Type III
Wald Chi-
Square df Sig.
(Intercept)
timepoint
flashintensitymcd
Injured
timepoint * 
flashintensitymcd
timepoint * Injured
flashintensitymcd * Injured
timepoint * 
flashintensitymcd * Injured
489.916 1 .000
14.093 2 .001
1042.949 2 .000
61.656 1 .000
10.404 4 .034
.883 2 .643
12.648 2 .002
11.543 4 .021
Dependent Variable: awaveslopevms
 Model: (Intercept), timepoint, flashintensitymcd, Injured, timepoint * 
flashintensitymcd, timepoint * Injured, flashintensitymcd * Injured, 
timepoint * flashintensitymcd * Injured
Working Correlation Matrixa
Measurement
Measurement
[ Injured = 0 ]* 
[ timepoint = 2 
]* [ 
flashintensity
mcd = 10 ]
[ Injured = 0 ]* 
[ timepoint = 2 
]* [ 
flashintensity
mcd = 3000 ]
[ Injured = 0 ]* 
[ timepoint = 2 
]* [ 
flashintensity
mcd = 10000 ]
[ Injured = 0 ]* 
[ timepoint = 7 
]* [ 
flashintensity
mcd = 10 ]
[ Injured = 0 ]* [ timepoint 
= 2 ]* [ flashintensitymcd = 
10 ]
[ Injured = 0 ]* [ timepoint 
= 2 ]* [ flashintensitymcd = 
3000 ]
[ Injured = 0 ]* [ timepoint 
= 2 ]* [ flashintensitymcd = 
10000 ]
[ Injured = 0 ]* [ timepoint 
= 7 ]* [ flashintensitymcd = 
10 ]
[ Injured = 0 ]* [ timepoint 
= 7 ]* [ flashintensitymcd = 
3000 ]
[ Injured = 0 ]* [ timepoint 
= 7 ]* [ flashintensitymcd = 
10000 ]
1.000 .506 .256 .129
.506 1.000 .506 .256
.256 .506 1.000 .506
.129 .256 .506 1.000
.065 .129 .256 .506
.033 .065 .129 .256
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Working Correlation Matrixa
Measurement
Measurement
[ Injured = 0 ]* 
[ timepoint = 7 
]* [ 
flashintensity
mcd = 3000 ]
[ Injured = 0 ]* 
[ timepoint = 7 
]* [ 
flashintensity
mcd = 10000 ]
[ Injured = 0 ]* 
[ timepoint = 
14 ]* [ 
flashintensity
mcd = 10 ]
[ Injured = 0 ]* 
[ timepoint = 
14 ]* [ 
flashintensity
mcd = 3000 ]
[ Injured = 0 ]* [ timepoint 
= 2 ]* [ flashintensitymcd = 
10 ]
[ Injured = 0 ]* [ timepoint 
= 2 ]* [ flashintensitymcd = 
3000 ]
[ Injured = 0 ]* [ timepoint 
= 2 ]* [ flashintensitymcd = 
10000 ]
[ Injured = 0 ]* [ timepoint 
= 7 ]* [ flashintensitymcd = 
10 ]
[ Injured = 0 ]* [ timepoint 
= 7 ]* [ flashintensitymcd = 
3000 ]
[ Injured = 0 ]* [ timepoint 
= 7 ]* [ flashintensitymcd = 
10000 ]
.065 .033 .017 .008
.129 .065 .033 .017
.256 .129 .065 .033
.506 .256 .129 .065
1.000 .506 .256 .129
.506 1.000 .506 .256
Working Correlation Matrixa
Measurement
Measurement
[ Injured = 0 ]* 
[ timepoint = 
14 ]* [ 
flashintensity
mcd = 10000 ]
[ Injured = 1 ]* 
[ timepoint = 2 
]* [ 
flashintensity
mcd = 10 ]
[ Injured = 1 ]* 
[ timepoint = 2 
]* [ 
flashintensity
mcd = 3000 ]
[ Injured = 1 ]* 
[ timepoint = 2 
]* [ 
flashintensity
mcd = 10000 ]
[ Injured = 0 ]* [ timepoint 
= 2 ]* [ flashintensitymcd = 
10 ]
[ Injured = 0 ]* [ timepoint 
= 2 ]* [ flashintensitymcd = 
3000 ]
[ Injured = 0 ]* [ timepoint 
= 2 ]* [ flashintensitymcd = 
10000 ]
[ Injured = 0 ]* [ timepoint 
= 7 ]* [ flashintensitymcd = 
10 ]
[ Injured = 0 ]* [ timepoint 
= 7 ]* [ flashintensitymcd = 
3000 ]
[ Injured = 0 ]* [ timepoint 
= 7 ]* [ flashintensitymcd = 
10000 ]
.004 .002 .001 .001
.008 .004 .002 .001
.017 .008 .004 .002
.033 .017 .008 .004
.065 .033 .017 .008
.129 .065 .033 .017
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Working Correlation Matrixa
Measurement
Measurement
[ Injured = 1 ]* 
[ timepoint = 7 
]* [ 
flashintensity
mcd = 10 ]
[ Injured = 1 ]* 
[ timepoint = 7 
]* [ 
flashintensity
mcd = 3000 ]
[ Injured = 1 ]* 
[ timepoint = 7 
]* [ 
flashintensity
mcd = 10000 ]
[ Injured = 1 ]* 
[ timepoint = 
14 ]* [ 
flashintensity
mcd = 10 ]
[ Injured = 0 ]* [ timepoint 
= 2 ]* [ flashintensitymcd = 
10 ]
[ Injured = 0 ]* [ timepoint 
= 2 ]* [ flashintensitymcd = 
3000 ]
[ Injured = 0 ]* [ timepoint 
= 2 ]* [ flashintensitymcd = 
10000 ]
[ Injured = 0 ]* [ timepoint 
= 7 ]* [ flashintensitymcd = 
10 ]
[ Injured = 0 ]* [ timepoint 
= 7 ]* [ flashintensitymcd = 
3000 ]
[ Injured = 0 ]* [ timepoint 
= 7 ]* [ flashintensitymcd = 
10000 ]
.000 .000 .000 .000
.001 .000 .000 .000
.001 .001 .000 .000
.002 .001 .001 .000
.004 .002 .001 .001
.008 .004 .002 .001
Working Correlation Matrixa
Measurement
Measurement
[ Injured = 1 ]* 
[ timepoint = 
14 ]* [ 
flashintensity
mcd = 3000 ]
[ Injured = 1 ]* 
[ timepoint = 
14 ]* [ 
flashintensity
mcd = 10000 ]
[ Injured = 0 ]* [ timepoint 
= 2 ]* [ flashintensitymcd = 
10 ]
[ Injured = 0 ]* [ timepoint 
= 2 ]* [ flashintensitymcd = 
3000 ]
[ Injured = 0 ]* [ timepoint 
= 2 ]* [ flashintensitymcd = 
10000 ]
[ Injured = 0 ]* [ timepoint 
= 7 ]* [ flashintensitymcd = 
10 ]
[ Injured = 0 ]* [ timepoint 
= 7 ]* [ flashintensitymcd = 
3000 ]
[ Injured = 0 ]* [ timepoint 
= 7 ]* [ flashintensitymcd = 
10000 ]
.000 .000
.000 .000
.000 .000
.000 .000
.000 .000
.001 .000
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Working Correlation Matrixa
Measurement
Measurement
[ Injured = 0 ]* 
[ timepoint = 2 
]* [ 
flashintensity
mcd = 10 ]
[ Injured = 0 ]* 
[ timepoint = 2 
]* [ 
flashintensity
mcd = 3000 ]
[ Injured = 0 ]* 
[ timepoint = 2 
]* [ 
flashintensity
mcd = 10000 ]
[ Injured = 0 ]* 
[ timepoint = 7 
]* [ 
flashintensity
mcd = 10 ]
[ Injured = 0 ]* [ timepoint 
= 14 ]* [ flashintensitymcd 
= 10 ]
[ Injured = 0 ]* [ timepoint 
= 14 ]* [ flashintensitymcd 
= 3000 ]
[ Injured = 0 ]* [ timepoint 
= 14 ]* [ flashintensitymcd 
= 10000 ]
[ Injured = 1 ]* [ timepoint 
= 2 ]* [ flashintensitymcd = 
10 ]
[ Injured = 1 ]* [ timepoint 
= 2 ]* [ flashintensitymcd = 
3000 ]
[ Injured = 1 ]* [ timepoint 
= 2 ]* [ flashintensitymcd = 
10000 ]
[ Injured = 1 ]* [ timepoint 
= 7 ]* [ flashintensitymcd = 
10 ]
[ Injured = 1 ]* [ timepoint 
= 7 ]* [ flashintensitymcd = 
3000 ]
[ Injured = 1 ]* [ timepoint 
= 7 ]* [ flashintensitymcd = 
10000 ]
[ Injured = 1 ]* [ timepoint 
= 14 ]* [ flashintensitymcd 
= 10 ]
[ Injured = 1 ]* [ timepoint 
= 14 ]* [ flashintensitymcd 
= 3000 ]
[ Injured = 1 ]* [ timepoint 
= 14 ]* [ flashintensitymcd 
= 10000 ]
.017 .033 .065 .129
.008 .017 .033 .065
.004 .008 .017 .033
.002 .004 .008 .017
.001 .002 .004 .008
.001 .001 .002 .004
.000 .001 .001 .002
.000 .000 .001 .001
.000 .000 .000 .001
.000 .000 .000 .000
.000 .000 .000 .000
.000 .000 .000 .000
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Working Correlation Matrixa
Measurement
Measurement
[ Injured = 0 ]* 
[ timepoint = 7 
]* [ 
flashintensity
mcd = 3000 ]
[ Injured = 0 ]* 
[ timepoint = 7 
]* [ 
flashintensity
mcd = 10000 ]
[ Injured = 0 ]* 
[ timepoint = 
14 ]* [ 
flashintensity
mcd = 10 ]
[ Injured = 0 ]* 
[ timepoint = 
14 ]* [ 
flashintensity
mcd = 3000 ]
[ Injured = 0 ]* [ timepoint 
= 14 ]* [ flashintensitymcd 
= 10 ]
[ Injured = 0 ]* [ timepoint 
= 14 ]* [ flashintensitymcd 
= 3000 ]
[ Injured = 0 ]* [ timepoint 
= 14 ]* [ flashintensitymcd 
= 10000 ]
[ Injured = 1 ]* [ timepoint 
= 2 ]* [ flashintensitymcd = 
10 ]
[ Injured = 1 ]* [ timepoint 
= 2 ]* [ flashintensitymcd = 
3000 ]
[ Injured = 1 ]* [ timepoint 
= 2 ]* [ flashintensitymcd = 
10000 ]
[ Injured = 1 ]* [ timepoint 
= 7 ]* [ flashintensitymcd = 
10 ]
[ Injured = 1 ]* [ timepoint 
= 7 ]* [ flashintensitymcd = 
3000 ]
[ Injured = 1 ]* [ timepoint 
= 7 ]* [ flashintensitymcd = 
10000 ]
[ Injured = 1 ]* [ timepoint 
= 14 ]* [ flashintensitymcd 
= 10 ]
[ Injured = 1 ]* [ timepoint 
= 14 ]* [ flashintensitymcd 
= 3000 ]
[ Injured = 1 ]* [ timepoint 
= 14 ]* [ flashintensitymcd 
= 10000 ]
.256 .506 1.000 .506
.129 .256 .506 1.000
.065 .129 .256 .506
.033 .065 .129 .256
.017 .033 .065 .129
.008 .017 .033 .065
.004 .008 .017 .033
.002 .004 .008 .017
.001 .002 .004 .008
.001 .001 .002 .004
.000 .001 .001 .002
.000 .000 .001 .001
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Working Correlation Matrixa
Measurement
Measurement
[ Injured = 0 ]* 
[ timepoint = 
14 ]* [ 
flashintensity
mcd = 10000 ]
[ Injured = 1 ]* 
[ timepoint = 2 
]* [ 
flashintensity
mcd = 10 ]
[ Injured = 1 ]* 
[ timepoint = 2 
]* [ 
flashintensity
mcd = 3000 ]
[ Injured = 1 ]* 
[ timepoint = 2 
]* [ 
flashintensity
mcd = 10000 ]
[ Injured = 0 ]* [ timepoint 
= 14 ]* [ flashintensitymcd 
= 10 ]
[ Injured = 0 ]* [ timepoint 
= 14 ]* [ flashintensitymcd 
= 3000 ]
[ Injured = 0 ]* [ timepoint 
= 14 ]* [ flashintensitymcd 
= 10000 ]
[ Injured = 1 ]* [ timepoint 
= 2 ]* [ flashintensitymcd = 
10 ]
[ Injured = 1 ]* [ timepoint 
= 2 ]* [ flashintensitymcd = 
3000 ]
[ Injured = 1 ]* [ timepoint 
= 2 ]* [ flashintensitymcd = 
10000 ]
[ Injured = 1 ]* [ timepoint 
= 7 ]* [ flashintensitymcd = 
10 ]
[ Injured = 1 ]* [ timepoint 
= 7 ]* [ flashintensitymcd = 
3000 ]
[ Injured = 1 ]* [ timepoint 
= 7 ]* [ flashintensitymcd = 
10000 ]
[ Injured = 1 ]* [ timepoint 
= 14 ]* [ flashintensitymcd 
= 10 ]
[ Injured = 1 ]* [ timepoint 
= 14 ]* [ flashintensitymcd 
= 3000 ]
[ Injured = 1 ]* [ timepoint 
= 14 ]* [ flashintensitymcd 
= 10000 ]
.256 .129 .065 .033
.506 .256 .129 .065
1.000 .506 .256 .129
.506 1.000 .506 .256
.256 .506 1.000 .506
.129 .256 .506 1.000
.065 .129 .256 .506
.033 .065 .129 .256
.017 .033 .065 .129
.008 .017 .033 .065
.004 .008 .017 .033
.002 .004 .008 .017
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Working Correlation Matrixa
Measurement
Measurement
[ Injured = 1 ]* 
[ timepoint = 7 
]* [ 
flashintensity
mcd = 10 ]
[ Injured = 1 ]* 
[ timepoint = 7 
]* [ 
flashintensity
mcd = 3000 ]
[ Injured = 1 ]* 
[ timepoint = 7 
]* [ 
flashintensity
mcd = 10000 ]
[ Injured = 1 ]* 
[ timepoint = 
14 ]* [ 
flashintensity
mcd = 10 ]
[ Injured = 0 ]* [ timepoint 
= 14 ]* [ flashintensitymcd 
= 10 ]
[ Injured = 0 ]* [ timepoint 
= 14 ]* [ flashintensitymcd 
= 3000 ]
[ Injured = 0 ]* [ timepoint 
= 14 ]* [ flashintensitymcd 
= 10000 ]
[ Injured = 1 ]* [ timepoint 
= 2 ]* [ flashintensitymcd = 
10 ]
[ Injured = 1 ]* [ timepoint 
= 2 ]* [ flashintensitymcd = 
3000 ]
[ Injured = 1 ]* [ timepoint 
= 2 ]* [ flashintensitymcd = 
10000 ]
[ Injured = 1 ]* [ timepoint 
= 7 ]* [ flashintensitymcd = 
10 ]
[ Injured = 1 ]* [ timepoint 
= 7 ]* [ flashintensitymcd = 
3000 ]
[ Injured = 1 ]* [ timepoint 
= 7 ]* [ flashintensitymcd = 
10000 ]
[ Injured = 1 ]* [ timepoint 
= 14 ]* [ flashintensitymcd 
= 10 ]
[ Injured = 1 ]* [ timepoint 
= 14 ]* [ flashintensitymcd 
= 3000 ]
[ Injured = 1 ]* [ timepoint 
= 14 ]* [ flashintensitymcd 
= 10000 ]
.017 .008 .004 .002
.033 .017 .008 .004
.065 .033 .017 .008
.129 .065 .033 .017
.256 .129 .065 .033
.506 .256 .129 .065
1.000 .506 .256 .129
.506 1.000 .506 .256
.256 .506 1.000 .506
.129 .256 .506 1.000
.065 .129 .256 .506
.033 .065 .129 .256
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Working Correlation Matrixa
Measurement
Measurement
[ Injured = 1 ]* 
[ timepoint = 
14 ]* [ 
flashintensity
mcd = 3000 ]
[ Injured = 1 ]* 
[ timepoint = 
14 ]* [ 
flashintensity
mcd = 10000 ]
[ Injured = 0 ]* [ timepoint 
= 14 ]* [ flashintensitymcd 
= 10 ]
[ Injured = 0 ]* [ timepoint 
= 14 ]* [ flashintensitymcd 
= 3000 ]
[ Injured = 0 ]* [ timepoint 
= 14 ]* [ flashintensitymcd 
= 10000 ]
[ Injured = 1 ]* [ timepoint 
= 2 ]* [ flashintensitymcd = 
10 ]
[ Injured = 1 ]* [ timepoint 
= 2 ]* [ flashintensitymcd = 
3000 ]
[ Injured = 1 ]* [ timepoint 
= 2 ]* [ flashintensitymcd = 
10000 ]
[ Injured = 1 ]* [ timepoint 
= 7 ]* [ flashintensitymcd = 
10 ]
[ Injured = 1 ]* [ timepoint 
= 7 ]* [ flashintensitymcd = 
3000 ]
[ Injured = 1 ]* [ timepoint 
= 7 ]* [ flashintensitymcd = 
10000 ]
[ Injured = 1 ]* [ timepoint 
= 14 ]* [ flashintensitymcd 
= 10 ]
[ Injured = 1 ]* [ timepoint 
= 14 ]* [ flashintensitymcd 
= 3000 ]
[ Injured = 1 ]* [ timepoint 
= 14 ]* [ flashintensitymcd 
= 10000 ]
.001 .001
.002 .001
.004 .002
.008 .004
.017 .008
.033 .017
.065 .033
.129 .065
.256 .129
.506 .256
1.000 .506
.506 1.000
Dependent Variable: awaveslopevms
 Model: (Intercept), timepoint, flashintensitymcd, Injured, timepoint * flashintensitymcd, timepoint * Injured, 
flashintensitymcd * Injured, timepoint * flashintensitymcd * Injured
The AR(1) working correlation matrix structure is computed assuming the measurements are equally 
spaced for all subjects.
a.
Estimated Marginal Means: timepoint* flashintensitymcd* Injured
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Estimates
timepoint flashintensitymcd Injured Mean Std. Error
95% Wald Confidence Interval
Lower Upper
2 10 1
0
3000 1
0
10000 1
0
7 10 1
0
3000 1
0
10000 1
0
14 10 1
0
3000 1
0
10000 1
0
.61438 .146839 .38458 .98147
1.17313 .273227 .74318 1.85180
6.31875 1.561073 3.89348 10.25472
24.55375 3.871302 18.02652 33.44442
11.80500 2.492307 7.80473 17.85559
41.61250 6.477327 30.67096 56.45733
.79120 .259321 .41620 1.50409
1.79063 .565919 .96380 3.32677
11.99125 2.683348 7.73368 18.59270
32.72500 4.375241 25.18120 42.52878
20.11125 3.380244 14.46677 27.95804
49.28750 6.143046 38.60518 62.92569
1.12350 .217217 .76913 1.64113
2.41375 .366802 1.79201 3.25120
15.01375 3.046657 10.08694 22.34698
39.30000 4.976131 30.66297 50.36988
25.07000 4.849224 17.15966 36.62689
59.68750 6.720920 47.86704 74.42695
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 APPENDIX 9  
  
Appendix 9, p1
* Generalized Estimating Equations.
GENLIN abwaveratio BY timepoint flashintensitymcd Injured (ORDER=DATA)
  /MODEL timepoint flashintensitymcd Injured timepoint*flashintensitymcd timepoint*Injured f
 DISTRIBUTION=GAMMA LINK=LOG
  /CRITERIA METHOD=FISHER(1) SCALE=MLE MAXITERATIONS=100 MAXSTEPHALVING=5 PCONVERGE=1E-006(A
  /EMMEANS TABLES=timepoint*flashintensitymcd*Injured SCALE=ORIGINAL
  /REPEATED SUBJECT=animal WITHINSUBJECT=Injured*timepoint*flashintensitymcd SORT=YES CORRTY
  /MISSING CLASSMISSING=EXCLUDE
  /PRINT CPS DESCRIPTIVES MODELINFO FIT SUMMARY WORKINGCORR.
Generalized Linear Models
Notes
Output Created
Comments
Input Data
Active Dataset
Filter
Weight
Split File
N of Rows in Working 
Data File
Missing Value Handling Definition of Missing
Cases Used
Weight Handling
02-MAY-2013 10:13:14
C:
\Users\Public\Documents\PhD\ERG\
Results\T-CEM423-6\scotopic data 
T.sav
DataSet5
<none>
<none>
<none>
152
User-defined missing values for 
factor, subject and within-subject 
variables are treated as missing.
Statistics are based on cases with 
valid data for all variables in the 
model.
not applicable
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Notes
Syntax
Resources Processor Time
Elapsed Time
GENLIN V12 BY timepoint 
flashintensitymcd Injured 
(ORDER=DATA)
   /MODEL timepoint 
flashintensitymcd Injured 
timepoint*flashintensitymcd
timepoint*Injured
flashintensitymcd*Injured
timepoint*flashintensitymcd*Injured
INTERCEPT=YES
  DISTRIBUTION=GAMMA 
LINK=LOG
   /CRITERIA METHOD=FISHER(1) 
SCALE=MLE
MAXITERATIONS=100
MAXSTEPHALVING=5
PCONVERGE=1E-006(ABSOLUTE)
SINGULAR=1E-012
ANALYSISTYPE=3(WALD)
CILEVEL=95 LIKELIHOOD=FULL
   /EMMEANS 
TABLES=timepoint*flashintensitymc
d*Injured SCALE=ORIGINAL
   /REPEATED SUBJECT=animal 
WITHINSUBJECT=Injured*timepoint
*flashintensitymcd SORT=YES 
CORRTYPE=AR(1)
ADJUSTCORR=YES
COVB=ROBUST
MAXITERATIONS=100
PCONVERGE=1e-006(ABSOLUTE)
UPDATECORR=1
   /MISSING 
CLASSMISSING=EXCLUDE
   /PRINT CPS DESCRIPTIVES ...
00:00:00.08
00:00:00.15
[DataSet5] C:\Users\Public\Documents\PhD\ERG\Results\T-CEM423-6\scotopic d
ata T.sav
Model Information
Dependent Variable
Probability Distribution
Link Function
Subject Effect 1
Within-Subject Effect 1
2
3
Working Correlation Matrix Structure
V12
Gamma
Log
animal
Injured
timepoint
flashintensitymcd
AR(1)
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Case Processing Summary
N Percent
Included
Excluded
Total
144 94.7%
8 5.3%
152 100.0%
Correlated Data Summary
Number of Levels Subject Effect animal
Within-Subject Effect Injured
timepoint
flashintensitymcd
Number of Subjects
Number of Measurements 
per Subject
Minimum
Maximum
Correlation Matrix Dimension
8
2
3
3
8
18
18
18
Categorical Variable Information
N Percent
Factor timepoint 2
7
14
Total
flashintensitymcd 10
3000
10000
Total
Injured 1
0
Total
48 33.3%
48 33.3%
48 33.3%
144 100.0%
48 33.3%
48 33.3%
48 33.3%
144 100.0%
72 50.0%
72 50.0%
144 100.0%
Continuous Variable Information
N Minimum Maximum Mean Std. Deviation
Dependent Variable V12 144 1 3436 119.25 472.496
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Goodness of Fita
Value
Quasi Likelihood under 
Independence Model 
Criterion (QIC)b
Corrected Quasi 
Likelihood under 
Independence Model 
Criterion (QICC)b
185.896
197.166
Dependent Variable: V12
 Model: (Intercept), timepoint, 
flashintensitymcd, Injured, timepoint * 
flashintensitymcd, timepoint * Injured, 
flashintensitymcd * Injured, timepoint * 
flashintensitymcd * Injured
Information criteria are in small-is-better form.a.
Computed using the full log quasi-likelihood function.b.
Tests of Model Effects
Source
Type III
Wald Chi-
Square df Sig.
(Intercept)
timepoint
flashintensitymcd
Injured
timepoint * 
flashintensitymcd
timepoint * Injured
flashintensitymcd * Injured
timepoint * 
flashintensitymcd * Injured
217.835 1 .000
19.098 2 .000
175.955 2 .000
1.028 1 .311
237.445 4 .000
1.056 2 .590
9.009 2 .011
6.612 4 .158
Dependent Variable: V12
 Model: (Intercept), timepoint, flashintensitymcd, Injured, timepoint * 
flashintensitymcd, timepoint * Injured, flashintensitymcd * Injured, 
timepoint * flashintensitymcd * Injured
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Working Correlation Matrixa
Measurement
Measurement
[ Injured = 0 ]* 
[ timepoint = 2 
]* [ 
flashintensity
mcd = 10 ]
[ Injured = 0 ]* 
[ timepoint = 2 
]* [ 
flashintensity
mcd = 3000 ]
[ Injured = 0 ]* 
[ timepoint = 2 
]* [ 
flashintensity
mcd = 10000 ]
[ Injured = 0 ]* 
[ timepoint = 7 
]* [ 
flashintensity
mcd = 10 ]
[ Injured = 0 ]* [ timepoint 
= 2 ]* [ flashintensitymcd = 
10 ]
[ Injured = 0 ]* [ timepoint 
= 2 ]* [ flashintensitymcd = 
3000 ]
[ Injured = 0 ]* [ timepoint 
= 2 ]* [ flashintensitymcd = 
10000 ]
[ Injured = 0 ]* [ timepoint 
= 7 ]* [ flashintensitymcd = 
10 ]
[ Injured = 0 ]* [ timepoint 
= 7 ]* [ flashintensitymcd = 
3000 ]
[ Injured = 0 ]* [ timepoint 
= 7 ]* [ flashintensitymcd = 
10000 ]
[ Injured = 0 ]* [ timepoint 
= 14 ]* [ flashintensitymcd 
= 10 ]
[ Injured = 0 ]* [ timepoint 
= 14 ]* [ flashintensitymcd 
= 3000 ]
[ Injured = 0 ]* [ timepoint 
= 14 ]* [ flashintensitymcd 
= 10000 ]
[ Injured = 1 ]* [ timepoint 
= 2 ]* [ flashintensitymcd = 
10 ]
[ Injured = 1 ]* [ timepoint 
= 2 ]* [ flashintensitymcd = 
3000 ]
[ Injured = 1 ]* [ timepoint 
= 2 ]* [ flashintensitymcd = 
10000 ]
[ Injured = 1 ]* [ timepoint 
= 7 ]* [ flashintensitymcd = 
10 ]
[ Injured = 1 ]* [ timepoint 
= 7 ]* [ flashintensitymcd = 
3000 ]
1.000 .041 .002 .000
.041 1.000 .041 .002
.002 .041 1.000 .041
.000 .002 .041 1.000
.000 .000 .002 .041
.000 .000 .000 .002
.000 .000 .000 .000
.000 .000 .000 .000
.000 .000 .000 .000
.000 .000 .000 .000
.000 .000 .000 .000
.000 .000 .000 .000
.000 .000 .000 .000
.000 .000 .000 .000
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Working Correlation Matrixa
Measurement
Measurement
[ Injured = 0 ]* 
[ timepoint = 7 
]* [ 
flashintensity
mcd = 3000 ]
[ Injured = 0 ]* 
[ timepoint = 7 
]* [ 
flashintensity
mcd = 10000 ]
[ Injured = 0 ]* 
[ timepoint = 
14 ]* [ 
flashintensity
mcd = 10 ]
[ Injured = 0 ]* 
[ timepoint = 
14 ]* [ 
flashintensity
mcd = 3000 ]
[ Injured = 0 ]* [ timepoint 
= 2 ]* [ flashintensitymcd = 
10 ]
[ Injured = 0 ]* [ timepoint 
= 2 ]* [ flashintensitymcd = 
3000 ]
[ Injured = 0 ]* [ timepoint 
= 2 ]* [ flashintensitymcd = 
10000 ]
[ Injured = 0 ]* [ timepoint 
= 7 ]* [ flashintensitymcd = 
10 ]
[ Injured = 0 ]* [ timepoint 
= 7 ]* [ flashintensitymcd = 
3000 ]
[ Injured = 0 ]* [ timepoint 
= 7 ]* [ flashintensitymcd = 
10000 ]
[ Injured = 0 ]* [ timepoint 
= 14 ]* [ flashintensitymcd 
= 10 ]
[ Injured = 0 ]* [ timepoint 
= 14 ]* [ flashintensitymcd 
= 3000 ]
[ Injured = 0 ]* [ timepoint 
= 14 ]* [ flashintensitymcd 
= 10000 ]
[ Injured = 1 ]* [ timepoint 
= 2 ]* [ flashintensitymcd = 
10 ]
[ Injured = 1 ]* [ timepoint 
= 2 ]* [ flashintensitymcd = 
3000 ]
[ Injured = 1 ]* [ timepoint 
= 2 ]* [ flashintensitymcd = 
10000 ]
[ Injured = 1 ]* [ timepoint 
= 7 ]* [ flashintensitymcd = 
10 ]
[ Injured = 1 ]* [ timepoint 
= 7 ]* [ flashintensitymcd = 
3000 ]
.000 .000 .000 .000
.000 .000 .000 .000
.002 .000 .000 .000
.041 .002 .000 .000
1.000 .041 .002 .000
.041 1.000 .041 .002
.002 .041 1.000 .041
.000 .002 .041 1.000
.000 .000 .002 .041
.000 .000 .000 .002
.000 .000 .000 .000
.000 .000 .000 .000
.000 .000 .000 .000
.000 .000 .000 .000
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Working Correlation Matrixa
Measurement
Measurement
[ Injured = 0 ]* 
[ timepoint = 
14 ]* [ 
flashintensity
mcd = 10000 ]
[ Injured = 1 ]* 
[ timepoint = 2 
]* [ 
flashintensity
mcd = 10 ]
[ Injured = 1 ]* 
[ timepoint = 2 
]* [ 
flashintensity
mcd = 3000 ]
[ Injured = 1 ]* 
[ timepoint = 2 
]* [ 
flashintensity
mcd = 10000 ]
[ Injured = 0 ]* [ timepoint 
= 2 ]* [ flashintensitymcd = 
10 ]
[ Injured = 0 ]* [ timepoint 
= 2 ]* [ flashintensitymcd = 
3000 ]
[ Injured = 0 ]* [ timepoint 
= 2 ]* [ flashintensitymcd = 
10000 ]
[ Injured = 0 ]* [ timepoint 
= 7 ]* [ flashintensitymcd = 
10 ]
[ Injured = 0 ]* [ timepoint 
= 7 ]* [ flashintensitymcd = 
3000 ]
[ Injured = 0 ]* [ timepoint 
= 7 ]* [ flashintensitymcd = 
10000 ]
[ Injured = 0 ]* [ timepoint 
= 14 ]* [ flashintensitymcd 
= 10 ]
[ Injured = 0 ]* [ timepoint 
= 14 ]* [ flashintensitymcd 
= 3000 ]
[ Injured = 0 ]* [ timepoint 
= 14 ]* [ flashintensitymcd 
= 10000 ]
[ Injured = 1 ]* [ timepoint 
= 2 ]* [ flashintensitymcd = 
10 ]
[ Injured = 1 ]* [ timepoint 
= 2 ]* [ flashintensitymcd = 
3000 ]
[ Injured = 1 ]* [ timepoint 
= 2 ]* [ flashintensitymcd = 
10000 ]
[ Injured = 1 ]* [ timepoint 
= 7 ]* [ flashintensitymcd = 
10 ]
[ Injured = 1 ]* [ timepoint 
= 7 ]* [ flashintensitymcd = 
3000 ]
.000 .000 .000 .000
.000 .000 .000 .000
.000 .000 .000 .000
.000 .000 .000 .000
.000 .000 .000 .000
.000 .000 .000 .000
.002 .000 .000 .000
.041 .002 .000 .000
1.000 .041 .002 .000
.041 1.000 .041 .002
.002 .041 1.000 .041
.000 .002 .041 1.000
.000 .000 .002 .041
.000 .000 .000 .002
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Working Correlation Matrixa
Measurement
Measurement
[ Injured = 1 ]* 
[ timepoint = 7 
]* [ 
flashintensity
mcd = 10 ]
[ Injured = 1 ]* 
[ timepoint = 7 
]* [ 
flashintensity
mcd = 3000 ]
[ Injured = 1 ]* 
[ timepoint = 7 
]* [ 
flashintensity
mcd = 10000 ]
[ Injured = 1 ]* 
[ timepoint = 
14 ]* [ 
flashintensity
mcd = 10 ]
[ Injured = 0 ]* [ timepoint 
= 2 ]* [ flashintensitymcd = 
10 ]
[ Injured = 0 ]* [ timepoint 
= 2 ]* [ flashintensitymcd = 
3000 ]
[ Injured = 0 ]* [ timepoint 
= 2 ]* [ flashintensitymcd = 
10000 ]
[ Injured = 0 ]* [ timepoint 
= 7 ]* [ flashintensitymcd = 
10 ]
[ Injured = 0 ]* [ timepoint 
= 7 ]* [ flashintensitymcd = 
3000 ]
[ Injured = 0 ]* [ timepoint 
= 7 ]* [ flashintensitymcd = 
10000 ]
[ Injured = 0 ]* [ timepoint 
= 14 ]* [ flashintensitymcd 
= 10 ]
[ Injured = 0 ]* [ timepoint 
= 14 ]* [ flashintensitymcd 
= 3000 ]
[ Injured = 0 ]* [ timepoint 
= 14 ]* [ flashintensitymcd 
= 10000 ]
[ Injured = 1 ]* [ timepoint 
= 2 ]* [ flashintensitymcd = 
10 ]
[ Injured = 1 ]* [ timepoint 
= 2 ]* [ flashintensitymcd = 
3000 ]
[ Injured = 1 ]* [ timepoint 
= 2 ]* [ flashintensitymcd = 
10000 ]
[ Injured = 1 ]* [ timepoint 
= 7 ]* [ flashintensitymcd = 
10 ]
[ Injured = 1 ]* [ timepoint 
= 7 ]* [ flashintensitymcd = 
3000 ]
.000 .000 .000 .000
.000 .000 .000 .000
.000 .000 .000 .000
.000 .000 .000 .000
.000 .000 .000 .000
.000 .000 .000 .000
.000 .000 .000 .000
.000 .000 .000 .000
.000 .000 .000 .000
.000 .000 .000 .000
.002 .000 .000 .000
.041 .002 .000 .000
1.000 .041 .002 .000
.041 1.000 .041 .002
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Working Correlation Matrixa
Measurement
Measurement
[ Injured = 1 ]* 
[ timepoint = 
14 ]* [ 
flashintensity
mcd = 3000 ]
[ Injured = 1 ]* 
[ timepoint = 
14 ]* [ 
flashintensity
mcd = 10000 ]
[ Injured = 0 ]* [ timepoint 
= 2 ]* [ flashintensitymcd = 
10 ]
[ Injured = 0 ]* [ timepoint 
= 2 ]* [ flashintensitymcd = 
3000 ]
[ Injured = 0 ]* [ timepoint 
= 2 ]* [ flashintensitymcd = 
10000 ]
[ Injured = 0 ]* [ timepoint 
= 7 ]* [ flashintensitymcd = 
10 ]
[ Injured = 0 ]* [ timepoint 
= 7 ]* [ flashintensitymcd = 
3000 ]
[ Injured = 0 ]* [ timepoint 
= 7 ]* [ flashintensitymcd = 
10000 ]
[ Injured = 0 ]* [ timepoint 
= 14 ]* [ flashintensitymcd 
= 10 ]
[ Injured = 0 ]* [ timepoint 
= 14 ]* [ flashintensitymcd 
= 3000 ]
[ Injured = 0 ]* [ timepoint 
= 14 ]* [ flashintensitymcd 
= 10000 ]
[ Injured = 1 ]* [ timepoint 
= 2 ]* [ flashintensitymcd = 
10 ]
[ Injured = 1 ]* [ timepoint 
= 2 ]* [ flashintensitymcd = 
3000 ]
[ Injured = 1 ]* [ timepoint 
= 2 ]* [ flashintensitymcd = 
10000 ]
[ Injured = 1 ]* [ timepoint 
= 7 ]* [ flashintensitymcd = 
10 ]
[ Injured = 1 ]* [ timepoint 
= 7 ]* [ flashintensitymcd = 
3000 ]
.000 .000
.000 .000
.000 .000
.000 .000
.000 .000
.000 .000
.000 .000
.000 .000
.000 .000
.000 .000
.000 .000
.000 .000
.000 .000
.000 .000
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Working Correlation Matrixa
Measurement
Measurement
[ Injured = 0 ]* 
[ timepoint = 2 
]* [ 
flashintensity
mcd = 10 ]
[ Injured = 0 ]* 
[ timepoint = 2 
]* [ 
flashintensity
mcd = 3000 ]
[ Injured = 0 ]* 
[ timepoint = 2 
]* [ 
flashintensity
mcd = 10000 ]
[ Injured = 0 ]* 
[ timepoint = 7 
]* [ 
flashintensity
mcd = 10 ]
[ Injured = 1 ]* [ timepoint 
= 7 ]* [ flashintensitymcd = 
10000 ]
[ Injured = 1 ]* [ timepoint 
= 14 ]* [ flashintensitymcd 
= 10 ]
[ Injured = 1 ]* [ timepoint 
= 14 ]* [ flashintensitymcd 
= 3000 ]
[ Injured = 1 ]* [ timepoint 
= 14 ]* [ flashintensitymcd 
= 10000 ]
.000 .000 .000 .000
.000 .000 .000 .000
.000 .000 .000 .000
.000 .000 .000 .000
Working Correlation Matrixa
Measurement
Measurement
[ Injured = 0 ]* 
[ timepoint = 7 
]* [ 
flashintensity
mcd = 3000 ]
[ Injured = 0 ]* 
[ timepoint = 7 
]* [ 
flashintensity
mcd = 10000 ]
[ Injured = 0 ]* 
[ timepoint = 
14 ]* [ 
flashintensity
mcd = 10 ]
[ Injured = 0 ]* 
[ timepoint = 
14 ]* [ 
flashintensity
mcd = 3000 ]
[ Injured = 1 ]* [ timepoint 
= 7 ]* [ flashintensitymcd = 
10000 ]
[ Injured = 1 ]* [ timepoint 
= 14 ]* [ flashintensitymcd 
= 10 ]
[ Injured = 1 ]* [ timepoint 
= 14 ]* [ flashintensitymcd 
= 3000 ]
[ Injured = 1 ]* [ timepoint 
= 14 ]* [ flashintensitymcd 
= 10000 ]
.000 .000 .000 .000
.000 .000 .000 .000
.000 .000 .000 .000
.000 .000 .000 .000
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Working Correlation Matrixa
Measurement
Measurement
[ Injured = 0 ]* 
[ timepoint = 
14 ]* [ 
flashintensity
mcd = 10000 ]
[ Injured = 1 ]* 
[ timepoint = 2 
]* [ 
flashintensity
mcd = 10 ]
[ Injured = 1 ]* 
[ timepoint = 2 
]* [ 
flashintensity
mcd = 3000 ]
[ Injured = 1 ]* 
[ timepoint = 2 
]* [ 
flashintensity
mcd = 10000 ]
[ Injured = 1 ]* [ timepoint 
= 7 ]* [ flashintensitymcd = 
10000 ]
[ Injured = 1 ]* [ timepoint 
= 14 ]* [ flashintensitymcd 
= 10 ]
[ Injured = 1 ]* [ timepoint 
= 14 ]* [ flashintensitymcd 
= 3000 ]
[ Injured = 1 ]* [ timepoint 
= 14 ]* [ flashintensitymcd 
= 10000 ]
.000 .000 .000 .000
.000 .000 .000 .000
.000 .000 .000 .000
.000 .000 .000 .000
Working Correlation Matrixa
Measurement
Measurement
[ Injured = 1 ]* 
[ timepoint = 7 
]* [ 
flashintensity
mcd = 10 ]
[ Injured = 1 ]* 
[ timepoint = 7 
]* [ 
flashintensity
mcd = 3000 ]
[ Injured = 1 ]* 
[ timepoint = 7 
]* [ 
flashintensity
mcd = 10000 ]
[ Injured = 1 ]* 
[ timepoint = 
14 ]* [ 
flashintensity
mcd = 10 ]
[ Injured = 1 ]* [ timepoint 
= 7 ]* [ flashintensitymcd = 
10000 ]
[ Injured = 1 ]* [ timepoint 
= 14 ]* [ flashintensitymcd 
= 10 ]
[ Injured = 1 ]* [ timepoint 
= 14 ]* [ flashintensitymcd 
= 3000 ]
[ Injured = 1 ]* [ timepoint 
= 14 ]* [ flashintensitymcd 
= 10000 ]
.002 .041 1.000 .041
.000 .002 .041 1.000
.000 .000 .002 .041
.000 .000 .000 .002
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Working Correlation Matrixa
Measurement
Measurement
[ Injured = 1 ]* 
[ timepoint = 
14 ]* [ 
flashintensity
mcd = 3000 ]
[ Injured = 1 ]* 
[ timepoint = 
14 ]* [ 
flashintensity
mcd = 10000 ]
[ Injured = 1 ]* [ timepoint 
= 7 ]* [ flashintensitymcd = 
10000 ]
[ Injured = 1 ]* [ timepoint 
= 14 ]* [ flashintensitymcd 
= 10 ]
[ Injured = 1 ]* [ timepoint 
= 14 ]* [ flashintensitymcd 
= 3000 ]
[ Injured = 1 ]* [ timepoint 
= 14 ]* [ flashintensitymcd 
= 10000 ]
.002 .000
.041 .002
1.000 .041
.041 1.000
Dependent Variable: V12
 Model: (Intercept), timepoint, flashintensitymcd, Injured, timepoint * flashintensitymcd, timepoint * Injured, 
flashintensitymcd * Injured, timepoint * flashintensitymcd * Injured
The AR(1) working correlation matrix structure is computed assuming the measurements are equally 
spaced for all subjects.
a.
Estimated Marginal Means: timepoint* flashintensitymcd* Injured
Estimates
timepoint flashintensitymcd Injured Mean Std. Error
95% Wald Confidence Interval
Lower Upper
2 10 1
0
3000 1
0
10000 1
0
7 10 1
0
3000 1
0
10000 1
0
14 10 1
0
3000 1
0
10000 1
0
70.77 53.084 16.27 307.85
26.29 4.798 18.38 37.59
3.06 .864 1.76 5.32
3.09 .602 2.11 4.52
2.03 .414 1.36 3.03
2.31 .329 1.74 3.05
568.73 219.566 266.86 1212.06
732.16 445.344 222.26 2411.90
2.25 .192 1.91 2.66
2.23 .170 1.92 2.59
1.96 .135 1.71 2.24
1.98 .135 1.73 2.26
404.43 257.622 116.04 1409.49
316.96 271.867 59.01 1702.57
2.02 .140 1.77 2.32
2.09 .132 1.85 2.37
1.89 .134 1.65 2.17
2.24 .324 1.69 2.98
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* Generalized Estimating Equations.
GENLIN V12 BY timepoint flashintensitymcd Injured (ORDER=DATA)
  /MODEL timepoint flashintensitymcd Injured timepoint*flashintensitymcd timepoint*Injured f
 DISTRIBUTION=GAMMA LINK=LOG
  /CRITERIA METHOD=FISHER(1) SCALE=MLE MAXITERATIONS=100 MAXSTEPHALVING=5 PCONVERGE=1E-006(A
  /EMMEANS TABLES=timepoint*flashintensitymcd*Injured SCALE=ORIGINAL
  /REPEATED SUBJECT=animal WITHINSUBJECT=Injured*timepoint*flashintensitymcd SORT=YES CORRTY
  /MISSING CLASSMISSING=EXCLUDE
  /PRINT CPS DESCRIPTIVES MODELINFO FIT SUMMARY WORKINGCORR.
Generalized Linear Models
Notes
Output Created
Comments
Input Data
Active Dataset
Filter
Weight
Split File
N of Rows in Working 
Data File
Missing Value Handling Definition of Missing
Cases Used
Weight Handling
02-MAY-2013 10:14:49
C:
\Users\Public\Documents\PhD\ERG\
Results\T-CEM423-6\scotopic data 
T.sav
DataSet5
<none>
<none>
<none>
152
User-defined missing values for 
factor, subject and within-subject 
variables are treated as missing.
Statistics are based on cases with 
valid data for all variables in the 
model.
not applicable
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Notes
Syntax
Resources Processor Time
Elapsed Time
GENLIN V12 BY timepoint 
flashintensitymcd Injured 
(ORDER=DATA)
   /MODEL timepoint 
flashintensitymcd Injured 
timepoint*flashintensitymcd
timepoint*Injured
flashintensitymcd*Injured
INTERCEPT=YES
  DISTRIBUTION=GAMMA 
LINK=LOG
   /CRITERIA METHOD=FISHER(1) 
SCALE=MLE
MAXITERATIONS=100
MAXSTEPHALVING=5
PCONVERGE=1E-006(ABSOLUTE)
SINGULAR=1E-012
ANALYSISTYPE=3(WALD)
CILEVEL=95 LIKELIHOOD=FULL
   /EMMEANS 
TABLES=timepoint*flashintensitymc
d*Injured SCALE=ORIGINAL
   /REPEATED SUBJECT=animal 
WITHINSUBJECT=Injured*timepoint
*flashintensitymcd SORT=YES 
CORRTYPE=AR(1)
ADJUSTCORR=YES
COVB=ROBUST
MAXITERATIONS=100
PCONVERGE=1e-006(ABSOLUTE)
UPDATECORR=1
   /MISSING 
CLASSMISSING=EXCLUDE
   /PRINT CPS DESCRIPTIVES ...
00:00:00.08
00:00:00.14
[DataSet5] C:\Users\Public\Documents\PhD\ERG\Results\T-CEM423-6\scotopic d
ata T.sav
Model Information
Dependent Variable
Probability Distribution
Link Function
Subject Effect 1
Within-Subject Effect 1
2
3
Working Correlation Matrix Structure
V12
Gamma
Log
animal
Injured
timepoint
flashintensitymcd
AR(1)
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Case Processing Summary
N Percent
Included
Excluded
Total
144 94.7%
8 5.3%
152 100.0%
Correlated Data Summary
Number of Levels Subject Effect animal
Within-Subject Effect Injured
timepoint
flashintensitymcd
Number of Subjects
Number of Measurements 
per Subject
Minimum
Maximum
Correlation Matrix Dimension
8
2
3
3
8
18
18
18
Categorical Variable Information
N Percent
Factor timepoint 2
7
14
Total
flashintensitymcd 10
3000
10000
Total
Injured 1
0
Total
48 33.3%
48 33.3%
48 33.3%
144 100.0%
48 33.3%
48 33.3%
48 33.3%
144 100.0%
72 50.0%
72 50.0%
144 100.0%
Continuous Variable Information
N Minimum Maximum Mean Std. Deviation
Dependent Variable V12 144 1 3436 119.25 472.496
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Goodness of Fita
Value
Quasi Likelihood under 
Independence Model 
Criterion (QIC)b
Corrected Quasi 
Likelihood under 
Independence Model 
Criterion (QICC)b
203.605
191.457
Dependent Variable: V12
 Model: (Intercept), timepoint, 
flashintensitymcd, Injured, timepoint * 
flashintensitymcd, timepoint * Injured, 
flashintensitymcd * Injured
Information criteria are in small-is-better form.a.
Computed using the full log quasi-likelihood function.b.
Tests of Model Effects
Source
Type III
Wald Chi-
Square df Sig.
(Intercept)
timepoint
flashintensitymcd
Injured
timepoint * 
flashintensitymcd
timepoint * Injured
flashintensitymcd * Injured
194.038 1 .000
19.726 2 .000
145.029 2 .000
.740 1 .390
248.600 4 .000
.700 2 .705
6.425 2 .040
Dependent Variable: V12
 Model: (Intercept), timepoint, flashintensitymcd, Injured, timepoint * 
flashintensitymcd, timepoint * Injured, flashintensitymcd * Injured
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Working Correlation Matrixa
Measurement
Measurement
[ Injured = 0 ]* 
[ timepoint = 2 
]* [ 
flashintensity
mcd = 10 ]
[ Injured = 0 ]* 
[ timepoint = 2 
]* [ 
flashintensity
mcd = 3000 ]
[ Injured = 0 ]* 
[ timepoint = 2 
]* [ 
flashintensity
mcd = 10000 ]
[ Injured = 0 ]* 
[ timepoint = 7 
]* [ 
flashintensity
mcd = 10 ]
[ Injured = 0 ]* [ timepoint 
= 2 ]* [ flashintensitymcd = 
10 ]
[ Injured = 0 ]* [ timepoint 
= 2 ]* [ flashintensitymcd = 
3000 ]
[ Injured = 0 ]* [ timepoint 
= 2 ]* [ flashintensitymcd = 
10000 ]
[ Injured = 0 ]* [ timepoint 
= 7 ]* [ flashintensitymcd = 
10 ]
[ Injured = 0 ]* [ timepoint 
= 7 ]* [ flashintensitymcd = 
3000 ]
[ Injured = 0 ]* [ timepoint 
= 7 ]* [ flashintensitymcd = 
10000 ]
[ Injured = 0 ]* [ timepoint 
= 14 ]* [ flashintensitymcd 
= 10 ]
[ Injured = 0 ]* [ timepoint 
= 14 ]* [ flashintensitymcd 
= 3000 ]
[ Injured = 0 ]* [ timepoint 
= 14 ]* [ flashintensitymcd 
= 10000 ]
[ Injured = 1 ]* [ timepoint 
= 2 ]* [ flashintensitymcd = 
10 ]
[ Injured = 1 ]* [ timepoint 
= 2 ]* [ flashintensitymcd = 
3000 ]
[ Injured = 1 ]* [ timepoint 
= 2 ]* [ flashintensitymcd = 
10000 ]
[ Injured = 1 ]* [ timepoint 
= 7 ]* [ flashintensitymcd = 
10 ]
[ Injured = 1 ]* [ timepoint 
= 7 ]* [ flashintensitymcd = 
3000 ]
1.000 .030 .001 .000
.030 1.000 .030 .001
.001 .030 1.000 .030
.000 .001 .030 1.000
.000 .000 .001 .030
.000 .000 .000 .001
.000 .000 .000 .000
.000 .000 .000 .000
.000 .000 .000 .000
.000 .000 .000 .000
.000 .000 .000 .000
.000 .000 .000 .000
.000 .000 .000 .000
.000 .000 .000 .000
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Working Correlation Matrixa
Measurement
Measurement
[ Injured = 0 ]* 
[ timepoint = 7 
]* [ 
flashintensity
mcd = 3000 ]
[ Injured = 0 ]* 
[ timepoint = 7 
]* [ 
flashintensity
mcd = 10000 ]
[ Injured = 0 ]* 
[ timepoint = 
14 ]* [ 
flashintensity
mcd = 10 ]
[ Injured = 0 ]* 
[ timepoint = 
14 ]* [ 
flashintensity
mcd = 3000 ]
[ Injured = 0 ]* [ timepoint 
= 2 ]* [ flashintensitymcd = 
10 ]
[ Injured = 0 ]* [ timepoint 
= 2 ]* [ flashintensitymcd = 
3000 ]
[ Injured = 0 ]* [ timepoint 
= 2 ]* [ flashintensitymcd = 
10000 ]
[ Injured = 0 ]* [ timepoint 
= 7 ]* [ flashintensitymcd = 
10 ]
[ Injured = 0 ]* [ timepoint 
= 7 ]* [ flashintensitymcd = 
3000 ]
[ Injured = 0 ]* [ timepoint 
= 7 ]* [ flashintensitymcd = 
10000 ]
[ Injured = 0 ]* [ timepoint 
= 14 ]* [ flashintensitymcd 
= 10 ]
[ Injured = 0 ]* [ timepoint 
= 14 ]* [ flashintensitymcd 
= 3000 ]
[ Injured = 0 ]* [ timepoint 
= 14 ]* [ flashintensitymcd 
= 10000 ]
[ Injured = 1 ]* [ timepoint 
= 2 ]* [ flashintensitymcd = 
10 ]
[ Injured = 1 ]* [ timepoint 
= 2 ]* [ flashintensitymcd = 
3000 ]
[ Injured = 1 ]* [ timepoint 
= 2 ]* [ flashintensitymcd = 
10000 ]
[ Injured = 1 ]* [ timepoint 
= 7 ]* [ flashintensitymcd = 
10 ]
[ Injured = 1 ]* [ timepoint 
= 7 ]* [ flashintensitymcd = 
3000 ]
.000 .000 .000 .000
.000 .000 .000 .000
.001 .000 .000 .000
.030 .001 .000 .000
1.000 .030 .001 .000
.030 1.000 .030 .001
.001 .030 1.000 .030
.000 .001 .030 1.000
.000 .000 .001 .030
.000 .000 .000 .001
.000 .000 .000 .000
.000 .000 .000 .000
.000 .000 .000 .000
.000 .000 .000 .000
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Working Correlation Matrixa
Measurement
Measurement
[ Injured = 0 ]* 
[ timepoint = 
14 ]* [ 
flashintensity
mcd = 10000 ]
[ Injured = 1 ]* 
[ timepoint = 2 
]* [ 
flashintensity
mcd = 10 ]
[ Injured = 1 ]* 
[ timepoint = 2 
]* [ 
flashintensity
mcd = 3000 ]
[ Injured = 1 ]* 
[ timepoint = 2 
]* [ 
flashintensity
mcd = 10000 ]
[ Injured = 0 ]* [ timepoint 
= 2 ]* [ flashintensitymcd = 
10 ]
[ Injured = 0 ]* [ timepoint 
= 2 ]* [ flashintensitymcd = 
3000 ]
[ Injured = 0 ]* [ timepoint 
= 2 ]* [ flashintensitymcd = 
10000 ]
[ Injured = 0 ]* [ timepoint 
= 7 ]* [ flashintensitymcd = 
10 ]
[ Injured = 0 ]* [ timepoint 
= 7 ]* [ flashintensitymcd = 
3000 ]
[ Injured = 0 ]* [ timepoint 
= 7 ]* [ flashintensitymcd = 
10000 ]
[ Injured = 0 ]* [ timepoint 
= 14 ]* [ flashintensitymcd 
= 10 ]
[ Injured = 0 ]* [ timepoint 
= 14 ]* [ flashintensitymcd 
= 3000 ]
[ Injured = 0 ]* [ timepoint 
= 14 ]* [ flashintensitymcd 
= 10000 ]
[ Injured = 1 ]* [ timepoint 
= 2 ]* [ flashintensitymcd = 
10 ]
[ Injured = 1 ]* [ timepoint 
= 2 ]* [ flashintensitymcd = 
3000 ]
[ Injured = 1 ]* [ timepoint 
= 2 ]* [ flashintensitymcd = 
10000 ]
[ Injured = 1 ]* [ timepoint 
= 7 ]* [ flashintensitymcd = 
10 ]
[ Injured = 1 ]* [ timepoint 
= 7 ]* [ flashintensitymcd = 
3000 ]
.000 .000 .000 .000
.000 .000 .000 .000
.000 .000 .000 .000
.000 .000 .000 .000
.000 .000 .000 .000
.000 .000 .000 .000
.001 .000 .000 .000
.030 .001 .000 .000
1.000 .030 .001 .000
.030 1.000 .030 .001
.001 .030 1.000 .030
.000 .001 .030 1.000
.000 .000 .001 .030
.000 .000 .000 .001
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Working Correlation Matrixa
Measurement
Measurement
[ Injured = 1 ]* 
[ timepoint = 7 
]* [ 
flashintensity
mcd = 10 ]
[ Injured = 1 ]* 
[ timepoint = 7 
]* [ 
flashintensity
mcd = 3000 ]
[ Injured = 1 ]* 
[ timepoint = 7 
]* [ 
flashintensity
mcd = 10000 ]
[ Injured = 1 ]* 
[ timepoint = 
14 ]* [ 
flashintensity
mcd = 10 ]
[ Injured = 0 ]* [ timepoint 
= 2 ]* [ flashintensitymcd = 
10 ]
[ Injured = 0 ]* [ timepoint 
= 2 ]* [ flashintensitymcd = 
3000 ]
[ Injured = 0 ]* [ timepoint 
= 2 ]* [ flashintensitymcd = 
10000 ]
[ Injured = 0 ]* [ timepoint 
= 7 ]* [ flashintensitymcd = 
10 ]
[ Injured = 0 ]* [ timepoint 
= 7 ]* [ flashintensitymcd = 
3000 ]
[ Injured = 0 ]* [ timepoint 
= 7 ]* [ flashintensitymcd = 
10000 ]
[ Injured = 0 ]* [ timepoint 
= 14 ]* [ flashintensitymcd 
= 10 ]
[ Injured = 0 ]* [ timepoint 
= 14 ]* [ flashintensitymcd 
= 3000 ]
[ Injured = 0 ]* [ timepoint 
= 14 ]* [ flashintensitymcd 
= 10000 ]
[ Injured = 1 ]* [ timepoint 
= 2 ]* [ flashintensitymcd = 
10 ]
[ Injured = 1 ]* [ timepoint 
= 2 ]* [ flashintensitymcd = 
3000 ]
[ Injured = 1 ]* [ timepoint 
= 2 ]* [ flashintensitymcd = 
10000 ]
[ Injured = 1 ]* [ timepoint 
= 7 ]* [ flashintensitymcd = 
10 ]
[ Injured = 1 ]* [ timepoint 
= 7 ]* [ flashintensitymcd = 
3000 ]
.000 .000 .000 .000
.000 .000 .000 .000
.000 .000 .000 .000
.000 .000 .000 .000
.000 .000 .000 .000
.000 .000 .000 .000
.000 .000 .000 .000
.000 .000 .000 .000
.000 .000 .000 .000
.000 .000 .000 .000
.001 .000 .000 .000
.030 .001 .000 .000
1.000 .030 .001 .000
.030 1.000 .030 .001
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Working Correlation Matrixa
Measurement
Measurement
[ Injured = 1 ]* 
[ timepoint = 
14 ]* [ 
flashintensity
mcd = 3000 ]
[ Injured = 1 ]* 
[ timepoint = 
14 ]* [ 
flashintensity
mcd = 10000 ]
[ Injured = 0 ]* [ timepoint 
= 2 ]* [ flashintensitymcd = 
10 ]
[ Injured = 0 ]* [ timepoint 
= 2 ]* [ flashintensitymcd = 
3000 ]
[ Injured = 0 ]* [ timepoint 
= 2 ]* [ flashintensitymcd = 
10000 ]
[ Injured = 0 ]* [ timepoint 
= 7 ]* [ flashintensitymcd = 
10 ]
[ Injured = 0 ]* [ timepoint 
= 7 ]* [ flashintensitymcd = 
3000 ]
[ Injured = 0 ]* [ timepoint 
= 7 ]* [ flashintensitymcd = 
10000 ]
[ Injured = 0 ]* [ timepoint 
= 14 ]* [ flashintensitymcd 
= 10 ]
[ Injured = 0 ]* [ timepoint 
= 14 ]* [ flashintensitymcd 
= 3000 ]
[ Injured = 0 ]* [ timepoint 
= 14 ]* [ flashintensitymcd 
= 10000 ]
[ Injured = 1 ]* [ timepoint 
= 2 ]* [ flashintensitymcd = 
10 ]
[ Injured = 1 ]* [ timepoint 
= 2 ]* [ flashintensitymcd = 
3000 ]
[ Injured = 1 ]* [ timepoint 
= 2 ]* [ flashintensitymcd = 
10000 ]
[ Injured = 1 ]* [ timepoint 
= 7 ]* [ flashintensitymcd = 
10 ]
[ Injured = 1 ]* [ timepoint 
= 7 ]* [ flashintensitymcd = 
3000 ]
.000 .000
.000 .000
.000 .000
.000 .000
.000 .000
.000 .000
.000 .000
.000 .000
.000 .000
.000 .000
.000 .000
.000 .000
.000 .000
.000 .000
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Working Correlation Matrixa
Measurement
Measurement
[ Injured = 0 ]* 
[ timepoint = 2 
]* [ 
flashintensity
mcd = 10 ]
[ Injured = 0 ]* 
[ timepoint = 2 
]* [ 
flashintensity
mcd = 3000 ]
[ Injured = 0 ]* 
[ timepoint = 2 
]* [ 
flashintensity
mcd = 10000 ]
[ Injured = 0 ]* 
[ timepoint = 7 
]* [ 
flashintensity
mcd = 10 ]
[ Injured = 1 ]* [ timepoint 
= 7 ]* [ flashintensitymcd = 
10000 ]
[ Injured = 1 ]* [ timepoint 
= 14 ]* [ flashintensitymcd 
= 10 ]
[ Injured = 1 ]* [ timepoint 
= 14 ]* [ flashintensitymcd 
= 3000 ]
[ Injured = 1 ]* [ timepoint 
= 14 ]* [ flashintensitymcd 
= 10000 ]
.000 .000 .000 .000
.000 .000 .000 .000
.000 .000 .000 .000
.000 .000 .000 .000
Working Correlation Matrixa
Measurement
Measurement
[ Injured = 0 ]* 
[ timepoint = 7 
]* [ 
flashintensity
mcd = 3000 ]
[ Injured = 0 ]* 
[ timepoint = 7 
]* [ 
flashintensity
mcd = 10000 ]
[ Injured = 0 ]* 
[ timepoint = 
14 ]* [ 
flashintensity
mcd = 10 ]
[ Injured = 0 ]* 
[ timepoint = 
14 ]* [ 
flashintensity
mcd = 3000 ]
[ Injured = 1 ]* [ timepoint 
= 7 ]* [ flashintensitymcd = 
10000 ]
[ Injured = 1 ]* [ timepoint 
= 14 ]* [ flashintensitymcd 
= 10 ]
[ Injured = 1 ]* [ timepoint 
= 14 ]* [ flashintensitymcd 
= 3000 ]
[ Injured = 1 ]* [ timepoint 
= 14 ]* [ flashintensitymcd 
= 10000 ]
.000 .000 .000 .000
.000 .000 .000 .000
.000 .000 .000 .000
.000 .000 .000 .000
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Working Correlation Matrixa
Measurement
Measurement
[ Injured = 0 ]* 
[ timepoint = 
14 ]* [ 
flashintensity
mcd = 10000 ]
[ Injured = 1 ]* 
[ timepoint = 2 
]* [ 
flashintensity
mcd = 10 ]
[ Injured = 1 ]* 
[ timepoint = 2 
]* [ 
flashintensity
mcd = 3000 ]
[ Injured = 1 ]* 
[ timepoint = 2 
]* [ 
flashintensity
mcd = 10000 ]
[ Injured = 1 ]* [ timepoint 
= 7 ]* [ flashintensitymcd = 
10000 ]
[ Injured = 1 ]* [ timepoint 
= 14 ]* [ flashintensitymcd 
= 10 ]
[ Injured = 1 ]* [ timepoint 
= 14 ]* [ flashintensitymcd 
= 3000 ]
[ Injured = 1 ]* [ timepoint 
= 14 ]* [ flashintensitymcd 
= 10000 ]
.000 .000 .000 .000
.000 .000 .000 .000
.000 .000 .000 .000
.000 .000 .000 .000
Working Correlation Matrixa
Measurement
Measurement
[ Injured = 1 ]* 
[ timepoint = 7 
]* [ 
flashintensity
mcd = 10 ]
[ Injured = 1 ]* 
[ timepoint = 7 
]* [ 
flashintensity
mcd = 3000 ]
[ Injured = 1 ]* 
[ timepoint = 7 
]* [ 
flashintensity
mcd = 10000 ]
[ Injured = 1 ]* 
[ timepoint = 
14 ]* [ 
flashintensity
mcd = 10 ]
[ Injured = 1 ]* [ timepoint 
= 7 ]* [ flashintensitymcd = 
10000 ]
[ Injured = 1 ]* [ timepoint 
= 14 ]* [ flashintensitymcd 
= 10 ]
[ Injured = 1 ]* [ timepoint 
= 14 ]* [ flashintensitymcd 
= 3000 ]
[ Injured = 1 ]* [ timepoint 
= 14 ]* [ flashintensitymcd 
= 10000 ]
.001 .030 1.000 .030
.000 .001 .030 1.000
.000 .000 .001 .030
.000 .000 .000 .001
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Working Correlation Matrixa
Measurement
Measurement
[ Injured = 1 ]* 
[ timepoint = 
14 ]* [ 
flashintensity
mcd = 3000 ]
[ Injured = 1 ]* 
[ timepoint = 
14 ]* [ 
flashintensity
mcd = 10000 ]
[ Injured = 1 ]* [ timepoint 
= 7 ]* [ flashintensitymcd = 
10000 ]
[ Injured = 1 ]* [ timepoint 
= 14 ]* [ flashintensitymcd 
= 10 ]
[ Injured = 1 ]* [ timepoint 
= 14 ]* [ flashintensitymcd 
= 3000 ]
[ Injured = 1 ]* [ timepoint 
= 14 ]* [ flashintensitymcd 
= 10000 ]
.001 .000
.030 .001
1.000 .030
.030 1.000
Dependent Variable: V12
 Model: (Intercept), timepoint, flashintensitymcd, Injured, timepoint * flashintensitymcd, timepoint * Injured, 
flashintensitymcd * Injured
The AR(1) working correlation matrix structure is computed assuming the measurements are equally 
spaced for all subjects.
a.
Estimated Marginal Means: timepoint* flashintensitymcd* Injured
Estimates
timepoint flashintensitymcd Injured Mean Std. Error
95% Wald Confidence Interval
Lower Upper
2 10 1
0
3000 1
0
10000 1
0
7 10 1
0
3000 1
0
10000 1
0
14 10 1
0
3000 1
0
10000 1
0
58.01 38.001 16.07 209.46
33.70 10.308 18.50 61.37
3.43 .914 2.03 5.78
2.79 .807 1.58 4.92
2.32 .407 1.64 3.27
2.05 .569 1.19 3.53
718.53 263.253 350.42 1473.35
605.85 356.328 191.31 1918.65
2.07 .197 1.72 2.50
2.45 .353 1.85 3.25
1.75 .156 1.47 2.08
2.25 .265 1.79 2.83
409.02 303.826 95.38 1754.00
313.44 233.939 72.59 1353.50
1.99 .200 1.63 2.42
2.13 .198 1.78 2.56
1.90 .198 1.55 2.33
2.22 .284 1.73 2.85
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* Generalized Estimating Equations.
GENLIN V12 BY timepoint flashintensitymcd Injured (ORDER=DATA)
  /MODEL timepoint flashintensitymcd Injured timepoint*flashintensitymcd flashintensitymcd*I
 DISTRIBUTION=GAMMA LINK=LOG
  /CRITERIA METHOD=FISHER(1) SCALE=MLE MAXITERATIONS=100 MAXSTEPHALVING=5 PCONVERGE=1E-006(A
  /EMMEANS TABLES=timepoint*flashintensitymcd*Injured SCALE=ORIGINAL
  /REPEATED SUBJECT=animal WITHINSUBJECT=Injured*timepoint*flashintensitymcd SORT=YES CORRTY
  /MISSING CLASSMISSING=EXCLUDE
  /PRINT CPS DESCRIPTIVES MODELINFO FIT SUMMARY WORKINGCORR.
Generalized Linear Models
Notes
Output Created
Comments
Input Data
Active Dataset
Filter
Weight
Split File
N of Rows in Working 
Data File
Missing Value Handling Definition of Missing
Cases Used
Weight Handling
02-MAY-2013 10:15:22
C:
\Users\Public\Documents\PhD\ERG\
Results\T-CEM423-6\scotopic data 
T.sav
DataSet5
<none>
<none>
<none>
152
User-defined missing values for 
factor, subject and within-subject 
variables are treated as missing.
Statistics are based on cases with 
valid data for all variables in the 
model.
not applicable
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Notes
Syntax
Resources Processor Time
Elapsed Time
GENLIN V12 BY timepoint 
flashintensitymcd Injured 
(ORDER=DATA)
   /MODEL timepoint 
flashintensitymcd Injured 
timepoint*flashintensitymcd
flashintensitymcd*Injured
INTERCEPT=YES
  DISTRIBUTION=GAMMA 
LINK=LOG
   /CRITERIA METHOD=FISHER(1) 
SCALE=MLE
MAXITERATIONS=100
MAXSTEPHALVING=5
PCONVERGE=1E-006(ABSOLUTE)
SINGULAR=1E-012
ANALYSISTYPE=3(WALD)
CILEVEL=95 LIKELIHOOD=FULL
   /EMMEANS 
TABLES=timepoint*flashintensitymc
d*Injured SCALE=ORIGINAL
   /REPEATED SUBJECT=animal 
WITHINSUBJECT=Injured*timepoint
*flashintensitymcd SORT=YES 
CORRTYPE=AR(1)
ADJUSTCORR=YES
COVB=ROBUST
MAXITERATIONS=100
PCONVERGE=1e-006(ABSOLUTE)
UPDATECORR=1
   /MISSING 
CLASSMISSING=EXCLUDE
   /PRINT CPS DESCRIPTIVES ...
00:00:00.13
00:00:00.14
[DataSet5] C:\Users\Public\Documents\PhD\ERG\Results\T-CEM423-6\scotopic d
ata T.sav
Model Information
Dependent Variable
Probability Distribution
Link Function
Subject Effect 1
Within-Subject Effect 1
2
3
Working Correlation Matrix Structure
V12
Gamma
Log
animal
Injured
timepoint
flashintensitymcd
AR(1)
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Case Processing Summary
N Percent
Included
Excluded
Total
144 94.7%
8 5.3%
152 100.0%
Correlated Data Summary
Number of Levels Subject Effect animal
Within-Subject Effect Injured
timepoint
flashintensitymcd
Number of Subjects
Number of Measurements 
per Subject
Minimum
Maximum
Correlation Matrix Dimension
8
2
3
3
8
18
18
18
Categorical Variable Information
N Percent
Factor timepoint 2
7
14
Total
flashintensitymcd 10
3000
10000
Total
Injured 1
0
Total
48 33.3%
48 33.3%
48 33.3%
144 100.0%
48 33.3%
48 33.3%
48 33.3%
144 100.0%
72 50.0%
72 50.0%
144 100.0%
Continuous Variable Information
N Minimum Maximum Mean Std. Deviation
Dependent Variable V12 144 1 3436 119.25 472.496
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Goodness of Fita
Value
Quasi Likelihood under 
Independence Model 
Criterion (QIC)b
Corrected Quasi 
Likelihood under 
Independence Model 
Criterion (QICC)b
202.567
188.305
Dependent Variable: V12
 Model: (Intercept), timepoint, 
flashintensitymcd, Injured, timepoint * 
flashintensitymcd, flashintensitymcd * 
Injured
Information criteria are in small-is-better form.a.
Computed using the full log quasi-likelihood function.b.
Tests of Model Effects
Source
Type III
Wald Chi-
Square df Sig.
(Intercept)
timepoint
flashintensitymcd
Injured
timepoint * 
flashintensitymcd
flashintensitymcd * Injured
183.994 1 .000
19.088 2 .000
132.105 2 .000
.676 1 .411
244.249 4 .000
5.393 2 .067
Dependent Variable: V12
 Model: (Intercept), timepoint, flashintensitymcd, Injured, timepoint * 
flashintensitymcd, flashintensitymcd * Injured
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Working Correlation Matrixa
Measurement
Measurement
[ Injured = 0 ]* 
[ timepoint = 2 
]* [ 
flashintensity
mcd = 10 ]
[ Injured = 0 ]* 
[ timepoint = 2 
]* [ 
flashintensity
mcd = 3000 ]
[ Injured = 0 ]* 
[ timepoint = 2 
]* [ 
flashintensity
mcd = 10000 ]
[ Injured = 0 ]* 
[ timepoint = 7 
]* [ 
flashintensity
mcd = 10 ]
[ Injured = 0 ]* [ timepoint 
= 2 ]* [ flashintensitymcd = 
10 ]
[ Injured = 0 ]* [ timepoint 
= 2 ]* [ flashintensitymcd = 
3000 ]
[ Injured = 0 ]* [ timepoint 
= 2 ]* [ flashintensitymcd = 
10000 ]
[ Injured = 0 ]* [ timepoint 
= 7 ]* [ flashintensitymcd = 
10 ]
[ Injured = 0 ]* [ timepoint 
= 7 ]* [ flashintensitymcd = 
3000 ]
[ Injured = 0 ]* [ timepoint 
= 7 ]* [ flashintensitymcd = 
10000 ]
[ Injured = 0 ]* [ timepoint 
= 14 ]* [ flashintensitymcd 
= 10 ]
[ Injured = 0 ]* [ timepoint 
= 14 ]* [ flashintensitymcd 
= 3000 ]
[ Injured = 0 ]* [ timepoint 
= 14 ]* [ flashintensitymcd 
= 10000 ]
[ Injured = 1 ]* [ timepoint 
= 2 ]* [ flashintensitymcd = 
10 ]
[ Injured = 1 ]* [ timepoint 
= 2 ]* [ flashintensitymcd = 
3000 ]
[ Injured = 1 ]* [ timepoint 
= 2 ]* [ flashintensitymcd = 
10000 ]
[ Injured = 1 ]* [ timepoint 
= 7 ]* [ flashintensitymcd = 
10 ]
[ Injured = 1 ]* [ timepoint 
= 7 ]* [ flashintensitymcd = 
3000 ]
1.000 .026 .001 .000
.026 1.000 .026 .001
.001 .026 1.000 .026
.000 .001 .026 1.000
.000 .000 .001 .026
.000 .000 .000 .001
.000 .000 .000 .000
.000 .000 .000 .000
.000 .000 .000 .000
.000 .000 .000 .000
.000 .000 .000 .000
.000 .000 .000 .000
.000 .000 .000 .000
.000 .000 .000 .000
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Working Correlation Matrixa
Measurement
Measurement
[ Injured = 0 ]* 
[ timepoint = 7 
]* [ 
flashintensity
mcd = 3000 ]
[ Injured = 0 ]* 
[ timepoint = 7 
]* [ 
flashintensity
mcd = 10000 ]
[ Injured = 0 ]* 
[ timepoint = 
14 ]* [ 
flashintensity
mcd = 10 ]
[ Injured = 0 ]* 
[ timepoint = 
14 ]* [ 
flashintensity
mcd = 3000 ]
[ Injured = 0 ]* [ timepoint 
= 2 ]* [ flashintensitymcd = 
10 ]
[ Injured = 0 ]* [ timepoint 
= 2 ]* [ flashintensitymcd = 
3000 ]
[ Injured = 0 ]* [ timepoint 
= 2 ]* [ flashintensitymcd = 
10000 ]
[ Injured = 0 ]* [ timepoint 
= 7 ]* [ flashintensitymcd = 
10 ]
[ Injured = 0 ]* [ timepoint 
= 7 ]* [ flashintensitymcd = 
3000 ]
[ Injured = 0 ]* [ timepoint 
= 7 ]* [ flashintensitymcd = 
10000 ]
[ Injured = 0 ]* [ timepoint 
= 14 ]* [ flashintensitymcd 
= 10 ]
[ Injured = 0 ]* [ timepoint 
= 14 ]* [ flashintensitymcd 
= 3000 ]
[ Injured = 0 ]* [ timepoint 
= 14 ]* [ flashintensitymcd 
= 10000 ]
[ Injured = 1 ]* [ timepoint 
= 2 ]* [ flashintensitymcd = 
10 ]
[ Injured = 1 ]* [ timepoint 
= 2 ]* [ flashintensitymcd = 
3000 ]
[ Injured = 1 ]* [ timepoint 
= 2 ]* [ flashintensitymcd = 
10000 ]
[ Injured = 1 ]* [ timepoint 
= 7 ]* [ flashintensitymcd = 
10 ]
[ Injured = 1 ]* [ timepoint 
= 7 ]* [ flashintensitymcd = 
3000 ]
.000 .000 .000 .000
.000 .000 .000 .000
.001 .000 .000 .000
.026 .001 .000 .000
1.000 .026 .001 .000
.026 1.000 .026 .001
.001 .026 1.000 .026
.000 .001 .026 1.000
.000 .000 .001 .026
.000 .000 .000 .001
.000 .000 .000 .000
.000 .000 .000 .000
.000 .000 .000 .000
.000 .000 .000 .000
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Working Correlation Matrixa
Measurement
Measurement
[ Injured = 0 ]* 
[ timepoint = 
14 ]* [ 
flashintensity
mcd = 10000 ]
[ Injured = 1 ]* 
[ timepoint = 2 
]* [ 
flashintensity
mcd = 10 ]
[ Injured = 1 ]* 
[ timepoint = 2 
]* [ 
flashintensity
mcd = 3000 ]
[ Injured = 1 ]* 
[ timepoint = 2 
]* [ 
flashintensity
mcd = 10000 ]
[ Injured = 0 ]* [ timepoint 
= 2 ]* [ flashintensitymcd = 
10 ]
[ Injured = 0 ]* [ timepoint 
= 2 ]* [ flashintensitymcd = 
3000 ]
[ Injured = 0 ]* [ timepoint 
= 2 ]* [ flashintensitymcd = 
10000 ]
[ Injured = 0 ]* [ timepoint 
= 7 ]* [ flashintensitymcd = 
10 ]
[ Injured = 0 ]* [ timepoint 
= 7 ]* [ flashintensitymcd = 
3000 ]
[ Injured = 0 ]* [ timepoint 
= 7 ]* [ flashintensitymcd = 
10000 ]
[ Injured = 0 ]* [ timepoint 
= 14 ]* [ flashintensitymcd 
= 10 ]
[ Injured = 0 ]* [ timepoint 
= 14 ]* [ flashintensitymcd 
= 3000 ]
[ Injured = 0 ]* [ timepoint 
= 14 ]* [ flashintensitymcd 
= 10000 ]
[ Injured = 1 ]* [ timepoint 
= 2 ]* [ flashintensitymcd = 
10 ]
[ Injured = 1 ]* [ timepoint 
= 2 ]* [ flashintensitymcd = 
3000 ]
[ Injured = 1 ]* [ timepoint 
= 2 ]* [ flashintensitymcd = 
10000 ]
[ Injured = 1 ]* [ timepoint 
= 7 ]* [ flashintensitymcd = 
10 ]
[ Injured = 1 ]* [ timepoint 
= 7 ]* [ flashintensitymcd = 
3000 ]
.000 .000 .000 .000
.000 .000 .000 .000
.000 .000 .000 .000
.000 .000 .000 .000
.000 .000 .000 .000
.000 .000 .000 .000
.001 .000 .000 .000
.026 .001 .000 .000
1.000 .026 .001 .000
.026 1.000 .026 .001
.001 .026 1.000 .026
.000 .001 .026 1.000
.000 .000 .001 .026
.000 .000 .000 .001
Page 31
Appendix 9, p32
Working Correlation Matrixa
Measurement
Measurement
[ Injured = 1 ]* 
[ timepoint = 7 
]* [ 
flashintensity
mcd = 10 ]
[ Injured = 1 ]* 
[ timepoint = 7 
]* [ 
flashintensity
mcd = 3000 ]
[ Injured = 1 ]* 
[ timepoint = 7 
]* [ 
flashintensity
mcd = 10000 ]
[ Injured = 1 ]* 
[ timepoint = 
14 ]* [ 
flashintensity
mcd = 10 ]
[ Injured = 0 ]* [ timepoint 
= 2 ]* [ flashintensitymcd = 
10 ]
[ Injured = 0 ]* [ timepoint 
= 2 ]* [ flashintensitymcd = 
3000 ]
[ Injured = 0 ]* [ timepoint 
= 2 ]* [ flashintensitymcd = 
10000 ]
[ Injured = 0 ]* [ timepoint 
= 7 ]* [ flashintensitymcd = 
10 ]
[ Injured = 0 ]* [ timepoint 
= 7 ]* [ flashintensitymcd = 
3000 ]
[ Injured = 0 ]* [ timepoint 
= 7 ]* [ flashintensitymcd = 
10000 ]
[ Injured = 0 ]* [ timepoint 
= 14 ]* [ flashintensitymcd 
= 10 ]
[ Injured = 0 ]* [ timepoint 
= 14 ]* [ flashintensitymcd 
= 3000 ]
[ Injured = 0 ]* [ timepoint 
= 14 ]* [ flashintensitymcd 
= 10000 ]
[ Injured = 1 ]* [ timepoint 
= 2 ]* [ flashintensitymcd = 
10 ]
[ Injured = 1 ]* [ timepoint 
= 2 ]* [ flashintensitymcd = 
3000 ]
[ Injured = 1 ]* [ timepoint 
= 2 ]* [ flashintensitymcd = 
10000 ]
[ Injured = 1 ]* [ timepoint 
= 7 ]* [ flashintensitymcd = 
10 ]
[ Injured = 1 ]* [ timepoint 
= 7 ]* [ flashintensitymcd = 
3000 ]
.000 .000 .000 .000
.000 .000 .000 .000
.000 .000 .000 .000
.000 .000 .000 .000
.000 .000 .000 .000
.000 .000 .000 .000
.000 .000 .000 .000
.000 .000 .000 .000
.000 .000 .000 .000
.000 .000 .000 .000
.001 .000 .000 .000
.026 .001 .000 .000
1.000 .026 .001 .000
.026 1.000 .026 .001
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Working Correlation Matrixa
Measurement
Measurement
[ Injured = 1 ]* 
[ timepoint = 
14 ]* [ 
flashintensity
mcd = 3000 ]
[ Injured = 1 ]* 
[ timepoint = 
14 ]* [ 
flashintensity
mcd = 10000 ]
[ Injured = 0 ]* [ timepoint 
= 2 ]* [ flashintensitymcd = 
10 ]
[ Injured = 0 ]* [ timepoint 
= 2 ]* [ flashintensitymcd = 
3000 ]
[ Injured = 0 ]* [ timepoint 
= 2 ]* [ flashintensitymcd = 
10000 ]
[ Injured = 0 ]* [ timepoint 
= 7 ]* [ flashintensitymcd = 
10 ]
[ Injured = 0 ]* [ timepoint 
= 7 ]* [ flashintensitymcd = 
3000 ]
[ Injured = 0 ]* [ timepoint 
= 7 ]* [ flashintensitymcd = 
10000 ]
[ Injured = 0 ]* [ timepoint 
= 14 ]* [ flashintensitymcd 
= 10 ]
[ Injured = 0 ]* [ timepoint 
= 14 ]* [ flashintensitymcd 
= 3000 ]
[ Injured = 0 ]* [ timepoint 
= 14 ]* [ flashintensitymcd 
= 10000 ]
[ Injured = 1 ]* [ timepoint 
= 2 ]* [ flashintensitymcd = 
10 ]
[ Injured = 1 ]* [ timepoint 
= 2 ]* [ flashintensitymcd = 
3000 ]
[ Injured = 1 ]* [ timepoint 
= 2 ]* [ flashintensitymcd = 
10000 ]
[ Injured = 1 ]* [ timepoint 
= 7 ]* [ flashintensitymcd = 
10 ]
[ Injured = 1 ]* [ timepoint 
= 7 ]* [ flashintensitymcd = 
3000 ]
.000 .000
.000 .000
.000 .000
.000 .000
.000 .000
.000 .000
.000 .000
.000 .000
.000 .000
.000 .000
.000 .000
.000 .000
.000 .000
.000 .000
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Working Correlation Matrixa
Measurement
Measurement
[ Injured = 0 ]* 
[ timepoint = 2 
]* [ 
flashintensity
mcd = 10 ]
[ Injured = 0 ]* 
[ timepoint = 2 
]* [ 
flashintensity
mcd = 3000 ]
[ Injured = 0 ]* 
[ timepoint = 2 
]* [ 
flashintensity
mcd = 10000 ]
[ Injured = 0 ]* 
[ timepoint = 7 
]* [ 
flashintensity
mcd = 10 ]
[ Injured = 1 ]* [ timepoint 
= 7 ]* [ flashintensitymcd = 
10000 ]
[ Injured = 1 ]* [ timepoint 
= 14 ]* [ flashintensitymcd 
= 10 ]
[ Injured = 1 ]* [ timepoint 
= 14 ]* [ flashintensitymcd 
= 3000 ]
[ Injured = 1 ]* [ timepoint 
= 14 ]* [ flashintensitymcd 
= 10000 ]
.000 .000 .000 .000
.000 .000 .000 .000
.000 .000 .000 .000
.000 .000 .000 .000
Working Correlation Matrixa
Measurement
Measurement
[ Injured = 0 ]* 
[ timepoint = 7 
]* [ 
flashintensity
mcd = 3000 ]
[ Injured = 0 ]* 
[ timepoint = 7 
]* [ 
flashintensity
mcd = 10000 ]
[ Injured = 0 ]* 
[ timepoint = 
14 ]* [ 
flashintensity
mcd = 10 ]
[ Injured = 0 ]* 
[ timepoint = 
14 ]* [ 
flashintensity
mcd = 3000 ]
[ Injured = 1 ]* [ timepoint 
= 7 ]* [ flashintensitymcd = 
10000 ]
[ Injured = 1 ]* [ timepoint 
= 14 ]* [ flashintensitymcd 
= 10 ]
[ Injured = 1 ]* [ timepoint 
= 14 ]* [ flashintensitymcd 
= 3000 ]
[ Injured = 1 ]* [ timepoint 
= 14 ]* [ flashintensitymcd 
= 10000 ]
.000 .000 .000 .000
.000 .000 .000 .000
.000 .000 .000 .000
.000 .000 .000 .000
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Working Correlation Matrixa
Measurement
Measurement
[ Injured = 0 ]* 
[ timepoint = 
14 ]* [ 
flashintensity
mcd = 10000 ]
[ Injured = 1 ]* 
[ timepoint = 2 
]* [ 
flashintensity
mcd = 10 ]
[ Injured = 1 ]* 
[ timepoint = 2 
]* [ 
flashintensity
mcd = 3000 ]
[ Injured = 1 ]* 
[ timepoint = 2 
]* [ 
flashintensity
mcd = 10000 ]
[ Injured = 1 ]* [ timepoint 
= 7 ]* [ flashintensitymcd = 
10000 ]
[ Injured = 1 ]* [ timepoint 
= 14 ]* [ flashintensitymcd 
= 10 ]
[ Injured = 1 ]* [ timepoint 
= 14 ]* [ flashintensitymcd 
= 3000 ]
[ Injured = 1 ]* [ timepoint 
= 14 ]* [ flashintensitymcd 
= 10000 ]
.000 .000 .000 .000
.000 .000 .000 .000
.000 .000 .000 .000
.000 .000 .000 .000
Working Correlation Matrixa
Measurement
Measurement
[ Injured = 1 ]* 
[ timepoint = 7 
]* [ 
flashintensity
mcd = 10 ]
[ Injured = 1 ]* 
[ timepoint = 7 
]* [ 
flashintensity
mcd = 3000 ]
[ Injured = 1 ]* 
[ timepoint = 7 
]* [ 
flashintensity
mcd = 10000 ]
[ Injured = 1 ]* 
[ timepoint = 
14 ]* [ 
flashintensity
mcd = 10 ]
[ Injured = 1 ]* [ timepoint 
= 7 ]* [ flashintensitymcd = 
10000 ]
[ Injured = 1 ]* [ timepoint 
= 14 ]* [ flashintensitymcd 
= 10 ]
[ Injured = 1 ]* [ timepoint 
= 14 ]* [ flashintensitymcd 
= 3000 ]
[ Injured = 1 ]* [ timepoint 
= 14 ]* [ flashintensitymcd 
= 10000 ]
.001 .026 1.000 .026
.000 .001 .026 1.000
.000 .000 .001 .026
.000 .000 .000 .001
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Working Correlation Matrixa
Measurement
Measurement
[ Injured = 1 ]* 
[ timepoint = 
14 ]* [ 
flashintensity
mcd = 3000 ]
[ Injured = 1 ]* 
[ timepoint = 
14 ]* [ 
flashintensity
mcd = 10000 ]
[ Injured = 1 ]* [ timepoint 
= 7 ]* [ flashintensitymcd = 
10000 ]
[ Injured = 1 ]* [ timepoint 
= 14 ]* [ flashintensitymcd 
= 10 ]
[ Injured = 1 ]* [ timepoint 
= 14 ]* [ flashintensitymcd 
= 3000 ]
[ Injured = 1 ]* [ timepoint 
= 14 ]* [ flashintensitymcd 
= 10000 ]
.001 .000
.026 .001
1.000 .026
.026 1.000
Dependent Variable: V12
 Model: (Intercept), timepoint, flashintensitymcd, Injured, timepoint * flashintensitymcd, flashintensitymcd * 
Injured
The AR(1) working correlation matrix structure is computed assuming the measurements are equally 
spaced for all subjects.
a.
Estimated Marginal Means: timepoint* flashintensitymcd* Injured
Estimates
timepoint flashintensitymcd Injured Mean Std. Error
95% Wald Confidence Interval
Lower Upper
2 10 1
0
3000 1
0
10000 1
0
7 10 1
0
3000 1
0
10000 1
0
14 10 1
0
3000 1
0
10000 1
0
53.53 30.159 17.74 161.50
38.73 18.248 15.38 97.52
3.06 .799 1.83 5.10
3.09 .660 2.04 4.70
2.06 .341 1.49 2.85
2.27 .403 1.60 3.21
790.32 335.884 343.59 1817.86
571.83 314.181 194.80 1678.58
2.23 .171 1.92 2.59
2.26 .193 1.91 2.67
1.88 .124 1.65 2.14
2.07 .139 1.81 2.36
421.25 338.481 87.21 2034.68
304.79 210.675 78.64 1181.31
2.05 .138 1.79 2.34
2.07 .133 1.83 2.35
1.96 .168 1.66 2.32
2.15 .217 1.77 2.62
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* Generalized Estimating Equations.
GENLIN V12 BY timepoint flashintensitymcd Injured (ORDER=DATA)
  /MODEL timepoint flashintensitymcd Injured timepoint*flashintensitymcd INTERCEPT=YES
 DISTRIBUTION=GAMMA LINK=LOG
  /CRITERIA METHOD=FISHER(1) SCALE=MLE MAXITERATIONS=100 MAXSTEPHALVING=5 PCONVERGE=1E-006(A
  /EMMEANS TABLES=timepoint*flashintensitymcd*Injured SCALE=ORIGINAL
  /REPEATED SUBJECT=animal WITHINSUBJECT=Injured*timepoint*flashintensitymcd SORT=YES CORRTY
  /MISSING CLASSMISSING=EXCLUDE
  /PRINT CPS DESCRIPTIVES MODELINFO FIT SUMMARY WORKINGCORR.
Generalized Linear Models
Notes
Output Created
Comments
Input Data
Active Dataset
Filter
Weight
Split File
N of Rows in Working 
Data File
Missing Value Handling Definition of Missing
Cases Used
Weight Handling
02-MAY-2013 10:16:02
C:
\Users\Public\Documents\PhD\ERG\
Results\T-CEM423-6\scotopic data 
T.sav
DataSet5
<none>
<none>
<none>
152
User-defined missing values for 
factor, subject and within-subject 
variables are treated as missing.
Statistics are based on cases with 
valid data for all variables in the 
model.
not applicable
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Notes
Syntax
Resources Processor Time
Elapsed Time
GENLIN V12 BY timepoint 
flashintensitymcd Injured 
(ORDER=DATA)
   /MODEL timepoint 
flashintensitymcd Injured 
timepoint*flashintensitymcd
INTERCEPT=YES
  DISTRIBUTION=GAMMA 
LINK=LOG
   /CRITERIA METHOD=FISHER(1) 
SCALE=MLE
MAXITERATIONS=100
MAXSTEPHALVING=5
PCONVERGE=1E-006(ABSOLUTE)
SINGULAR=1E-012
ANALYSISTYPE=3(WALD)
CILEVEL=95 LIKELIHOOD=FULL
   /EMMEANS 
TABLES=timepoint*flashintensitymc
d*Injured SCALE=ORIGINAL
   /REPEATED SUBJECT=animal 
WITHINSUBJECT=Injured*timepoint
*flashintensitymcd SORT=YES 
CORRTYPE=AR(1)
ADJUSTCORR=YES
COVB=ROBUST
MAXITERATIONS=100
PCONVERGE=1e-006(ABSOLUTE)
UPDATECORR=1
   /MISSING 
CLASSMISSING=EXCLUDE
   /PRINT CPS DESCRIPTIVES ...
00:00:00.06
00:00:00.13
[DataSet5] C:\Users\Public\Documents\PhD\ERG\Results\T-CEM423-6\scotopic d
ata T.sav
Model Information
Dependent Variable
Probability Distribution
Link Function
Subject Effect 1
Within-Subject Effect 1
2
3
Working Correlation Matrix Structure
V12
Gamma
Log
animal
Injured
timepoint
flashintensitymcd
AR(1)
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Case Processing Summary
N Percent
Included
Excluded
Total
144 94.7%
8 5.3%
152 100.0%
Correlated Data Summary
Number of Levels Subject Effect animal
Within-Subject Effect Injured
timepoint
flashintensitymcd
Number of Subjects
Number of Measurements 
per Subject
Minimum
Maximum
Correlation Matrix Dimension
8
2
3
3
8
18
18
18
Categorical Variable Information
N Percent
Factor timepoint 2
7
14
Total
flashintensitymcd 10
3000
10000
Total
Injured 1
0
Total
48 33.3%
48 33.3%
48 33.3%
144 100.0%
48 33.3%
48 33.3%
48 33.3%
144 100.0%
72 50.0%
72 50.0%
144 100.0%
Continuous Variable Information
N Minimum Maximum Mean Std. Deviation
Dependent Variable V12 144 1 3436 119.25 472.496
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Goodness of Fita
Value
Quasi Likelihood under 
Independence Model 
Criterion (QIC)b
Corrected Quasi 
Likelihood under 
Independence Model 
Criterion (QICC)b
202.668
185.470
Dependent Variable: V12
 Model: (Intercept), timepoint, 
flashintensitymcd, Injured, timepoint * 
flashintensitymcd
Information criteria are in small-is-better form.a.
Computed using the full log quasi-likelihood function.b.
Tests of Model Effects
Source
Type III
Wald Chi-
Square df Sig.
(Intercept)
timepoint
flashintensitymcd
Injured
timepoint * 
flashintensitymcd
184.414 1 .000
19.216 2 .000
122.411 2 .000
.425 1 .514
227.503 4 .000
Dependent Variable: V12
 Model: (Intercept), timepoint, flashintensitymcd, Injured, timepoint * 
flashintensitymcd
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Working Correlation Matrixa
Measurement
Measurement
[ Injured = 0 ]* 
[ timepoint = 2 
]* [ 
flashintensity
mcd = 10 ]
[ Injured = 0 ]* 
[ timepoint = 2 
]* [ 
flashintensity
mcd = 3000 ]
[ Injured = 0 ]* 
[ timepoint = 2 
]* [ 
flashintensity
mcd = 10000 ]
[ Injured = 0 ]* 
[ timepoint = 7 
]* [ 
flashintensity
mcd = 10 ]
[ Injured = 0 ]* [ timepoint 
= 2 ]* [ flashintensitymcd = 
10 ]
[ Injured = 0 ]* [ timepoint 
= 2 ]* [ flashintensitymcd = 
3000 ]
[ Injured = 0 ]* [ timepoint 
= 2 ]* [ flashintensitymcd = 
10000 ]
[ Injured = 0 ]* [ timepoint 
= 7 ]* [ flashintensitymcd = 
10 ]
[ Injured = 0 ]* [ timepoint 
= 7 ]* [ flashintensitymcd = 
3000 ]
[ Injured = 0 ]* [ timepoint 
= 7 ]* [ flashintensitymcd = 
10000 ]
[ Injured = 0 ]* [ timepoint 
= 14 ]* [ flashintensitymcd 
= 10 ]
[ Injured = 0 ]* [ timepoint 
= 14 ]* [ flashintensitymcd 
= 3000 ]
[ Injured = 0 ]* [ timepoint 
= 14 ]* [ flashintensitymcd 
= 10000 ]
[ Injured = 1 ]* [ timepoint 
= 2 ]* [ flashintensitymcd = 
10 ]
[ Injured = 1 ]* [ timepoint 
= 2 ]* [ flashintensitymcd = 
3000 ]
[ Injured = 1 ]* [ timepoint 
= 2 ]* [ flashintensitymcd = 
10000 ]
[ Injured = 1 ]* [ timepoint 
= 7 ]* [ flashintensitymcd = 
10 ]
[ Injured = 1 ]* [ timepoint 
= 7 ]* [ flashintensitymcd = 
3000 ]
1.000 .026 .001 .000
.026 1.000 .026 .001
.001 .026 1.000 .026
.000 .001 .026 1.000
.000 .000 .001 .026
.000 .000 .000 .001
.000 .000 .000 .000
.000 .000 .000 .000
.000 .000 .000 .000
.000 .000 .000 .000
.000 .000 .000 .000
.000 .000 .000 .000
.000 .000 .000 .000
.000 .000 .000 .000
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Working Correlation Matrixa
Measurement
Measurement
[ Injured = 0 ]* 
[ timepoint = 7 
]* [ 
flashintensity
mcd = 3000 ]
[ Injured = 0 ]* 
[ timepoint = 7 
]* [ 
flashintensity
mcd = 10000 ]
[ Injured = 0 ]* 
[ timepoint = 
14 ]* [ 
flashintensity
mcd = 10 ]
[ Injured = 0 ]* 
[ timepoint = 
14 ]* [ 
flashintensity
mcd = 3000 ]
[ Injured = 0 ]* [ timepoint 
= 2 ]* [ flashintensitymcd = 
10 ]
[ Injured = 0 ]* [ timepoint 
= 2 ]* [ flashintensitymcd = 
3000 ]
[ Injured = 0 ]* [ timepoint 
= 2 ]* [ flashintensitymcd = 
10000 ]
[ Injured = 0 ]* [ timepoint 
= 7 ]* [ flashintensitymcd = 
10 ]
[ Injured = 0 ]* [ timepoint 
= 7 ]* [ flashintensitymcd = 
3000 ]
[ Injured = 0 ]* [ timepoint 
= 7 ]* [ flashintensitymcd = 
10000 ]
[ Injured = 0 ]* [ timepoint 
= 14 ]* [ flashintensitymcd 
= 10 ]
[ Injured = 0 ]* [ timepoint 
= 14 ]* [ flashintensitymcd 
= 3000 ]
[ Injured = 0 ]* [ timepoint 
= 14 ]* [ flashintensitymcd 
= 10000 ]
[ Injured = 1 ]* [ timepoint 
= 2 ]* [ flashintensitymcd = 
10 ]
[ Injured = 1 ]* [ timepoint 
= 2 ]* [ flashintensitymcd = 
3000 ]
[ Injured = 1 ]* [ timepoint 
= 2 ]* [ flashintensitymcd = 
10000 ]
[ Injured = 1 ]* [ timepoint 
= 7 ]* [ flashintensitymcd = 
10 ]
[ Injured = 1 ]* [ timepoint 
= 7 ]* [ flashintensitymcd = 
3000 ]
.000 .000 .000 .000
.000 .000 .000 .000
.001 .000 .000 .000
.026 .001 .000 .000
1.000 .026 .001 .000
.026 1.000 .026 .001
.001 .026 1.000 .026
.000 .001 .026 1.000
.000 .000 .001 .026
.000 .000 .000 .001
.000 .000 .000 .000
.000 .000 .000 .000
.000 .000 .000 .000
.000 .000 .000 .000
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Working Correlation Matrixa
Measurement
Measurement
[ Injured = 0 ]* 
[ timepoint = 
14 ]* [ 
flashintensity
mcd = 10000 ]
[ Injured = 1 ]* 
[ timepoint = 2 
]* [ 
flashintensity
mcd = 10 ]
[ Injured = 1 ]* 
[ timepoint = 2 
]* [ 
flashintensity
mcd = 3000 ]
[ Injured = 1 ]* 
[ timepoint = 2 
]* [ 
flashintensity
mcd = 10000 ]
[ Injured = 0 ]* [ timepoint 
= 2 ]* [ flashintensitymcd = 
10 ]
[ Injured = 0 ]* [ timepoint 
= 2 ]* [ flashintensitymcd = 
3000 ]
[ Injured = 0 ]* [ timepoint 
= 2 ]* [ flashintensitymcd = 
10000 ]
[ Injured = 0 ]* [ timepoint 
= 7 ]* [ flashintensitymcd = 
10 ]
[ Injured = 0 ]* [ timepoint 
= 7 ]* [ flashintensitymcd = 
3000 ]
[ Injured = 0 ]* [ timepoint 
= 7 ]* [ flashintensitymcd = 
10000 ]
[ Injured = 0 ]* [ timepoint 
= 14 ]* [ flashintensitymcd 
= 10 ]
[ Injured = 0 ]* [ timepoint 
= 14 ]* [ flashintensitymcd 
= 3000 ]
[ Injured = 0 ]* [ timepoint 
= 14 ]* [ flashintensitymcd 
= 10000 ]
[ Injured = 1 ]* [ timepoint 
= 2 ]* [ flashintensitymcd = 
10 ]
[ Injured = 1 ]* [ timepoint 
= 2 ]* [ flashintensitymcd = 
3000 ]
[ Injured = 1 ]* [ timepoint 
= 2 ]* [ flashintensitymcd = 
10000 ]
[ Injured = 1 ]* [ timepoint 
= 7 ]* [ flashintensitymcd = 
10 ]
[ Injured = 1 ]* [ timepoint 
= 7 ]* [ flashintensitymcd = 
3000 ]
.000 .000 .000 .000
.000 .000 .000 .000
.000 .000 .000 .000
.000 .000 .000 .000
.000 .000 .000 .000
.000 .000 .000 .000
.001 .000 .000 .000
.026 .001 .000 .000
1.000 .026 .001 .000
.026 1.000 .026 .001
.001 .026 1.000 .026
.000 .001 .026 1.000
.000 .000 .001 .026
.000 .000 .000 .001
Page 43
Appendix 9, p44
Working Correlation Matrixa
Measurement
Measurement
[ Injured = 1 ]* 
[ timepoint = 7 
]* [ 
flashintensity
mcd = 10 ]
[ Injured = 1 ]* 
[ timepoint = 7 
]* [ 
flashintensity
mcd = 3000 ]
[ Injured = 1 ]* 
[ timepoint = 7 
]* [ 
flashintensity
mcd = 10000 ]
[ Injured = 1 ]* 
[ timepoint = 
14 ]* [ 
flashintensity
mcd = 10 ]
[ Injured = 0 ]* [ timepoint 
= 2 ]* [ flashintensitymcd = 
10 ]
[ Injured = 0 ]* [ timepoint 
= 2 ]* [ flashintensitymcd = 
3000 ]
[ Injured = 0 ]* [ timepoint 
= 2 ]* [ flashintensitymcd = 
10000 ]
[ Injured = 0 ]* [ timepoint 
= 7 ]* [ flashintensitymcd = 
10 ]
[ Injured = 0 ]* [ timepoint 
= 7 ]* [ flashintensitymcd = 
3000 ]
[ Injured = 0 ]* [ timepoint 
= 7 ]* [ flashintensitymcd = 
10000 ]
[ Injured = 0 ]* [ timepoint 
= 14 ]* [ flashintensitymcd 
= 10 ]
[ Injured = 0 ]* [ timepoint 
= 14 ]* [ flashintensitymcd 
= 3000 ]
[ Injured = 0 ]* [ timepoint 
= 14 ]* [ flashintensitymcd 
= 10000 ]
[ Injured = 1 ]* [ timepoint 
= 2 ]* [ flashintensitymcd = 
10 ]
[ Injured = 1 ]* [ timepoint 
= 2 ]* [ flashintensitymcd = 
3000 ]
[ Injured = 1 ]* [ timepoint 
= 2 ]* [ flashintensitymcd = 
10000 ]
[ Injured = 1 ]* [ timepoint 
= 7 ]* [ flashintensitymcd = 
10 ]
[ Injured = 1 ]* [ timepoint 
= 7 ]* [ flashintensitymcd = 
3000 ]
.000 .000 .000 .000
.000 .000 .000 .000
.000 .000 .000 .000
.000 .000 .000 .000
.000 .000 .000 .000
.000 .000 .000 .000
.000 .000 .000 .000
.000 .000 .000 .000
.000 .000 .000 .000
.000 .000 .000 .000
.001 .000 .000 .000
.026 .001 .000 .000
1.000 .026 .001 .000
.026 1.000 .026 .001
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Working Correlation Matrixa
Measurement
Measurement
[ Injured = 1 ]* 
[ timepoint = 
14 ]* [ 
flashintensity
mcd = 3000 ]
[ Injured = 1 ]* 
[ timepoint = 
14 ]* [ 
flashintensity
mcd = 10000 ]
[ Injured = 0 ]* [ timepoint 
= 2 ]* [ flashintensitymcd = 
10 ]
[ Injured = 0 ]* [ timepoint 
= 2 ]* [ flashintensitymcd = 
3000 ]
[ Injured = 0 ]* [ timepoint 
= 2 ]* [ flashintensitymcd = 
10000 ]
[ Injured = 0 ]* [ timepoint 
= 7 ]* [ flashintensitymcd = 
10 ]
[ Injured = 0 ]* [ timepoint 
= 7 ]* [ flashintensitymcd = 
3000 ]
[ Injured = 0 ]* [ timepoint 
= 7 ]* [ flashintensitymcd = 
10000 ]
[ Injured = 0 ]* [ timepoint 
= 14 ]* [ flashintensitymcd 
= 10 ]
[ Injured = 0 ]* [ timepoint 
= 14 ]* [ flashintensitymcd 
= 3000 ]
[ Injured = 0 ]* [ timepoint 
= 14 ]* [ flashintensitymcd 
= 10000 ]
[ Injured = 1 ]* [ timepoint 
= 2 ]* [ flashintensitymcd = 
10 ]
[ Injured = 1 ]* [ timepoint 
= 2 ]* [ flashintensitymcd = 
3000 ]
[ Injured = 1 ]* [ timepoint 
= 2 ]* [ flashintensitymcd = 
10000 ]
[ Injured = 1 ]* [ timepoint 
= 7 ]* [ flashintensitymcd = 
10 ]
[ Injured = 1 ]* [ timepoint 
= 7 ]* [ flashintensitymcd = 
3000 ]
.000 .000
.000 .000
.000 .000
.000 .000
.000 .000
.000 .000
.000 .000
.000 .000
.000 .000
.000 .000
.000 .000
.000 .000
.000 .000
.000 .000
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Working Correlation Matrixa
Measurement
Measurement
[ Injured = 0 ]* 
[ timepoint = 2 
]* [ 
flashintensity
mcd = 10 ]
[ Injured = 0 ]* 
[ timepoint = 2 
]* [ 
flashintensity
mcd = 3000 ]
[ Injured = 0 ]* 
[ timepoint = 2 
]* [ 
flashintensity
mcd = 10000 ]
[ Injured = 0 ]* 
[ timepoint = 7 
]* [ 
flashintensity
mcd = 10 ]
[ Injured = 1 ]* [ timepoint 
= 7 ]* [ flashintensitymcd = 
10000 ]
[ Injured = 1 ]* [ timepoint 
= 14 ]* [ flashintensitymcd 
= 10 ]
[ Injured = 1 ]* [ timepoint 
= 14 ]* [ flashintensitymcd 
= 3000 ]
[ Injured = 1 ]* [ timepoint 
= 14 ]* [ flashintensitymcd 
= 10000 ]
.000 .000 .000 .000
.000 .000 .000 .000
.000 .000 .000 .000
.000 .000 .000 .000
Working Correlation Matrixa
Measurement
Measurement
[ Injured = 0 ]* 
[ timepoint = 7 
]* [ 
flashintensity
mcd = 3000 ]
[ Injured = 0 ]* 
[ timepoint = 7 
]* [ 
flashintensity
mcd = 10000 ]
[ Injured = 0 ]* 
[ timepoint = 
14 ]* [ 
flashintensity
mcd = 10 ]
[ Injured = 0 ]* 
[ timepoint = 
14 ]* [ 
flashintensity
mcd = 3000 ]
[ Injured = 1 ]* [ timepoint 
= 7 ]* [ flashintensitymcd = 
10000 ]
[ Injured = 1 ]* [ timepoint 
= 14 ]* [ flashintensitymcd 
= 10 ]
[ Injured = 1 ]* [ timepoint 
= 14 ]* [ flashintensitymcd 
= 3000 ]
[ Injured = 1 ]* [ timepoint 
= 14 ]* [ flashintensitymcd 
= 10000 ]
.000 .000 .000 .000
.000 .000 .000 .000
.000 .000 .000 .000
.000 .000 .000 .000
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Working Correlation Matrixa
Measurement
Measurement
[ Injured = 0 ]* 
[ timepoint = 
14 ]* [ 
flashintensity
mcd = 10000 ]
[ Injured = 1 ]* 
[ timepoint = 2 
]* [ 
flashintensity
mcd = 10 ]
[ Injured = 1 ]* 
[ timepoint = 2 
]* [ 
flashintensity
mcd = 3000 ]
[ Injured = 1 ]* 
[ timepoint = 2 
]* [ 
flashintensity
mcd = 10000 ]
[ Injured = 1 ]* [ timepoint 
= 7 ]* [ flashintensitymcd = 
10000 ]
[ Injured = 1 ]* [ timepoint 
= 14 ]* [ flashintensitymcd 
= 10 ]
[ Injured = 1 ]* [ timepoint 
= 14 ]* [ flashintensitymcd 
= 3000 ]
[ Injured = 1 ]* [ timepoint 
= 14 ]* [ flashintensitymcd 
= 10000 ]
.000 .000 .000 .000
.000 .000 .000 .000
.000 .000 .000 .000
.000 .000 .000 .000
Working Correlation Matrixa
Measurement
Measurement
[ Injured = 1 ]* 
[ timepoint = 7 
]* [ 
flashintensity
mcd = 10 ]
[ Injured = 1 ]* 
[ timepoint = 7 
]* [ 
flashintensity
mcd = 3000 ]
[ Injured = 1 ]* 
[ timepoint = 7 
]* [ 
flashintensity
mcd = 10000 ]
[ Injured = 1 ]* 
[ timepoint = 
14 ]* [ 
flashintensity
mcd = 10 ]
[ Injured = 1 ]* [ timepoint 
= 7 ]* [ flashintensitymcd = 
10000 ]
[ Injured = 1 ]* [ timepoint 
= 14 ]* [ flashintensitymcd 
= 10 ]
[ Injured = 1 ]* [ timepoint 
= 14 ]* [ flashintensitymcd 
= 3000 ]
[ Injured = 1 ]* [ timepoint 
= 14 ]* [ flashintensitymcd 
= 10000 ]
.001 .026 1.000 .026
.000 .001 .026 1.000
.000 .000 .001 .026
.000 .000 .000 .001
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Working Correlation Matrixa
Measurement
Measurement
[ Injured = 1 ]* 
[ timepoint = 
14 ]* [ 
flashintensity
mcd = 3000 ]
[ Injured = 1 ]* 
[ timepoint = 
14 ]* [ 
flashintensity
mcd = 10000 ]
[ Injured = 1 ]* [ timepoint 
= 7 ]* [ flashintensitymcd = 
10000 ]
[ Injured = 1 ]* [ timepoint 
= 14 ]* [ flashintensitymcd 
= 10 ]
[ Injured = 1 ]* [ timepoint 
= 14 ]* [ flashintensitymcd 
= 3000 ]
[ Injured = 1 ]* [ timepoint 
= 14 ]* [ flashintensitymcd 
= 10000 ]
.001 .000
.026 .001
1.000 .026
.026 1.000
Dependent Variable: V12
 Model: (Intercept), timepoint, flashintensitymcd, Injured, timepoint * flashintensitymcd
The AR(1) working correlation matrix structure is computed assuming the measurements are equally 
spaced for all subjects.
a.
Estimated Marginal Means: timepoint* flashintensitymcd* Injured
Estimates
timepoint flashintensitymcd Injured Mean Std. Error
95% Wald Confidence Interval
Lower Upper
2 10 1
0
3000 1
0
10000 1
0
7 10 1
0
3000 1
0
10000 1
0
14 10 1
0
3000 1
0
10000 1
0
49.37 28.610 15.86 153.72
46.16 23.500 17.02 125.20
3.18 .739 2.02 5.02
2.98 .744 1.82 4.86
2.25 .362 1.64 3.08
2.10 .398 1.45 3.05
675.93 303.673 280.21 1630.49
631.93 295.786 252.50 1581.57
2.32 .236 1.90 2.83
2.17 .179 1.85 2.55
2.04 .181 1.71 2.42
1.90 .141 1.65 2.20
371.73 283.966 83.17 1661.37
347.53 238.505 90.54 1334.02
2.13 .178 1.81 2.51
1.99 .150 1.72 2.31
2.13 .228 1.73 2.63
2.00 .220 1.61 2.48
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* Generalized Estimating Equations.
GENLIN V12 BY timepoint flashintensitymcd Injured (ORDER=DATA)
  /MODEL timepoint flashintensitymcd timepoint*flashintensitymcd INTERCEPT=YES
 DISTRIBUTION=GAMMA LINK=LOG
  /CRITERIA METHOD=FISHER(1) SCALE=MLE MAXITERATIONS=100 MAXSTEPHALVING=5 PCONVERGE=1E-006(A
  /EMMEANS TABLES=timepoint*flashintensitymcd*Injured SCALE=ORIGINAL
  /REPEATED SUBJECT=animal WITHINSUBJECT=Injured*timepoint*flashintensitymcd SORT=YES CORRTY
  /MISSING CLASSMISSING=EXCLUDE
Generalized Linear Models
Notes
Output Created
Comments
Input Data
Active Dataset
Filter
Weight
Split File
N of Rows in Working 
Data File
Missing Value Handling Definition of Missing
Cases Used
Weight Handling
02-MAY-2013 10:16:13
C:
\Users\Public\Documents\PhD\ERG\
Results\T-CEM423-6\scotopic data 
T.sav
DataSet5
<none>
<none>
<none>
152
User-defined missing values for 
factor, subject and within-subject 
variables are treated as missing.
Statistics are based on cases with 
valid data for all variables in the 
model.
not applicable
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Notes
Syntax
Resources Processor Time
Elapsed Time
GENLIN V12 BY timepoint 
flashintensitymcd Injured 
(ORDER=DATA)
   /MODEL timepoint 
flashintensitymcd
timepoint*flashintensitymcd
INTERCEPT=YES
  DISTRIBUTION=GAMMA 
LINK=LOG
   /CRITERIA METHOD=FISHER(1) 
SCALE=MLE
MAXITERATIONS=100
MAXSTEPHALVING=5
PCONVERGE=1E-006(ABSOLUTE)
SINGULAR=1E-012
ANALYSISTYPE=3(WALD)
CILEVEL=95 LIKELIHOOD=FULL
   /EMMEANS 
TABLES=timepoint*flashintensitymc
d*Injured SCALE=ORIGINAL
   /REPEATED SUBJECT=animal 
WITHINSUBJECT=Injured*timepoint
*flashintensitymcd SORT=YES 
CORRTYPE=AR(1)
ADJUSTCORR=YES
COVB=ROBUST
MAXITERATIONS=100
PCONVERGE=1e-006(ABSOLUTE)
UPDATECORR=1
   /MISSING 
CLASSMISSING=EXCLUDE
   /PRINT CPS DESCRIPTIVES ...
00:00:00.11
00:00:00.14
[DataSet5] C:\Users\Public\Documents\PhD\ERG\Results\T-CEM423-6\scotopic d
ata T.sav
Model Information
Dependent Variable
Probability Distribution
Link Function
Subject Effect 1
Within-Subject Effect 1
2
3
Working Correlation Matrix Structure
V12
Gamma
Log
animal
Injured
timepoint
flashintensitymcd
AR(1)
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Case Processing Summary
N Percent
Included
Excluded
Total
144 94.7%
8 5.3%
152 100.0%
Correlated Data Summary
Number of Levels Subject Effect animal
Within-Subject Effect Injured
timepoint
flashintensitymcd
Number of Subjects
Number of Measurements 
per Subject
Minimum
Maximum
Correlation Matrix Dimension
8
2
3
3
8
18
18
18
Categorical Variable Information
N Percent
Factor timepoint 2
7
14
Total
flashintensitymcd 10
3000
10000
Total
Injured 1
0
Total
48 33.3%
48 33.3%
48 33.3%
144 100.0%
48 33.3%
48 33.3%
48 33.3%
144 100.0%
72 50.0%
72 50.0%
144 100.0%
Continuous Variable Information
N Minimum Maximum Mean Std. Deviation
Dependent Variable V12 144 1 3436 119.25 472.496
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Goodness of Fita
Value
Quasi Likelihood under 
Independence Model 
Criterion (QIC)b
Corrected Quasi 
Likelihood under 
Independence Model 
Criterion (QICC)b
202.080
183.615
Dependent Variable: V12
 Model: (Intercept), timepoint, 
flashintensitymcd, timepoint * 
flashintensitymcd
Information criteria are in small-is-better form.a.
Computed using the full log quasi-likelihood function.b.
Tests of Model Effects
Source
Type III
Wald Chi-
Square df Sig.
(Intercept)
timepoint
flashintensitymcd
timepoint * 
flashintensitymcd
184.459 1 .000
18.828 2 .000
126.078 2 .000
216.733 4 .000
Dependent Variable: V12
 Model: (Intercept), timepoint, flashintensitymcd, timepoint * 
flashintensitymcd
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Working Correlation Matrixa
Measurement
Measurement
[ Injured = 0 ]* 
[ timepoint = 2 
]* [ 
flashintensity
mcd = 10 ]
[ Injured = 0 ]* 
[ timepoint = 2 
]* [ 
flashintensity
mcd = 3000 ]
[ Injured = 0 ]* 
[ timepoint = 2 
]* [ 
flashintensity
mcd = 10000 ]
[ Injured = 0 ]* 
[ timepoint = 7 
]* [ 
flashintensity
mcd = 10 ]
[ Injured = 0 ]* [ timepoint 
= 2 ]* [ flashintensitymcd = 
10 ]
[ Injured = 0 ]* [ timepoint 
= 2 ]* [ flashintensitymcd = 
3000 ]
[ Injured = 0 ]* [ timepoint 
= 2 ]* [ flashintensitymcd = 
10000 ]
[ Injured = 0 ]* [ timepoint 
= 7 ]* [ flashintensitymcd = 
10 ]
[ Injured = 0 ]* [ timepoint 
= 7 ]* [ flashintensitymcd = 
3000 ]
[ Injured = 0 ]* [ timepoint 
= 7 ]* [ flashintensitymcd = 
10000 ]
[ Injured = 0 ]* [ timepoint 
= 14 ]* [ flashintensitymcd 
= 10 ]
[ Injured = 0 ]* [ timepoint 
= 14 ]* [ flashintensitymcd 
= 3000 ]
[ Injured = 0 ]* [ timepoint 
= 14 ]* [ flashintensitymcd 
= 10000 ]
[ Injured = 1 ]* [ timepoint 
= 2 ]* [ flashintensitymcd = 
10 ]
[ Injured = 1 ]* [ timepoint 
= 2 ]* [ flashintensitymcd = 
3000 ]
[ Injured = 1 ]* [ timepoint 
= 2 ]* [ flashintensitymcd = 
10000 ]
[ Injured = 1 ]* [ timepoint 
= 7 ]* [ flashintensitymcd = 
10 ]
[ Injured = 1 ]* [ timepoint 
= 7 ]* [ flashintensitymcd = 
3000 ]
1.000 .024 .001 .000
.024 1.000 .024 .001
.001 .024 1.000 .024
.000 .001 .024 1.000
.000 .000 .001 .024
.000 .000 .000 .001
.000 .000 .000 .000
.000 .000 .000 .000
.000 .000 .000 .000
.000 .000 .000 .000
.000 .000 .000 .000
.000 .000 .000 .000
.000 .000 .000 .000
.000 .000 .000 .000
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Working Correlation Matrixa
Measurement
Measurement
[ Injured = 0 ]* 
[ timepoint = 7 
]* [ 
flashintensity
mcd = 3000 ]
[ Injured = 0 ]* 
[ timepoint = 7 
]* [ 
flashintensity
mcd = 10000 ]
[ Injured = 0 ]* 
[ timepoint = 
14 ]* [ 
flashintensity
mcd = 10 ]
[ Injured = 0 ]* 
[ timepoint = 
14 ]* [ 
flashintensity
mcd = 3000 ]
[ Injured = 0 ]* [ timepoint 
= 2 ]* [ flashintensitymcd = 
10 ]
[ Injured = 0 ]* [ timepoint 
= 2 ]* [ flashintensitymcd = 
3000 ]
[ Injured = 0 ]* [ timepoint 
= 2 ]* [ flashintensitymcd = 
10000 ]
[ Injured = 0 ]* [ timepoint 
= 7 ]* [ flashintensitymcd = 
10 ]
[ Injured = 0 ]* [ timepoint 
= 7 ]* [ flashintensitymcd = 
3000 ]
[ Injured = 0 ]* [ timepoint 
= 7 ]* [ flashintensitymcd = 
10000 ]
[ Injured = 0 ]* [ timepoint 
= 14 ]* [ flashintensitymcd 
= 10 ]
[ Injured = 0 ]* [ timepoint 
= 14 ]* [ flashintensitymcd 
= 3000 ]
[ Injured = 0 ]* [ timepoint 
= 14 ]* [ flashintensitymcd 
= 10000 ]
[ Injured = 1 ]* [ timepoint 
= 2 ]* [ flashintensitymcd = 
10 ]
[ Injured = 1 ]* [ timepoint 
= 2 ]* [ flashintensitymcd = 
3000 ]
[ Injured = 1 ]* [ timepoint 
= 2 ]* [ flashintensitymcd = 
10000 ]
[ Injured = 1 ]* [ timepoint 
= 7 ]* [ flashintensitymcd = 
10 ]
[ Injured = 1 ]* [ timepoint 
= 7 ]* [ flashintensitymcd = 
3000 ]
.000 .000 .000 .000
.000 .000 .000 .000
.001 .000 .000 .000
.024 .001 .000 .000
1.000 .024 .001 .000
.024 1.000 .024 .001
.001 .024 1.000 .024
.000 .001 .024 1.000
.000 .000 .001 .024
.000 .000 .000 .001
.000 .000 .000 .000
.000 .000 .000 .000
.000 .000 .000 .000
.000 .000 .000 .000
Page 54
Appendix 9, p55
Working Correlation Matrixa
Measurement
Measurement
[ Injured = 0 ]* 
[ timepoint = 
14 ]* [ 
flashintensity
mcd = 10000 ]
[ Injured = 1 ]* 
[ timepoint = 2 
]* [ 
flashintensity
mcd = 10 ]
[ Injured = 1 ]* 
[ timepoint = 2 
]* [ 
flashintensity
mcd = 3000 ]
[ Injured = 1 ]* 
[ timepoint = 2 
]* [ 
flashintensity
mcd = 10000 ]
[ Injured = 0 ]* [ timepoint 
= 2 ]* [ flashintensitymcd = 
10 ]
[ Injured = 0 ]* [ timepoint 
= 2 ]* [ flashintensitymcd = 
3000 ]
[ Injured = 0 ]* [ timepoint 
= 2 ]* [ flashintensitymcd = 
10000 ]
[ Injured = 0 ]* [ timepoint 
= 7 ]* [ flashintensitymcd = 
10 ]
[ Injured = 0 ]* [ timepoint 
= 7 ]* [ flashintensitymcd = 
3000 ]
[ Injured = 0 ]* [ timepoint 
= 7 ]* [ flashintensitymcd = 
10000 ]
[ Injured = 0 ]* [ timepoint 
= 14 ]* [ flashintensitymcd 
= 10 ]
[ Injured = 0 ]* [ timepoint 
= 14 ]* [ flashintensitymcd 
= 3000 ]
[ Injured = 0 ]* [ timepoint 
= 14 ]* [ flashintensitymcd 
= 10000 ]
[ Injured = 1 ]* [ timepoint 
= 2 ]* [ flashintensitymcd = 
10 ]
[ Injured = 1 ]* [ timepoint 
= 2 ]* [ flashintensitymcd = 
3000 ]
[ Injured = 1 ]* [ timepoint 
= 2 ]* [ flashintensitymcd = 
10000 ]
[ Injured = 1 ]* [ timepoint 
= 7 ]* [ flashintensitymcd = 
10 ]
[ Injured = 1 ]* [ timepoint 
= 7 ]* [ flashintensitymcd = 
3000 ]
.000 .000 .000 .000
.000 .000 .000 .000
.000 .000 .000 .000
.000 .000 .000 .000
.000 .000 .000 .000
.000 .000 .000 .000
.001 .000 .000 .000
.024 .001 .000 .000
1.000 .024 .001 .000
.024 1.000 .024 .001
.001 .024 1.000 .024
.000 .001 .024 1.000
.000 .000 .001 .024
.000 .000 .000 .001
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Working Correlation Matrixa
Measurement
Measurement
[ Injured = 1 ]* 
[ timepoint = 7 
]* [ 
flashintensity
mcd = 10 ]
[ Injured = 1 ]* 
[ timepoint = 7 
]* [ 
flashintensity
mcd = 3000 ]
[ Injured = 1 ]* 
[ timepoint = 7 
]* [ 
flashintensity
mcd = 10000 ]
[ Injured = 1 ]* 
[ timepoint = 
14 ]* [ 
flashintensity
mcd = 10 ]
[ Injured = 0 ]* [ timepoint 
= 2 ]* [ flashintensitymcd = 
10 ]
[ Injured = 0 ]* [ timepoint 
= 2 ]* [ flashintensitymcd = 
3000 ]
[ Injured = 0 ]* [ timepoint 
= 2 ]* [ flashintensitymcd = 
10000 ]
[ Injured = 0 ]* [ timepoint 
= 7 ]* [ flashintensitymcd = 
10 ]
[ Injured = 0 ]* [ timepoint 
= 7 ]* [ flashintensitymcd = 
3000 ]
[ Injured = 0 ]* [ timepoint 
= 7 ]* [ flashintensitymcd = 
10000 ]
[ Injured = 0 ]* [ timepoint 
= 14 ]* [ flashintensitymcd 
= 10 ]
[ Injured = 0 ]* [ timepoint 
= 14 ]* [ flashintensitymcd 
= 3000 ]
[ Injured = 0 ]* [ timepoint 
= 14 ]* [ flashintensitymcd 
= 10000 ]
[ Injured = 1 ]* [ timepoint 
= 2 ]* [ flashintensitymcd = 
10 ]
[ Injured = 1 ]* [ timepoint 
= 2 ]* [ flashintensitymcd = 
3000 ]
[ Injured = 1 ]* [ timepoint 
= 2 ]* [ flashintensitymcd = 
10000 ]
[ Injured = 1 ]* [ timepoint 
= 7 ]* [ flashintensitymcd = 
10 ]
[ Injured = 1 ]* [ timepoint 
= 7 ]* [ flashintensitymcd = 
3000 ]
.000 .000 .000 .000
.000 .000 .000 .000
.000 .000 .000 .000
.000 .000 .000 .000
.000 .000 .000 .000
.000 .000 .000 .000
.000 .000 .000 .000
.000 .000 .000 .000
.000 .000 .000 .000
.000 .000 .000 .000
.001 .000 .000 .000
.024 .001 .000 .000
1.000 .024 .001 .000
.024 1.000 .024 .001
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Working Correlation Matrixa
Measurement
Measurement
[ Injured = 1 ]* 
[ timepoint = 
14 ]* [ 
flashintensity
mcd = 3000 ]
[ Injured = 1 ]* 
[ timepoint = 
14 ]* [ 
flashintensity
mcd = 10000 ]
[ Injured = 0 ]* [ timepoint 
= 2 ]* [ flashintensitymcd = 
10 ]
[ Injured = 0 ]* [ timepoint 
= 2 ]* [ flashintensitymcd = 
3000 ]
[ Injured = 0 ]* [ timepoint 
= 2 ]* [ flashintensitymcd = 
10000 ]
[ Injured = 0 ]* [ timepoint 
= 7 ]* [ flashintensitymcd = 
10 ]
[ Injured = 0 ]* [ timepoint 
= 7 ]* [ flashintensitymcd = 
3000 ]
[ Injured = 0 ]* [ timepoint 
= 7 ]* [ flashintensitymcd = 
10000 ]
[ Injured = 0 ]* [ timepoint 
= 14 ]* [ flashintensitymcd 
= 10 ]
[ Injured = 0 ]* [ timepoint 
= 14 ]* [ flashintensitymcd 
= 3000 ]
[ Injured = 0 ]* [ timepoint 
= 14 ]* [ flashintensitymcd 
= 10000 ]
[ Injured = 1 ]* [ timepoint 
= 2 ]* [ flashintensitymcd = 
10 ]
[ Injured = 1 ]* [ timepoint 
= 2 ]* [ flashintensitymcd = 
3000 ]
[ Injured = 1 ]* [ timepoint 
= 2 ]* [ flashintensitymcd = 
10000 ]
[ Injured = 1 ]* [ timepoint 
= 7 ]* [ flashintensitymcd = 
10 ]
[ Injured = 1 ]* [ timepoint 
= 7 ]* [ flashintensitymcd = 
3000 ]
.000 .000
.000 .000
.000 .000
.000 .000
.000 .000
.000 .000
.000 .000
.000 .000
.000 .000
.000 .000
.000 .000
.000 .000
.000 .000
.000 .000
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Working Correlation Matrixa
Measurement
Measurement
[ Injured = 0 ]* 
[ timepoint = 2 
]* [ 
flashintensity
mcd = 10 ]
[ Injured = 0 ]* 
[ timepoint = 2 
]* [ 
flashintensity
mcd = 3000 ]
[ Injured = 0 ]* 
[ timepoint = 2 
]* [ 
flashintensity
mcd = 10000 ]
[ Injured = 0 ]* 
[ timepoint = 7 
]* [ 
flashintensity
mcd = 10 ]
[ Injured = 1 ]* [ timepoint 
= 7 ]* [ flashintensitymcd = 
10000 ]
[ Injured = 1 ]* [ timepoint 
= 14 ]* [ flashintensitymcd 
= 10 ]
[ Injured = 1 ]* [ timepoint 
= 14 ]* [ flashintensitymcd 
= 3000 ]
[ Injured = 1 ]* [ timepoint 
= 14 ]* [ flashintensitymcd 
= 10000 ]
.000 .000 .000 .000
.000 .000 .000 .000
.000 .000 .000 .000
.000 .000 .000 .000
Working Correlation Matrixa
Measurement
Measurement
[ Injured = 0 ]* 
[ timepoint = 7 
]* [ 
flashintensity
mcd = 3000 ]
[ Injured = 0 ]* 
[ timepoint = 7 
]* [ 
flashintensity
mcd = 10000 ]
[ Injured = 0 ]* 
[ timepoint = 
14 ]* [ 
flashintensity
mcd = 10 ]
[ Injured = 0 ]* 
[ timepoint = 
14 ]* [ 
flashintensity
mcd = 3000 ]
[ Injured = 1 ]* [ timepoint 
= 7 ]* [ flashintensitymcd = 
10000 ]
[ Injured = 1 ]* [ timepoint 
= 14 ]* [ flashintensitymcd 
= 10 ]
[ Injured = 1 ]* [ timepoint 
= 14 ]* [ flashintensitymcd 
= 3000 ]
[ Injured = 1 ]* [ timepoint 
= 14 ]* [ flashintensitymcd 
= 10000 ]
.000 .000 .000 .000
.000 .000 .000 .000
.000 .000 .000 .000
.000 .000 .000 .000
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Working Correlation Matrixa
Measurement
Measurement
[ Injured = 0 ]* 
[ timepoint = 
14 ]* [ 
flashintensity
mcd = 10000 ]
[ Injured = 1 ]* 
[ timepoint = 2 
]* [ 
flashintensity
mcd = 10 ]
[ Injured = 1 ]* 
[ timepoint = 2 
]* [ 
flashintensity
mcd = 3000 ]
[ Injured = 1 ]* 
[ timepoint = 2 
]* [ 
flashintensity
mcd = 10000 ]
[ Injured = 1 ]* [ timepoint 
= 7 ]* [ flashintensitymcd = 
10000 ]
[ Injured = 1 ]* [ timepoint 
= 14 ]* [ flashintensitymcd 
= 10 ]
[ Injured = 1 ]* [ timepoint 
= 14 ]* [ flashintensitymcd 
= 3000 ]
[ Injured = 1 ]* [ timepoint 
= 14 ]* [ flashintensitymcd 
= 10000 ]
.000 .000 .000 .000
.000 .000 .000 .000
.000 .000 .000 .000
.000 .000 .000 .000
Working Correlation Matrixa
Measurement
Measurement
[ Injured = 1 ]* 
[ timepoint = 7 
]* [ 
flashintensity
mcd = 10 ]
[ Injured = 1 ]* 
[ timepoint = 7 
]* [ 
flashintensity
mcd = 3000 ]
[ Injured = 1 ]* 
[ timepoint = 7 
]* [ 
flashintensity
mcd = 10000 ]
[ Injured = 1 ]* 
[ timepoint = 
14 ]* [ 
flashintensity
mcd = 10 ]
[ Injured = 1 ]* [ timepoint 
= 7 ]* [ flashintensitymcd = 
10000 ]
[ Injured = 1 ]* [ timepoint 
= 14 ]* [ flashintensitymcd 
= 10 ]
[ Injured = 1 ]* [ timepoint 
= 14 ]* [ flashintensitymcd 
= 3000 ]
[ Injured = 1 ]* [ timepoint 
= 14 ]* [ flashintensitymcd 
= 10000 ]
.001 .024 1.000 .024
.000 .001 .024 1.000
.000 .000 .001 .024
.000 .000 .000 .001
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Working Correlation Matrixa
Measurement
Measurement
[ Injured = 1 ]* 
[ timepoint = 
14 ]* [ 
flashintensity
mcd = 3000 ]
[ Injured = 1 ]* 
[ timepoint = 
14 ]* [ 
flashintensity
mcd = 10000 ]
[ Injured = 1 ]* [ timepoint 
= 7 ]* [ flashintensitymcd = 
10000 ]
[ Injured = 1 ]* [ timepoint 
= 14 ]* [ flashintensitymcd 
= 10 ]
[ Injured = 1 ]* [ timepoint 
= 14 ]* [ flashintensitymcd 
= 3000 ]
[ Injured = 1 ]* [ timepoint 
= 14 ]* [ flashintensitymcd 
= 10000 ]
.001 .000
.024 .001
1.000 .024
.024 1.000
Dependent Variable: V12
 Model: (Intercept), timepoint, flashintensitymcd, timepoint * flashintensitymcd
The AR(1) working correlation matrix structure is computed assuming the measurements are equally 
spaced for all subjects.
a.
Estimated Marginal Means: timepoint* flashintensitymcd* Injured
Estimates
timepoint flashintensitymcd Injured Mean Std. Error
95% Wald Confidence Interval
Lower Upper
2 10 1
0
3000 1
0
10000 1
0
7 10 1
0
3000 1
0
10000 1
0
14 10 1
0
3000 1
0
10000 1
0
48.48 26.805 16.40 143.28
48.48 26.805 16.40 143.28
3.08 .729 1.93 4.89
3.08 .729 1.93 4.89
2.17 .366 1.56 3.02
2.17 .366 1.56 3.02
650.44 293.415 268.68 1574.66
650.44 293.415 268.68 1574.66
2.24 .173 1.93 2.61
2.24 .173 1.93 2.61
1.97 .125 1.74 2.23
1.97 .125 1.74 2.23
360.69 259.935 87.84 1481.02
360.69 259.935 87.84 1481.02
2.06 .125 1.83 2.32
2.06 .125 1.83 2.32
2.06 .193 1.71 2.47
2.06 .193 1.71 2.47
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DATASET ACTIVATE DataSet2.
GET DATA
 /TYPE=XLS
 /FILE='C:\Users\Public\Documents\PhD\ERG\Results\T-CEM423-6\photopic b wave amplitude for 
 /SHEET=name 'Sheet1'
 /CELLRANGE=full
 /READNAMES=on
 /ASSUMEDSTRWIDTH=32767.
>Error.  Command name: GET DATA
>(2054) The file is not in a recognized Excel file format.
>* File: "C:\Users\Public\Documents\PhD\ERG\Results\T-CEM423-6\photopic b wave amplitude for
>Execution of this command stops.
EXECUTE.
>Error # 105.  Command name: EXECUTE
>This command is not valid before a working file has been defined.
>Execution of this command stops.
DATASET NAME DataSet7 WINDOW=FRONT.
DATASET ACTIVATE DataSet2.
DATASET CLOSE DataSet7.
GET DATA
 /TYPE=XLS
 /FILE='C:\Users\Public\Documents\PhD\ERG\Results\T-CEM423-6\photopic b wave amplitude for 
 /SHEET=name 'Sheet1'
 /CELLRANGE=full
 /READNAMES=on
 /ASSUMEDSTRWIDTH=32767.
EXECUTE.
DATASET NAME DataSet8 WINDOW=FRONT.
* Generalized Estimating Equations.
GENLIN bwaveamplitudevdependentvariable BY Injured timepoint flashintensity (ORDER=ASCENDIN
 /MODEL Injured timepoint flashintensity Injured*timepoint Injured*flashintensity timepoint
DISTRIBUTION=GAMMA LINK=LOG
 /CRITERIA METHOD=FISHER(1) SCALE=MLE MAXITERATIONS=100 MAXSTEPHALVING=5 PCONVERGE=1E-006(A
(WALD) CILEVEL=95 LIKELIHOOD=FULL
 /EMMEANS TABLES=Injured*timepoint*flashintensity SCALE=ORIGINAL
 /REPEATED SUBJECT=animal WITHINSUBJECT=Injured*timepoint*flashintensity SORT=YES CORRTYPE=
(1) ADJUSTCORR=YES COVB=ROBUST MAXITERATIONS=100 PCONVERGE=1e-006(ABSOLUTE) UPDATECORR=1
 /MISSING CLASSMISSING=EXCLUDE
 /PRINT CPS DESCRIPTIVES MODELINFO FIT SUMMARY WORKINGCORR.
Generalized Linear Models
Page 1
Appendix 10, p2
Notes
Output Created
Comments
Input Active Dataset
Filter
Weight
Split File
N of Rows in Working 
Data File
Missing Value Handling Definition of Missing
Cases Used
Weight Handling
Syntax
Resources Processor Time
Elapsed Time
02-MAY-2013 09:55:19
DataSet8
<none>
<none>
<none>
96
User-defined missing values for 
factor, subject and within-subject 
variables are treated as missing.
Statistics are based on cases with 
valid data for all variables in the 
model.
not applicable
GENLIN
bwaveamplitudevdependentvariabl
e BY Injured timepoint flashintensity 
(ORDER=ASCENDING)
   /MODEL Injured timepoint 
flashintensity Injured*timepoint 
Injured*flashintensity
timepoint*flashintensity
Injured*timepoint*flashintensity
INTERCEPT=YES
  DISTRIBUTION=GAMMA 
LINK=LOG
   /CRITERIA METHOD=FISHER(1) 
SCALE=MLE
MAXITERATIONS=100
MAXSTEPHALVING=5
PCONVERGE=1E-006(ABSOLUTE)
SINGULAR=1E-012
ANALYSISTYPE=3(WALD)
CILEVEL=95 LIKELIHOOD=FULL
   /EMMEANS 
TABLES=Injured*timepoint*flashinte
nsity SCALE=ORIGINAL
   /REPEATED SUBJECT=animal 
WITHINSUBJECT=Injured*timepoint
*flashintensity SORT=YES 
CORRTYPE=AR(1)
ADJUSTCORR=YES
COVB=ROBUST
MAXITERATIONS=100
PCONVERGE=1e-006(ABSOLUTE)
UPDATECORR=1
   /MISSING 
CLASSMISSING=EXCLUDE
   /PRINT CPS DESCRIPTIVES ...
00:00:00.05
00:00:00.13
[DataSet8] 
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Model Information
Dependent Variable
Probability Distribution
Link Function
Subject Effect 1
Within-Subject Effect 1
2
3
Working Correlation Matrix Structure
b wave amplitude (v; dependent 
variable)
Gamma
Log
animal
injury condition (1=injured, 
2=control)
time point (days)
stimulus intensity (mcd)
AR(1)
Case Processing Summary
N Percent
Included
Excluded
Total
83 86.5%
13 13.5%
96 100.0%
Correlated Data Summary
Number of Levels Subject Effect animal
Within-Subject Effect injury condition (1=injured, 
2=control)
time point (days)
stimulus intensity (mcd)
Number of Subjects
Number of Measurements 
per Subject
Minimum
Maximum
Correlation Matrix Dimension
8
2
3
2
8
4
12
12
Categorical Variable Information
N Percent
Factor injury condition (1=injured, 
2=control)
1
2
Total
time point (days) 2
7
14
Total
stimulus intensity (mcd) 3000
10000
Total
39 47.0%
44 53.0%
83 100.0%
27 32.5%
32 38.6%
24 28.9%
83 100.0%
42 50.6%
41 49.4%
83 100.0%
Continuous Variable Information
N Minimum Maximum Mean
Dependent Variable b wave amplitude (v; 
dependent variable) 83 11 357 101.93
Page 3
Appendix 10, p4
Continuous Variable Information
Std. Deviation
Dependent Variable b wave amplitude (v; 
dependent variable) 75.874
Goodness of Fita
Value
Quasi Likelihood under 
Independence Model 
Criterion (QIC)b
Corrected Quasi 
Likelihood under 
Independence Model 
Criterion (QICC)b
40.328
41.070
Dependent Variable: b wave amplitude 
(v; dependent variable)
 Model: (Intercept), Injured, timepoint, 
flashintensity, Injured * timepoint, 
Injured * flashintensity, timepoint * 
flashintensity, Injured * timepoint * 
flashintensity
Information criteria are in small-is-better form.a.
Computed using the full log quasi-likelihood function.b.
Tests of Model Effects
Source
Type III
Wald Chi-
Square df Sig.
(Intercept)
Injured
timepoint
flashintensity
Injured * timepoint
Injured * flashintensity
timepoint * flashintensity
Injured * timepoint * 
flashintensity
4275.570 1 .000
56.740 1 .000
5.751 2 .056
41.645 1 .000
1.512 2 .470
5.074 1 .024
1.340 2 .512
21.273 2 .000
Dependent Variable: b wave amplitude (v; dependent variable)
 Model: (Intercept), Injured, timepoint, flashintensity, Injured * 
timepoint, Injured * flashintensity, timepoint * flashintensity, Injured * 
timepoint * flashintensity
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Working Correlation Matrixa
Measurement
Measurement
[ Injured = 1 ]* 
[ timepoint = 2 
]* [ 
flashintensity
= 3000 ]
[ Injured = 1 ]* 
[ timepoint = 2 
]* [ 
flashintensity
= 10000 ]
[ Injured = 1 ]* 
[ timepoint = 7 
]* [ 
flashintensity
= 3000 ]
[ Injured = 1 ]* 
[ timepoint = 7 
]* [ 
flashintensity
= 10000 ]
[ Injured = 1 ]* [ timepoint 
= 2 ]* [ flashintensity = 
3000 ]
[ Injured = 1 ]* [ timepoint 
= 2 ]* [ flashintensity = 
10000 ]
[ Injured = 1 ]* [ timepoint 
= 7 ]* [ flashintensity = 
3000 ]
[ Injured = 1 ]* [ timepoint 
= 7 ]* [ flashintensity = 
10000 ]
[ Injured = 1 ]* [ timepoint 
= 14 ]* [ flashintensity = 
3000 ]
[ Injured = 1 ]* [ timepoint 
= 14 ]* [ flashintensity = 
10000 ]
[ Injured = 2 ]* [ timepoint 
= 2 ]* [ flashintensity = 
3000 ]
[ Injured = 2 ]* [ timepoint 
= 2 ]* [ flashintensity = 
10000 ]
[ Injured = 2 ]* [ timepoint 
= 7 ]* [ flashintensity = 
3000 ]
[ Injured = 2 ]* [ timepoint 
= 7 ]* [ flashintensity = 
10000 ]
[ Injured = 2 ]* [ timepoint 
= 14 ]* [ flashintensity = 
3000 ]
[ Injured = 2 ]* [ timepoint 
= 14 ]* [ flashintensity = 
10000 ]
1.000 .692 .479 .332
.692 1.000 .692 .479
.479 .692 1.000 .692
.332 .479 .692 1.000
.229 .332 .479 .692
.159 .229 .332 .479
.110 .159 .229 .332
.076 .110 .159 .229
.053 .076 .110 .159
.036 .053 .076 .110
.025 .036 .053 .076
.017 .025 .036 .053
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Working Correlation Matrixa
Measurement
Measurement
[ Injured = 1 ]* 
[ timepoint = 
14 ]* [ 
flashintensity
= 3000 ]
[ Injured = 1 ]* 
[ timepoint = 
14 ]* [ 
flashintensity
= 10000 ]
[ Injured = 2 ]* 
[ timepoint = 2 
]* [ 
flashintensity
= 3000 ]
[ Injured = 2 ]* 
[ timepoint = 2 
]* [ 
flashintensity
= 10000 ]
[ Injured = 1 ]* [ timepoint 
= 2 ]* [ flashintensity = 
3000 ]
[ Injured = 1 ]* [ timepoint 
= 2 ]* [ flashintensity = 
10000 ]
[ Injured = 1 ]* [ timepoint 
= 7 ]* [ flashintensity = 
3000 ]
[ Injured = 1 ]* [ timepoint 
= 7 ]* [ flashintensity = 
10000 ]
[ Injured = 1 ]* [ timepoint 
= 14 ]* [ flashintensity = 
3000 ]
[ Injured = 1 ]* [ timepoint 
= 14 ]* [ flashintensity = 
10000 ]
[ Injured = 2 ]* [ timepoint 
= 2 ]* [ flashintensity = 
3000 ]
[ Injured = 2 ]* [ timepoint 
= 2 ]* [ flashintensity = 
10000 ]
[ Injured = 2 ]* [ timepoint 
= 7 ]* [ flashintensity = 
3000 ]
[ Injured = 2 ]* [ timepoint 
= 7 ]* [ flashintensity = 
10000 ]
[ Injured = 2 ]* [ timepoint 
= 14 ]* [ flashintensity = 
3000 ]
[ Injured = 2 ]* [ timepoint 
= 14 ]* [ flashintensity = 
10000 ]
.229 .159 .110 .076
.332 .229 .159 .110
.479 .332 .229 .159
.692 .479 .332 .229
1.000 .692 .479 .332
.692 1.000 .692 .479
.479 .692 1.000 .692
.332 .479 .692 1.000
.229 .332 .479 .692
.159 .229 .332 .479
.110 .159 .229 .332
.076 .110 .159 .229
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Working Correlation Matrixa
Measurement
Measurement
[ Injured = 2 ]* 
[ timepoint = 7 
]* [ 
flashintensity
= 3000 ]
[ Injured = 2 ]* 
[ timepoint = 7 
]* [ 
flashintensity
= 10000 ]
[ Injured = 2 ]* 
[ timepoint = 
14 ]* [ 
flashintensity
= 3000 ]
[ Injured = 2 ]* 
[ timepoint = 
14 ]* [ 
flashintensity
= 10000 ]
[ Injured = 1 ]* [ timepoint 
= 2 ]* [ flashintensity = 
3000 ]
[ Injured = 1 ]* [ timepoint 
= 2 ]* [ flashintensity = 
10000 ]
[ Injured = 1 ]* [ timepoint 
= 7 ]* [ flashintensity = 
3000 ]
[ Injured = 1 ]* [ timepoint 
= 7 ]* [ flashintensity = 
10000 ]
[ Injured = 1 ]* [ timepoint 
= 14 ]* [ flashintensity = 
3000 ]
[ Injured = 1 ]* [ timepoint 
= 14 ]* [ flashintensity = 
10000 ]
[ Injured = 2 ]* [ timepoint 
= 2 ]* [ flashintensity = 
3000 ]
[ Injured = 2 ]* [ timepoint 
= 2 ]* [ flashintensity = 
10000 ]
[ Injured = 2 ]* [ timepoint 
= 7 ]* [ flashintensity = 
3000 ]
[ Injured = 2 ]* [ timepoint 
= 7 ]* [ flashintensity = 
10000 ]
[ Injured = 2 ]* [ timepoint 
= 14 ]* [ flashintensity = 
3000 ]
[ Injured = 2 ]* [ timepoint 
= 14 ]* [ flashintensity = 
10000 ]
.053 .036 .025 .017
.076 .053 .036 .025
.110 .076 .053 .036
.159 .110 .076 .053
.229 .159 .110 .076
.332 .229 .159 .110
.479 .332 .229 .159
.692 .479 .332 .229
1.000 .692 .479 .332
.692 1.000 .692 .479
.479 .692 1.000 .692
.332 .479 .692 1.000
Dependent Variable: b wave amplitude (v; dependent variable)
 Model: (Intercept), Injured, timepoint, flashintensity, Injured * timepoint, Injured * flashintensity, timepoint * 
flashintensity, Injured * timepoint * flashintensity
The AR(1) working correlation matrix structure is computed assuming the measurements are equally 
spaced for all subjects.
a.
Estimated Marginal Means: injury condition (1=injured, 2=control)* t
ime point (days)* stimulus intensity (mcd)
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Estimates
injury condition (1=injured, 
2=control) time point (days) stimulus intensity (mcd) Mean Std. Error
1 2 3000
10000
7 3000
10000
14 3000
10000
2 2 3000
10000
7 3000
10000
14 3000
10000
32.16 5.436
37.75 7.032
32.58 5.254
53.99 6.421
53.48 14.235
74.82 15.520
122.10 20.663
178.98 22.468
119.53 14.682
176.39 28.050
116.42 20.201
190.55 29.118
Estimates
injury condition (1=injured, 
2=control) time point (days) stimulus intensity (mcd)
95% Wald ...
Lower
1 2 3000
10000
7 3000
10000
14 3000
10000
2 2 3000
10000
7 3000
10000
14 3000
10000
23.09
26.20
23.75
42.76
31.74
49.83
87.63
139.94
93.95
129.15
82.86
141.23
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Estimates
injury condition (1=injured, 
2=control) time point (days) stimulus intensity (mcd)
95% Wald ...
Upper
1 2 3000
10000
7 3000
10000
14 3000
10000
2 2 3000
10000
7 3000
10000
14 3000
10000
44.79
54.38
44.69
68.16
90.10
112.35
170.12
228.91
152.06
240.90
163.58
257.09
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Programmed cell death by apoptosis occurs in developing tissues, but in the mature animal, 
dysregulated apoptosis is induced after injury and the ensuing cell loss often causes permanent 
functional impairment1.  Different cells exhibit differential biochemical and cellular responses to 
injury and multiple mechanisms of cell death may co-exist in the same tissue1.  Cell death by 
apoptosis is mediated by initiator caspases belonging to either the intrinsic or extrinsic signalling 
pathways, both of which converge to activate the executioner caspases, 3, 6 and 7.  Intracellular 
damage initiates the intrinsic pathway in which mitochondrial outer membrane permeabilisation 
(MOMP) causes the intermembrane spaces to release cytochrome c, which complexes with 
apoptosis activating factor-1 (apaf-1) forming an apoptosome. The apoptosome recruits and 
activates initiator caspase-9, which activates the executioner caspases.  The extrinsic pathway is 
activated by cell surface “death receptor” ligation and activates caspase 8, which activates the 
executioner caspases1. 
Ocular trauma is common in military personnel and civilians, with a civilian lifetime prevalence of 
20%2,3.  The condition of commotio retinae is characterised by photoreceptor damage after blunt 
ocular trauma and has an incidence of 15% of military and 0.4% in civilian eye injuries 2,4, affecting 
the macula in 73% of military and 31% of civilian cases2,5.  In cases of macular commotio, 26% of 
cases stabilise with a visual acuity <6/9 and persistent, visually debilitating, paracentral scotomas are 
common, with visual impairment caused by photoreceptor degeneration5,6.  In animal models of 
commotio retinae, photoreceptors die by apoptosis and necrosis 7,8.  Thus, regulated apoptotic 
signalling mediates cell death in a proportion of photoreceptors, implying that antiapoptotic 
neuroprotective therapies have a potential role in the treatment of commotio retinae.  In animal 
models of retinal detachment, for example, photoreceptor death is correlated with raised levels of 
caspase 3, 7 and 9 and detachment-induced photoreceptor death is partially reversed when the 
intrinsic pathway is inhibited by over-expression of an AAV-transduced X-linked inhibitor of 
apoptosis, inhibition of MOMP and heat shock protein (HSP70) down regulation of the mTOR 
pathway 9,10,11,12.  Extrinsic pathway inhibition by Fas receptor blockade, TNF-? blockade and TNF-? 
knockout 13,14 also protect photoreceptors, implicating both the intrinsic and extrinsic apoptotic 
pathways. 
Inhibiting apoptosis by neuroprotective therapies improves structural and functional outcomes in 
pre-clinical studies of acute neuronal injury 1,15, and recent phase 2 clinical studies in traumatic brain 
injury have shown promising results16. In this report, using a rat model of commotio retinae7, we 
demonstrate that the intrinsic apoptotic pathway predominantly mediates photoreceptor death and 
that inhibition of caspase-9 using X-linked inhibitor of apoptosis (IAP)-baculoviral IAP repeat 3 
domain (XBIR3), a highly specific caspase-9 inhibitor linked to a cell transduction peptide Penetratin 
1 (Pen1) 17 prevents photoreceptor death and preserves their function.  In contrast, inhibition of 
caspase-6 activity using a dominant negative molecule (C6DN) linked to Pen1 was detrimental to 
photoreceptor function. 
Results 
Activated caspase-9 was present in photoreceptors after injury 
We have previously demonstrated photoreceptor apoptosis after ballistic injury [Blanch,2012].  
However, in the current experiments TUNEL+ cells were localised in the outer nuclear layer (ONL; 
Figure 1A-D) in sections of eyes assayed 2 days after ballistic injury, confirming photoreceptor 
apoptosis.  Western blotting was performed to investigate the expression and processing of caspase-
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9 in the retina.  Compared to uninjured retinae, levels of cleaved caspase-9 were increased by 5 
hours and decreased to basal levels by 24 hours after ballistic injury (Figure 2A-B; p=0.018, one way 
ANOVA).  Levels of full length caspase-9 were upregulated by 48 hours after injury (Figure 1A-B; 
p<0.001, one way ANOVA).  To determine whether caspase-9 was active after ballistic injury, we 
used the biotinylated caspase activity probe bVAD-fmk, a broad spectrum inhibitor which covalently 
binds active caspases.  To capture initiator caspases, we injected bVAD-fmk intravitreally 2 hours 
before injury and harvested retinae at 5 hours, then used streptavidin-coated beads to pull out the 
biotinylated inhibitor-bound caspase. In this way, higher levels of active caspase-9 were isolated 
from injured than from uninjured retinae (Figure 2C-D; p=0.028, 2 sample t-test), indicating that the 
increased levels of cleaved caspase-9 seen by western blotting reflects active enzyme.  To localise 
caspase-9 within the retina, we performed immunohistochemistry on the eyes of animals killed at 5 
and 48 hours after injury.  Compared to uninjured control retinae, caspase-9 levels were increased in 
photoreceptor inner segments of injured animals at 5 hours after injury (Figure 1E-F) and in 
photoreceptor cell bodies at 48 hours after injury (Figure 1G-J), indicating that cataytically active 
caspase-9 was present in photoreceptors 5 hours after injury, consistent with its function as an 
initiator and full length caspase-9 was upregulated in photoreceptors by 48 hours, correlating with 
photoreceptor apoptosis. 
Caspase-9 inhibition induced structural neuroprotection 
To determine the contribution of caspase-9 to photoreceptor death in commotio retinae, we treated 
animals with unilateral intravitreal injections of the highly specific caspase-9 inhibitor Pen1-XBIR3 
after ballistic injury.  Contralateral eyes received control injections of Pen1.  Caspase-9 inhibition 
reduced photoreceptor death, demonstrated by preserved ONL thickness on retinal sections (Figure 
3A-B).  The effect of treatment on ONL thickness was modelled using generalised estimating 
equations showing: (1), a non-significant effect of caspase-9 inhibition across all distances from the 
impact site (p=0.29); (2), a highly significant effect of distance from the centre of the impact site, i.e. 
the outer nuclear layer was thinner towards the centre of the impact site (p<0.001), as we have 
previously reported7; (3), a significantly thicker ONL peripheral, but not central, to the impact site in 
caspase-9-suppressed than in Pen1-treated eyes (p=0.019 for the 2-way interaction 
distance*caspase-9 inhibition), demonstrating that caspase-9 mediates photoreceptor apoptosis 
after ballistic injury. 
Caspase-9 inhibition induced functional neuroprotection 
At 7 and 14 days after ballistic injury and unilateral intravitreal Pen1-XBIR3 injections, we recorded 
scotopic (dark-adapted) and photopic (light-adapted) electroretinograms (ERG) to assess rod and 
cone function respectively.  The effect of treatment on scotopic a-wave amplitude was modelled 
using generalised estimating equations (Figure 3D) showing: (1), a borderline significant increase in 
a-wave amplitude after caspase-9 inhibition across all stimulus intensities and time points (p=0.059); 
(2), a positive effect of caspase-9 inhibition on a-wave amplitude that increases with stimulus 
intensity (p<0.001 for 2-way interaction caspase-9 inhibition*stimulus intensity); (3), a significant 
difference in the effect of caspase-9 inhibition between the 2 time points with a more pronounced 
positive effect (with smaller error bars) at 14 than at 7 days (p<0.001 for the 3-way interaction 
caspase-9 inhibition*stimulus intensity*time).  In summary, compared to eyes injected with 
intravitreal Pen1 alone, caspase-9 inhibition improved rod and cone function, demonstrated by 
increased scotopic a-wave amplitude and photopic b-wave amplitude, and this benefit increased 
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with time after injury (Figure 3C-F).  Photopic b-wave analysis showed similar effects (Figure 3E-F), 
indicating that caspase-9 mediates both rod and cone apoptosis after ballistic injury and its 
inhibition is functionally neuroprotective. 
Assessment of executioner caspases in photoreceptors after injury 
Caspase-9 is an initiator caspase, and as such usually activates downstream executioner caspases 
(such as caspase-3, -6, and -7) to bring about apoptosis1.  Western blotting, immunohistochemistry 
and the bVAD pulldown assay were used to investigate which executioner caspases were cleaved 
and activated after ballistic injury.  Retinal levels of the full length (p32) and cleaved (p17) caspase 3 
were detectable by western blotting, but were unchanged over the 48 hours after injury (p=0.519, 
0.536 respectively; one way ANOVA), whilst the p11 fragment was undetectable (Figure 4C-D).  
Cleaved caspase 3 was not detectable in the ONL by immunohistochemistry (data not shown).  
Similarly, western blots detected full length caspase 7 in the retina (p35) that remained unchanged 
in the 48 hours after injury (p=0.317; one way ANOVA), whilst the p20 cleaved fragment was not 
detectable (Figure 4E-F).  Cleaved caspase 7 was also not detectable in the ONL by 
immunohistochemistry (data not shown).  However, western blots showed that retinal levels of 
cleaved caspase-6 (p18),  increased up to 48 hours after injury (p=0.009; one way ANOVA), but the 
levels of full length caspase-6 (p33-35) were not significantly altered (p=0.059; one way ANOVA) 
(Figure 4A-B). Cleaved caspase-6 was also immunolocalised in cones and rods at 48 hours after injury 
(Figure 2C-F showing all photoreceptors; Supplementary Figure 1 showing co-staining with cone-
arrestin).  To determine whether caspase-6 was active after ballistic injury, we injected bVAD-fmk 
intravitreally 43 hours after injury and killed animals 5 hours later, demonstrating active caspase-6 at 
48 hours after injury (p=0.003, 2 sample t-test; Figure 4G-H).  Thus the only active executioner 
caspase present in photoreceptors after ballistic injury is caspase-6 and therefore we hypothesised 
that caspase-6 executes the apoptotic programme in photoreceptors after initiation by caspase-9. 
Inhibition of caspase-6 did not prevent photoreceptor death and was 
detrimental to photoreceptor function  
To investigate whether caspase-6 mediates photoreceptor apoptosis, we treated animals with 
unilateral intravitreal injections of Pen1-C6DN after ballistic injury.  Contralateral eyes received 
control injections of Pen1.  The effect of caspase-6 inhibition on ONL thickness was modelled using 
generalised estimating equations and did not show any significant differences compared to control 
eyes in main effects or interaction terms (Figure 5A-B), indicating that caspase-6 inhibition did not 
reduce rod death after ballistic injury compared to Pen1-treated control eyes.  The effect of caspase-
6 inhibition on scotopic a-wave amplitude was modelled using generalised estimating equations 
(Figure 5D) and showed: (1), a non-significant effect of caspase-6 inhibition across all stimulus 
intensities and time-points (p=0.983); (2), a negative effect of caspase-6 inhibition on a-wave 
amplitude that increases with stimulus intensity (p<0.001 for the 2-way interaction caspase-6 
inhibition*stimulus intensity); (3), a significant difference in the effect of caspase-6 inhibition 
between the 2 time points, with a greater negative effect at 7 than at 14 days (p<0.001 for the 3-way 
interaction caspase-6 inhibition*stimulus intensity*time).  Surprisingly, caspase-6 inhibition reduced 
rod and cone photoreceptor function, demonstrated by reduced scotopic a- and photopic b-wave 
amplitude (Figure 5C-F).  Photopic ERG assessment of cone function showed similar effects, with 
reduced b-wave amplitudes in eyes injected with Pen1-C6DN, but there was no significant difference 
in b wave amplitudes between those recorded at 7 compared to 14 days after injury (Figure 5E-F).   
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Discussion 
To our knowledge, this is the first report elucidating the mechanisms of photoreceptor apoptosis 
after blunt ocular trauma and highlights a new therapeutic angle in the treatment of this condition. 
We demonstrate that rod and cone apoptosis after blunt ocular trauma occur through the intrinsic 
pathway, initiated by caspase-9.  Despite the presence of catalytically active caspase-6 in rods and 
cones after injury, its inhibition using a highly specific inhibitor did not prevent photoreceptor 
apoptosis but instead was detrimental to retinal function. In contrast, active caspase trapping assays 
revealed that caspase-9 is an early mediator of photoreceptor death and its inhibition reduced 
photoreceptor death and preserved visual function in both rods and cones, inducing structural and 
functional neuroprotection that was sustained at 2 weeks post-injury.    
VAD-fmk is a pan-caspase inhibitor that covalently binds and, in its biotinlyated form (bVAD-fmk),  
isolates caspases-1, -2, -3, -8 and -9 through interaction with immobilised streptavidin18,19.  In this 
study, we used bVAD-fmk to isolate active caspase-9 within the first 5 hours after trauma, which is 
the first demonstration of catalytically active caspase-9 after eye injury.  Caspase-6 was also isolated 
by this method 48 hours after ballistic injury, which is the first report of catalytically active caspase-6 
isolation using bVAD-fmk.  Activated caspase-6 levels detected by Western blotting and bVAD-fmk 
increased up to 48 hours after injury, but were near the lower limits of detection of the assays, 
suggesting that although caspase-6 is active after ballistic injury, it is present in only a small number 
of photoreceptors. 
Use of peptide pharmacological inhibitors (like VAD-fmk) to study caspase activity is common.  
However, overlap in cleavage motifs means that these inhibitors are non-specific20.  XBIR3 –the BIR3 
domain of XIAP – is a highly specific inhibitor of caspase-921 and so the observed neuroprotective 
effects of caspase-9 inhibition were not XBIR3 off-target effects 22. 
As 98% of rat photoreceptors are rods and the ONL contains exclusively photoreceptors, ONL 
thickness reflects rod survival15.  Caspase-9 inhibition after blunt ocular trauma most affected ONL 
thickness peripheral to the impact site, where the highest proportion of apoptotic cells are found, as 
opposed to central to the impact site, where most cell death is necrotic and therefore less 
susceptible to modulation by altered caspase activity7.  Consistent with the function of caspase-9 as 
an initiator caspase, the spike in retinal levels of activated caspase-9 was recorded 5 hours after 
injury and was followed by compensatory upregulation of full length caspase-9 by 48 hours.  The 
western blotting, immunohistochemical and survival data therefore demonstrate unequivocally that 
caspase-9 initiates rod apoptosis after commotio retinae caused by blunt ocular trauma. 
The a-wave is the first negative deflection on the ERG, caused by photoreceptor hyperpolarisation, 
and its amplitude is routinely measured to assess photoreceptor function.  Commotio retinae 
reduces photoreceptor function (demonstrated by reduced a-wave amplitude) out of proportion to 
the extent of photoreceptor death7.  Scotopic a-wave amplitude in rats reflects rod function and was 
increased by caspase-9 inhibition, indicating that the increased survival seen on ONL thickness 
measurements was accompanied by increased rod function.   
Photopic ERG are recorded under conditions of light adaptation, which bleaches rod photoreceptors 
and ensures that the ERG response is cone-mediated.  In rats, the photopic a-waves are small and 
often undetectable after injury7.  The b-wave is the first positive deflection, immediately following 
the a-wave and is generated by the activity of second order neurons (such as ON bipolar cells in the 
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inner nuclear layer).  The b-wave is therefore dependent on photoreceptor activation and synaptic 
transmission in addition to inner retinal function.  In addition, the b-wave is measured from the base 
of the a-wave and thus incorporates both responses.  The b- to a-wave ratio is a measure of how 
much of the variation in b-wave amplitude is due to variation in the magnitude of photoreceptor 
activation compared to the function of second order neurons.  In rats, the b- to a-wave ratio is 
unaffected by commotio retinae7, indicating that any variation in b-wave amplitude is due to 
variation in the magnitude of the photoreceptor response.  The observed changes in photopic b-
wave amplitude therefore reflect cone photoreceptor function, which was increased by caspase-9 
inhibition, indicating that caspase-9 also initiates cone apoptosis after blunt ocular trauma. 
The most commonly reported ultrastructural feature of acute commotio retinae is photoreceptor 
outer segment disruption23,6.  In mild cases of commotio retinae there is visual recovery, correlated 
with outer segment regeneration over weeks to months23,6.  The effect of caspase-9 inhibition on 
cone and rod function was greater at 14 than at 7 days, consistent with functional regeneration of 
damaged outer segments of photoreceptors rescued from apoptosis by caspase-9 inhibition.  
Of the three executioner caspases (-3, -6 and -7), only caspase-6 activity was increased after ballistic 
injury.  Caspase-6 was active in both rods and cones after injury, but does not seem to serve as an 
executioner in this model.  Although caspase-6 inhibition did not affect ONL thickness compared to 
Pen1 injected control eyes, it did reduce both scotopic and photopic ERG amplitudes, indicating that 
caspase-6 inhibition is detrimental to retinal function after blunt ocular trauma.  Caspase-6 has been 
implicated in cell death after ischaemic stroke22, in axonal degeneration in vitro and after optic nerve 
crush24,25, and in cleavage of microtubules and cytoskeletal proteins in Alzheimer’s disease 26,27.  That 
ONL thickness was not affected, suggests that the observed functional effects do not relate to the 
role of caspase-6 in apoptosis.  It may be that caspase-6’s role in microtubule processing is required 
for photoreceptor outer segment survival or regeneration after commotio retinae. 
In conclusion, we show that after ballistic ocular trauma, caspase-9 initiated photoreceptor 
apoptosis and caspase-9 inhibition reduced photoreceptor death with preservation of both rod and 
cone function.  In contrast, though catalytically active caspase-6 was present in rods and cones after 
ballistic injury, cspase-6 inhibition did not reduce cell death and was detrimental to both rod and 
cone function. 
 
Materials and Methods 
Animal Care and Procedures 
Animal procedures were licensed by the UK Home Office, approved by the University of 
Birmingham’s Biomedical Ethics Review Sub-Committee and conducted in accordance with the ARVO 
Statement for the Use of Animals in Ophthalmic and Vision Research.  Female Lister-hooded rats 
weighing 170-200g were purchased from Charles River Laboratories (Margate, UK), kept on a 12 
hour light-dark cycle with a daytime luminance of 80 lux and fed and watered ad libitum.  Surgery 
and ERG recording were performed under inhalation anaesthesia with 2.5% isofluorane in oxygen.  
Ballistic injury was induced as previously described7: a spherical 0.095g spherical plastic pellet was 
fired using compressed air to directly impact the inferior scleral surface at 20m/s. 
Western Blotting 
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At 5, 24 and 48 hours post-ballistic injury and in uninjured controls, 3 rats were killed by overdose of 
anaesthetic, both retinae were removed, protein was extracted in lysis buffer (150mM NaCl, 20mM 
Tris, 1mM EDTA, 0.5mM EGTA, 1% NP-40, pH 7.4) supplemented with protease inhibitor cocktail 
(Sigma, Gillingham, UK) denatured by heating to 90°C for 5 minutes, separated on a tris-glycine gel 
with 80?g protein/lane and transferred to a Polyvinylidene fluoride membrane (Millipore, Watford, 
UK).  After probing with primary and secondary antibodies, specific protein bands were detected 
using an enhanced chemiluminescence system (GE Healthcare, Little Chalfont, UK) membranes were 
read on a digital imaging system (ChemiDocTM MP System, Bio-Rad, Hemel Hempstead, UK) for 
short exposure times (<5 minutes) and exposed to photographic film when longer exposure times 
were required.   
Caspase Pull-down Assay 
To capture active caspases, 5?l of 1mM bVAD-fmk (MP Biomedicals, Cambridge, UK) in 10% 
DMSO/PBS was injected intravitreally into both eyes of 6 animals, 3 of which were bilaterally 
ballistically injured.  To capture active caspase-9, injuries were induced 2 hours after injection and all 
animals were killed 5 hours after injury.  To capture active caspase-6, injuries were induced 43 hours 
before injection and all animals were killed 5 hours after injection.  Retinal protein was extracted in 
CHAPS lysis buffer (150mM KCl, 50mM HEPES, 0.1% CHAPS pH 8.5).  Active caspase was extracted by 
incubation overnight at 4°C with 2mg of streptavidin-coated dynabeads (Invitrogen) and then 
prepared and run as for western blotting. 
Immunohistochemistry and TUNEL 
At 5 and 48 hours after unilateral ballistic injury, 4 rats in each group were killed by perfusion with 
4% paraformaldehyde in phosphate buffered saline (PBS), both eyes were removed, cryoprotected 
in ascending concentrations of sucrose in phosphate buffered saline (PBS) at 4°C, the anterior 
segments removed and the retinal cup embedded in OCT and stored at -80°C until required.  
Sections were cut at 15?m thick using a cryostat (Bright Instruments, Huntingdon, UK) and adhered 
onto SuperfrostTM (Fisher, UK) coated glass microscope slides. The TUNEL FragEL™ DNA 
Fragmentation Detection Kit (Merck, Nottingham, UK) was used as per manufacturer’s instructions, 
except that proteinase K permeabilisation was replaced by immersion in Triton-X 100 0.1% in PBS for 
15 minutes. 
Antibodies 
The polyclonal primary antibodies used were against: activated caspase-6 to detect both the active 
(p18) and full length (p35) fragments by Western blotting (rabbit, New England Biolabs, Hitchin, UK) 
and the p18 fragment by immunohistochemistry (rabbit, New England Biolabs; goat, Santa Cruz 
Biotechnology, Dallas, TX, USA); activated caspase 7, to detect the full length (p35) and active (p20) 
fragments by Western blotting (rabbit, New England Biolabs); ?-tubulin as a Western blotting 
loading control (rabbit, ); caspase 3 (goat, Santa Cruz Biotechnology); caspase-9 to detect the full 
length (p60) and cleaved (p35-39) fragments by Western blotting (rabbit, New England Biolabs and  
immunohistochemistry (rabbit, Santa Cruz).  Monoclonal ED1 (mouse, Serotec Kidlington, UK) was 
used to detect inflammatory cells.  Secondary antibodies used were species-specific peroxidase-
conjugated for Western blotting (GE Healthcare) and Alexa Fluor 488 or Texas red-conjugated for 
immunohistochemistry (Invitrogen, Paisley, UK). 
Caspase Inhibition 
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Pen1-XBIR3 was prepared as previously described28, and 5?l of 5?M solution was delivered by 
unilateral intravitreal injection to inhibit caspase-9 in 8 rats (n=8 eyes).  Contralateral eyes were 
given control treatment with Pen1 (PolyPeptide Laboratories,Torrance, CA USA) alone.  Caspase-6 
(Cys163Ala) dominant negative (C6DN) construct was a gift from G. S. Salvesen, Sanford-Burnham 
Institute, La Jolla, CA and C6DN was purified as previously described29.  Pen-1 and C6DN/XBIR3 were 
linked by incubating equimolar concentrations at 37°C for 24 hours and linkage was confirmed by 
nonreducing 20% PAGE with western blotting using anti-his antibodies.  Pen1-C6DN was used to 
inhibit caspase-6 by 5?l of 5?M solution unilateral intravitreal injection to 8 rats, contralateral 
control eyes were treated with Pen1 alone.  Validation of efficacy/specificity?  
Electroretinography (ERG) 
ERG were recorded (HMsERG – Ocuscience, Kansas City, MO USA) at 7 and 14 days after injury and 
interpreted using ERGView (Ocuscience).  Animals were dark-adapted overnight and prepared for 
ERG under dim red light (>630nm).  Scotopic flash ERG were recorded from -2.5 to +1 log units with 
respect to standard flash in half log unit steps and photopic flash ERG were recorded with 
background illumination of 30,000mcd/m2 over the same range.  DTL fibre (Unimed Electrode 
Supplies, Farnham, UK) corneal electrodes with pressure-moulded Aclar (Agar scientific, Stansted, 
UK) contact lenses were used with needle skin electrodes (Unimed). 
Assessment of Photoreceptor Survival 
Animals were killed and eyes processed as for immunohistochemistry.  Sections were cut through 
the optic disc and centre of the impact site and at 600, 1200 and 1800?m to either side of this plane.  
Haematoxyllin and eosin (H&E) stained slides were scanned on a MIrax slide scanner (Zeiss, 
Cambridge, UK) and the ONL manually segmented in Adobe Photoshop by a blinded observer.  ONL 
images were thresholded and average thickness measured as area of above threshold pixels divided 
by section length using ImageJ (http://rsbweb.nih.gov/ij).     
Statistics 
All statistical analysis was performed in SPSS 21.  One way ANOVA with Tukey post-hoc testing was 
used to analyse Western blotting results and 2 sample t-tests assuming equal variances were used to 
analyse pull down assays.  ERG and ONL thickness data were analysed using generalised estimating 
equations (type III sum of squares; autoregressive correlation matrix; gamma distribution with log 
link) and model fit assessed by plotting residuals and calculating quasi-likelihood information 
criteria.  
 
 
Figure Legends 
Figure 1. Immunohistochemical staining of rat outer retinal layers after injury (DAPI-stained nuclei 
shown in blue, 50?m scale bar).  A-D. TUNEL stained photoreceptor nuclei in green (arrowed) at 2 
days after injury (A, blue and green channels in B-C, respectively), but not in uninjured control retina 
(D).  E-F. Caspase-9 (arrows) in photoreceptor inner segments, seen between the DAPI stained outer 
nuclear layer (ONL) and the autofluorescent outer segments (OS) at 5 hours after injury (E), but not 
in uninjured control retina (F). G-J. Increased caspase-9 levels in photoreceptor cell bodies (arrows) 
at 2 days in injured (G, blue and green channels in H-I, respectively) but not uninjured control retina 
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(J). K-N. Activated caspase-6 (Cell Signalling, rabbit; arrow) in photoreceptor cell body (green) at 2 
days after injury (K, blue and green channels in L-M, respectively), but not in uninjured control tissue 
(N).  Inflammatory cells are stained red by ED1.   
Figure 2. A-B. Retinal levels of full length (p60) and cleaved (p35-39) caspase-9 after ballistic injury 
assessed by western blotting showing increased p35-39 at 5 hours and increased p60 at 48 hours. 
(*p=0.018, **p<0.001)  C-D. Increased retinal levels of catalytically active caspase-9 at 5 hours 
detected by bVAD-fmk pull-down. (*=0.028) 
Figure 3. A. Outer nuclear layer (ONL) thickness as a function of distance from the impact site. B. 
Test of model effects after analysis of ONL thickness including treatment, distance from the impact 
site and a term to model their interaction. C Scotopic a-wave amplitude as a function of stimulus 
intensity.  D. Test of model effects after analysis of scotopic a-wave amplitude including time after 
injury (timepointdays), stimulus intensity (flashintensitymcd), Pen1-XBIR3 compared to Pen1 alone 
(TreatedXBIR3vspen) and terms to model all 2 and 3 way interactions. E. Photopic b-wave amplitude 
as a function of stimulus intensity.  F. Test of model effects after analysis of photopic b-wave 
amplitude including time after injury, stimulus intensity, treatment and terms to model all 2- and 3-
way interactions.  Caspase-9 inhibition by dominant negative protein increases scotopic a- and 
photopic b-wave amplitudes with an effect that is more pronounced at higher stimulus intensities 
and at 14 as opposed to 7 days after injury.  Caspase-9 inhibition also increased ONL thickness 
peripheral but not central to the impact site. 
Figure 4. A-B. Retinal levels of full length (p33-35) and cleaved (p18) caspase-6 after injury assessed 
by western blotting showing an increase in levels of p18 up to 48 hours.  Note that the level of p18 
falls near the lower limit of detection for this assay. (*=0.009)  C-D. Retinal levels of full length 
(32kDA), and cleaved (p17) caspase 3 after injury were unchanged, the p11 fragment was not 
detected.  E-F. Retinal levels of full length caspase 7 (p35) were unchanged after injury, the cleaved 
form (p20) was not detected. G-H.  Increased retinal levels of catalytically active caspase-6 (p18) at 
48 hours detected by bVAD-fmk pull-down. (*=0.003) 
Figure 5. A. Outer nuclear layer (ONL) thickness as a function of distance from the impact site. B. 
Test of model effects after analysis of ONL thickness including treatment and distance from the 
impact site, with non-significant terms removed (before removal, p=0.345 for 
normalisedslidenumber*TreatedCasp6DNvspen and p=0.689 for TreatedCasp6DNvspen).  C. 
Scotopic a-wave amplitude as a function of stimulus intensity.  D. Test of model effects after analysis 
of scotopic a-wave amplitude including time after injury (timepointdays), stimulus intensity 
(flashintensitymcd), Pen1-C6DN compared to Pen1 alone (TreatedCasp6DNvspen) and terms to 
model all 2- and 3-way interactions. E. Photopic b-wave amplitude as a function of stimulus 
intensity.  F. Test of model effects after analysis of photopic b-wave amplitude including time after 
injury, stimulus intensity, treatment and terms to model significant interactions only.  Caspase-6 
inhibition using Pen1-C6DN had no effect on ONL thickness, but reduced scotopic a- and photopic b-
wave amplitudes with an effect that was more pronounced at higher stimulus intensities.   
Supplementary Figure 1. Immunohistochemical staining of rat outer retina with DAPI-stained nuclei 
shown in blue, cone arrestin in red and activated caspase-6 (Santa Cruz, goat) in green.  Scale bar is 
50?m.  A. 2 days after injury activated caspase-6 colocalised with cone arrestin and so was present 
in cones in the outer nuclear layer (ONL).  B-C. Red and green channels of A. D. Uninjured control 
retina with cone arrestin staining cones green (example cell body arrowed), but no caspase-6 
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staining (red).  E-F. Red and green channels of D. 
Full length caspase 6 has multiple high molecular weight forms between 30 and 36 kDA 30.  The 2 
bands seen for full-length caspase 6 on western blotting in the current study may reflect a 
suppressed, phosphorylated form with altered mobility, or deletion of the N-terminal pro-domain 
from aberrant processing 31,32. 
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DATASET ACTIVATE DataSet1.
* Generalized Estimating Equations.
GENLIN AvgONLthickness BY Treated1nottreated0 normalisedslidenumber (ORDER
  /MODEL Treated1nottreated0 normalisedslidenumber Treated1nottreated0*nor
 DISTRIBUTION=GAMMA LINK=LOG
  /CRITERIA METHOD=FISHER(1) SCALE=MLE MAXITERATIONS=100 MAXSTEPHALVING=5 
  /EMMEANS TABLES=Treated1nottreated0 SCALE=ORIGINAL
  /EMMEANS TABLES=normalisedslidenumber SCALE=ORIGINAL
  /EMMEANS TABLES=Treated1nottreated0*normalisedslidenumber SCALE=ORIGINAL
  /REPEATED SUBJECT=Animal WITHINSUBJECT=Treated1nottreated0*normalisedsli
  /MISSING CLASSMISSING=EXCLUDE
  /PRINT CPS DESCRIPTIVES MODELINFO FIT SUMMARY WORKINGCORR.
Generalized Linear Models
Notes
Output Created
Comments
Input Active Dataset
Filter
Weight
Split File
N of Rows in Working 
Data File
Missing Value Handling Definition of Missing
Cases Used
Weight Handling
26-JUL-2013 23:40:06
DataSet1
<none>
<none>
<none>
112
User-defined missing values for factor, subject 
and within-subject variables are treated as 
missing.
Statistics are based on cases with valid data 
for all variables in the model.
not applicable
Page 1
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Notes
Syntax
Resources Processor Time
Elapsed Time
GENLIN AvgONLthickness BY 
Treated1nottreated0 normalisedslidenumber 
(ORDER=ASCENDING)
   /MODEL Treated1nottreated0 
normalisedslidenumber
Treated1nottreated0*normalisedslidenumber
INTERCEPT=YES
  DISTRIBUTION=GAMMA LINK=LOG
   /CRITERIA METHOD=FISHER(1) 
SCALE=MLE MAXITERATIONS=100 
MAXSTEPHALVING=5 PCONVERGE=1E-006
(ABSOLUTE) SINGULAR=1E-012 
ANALYSISTYPE=3(WALD) CILEVEL=95 
LIKELIHOOD=FULL
   /EMMEANS TABLES=Treated1nottreated0 
SCALE=ORIGINAL
   /EMMEANS TABLES=normalisedslidenumber 
SCALE=ORIGINAL
   /EMMEANS 
TABLES=Treated1nottreated0*normalisedslide
number SCALE=ORIGINAL
   /REPEATED SUBJECT=Animal 
WITHINSUBJECT=Treated1nottreated0*norma
lisedslidenumber SORT=YES CORRTYPE=AR
(1) ADJUSTCORR=YES COVB=ROBUST 
MAXITERATIONS=100 PCONVERGE=1e-006
(ABSOLUTE) UPDATECORR=1
   /MISSING CLASSMISSING=EXCLUDE
   /PRINT CPS DESCRIPTIVES MODELINFO 
FIT SUMMARY WORKINGCORR.
00:00:00.25
00:00:00.27
[DataSet1] 
Model Information
Dependent Variable
Probability Distribution
Link Function
Subject Effect 1
Within-Subject Effect 1
2
Working Correlation Matrix Structure
AvgONLthickness
Gamma
Log
Animal
Treated1nottreated0
normalisedslidenumber
AR(1)
Case Processing Summary
N Percent
Included
Excluded
Total
110 98.2%
2 1.8%
112 100.0%
Page 2
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Correlated Data Summary
Number of Levels Subject Effect Animal
Within-Subject Effect Treated1nottreated0
normalisedslidenumber
Number of Subjects
Number of Measurements 
per Subject
Minimum
Maximum
Correlation Matrix Dimension
8
2
7
8
13
14
14
Categorical Variable Information
N Percent
Factor Treated1nottreated0 .0
1.0
Total
normalisedslidenumber 1.0
2.0
3.0
4.0
5.0
6.0
7.0
Total
54 49.1%
56 50.9%
110 100.0%
14 12.7%
16 14.5%
16 14.5%
16 14.5%
16 14.5%
16 14.5%
16 14.5%
110 100.0%
Continuous Variable Information
N Minimum Maximum Mean
Dependent Variable AvgONLthickness 110 24.50923623 134.3101555 51.94469764
Continuous Variable Information
Std. Deviation
Dependent Variable AvgONLthickness 17.82410798
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Goodness of Fita
Value
Quasi Likelihood under 
Independence Model 
Criterion (QIC)b
Corrected Quasi 
Likelihood under 
Independence Model 
Criterion (QICC)b
34.977
35.937
Dependent Variable: AvgONLthickness
 Model: (Intercept), 
Treated1nottreated0,
normalisedslidenumber,
Treated1nottreated0 * 
normalisedslidenumber
Information criteria are in small-is-better form.a.
Computed using the full log quasi-likelihood function.b.
Tests of Model Effects
Source
Type III
Wald Chi-
Square df Sig.
(Intercept)
Treated1nottreated0
normalisedslidenumber
Treated1nottreated0 * 
normalisedslidenumber
6286.697 1 .000
1.121 1 .290
81.447 6 .000
15.115 6 .019
Dependent Variable: AvgONLthickness
 Model: (Intercept), Treated1nottreated0, normalisedslidenumber, 
Treated1nottreated0 * normalisedslidenumber
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Working Correlation Matrixa
Measurement
Measurement
[
Treated1nottr
eated0 = .0 ]* 
[
normalisedslid
enumber = 1.0 
]
[
Treated1nottr
eated0 = .0 ]* 
[
normalisedslid
enumber = 2.0 
]
[
Treated1nottr
eated0 = .0 ]* 
[
normalisedslid
enumber = 3.0 
]
[
Treated1nottr
eated0 = .0 ]* 
[
normalisedslid
enumber = 4.0 
]
[ Treated1nottreated0 = .0 
]* [ 
normalisedslidenumber = 
1.0 ]
[ Treated1nottreated0 = .0 
]* [ 
normalisedslidenumber = 
2.0 ]
[ Treated1nottreated0 = .0 
]* [ 
normalisedslidenumber = 
3.0 ]
[ Treated1nottreated0 = .0 
]* [ 
normalisedslidenumber = 
4.0 ]
[ Treated1nottreated0 = .0 
]* [ 
normalisedslidenumber = 
5.0 ]
[ Treated1nottreated0 = .0 
]* [ 
normalisedslidenumber = 
6.0 ]
[ Treated1nottreated0 = .0 
]* [ 
normalisedslidenumber = 
7.0 ]
[ Treated1nottreated0 = 
1.0 ]* [ 
normalisedslidenumber = 
1.0 ]
[ Treated1nottreated0 = 
1.0 ]* [ 
normalisedslidenumber = 
2.0 ]
[ Treated1nottreated0 = 
1.0 ]* [ 
normalisedslidenumber = 
3.0 ]
1.000 .692 .479 .332
.692 1.000 .692 .479
.479 .692 1.000 .692
.332 .479 .692 1.000
.230 .332 .479 .692
.159 .230 .332 .479
.110 .159 .230 .332
.076 .110 .159 .230
.053 .076 .110 .159
.036 .053 .076 .110
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Working Correlation Matrixa
Measurement
Measurement
[
Treated1nottr
eated0 = .0 ]* 
[
normalisedslid
enumber = 5.0 
]
[
Treated1nottr
eated0 = .0 ]* 
[
normalisedslid
enumber = 6.0 
]
[
Treated1nottr
eated0 = .0 ]* 
[
normalisedslid
enumber = 7.0 
]
[
Treated1nottr
eated0 = 1.0 ]
* [ 
normalisedslid
enumber = 1.0 
]
[ Treated1nottreated0 = .0 
]* [ 
normalisedslidenumber = 
1.0 ]
[ Treated1nottreated0 = .0 
]* [ 
normalisedslidenumber = 
2.0 ]
[ Treated1nottreated0 = .0 
]* [ 
normalisedslidenumber = 
3.0 ]
[ Treated1nottreated0 = .0 
]* [ 
normalisedslidenumber = 
4.0 ]
[ Treated1nottreated0 = .0 
]* [ 
normalisedslidenumber = 
5.0 ]
[ Treated1nottreated0 = .0 
]* [ 
normalisedslidenumber = 
6.0 ]
[ Treated1nottreated0 = .0 
]* [ 
normalisedslidenumber = 
7.0 ]
[ Treated1nottreated0 = 
1.0 ]* [ 
normalisedslidenumber = 
1.0 ]
[ Treated1nottreated0 = 
1.0 ]* [ 
normalisedslidenumber = 
2.0 ]
[ Treated1nottreated0 = 
1.0 ]* [ 
normalisedslidenumber = 
3.0 ]
.230 .159 .110 .076
.332 .230 .159 .110
.479 .332 .230 .159
.692 .479 .332 .230
1.000 .692 .479 .332
.692 1.000 .692 .479
.479 .692 1.000 .692
.332 .479 .692 1.000
.230 .332 .479 .692
.159 .230 .332 .479
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Working Correlation Matrixa
Measurement
Measurement
[
Treated1nottr
eated0 = 1.0 ]
* [ 
normalisedslid
enumber = 2.0 
]
[
Treated1nottr
eated0 = 1.0 ]
* [ 
normalisedslid
enumber = 3.0 
]
[
Treated1nottr
eated0 = 1.0 ]
* [ 
normalisedslid
enumber = 4.0 
]
[
Treated1nottr
eated0 = 1.0 ]
* [ 
normalisedslid
enumber = 5.0 
]
[ Treated1nottreated0 = .0 
]* [ 
normalisedslidenumber = 
1.0 ]
[ Treated1nottreated0 = .0 
]* [ 
normalisedslidenumber = 
2.0 ]
[ Treated1nottreated0 = .0 
]* [ 
normalisedslidenumber = 
3.0 ]
[ Treated1nottreated0 = .0 
]* [ 
normalisedslidenumber = 
4.0 ]
[ Treated1nottreated0 = .0 
]* [ 
normalisedslidenumber = 
5.0 ]
[ Treated1nottreated0 = .0 
]* [ 
normalisedslidenumber = 
6.0 ]
[ Treated1nottreated0 = .0 
]* [ 
normalisedslidenumber = 
7.0 ]
[ Treated1nottreated0 = 
1.0 ]* [ 
normalisedslidenumber = 
1.0 ]
[ Treated1nottreated0 = 
1.0 ]* [ 
normalisedslidenumber = 
2.0 ]
[ Treated1nottreated0 = 
1.0 ]* [ 
normalisedslidenumber = 
3.0 ]
.053 .036 .025 .017
.076 .053 .036 .025
.110 .076 .053 .036
.159 .110 .076 .053
.230 .159 .110 .076
.332 .230 .159 .110
.479 .332 .230 .159
.692 .479 .332 .230
1.000 .692 .479 .332
.692 1.000 .692 .479
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Working Correlation Matrixa
Measurement
Measurement
[
Treated1nottr
eated0 = 1.0 ]
* [ 
normalisedslid
enumber = 6.0 
]
[
Treated1nottr
eated0 = 1.0 ]
* [ 
normalisedslid
enumber = 7.0 
]
[ Treated1nottreated0 = .0 
]* [ 
normalisedslidenumber = 
1.0 ]
[ Treated1nottreated0 = .0 
]* [ 
normalisedslidenumber = 
2.0 ]
[ Treated1nottreated0 = .0 
]* [ 
normalisedslidenumber = 
3.0 ]
[ Treated1nottreated0 = .0 
]* [ 
normalisedslidenumber = 
4.0 ]
[ Treated1nottreated0 = .0 
]* [ 
normalisedslidenumber = 
5.0 ]
[ Treated1nottreated0 = .0 
]* [ 
normalisedslidenumber = 
6.0 ]
[ Treated1nottreated0 = .0 
]* [ 
normalisedslidenumber = 
7.0 ]
[ Treated1nottreated0 = 
1.0 ]* [ 
normalisedslidenumber = 
1.0 ]
[ Treated1nottreated0 = 
1.0 ]* [ 
normalisedslidenumber = 
2.0 ]
[ Treated1nottreated0 = 
1.0 ]* [ 
normalisedslidenumber = 
3.0 ]
.012 .008
.017 .012
.025 .017
.036 .025
.053 .036
.076 .053
.110 .076
.159 .110
.230 .159
.332 .230
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Working Correlation Matrixa
Measurement
Measurement
[
Treated1nottr
eated0 = .0 ]* 
[
normalisedslid
enumber = 1.0 
]
[
Treated1nottr
eated0 = .0 ]* 
[
normalisedslid
enumber = 2.0 
]
[
Treated1nottr
eated0 = .0 ]* 
[
normalisedslid
enumber = 3.0 
]
[
Treated1nottr
eated0 = .0 ]* 
[
normalisedslid
enumber = 4.0 
]
[ Treated1nottreated0 = 
1.0 ]* [ 
normalisedslidenumber = 
4.0 ]
[ Treated1nottreated0 = 
1.0 ]* [ 
normalisedslidenumber = 
5.0 ]
[ Treated1nottreated0 = 
1.0 ]* [ 
normalisedslidenumber = 
6.0 ]
[ Treated1nottreated0 = 
1.0 ]* [ 
normalisedslidenumber = 
7.0 ]
.025 .036 .053 .076
.017 .025 .036 .053
.012 .017 .025 .036
.008 .012 .017 .025
Working Correlation Matrixa
Measurement
Measurement
[
Treated1nottr
eated0 = .0 ]* 
[
normalisedslid
enumber = 5.0 
]
[
Treated1nottr
eated0 = .0 ]* 
[
normalisedslid
enumber = 6.0 
]
[
Treated1nottr
eated0 = .0 ]* 
[
normalisedslid
enumber = 7.0 
]
[
Treated1nottr
eated0 = 1.0 ]
* [ 
normalisedslid
enumber = 1.0 
]
[ Treated1nottreated0 = 
1.0 ]* [ 
normalisedslidenumber = 
4.0 ]
[ Treated1nottreated0 = 
1.0 ]* [ 
normalisedslidenumber = 
5.0 ]
[ Treated1nottreated0 = 
1.0 ]* [ 
normalisedslidenumber = 
6.0 ]
[ Treated1nottreated0 = 
1.0 ]* [ 
normalisedslidenumber = 
7.0 ]
.110 .159 .230 .332
.076 .110 .159 .230
.053 .076 .110 .159
.036 .053 .076 .110
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Working Correlation Matrixa
Measurement
Measurement
[
Treated1nottr
eated0 = 1.0 ]
* [ 
normalisedslid
enumber = 2.0 
]
[
Treated1nottr
eated0 = 1.0 ]
* [ 
normalisedslid
enumber = 3.0 
]
[
Treated1nottr
eated0 = 1.0 ]
* [ 
normalisedslid
enumber = 4.0 
]
[
Treated1nottr
eated0 = 1.0 ]
* [ 
normalisedslid
enumber = 5.0 
]
[ Treated1nottreated0 = 
1.0 ]* [ 
normalisedslidenumber = 
4.0 ]
[ Treated1nottreated0 = 
1.0 ]* [ 
normalisedslidenumber = 
5.0 ]
[ Treated1nottreated0 = 
1.0 ]* [ 
normalisedslidenumber = 
6.0 ]
[ Treated1nottreated0 = 
1.0 ]* [ 
normalisedslidenumber = 
7.0 ]
.479 .692 1.000 .692
.332 .479 .692 1.000
.230 .332 .479 .692
.159 .230 .332 .479
Working Correlation Matrixa
Measurement
Measurement
[
Treated1nottr
eated0 = 1.0 ]
* [ 
normalisedslid
enumber = 6.0 
]
[
Treated1nottr
eated0 = 1.0 ]
* [ 
normalisedslid
enumber = 7.0 
]
[ Treated1nottreated0 = 
1.0 ]* [ 
normalisedslidenumber = 
4.0 ]
[ Treated1nottreated0 = 
1.0 ]* [ 
normalisedslidenumber = 
5.0 ]
[ Treated1nottreated0 = 
1.0 ]* [ 
normalisedslidenumber = 
6.0 ]
[ Treated1nottreated0 = 
1.0 ]* [ 
normalisedslidenumber = 
7.0 ]
.479 .332
.692 .479
1.000 .692
.692 1.000
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Dependent Variable: AvgONLthickness
 Model: (Intercept), Treated1nottreated0, normalisedslidenumber, Treated1nottreated0 * 
normalisedslidenumber
The AR(1) working correlation matrix structure is computed assuming the measurements are equally 
spaced for all subjects.
a.
Estimated Marginal Means 1: Treated1nottreated0
Estimates
Treated1nottreated0 Mean Std. Error
95% Wald Confidence Interval
Lower Upper
.0
1.0
48.84507977 3.219693032 42.92523294 55.58133654
53.84267315 3.737703466 46.99342192 61.69019691
Estimated Marginal Means 2: normalisedslidenumber
Estimates
normalisedslidenumber Mean Std. Error
95% Wald Confidence Interval
Lower Upper
1.0
2.0
3.0
4.0
5.0
6.0
7.0
71.51399022 5.624644645 61.29755958 83.43318777
58.71404010 2.865181543 53.35857860 64.60701532
47.08120376 3.025788110 41.50907161 53.40133281
42.95773618 3.038166234 37.39732571 49.34489465
45.53504641 4.132473989 38.11501484 54.39957089
45.81437743 2.967122283 40.35288351 52.01504817
52.65583867 3.131803527 46.86188415 59.16615168
Estimated Marginal Means 3: Treated1nottreated0* normalisedslide
number
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Estimates
Treated1nottreated0 normalisedslidenumber Mean Std. Error
95% Wald ...
Lower
.0 1.0
2.0
3.0
4.0
5.0
6.0
7.0
1.0 1.0
2.0
3.0
4.0
5.0
6.0
7.0
62.82405868 6.580160368 51.16483381
61.64259335 5.333373256 52.02764516
47.03576127 5.158831753 37.93755227
41.69684928 4.139168856 34.32464404
44.22580609 4.990641931 35.45049372
43.09146323 3.583208566 36.61093353
45.82900780 2.885258598 40.50898175
81.40592800 9.692137710 64.46329794
55.92461832 4.450519461 47.84800409
47.12669016 4.102280900 39.73485252
44.25675151 4.119621723 36.87616789
46.88304488 4.875191438 38.23865111
48.70935035 3.616756567 42.11231315
60.49961540 4.749351773 51.87181402
Estimates
Treated1nottreated0 normalisedslidenumber
95% Wald ...
Upper
.0 1.0
2.0
3.0
4.0
5.0
6.0
7.0
1.0 1.0
2.0
3.0
4.0
5.0
6.0
7.0
77.14013817
73.03442819
58.31590879
50.65244779
55.17333383
50.71911651
51.84771043
102.8015216
65.36454329
55.89362447
53.11452265
57.48162744
56.33983588
70.56247277
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* Generalized Estimating Equations.
GENLIN awaveamplitudev BY timepointdays flashintensitymcd Treated1casp9DN
  /MODEL timepointdays flashintensitymcd Treated1casp9DN0pen1 timepointday
 DISTRIBUTION=GAMMA LINK=LOG
  /CRITERIA METHOD=FISHER(1) SCALE=MLE MAXITERATIONS=100 MAXSTEPHALVING=5 
  /EMMEANS TABLES=Treated1casp9DN0pen1 SCALE=ORIGINAL
  /EMMEANS TABLES=timepointdays*flashintensitymcd*Treated1casp9DN0pen1 SCA
  /REPEATED SUBJECT=animal WITHINSUBJECT=Treated1casp9DN0pen1*timepointday
  /MISSING CLASSMISSING=EXCLUDE
  /PRINT CPS DESCRIPTIVES MODELINFO FIT SUMMARY WORKINGCORR.
Generalized Linear Models
Notes
Output Created
Comments
Input Active Dataset
Filter
Weight
Split File
N of Rows in Working 
Data File
Missing Value Handling Definition of Missing
Cases Used
Weight Handling
27-JUL-2013 00:00:34
DataSet3
<none>
<none>
<none>
413
User-defined missing values for factor, subject 
and within-subject variables are treated as 
missing.
Statistics are based on cases with valid data 
for all variables in the model.
not applicable
Page 1
Appendix 13, p2
Notes
Syntax
Resources Processor Time
Elapsed Time
GENLIN awaveamplitudev BY timepointdays 
flashintensitymcd Treated1casp9DN0pen1 
(ORDER=ASCENDING)
   /MODEL timepointdays flashintensitymcd 
Treated1casp9DN0pen1
timepointdays*flashintensitymcd
timepointdays*Treated1casp9DN0pen1
flashintensitymcd*Treated1casp9DN0pen1
timepointdays*flashintensitymcd*Treated1casp
9DN0pen1 INTERCEPT=YES
  DISTRIBUTION=GAMMA LINK=LOG
   /CRITERIA METHOD=FISHER(1) 
SCALE=MLE MAXITERATIONS=100 
MAXSTEPHALVING=5 PCONVERGE=1E-006
(ABSOLUTE) SINGULAR=1E-012 
ANALYSISTYPE=3(WALD) CILEVEL=95 
LIKELIHOOD=FULL
   /EMMEANS 
TABLES=Treated1casp9DN0pen1
SCALE=ORIGINAL
   /EMMEANS 
TABLES=timepointdays*flashintensitymcd*Tre
ated1casp9DN0pen1 SCALE=ORIGINAL
   /REPEATED SUBJECT=animal 
WITHINSUBJECT=Treated1casp9DN0pen1*ti
mepointdays*flashintensitymcd SORT=YES 
CORRTYPE=AR(1) ADJUSTCORR=YES 
COVB=ROBUST MAXITERATIONS=100 
PCONVERGE=1e-006(ABSOLUTE)
UPDATECORR=1
   /MISSING CLASSMISSING=EXCLUDE
   /PRINT CPS DESCRIPTIVES MODELINFO 
FIT SUMMARY WORKINGCORR.
00:00:00.70
00:00:00.70
[DataSet3] 
Model Information
Dependent Variable
Probability Distribution
Link Function
Subject Effect 1
Within-Subject Effect 1
2
3
Working Correlation Matrix Structure
awaveamplitudev
Gamma
Log
animal
Treated1casp9DN0pen1
timepointdays
flashintensitymcd
AR(1)
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Case Processing Summary
N Percent
Included
Excluded
Total
249 60.3%
164 39.7%
413 100.0%
Correlated Data Summary
Number of Levels Subject Effect animal
Within-Subject Effect Treated1casp9DN0pen1
timepointdays
flashintensitymcd
Number of Subjects
Number of Measurements 
per Subject
Minimum
Maximum
Correlation Matrix Dimension
8
2
2
8
8
28
32
32
Categorical Variable Information
N Percent
Factor timepointdays 7.0
14.0
Total
flashintensitymcd 10.0
30.0
100.0
300.0
1000.0
3000.0
10000.0
25000.0
Total
Treated1casp9DN0pen1 .0
1.0
Total
128 51.4%
121 48.6%
249 100.0%
32 12.9%
32 12.9%
32 12.9%
32 12.9%
31 12.4%
30 12.0%
30 12.0%
30 12.0%
249 100.0%
125 50.2%
124 49.8%
249 100.0%
Continuous Variable Information
N Minimum Maximum Mean
Dependent Variable awaveamplitudev 249 .1 454.2 52.737
Continuous Variable Information
Std. Deviation
Dependent Variable awaveamplitudev 65.0063
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Goodness of Fita
Value
Quasi Likelihood under 
Independence Model 
Criterion (QIC)b
Corrected Quasi 
Likelihood under 
Independence Model 
Criterion (QICC)b
183.955
188.537
Dependent Variable: 
awaveamplitudev
 Model: (Intercept), timepointdays, 
flashintensitymcd,
Treated1casp9DN0pen1, timepointdays 
* flashintensitymcd, timepointdays * 
Treated1casp9DN0pen1,
flashintensitymcd * 
Treated1casp9DN0pen1, timepointdays 
* flashintensitymcd * 
Treated1casp9DN0pen1
Information criteria are in small-is-better form.a.
Computed using the full log quasi-likelihood function.b.
Tests of Model Effects
Source
Type III
Wald Chi-
Square df Sig.
(Intercept)
timepointdays
flashintensitymcd
Treated1casp9DN0pen1
timepointdays * 
flashintensitymcd
timepointdays * 
Treated1casp9DN0pen1
flashintensitymcd * 
Treated1casp9DN0pen1
timepointdays * 
flashintensitymcd * 
Treated1casp9DN0pen1
1254.985 1 .000
1.634 1 .201
5178.626 7 .000
3.283 1 .070
12087.487 7 .000
.666 1 .414
242.964 7 .000
99.442 7 .000
Dependent Variable: awaveamplitudev
 Model: (Intercept), timepointdays, flashintensitymcd, 
Treated1casp9DN0pen1, timepointdays * flashintensitymcd, 
timepointdays * Treated1casp9DN0pen1, flashintensitymcd * 
Treated1casp9DN0pen1, timepointdays * flashintensitymcd * 
Treated1casp9DN0pen1
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Estimated Marginal Means 1: Treated1casp9DN0pen1
Estimates
Treated1casp9DN0pen1 Mean Std. Error
95% Wald Confidence Interval
Lower Upper
.0
1.0
22.271 2.7174 17.534 28.288
34.124 5.9471 24.250 48.018
Estimated Marginal Means 2: timepointdays* flashintensitymcd* Tre
ated1casp9DN0pen1
Estimates
timepointdays flashintensitymcd Treated1casp9DN0pen1 Mean Std. Error
95% Wald ...
Lower
7.0 10.0 .0
1.0
30.0 .0
1.0
100.0 .0
1.0
300.0 .0
1.0
1000.0 .0
1.0
3000.0 .0
1.0
10000.0 .0
1.0
25000.0 .0
1.0
14.0 10.0 .0
1.0
30.0 .0
1.0
100.0 .0
1.0
300.0 .0
1.0
1000.0 .0
1.0
3000.0 .0
1.0
10000.0 .0
1.0
1.463 .5043 .744
2.375 .4785 1.600
4.663 1.1910 2.826
7.700 2.2721 4.318
12.175 2.4543 8.201
18.675 5.7044 10.263
35.263 5.9799 25.291
46.525 15.2154 24.508
62.188 12.3717 42.108
85.950 28.5355 44.838
85.225 13.8615 61.962
122.000 37.9968 66.260
113.013 17.6965 83.145
144.713 42.8324 81.015
119.075 19.1849 86.832
144.500 43.3475 80.264
1.250 .2537 .840
5.313 1.1526 3.472
3.975 1.3971 1.996
7.775 2.2643 4.393
8.000 1.6203 5.379
14.250 3.1733 9.210
24.788 5.1928 16.440
31.150 6.7671 20.349
52.138 8.5893 37.750
61.010 9.6612 44.731
61.633 9.4848 45.585
80.129 11.4102 60.615
72.447 11.6880 52.807
99.013 13.4938 75.804
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Estimates
timepointdays flashintensitymcd Treated1casp9DN0pen1
95% Wald ...
Upper
7.0 10.0 .0
1.0
30.0 .0
1.0
100.0 .0
1.0
300.0 .0
1.0
1000.0 .0
1.0
3000.0 .0
1.0
10000.0 .0
1.0
25000.0 .0
1.0
14.0 10.0 .0
1.0
30.0 .0
1.0
100.0 .0
1.0
300.0 .0
1.0
1000.0 .0
1.0
3000.0 .0
1.0
10000.0 .0
1.0
2.875
3.525
7.692
13.730
18.074
33.983
49.166
88.320
91.842
164.758
117.223
224.629
153.609
258.492
163.291
260.144
1.861
8.128
7.916
13.759
11.898
22.048
37.373
47.684
72.008
83.213
83.331
105.925
99.391
129.330
Estimates
timepointdays flashintensitymcd Treated1casp9DN0pen1 Mean Std. Error
95% Wald ...
Lower
25000.0 .0
1.0
76.503 11.5244 56.945
109.340 15.3044 83.107
Estimates
timepointdays flashintensitymcd Treated1casp9DN0pen1
95% Wald ...
Upper
25000.0 .0
1.0
102.778
143.854
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SORT CASES BY awaveamplitude(A).
* Generalized Estimating Equations.
GENLIN bwaveamplitudev BY timepointdays flashintensitymcd Treated1casp9DN
  /MODEL timepointdays flashintensitymcd Treated1casp9DN0pen1 timepointday
 DISTRIBUTION=GAMMA LINK=LOG
  /CRITERIA METHOD=FISHER(1) SCALE=MLE MAXITERATIONS=100 MAXSTEPHALVING=5 
  /EMMEANS TABLES=Treated1casp9DN0pen1 SCALE=ORIGINAL
  /EMMEANS TABLES=timepointdays*flashintensitymcd*Treated1casp9DN0pen1 SCA
  /REPEATED SUBJECT=animal WITHINSUBJECT=Treated1casp9DN0pen1*timepointday
  /MISSING CLASSMISSING=EXCLUDE
  /PRINT CPS DESCRIPTIVES MODELINFO FIT SUMMARY WORKINGCORR.
Generalized Linear Models
Notes
Output Created
Comments
Input Active Dataset
Filter
Weight
Split File
N of Rows in Working 
Data File
Missing Value Handling Definition of Missing
Cases Used
Weight Handling
27-JUL-2013 00:17:37
DataSet4
<none>
<none>
<none>
112
User-defined missing values for factor, subject 
and within-subject variables are treated as 
missing.
Statistics are based on cases with valid data 
for all variables in the model.
not applicable
Page 1
Appendix 14, p2
Notes
Syntax
Resources Processor Time
Elapsed Time
GENLIN bwaveamplitudev BY timepointdays 
flashintensitymcd Treated1casp9DN0pen1 
(ORDER=ASCENDING)
   /MODEL timepointdays flashintensitymcd 
Treated1casp9DN0pen1
timepointdays*flashintensitymcd
timepointdays*Treated1casp9DN0pen1
flashintensitymcd*Treated1casp9DN0pen1
timepointdays*flashintensitymcd*Treated1casp
9DN0pen1 INTERCEPT=YES
  DISTRIBUTION=GAMMA LINK=LOG
   /CRITERIA METHOD=FISHER(1) 
SCALE=MLE MAXITERATIONS=100 
MAXSTEPHALVING=5 PCONVERGE=1E-006
(ABSOLUTE) SINGULAR=1E-012 
ANALYSISTYPE=3(WALD) CILEVEL=95 
LIKELIHOOD=FULL
   /EMMEANS 
TABLES=Treated1casp9DN0pen1
SCALE=ORIGINAL
   /EMMEANS 
TABLES=timepointdays*flashintensitymcd*Tre
ated1casp9DN0pen1 SCALE=ORIGINAL
   /REPEATED SUBJECT=animal 
WITHINSUBJECT=Treated1casp9DN0pen1*ti
mepointdays*flashintensitymcd SORT=YES 
CORRTYPE=AR(1) ADJUSTCORR=YES 
COVB=ROBUST MAXITERATIONS=100 
PCONVERGE=1e-006(ABSOLUTE)
UPDATECORR=1
   /MISSING CLASSMISSING=EXCLUDE
   /PRINT CPS DESCRIPTIVES MODELINFO 
FIT SUMMARY WORKINGCORR.
00:00:00.59
00:00:00.60
[DataSet4] 
Model Information
Dependent Variable
Probability Distribution
Link Function
Subject Effect 1
Within-Subject Effect 1
2
3
Working Correlation Matrix Structure
bwaveamplitudev
Gamma
Log
animal
Treated1casp9DN0pen1
timepointdays
flashintensitymcd
AR(1)
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Case Processing Summary
N Percent
Included
Excluded
Total
112 100.0%
0 0.0%
112 100.0%
Correlated Data Summary
Number of Levels Subject Effect animal
Within-Subject Effect Treated1casp9DN0pen1
timepointdays
flashintensitymcd
Number of Subjects
Number of Measurements 
per Subject
Minimum
Maximum
Correlation Matrix Dimension
8
2
2
6
8
8
19
21
Categorical Variable Information
N Percent
Factor timepointdays 7.0
14.0
Total
flashintensitymcd 100.0
300.0
1000.0
3000.0
10000.0
25000.0
Total
Treated1casp9DN0pen1 .0
1.0
Total
63 56.3%
49 43.8%
112 100.0%
1 0.9%
14 12.5%
22 19.6%
25 22.3%
25 22.3%
25 22.3%
112 100.0%
47 42.0%
65 58.0%
112 100.0%
Continuous Variable Information
N Minimum Maximum Mean
Dependent Variable bwaveamplitudev 112 2.4 216.7 35.407
Continuous Variable Information
Std. Deviation
Dependent Variable bwaveamplitudev 36.3579
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Goodness of Fita
Value
Quasi Likelihood under 
Independence Model 
Criterion (QIC)b
Corrected Quasi 
Likelihood under 
Independence Model 
Criterion (QICC)b
83.778
82.546
Dependent Variable: 
bwaveamplitudev
 Model: (Intercept), timepointdays, 
flashintensitymcd,
Treated1casp9DN0pen1, timepointdays 
* flashintensitymcd, timepointdays * 
Treated1casp9DN0pen1,
flashintensitymcd * 
Treated1casp9DN0pen1, timepointdays 
* flashintensitymcd * 
Treated1casp9DN0pen1
Information criteria are in small-is-better form.a.
Computed using the full log quasi-likelihood function.b.
Tests of Model Effects
Source
Type III
Wald Chi-
Square df Sig.
(Intercept)
timepointdays
flashintensitymcd
Treated1casp9DN0pen1
timepointdays * 
flashintensitymcd
timepointdays * 
Treated1casp9DN0pen1
flashintensitymcd * 
Treated1casp9DN0pen1
timepointdays * 
flashintensitymcd * 
Treated1casp9DN0pen1
364.679 1 .000
18.175 1 .000
32807.582 5 .000
1.690 1 .194
36.289 4 .000
.411 1 .522
40.477 4 .000
28.365 4 .000
Dependent Variable: bwaveamplitudev
 Model: (Intercept), timepointdays, flashintensitymcd, 
Treated1casp9DN0pen1, timepointdays * flashintensitymcd, 
timepointdays * Treated1casp9DN0pen1, flashintensitymcd * 
Treated1casp9DN0pen1, timepointdays * flashintensitymcd * 
Treated1casp9DN0pen1
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Working Correlation Matrixa
Measurement
Measurement
[
Treated1casp
9DN0pen1 = .
0 ]* [ 
timepointdays
= 7.0 ]* [ 
flashintensity
mcd = 300.0 ]
[
Treated1casp
9DN0pen1 = .
0 ]* [ 
timepointdays
= 7.0 ]* [ 
flashintensity
mcd = 1000.0 
]
[
Treated1casp
9DN0pen1 = .
0 ]* [ 
timepointdays
= 7.0 ]* [ 
flashintensity
mcd = 3000.0 
]
[
Treated1casp
9DN0pen1 = .
0 ]* [ 
timepointdays
= 7.0 ]* [ 
flashintensity
mcd = 
10000.0 ]
[ Treated1casp9DN0pen1 
= .0 ]* [ timepointdays = 
7.0 ]* [ flashintensitymcd = 
300.0 ]
[ Treated1casp9DN0pen1 
= .0 ]* [ timepointdays = 
7.0 ]* [ flashintensitymcd = 
1000.0 ]
[ Treated1casp9DN0pen1 
= .0 ]* [ timepointdays = 
7.0 ]* [ flashintensitymcd = 
3000.0 ]
[ Treated1casp9DN0pen1 
= .0 ]* [ timepointdays = 
7.0 ]* [ flashintensitymcd = 
10000.0 ]
[ Treated1casp9DN0pen1 
= .0 ]* [ timepointdays = 
7.0 ]* [ flashintensitymcd = 
25000.0 ]
[ Treated1casp9DN0pen1 
= .0 ]* [ timepointdays = 
14.0 ]* [ flashintensitymcd 
= 300.0 ]
[ Treated1casp9DN0pen1 
= .0 ]* [ timepointdays = 
14.0 ]* [ flashintensitymcd 
= 1000.0 ]
[ Treated1casp9DN0pen1 
= .0 ]* [ timepointdays = 
14.0 ]* [ flashintensitymcd 
= 3000.0 ]
[ Treated1casp9DN0pen1 
= .0 ]* [ timepointdays = 
14.0 ]* [ flashintensitymcd 
= 10000.0 ]
[ Treated1casp9DN0pen1 
= .0 ]* [ timepointdays = 
14.0 ]* [ flashintensitymcd 
= 25000.0 ]
1.000 1.000 1.000 1.000
1.000 1.000 1.000 1.000
1.000 1.000 1.000 1.000
1.000 1.000 1.000 1.000
1.000 1.000 1.000 1.000
1.000 1.000 1.000 1.000
.999 1.000 1.000 1.000
.999 .999 1.000 1.000
.999 .999 .999 1.000
.999 .999 .999 .999
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Working Correlation Matrixa
Measurement
Measurement
[
Treated1casp
9DN0pen1 = .
0 ]* [ 
timepointdays
= 7.0 ]* [ 
flashintensity
mcd = 
25000.0 ]
[
Treated1casp
9DN0pen1 = .
0 ]* [ 
timepointdays
= 14.0 ]* [ 
flashintensity
mcd = 300.0 ]
[
Treated1casp
9DN0pen1 = .
0 ]* [ 
timepointdays
= 14.0 ]* [ 
flashintensity
mcd = 1000.0 
]
[
Treated1casp
9DN0pen1 = .
0 ]* [ 
timepointdays
= 14.0 ]* [ 
flashintensity
mcd = 3000.0 
]
[ Treated1casp9DN0pen1 
= .0 ]* [ timepointdays = 
7.0 ]* [ flashintensitymcd = 
300.0 ]
[ Treated1casp9DN0pen1 
= .0 ]* [ timepointdays = 
7.0 ]* [ flashintensitymcd = 
1000.0 ]
[ Treated1casp9DN0pen1 
= .0 ]* [ timepointdays = 
7.0 ]* [ flashintensitymcd = 
3000.0 ]
[ Treated1casp9DN0pen1 
= .0 ]* [ timepointdays = 
7.0 ]* [ flashintensitymcd = 
10000.0 ]
[ Treated1casp9DN0pen1 
= .0 ]* [ timepointdays = 
7.0 ]* [ flashintensitymcd = 
25000.0 ]
[ Treated1casp9DN0pen1 
= .0 ]* [ timepointdays = 
14.0 ]* [ flashintensitymcd 
= 300.0 ]
[ Treated1casp9DN0pen1 
= .0 ]* [ timepointdays = 
14.0 ]* [ flashintensitymcd 
= 1000.0 ]
[ Treated1casp9DN0pen1 
= .0 ]* [ timepointdays = 
14.0 ]* [ flashintensitymcd 
= 3000.0 ]
[ Treated1casp9DN0pen1 
= .0 ]* [ timepointdays = 
14.0 ]* [ flashintensitymcd 
= 10000.0 ]
[ Treated1casp9DN0pen1 
= .0 ]* [ timepointdays = 
14.0 ]* [ flashintensitymcd 
= 25000.0 ]
1.000 1.000 .999 .999
1.000 1.000 1.000 .999
1.000 1.000 1.000 1.000
1.000 1.000 1.000 1.000
1.000 1.000 1.000 1.000
1.000 1.000 1.000 1.000
1.000 1.000 1.000 1.000
1.000 1.000 1.000 1.000
1.000 1.000 1.000 1.000
1.000 1.000 1.000 1.000
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Working Correlation Matrixa
Measurement
Measurement
[
Treated1casp
9DN0pen1 = .
0 ]* [ 
timepointdays
= 14.0 ]* [ 
flashintensity
mcd = 
10000.0 ]
[
Treated1casp
9DN0pen1 = .
0 ]* [ 
timepointdays
= 14.0 ]* [ 
flashintensity
mcd = 
25000.0 ]
[
Treated1casp
9DN0pen1 = 
1.0 ]* [ 
timepointdays
= 7.0 ]* [ 
flashintensity
mcd = 100.0 ]
[
Treated1casp
9DN0pen1 = 
1.0 ]* [ 
timepointdays
= 7.0 ]* [ 
flashintensity
mcd = 300.0 ]
[ Treated1casp9DN0pen1 
= .0 ]* [ timepointdays = 
7.0 ]* [ flashintensitymcd = 
300.0 ]
[ Treated1casp9DN0pen1 
= .0 ]* [ timepointdays = 
7.0 ]* [ flashintensitymcd = 
1000.0 ]
[ Treated1casp9DN0pen1 
= .0 ]* [ timepointdays = 
7.0 ]* [ flashintensitymcd = 
3000.0 ]
[ Treated1casp9DN0pen1 
= .0 ]* [ timepointdays = 
7.0 ]* [ flashintensitymcd = 
10000.0 ]
[ Treated1casp9DN0pen1 
= .0 ]* [ timepointdays = 
7.0 ]* [ flashintensitymcd = 
25000.0 ]
[ Treated1casp9DN0pen1 
= .0 ]* [ timepointdays = 
14.0 ]* [ flashintensitymcd 
= 300.0 ]
[ Treated1casp9DN0pen1 
= .0 ]* [ timepointdays = 
14.0 ]* [ flashintensitymcd 
= 1000.0 ]
[ Treated1casp9DN0pen1 
= .0 ]* [ timepointdays = 
14.0 ]* [ flashintensitymcd 
= 3000.0 ]
[ Treated1casp9DN0pen1 
= .0 ]* [ timepointdays = 
14.0 ]* [ flashintensitymcd 
= 10000.0 ]
[ Treated1casp9DN0pen1 
= .0 ]* [ timepointdays = 
14.0 ]* [ flashintensitymcd 
= 25000.0 ]
.999 .999 .999 .999
.999 .999 .999 .999
.999 .999 .999 .999
1.000 .999 .999 .999
1.000 1.000 .999 .999
1.000 1.000 1.000 .999
1.000 1.000 1.000 1.000
1.000 1.000 1.000 1.000
1.000 1.000 1.000 1.000
1.000 1.000 1.000 1.000
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Working Correlation Matrixa
Measurement
Measurement
[
Treated1casp
9DN0pen1 = 
1.0 ]* [ 
timepointdays
= 7.0 ]* [ 
flashintensity
mcd = 1000.0 
]
[
Treated1casp
9DN0pen1 = 
1.0 ]* [ 
timepointdays
= 7.0 ]* [ 
flashintensity
mcd = 3000.0 
]
[
Treated1casp
9DN0pen1 = 
1.0 ]* [ 
timepointdays
= 7.0 ]* [ 
flashintensity
mcd = 
10000.0 ]
[
Treated1casp
9DN0pen1 = 
1.0 ]* [ 
timepointdays
= 7.0 ]* [ 
flashintensity
mcd = 
25000.0 ]
[ Treated1casp9DN0pen1 
= .0 ]* [ timepointdays = 
7.0 ]* [ flashintensitymcd = 
300.0 ]
[ Treated1casp9DN0pen1 
= .0 ]* [ timepointdays = 
7.0 ]* [ flashintensitymcd = 
1000.0 ]
[ Treated1casp9DN0pen1 
= .0 ]* [ timepointdays = 
7.0 ]* [ flashintensitymcd = 
3000.0 ]
[ Treated1casp9DN0pen1 
= .0 ]* [ timepointdays = 
7.0 ]* [ flashintensitymcd = 
10000.0 ]
[ Treated1casp9DN0pen1 
= .0 ]* [ timepointdays = 
7.0 ]* [ flashintensitymcd = 
25000.0 ]
[ Treated1casp9DN0pen1 
= .0 ]* [ timepointdays = 
14.0 ]* [ flashintensitymcd 
= 300.0 ]
[ Treated1casp9DN0pen1 
= .0 ]* [ timepointdays = 
14.0 ]* [ flashintensitymcd 
= 1000.0 ]
[ Treated1casp9DN0pen1 
= .0 ]* [ timepointdays = 
14.0 ]* [ flashintensitymcd 
= 3000.0 ]
[ Treated1casp9DN0pen1 
= .0 ]* [ timepointdays = 
14.0 ]* [ flashintensitymcd 
= 10000.0 ]
[ Treated1casp9DN0pen1 
= .0 ]* [ timepointdays = 
14.0 ]* [ flashintensitymcd 
= 25000.0 ]
.999 .999 .999 .999
.999 .999 .999 .999
.999 .999 .999 .999
.999 .999 .999 .999
.999 .999 .999 .999
.999 .999 .999 .999
.999 .999 .999 .999
1.000 .999 .999 .999
1.000 1.000 .999 .999
1.000 1.000 1.000 .999
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Working Correlation Matrixa
Measurement
Measurement
[
Treated1casp
9DN0pen1 = 
1.0 ]* [ 
timepointdays
= 14.0 ]* [ 
flashintensity
mcd = 300.0 ]
[
Treated1casp
9DN0pen1 = 
1.0 ]* [ 
timepointdays
= 14.0 ]* [ 
flashintensity
mcd = 1000.0 
]
[
Treated1casp
9DN0pen1 = 
1.0 ]* [ 
timepointdays
= 14.0 ]* [ 
flashintensity
mcd = 3000.0 
]
[
Treated1casp
9DN0pen1 = 
1.0 ]* [ 
timepointdays
= 14.0 ]* [ 
flashintensity
mcd = 
10000.0 ]
[ Treated1casp9DN0pen1 
= .0 ]* [ timepointdays = 
7.0 ]* [ flashintensitymcd = 
300.0 ]
[ Treated1casp9DN0pen1 
= .0 ]* [ timepointdays = 
7.0 ]* [ flashintensitymcd = 
1000.0 ]
[ Treated1casp9DN0pen1 
= .0 ]* [ timepointdays = 
7.0 ]* [ flashintensitymcd = 
3000.0 ]
[ Treated1casp9DN0pen1 
= .0 ]* [ timepointdays = 
7.0 ]* [ flashintensitymcd = 
10000.0 ]
[ Treated1casp9DN0pen1 
= .0 ]* [ timepointdays = 
7.0 ]* [ flashintensitymcd = 
25000.0 ]
[ Treated1casp9DN0pen1 
= .0 ]* [ timepointdays = 
14.0 ]* [ flashintensitymcd 
= 300.0 ]
[ Treated1casp9DN0pen1 
= .0 ]* [ timepointdays = 
14.0 ]* [ flashintensitymcd 
= 1000.0 ]
[ Treated1casp9DN0pen1 
= .0 ]* [ timepointdays = 
14.0 ]* [ flashintensitymcd 
= 3000.0 ]
[ Treated1casp9DN0pen1 
= .0 ]* [ timepointdays = 
14.0 ]* [ flashintensitymcd 
= 10000.0 ]
[ Treated1casp9DN0pen1 
= .0 ]* [ timepointdays = 
14.0 ]* [ flashintensitymcd 
= 25000.0 ]
.998 .998 .998 .998
.999 .998 .998 .998
.999 .999 .998 .998
.999 .999 .999 .998
.999 .999 .999 .999
.999 .999 .999 .999
.999 .999 .999 .999
.999 .999 .999 .999
.999 .999 .999 .999
.999 .999 .999 .999
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Working Correlation Matrixa
Measurement
Measurement
[
Treated1casp
9DN0pen1 = 
1.0 ]* [ 
timepointdays
= 14.0 ]* [ 
flashintensity
mcd = 
25000.0 ]
[ Treated1casp9DN0pen1 
= .0 ]* [ timepointdays = 
7.0 ]* [ flashintensitymcd = 
300.0 ]
[ Treated1casp9DN0pen1 
= .0 ]* [ timepointdays = 
7.0 ]* [ flashintensitymcd = 
1000.0 ]
[ Treated1casp9DN0pen1 
= .0 ]* [ timepointdays = 
7.0 ]* [ flashintensitymcd = 
3000.0 ]
[ Treated1casp9DN0pen1 
= .0 ]* [ timepointdays = 
7.0 ]* [ flashintensitymcd = 
10000.0 ]
[ Treated1casp9DN0pen1 
= .0 ]* [ timepointdays = 
7.0 ]* [ flashintensitymcd = 
25000.0 ]
[ Treated1casp9DN0pen1 
= .0 ]* [ timepointdays = 
14.0 ]* [ flashintensitymcd 
= 300.0 ]
[ Treated1casp9DN0pen1 
= .0 ]* [ timepointdays = 
14.0 ]* [ flashintensitymcd 
= 1000.0 ]
[ Treated1casp9DN0pen1 
= .0 ]* [ timepointdays = 
14.0 ]* [ flashintensitymcd 
= 3000.0 ]
[ Treated1casp9DN0pen1 
= .0 ]* [ timepointdays = 
14.0 ]* [ flashintensitymcd 
= 10000.0 ]
[ Treated1casp9DN0pen1 
= .0 ]* [ timepointdays = 
14.0 ]* [ flashintensitymcd 
= 25000.0 ]
.998
.998
.998
.998
.998
.999
.999
.999
.999
.999
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Working Correlation Matrixa
Measurement
Measurement
[
Treated1casp
9DN0pen1 = .
0 ]* [ 
timepointdays
= 7.0 ]* [ 
flashintensity
mcd = 300.0 ]
[
Treated1casp
9DN0pen1 = .
0 ]* [ 
timepointdays
= 7.0 ]* [ 
flashintensity
mcd = 1000.0 
]
[
Treated1casp
9DN0pen1 = .
0 ]* [ 
timepointdays
= 7.0 ]* [ 
flashintensity
mcd = 3000.0 
]
[
Treated1casp
9DN0pen1 = .
0 ]* [ 
timepointdays
= 7.0 ]* [ 
flashintensity
mcd = 
10000.0 ]
[ Treated1casp9DN0pen1 
= 1.0 ]* [ timepointdays = 
7.0 ]* [ flashintensitymcd = 
100.0 ]
[ Treated1casp9DN0pen1 
= 1.0 ]* [ timepointdays = 
7.0 ]* [ flashintensitymcd = 
300.0 ]
[ Treated1casp9DN0pen1 
= 1.0 ]* [ timepointdays = 
7.0 ]* [ flashintensitymcd = 
1000.0 ]
[ Treated1casp9DN0pen1 
= 1.0 ]* [ timepointdays = 
7.0 ]* [ flashintensitymcd = 
3000.0 ]
[ Treated1casp9DN0pen1 
= 1.0 ]* [ timepointdays = 
7.0 ]* [ flashintensitymcd = 
10000.0 ]
[ Treated1casp9DN0pen1 
= 1.0 ]* [ timepointdays = 
7.0 ]* [ flashintensitymcd = 
25000.0 ]
[ Treated1casp9DN0pen1 
= 1.0 ]* [ timepointdays = 
14.0 ]* [ flashintensitymcd 
= 300.0 ]
[ Treated1casp9DN0pen1 
= 1.0 ]* [ timepointdays = 
14.0 ]* [ flashintensitymcd 
= 1000.0 ]
[ Treated1casp9DN0pen1 
= 1.0 ]* [ timepointdays = 
14.0 ]* [ flashintensitymcd 
= 3000.0 ]
[ Treated1casp9DN0pen1 
= 1.0 ]* [ timepointdays = 
14.0 ]* [ flashintensitymcd 
= 10000.0 ]
[ Treated1casp9DN0pen1 
= 1.0 ]* [ timepointdays = 
14.0 ]* [ flashintensitymcd 
= 25000.0 ]
.999 .999 .999 .999
.999 .999 .999 .999
.999 .999 .999 .999
.999 .999 .999 .999
.999 .999 .999 .999
.999 .999 .999 .999
.998 .999 .999 .999
.998 .998 .999 .999
.998 .998 .998 .999
.998 .998 .998 .998
.998 .998 .998 .998
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Working Correlation Matrixa
Measurement
Measurement
[
Treated1casp
9DN0pen1 = .
0 ]* [ 
timepointdays
= 7.0 ]* [ 
flashintensity
mcd = 
25000.0 ]
[
Treated1casp
9DN0pen1 = .
0 ]* [ 
timepointdays
= 14.0 ]* [ 
flashintensity
mcd = 300.0 ]
[
Treated1casp
9DN0pen1 = .
0 ]* [ 
timepointdays
= 14.0 ]* [ 
flashintensity
mcd = 1000.0 
]
[
Treated1casp
9DN0pen1 = .
0 ]* [ 
timepointdays
= 14.0 ]* [ 
flashintensity
mcd = 3000.0 
]
[ Treated1casp9DN0pen1 
= 1.0 ]* [ timepointdays = 
7.0 ]* [ flashintensitymcd = 
100.0 ]
[ Treated1casp9DN0pen1 
= 1.0 ]* [ timepointdays = 
7.0 ]* [ flashintensitymcd = 
300.0 ]
[ Treated1casp9DN0pen1 
= 1.0 ]* [ timepointdays = 
7.0 ]* [ flashintensitymcd = 
1000.0 ]
[ Treated1casp9DN0pen1 
= 1.0 ]* [ timepointdays = 
7.0 ]* [ flashintensitymcd = 
3000.0 ]
[ Treated1casp9DN0pen1 
= 1.0 ]* [ timepointdays = 
7.0 ]* [ flashintensitymcd = 
10000.0 ]
[ Treated1casp9DN0pen1 
= 1.0 ]* [ timepointdays = 
7.0 ]* [ flashintensitymcd = 
25000.0 ]
[ Treated1casp9DN0pen1 
= 1.0 ]* [ timepointdays = 
14.0 ]* [ flashintensitymcd 
= 300.0 ]
[ Treated1casp9DN0pen1 
= 1.0 ]* [ timepointdays = 
14.0 ]* [ flashintensitymcd 
= 1000.0 ]
[ Treated1casp9DN0pen1 
= 1.0 ]* [ timepointdays = 
14.0 ]* [ flashintensitymcd 
= 3000.0 ]
[ Treated1casp9DN0pen1 
= 1.0 ]* [ timepointdays = 
14.0 ]* [ flashintensitymcd 
= 10000.0 ]
[ Treated1casp9DN0pen1 
= 1.0 ]* [ timepointdays = 
14.0 ]* [ flashintensitymcd 
= 25000.0 ]
.999 1.000 1.000 1.000
.999 .999 1.000 1.000
.999 .999 .999 1.000
.999 .999 .999 .999
.999 .999 .999 .999
.999 .999 .999 .999
.999 .999 .999 .999
.999 .999 .999 .999
.999 .999 .999 .999
.999 .999 .999 .999
.998 .999 .999 .999
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Working Correlation Matrixa
Measurement
Measurement
[
Treated1casp
9DN0pen1 = .
0 ]* [ 
timepointdays
= 14.0 ]* [ 
flashintensity
mcd = 
10000.0 ]
[
Treated1casp
9DN0pen1 = .
0 ]* [ 
timepointdays
= 14.0 ]* [ 
flashintensity
mcd = 
25000.0 ]
[
Treated1casp
9DN0pen1 = 
1.0 ]* [ 
timepointdays
= 7.0 ]* [ 
flashintensity
mcd = 100.0 ]
[
Treated1casp
9DN0pen1 = 
1.0 ]* [ 
timepointdays
= 7.0 ]* [ 
flashintensity
mcd = 300.0 ]
[ Treated1casp9DN0pen1 
= 1.0 ]* [ timepointdays = 
7.0 ]* [ flashintensitymcd = 
100.0 ]
[ Treated1casp9DN0pen1 
= 1.0 ]* [ timepointdays = 
7.0 ]* [ flashintensitymcd = 
300.0 ]
[ Treated1casp9DN0pen1 
= 1.0 ]* [ timepointdays = 
7.0 ]* [ flashintensitymcd = 
1000.0 ]
[ Treated1casp9DN0pen1 
= 1.0 ]* [ timepointdays = 
7.0 ]* [ flashintensitymcd = 
3000.0 ]
[ Treated1casp9DN0pen1 
= 1.0 ]* [ timepointdays = 
7.0 ]* [ flashintensitymcd = 
10000.0 ]
[ Treated1casp9DN0pen1 
= 1.0 ]* [ timepointdays = 
7.0 ]* [ flashintensitymcd = 
25000.0 ]
[ Treated1casp9DN0pen1 
= 1.0 ]* [ timepointdays = 
14.0 ]* [ flashintensitymcd 
= 300.0 ]
[ Treated1casp9DN0pen1 
= 1.0 ]* [ timepointdays = 
14.0 ]* [ flashintensitymcd 
= 1000.0 ]
[ Treated1casp9DN0pen1 
= 1.0 ]* [ timepointdays = 
14.0 ]* [ flashintensitymcd 
= 3000.0 ]
[ Treated1casp9DN0pen1 
= 1.0 ]* [ timepointdays = 
14.0 ]* [ flashintensitymcd 
= 10000.0 ]
[ Treated1casp9DN0pen1 
= 1.0 ]* [ timepointdays = 
14.0 ]* [ flashintensitymcd 
= 25000.0 ]
1.000 1.000 1.000 1.000
1.000 1.000 1.000 1.000
1.000 1.000 1.000 1.000
1.000 1.000 1.000 1.000
.999 1.000 1.000 1.000
.999 .999 1.000 1.000
.999 .999 .999 1.000
.999 .999 .999 .999
.999 .999 .999 .999
.999 .999 .999 .999
.999 .999 .999 .999
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Working Correlation Matrixa
Measurement
Measurement
[
Treated1casp
9DN0pen1 = 
1.0 ]* [ 
timepointdays
= 7.0 ]* [ 
flashintensity
mcd = 1000.0 
]
[
Treated1casp
9DN0pen1 = 
1.0 ]* [ 
timepointdays
= 7.0 ]* [ 
flashintensity
mcd = 3000.0 
]
[
Treated1casp
9DN0pen1 = 
1.0 ]* [ 
timepointdays
= 7.0 ]* [ 
flashintensity
mcd = 
10000.0 ]
[
Treated1casp
9DN0pen1 = 
1.0 ]* [ 
timepointdays
= 7.0 ]* [ 
flashintensity
mcd = 
25000.0 ]
[ Treated1casp9DN0pen1 
= 1.0 ]* [ timepointdays = 
7.0 ]* [ flashintensitymcd = 
100.0 ]
[ Treated1casp9DN0pen1 
= 1.0 ]* [ timepointdays = 
7.0 ]* [ flashintensitymcd = 
300.0 ]
[ Treated1casp9DN0pen1 
= 1.0 ]* [ timepointdays = 
7.0 ]* [ flashintensitymcd = 
1000.0 ]
[ Treated1casp9DN0pen1 
= 1.0 ]* [ timepointdays = 
7.0 ]* [ flashintensitymcd = 
3000.0 ]
[ Treated1casp9DN0pen1 
= 1.0 ]* [ timepointdays = 
7.0 ]* [ flashintensitymcd = 
10000.0 ]
[ Treated1casp9DN0pen1 
= 1.0 ]* [ timepointdays = 
7.0 ]* [ flashintensitymcd = 
25000.0 ]
[ Treated1casp9DN0pen1 
= 1.0 ]* [ timepointdays = 
14.0 ]* [ flashintensitymcd 
= 300.0 ]
[ Treated1casp9DN0pen1 
= 1.0 ]* [ timepointdays = 
14.0 ]* [ flashintensitymcd 
= 1000.0 ]
[ Treated1casp9DN0pen1 
= 1.0 ]* [ timepointdays = 
14.0 ]* [ flashintensitymcd 
= 3000.0 ]
[ Treated1casp9DN0pen1 
= 1.0 ]* [ timepointdays = 
14.0 ]* [ flashintensitymcd 
= 10000.0 ]
[ Treated1casp9DN0pen1 
= 1.0 ]* [ timepointdays = 
14.0 ]* [ flashintensitymcd 
= 25000.0 ]
1.000 1.000 1.000 1.000
1.000 1.000 1.000 1.000
1.000 1.000 1.000 1.000
1.000 1.000 1.000 1.000
1.000 1.000 1.000 1.000
1.000 1.000 1.000 1.000
1.000 1.000 1.000 1.000
1.000 1.000 1.000 1.000
.999 1.000 1.000 1.000
.999 .999 1.000 1.000
.999 .999 .999 1.000
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Working Correlation Matrixa
Measurement
Measurement
[
Treated1casp
9DN0pen1 = 
1.0 ]* [ 
timepointdays
= 14.0 ]* [ 
flashintensity
mcd = 300.0 ]
[
Treated1casp
9DN0pen1 = 
1.0 ]* [ 
timepointdays
= 14.0 ]* [ 
flashintensity
mcd = 1000.0 
]
[
Treated1casp
9DN0pen1 = 
1.0 ]* [ 
timepointdays
= 14.0 ]* [ 
flashintensity
mcd = 3000.0 
]
[
Treated1casp
9DN0pen1 = 
1.0 ]* [ 
timepointdays
= 14.0 ]* [ 
flashintensity
mcd = 
10000.0 ]
[ Treated1casp9DN0pen1 
= 1.0 ]* [ timepointdays = 
7.0 ]* [ flashintensitymcd = 
100.0 ]
[ Treated1casp9DN0pen1 
= 1.0 ]* [ timepointdays = 
7.0 ]* [ flashintensitymcd = 
300.0 ]
[ Treated1casp9DN0pen1 
= 1.0 ]* [ timepointdays = 
7.0 ]* [ flashintensitymcd = 
1000.0 ]
[ Treated1casp9DN0pen1 
= 1.0 ]* [ timepointdays = 
7.0 ]* [ flashintensitymcd = 
3000.0 ]
[ Treated1casp9DN0pen1 
= 1.0 ]* [ timepointdays = 
7.0 ]* [ flashintensitymcd = 
10000.0 ]
[ Treated1casp9DN0pen1 
= 1.0 ]* [ timepointdays = 
7.0 ]* [ flashintensitymcd = 
25000.0 ]
[ Treated1casp9DN0pen1 
= 1.0 ]* [ timepointdays = 
14.0 ]* [ flashintensitymcd 
= 300.0 ]
[ Treated1casp9DN0pen1 
= 1.0 ]* [ timepointdays = 
14.0 ]* [ flashintensitymcd 
= 1000.0 ]
[ Treated1casp9DN0pen1 
= 1.0 ]* [ timepointdays = 
14.0 ]* [ flashintensitymcd 
= 3000.0 ]
[ Treated1casp9DN0pen1 
= 1.0 ]* [ timepointdays = 
14.0 ]* [ flashintensitymcd 
= 10000.0 ]
[ Treated1casp9DN0pen1 
= 1.0 ]* [ timepointdays = 
14.0 ]* [ flashintensitymcd 
= 25000.0 ]
.999 .999 .999 .999
1.000 .999 .999 .999
1.000 1.000 .999 .999
1.000 1.000 1.000 .999
1.000 1.000 1.000 1.000
1.000 1.000 1.000 1.000
1.000 1.000 1.000 1.000
1.000 1.000 1.000 1.000
1.000 1.000 1.000 1.000
1.000 1.000 1.000 1.000
1.000 1.000 1.000 1.000
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Working Correlation Matrixa
Measurement
Measurement
[
Treated1casp
9DN0pen1 = 
1.0 ]* [ 
timepointdays
= 14.0 ]* [ 
flashintensity
mcd = 
25000.0 ]
[ Treated1casp9DN0pen1 
= 1.0 ]* [ timepointdays = 
7.0 ]* [ flashintensitymcd = 
100.0 ]
[ Treated1casp9DN0pen1 
= 1.0 ]* [ timepointdays = 
7.0 ]* [ flashintensitymcd = 
300.0 ]
[ Treated1casp9DN0pen1 
= 1.0 ]* [ timepointdays = 
7.0 ]* [ flashintensitymcd = 
1000.0 ]
[ Treated1casp9DN0pen1 
= 1.0 ]* [ timepointdays = 
7.0 ]* [ flashintensitymcd = 
3000.0 ]
[ Treated1casp9DN0pen1 
= 1.0 ]* [ timepointdays = 
7.0 ]* [ flashintensitymcd = 
10000.0 ]
[ Treated1casp9DN0pen1 
= 1.0 ]* [ timepointdays = 
7.0 ]* [ flashintensitymcd = 
25000.0 ]
[ Treated1casp9DN0pen1 
= 1.0 ]* [ timepointdays = 
14.0 ]* [ flashintensitymcd 
= 300.0 ]
[ Treated1casp9DN0pen1 
= 1.0 ]* [ timepointdays = 
14.0 ]* [ flashintensitymcd 
= 1000.0 ]
[ Treated1casp9DN0pen1 
= 1.0 ]* [ timepointdays = 
14.0 ]* [ flashintensitymcd 
= 3000.0 ]
[ Treated1casp9DN0pen1 
= 1.0 ]* [ timepointdays = 
14.0 ]* [ flashintensitymcd 
= 10000.0 ]
[ Treated1casp9DN0pen1 
= 1.0 ]* [ timepointdays = 
14.0 ]* [ flashintensitymcd 
= 25000.0 ]
.999
.999
.999
.999
.999
1.000
1.000
1.000
1.000
1.000
1.000
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Dependent Variable: bwaveamplitudev
 Model: (Intercept), timepointdays, flashintensitymcd, Treated1casp9DN0pen1, timepointdays * 
flashintensitymcd, timepointdays * Treated1casp9DN0pen1, flashintensitymcd * Treated1casp9DN0pen1, 
timepointdays * flashintensitymcd * Treated1casp9DN0pen1
The AR(1) working correlation matrix structure is computed assuming the measurements are equally 
spaced for all subjects.
a.
Estimated Marginal Means 1: Treated1casp9DN0pen1
Estimates
Treated1casp9DN0pen1 Mean Std. Error
95% Wald Confidence Interval
Lower Upper
.0
1.0
14.277 3.6012 8.708 23.407
21.388 3.9229 14.929 30.640
Estimated Marginal Means 2: timepointdays* flashintensitymcd* Tre
ated1casp9DN0pen1
Estimates
timepointdays flashintensitymcd Treated1casp9DN0pen1 Mean Std. Error
95% Wald ...
Lower
7.0 100.0 .0
1.0
300.0 .0
1.0
1000.0 .0
1.0
3000.0 .0
1.0
10000.0 .0
1.0
25000.0 .0
1.0
14.0 300.0 .0
1.0
1000.0 .0
1.0
3000.0 .0
1.0
10000.0 .0
1.0
25000.0 .0
1.0
2.841 1.3837 1.094
4.001 .6931 2.849
6.725 1.2475 4.675
8.819 2.7331 4.804
16.884 3.7767 10.891
22.204 6.9351 12.039
29.829 7.4697 18.259
45.663 13.9157 25.128
51.219 12.8263 31.353
74.263 19.6638 44.196
56.729 15.0556 33.721
79.888 21.3549 47.309
1.916 .4399 1.222
4.461 .8865 3.022
7.912 1.8744 4.974
13.383 2.0322 9.938
15.247 3.6020 9.596
22.659 3.1637 17.234
26.047 8.7760 13.457
36.391 7.1692 24.735
29.840 8.9412 16.586
40.999 6.6836 29.786
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Estimates
timepointdays flashintensitymcd Treated1casp9DN0pen1
95% Wald ...
Upper
7.0 100.0 .0
1.0
300.0 .0
1.0
1000.0 .0
1.0
3000.0 .0
1.0
10000.0 .0
1.0
25000.0 .0
1.0
14.0 300.0 .0
1.0
1000.0 .0
1.0
3000.0 .0
1.0
10000.0 .0
1.0
25000.0 .0
1.0
7.380
5.618
9.673
16.189
26.175
40.954
48.730
82.978
83.674
124.783
95.435
134.901
3.005
6.585
12.588
18.022
24.226
29.791
50.414
53.541
53.685
56.433
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 APPENDIX 15  
  
Appendix 15, p1
* Generalized Estimating Equations.
GENLIN AvgONLthickness BY Treated1nottreated0 normalisedslidenumber (ORDER
  /MODEL Treated1nottreated0 normalisedslidenumber Treated1nottreated0*nor
 DISTRIBUTION=GAMMA LINK=LOG
  /CRITERIA METHOD=FISHER(1) SCALE=MLE MAXITERATIONS=100 MAXSTEPHALVING=5 
  /EMMEANS TABLES=Treated1nottreated0 SCALE=ORIGINAL
  /EMMEANS TABLES=normalisedslidenumber SCALE=ORIGINAL
  /EMMEANS TABLES=Treated1nottreated0*normalisedslidenumber SCALE=ORIGINAL
  /REPEATED SUBJECT=Animal WITHINSUBJECT=Treated1nottreated0*normalisedsli
  /MISSING CLASSMISSING=EXCLUDE
  /PRINT CPS DESCRIPTIVES MODELINFO FIT SUMMARY WORKINGCORR.
Generalized Linear Models
Notes
Output Created
Comments
Input Active Dataset
Filter
Weight
Split File
N of Rows in Working 
Data File
Missing Value Handling Definition of Missing
Cases Used
Weight Handling
26-JUL-2013 23:36:31
DataSet2
<none>
<none>
<none>
112
User-defined missing values for factor, subject 
and within-subject variables are treated as 
missing.
Statistics are based on cases with valid data 
for all variables in the model.
not applicable
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Notes
Syntax
Resources Processor Time
Elapsed Time
GENLIN AvgONLthickness BY 
Treated1nottreated0 normalisedslidenumber 
(ORDER=ASCENDING)
   /MODEL Treated1nottreated0 
normalisedslidenumber
Treated1nottreated0*normalisedslidenumber
INTERCEPT=YES
  DISTRIBUTION=GAMMA LINK=LOG
   /CRITERIA METHOD=FISHER(1) 
SCALE=MLE MAXITERATIONS=100 
MAXSTEPHALVING=5 PCONVERGE=1E-006
(ABSOLUTE) SINGULAR=1E-012 
ANALYSISTYPE=3(WALD) CILEVEL=95 
LIKELIHOOD=FULL
   /EMMEANS TABLES=Treated1nottreated0 
SCALE=ORIGINAL
   /EMMEANS TABLES=normalisedslidenumber 
SCALE=ORIGINAL
   /EMMEANS 
TABLES=Treated1nottreated0*normalisedslide
number SCALE=ORIGINAL
   /REPEATED SUBJECT=Animal 
WITHINSUBJECT=Treated1nottreated0*norma
lisedslidenumber SORT=YES CORRTYPE=AR
(1) ADJUSTCORR=YES COVB=ROBUST 
MAXITERATIONS=100 PCONVERGE=1e-006
(ABSOLUTE) UPDATECORR=1
   /MISSING CLASSMISSING=EXCLUDE
   /PRINT CPS DESCRIPTIVES MODELINFO 
FIT SUMMARY WORKINGCORR.
00:00:00.33
00:00:00.32
[DataSet2] 
Model Information
Dependent Variable
Probability Distribution
Link Function
Subject Effect 1
Within-Subject Effect 1
2
Working Correlation Matrix Structure
AvgONLthickness
Gamma
Log
Animal
Treated1nottreated0
normalisedslidenumber
AR(1)
Case Processing Summary
N Percent
Included
Excluded
Total
111 99.1%
1 0.9%
112 100.0%
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Correlated Data Summary
Number of Levels Subject Effect Animal
Within-Subject Effect Treated1nottreated0
normalisedslidenumber
Number of Subjects
Number of Measurements 
per Subject
Minimum
Maximum
Correlation Matrix Dimension
8
2
7
8
13
14
14
Categorical Variable Information
N Percent
Factor Treated1nottreated0 .0
1.0
Total
normalisedslidenumber 1
2
3
4
5
6
7
Total
56 50.5%
55 49.5%
111 100.0%
16 14.4%
16 14.4%
16 14.4%
15 13.5%
16 14.4%
16 14.4%
16 14.4%
111 100.0%
Continuous Variable Information
N Minimum Maximum Mean
Dependent Variable AvgONLthickness 111 39.94070536 123.6170213 69.41941045
Continuous Variable Information
Std. Deviation
Dependent Variable AvgONLthickness 20.12078517
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Goodness of Fita
Value
Quasi Likelihood under 
Independence Model 
Criterion (QIC)b
Corrected Quasi 
Likelihood under 
Independence Model 
Criterion (QICC)b
33.422
33.934
Dependent Variable: AvgONLthickness
 Model: (Intercept), 
Treated1nottreated0,
normalisedslidenumber,
Treated1nottreated0 * 
normalisedslidenumber
Information criteria are in small-is-better form.a.
Computed using the full log quasi-likelihood function.b.
Tests of Model Effects
Source
Type III
Wald Chi-
Square df Sig.
(Intercept)
Treated1nottreated0
normalisedslidenumber
Treated1nottreated0 * 
normalisedslidenumber
17601.120 1 .000
.313 1 .576
13709.115 6 .000
6.746 6 .345
Dependent Variable: AvgONLthickness
 Model: (Intercept), Treated1nottreated0, normalisedslidenumber, 
Treated1nottreated0 * normalisedslidenumber
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Working Correlation Matrixa
Measurement
Measurement
[
Treated1nottr
eated0 = .0 ]* 
[
normalisedslid
enumber = 1 ]
[
Treated1nottr
eated0 = .0 ]* 
[
normalisedslid
enumber = 2 ]
[
Treated1nottr
eated0 = .0 ]* 
[
normalisedslid
enumber = 3 ]
[
Treated1nottr
eated0 = .0 ]* 
[
normalisedslid
enumber = 4 ]
[ Treated1nottreated0 = .0 
]* [ 
normalisedslidenumber = 
1 ]
[ Treated1nottreated0 = .0 
]* [ 
normalisedslidenumber = 
2 ]
[ Treated1nottreated0 = .0 
]* [ 
normalisedslidenumber = 
3 ]
[ Treated1nottreated0 = .0 
]* [ 
normalisedslidenumber = 
4 ]
[ Treated1nottreated0 = .0 
]* [ 
normalisedslidenumber = 
5 ]
[ Treated1nottreated0 = .0 
]* [ 
normalisedslidenumber = 
6 ]
[ Treated1nottreated0 = .0 
]* [ 
normalisedslidenumber = 
7 ]
[ Treated1nottreated0 = 
1.0 ]* [ 
normalisedslidenumber = 
1 ]
[ Treated1nottreated0 = 
1.0 ]* [ 
normalisedslidenumber = 
2 ]
[ Treated1nottreated0 = 
1.0 ]* [ 
normalisedslidenumber = 
3 ]
1.000 .554 .307 .170
.554 1.000 .554 .307
.307 .554 1.000 .554
.170 .307 .554 1.000
.094 .170 .307 .554
.052 .094 .170 .307
.029 .052 .094 .170
.016 .029 .052 .094
.009 .016 .029 .052
.005 .009 .016 .029
Page 5
Appendix 15, p6
Working Correlation Matrixa
Measurement
Measurement
[
Treated1nottr
eated0 = .0 ]* 
[
normalisedslid
enumber = 5 ]
[
Treated1nottr
eated0 = .0 ]* 
[
normalisedslid
enumber = 6 ]
[
Treated1nottr
eated0 = .0 ]* 
[
normalisedslid
enumber = 7 ]
[
Treated1nottr
eated0 = 1.0 ]
* [ 
normalisedslid
enumber = 1 ]
[ Treated1nottreated0 = .0 
]* [ 
normalisedslidenumber = 
1 ]
[ Treated1nottreated0 = .0 
]* [ 
normalisedslidenumber = 
2 ]
[ Treated1nottreated0 = .0 
]* [ 
normalisedslidenumber = 
3 ]
[ Treated1nottreated0 = .0 
]* [ 
normalisedslidenumber = 
4 ]
[ Treated1nottreated0 = .0 
]* [ 
normalisedslidenumber = 
5 ]
[ Treated1nottreated0 = .0 
]* [ 
normalisedslidenumber = 
6 ]
[ Treated1nottreated0 = .0 
]* [ 
normalisedslidenumber = 
7 ]
[ Treated1nottreated0 = 
1.0 ]* [ 
normalisedslidenumber = 
1 ]
[ Treated1nottreated0 = 
1.0 ]* [ 
normalisedslidenumber = 
2 ]
[ Treated1nottreated0 = 
1.0 ]* [ 
normalisedslidenumber = 
3 ]
.094 .052 .029 .016
.170 .094 .052 .029
.307 .170 .094 .052
.554 .307 .170 .094
1.000 .554 .307 .170
.554 1.000 .554 .307
.307 .554 1.000 .554
.170 .307 .554 1.000
.094 .170 .307 .554
.052 .094 .170 .307
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Working Correlation Matrixa
Measurement
Measurement
[
Treated1nottr
eated0 = 1.0 ]
* [ 
normalisedslid
enumber = 2 ]
[
Treated1nottr
eated0 = 1.0 ]
* [ 
normalisedslid
enumber = 3 ]
[
Treated1nottr
eated0 = 1.0 ]
* [ 
normalisedslid
enumber = 4 ]
[
Treated1nottr
eated0 = 1.0 ]
* [ 
normalisedslid
enumber = 5 ]
[ Treated1nottreated0 = .0 
]* [ 
normalisedslidenumber = 
1 ]
[ Treated1nottreated0 = .0 
]* [ 
normalisedslidenumber = 
2 ]
[ Treated1nottreated0 = .0 
]* [ 
normalisedslidenumber = 
3 ]
[ Treated1nottreated0 = .0 
]* [ 
normalisedslidenumber = 
4 ]
[ Treated1nottreated0 = .0 
]* [ 
normalisedslidenumber = 
5 ]
[ Treated1nottreated0 = .0 
]* [ 
normalisedslidenumber = 
6 ]
[ Treated1nottreated0 = .0 
]* [ 
normalisedslidenumber = 
7 ]
[ Treated1nottreated0 = 
1.0 ]* [ 
normalisedslidenumber = 
1 ]
[ Treated1nottreated0 = 
1.0 ]* [ 
normalisedslidenumber = 
2 ]
[ Treated1nottreated0 = 
1.0 ]* [ 
normalisedslidenumber = 
3 ]
.009 .005 .003 .002
.016 .009 .005 .003
.029 .016 .009 .005
.052 .029 .016 .009
.094 .052 .029 .016
.170 .094 .052 .029
.307 .170 .094 .052
.554 .307 .170 .094
1.000 .554 .307 .170
.554 1.000 .554 .307
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Working Correlation Matrixa
Measurement
Measurement
[
Treated1nottr
eated0 = 1.0 ]
* [ 
normalisedslid
enumber = 6 ]
[
Treated1nottr
eated0 = 1.0 ]
* [ 
normalisedslid
enumber = 7 ]
[ Treated1nottreated0 = .0 
]* [ 
normalisedslidenumber = 
1 ]
[ Treated1nottreated0 = .0 
]* [ 
normalisedslidenumber = 
2 ]
[ Treated1nottreated0 = .0 
]* [ 
normalisedslidenumber = 
3 ]
[ Treated1nottreated0 = .0 
]* [ 
normalisedslidenumber = 
4 ]
[ Treated1nottreated0 = .0 
]* [ 
normalisedslidenumber = 
5 ]
[ Treated1nottreated0 = .0 
]* [ 
normalisedslidenumber = 
6 ]
[ Treated1nottreated0 = .0 
]* [ 
normalisedslidenumber = 
7 ]
[ Treated1nottreated0 = 
1.0 ]* [ 
normalisedslidenumber = 
1 ]
[ Treated1nottreated0 = 
1.0 ]* [ 
normalisedslidenumber = 
2 ]
[ Treated1nottreated0 = 
1.0 ]* [ 
normalisedslidenumber = 
3 ]
.001 .000
.002 .001
.003 .002
.005 .003
.009 .005
.016 .009
.029 .016
.052 .029
.094 .052
.170 .094
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Working Correlation Matrixa
Measurement
Measurement
[
Treated1nottr
eated0 = .0 ]* 
[
normalisedslid
enumber = 1 ]
[
Treated1nottr
eated0 = .0 ]* 
[
normalisedslid
enumber = 2 ]
[
Treated1nottr
eated0 = .0 ]* 
[
normalisedslid
enumber = 3 ]
[
Treated1nottr
eated0 = .0 ]* 
[
normalisedslid
enumber = 4 ]
[ Treated1nottreated0 = 
1.0 ]* [ 
normalisedslidenumber = 
4 ]
[ Treated1nottreated0 = 
1.0 ]* [ 
normalisedslidenumber = 
5 ]
[ Treated1nottreated0 = 
1.0 ]* [ 
normalisedslidenumber = 
6 ]
[ Treated1nottreated0 = 
1.0 ]* [ 
normalisedslidenumber = 
7 ]
.003 .005 .009 .016
.002 .003 .005 .009
.001 .002 .003 .005
.000 .001 .002 .003
Working Correlation Matrixa
Measurement
Measurement
[
Treated1nottr
eated0 = .0 ]* 
[
normalisedslid
enumber = 5 ]
[
Treated1nottr
eated0 = .0 ]* 
[
normalisedslid
enumber = 6 ]
[
Treated1nottr
eated0 = .0 ]* 
[
normalisedslid
enumber = 7 ]
[
Treated1nottr
eated0 = 1.0 ]
* [ 
normalisedslid
enumber = 1 ]
[ Treated1nottreated0 = 
1.0 ]* [ 
normalisedslidenumber = 
4 ]
[ Treated1nottreated0 = 
1.0 ]* [ 
normalisedslidenumber = 
5 ]
[ Treated1nottreated0 = 
1.0 ]* [ 
normalisedslidenumber = 
6 ]
[ Treated1nottreated0 = 
1.0 ]* [ 
normalisedslidenumber = 
7 ]
.029 .052 .094 .170
.016 .029 .052 .094
.009 .016 .029 .052
.005 .009 .016 .029
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Working Correlation Matrixa
Measurement
Measurement
[
Treated1nottr
eated0 = 1.0 ]
* [ 
normalisedslid
enumber = 2 ]
[
Treated1nottr
eated0 = 1.0 ]
* [ 
normalisedslid
enumber = 3 ]
[
Treated1nottr
eated0 = 1.0 ]
* [ 
normalisedslid
enumber = 4 ]
[
Treated1nottr
eated0 = 1.0 ]
* [ 
normalisedslid
enumber = 5 ]
[ Treated1nottreated0 = 
1.0 ]* [ 
normalisedslidenumber = 
4 ]
[ Treated1nottreated0 = 
1.0 ]* [ 
normalisedslidenumber = 
5 ]
[ Treated1nottreated0 = 
1.0 ]* [ 
normalisedslidenumber = 
6 ]
[ Treated1nottreated0 = 
1.0 ]* [ 
normalisedslidenumber = 
7 ]
.307 .554 1.000 .554
.170 .307 .554 1.000
.094 .170 .307 .554
.052 .094 .170 .307
Working Correlation Matrixa
Measurement
Measurement
[
Treated1nottr
eated0 = 1.0 ]
* [ 
normalisedslid
enumber = 6 ]
[
Treated1nottr
eated0 = 1.0 ]
* [ 
normalisedslid
enumber = 7 ]
[ Treated1nottreated0 = 
1.0 ]* [ 
normalisedslidenumber = 
4 ]
[ Treated1nottreated0 = 
1.0 ]* [ 
normalisedslidenumber = 
5 ]
[ Treated1nottreated0 = 
1.0 ]* [ 
normalisedslidenumber = 
6 ]
[ Treated1nottreated0 = 
1.0 ]* [ 
normalisedslidenumber = 
7 ]
.307 .170
.554 .307
1.000 .554
.554 1.000
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Dependent Variable: AvgONLthickness
 Model: (Intercept), Treated1nottreated0, normalisedslidenumber, Treated1nottreated0 * 
normalisedslidenumber
The AR(1) working correlation matrix structure is computed assuming the measurements are equally 
spaced for all subjects.
a.
Estimated Marginal Means 1: Treated1nottreated0
Estimates
Treated1nottreated0 Mean Std. Error
95% Wald Confidence Interval
Lower Upper
.0
1.0
69.85950532 4.112606223 62.24658782 78.40350217
67.28871774 1.912681035 63.64244535 71.14389636
Estimated Marginal Means 2: normalisedslidenumber
Estimates
normalisedslidenumber Mean Std. Error
95% Wald Confidence Interval
Lower Upper
1
2
3
4
5
6
7
88.05663912 5.944779439 77.14304144 100.5142077
68.90674295 2.568269231 64.05249057 74.12887744
61.92577866 2.330846939 57.52184284 66.66688466
58.43305501 2.075539455 54.50344488 62.64598366
60.58101806 3.188380674 54.64341162 67.16381062
65.43657841 5.298489468 55.83385658 76.69084775
81.82313362 5.509295251 71.70727410 93.36605358
Estimated Marginal Means 3: Treated1nottreated0* normalisedslide
number
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Estimates
Treated1nottreated0 normalisedslidenumber Mean Std. Error
95% Wald ...
Lower
.0 1
2
3
4
5
6
7
1.0 1
2
3
4
5
6
7
87.83600910 7.734649320 73.91245454
75.08609738 6.588595422 63.22210814
64.23233662 6.010611476 53.46894330
60.96729483 4.531685000 52.70202596
59.55281837 3.962682303 52.27124317
63.62614070 3.993716958 56.26093476
82.97702642 6.480948218 71.19909739
88.27782333 9.435468440 71.59323193
63.23593034 4.346846787 55.26525751
59.70204828 4.100323017 52.18298330
56.00415644 1.942663635 52.32315348
61.62696996 2.487782598 56.93891208
67.29853088 8.069474740 53.20368349
80.68528705 7.600407484 67.08303596
Estimates
Treated1nottreated0 normalisedslidenumber
95% Wald ...
Upper
.0 1
2
3
4
5
6
7
1.0 1
2
3
4
5
6
7
104.3824690
89.17643188
77.16242016
70.52880742
67.84874362
71.95553714
96.70328932
108.8507095
72.35617937
68.30453806
59.94412281
66.70101848
85.12741903
97.04563088
* Generalized Estimating Equations.
GENLIN AvgONLthickness BY Treated1nottreated0 normalisedslidenumber (ORDER
  /MODEL Treated1nottreated0 normalisedslidenumber INTERCEPT=YES
 DISTRIBUTION=GAMMA LINK=LOG
  /CRITERIA METHOD=FISHER(1) SCALE=MLE MAXITERATIONS=100 MAXSTEPHALVING=5 
  /EMMEANS TABLES=Treated1nottreated0 SCALE=ORIGINAL
  /EMMEANS TABLES=normalisedslidenumber SCALE=ORIGINAL
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  /EMMEANS TABLES=Treated1nottreated0*normalisedslidenumber SCALE=ORIGINAL
  /REPEATED SUBJECT=Animal WITHINSUBJECT=Treated1nottreated0*normalisedsli
  /MISSING CLASSMISSING=EXCLUDE
  /PRINT CPS DESCRIPTIVES MODELINFO FIT SUMMARY WORKINGCORR.
Generalized Linear Models
Notes
Output Created
Comments
Input Active Dataset
Filter
Weight
Split File
N of Rows in Working 
Data File
Missing Value Handling Definition of Missing
Cases Used
Weight Handling
Syntax
Resources Processor Time
Elapsed Time
26-JUL-2013 23:36:58
DataSet2
<none>
<none>
<none>
112
User-defined missing values for factor, subject 
and within-subject variables are treated as 
missing.
Statistics are based on cases with valid data 
for all variables in the model.
not applicable
GENLIN AvgONLthickness BY 
Treated1nottreated0 normalisedslidenumber 
(ORDER=ASCENDING)
   /MODEL Treated1nottreated0 
normalisedslidenumber INTERCEPT=YES
  DISTRIBUTION=GAMMA LINK=LOG
   /CRITERIA METHOD=FISHER(1) 
SCALE=MLE MAXITERATIONS=100 
MAXSTEPHALVING=5 PCONVERGE=1E-006
(ABSOLUTE) SINGULAR=1E-012 
ANALYSISTYPE=3(WALD) CILEVEL=95 
LIKELIHOOD=FULL
   /EMMEANS TABLES=Treated1nottreated0 
SCALE=ORIGINAL
   /EMMEANS TABLES=normalisedslidenumber 
SCALE=ORIGINAL
   /EMMEANS 
TABLES=Treated1nottreated0*normalisedslide
number SCALE=ORIGINAL
   /REPEATED SUBJECT=Animal 
WITHINSUBJECT=Treated1nottreated0*norma
lisedslidenumber SORT=YES CORRTYPE=AR
(1) ADJUSTCORR=YES COVB=ROBUST 
MAXITERATIONS=100 PCONVERGE=1e-006
(ABSOLUTE) UPDATECORR=1
   /MISSING CLASSMISSING=EXCLUDE
   /PRINT CPS DESCRIPTIVES MODELINFO 
FIT SUMMARY WORKINGCORR.
00:00:00.31
00:00:00.37
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[DataSet2] 
Model Information
Dependent Variable
Probability Distribution
Link Function
Subject Effect 1
Within-Subject Effect 1
2
Working Correlation Matrix Structure
AvgONLthickness
Gamma
Log
Animal
Treated1nottreated0
normalisedslidenumber
AR(1)
Case Processing Summary
N Percent
Included
Excluded
Total
111 99.1%
1 0.9%
112 100.0%
Correlated Data Summary
Number of Levels Subject Effect Animal
Within-Subject Effect Treated1nottreated0
normalisedslidenumber
Number of Subjects
Number of Measurements 
per Subject
Minimum
Maximum
Correlation Matrix Dimension
8
2
7
8
13
14
14
Categorical Variable Information
N Percent
Factor Treated1nottreated0 .0
1.0
Total
normalisedslidenumber 1
2
3
4
5
6
7
Total
56 50.5%
55 49.5%
111 100.0%
16 14.4%
16 14.4%
16 14.4%
15 13.5%
16 14.4%
16 14.4%
16 14.4%
111 100.0%
Continuous Variable Information
N Minimum Maximum Mean
Dependent Variable AvgONLthickness 111 39.94070536 123.6170213 69.41941045
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Continuous Variable Information
Std. Deviation
Dependent Variable AvgONLthickness 20.12078517
Goodness of Fita
Value
Quasi Likelihood under 
Independence Model 
Criterion (QIC)b
Corrected Quasi 
Likelihood under 
Independence Model 
Criterion (QICC)b
24.491
22.094
Dependent Variable: AvgONLthickness
 Model: (Intercept), 
Treated1nottreated0,
normalisedslidenumber
Information criteria are in small-is-better form.a.
Computed using the full log quasi-likelihood function.b.
Tests of Model Effects
Source
Type III
Wald Chi-
Square df Sig.
(Intercept)
Treated1nottreated0
normalisedslidenumber
13584.325 1 .000
.160 1 .689
2007.383 6 .000
Dependent Variable: AvgONLthickness
 Model: (Intercept), Treated1nottreated0, normalisedslidenumber
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Working Correlation Matrixa
Measurement
Measurement
[
Treated1nottr
eated0 = .0 ]* 
[
normalisedslid
enumber = 1 ]
[
Treated1nottr
eated0 = .0 ]* 
[
normalisedslid
enumber = 2 ]
[
Treated1nottr
eated0 = .0 ]* 
[
normalisedslid
enumber = 3 ]
[
Treated1nottr
eated0 = .0 ]* 
[
normalisedslid
enumber = 4 ]
[ Treated1nottreated0 = .0 
]* [ 
normalisedslidenumber = 
1 ]
[ Treated1nottreated0 = .0 
]* [ 
normalisedslidenumber = 
2 ]
[ Treated1nottreated0 = .0 
]* [ 
normalisedslidenumber = 
3 ]
[ Treated1nottreated0 = .0 
]* [ 
normalisedslidenumber = 
4 ]
[ Treated1nottreated0 = .0 
]* [ 
normalisedslidenumber = 
5 ]
[ Treated1nottreated0 = .0 
]* [ 
normalisedslidenumber = 
6 ]
[ Treated1nottreated0 = .0 
]* [ 
normalisedslidenumber = 
7 ]
[ Treated1nottreated0 = 
1.0 ]* [ 
normalisedslidenumber = 
1 ]
[ Treated1nottreated0 = 
1.0 ]* [ 
normalisedslidenumber = 
2 ]
[ Treated1nottreated0 = 
1.0 ]* [ 
normalisedslidenumber = 
3 ]
1.000 .542 .294 .159
.542 1.000 .542 .294
.294 .542 1.000 .542
.159 .294 .542 1.000
.086 .159 .294 .542
.047 .086 .159 .294
.025 .047 .086 .159
.014 .025 .047 .086
.007 .014 .025 .047
.004 .007 .014 .025
Page 16
Appendix 15, p17
Working Correlation Matrixa
Measurement
Measurement
[
Treated1nottr
eated0 = .0 ]* 
[
normalisedslid
enumber = 5 ]
[
Treated1nottr
eated0 = .0 ]* 
[
normalisedslid
enumber = 6 ]
[
Treated1nottr
eated0 = .0 ]* 
[
normalisedslid
enumber = 7 ]
[
Treated1nottr
eated0 = 1.0 ]
* [ 
normalisedslid
enumber = 1 ]
[ Treated1nottreated0 = .0 
]* [ 
normalisedslidenumber = 
1 ]
[ Treated1nottreated0 = .0 
]* [ 
normalisedslidenumber = 
2 ]
[ Treated1nottreated0 = .0 
]* [ 
normalisedslidenumber = 
3 ]
[ Treated1nottreated0 = .0 
]* [ 
normalisedslidenumber = 
4 ]
[ Treated1nottreated0 = .0 
]* [ 
normalisedslidenumber = 
5 ]
[ Treated1nottreated0 = .0 
]* [ 
normalisedslidenumber = 
6 ]
[ Treated1nottreated0 = .0 
]* [ 
normalisedslidenumber = 
7 ]
[ Treated1nottreated0 = 
1.0 ]* [ 
normalisedslidenumber = 
1 ]
[ Treated1nottreated0 = 
1.0 ]* [ 
normalisedslidenumber = 
2 ]
[ Treated1nottreated0 = 
1.0 ]* [ 
normalisedslidenumber = 
3 ]
.086 .047 .025 .014
.159 .086 .047 .025
.294 .159 .086 .047
.542 .294 .159 .086
1.000 .542 .294 .159
.542 1.000 .542 .294
.294 .542 1.000 .542
.159 .294 .542 1.000
.086 .159 .294 .542
.047 .086 .159 .294
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Working Correlation Matrixa
Measurement
Measurement
[
Treated1nottr
eated0 = 1.0 ]
* [ 
normalisedslid
enumber = 2 ]
[
Treated1nottr
eated0 = 1.0 ]
* [ 
normalisedslid
enumber = 3 ]
[
Treated1nottr
eated0 = 1.0 ]
* [ 
normalisedslid
enumber = 4 ]
[
Treated1nottr
eated0 = 1.0 ]
* [ 
normalisedslid
enumber = 5 ]
[ Treated1nottreated0 = .0 
]* [ 
normalisedslidenumber = 
1 ]
[ Treated1nottreated0 = .0 
]* [ 
normalisedslidenumber = 
2 ]
[ Treated1nottreated0 = .0 
]* [ 
normalisedslidenumber = 
3 ]
[ Treated1nottreated0 = .0 
]* [ 
normalisedslidenumber = 
4 ]
[ Treated1nottreated0 = .0 
]* [ 
normalisedslidenumber = 
5 ]
[ Treated1nottreated0 = .0 
]* [ 
normalisedslidenumber = 
6 ]
[ Treated1nottreated0 = .0 
]* [ 
normalisedslidenumber = 
7 ]
[ Treated1nottreated0 = 
1.0 ]* [ 
normalisedslidenumber = 
1 ]
[ Treated1nottreated0 = 
1.0 ]* [ 
normalisedslidenumber = 
2 ]
[ Treated1nottreated0 = 
1.0 ]* [ 
normalisedslidenumber = 
3 ]
.007 .004 .002 .001
.014 .007 .004 .002
.025 .014 .007 .004
.047 .025 .014 .007
.086 .047 .025 .014
.159 .086 .047 .025
.294 .159 .086 .047
.542 .294 .159 .086
1.000 .542 .294 .159
.542 1.000 .542 .294
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Working Correlation Matrixa
Measurement
Measurement
[
Treated1nottr
eated0 = 1.0 ]
* [ 
normalisedslid
enumber = 6 ]
[
Treated1nottr
eated0 = 1.0 ]
* [ 
normalisedslid
enumber = 7 ]
[ Treated1nottreated0 = .0 
]* [ 
normalisedslidenumber = 
1 ]
[ Treated1nottreated0 = .0 
]* [ 
normalisedslidenumber = 
2 ]
[ Treated1nottreated0 = .0 
]* [ 
normalisedslidenumber = 
3 ]
[ Treated1nottreated0 = .0 
]* [ 
normalisedslidenumber = 
4 ]
[ Treated1nottreated0 = .0 
]* [ 
normalisedslidenumber = 
5 ]
[ Treated1nottreated0 = .0 
]* [ 
normalisedslidenumber = 
6 ]
[ Treated1nottreated0 = .0 
]* [ 
normalisedslidenumber = 
7 ]
[ Treated1nottreated0 = 
1.0 ]* [ 
normalisedslidenumber = 
1 ]
[ Treated1nottreated0 = 
1.0 ]* [ 
normalisedslidenumber = 
2 ]
[ Treated1nottreated0 = 
1.0 ]* [ 
normalisedslidenumber = 
3 ]
.001 .000
.001 .001
.002 .001
.004 .002
.007 .004
.014 .007
.025 .014
.047 .025
.086 .047
.159 .086
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Working Correlation Matrixa
Measurement
Measurement
[
Treated1nottr
eated0 = .0 ]* 
[
normalisedslid
enumber = 1 ]
[
Treated1nottr
eated0 = .0 ]* 
[
normalisedslid
enumber = 2 ]
[
Treated1nottr
eated0 = .0 ]* 
[
normalisedslid
enumber = 3 ]
[
Treated1nottr
eated0 = .0 ]* 
[
normalisedslid
enumber = 4 ]
[ Treated1nottreated0 = 
1.0 ]* [ 
normalisedslidenumber = 
4 ]
[ Treated1nottreated0 = 
1.0 ]* [ 
normalisedslidenumber = 
5 ]
[ Treated1nottreated0 = 
1.0 ]* [ 
normalisedslidenumber = 
6 ]
[ Treated1nottreated0 = 
1.0 ]* [ 
normalisedslidenumber = 
7 ]
.002 .004 .007 .014
.001 .002 .004 .007
.001 .001 .002 .004
.000 .001 .001 .002
Working Correlation Matrixa
Measurement
Measurement
[
Treated1nottr
eated0 = .0 ]* 
[
normalisedslid
enumber = 5 ]
[
Treated1nottr
eated0 = .0 ]* 
[
normalisedslid
enumber = 6 ]
[
Treated1nottr
eated0 = .0 ]* 
[
normalisedslid
enumber = 7 ]
[
Treated1nottr
eated0 = 1.0 ]
* [ 
normalisedslid
enumber = 1 ]
[ Treated1nottreated0 = 
1.0 ]* [ 
normalisedslidenumber = 
4 ]
[ Treated1nottreated0 = 
1.0 ]* [ 
normalisedslidenumber = 
5 ]
[ Treated1nottreated0 = 
1.0 ]* [ 
normalisedslidenumber = 
6 ]
[ Treated1nottreated0 = 
1.0 ]* [ 
normalisedslidenumber = 
7 ]
.025 .047 .086 .159
.014 .025 .047 .086
.007 .014 .025 .047
.004 .007 .014 .025
Page 20
Appendix 15, p21
Working Correlation Matrixa
Measurement
Measurement
[
Treated1nottr
eated0 = 1.0 ]
* [ 
normalisedslid
enumber = 2 ]
[
Treated1nottr
eated0 = 1.0 ]
* [ 
normalisedslid
enumber = 3 ]
[
Treated1nottr
eated0 = 1.0 ]
* [ 
normalisedslid
enumber = 4 ]
[
Treated1nottr
eated0 = 1.0 ]
* [ 
normalisedslid
enumber = 5 ]
[ Treated1nottreated0 = 
1.0 ]* [ 
normalisedslidenumber = 
4 ]
[ Treated1nottreated0 = 
1.0 ]* [ 
normalisedslidenumber = 
5 ]
[ Treated1nottreated0 = 
1.0 ]* [ 
normalisedslidenumber = 
6 ]
[ Treated1nottreated0 = 
1.0 ]* [ 
normalisedslidenumber = 
7 ]
.294 .542 1.000 .542
.159 .294 .542 1.000
.086 .159 .294 .542
.047 .086 .159 .294
Working Correlation Matrixa
Measurement
Measurement
[
Treated1nottr
eated0 = 1.0 ]
* [ 
normalisedslid
enumber = 6 ]
[
Treated1nottr
eated0 = 1.0 ]
* [ 
normalisedslid
enumber = 7 ]
[ Treated1nottreated0 = 
1.0 ]* [ 
normalisedslidenumber = 
4 ]
[ Treated1nottreated0 = 
1.0 ]* [ 
normalisedslidenumber = 
5 ]
[ Treated1nottreated0 = 
1.0 ]* [ 
normalisedslidenumber = 
6 ]
[ Treated1nottreated0 = 
1.0 ]* [ 
normalisedslidenumber = 
7 ]
.294 .159
.542 .294
1.000 .542
.542 1.000
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Dependent Variable: AvgONLthickness
 Model: (Intercept), Treated1nottreated0, normalisedslidenumber
The AR(1) working correlation matrix structure is computed assuming the measurements are equally 
spaced for all subjects.
a.
Estimated Marginal Means 1: Treated1nottreated0
Estimates
Treated1nottreated0 Mean Std. Error
95% Wald Confidence Interval
Lower Upper
.0
1.0
69.46610242 4.302361785 61.52534042 78.43173808
67.65685973 2.110143327 63.64492701 71.92168934
Estimated Marginal Means 2: normalisedslidenumber
Estimates
normalisedslidenumber Mean Std. Error
95% Wald Confidence Interval
Lower Upper
1
2
3
4
5
6
7
88.14746073 5.436683852 78.11062696 99.47397857
69.11241924 2.701752167 64.01486118 74.61590019
61.93692772 2.497201673 57.23089293 67.02993469
58.55154001 2.297248294 54.21778119 63.23170669
60.53309176 3.300297963 54.39824302 67.35980786
65.33389186 5.629503867 55.18164337 77.35393809
81.45381344 5.655572615 71.09025131 93.32817935
Estimated Marginal Means 3: Treated1nottreated0* normalisedslide
number
Estimates
Treated1nottreated0 normalisedslidenumber Mean Std. Error
95% Wald ...
Lower
.0 1
2
3
4
5
6
7
1.0 1
2
3
4
5
6
7
89.31828057 6.104277112 78.12080455
70.03040588 4.703267374 61.39311085
62.75960581 4.159313716 55.11475719
59.32925163 3.695102932 52.51156133
61.33712337 4.976595353 52.31919560
66.20169016 6.614576600 54.42780606
82.53572482 7.070178987 69.77925117
86.99198846 6.221369552 75.61435193
68.20646593 1.834131442 64.70472481
61.12503363 1.967610177 57.38772364
57.78402294 2.144243289 53.73057389
59.73959972 2.343830833 55.31796075
64.47746900 5.411113132 54.69819355
80.38608419 5.381129809 70.50185413
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Estimates
Treated1nottreated0 normalisedslidenumber
95% Wald ...
Upper
.0 1
2
3
4
5
6
7
1.0 1
2
3
4
5
6
7
102.1207512
79.88286764
71.46485482
67.03209750
71.90941413
80.52251409
97.62423296
100.0816097
71.89771702
65.10573167
62.14326528
64.51466623
76.00514275
91.65606508
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 APPENDIX 16  
  
Appendix 16, p1
DATASET ACTIVATE DataSet3.
DATASET CLOSE DataSet4.
GET DATA /TYPE=XLSX
 /FILE='C:\Users\Public\Documents\PhD\ERG\Results\U-CEM423-43\U - ERG Num
 /SHEET=name 'Sheet1'
 /CELLRANGE=full
 /READNAMES=on
 /ASSUMEDSTRWIDTH=32767.
EXECUTE.
DATASET NAME DataSet5 WINDOW=FRONT.
* Generalized Estimating Equations.
GENLIN awaveamplitudev BY timepointdays flashintensitymcd Treated1casp6DN
 /MODEL timepointdays flashintensitymcd Treated1casp6DN0pen1 timepointday
DISTRIBUTION=GAMMA LINK=LOG
 /CRITERIA METHOD=FISHER(1) SCALE=MLE MAXITERATIONS=100 MAXSTEPHALVING=5 
 /EMMEANS TABLES=Treated1casp6DN0pen1 SCALE=ORIGINAL
 /EMMEANS TABLES=timepointdays*flashintensitymcd*Treated1casp6DN0pen1 SCA
 /REPEATED SUBJECT=animal WITHINSUBJECT=Treated1casp6DN0pen1*timepointday
 /MISSING CLASSMISSING=EXCLUDE
 /PRINT CPS DESCRIPTIVES MODELINFO FIT SUMMARY WORKINGCORR.
Generalized Linear Models
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Notes
Output Created
Comments
Input Active Dataset
Filter
Weight
Split File
N of Rows in Working 
Data File
Missing Value Handling Definition of Missing
Cases Used
Weight Handling
Syntax
Resources Processor Time
Elapsed Time
27-JUL-2013 00:23:26
DataSet5
<none>
<none>
<none>
315
User-defined missing values for factor, subject 
and within-subject variables are treated as 
missing.
Statistics are based on cases with valid data 
for all variables in the model.
not applicable
GENLIN awaveamplitudev BY timepointdays 
flashintensitymcd Treated1casp6DN0pen1 
(ORDER=ASCENDING)
   /MODEL timepointdays flashintensitymcd 
Treated1casp6DN0pen1
timepointdays*flashintensitymcd
timepointdays*Treated1casp6DN0pen1
flashintensitymcd*Treated1casp6DN0pen1
timepointdays*flashintensitymcd*Treated1casp
6DN0pen1 INTERCEPT=YES
  DISTRIBUTION=GAMMA LINK=LOG
   /CRITERIA METHOD=FISHER(1) 
SCALE=MLE MAXITERATIONS=100 
MAXSTEPHALVING=5 PCONVERGE=1E-006
(ABSOLUTE) SINGULAR=1E-012 
ANALYSISTYPE=3(WALD) CILEVEL=95 
LIKELIHOOD=FULL
   /EMMEANS 
TABLES=Treated1casp6DN0pen1
SCALE=ORIGINAL
   /EMMEANS 
TABLES=timepointdays*flashintensitymcd*Tre
ated1casp6DN0pen1 SCALE=ORIGINAL
   /REPEATED SUBJECT=animal 
WITHINSUBJECT=Treated1casp6DN0pen1*ti
mepointdays*flashintensitymcd SORT=YES 
CORRTYPE=AR(1) ADJUSTCORR=YES 
COVB=ROBUST MAXITERATIONS=100 
PCONVERGE=1e-006(ABSOLUTE)
UPDATECORR=1
   /MISSING CLASSMISSING=EXCLUDE
   /PRINT CPS DESCRIPTIVES MODELINFO 
FIT SUMMARY WORKINGCORR.
00:00:00.72
00:00:00.68
[DataSet5] 
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Warnings
One or more cases were found with dependent variable data values that are less than or equal to zero. These 
values are invalid for the gamma probability distribution, and the cases are not used in the analysis.
Model Information
Dependent Variable
Probability Distribution
Link Function
Subject Effect 1
Within-Subject Effect 1
2
3
Working Correlation Matrix Structure
awaveamplitudev
Gamma
Log
animal
Treated1casp6DN0pen1
timepointdays
flashintensitymcd
AR(1)
Case Processing Summary
N Percent
Included
Excluded
Total
222 70.5%
93 29.5%
315 100.0%
Correlated Data Summary
Number of Levels Subject Effect animal
Within-Subject Effect Treated1casp6DN0pen1
timepointdays
flashintensitymcd
Number of Subjects
Number of Measurements 
per Subject
Minimum
Maximum
Correlation Matrix Dimension
8
2
2
8
8
16
32
32
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Categorical Variable Information
N Percent
Factor timepointdays 7.0
14.0
Total
flashintensitymcd 10.0
30.0
100.0
300.0
1000.0
3000.0
10000.0
25000.0
Total
Treated1casp6DN0pen1 .0
1.0
Total
125 56.3%
97 43.7%
222 100.0%
29 13.1%
29 13.1%
28 12.6%
27 12.2%
27 12.2%
27 12.2%
27 12.2%
28 12.6%
222 100.0%
112 50.5%
110 49.5%
222 100.0%
Continuous Variable Information
N Minimum Maximum Mean
Dependent Variable awaveamplitudev 222 .1 251.5 76.893
Continuous Variable Information
Std. Deviation
Dependent Variable awaveamplitudev 64.5519
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Goodness of Fita
Value
Quasi Likelihood under 
Independence Model 
Criterion (QIC)b
Corrected Quasi 
Likelihood under 
Independence Model 
Criterion (QICC)b
126.584
139.601
Dependent Variable: 
awaveamplitudev
 Model: (Intercept), timepointdays, 
flashintensitymcd,
Treated1casp6DN0pen1, timepointdays 
* flashintensitymcd, timepointdays * 
Treated1casp6DN0pen1,
flashintensitymcd * 
Treated1casp6DN0pen1, timepointdays 
* flashintensitymcd * 
Treated1casp6DN0pen1
Information criteria are in small-is-better form.a.
Computed using the full log quasi-likelihood function.b.
Tests of Model Effects
Source
Type III
Wald Chi-
Square df Sig.
(Intercept)
timepointdays
flashintensitymcd
Treated1casp6DN0pen1
timepointdays * 
flashintensitymcd
timepointdays * 
Treated1casp6DN0pen1
flashintensitymcd * 
Treated1casp6DN0pen1
timepointdays * 
flashintensitymcd * 
Treated1casp6DN0pen1
3872.703 1 .000
4.613 1 .032
71302.045 7 .000
.070 1 .791
138.081 7 .000
.252 1 .616
46.727 7 .000
177.273 7 .000
Dependent Variable: awaveamplitudev
 Model: (Intercept), timepointdays, flashintensitymcd, 
Treated1casp6DN0pen1, timepointdays * flashintensitymcd, 
timepointdays * Treated1casp6DN0pen1, flashintensitymcd * 
Treated1casp6DN0pen1, timepointdays * flashintensitymcd * 
Treated1casp6DN0pen1
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Estimated Marginal Means 1: Treated1casp6DN0pen1
Estimates
Treated1casp6DN0pen1 Mean Std. Error
95% Wald Confidence Interval
Lower Upper
.0
1.0
49.171 4.6669 40.824 59.224
47.481 4.1101 40.072 56.260
Estimated Marginal Means 2: timepointdays* flashintensitymcd* Tre
ated1casp6DN0pen1
Estimates
timepointdays flashintensitymcd Treated1casp6DN0pen1 Mean Std. Error
95% Wald ...
Lower
7.0 10.0 .0
1.0
30.0 .0
1.0
100.0 .0
1.0
300.0 .0
1.0
1000.0 .0
1.0
3000.0 .0
1.0
10000.0 .0
1.0
25000.0 .0
1.0
14.0 10.0 .0
1.0
30.0 .0
1.0
100.0 .0
1.0
300.0 .0
1.0
1000.0 .0
1.0
3000.0 .0
1.0
10000.0 .0
1.0
2.190 .8084 1.062
2.388 .8034 1.235
9.304 2.6850 5.285
9.013 1.5275 6.465
24.888 6.0880 15.408
26.100 4.6984 18.341
80.038 15.1649 55.210
67.535 5.7025 57.234
98.800 17.1216 70.347
85.238 9.4596 68.575
117.538 21.3811 82.288
104.113 8.3963 88.891
150.500 25.0738 108.573
124.338 11.2748 104.092
153.213 26.7164 108.859
126.000 11.3302 105.640
3.378 .8886 2.018
8.094 1.4520 5.695
16.942 3.2639 11.614
12.298 2.6421 8.072
50.711 8.8159 36.069
57.188 13.5872 35.898
89.263 12.4667 67.887
77.630 15.3078 52.745
107.010 14.2224 82.470
98.067 16.5810 70.405
127.873 17.5226 97.755
122.410 19.0877 90.176
161.708 22.3359 123.356
149.160 19.1002 116.052
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Estimates
timepointdays flashintensitymcd Treated1casp6DN0pen1
95% Wald ...
Upper
7.0 10.0 .0
1.0
30.0 .0
1.0
100.0 .0
1.0
300.0 .0
1.0
1000.0 .0
1.0
3000.0 .0
1.0
10000.0 .0
1.0
25000.0 .0
1.0
14.0 10.0 .0
1.0
30.0 .0
1.0
100.0 .0
1.0
300.0 .0
1.0
1000.0 .0
1.0
3000.0 .0
1.0
10000.0 .0
1.0
4.515
4.617
16.380
12.564
40.198
37.142
116.031
79.690
138.761
105.949
167.887
121.941
208.617
148.521
215.637
150.284
5.657
11.505
24.714
18.738
71.299
91.105
117.368
114.256
138.853
136.598
167.271
166.168
211.985
191.712
Estimates
timepointdays flashintensitymcd Treated1casp6DN0pen1 Mean Std. Error
95% Wald ...
Lower
25000.0 .0
1.0
187.437 35.5042 129.307
159.912 22.5498 121.297
Estimates
timepointdays flashintensitymcd Treated1casp6DN0pen1
95% Wald ...
Upper
25000.0 .0
1.0
271.700
210.820
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 APPENDIX 17  
  
Appendix 17, p1
GET DATA /TYPE=XLSX
 /FILE='C:\Users\Public\Documents\PhD\ERG\Results\U-CEM423-43\U - ERG Num
 /SHEET=name 'photopic numbers'
 /CELLRANGE=full
 /READNAMES=on
 /ASSUMEDSTRWIDTH=32767.
EXECUTE.
DATASET NAME DataSet1 WINDOW=FRONT.
SORT CASES BY awaveamplitudev(A).
* Generalized Estimating Equations.
GENLIN bwaveamplitudev BY timepointdays flashintensitymcd Treated1casp6DN
 /MODEL timepointdays flashintensitymcd Treated1casp6DN0pen1 timepointday
DISTRIBUTION=GAMMA LINK=LOG
 /CRITERIA METHOD=FISHER(1) SCALE=MLE MAXITERATIONS=100 MAXSTEPHALVING=5 
 /EMMEANS TABLES=Treated1casp6DN0pen1 SCALE=ORIGINAL
 /EMMEANS TABLES=timepointdays*flashintensitymcd*Treated1casp6DN0pen1 SCA
 /REPEATED SUBJECT=animal WITHINSUBJECT=Treated1casp6DN0pen1*timepointday
 /MISSING CLASSMISSING=EXCLUDE
 /PRINT CPS DESCRIPTIVES MODELINFO FIT SUMMARY WORKINGCORR.
Generalized Linear Models
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Notes
Output Created
Comments
Input Active Dataset
Filter
Weight
Split File
N of Rows in Working 
Data File
Missing Value Handling Definition of Missing
Cases Used
Weight Handling
Syntax
Resources Processor Time
Elapsed Time
27-JUL-2013 00:51:47
DataSet1
<none>
<none>
<none>
72
User-defined missing values for factor, subject 
and within-subject variables are treated as 
missing.
Statistics are based on cases with valid data 
for all variables in the model.
not applicable
GENLIN bwaveamplitudev BY timepointdays 
flashintensitymcd Treated1casp6DN0pen1 
(ORDER=ASCENDING)
   /MODEL timepointdays flashintensitymcd 
Treated1casp6DN0pen1
timepointdays*flashintensitymcd
timepointdays*Treated1casp6DN0pen1
flashintensitymcd*Treated1casp6DN0pen1
timepointdays*flashintensitymcd*Treated1casp
6DN0pen1 INTERCEPT=YES
  DISTRIBUTION=GAMMA LINK=LOG
   /CRITERIA METHOD=FISHER(1) 
SCALE=MLE MAXITERATIONS=100 
MAXSTEPHALVING=5 PCONVERGE=1E-006
(ABSOLUTE) SINGULAR=1E-012 
ANALYSISTYPE=3(WALD) CILEVEL=95 
LIKELIHOOD=FULL
   /EMMEANS 
TABLES=Treated1casp6DN0pen1
SCALE=ORIGINAL
   /EMMEANS 
TABLES=timepointdays*flashintensitymcd*Tre
ated1casp6DN0pen1 SCALE=ORIGINAL
   /REPEATED SUBJECT=animal 
WITHINSUBJECT=Treated1casp6DN0pen1*ti
mepointdays*flashintensitymcd SORT=YES 
CORRTYPE=AR(1) ADJUSTCORR=YES 
COVB=ROBUST MAXITERATIONS=100 
PCONVERGE=1e-006(ABSOLUTE)
UPDATECORR=1
   /MISSING CLASSMISSING=EXCLUDE
   /PRINT CPS DESCRIPTIVES MODELINFO 
FIT SUMMARY WORKINGCORR.
00:00:00.39
00:00:00.40
[DataSet1] 
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Model Information
Dependent Variable
Probability Distribution
Link Function
Subject Effect 1
Within-Subject Effect 1
2
3
Working Correlation Matrix Structure
bwaveamplitudev
Gamma
Log
animal
Treated1casp6DN0pen1
timepointdays
flashintensitymcd
AR(1)
Case Processing Summary
N Percent
Included
Excluded
Total
72 100.0%
0 0.0%
72 100.0%
Correlated Data Summary
Number of Levels Subject Effect animal
Within-Subject Effect Treated1casp6DN0pen1
timepointdays
flashintensitymcd
Number of Subjects
Number of Measurements 
per Subject
Minimum
Maximum
Correlation Matrix Dimension
8
2
2
5
8
3
14
20
Categorical Variable Information
N Percent
Factor timepointdays 7.0
14.0
Total
flashintensitymcd 300.0
1000.0
3000.0
10000.0
25000.0
Total
Treated1casp6DN0pen1 .0
1.0
Total
34 47.2%
38 52.8%
72 100.0%
9 12.5%
16 22.2%
17 23.6%
16 22.2%
14 19.4%
72 100.0%
31 43.1%
41 56.9%
72 100.0%
Continuous Variable Information
N Minimum Maximum Mean
Dependent Variable bwaveamplitudev 72 5.9 135.8 52.056
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Continuous Variable Information
Std. Deviation
Dependent Variable bwaveamplitudev 34.4985
Goodness of Fita
Value
Quasi Likelihood under 
Independence Model 
Criterion (QIC)b
Corrected Quasi 
Likelihood under 
Independence Model 
Criterion (QICC)b
42.773
50.979
Dependent Variable: 
bwaveamplitudev
 Model: (Intercept), timepointdays, 
flashintensitymcd,
Treated1casp6DN0pen1, timepointdays 
* flashintensitymcd, timepointdays * 
Treated1casp6DN0pen1,
flashintensitymcd * 
Treated1casp6DN0pen1, timepointdays 
* flashintensitymcd * 
Treated1casp6DN0pen1
Information criteria are in small-is-better form.a.
Computed using the full log quasi-likelihood function.b.
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Tests of Model Effects
Source
Type III
Wald Chi-
Square df Sig.
(Intercept)
timepointdays
flashintensitymcd
Treated1casp6DN0pen1
timepointdays * 
flashintensitymcd
timepointdays * 
Treated1casp6DN0pen1
flashintensitymcd * 
Treated1casp6DN0pen1
timepointdays * 
flashintensitymcd * 
Treated1casp6DN0pen1
1004.472 1 .000
17.688 1 .000
1547.191 4 .000
.523 1 .469
16.279 4 .003
.855 1 .355
18.163 4 .001
5.375 4 .251
Dependent Variable: bwaveamplitudev
 Model: (Intercept), timepointdays, flashintensitymcd, 
Treated1casp6DN0pen1, timepointdays * flashintensitymcd, 
timepointdays * Treated1casp6DN0pen1, flashintensitymcd * 
Treated1casp6DN0pen1, timepointdays * flashintensitymcd * 
Treated1casp6DN0pen1
* Generalized Estimating Equations.
GENLIN bwaveamplitudev BY timepointdays flashintensitymcd Treated1casp6DN
 /MODEL timepointdays flashintensitymcd Treated1casp6DN0pen1 timepointday
DISTRIBUTION=GAMMA LINK=LOG
 /CRITERIA METHOD=FISHER(1) SCALE=MLE MAXITERATIONS=100 MAXSTEPHALVING=5 
 /EMMEANS TABLES=Treated1casp6DN0pen1 SCALE=ORIGINAL
 /EMMEANS TABLES=timepointdays*flashintensitymcd*Treated1casp6DN0pen1 SCA
 /REPEATED SUBJECT=animal WITHINSUBJECT=Treated1casp6DN0pen1*timepointday
(ABSOLUTE) UPDATECORR=1
 /MISSING CLASSMISSING=EXCLUDE
 /PRINT CPS DESCRIPTIVES MODELINFO FIT SUMMARY WORKINGCORR.
Generalized Linear Models
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Notes
Output Created
Comments
Input Active Dataset
Filter
Weight
Split File
N of Rows in Working 
Data File
Missing Value Handling Definition of Missing
Cases Used
Weight Handling
Syntax
Resources Processor Time
Elapsed Time
27-JUL-2013 00:52:07
DataSet1
<none>
<none>
<none>
72
User-defined missing values for factor, subject 
and within-subject variables are treated as 
missing.
Statistics are based on cases with valid data 
for all variables in the model.
not applicable
GENLIN bwaveamplitudev BY timepointdays 
flashintensitymcd Treated1casp6DN0pen1 
(ORDER=ASCENDING)
   /MODEL timepointdays flashintensitymcd 
Treated1casp6DN0pen1
timepointdays*flashintensitymcd
timepointdays*Treated1casp6DN0pen1
flashintensitymcd*Treated1casp6DN0pen1
INTERCEPT=YES
  DISTRIBUTION=GAMMA LINK=LOG
   /CRITERIA METHOD=FISHER(1) 
SCALE=MLE MAXITERATIONS=100 
MAXSTEPHALVING=5 PCONVERGE=1E-006
(ABSOLUTE) SINGULAR=1E-012 
ANALYSISTYPE=3(WALD) CILEVEL=95 
LIKELIHOOD=FULL
   /EMMEANS 
TABLES=Treated1casp6DN0pen1
SCALE=ORIGINAL
   /EMMEANS 
TABLES=timepointdays*flashintensitymcd*Tre
ated1casp6DN0pen1 SCALE=ORIGINAL
   /REPEATED SUBJECT=animal 
WITHINSUBJECT=Treated1casp6DN0pen1*ti
mepointdays*flashintensitymcd SORT=YES 
CORRTYPE=AR(1) ADJUSTCORR=YES 
COVB=ROBUST MAXITERATIONS=100 
PCONVERGE=1e-006(ABSOLUTE)
UPDATECORR=1
   /MISSING CLASSMISSING=EXCLUDE
   /PRINT CPS DESCRIPTIVES MODELINFO 
FIT SUMMARY WORKINGCORR.
00:00:00.34
00:00:00.34
[DataSet1] 
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Model Information
Dependent Variable
Probability Distribution
Link Function
Subject Effect 1
Within-Subject Effect 1
2
3
Working Correlation Matrix Structure
bwaveamplitudev
Gamma
Log
animal
Treated1casp6DN0pen1
timepointdays
flashintensitymcd
AR(1)
Case Processing Summary
N Percent
Included
Excluded
Total
72 100.0%
0 0.0%
72 100.0%
Correlated Data Summary
Number of Levels Subject Effect animal
Within-Subject Effect Treated1casp6DN0pen1
timepointdays
flashintensitymcd
Number of Subjects
Number of Measurements 
per Subject
Minimum
Maximum
Correlation Matrix Dimension
8
2
2
5
8
3
14
20
Categorical Variable Information
N Percent
Factor timepointdays 7.0
14.0
Total
flashintensitymcd 300.0
1000.0
3000.0
10000.0
25000.0
Total
Treated1casp6DN0pen1 .0
1.0
Total
34 47.2%
38 52.8%
72 100.0%
9 12.5%
16 22.2%
17 23.6%
16 22.2%
14 19.4%
72 100.0%
31 43.1%
41 56.9%
72 100.0%
Continuous Variable Information
N Minimum Maximum Mean
Dependent Variable bwaveamplitudev 72 5.9 135.8 52.056
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Continuous Variable Information
Std. Deviation
Dependent Variable bwaveamplitudev 34.4985
Goodness of Fita
Value
Quasi Likelihood under 
Independence Model 
Criterion (QIC)b
Corrected Quasi 
Likelihood under 
Independence Model 
Criterion (QICC)b
39.926
42.835
Dependent Variable: 
bwaveamplitudev
 Model: (Intercept), timepointdays, 
flashintensitymcd,
Treated1casp6DN0pen1, timepointdays 
* flashintensitymcd, timepointdays * 
Treated1casp6DN0pen1,
flashintensitymcd * 
Treated1casp6DN0pen1
Information criteria are in small-is-better form.a.
Computed using the full log quasi-likelihood function.b.
Tests of Model Effects
Source
Type III
Wald Chi-
Square df Sig.
(Intercept)
timepointdays
flashintensitymcd
Treated1casp6DN0pen1
timepointdays * 
flashintensitymcd
timepointdays * 
Treated1casp6DN0pen1
flashintensitymcd * 
Treated1casp6DN0pen1
1091.572 1 .000
13.120 1 .000
1594.751 4 .000
.575 1 .448
9.007 4 .061
.528 1 .467
21.912 4 .000
Dependent Variable: bwaveamplitudev
 Model: (Intercept), timepointdays, flashintensitymcd, 
Treated1casp6DN0pen1, timepointdays * flashintensitymcd, 
timepointdays * Treated1casp6DN0pen1, flashintensitymcd * 
Treated1casp6DN0pen1
* Generalized Estimating Equations.
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GENLIN bwaveamplitudev BY timepointdays flashintensitymcd Treated1casp6DN
  /MODEL timepointdays flashintensitymcd Treated1casp6DN0pen1 timepointday
 DISTRIBUTION=GAMMA LINK=LOG
  /CRITERIA METHOD=FISHER(1) SCALE=MLE MAXITERATIONS=100 MAXSTEPHALVING=5 
(WALD) CILEVEL=95 LIKELIHOOD=FULL
  /EMMEANS TABLES=Treated1casp6DN0pen1 SCALE=ORIGINAL
  /EMMEANS TABLES=timepointdays*flashintensitymcd*Treated1casp6DN0pen1 SCA
  /REPEATED SUBJECT=animal WITHINSUBJECT=Treated1casp6DN0pen1*timepointday
(1) ADJUSTCORR=YES COVB=ROBUST MAXITERATIONS=100 PCONVERGE=1e-006(ABSOLUTE
  /MISSING CLASSMISSING=EXCLUDE
  /PRINT CPS DESCRIPTIVES MODELINFO FIT SUMMARY WORKINGCORR.
Generalized Linear Models
Notes
Output Created
Comments
Input Active Dataset
Filter
Weight
Split File
N of Rows in Working 
Data File
Missing Value Handling Definition of Missing
Cases Used
Weight Handling
27-JUL-2013 00:52:27
DataSet1
<none>
<none>
<none>
72
User-defined missing values for factor, subject 
and within-subject variables are treated as 
missing.
Statistics are based on cases with valid data 
for all variables in the model.
not applicable
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Notes
Syntax
Resources Processor Time
Elapsed Time
GENLIN bwaveamplitudev BY timepointdays 
flashintensitymcd Treated1casp6DN0pen1 
(ORDER=ASCENDING)
   /MODEL timepointdays flashintensitymcd 
Treated1casp6DN0pen1
timepointdays*flashintensitymcd
flashintensitymcd*Treated1casp6DN0pen1
INTERCEPT=YES
  DISTRIBUTION=GAMMA LINK=LOG
   /CRITERIA METHOD=FISHER(1) 
SCALE=MLE MAXITERATIONS=100 
MAXSTEPHALVING=5 PCONVERGE=1E-006
(ABSOLUTE) SINGULAR=1E-012 
ANALYSISTYPE=3(WALD) CILEVEL=95 
LIKELIHOOD=FULL
   /EMMEANS 
TABLES=Treated1casp6DN0pen1
SCALE=ORIGINAL
   /EMMEANS 
TABLES=timepointdays*flashintensitymcd*Tre
ated1casp6DN0pen1 SCALE=ORIGINAL
   /REPEATED SUBJECT=animal 
WITHINSUBJECT=Treated1casp6DN0pen1*ti
mepointdays*flashintensitymcd SORT=YES 
CORRTYPE=AR(1) ADJUSTCORR=YES 
COVB=ROBUST MAXITERATIONS=100 
PCONVERGE=1e-006(ABSOLUTE)
UPDATECORR=1
   /MISSING CLASSMISSING=EXCLUDE
   /PRINT CPS DESCRIPTIVES MODELINFO 
FIT SUMMARY WORKINGCORR.
00:00:00.33
00:00:00.37
[DataSet1] 
Model Information
Dependent Variable
Probability Distribution
Link Function
Subject Effect 1
Within-Subject Effect 1
2
3
Working Correlation Matrix Structure
bwaveamplitudev
Gamma
Log
animal
Treated1casp6DN0pen1
timepointdays
flashintensitymcd
AR(1)
Case Processing Summary
N Percent
Included
Excluded
Total
72 100.0%
0 0.0%
72 100.0%
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Correlated Data Summary
Number of Levels Subject Effect animal
Within-Subject Effect Treated1casp6DN0pen1
timepointdays
flashintensitymcd
Number of Subjects
Number of Measurements 
per Subject
Minimum
Maximum
Correlation Matrix Dimension
8
2
2
5
8
3
14
20
Categorical Variable Information
N Percent
Factor timepointdays 7.0
14.0
Total
flashintensitymcd 300.0
1000.0
3000.0
10000.0
25000.0
Total
Treated1casp6DN0pen1 .0
1.0
Total
34 47.2%
38 52.8%
72 100.0%
9 12.5%
16 22.2%
17 23.6%
16 22.2%
14 19.4%
72 100.0%
31 43.1%
41 56.9%
72 100.0%
Continuous Variable Information
N Minimum Maximum Mean
Dependent Variable bwaveamplitudev 72 5.9 135.8 52.056
Continuous Variable Information
Std. Deviation
Dependent Variable bwaveamplitudev 34.4985
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Goodness of Fita
Value
Quasi Likelihood under 
Independence Model 
Criterion (QIC)b
Corrected Quasi 
Likelihood under 
Independence Model 
Criterion (QICC)b
38.288
40.691
Dependent Variable: 
bwaveamplitudev
 Model: (Intercept), timepointdays, 
flashintensitymcd,
Treated1casp6DN0pen1, timepointdays 
* flashintensitymcd, flashintensitymcd * 
Treated1casp6DN0pen1
Information criteria are in small-is-better form.a.
Computed using the full log quasi-likelihood function.b.
Tests of Model Effects
Source
Type III
Wald Chi-
Square df Sig.
(Intercept)
timepointdays
flashintensitymcd
Treated1casp6DN0pen1
timepointdays * 
flashintensitymcd
flashintensitymcd * 
Treated1casp6DN0pen1
1159.385 1 .000
10.563 1 .001
1630.649 4 .000
.440 1 .507
7.930 4 .094
18.823 4 .001
Dependent Variable: bwaveamplitudev
 Model: (Intercept), timepointdays, flashintensitymcd, 
Treated1casp6DN0pen1, timepointdays * flashintensitymcd, 
flashintensitymcd * Treated1casp6DN0pen1
* Generalized Estimating Equations.
GENLIN bwaveamplitudev BY timepointdays flashintensitymcd Treated1casp6DN
  /MODEL timepointdays flashintensitymcd Treated1casp6DN0pen1 flashintensi
 DISTRIBUTION=GAMMA LINK=LOG
  /CRITERIA METHOD=FISHER(1) SCALE=MLE MAXITERATIONS=100 MAXSTEPHALVING=5 
012 ANALYSISTYPE=3(WALD) CILEVEL=95 LIKELIHOOD=FULL
  /EMMEANS TABLES=Treated1casp6DN0pen1 SCALE=ORIGINAL
  /EMMEANS TABLES=timepointdays*flashintensitymcd*Treated1casp6DN0pen1 SCA
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  /REPEATED SUBJECT=animal WITHINSUBJECT=Treated1casp6DN0pen1*timepointday
(1) ADJUSTCORR=YES COVB=ROBUST MAXITERATIONS=100 PCONVERGE=1e-006(ABSOLUTE
  /MISSING CLASSMISSING=EXCLUDE
  /PRINT CPS DESCRIPTIVES MODELINFO FIT SUMMARY WORKINGCORR.
Generalized Linear Models
Notes
Output Created
Comments
Input Active Dataset
Filter
Weight
Split File
N of Rows in Working 
Data File
Missing Value Handling Definition of Missing
Cases Used
Weight Handling
Syntax
Resources Processor Time
Elapsed Time
27-JUL-2013 00:53:08
DataSet1
<none>
<none>
<none>
72
User-defined missing values for factor, subject 
and within-subject variables are treated as 
missing.
Statistics are based on cases with valid data 
for all variables in the model.
not applicable
GENLIN bwaveamplitudev BY timepointdays 
flashintensitymcd Treated1casp6DN0pen1 
(ORDER=ASCENDING)
   /MODEL timepointdays flashintensitymcd 
Treated1casp6DN0pen1
flashintensitymcd*Treated1casp6DN0pen1
INTERCEPT=YES
  DISTRIBUTION=GAMMA LINK=LOG
   /CRITERIA METHOD=FISHER(1) 
SCALE=MLE MAXITERATIONS=100 
MAXSTEPHALVING=5 PCONVERGE=1E-006
(ABSOLUTE) SINGULAR=1E-012 
ANALYSISTYPE=3(WALD) CILEVEL=95 
LIKELIHOOD=FULL
   /EMMEANS 
TABLES=Treated1casp6DN0pen1
SCALE=ORIGINAL
   /EMMEANS 
TABLES=timepointdays*flashintensitymcd*Tre
ated1casp6DN0pen1 SCALE=ORIGINAL
   /REPEATED SUBJECT=animal 
WITHINSUBJECT=Treated1casp6DN0pen1*ti
mepointdays*flashintensitymcd SORT=YES 
CORRTYPE=AR(1) ADJUSTCORR=YES 
COVB=ROBUST MAXITERATIONS=100 
PCONVERGE=1e-006(ABSOLUTE)
UPDATECORR=1
   /MISSING CLASSMISSING=EXCLUDE
   /PRINT CPS DESCRIPTIVES MODELINFO 
FIT SUMMARY WORKINGCORR.
00:00:00.34
00:00:00.33
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[DataSet1] 
Model Information
Dependent Variable
Probability Distribution
Link Function
Subject Effect 1
Within-Subject Effect 1
2
3
Working Correlation Matrix Structure
bwaveamplitudev
Gamma
Log
animal
Treated1casp6DN0pen1
timepointdays
flashintensitymcd
AR(1)
Case Processing Summary
N Percent
Included
Excluded
Total
72 100.0%
0 0.0%
72 100.0%
Correlated Data Summary
Number of Levels Subject Effect animal
Within-Subject Effect Treated1casp6DN0pen1
timepointdays
flashintensitymcd
Number of Subjects
Number of Measurements 
per Subject
Minimum
Maximum
Correlation Matrix Dimension
8
2
2
5
8
3
14
20
Categorical Variable Information
N Percent
Factor timepointdays 7.0
14.0
Total
flashintensitymcd 300.0
1000.0
3000.0
10000.0
25000.0
Total
Treated1casp6DN0pen1 .0
1.0
Total
34 47.2%
38 52.8%
72 100.0%
9 12.5%
16 22.2%
17 23.6%
16 22.2%
14 19.4%
72 100.0%
31 43.1%
41 56.9%
72 100.0%
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Continuous Variable Information
N Minimum Maximum Mean
Dependent Variable bwaveamplitudev 72 5.9 135.8 52.056
Continuous Variable Information
Std. Deviation
Dependent Variable bwaveamplitudev 34.4985
Goodness of Fita
Value
Quasi Likelihood under 
Independence Model 
Criterion (QIC)b
Corrected Quasi 
Likelihood under 
Independence Model 
Criterion (QICC)b
34.367
32.725
Dependent Variable: 
bwaveamplitudev
 Model: (Intercept), timepointdays, 
flashintensitymcd,
Treated1casp6DN0pen1,
flashintensitymcd * 
Treated1casp6DN0pen1
Information criteria are in small-is-better form.a.
Computed using the full log quasi-likelihood function.b.
Tests of Model Effects
Source
Type III
Wald Chi-
Square df Sig.
(Intercept)
timepointdays
flashintensitymcd
Treated1casp6DN0pen1
flashintensitymcd * 
Treated1casp6DN0pen1
1108.201 1 .000
13.349 1 .000
4630.683 4 .000
.293 1 .589
10.650 4 .031
Dependent Variable: bwaveamplitudev
 Model: (Intercept), timepointdays, flashintensitymcd, 
Treated1casp6DN0pen1, flashintensitymcd * Treated1casp6DN0pen1
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Working Correlation Matrixa
Measurement
Measurement
[
Treated1casp
6DN0pen1 = .
0 ]* [ 
timepointdays
= 7.0 ]* [ 
flashintensity
mcd = 300.0 ]
[
Treated1casp
6DN0pen1 = .
0 ]* [ 
timepointdays
= 7.0 ]* [ 
flashintensity
mcd = 1000.0 
]
[
Treated1casp
6DN0pen1 = .
0 ]* [ 
timepointdays
= 7.0 ]* [ 
flashintensity
mcd = 3000.0 
]
[
Treated1casp
6DN0pen1 = .
0 ]* [ 
timepointdays
= 7.0 ]* [ 
flashintensity
mcd = 
10000.0 ]
[ Treated1casp6DN0pen1 
= .0 ]* [ timepointdays = 
7.0 ]* [ flashintensitymcd = 
300.0 ]
[ Treated1casp6DN0pen1 
= .0 ]* [ timepointdays = 
7.0 ]* [ flashintensitymcd = 
1000.0 ]
[ Treated1casp6DN0pen1 
= .0 ]* [ timepointdays = 
7.0 ]* [ flashintensitymcd = 
3000.0 ]
[ Treated1casp6DN0pen1 
= .0 ]* [ timepointdays = 
7.0 ]* [ flashintensitymcd = 
10000.0 ]
[ Treated1casp6DN0pen1 
= .0 ]* [ timepointdays = 
7.0 ]* [ flashintensitymcd = 
25000.0 ]
[ Treated1casp6DN0pen1 
= .0 ]* [ timepointdays = 
14.0 ]* [ flashintensitymcd 
= 300.0 ]
[ Treated1casp6DN0pen1 
= .0 ]* [ timepointdays = 
14.0 ]* [ flashintensitymcd 
= 1000.0 ]
[ Treated1casp6DN0pen1 
= .0 ]* [ timepointdays = 
14.0 ]* [ flashintensitymcd 
= 3000.0 ]
[ Treated1casp6DN0pen1 
= .0 ]* [ timepointdays = 
14.0 ]* [ flashintensitymcd 
= 10000.0 ]
[ Treated1casp6DN0pen1 
= .0 ]* [ timepointdays = 
14.0 ]* [ flashintensitymcd 
= 25000.0 ]
1.000 .929 .863 .801
.929 1.000 .929 .863
.863 .929 1.000 .929
.801 .863 .929 1.000
.744 .801 .863 .929
.691 .744 .801 .863
.642 .691 .744 .801
.596 .642 .691 .744
.553 .596 .642 .691
.514 .553 .596 .642
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Working Correlation Matrixa
Measurement
Measurement
[
Treated1casp
6DN0pen1 = .
0 ]* [ 
timepointdays
= 7.0 ]* [ 
flashintensity
mcd = 
25000.0 ]
[
Treated1casp
6DN0pen1 = .
0 ]* [ 
timepointdays
= 14.0 ]* [ 
flashintensity
mcd = 300.0 ]
[
Treated1casp
6DN0pen1 = .
0 ]* [ 
timepointdays
= 14.0 ]* [ 
flashintensity
mcd = 1000.0 
]
[
Treated1casp
6DN0pen1 = .
0 ]* [ 
timepointdays
= 14.0 ]* [ 
flashintensity
mcd = 3000.0 
]
[ Treated1casp6DN0pen1 
= .0 ]* [ timepointdays = 
7.0 ]* [ flashintensitymcd = 
300.0 ]
[ Treated1casp6DN0pen1 
= .0 ]* [ timepointdays = 
7.0 ]* [ flashintensitymcd = 
1000.0 ]
[ Treated1casp6DN0pen1 
= .0 ]* [ timepointdays = 
7.0 ]* [ flashintensitymcd = 
3000.0 ]
[ Treated1casp6DN0pen1 
= .0 ]* [ timepointdays = 
7.0 ]* [ flashintensitymcd = 
10000.0 ]
[ Treated1casp6DN0pen1 
= .0 ]* [ timepointdays = 
7.0 ]* [ flashintensitymcd = 
25000.0 ]
[ Treated1casp6DN0pen1 
= .0 ]* [ timepointdays = 
14.0 ]* [ flashintensitymcd 
= 300.0 ]
[ Treated1casp6DN0pen1 
= .0 ]* [ timepointdays = 
14.0 ]* [ flashintensitymcd 
= 1000.0 ]
[ Treated1casp6DN0pen1 
= .0 ]* [ timepointdays = 
14.0 ]* [ flashintensitymcd 
= 3000.0 ]
[ Treated1casp6DN0pen1 
= .0 ]* [ timepointdays = 
14.0 ]* [ flashintensitymcd 
= 10000.0 ]
[ Treated1casp6DN0pen1 
= .0 ]* [ timepointdays = 
14.0 ]* [ flashintensitymcd 
= 25000.0 ]
.744 .691 .642 .596
.801 .744 .691 .642
.863 .801 .744 .691
.929 .863 .801 .744
1.000 .929 .863 .801
.929 1.000 .929 .863
.863 .929 1.000 .929
.801 .863 .929 1.000
.744 .801 .863 .929
.691 .744 .801 .863
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Working Correlation Matrixa
Measurement
Measurement
[
Treated1casp
6DN0pen1 = .
0 ]* [ 
timepointdays
= 14.0 ]* [ 
flashintensity
mcd = 
10000.0 ]
[
Treated1casp
6DN0pen1 = .
0 ]* [ 
timepointdays
= 14.0 ]* [ 
flashintensity
mcd = 
25000.0 ]
[
Treated1casp
6DN0pen1 = 
1.0 ]* [ 
timepointdays
= 7.0 ]* [ 
flashintensity
mcd = 300.0 ]
[
Treated1casp
6DN0pen1 = 
1.0 ]* [ 
timepointdays
= 7.0 ]* [ 
flashintensity
mcd = 1000.0 
]
[ Treated1casp6DN0pen1 
= .0 ]* [ timepointdays = 
7.0 ]* [ flashintensitymcd = 
300.0 ]
[ Treated1casp6DN0pen1 
= .0 ]* [ timepointdays = 
7.0 ]* [ flashintensitymcd = 
1000.0 ]
[ Treated1casp6DN0pen1 
= .0 ]* [ timepointdays = 
7.0 ]* [ flashintensitymcd = 
3000.0 ]
[ Treated1casp6DN0pen1 
= .0 ]* [ timepointdays = 
7.0 ]* [ flashintensitymcd = 
10000.0 ]
[ Treated1casp6DN0pen1 
= .0 ]* [ timepointdays = 
7.0 ]* [ flashintensitymcd = 
25000.0 ]
[ Treated1casp6DN0pen1 
= .0 ]* [ timepointdays = 
14.0 ]* [ flashintensitymcd 
= 300.0 ]
[ Treated1casp6DN0pen1 
= .0 ]* [ timepointdays = 
14.0 ]* [ flashintensitymcd 
= 1000.0 ]
[ Treated1casp6DN0pen1 
= .0 ]* [ timepointdays = 
14.0 ]* [ flashintensitymcd 
= 3000.0 ]
[ Treated1casp6DN0pen1 
= .0 ]* [ timepointdays = 
14.0 ]* [ flashintensitymcd 
= 10000.0 ]
[ Treated1casp6DN0pen1 
= .0 ]* [ timepointdays = 
14.0 ]* [ flashintensitymcd 
= 25000.0 ]
.553 .514 .477 .443
.596 .553 .514 .477
.642 .596 .553 .514
.691 .642 .596 .553
.744 .691 .642 .596
.801 .744 .691 .642
.863 .801 .744 .691
.929 .863 .801 .744
1.000 .929 .863 .801
.929 1.000 .929 .863
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Working Correlation Matrixa
Measurement
Measurement
[
Treated1casp
6DN0pen1 = 
1.0 ]* [ 
timepointdays
= 7.0 ]* [ 
flashintensity
mcd = 3000.0 
]
[
Treated1casp
6DN0pen1 = 
1.0 ]* [ 
timepointdays
= 7.0 ]* [ 
flashintensity
mcd = 
10000.0 ]
[
Treated1casp
6DN0pen1 = 
1.0 ]* [ 
timepointdays
= 7.0 ]* [ 
flashintensity
mcd = 
25000.0 ]
[
Treated1casp
6DN0pen1 = 
1.0 ]* [ 
timepointdays
= 14.0 ]* [ 
flashintensity
mcd = 300.0 ]
[ Treated1casp6DN0pen1 
= .0 ]* [ timepointdays = 
7.0 ]* [ flashintensitymcd = 
300.0 ]
[ Treated1casp6DN0pen1 
= .0 ]* [ timepointdays = 
7.0 ]* [ flashintensitymcd = 
1000.0 ]
[ Treated1casp6DN0pen1 
= .0 ]* [ timepointdays = 
7.0 ]* [ flashintensitymcd = 
3000.0 ]
[ Treated1casp6DN0pen1 
= .0 ]* [ timepointdays = 
7.0 ]* [ flashintensitymcd = 
10000.0 ]
[ Treated1casp6DN0pen1 
= .0 ]* [ timepointdays = 
7.0 ]* [ flashintensitymcd = 
25000.0 ]
[ Treated1casp6DN0pen1 
= .0 ]* [ timepointdays = 
14.0 ]* [ flashintensitymcd 
= 300.0 ]
[ Treated1casp6DN0pen1 
= .0 ]* [ timepointdays = 
14.0 ]* [ flashintensitymcd 
= 1000.0 ]
[ Treated1casp6DN0pen1 
= .0 ]* [ timepointdays = 
14.0 ]* [ flashintensitymcd 
= 3000.0 ]
[ Treated1casp6DN0pen1 
= .0 ]* [ timepointdays = 
14.0 ]* [ flashintensitymcd 
= 10000.0 ]
[ Treated1casp6DN0pen1 
= .0 ]* [ timepointdays = 
14.0 ]* [ flashintensitymcd 
= 25000.0 ]
.412 .382 .355 .330
.443 .412 .382 .355
.477 .443 .412 .382
.514 .477 .443 .412
.553 .514 .477 .443
.596 .553 .514 .477
.642 .596 .553 .514
.691 .642 .596 .553
.744 .691 .642 .596
.801 .744 .691 .642
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Working Correlation Matrixa
Measurement
Measurement
[
Treated1casp
6DN0pen1 = 
1.0 ]* [ 
timepointdays
= 14.0 ]* [ 
flashintensity
mcd = 1000.0 
]
[
Treated1casp
6DN0pen1 = 
1.0 ]* [ 
timepointdays
= 14.0 ]* [ 
flashintensity
mcd = 3000.0 
]
[
Treated1casp
6DN0pen1 = 
1.0 ]* [ 
timepointdays
= 14.0 ]* [ 
flashintensity
mcd = 
10000.0 ]
[
Treated1casp
6DN0pen1 = 
1.0 ]* [ 
timepointdays
= 14.0 ]* [ 
flashintensity
mcd = 
25000.0 ]
[ Treated1casp6DN0pen1 
= .0 ]* [ timepointdays = 
7.0 ]* [ flashintensitymcd = 
300.0 ]
[ Treated1casp6DN0pen1 
= .0 ]* [ timepointdays = 
7.0 ]* [ flashintensitymcd = 
1000.0 ]
[ Treated1casp6DN0pen1 
= .0 ]* [ timepointdays = 
7.0 ]* [ flashintensitymcd = 
3000.0 ]
[ Treated1casp6DN0pen1 
= .0 ]* [ timepointdays = 
7.0 ]* [ flashintensitymcd = 
10000.0 ]
[ Treated1casp6DN0pen1 
= .0 ]* [ timepointdays = 
7.0 ]* [ flashintensitymcd = 
25000.0 ]
[ Treated1casp6DN0pen1 
= .0 ]* [ timepointdays = 
14.0 ]* [ flashintensitymcd 
= 300.0 ]
[ Treated1casp6DN0pen1 
= .0 ]* [ timepointdays = 
14.0 ]* [ flashintensitymcd 
= 1000.0 ]
[ Treated1casp6DN0pen1 
= .0 ]* [ timepointdays = 
14.0 ]* [ flashintensitymcd 
= 3000.0 ]
[ Treated1casp6DN0pen1 
= .0 ]* [ timepointdays = 
14.0 ]* [ flashintensitymcd 
= 10000.0 ]
[ Treated1casp6DN0pen1 
= .0 ]* [ timepointdays = 
14.0 ]* [ flashintensitymcd 
= 25000.0 ]
.306 .285 .264 .245
.330 .306 .285 .264
.355 .330 .306 .285
.382 .355 .330 .306
.412 .382 .355 .330
.443 .412 .382 .355
.477 .443 .412 .382
.514 .477 .443 .412
.553 .514 .477 .443
.596 .553 .514 .477
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Working Correlation Matrixa
Measurement
Measurement
[
Treated1casp
6DN0pen1 = .
0 ]* [ 
timepointdays
= 7.0 ]* [ 
flashintensity
mcd = 300.0 ]
[
Treated1casp
6DN0pen1 = .
0 ]* [ 
timepointdays
= 7.0 ]* [ 
flashintensity
mcd = 1000.0 
]
[
Treated1casp
6DN0pen1 = .
0 ]* [ 
timepointdays
= 7.0 ]* [ 
flashintensity
mcd = 3000.0 
]
[
Treated1casp
6DN0pen1 = .
0 ]* [ 
timepointdays
= 7.0 ]* [ 
flashintensity
mcd = 
10000.0 ]
[ Treated1casp6DN0pen1 
= 1.0 ]* [ timepointdays = 
7.0 ]* [ flashintensitymcd = 
300.0 ]
[ Treated1casp6DN0pen1 
= 1.0 ]* [ timepointdays = 
7.0 ]* [ flashintensitymcd = 
1000.0 ]
[ Treated1casp6DN0pen1 
= 1.0 ]* [ timepointdays = 
7.0 ]* [ flashintensitymcd = 
3000.0 ]
[ Treated1casp6DN0pen1 
= 1.0 ]* [ timepointdays = 
7.0 ]* [ flashintensitymcd = 
10000.0 ]
[ Treated1casp6DN0pen1 
= 1.0 ]* [ timepointdays = 
7.0 ]* [ flashintensitymcd = 
25000.0 ]
[ Treated1casp6DN0pen1 
= 1.0 ]* [ timepointdays = 
14.0 ]* [ flashintensitymcd 
= 300.0 ]
[ Treated1casp6DN0pen1 
= 1.0 ]* [ timepointdays = 
14.0 ]* [ flashintensitymcd 
= 1000.0 ]
[ Treated1casp6DN0pen1 
= 1.0 ]* [ timepointdays = 
14.0 ]* [ flashintensitymcd 
= 3000.0 ]
[ Treated1casp6DN0pen1 
= 1.0 ]* [ timepointdays = 
14.0 ]* [ flashintensitymcd 
= 10000.0 ]
[ Treated1casp6DN0pen1 
= 1.0 ]* [ timepointdays = 
14.0 ]* [ flashintensitymcd 
= 25000.0 ]
.477 .514 .553 .596
.443 .477 .514 .553
.412 .443 .477 .514
.382 .412 .443 .477
.355 .382 .412 .443
.330 .355 .382 .412
.306 .330 .355 .382
.285 .306 .330 .355
.264 .285 .306 .330
.245 .264 .285 .306
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Working Correlation Matrixa
Measurement
Measurement
[
Treated1casp
6DN0pen1 = .
0 ]* [ 
timepointdays
= 7.0 ]* [ 
flashintensity
mcd = 
25000.0 ]
[
Treated1casp
6DN0pen1 = .
0 ]* [ 
timepointdays
= 14.0 ]* [ 
flashintensity
mcd = 300.0 ]
[
Treated1casp
6DN0pen1 = .
0 ]* [ 
timepointdays
= 14.0 ]* [ 
flashintensity
mcd = 1000.0 
]
[
Treated1casp
6DN0pen1 = .
0 ]* [ 
timepointdays
= 14.0 ]* [ 
flashintensity
mcd = 3000.0 
]
[ Treated1casp6DN0pen1 
= 1.0 ]* [ timepointdays = 
7.0 ]* [ flashintensitymcd = 
300.0 ]
[ Treated1casp6DN0pen1 
= 1.0 ]* [ timepointdays = 
7.0 ]* [ flashintensitymcd = 
1000.0 ]
[ Treated1casp6DN0pen1 
= 1.0 ]* [ timepointdays = 
7.0 ]* [ flashintensitymcd = 
3000.0 ]
[ Treated1casp6DN0pen1 
= 1.0 ]* [ timepointdays = 
7.0 ]* [ flashintensitymcd = 
10000.0 ]
[ Treated1casp6DN0pen1 
= 1.0 ]* [ timepointdays = 
7.0 ]* [ flashintensitymcd = 
25000.0 ]
[ Treated1casp6DN0pen1 
= 1.0 ]* [ timepointdays = 
14.0 ]* [ flashintensitymcd 
= 300.0 ]
[ Treated1casp6DN0pen1 
= 1.0 ]* [ timepointdays = 
14.0 ]* [ flashintensitymcd 
= 1000.0 ]
[ Treated1casp6DN0pen1 
= 1.0 ]* [ timepointdays = 
14.0 ]* [ flashintensitymcd 
= 3000.0 ]
[ Treated1casp6DN0pen1 
= 1.0 ]* [ timepointdays = 
14.0 ]* [ flashintensitymcd 
= 10000.0 ]
[ Treated1casp6DN0pen1 
= 1.0 ]* [ timepointdays = 
14.0 ]* [ flashintensitymcd 
= 25000.0 ]
.642 .691 .744 .801
.596 .642 .691 .744
.553 .596 .642 .691
.514 .553 .596 .642
.477 .514 .553 .596
.443 .477 .514 .553
.412 .443 .477 .514
.382 .412 .443 .477
.355 .382 .412 .443
.330 .355 .382 .412
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Working Correlation Matrixa
Measurement
Measurement
[
Treated1casp
6DN0pen1 = .
0 ]* [ 
timepointdays
= 14.0 ]* [ 
flashintensity
mcd = 
10000.0 ]
[
Treated1casp
6DN0pen1 = .
0 ]* [ 
timepointdays
= 14.0 ]* [ 
flashintensity
mcd = 
25000.0 ]
[
Treated1casp
6DN0pen1 = 
1.0 ]* [ 
timepointdays
= 7.0 ]* [ 
flashintensity
mcd = 300.0 ]
[
Treated1casp
6DN0pen1 = 
1.0 ]* [ 
timepointdays
= 7.0 ]* [ 
flashintensity
mcd = 1000.0 
]
[ Treated1casp6DN0pen1 
= 1.0 ]* [ timepointdays = 
7.0 ]* [ flashintensitymcd = 
300.0 ]
[ Treated1casp6DN0pen1 
= 1.0 ]* [ timepointdays = 
7.0 ]* [ flashintensitymcd = 
1000.0 ]
[ Treated1casp6DN0pen1 
= 1.0 ]* [ timepointdays = 
7.0 ]* [ flashintensitymcd = 
3000.0 ]
[ Treated1casp6DN0pen1 
= 1.0 ]* [ timepointdays = 
7.0 ]* [ flashintensitymcd = 
10000.0 ]
[ Treated1casp6DN0pen1 
= 1.0 ]* [ timepointdays = 
7.0 ]* [ flashintensitymcd = 
25000.0 ]
[ Treated1casp6DN0pen1 
= 1.0 ]* [ timepointdays = 
14.0 ]* [ flashintensitymcd 
= 300.0 ]
[ Treated1casp6DN0pen1 
= 1.0 ]* [ timepointdays = 
14.0 ]* [ flashintensitymcd 
= 1000.0 ]
[ Treated1casp6DN0pen1 
= 1.0 ]* [ timepointdays = 
14.0 ]* [ flashintensitymcd 
= 3000.0 ]
[ Treated1casp6DN0pen1 
= 1.0 ]* [ timepointdays = 
14.0 ]* [ flashintensitymcd 
= 10000.0 ]
[ Treated1casp6DN0pen1 
= 1.0 ]* [ timepointdays = 
14.0 ]* [ flashintensitymcd 
= 25000.0 ]
.863 .929 1.000 .929
.801 .863 .929 1.000
.744 .801 .863 .929
.691 .744 .801 .863
.642 .691 .744 .801
.596 .642 .691 .744
.553 .596 .642 .691
.514 .553 .596 .642
.477 .514 .553 .596
.443 .477 .514 .553
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Working Correlation Matrixa
Measurement
Measurement
[
Treated1casp
6DN0pen1 = 
1.0 ]* [ 
timepointdays
= 7.0 ]* [ 
flashintensity
mcd = 3000.0 
]
[
Treated1casp
6DN0pen1 = 
1.0 ]* [ 
timepointdays
= 7.0 ]* [ 
flashintensity
mcd = 
10000.0 ]
[
Treated1casp
6DN0pen1 = 
1.0 ]* [ 
timepointdays
= 7.0 ]* [ 
flashintensity
mcd = 
25000.0 ]
[
Treated1casp
6DN0pen1 = 
1.0 ]* [ 
timepointdays
= 14.0 ]* [ 
flashintensity
mcd = 300.0 ]
[ Treated1casp6DN0pen1 
= 1.0 ]* [ timepointdays = 
7.0 ]* [ flashintensitymcd = 
300.0 ]
[ Treated1casp6DN0pen1 
= 1.0 ]* [ timepointdays = 
7.0 ]* [ flashintensitymcd = 
1000.0 ]
[ Treated1casp6DN0pen1 
= 1.0 ]* [ timepointdays = 
7.0 ]* [ flashintensitymcd = 
3000.0 ]
[ Treated1casp6DN0pen1 
= 1.0 ]* [ timepointdays = 
7.0 ]* [ flashintensitymcd = 
10000.0 ]
[ Treated1casp6DN0pen1 
= 1.0 ]* [ timepointdays = 
7.0 ]* [ flashintensitymcd = 
25000.0 ]
[ Treated1casp6DN0pen1 
= 1.0 ]* [ timepointdays = 
14.0 ]* [ flashintensitymcd 
= 300.0 ]
[ Treated1casp6DN0pen1 
= 1.0 ]* [ timepointdays = 
14.0 ]* [ flashintensitymcd 
= 1000.0 ]
[ Treated1casp6DN0pen1 
= 1.0 ]* [ timepointdays = 
14.0 ]* [ flashintensitymcd 
= 3000.0 ]
[ Treated1casp6DN0pen1 
= 1.0 ]* [ timepointdays = 
14.0 ]* [ flashintensitymcd 
= 10000.0 ]
[ Treated1casp6DN0pen1 
= 1.0 ]* [ timepointdays = 
14.0 ]* [ flashintensitymcd 
= 25000.0 ]
.863 .801 .744 .691
.929 .863 .801 .744
1.000 .929 .863 .801
.929 1.000 .929 .863
.863 .929 1.000 .929
.801 .863 .929 1.000
.744 .801 .863 .929
.691 .744 .801 .863
.642 .691 .744 .801
.596 .642 .691 .744
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Working Correlation Matrixa
Measurement
Measurement
[
Treated1casp
6DN0pen1 = 
1.0 ]* [ 
timepointdays
= 14.0 ]* [ 
flashintensity
mcd = 1000.0 
]
[
Treated1casp
6DN0pen1 = 
1.0 ]* [ 
timepointdays
= 14.0 ]* [ 
flashintensity
mcd = 3000.0 
]
[
Treated1casp
6DN0pen1 = 
1.0 ]* [ 
timepointdays
= 14.0 ]* [ 
flashintensity
mcd = 
10000.0 ]
[
Treated1casp
6DN0pen1 = 
1.0 ]* [ 
timepointdays
= 14.0 ]* [ 
flashintensity
mcd = 
25000.0 ]
[ Treated1casp6DN0pen1 
= 1.0 ]* [ timepointdays = 
7.0 ]* [ flashintensitymcd = 
300.0 ]
[ Treated1casp6DN0pen1 
= 1.0 ]* [ timepointdays = 
7.0 ]* [ flashintensitymcd = 
1000.0 ]
[ Treated1casp6DN0pen1 
= 1.0 ]* [ timepointdays = 
7.0 ]* [ flashintensitymcd = 
3000.0 ]
[ Treated1casp6DN0pen1 
= 1.0 ]* [ timepointdays = 
7.0 ]* [ flashintensitymcd = 
10000.0 ]
[ Treated1casp6DN0pen1 
= 1.0 ]* [ timepointdays = 
7.0 ]* [ flashintensitymcd = 
25000.0 ]
[ Treated1casp6DN0pen1 
= 1.0 ]* [ timepointdays = 
14.0 ]* [ flashintensitymcd 
= 300.0 ]
[ Treated1casp6DN0pen1 
= 1.0 ]* [ timepointdays = 
14.0 ]* [ flashintensitymcd 
= 1000.0 ]
[ Treated1casp6DN0pen1 
= 1.0 ]* [ timepointdays = 
14.0 ]* [ flashintensitymcd 
= 3000.0 ]
[ Treated1casp6DN0pen1 
= 1.0 ]* [ timepointdays = 
14.0 ]* [ flashintensitymcd 
= 10000.0 ]
[ Treated1casp6DN0pen1 
= 1.0 ]* [ timepointdays = 
14.0 ]* [ flashintensitymcd 
= 25000.0 ]
.642 .596 .553 .514
.691 .642 .596 .553
.744 .691 .642 .596
.801 .744 .691 .642
.863 .801 .744 .691
.929 .863 .801 .744
1.000 .929 .863 .801
.929 1.000 .929 .863
.863 .929 1.000 .929
.801 .863 .929 1.000
Dependent Variable: bwaveamplitudev
 Model: (Intercept), timepointdays, flashintensitymcd, Treated1casp6DN0pen1, flashintensitymcd * 
Treated1casp6DN0pen1
The AR(1) working correlation matrix structure is computed assuming the measurements are equallya
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The AR(1) working correlation matrix structure is computed assuming the measurements are equally 
spaced for all subjects.
a.
Estimated Marginal Means 1: Treated1casp6DN0pen1
Estimates
Treated1casp6DN0pen1 Mean Std. Error
95% Wald Confidence Interval
Lower Upper
.0
1.0
38.227 6.1584 27.876 52.420
34.776 3.9163 27.888 43.364
Estimated Marginal Means 2: timepointdays* flashintensitymcd* Tre
ated1casp6DN0pen1
Estimates
timepointdays flashintensitymcd Treated1casp6DN0pen1 Mean Std. Error
95% Wald ...
Lower
7.0 300.0 .0
1.0
1000.0 .0
1.0
3000.0 .0
1.0
10000.0 .0
1.0
25000.0 .0
1.0
14.0 300.0 .0
1.0
1000.0 .0
1.0
3000.0 .0
1.0
10000.0 .0
1.0
25000.0 .0
1.0
11.487 2.5444 7.441
10.946 1.5712 8.262
27.109 4.5704 19.481
25.967 3.6923 19.651
57.313 10.2916 40.309
50.596 6.0531 40.020
85.579 15.6533 59.797
77.449 8.0206 63.222
104.102 16.4963 76.308
88.947 8.2070 74.232
8.798 1.8300 5.852
8.384 1.0240 6.599
20.763 2.8840 15.814
19.888 3.1393 14.596
43.896 6.7799 32.431
38.751 5.2367 29.734
65.546 12.1748 45.545
59.319 8.3012 45.089
79.732 12.8925 58.076
68.125 8.8868 52.755
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Estimates
timepointdays flashintensitymcd Treated1casp6DN0pen1
95% Wald ...
Upper
7.0 300.0 .0
1.0
1000.0 .0
1.0
3000.0 .0
1.0
10000.0 .0
1.0
25000.0 .0
1.0
14.0 300.0 .0
1.0
1000.0 .0
1.0
3000.0 .0
1.0
10000.0 .0
1.0
25000.0 .0
1.0
17.731
14.502
37.724
34.313
81.489
63.966
122.479
94.878
142.017
106.578
13.226
10.651
27.260
27.099
59.415
50.503
94.330
78.039
109.464
87.972
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 APPENDIX 18  
  
Appendix 18, p1
1. The neuroprotective effect of progesterone after high velocity injury 
Female rats have better functional outcomes and develop less cerebral oedema after traumatic 
brain injury than male rats, and this effect is more pronounced in pseudo-pregnant rats, which have 
high circulating progesterone and low oestrogen 1,2.   In contrast, female gender in humans is 
associated with a worse outcome after TBI 3.  Nonetheless, the beneficial effects of female gender in 
animal studies of CNS trauma are attributable to the higher levels of circulating progesterone 
compared to male rats and, in humans, phase II trials of progesterone after traumatic brain injury 
have shown promising results 4. 
Ocular trauma is common in military and civilian personnel and has a civilian lifetime prevalence of 
20%5,6.  Commotio retinae is a condition characterised by photoreceptor damage after blunt ocular 
trauma and comprises 15% of military and 0.4% of civilian eye injuries 5,7.  The macula is affected in 
73% of military and 31% of civilian cases5,8 and photoreceptor degeneration permanently reduces 
vision in 26% of these 8,9.  In animal models of commotio retinae, photoreceptors die by apoptosis 
and necrosis 10,11.  Thus, regulated apoptotic signalling mediates cell death in a proportion of 
photoreceptors, implying that antiapoptotic neuroprotective therapies have a potential role in the 
treatment of commotio retinae.  We have recently studies have identified a possible protective 
effect of female gender after commotio retinae 8, suggesting that progesterone should be 
considered as a potential neuroprotective therapy after retinal injury. 
Results from preclinical studies of progesterone in photoreceptor cell death models are variable.  In 
Sprague-Dawley rats exposed to 2700 lux for 24 hr, progesterone was not neuroprotective when 
given IP at a dose of 60mg/kg daily in benzyl alcohol whereas, the synthetic progestin Norgestrel was 
neuroprotective when given IP to both Balb/c mice exposed to 5000 lux for 2 hr and rd10 retinal 
degeneration mice 12,13.  The efficacy of Norgestrel conflicts with previous work suggesting that 
metabolites are responsible for the neuroprotective effect 14 and there were more TUNEL-positive 
cells in the Norgestrel-treated animals 14 days after injury13, suggesting that apoptosis had been 
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delayed rather than prevented.  Two other pre-clinical studies in phototoxicity models did not show 
a beneficial effect of progesterone 15,12, and one showed that ovariectomy (which lowers serum 
progesterone) was neuroprotective 15. One study using rd1 mice (a retinitis pigmentosa model) 
showed reduced photoreceptor death with progesterone treatment 16. 
There are limited pharmacokinetic data on progesterone in rats, reporting a half-life from ½ hr to 10 
hr 17, 18.  Therapeutic dosing range of progesterone in rats has not been reported, though peak 
plasma progesterone concentrations in pregnant mice range from 45.5 -81.9ng/ml 19,20.   
In the current study, we hypothesised that progesterone would reduce photoreceptor death and 
preserve photoreceptor function after ballistic injury and that continuous progesterone infusion 
would be the most effective means of delivery.  Surprisingly, we demonstrated that low dose 
continuously administered progesterone increases photoreceptor degeneration after ballistic injury.  
We also found progesterone pharmacokinetics in the rat at variance with previous reports 17,18. 
1.1. Materials and Methods 
1.1.1.Animal Care and Procedures 
Animal procedures were licensed by the UK Home Office, approved by the University of 
Birmingham’s Biomedical Ethics Review Sub-Committee and conducted in accordance with the ARVO 
Statement for the Use of Animals in Ophthalmic and Vision Research.  Female Lister-hooded rats 
weighing 170-200g were purchased from Charles River Laboratories (Margate, UK), kept on a 12 
hour light-dark cycle with a daytime luminance of 80 lux and fed and watered ad libitum.  Surgery 
and electroretinogram (ERG) recording were performed under inhalation anaesthesia with 2.5% 
isofluorane in oxygen.  Ballistic injury was induced as previously described10: a spherical 0.095g 
spherical plastic pellet was fired using compressed air to directly impact the inferior scleral surface 
at 20m/s. 
1.1.2.Progesterone Treatment 
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Progesterone was administered in ethyl oleate vehicle, as an 8mg/kg IP loading dose immediately 
after injury and then by continuous subcutaneous infusion of 100?g/h/kg from an osmotic 
minipump (Charles River) for the duration of the study.  Using data from Gangrade et al. (1992) this 
would be expected to give a steady state plasma concentration of 36.4ng/ml (infusion rate = steady 
state concentration x clearance; clearance = 2.75l/kg/hr) or 263ng/ml using data from Petroff et al. 
(2003; clearance =0.38l/kg/hr)17,18.   
1.1.3.Neuroprotection Experimental Protocol 
The right eyes of 16 male Lister-hooded rats (170-200g) were injured by ballistic trauma.  Eight rats 
were treated with progesterone and 8 with ethyl oleate vehicle.  ERG were recorded under 
inhalational anaesthesia at stimulus intensities ranging from -2.5 to +1 log units with respect to 
standard flash at 7 and 14 days after injury.  Animals were killed 14 days after injury and the right 
eyes processed as previously described (Section 8.7.4.) for measurement of ONL thickness.  Blood for 
serum progesterone enzyme linked immunosorbant assay (ELISA) was taken from the tail vein 2 
hours after progesterone injection and from the jugular vein before perfusion fixation, 14 days after 
injury. 
1.1.4.ERG 
ERG were recorded (HMsERG – Ocuscience, Kansas City, MO USA) at 7 and 14 days after injury and 
interpreted using ERGView (Ocuscience).  Animals were dark-adapted overnight and prepared for 
ERG under dim red light (>630nm).  Scotopic flash ERG were recorded from -2.5 to +1 log units with 
respect to standard flash in half log unit steps and photopic flash ERG were recorded with 
background illumination of 30,000mcd/m2 over the same range.  DTL fibre (Unimed Electrode 
Supplies, Farnham, UK) corneal electrodes with pressure-moulded Aclar (Agar scientific, Stansted, 
UK) contact lenses were used with needle skin electrodes (Unimed). 
1.1.5.Assessment of Photoreceptor Survival 
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Animals were killed by perfusion fixation with 4% paraformaldehyde in phosphate buffered saline 
(PBS) and right eyes were removed, cryoprotected in ascending concentrations of sucrose in PBS at 
4°C, the anterior segments removed and the retinal cup embedded in OCT and stored at -80°C until 
required.  Sections were cut at 15?m thick using a cryostat (Bright Instruments, Huntingdon, UK) and 
adhered onto SuperfrostTM (Fisher, UK) coated glass microscope slides.  Sections through the optic 
disc and centre of the impact site and at 600, 1200 and 1800?m to either side of this plane were 
stained with haematoxyllin and eosin (H&E) and scanned on a MIrax slide scanner (Zeiss, Cambridge, 
UK) and the ONL manually segmented in Adobe Photoshop by a blinded observer.  ONL images were 
thresholded and average thickness measured as area of above threshold pixels divided by section 
length using ImageJ (http://rsbweb.nih.gov/ij). 
1.1.6.Pharmacokinetics Experimental Protocol 
Three rats were given IP injections of 8mg/kg progesterone in ethyl oleate vehicle.  Blood samples 
were taken from the tail veins at 2, 6, 24 and 72 hr after injection. 
1.1.7.ELISA 
Blood was centrifuged for 5 mins at 10,000 rpm and the serum removed and frozen to -80°c for 
storage.   
Serum progesterone concentration was measured by competitive ELISA according to the 
manufacturer’s instructions.  Briefly, 20?l of diluted serum at 1/4 and 1/10 dilutions was used 
loaded into the wells, 200?l of progesterone-HRP conjugate added to each well and the plate 
incubated for 1 hour at 37°C before adding 100?l of tetramethylbenzidine/H2O2 substrate, 
incubating for 15 mins and stopping the reaction by adding 100?l 0.15M sulphuric acid.  Absorbance 
was measured at 450nm.   
1.1.8.Statistics 
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All statistical analysis was performed in SPSS 21.  ERG and ONL thickness data were analysed using 
generalised estimating equations (type III sum of squares; autoregressive correlation matrix; gamma 
distribution with log link) and model fit assessed by plotting residuals and calculating quasi-
likelihood information criteria. 
1.2. Results 
1.2.1.Progesterone Treatment Increased Photoreceptor Degeneration 
The ONL thickness in the injured eyes was significantly reduced in animals treated with progesterone 
compared to the vehicle-treated control animals (p=0.002; Figure 1.A-B), an effect that was greater 
further away from the impact site (p=0.051; Figure 1.A-B). 
1.2.2.Progesterone Treatment Reduced Retinal Function 
ERG data are presented in Figure 2.  Combining data from both 7 and 14 days, progesterone reduced 
a-wave amplitude compared to vehicle-treated controls (p<0.001 for flashintensitymcd * 
TreatedProgesteronevsControl).  However, progesterone increased a-wave amplitude at 7 days, 
whilst reducing it at 14 days after injury (p=0.001 for timepointdays * flashintensitymcd * 
TreatedProgesteronevsControl).  These changes in a-wave amplitude caused by progesterone were 
greater in the uninjured left eyes than the injured right eyes (Figure 2). 
1.2.2.1. Progesterone Pharmacokinetics 
In the injured animals, serum progesterone concentration 2 hours after 8mg/kg IP injection was  
64.2ng/ml and after 14 days of progesterone delivery at 100?g/kg/hr from an osmotic minipump 
serum progesterone was 6.04ng/ml, from which clearance was calculated as 16.7l/kg/hr (infusion 
rate = steady state concentration x clearance).  The serum progesterone in control animals was 
2.1ng/ml. 
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To verify progesterone pharmacokinetics, 3 rats were given an 8mg/kg IP bolus of progesterone and 
serum levels measured 2, 6, 24 and 72 hours after injection.  The serum progesterone 2 hours after 
injection was 67.1ng/ml and 6 hours after, 25.9ng/ml (Figure 3).  The half-life derived from these 
measurements is 2.91 hrs.  Working back from a 2 hr level of 67.1ng/ml gives an initial concentration 
of 108ng/ml, from which the volume of distribution was calculated as 74.1l/kg (Initial concentration 
= dose/volume of distribution).  The elimination rate constant, ke, was calculated as 0.238/hr 
(ln2/half-life) and clearance was calculated as 17.6l/kg/hr (volume of distribution x ke).   
 
Figure 3. Serum progesterone against time after IP injection. 
1.3. Discussion 
Progesterone treatment increases photoreceptor degeneration after ballistic injury and reduces 
photoreceptor function.  To our knowledge this is the first report of progesterone treatment 
increasing cell death. 
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Progesterone treatment significantly reduced ONL thickness after injury compared to vehicle-treated 
controls.  As 98% of rat photoreceptors are rods and the ONL contains photoreceptor somata only, 
ONL thickness reflects rod survival 21.  After traumatic brain injury, progesterone treatment reduces 
oedema and lesion size 22.  It is possible that a reduction in ONL thickness could occur because of 
reduced oedema.  However, the ONL thickness measurement assessed only haematoxylin-stained 
nuclei, thus excluding any oedema and the ONL is not oedematous 14 days after ballistic injury 10.  
Thus, it is likely that the reduction in ONL thickness occurred because treatment with progesterone 
increased the number of photoreceptors that died after ballistic injury.   
With a half-life of 2.9 hr, serum progesterone levels would have peaked at near to 100ng/ml and 
reached steady-state at 6ng/ml 11.6-14.5 hr after injury, which could be considered an abrupt 
withdrawal of treatment.  After traumatic brain injury, abrupt withdrawal of progesterone treatment 
increases the expression of cell death markers and worsens outcome compared to tapered 
withdrawal; however, both treatment regimens are still beneficial compared to placebo 23,22.  Thus, 
abrupt withdrawal is unlikely to explain the increase in cell death observed in the current study.   
Too short a duration of therapeutic plasma levels might explain the observed increase in 
photoreceptor death.  A mechanism for increased cell death could be that brief inhibition of 
programmed cell death pathways causes cells to undergo less regulated and more inflammatory 
necrotic cell death, with bystander damage to healthy cells, though this has not been reported to 
our knowledge. 
The a-wave is the first negative deflection on ERG after a light stimulus and is commonly used to 
assess photoreceptor function.  Progesterone treatment significantly reduced ERG a-wave amplitude 
in both injured and uninjured eyes.  An effect of sex steroids on the ERG has been previously 
reported 24; however, an effect of progesterone on the uninjured eye makes it difficult to assess the 
functional effects of treatment with respect to injury.  Considering data from both eyes, 
progesterone reduced a-wave amplitude differently in the injured and uninjured eyes, but the 
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reduction was greater in the uninjured eyes.  An interaction between progesterone treatment and 
injury is possible, for example injury could cause paracrine changes that prime the retina to decrease 
a-wave amplitude less in response to progesterone treatment than uninjured retina. 
The current studies of the neuroprotective effects of progesterone used a non-standard dosing 
regimen and found treatment to be detrimental to retinal structure and function.  Repeating the 
study using a previously reported intermittent regimen would clarify whether the detrimental effect 
is specific to the current dosing regimen 22.  However, a significant detrimental effect after 
administration of low dose treatment is not encouraging with respect to the translational potential 
of progesterone in ocular injury. 
After a bolus IP injection, progesterone was delivered by continuous subcutaneous infusion.  The 
dose for the bolus injection was derived from previous studies in which 8mg/kg bolus doses were 
used successfully to treat traumatic brain injury 25.  The rate of infusion of 100?g/kg/hr was derived 
from data suggesting that, in rats, the clearance of progesterone is 0.38-2.75/hr 17,18, which would 
have resulted in plasma levels of 36.4-236ng/ml.  The clearance in the current study was 17l/kg/hr, 
considerably higher than has been previously reported 17,18.  On this data (clearance = 17l/kg/hr), an 
infusion rate of 850?g/kg/hr or 20.4mg/kg/day would be required to maintain plasma progesterone 
at 50ng/ml, which is higher than has been administered in most studies of the neuroprotective 
effects of progesterone (which administer intermittent doses of 4-16mg/kg/day) 25.  Were the 
commonly used intermittent dosing regimen of 0, 6, 24, 48. 72, 96 and 120 hr after injury 
administered to 200g Lister-hooded rats, plasma progesterone levels would be at baseline from 18-
24, 36-48, 59-72, 73-96 and 107-120 hr after injury 25.  Male Sprague-Dawley rats weighing approx. 
300g are commonly used for traumatic brain injury studies and – though we do not have data on 
their pharmacokinetics – it seems unlikely that Sprague-Dawley rats would have radically different 
pharmacokinetics than the Lister-hooded rats used in the current studies. 
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Three days of daily dosing progesterone after traumatic brain injury is less effective than 5 at 
improving functional outcomes and reducing lesion size, suggesting that intermittent therapeutic 
serum levels of progesterone do not preclude a therapeutic effect 26.  Cutler et al. (2005) found that 
tapering progesterone dosing over 2 days reduced levels of inflammatory markers, apoptotic 
markers and behavioural tests for anxiety compared to an abrupt withdrawal after a daily dosing 
regimen continued for the same length of time, thus either, (1), the beneficial effects of 
progesterone in the brain do not directly relate to its persistence in the plasma which would 
contradict the mouse data of Wong et al. (2012) that brain progesterone levels drop below plasma 
levels approx. 2hr post-dosing 27, or (2), in the tapered dose group the beneficial effect was seen 
because levels became sub-therapeutic after 5 days whereas in the abrupt withdrawal group, 
therapeutic levels continued for 7 days and this prolonged dosing was damaging 23.  The latter 
explanation would also be consistent with our data in which treatment was continued for 14 days. 
Progesterone treatment administered as a high dose bolus followed by a low-dose infusion 
increased rod death 14 days after injury and reduced rod function.  Progesterone treatment affects 
ERG a-wave amplitude independent of the injury condition and this effect confounds ERG as a 
means of evaluating retinal function after progesterone treatment. Progesterone clearance in 200g 
male Lister-hooded rats is 17l/kg/hr and the half-life is 2.91 hr.  In conclusion, progesterone is not 
therefore a translatable treatment for ballistic ocular injury, due to the potential for detrimental 
effects with low dose treatment. 
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GET DATA /TYPE=XLSX
  /FILE='C:\Users\Public\Documents\PhD\lab work\Results\Z\average thickness spreadsheet shee
  /SHEET=name 'Sheet2'
  /CELLRANGE=full
  /READNAMES=on
  /ASSUMEDSTRWIDTH=32767.
EXECUTE.
DATASET NAME DataSet1 WINDOW=FRONT.
* Generalized Estimating Equations.
GENLIN AveragethicknessBCpixels BY Treatment0control1progesterone NORMALISEDSLIDENO (ORDER=A
  /MODEL Treatment0control1progesterone NORMALISEDSLIDENO Treatment0control1progesterone*NOR
 DISTRIBUTION=GAMMA LINK=LOG
  /CRITERIA METHOD=FISHER(1) SCALE=MLE MAXITERATIONS=100 MAXSTEPHALVING=5 PCONVERGE=1E-006(A
  /EMMEANS TABLES=Treatment0control1progesterone*NORMALISEDSLIDENO SCALE=ORIGINAL
  /REPEATED SUBJECT=ANIMALNUMBER*Treatment0control1progesterone WITHINSUBJECT=NORMALISEDSLID
  /MISSING CLASSMISSING=EXCLUDE
  /PRINT CPS DESCRIPTIVES MODELINFO FIT SUMMARY WORKINGCORR
  /SAVE RESID PEARSONRESID.
Generalized Linear Models
Notes
Output Created
Comments
Input Active Dataset
Filter
Weight
Split File
N of Rows in Working 
Data File
Missing Value Handling Definition of Missing
Cases Used
Weight Handling
07-JUN-2013 13:33:03
DataSet1
<none>
<none>
<none>
439
User-defined missing values for 
factor, subject and within-subject 
variables are treated as missing.
Statistics are based on cases with 
valid data for all variables in the 
model.
not applicable
Page 1
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Notes
Syntax
Resources Processor Time
Elapsed Time
Variables Created or 
Modified
Raw Residual
Pearson Residual
GENLIN AveragethicknessBCpixels 
BY Treatment0control1progesterone 
NORMALISEDSLIDENO
(ORDER=ASCENDING)
   /MODEL 
Treatment0control1progesterone
NORMALISEDSLIDENO
Treatment0control1progesterone*NO
RMALISEDSLIDENO
INTERCEPT=YES
  DISTRIBUTION=GAMMA 
LINK=LOG
   /CRITERIA METHOD=FISHER(1) 
SCALE=MLE
MAXITERATIONS=100
MAXSTEPHALVING=5
PCONVERGE=1E-006(ABSOLUTE)
SINGULAR=1E-012
ANALYSISTYPE=3(WALD)
CILEVEL=95 LIKELIHOOD=FULL
   /EMMEANS 
TABLES=Treatment0control1progest
erone*NORMALISEDSLIDENO
SCALE=ORIGINAL
   /REPEATED 
SUBJECT=ANIMALNUMBER*Treat
ment0control1progesterone
WITHINSUBJECT=NORMALISEDS
LIDENO SORT=YES 
CORRTYPE=AR(1)
ADJUSTCORR=YES
COVB=ROBUST
MAXITERATIONS=100
PCONVERGE=1e-006(ABSOLUTE)
UPDATECORR=1
   /MISSING 
CLASSMISSING=EXCLUDE
   /PRINT CPS DESCRIPTIVES 
MODELINFO FIT SUMMARY ...
00:00:00.20
00:00:00.19
Residual
PearsonResidual
[DataSet1] 
Model Information
Dependent Variable
Probability Distribution
Link Function
Subject Effect 1
2
Within-Subject Effect 1
Working Correlation Matrix Structure
AveragethicknessBCpixels
Gamma
Log
ANIMALNUMBER
Treatment0control1progesterone
NORMALISEDSLIDENO
AR(1)
Page 2
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Case Processing Summary
N Percent
Included
Excluded
Total
111 25.3%
328 74.7%
439 100.0%
Correlated Data Summary
Number of Levels Subject Effect ANIMALNUMBER
Treatment0control1proges
terone
Within-Subject Effect NORMALISEDSLIDENO
Number of Subjects
Number of Measurements 
per Subject
Minimum
Maximum
Correlation Matrix Dimension
16
2
7
16
6
7
7
Categorical Variable Information
N Percent
Factor Treatment0control1proges
terone
.0
1.0
Total
NORMALISEDSLIDENO 1.0
2.0
3.0
4.0
5.0
6.0
7.0
Total
55 49.5%
56 50.5%
111 100.0%
16 14.4%
16 14.4%
16 14.4%
16 14.4%
16 14.4%
16 14.4%
15 13.5%
111 100.0%
Continuous Variable Information
N Minimum Maximum
Dependent Variable AveragethicknessBCpixel
s 111 12.29820825 74.77330651
Continuous Variable Information
Mean Std. Deviation
Dependent Variable AveragethicknessBCpixel
s 33.03051119 14.23112397
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Goodness of Fita
Value
Quasi Likelihood under 
Independence Model 
Criterion (QIC)b
Corrected Quasi 
Likelihood under 
Independence Model 
Criterion (QICC)b
34.512
34.724
Dependent Variable: 
AveragethicknessBCpixels
 Model: (Intercept), 
Treatment0control1progesterone,
NORMALISEDSLIDENO,
Treatment0control1progesterone * 
NORMALISEDSLIDENO
Information criteria are in small-is-better form.a.
Computed using the full log quasi-likelihood function.b.
Tests of Model Effects
Source
Type III
Wald Chi-
Square df Sig.
(Intercept)
Treatment0control1proges
terone
NORMALISEDSLIDENO
Treatment0control1proges
terone * 
NORMALISEDSLIDENO
7620.857 1 .000
9.838 1 .002
256.968 6 .000
12.526 6 .051
Dependent Variable: AveragethicknessBCpixels
 Model: (Intercept), Treatment0control1progesterone, 
NORMALISEDSLIDENO, Treatment0control1progesterone * 
NORMALISEDSLIDENO
Page 4
Appendix 19, p5
Working Correlation Matrixa
Measurement
Measurement
[
NORMALISE
DSLIDENO = 
1.0 ]
[
NORMALISE
DSLIDENO = 
2.0 ]
[
NORMALISE
DSLIDENO = 
3.0 ]
[
NORMALISE
DSLIDENO = 
4.0 ]
[ NORMALISEDSLIDENO 
= 1.0 ]
[ NORMALISEDSLIDENO 
= 2.0 ]
[ NORMALISEDSLIDENO 
= 3.0 ]
[ NORMALISEDSLIDENO 
= 4.0 ]
[ NORMALISEDSLIDENO 
= 5.0 ]
[ NORMALISEDSLIDENO 
= 6.0 ]
[ NORMALISEDSLIDENO 
= 7.0 ]
1.000 .606 .367 .222
.606 1.000 .606 .367
.367 .606 1.000 .606
.222 .367 .606 1.000
.134 .222 .367 .606
.081 .134 .222 .367
.049 .081 .134 .222
Working Correlation Matrixa
Measurement
Measurement
[
NORMALISE
DSLIDENO = 
5.0 ]
[
NORMALISE
DSLIDENO = 
6.0 ]
[
NORMALISE
DSLIDENO = 
7.0 ]
[ NORMALISEDSLIDENO 
= 1.0 ]
[ NORMALISEDSLIDENO 
= 2.0 ]
[ NORMALISEDSLIDENO 
= 3.0 ]
[ NORMALISEDSLIDENO 
= 4.0 ]
[ NORMALISEDSLIDENO 
= 5.0 ]
[ NORMALISEDSLIDENO 
= 6.0 ]
[ NORMALISEDSLIDENO 
= 7.0 ]
.134 .081 .049
.222 .134 .081
.367 .222 .134
.606 .367 .222
1.000 .606 .367
.606 1.000 .606
.367 .606 1.000
Dependent Variable: AveragethicknessBCpixels
 Model: (Intercept), Treatment0control1progesterone, NORMALISEDSLIDENO, 
Treatment0control1progesterone * NORMALISEDSLIDENO
The AR(1) working correlation matrix structure is computed assuming the measurements are equally 
spaced for all subjects.
a.
Estimated Marginal Means: Treatment0control1progesterone* NOR
MALISEDSLIDENO
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Estimates
Treatment0control1proges
terone NORMALISEDSLIDENO Mean Std. Error
.0 1.0
2.0
3.0
4.0
5.0
6.0
7.0
1.0 1.0
2.0
3.0
4.0
5.0
6.0
7.0
60.07650718 4.383263739
43.11638104 3.730768509
32.05467463 3.084917918
24.28038784 2.691763282
27.80060506 2.895738289
32.38464861 3.800737267
38.38837737 4.792423572
51.09394954 2.225512732
36.76008455 2.768839079
26.31099924 1.600848052
21.65108026 1.253842762
20.21749075 1.002441065
20.55869538 1.457280259
27.72464911 2.686536112
Estimates
Treatment0control1proges
terone NORMALISEDSLIDENO
95% Wald Confidence Interval
Lower Upper
.0 1.0
2.0
3.0
4.0
5.0
6.0
7.0
1.0 1.0
2.0
3.0
4.0
5.0
6.0
7.0
52.07147164 69.31217040
36.39063609 51.08518326
26.54436698 38.70885927
19.53844660 30.17318857
22.66690689 34.09700519
25.73002494 40.76037501
30.05628800 49.03025671
46.91302774 55.64747800
31.71483029 42.60794725
23.35325546 29.64334810
19.32793071 24.25346424
18.34519127 22.28087603
17.89200772 23.62283554
22.92894582 33.52339765
GET
  FILE='C:\Users\Public\Documents\PhD\ERG\Results\Z-CEM1376-7\progesterone scotopic ERG data
DATASET NAME DataSet2 WINDOW=FRONT.
* Generalized Estimating Equations.
GENLIN awaveamplitudev BY timepointdays flashintensitymcd Treated1progesterone0vehicle EyeO
  /MODEL timepointdays flashintensitymcd Treated1progesterone0vehicle EyeOD1OS2 timepointday
    Treated1progesterone0vehicle*EyeOD1OS2 timepointdays*flashintensitymcd*Treated1progester
    timepointdays*flashintensitymcd*Treated1progesterone0vehicle*EyeOD1OS2 INTERCEPT=YES
 DISTRIBUTION=GAMMA LINK=LOG
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 /CRITERIA METHOD=FISHER(1) SCALE=MLE MAXITERATIONS=100 MAXSTEPHALVING=5 PCONVERGE=1E-006(A
 /EMMEANS TABLES=timepointdays*flashintensitymcd*Treated1progesterone0vehicle*EyeOD1OS2 SCA
 /REPEATED SUBJECT=animal WITHINSUBJECT=Treated1progesterone0vehicle*EyeOD1OS2*timepointday
 /MISSING CLASSMISSING=EXCLUDE
 /PRINT CPS DESCRIPTIVES MODELINFO FIT SUMMARY WORKINGCORR
 /SAVE RESID PEARSONRESID.
Generalized Linear Models
Notes
Output Created
Comments
Input Data
Active Dataset
Filter
Weight
Split File
N of Rows in Working 
Data File
Missing Value Handling Definition of Missing
Cases Used
Weight Handling
07-JUN-2013 16:17:50
C:
\Users\Public\Documents\PhD\ERG\
Results\Z-CEM1376-7\progesterone
scotopic ERG data.sav
DataSet2
<none>
<none>
<none>
512
User-defined missing values for 
factor, subject and within-subject 
variables are treated as missing.
Statistics are based on cases with 
valid data for all variables in the 
model.
not applicable
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Notes
Syntax GENLIN awaveamplitudev BY 
timepointdays flashintensitymcd 
Treated1progesterone0vehicle
EyeOD1OS2
(ORDER=ASCENDING)
   /MODEL timepointdays 
flashintensitymcd
Treated1progesterone0vehicle
EyeOD1OS2
timepointdays*flashintensitymcd
timepointdays*Treated1progesterone
0vehicle timepointdays*EyeOD1OS2 
flashintensitymcd*Treated1progester
one0vehicle
flashintensitymcd*EyeOD1OS2
Treated1progesterone0vehicle*EyeO
D1OS2
timepointdays*flashintensitymcd*Tre
ated1progesterone0vehicle
timepointdays*flashintensitymcd*Eye
OD1OS2
timepointdays*Treated1progesterone
0vehicle*EyeOD1OS2
flashintensitymcd*Treated1progester
one0vehicle*EyeOD1OS2
timepointdays*flashintensitymcd*Tre
ated1progesterone0vehicle*EyeOD1
OS2 INTERCEPT=YES
  DISTRIBUTION=GAMMA 
LINK=LOG
   /CRITERIA METHOD=FISHER(1) 
SCALE=MLE
MAXITERATIONS=100
MAXSTEPHALVING=5
PCONVERGE=1E-006(ABSOLUTE)
SINGULAR=1E-012
ANALYSISTYPE=3(WALD)
CILEVEL=95 LIKELIHOOD=FULL
   /EMMEANS 
TABLES=timepointdays*flashintensit
ymcd*Treated1progesterone0vehicle
*EyeOD1OS2 SCALE=ORIGINAL
   /REPEATED SUBJECT=animal 
WITHINSUBJECT=Treated1progest
erone0vehicle*EyeOD1OS2*timepoi
ntdays*flashintensitymcd
SORT=YES CORRTYPE=AR(1) 
ADJUSTCORR=YES
COVB=ROBUST
MAXITERATIONS=100
PCONVERGE=1e-006(ABSOLUTE)
UPDATECORR=1
   /MISSING 
CLASSMISSING=EXCLUDE
   /PRINT CPS DESCRIPTIVES 
MODELINFO FIT SUMMARY 
WORKINGCORR...
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Notes
Resources Processor Time
Elapsed Time
Variables Created or 
Modified
Raw Residual
Pearson Residual
00:00:03.81
00:00:03.80
Residual
PearsonResidual
[DataSet2] C:\Users\Public\Documents\PhD\ERG\Results\Z-CEM1376-7\progester
one scotopic ERG data.sav
Model Information
Dependent Variable
Probability Distribution
Link Function
Subject Effect 1
Within-Subject Effect 1
2
3
4
Working Correlation Matrix Structure
awaveamplitudev
Gamma
Log
animal
Treated1progesterone0vehicle
EyeOD1OS2
timepointdays
flashintensitymcd
AR(1)
Case Processing Summary
N Percent
Included
Excluded
Total
496 96.9%
16 3.1%
512 100.0%
Correlated Data Summary
Number of Levels Subject Effect animal
Within-Subject Effect Treated1progesterone0ve
hicle
EyeOD1OS2
timepointdays
flashintensitymcd
Number of Subjects
Number of Measurements 
per Subject
Minimum
Maximum
Correlation Matrix Dimension
16
2
2
2
8
16
16
32
64
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Categorical Variable Information
N Percent
Factor timepointdays 7
14
Total
flashintensitymcd 10
30
100
300
1000
3000
10000
25000
Total
Treated1progesterone0ve
hicle
0
1
Total
EyeOD1OS2 1
2
Total
256 51.6%
240 48.4%
496 100.0%
62 12.5%
62 12.5%
62 12.5%
62 12.5%
62 12.5%
62 12.5%
62 12.5%
62 12.5%
496 100.0%
256 51.6%
240 48.4%
496 100.0%
248 50.0%
248 50.0%
496 100.0%
Continuous Variable Information
N Minimum Maximum Mean
Dependent Variable awaveamplitudev 496 0 382 89.58
Continuous Variable Information
Std. Deviation
Dependent Variable awaveamplitudev 85.630
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Goodness of Fita
Value
Quasi Likelihood under 
Independence Model 
Criterion (QIC)b
Corrected Quasi 
Likelihood under 
Independence Model 
Criterion (QICC)b
275.800
304.230
Dependent Variable: 
awaveamplitudev
 Model: (Intercept), timepointdays, 
flashintensitymcd,
Treated1progesterone0vehicle,
EyeOD1OS2, timepointdays * 
flashintensitymcd, timepointdays * 
Treated1progesterone0vehicle,
timepointdays * EyeOD1OS2, 
flashintensitymcd * 
Treated1progesterone0vehicle,
flashintensitymcd * EyeOD1OS2, 
Treated1progesterone0vehicle * 
EyeOD1OS2, timepointdays * 
flashintensitymcd * 
Treated1progesterone0vehicle,
timepointdays * flashintensitymcd * 
EyeOD1OS2, timepointdays * 
Treated1progesterone0vehicle * 
EyeOD1OS2, flashintensitymcd * 
Treated1progesterone0vehicle * 
EyeOD1OS2, timepointdays * 
flashintensitymcd * 
Treated1progesterone0vehicle * 
EyeOD1OS2
Information criteria are in small-is-better form.a.
Computed using the full log quasi-likelihood function.b.
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Tests of Model Effects
Source
Type III
Wald Chi-
Square df Sig.
(Intercept)
timepointdays
flashintensitymcd
Treated1progesterone0ve
hicle
EyeOD1OS2
timepointdays * 
flashintensitymcd
timepointdays * 
Treated1progesterone0ve
hicle
timepointdays * 
EyeOD1OS2
flashintensitymcd * 
Treated1progesterone0ve
hicle
flashintensitymcd * 
EyeOD1OS2
Treated1progesterone0ve
hicle * EyeOD1OS2
timepointdays * 
flashintensitymcd * 
Treated1progesterone0ve
hicle
timepointdays * 
flashintensitymcd * 
EyeOD1OS2
timepointdays * 
Treated1progesterone0ve
hicle * EyeOD1OS2
flashintensitymcd * 
Treated1progesterone0ve
hicle * EyeOD1OS2
timepointdays * 
flashintensitymcd * 
Treated1progesterone0ve
hicle * EyeOD1OS2
8914.011 1 .000
.517 1 .472
13543.551 7 .000
.000 1 .998
12.032 1 .001
7.459 7 .383
3.006 1 .083
.006 1 .936
29.230 7 .000
25.888 7 .001
.512 1 .474
24.007 7 .001
7.746 7 .356
.000 1 .986
16.844 7 .018
22.618 7 .002
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Dependent Variable: awaveamplitudev
 Model: (Intercept), timepointdays, flashintensitymcd, 
Treated1progesterone0vehicle, EyeOD1OS2, timepointdays * 
flashintensitymcd, timepointdays * Treated1progesterone0vehicle, 
timepointdays * EyeOD1OS2, flashintensitymcd * 
Treated1progesterone0vehicle, flashintensitymcd * EyeOD1OS2, 
Treated1progesterone0vehicle * EyeOD1OS2, timepointdays * 
flashintensitymcd * Treated1progesterone0vehicle, timepointdays * 
flashintensitymcd * EyeOD1OS2, timepointdays * 
Treated1progesterone0vehicle * EyeOD1OS2, flashintensitymcd * 
Treated1progesterone0vehicle * EyeOD1OS2, timepointdays * 
flashintensitymcd * Treated1progesterone0vehicle * EyeOD1OS2
Estimated Marginal Means: timepointdays* flashintensitymcd* Trea
ted1progesterone0vehicle* EyeOD1OS2
Estimates
timepointdays flashintensitymcd
Treated1progesterone0ve
hicle EyeOD1OS2 Mean Std. Error
7 10 0 1
2
1 1
2
30 0 1
2
1 1
2
100 0 1
2
1 1
2
300 0 1
2
1 1
2
1000 0 1
2
1 1
2
3000 0 1
2
1 1
2
10000 0 1
2
1 1
2
1.75 .469
6.14 2.498
4.05 .911
6.36 .879
7.88 .920
12.30 3.065
9.64 2.058
11.90 2.651
18.35 2.856
32.19 7.041
26.34 4.458
34.38 4.929
49.39 5.643
62.88 10.654
63.02 11.042
83.70 11.756
90.46 8.712
106.04 17.682
107.49 17.092
140.71 17.462
115.50 11.202
143.72 23.410
142.30 19.537
181.01 22.087
139.50 12.077
187.24 28.090
168.93 24.919
220.61 23.182
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Estimates
timepointdays flashintensitymcd
Treated1progesterone0ve
hicle EyeOD1OS2
95% Wald ...
Lower
7 10 0 1
2
1 1
2
30 0 1
2
1 1
2
100 0 1
2
1 1
2
300 0 1
2
1 1
2
1000 0 1
2
1 1
2
3000 0 1
2
1 1
2
10000 0 1
2
1 1
2
1.03
2.76
2.61
4.85
6.26
7.55
6.34
7.69
13.53
20.96
18.90
25.95
39.48
45.11
44.71
63.56
74.90
76.47
78.71
110.33
95.51
104.45
108.73
142.51
117.73
139.54
126.51
179.55
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Estimates
timepointdays flashintensitymcd
Treated1progesterone0ve
hicle EyeOD1OS2
95% Wald ...
Upper
7 10 0 1
2
1 1
2
30 0 1
2
1 1
2
100 0 1
2
1 1
2
300 0 1
2
1 1
2
1000 0 1
2
1 1
2
3000 0 1
2
1 1
2
10000 0 1
2
1 1
2
2.96
13.63
6.29
8.34
9.90
20.05
14.65
18.42
24.89
49.42
36.70
45.53
61.79
87.64
88.85
110.22
109.26
147.03
146.79
179.46
139.68
197.78
186.24
229.92
165.30
251.24
225.56
271.07
Page 15
Appendix 19, p16
Estimates
timepointdays flashintensitymcd
Treated1progesterone0ve
hicle EyeOD1OS2 Mean Std. Error
25000 0 1
2
1 1
2
14 10 0 1
2
1 1
2
30 0 1
2
1 1
2
100 0 1
2
1 1
2
300 0 1
2
1 1
2
1000 0 1
2
1 1
2
3000 0 1
2
1 1
2
10000 0 1
2
1 1
2
25000 0 1
2
1 1
2
160.03 11.481
208.15 28.875
189.61 28.086
249.68 27.645
3.26 1.021
5.46 1.226
2.97 .498
6.04 1.450
6.26 1.476
11.85 1.931
7.44 1.154
11.31 3.537
21.19 5.327
36.36 5.351
19.07 3.811
20.52 3.646
56.06 12.832
89.21 10.151
45.09 9.821
58.78 11.084
94.95 21.329
145.16 15.341
78.75 16.822
90.75 17.462
125.23 27.224
180.31 18.020
102.61 20.415
122.42 20.602
151.58 31.987
218.06 22.756
112.48 20.592
156.79 19.998
173.31 33.635
239.18 23.546
135.43 23.851
177.62 21.151
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Estimates
timepointdays flashintensitymcd
Treated1progesterone0ve
hicle EyeOD1OS2
95% Wald ...
Lower
25000 0 1
2
1 1
2
14 10 0 1
2
1 1
2
30 0 1
2
1 1
2
100 0 1
2
1 1
2
300 0 1
2
1 1
2
1000 0 1
2
1 1
2
3000 0 1
2
1 1
2
10000 0 1
2
1 1
2
25000 0 1
2
1 1
2
139.03
158.60
141.84
200.97
1.77
3.52
2.14
3.77
3.95
8.61
5.49
6.13
12.94
27.25
12.89
14.48
35.80
71.38
29.42
40.62
61.14
118.01
51.81
62.24
81.78
148.24
69.47
88.02
100.23
177.73
78.57
122.11
118.48
197.20
95.90
140.65
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Estimates
timepointdays flashintensitymcd
Treated1progesterone0ve
hicle EyeOD1OS2
95% Wald ...
Upper
25000 0 1
2
1 1
2
14 10 0 1
2
1 1
2
30 0 1
2
1 1
2
100 0 1
2
1 1
2
300 0 1
2
1 1
2
1000 0 1
2
1 1
2
3000 0 1
2
1 1
2
10000 0 1
2
1 1
2
25000 0 1
2
1 1
2
184.19
273.19
253.48
310.19
6.03
8.48
4.13
9.67
9.94
16.31
10.08
20.88
34.68
48.52
28.21
29.06
87.80
111.50
69.10
85.06
147.47
178.57
119.70
132.32
191.75
219.33
151.54
170.25
229.22
267.55
161.03
201.32
253.53
290.08
191.26
224.31
EXAMINE VARIABLES=Residual PearsonResidual
  /PLOT BOXPLOT STEMLEAF NPPLOT
  /COMPARE GROUPS
  /STATISTICS DESCRIPTIVES
  /CINTERVAL 95
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  /MISSING LISTWISE
  /NOTOTAL.
Explore
Notes
Output Created
Comments
Input Data
Active Dataset
Filter
Weight
Split File
N of Rows in Working 
Data File
Missing Value Handling Definition of Missing
Cases Used
Syntax
Resources Processor Time
Elapsed Time
07-JUN-2013 16:19:26
C:
\Users\Public\Documents\PhD\ERG\
Results\Z-CEM1376-7\progesterone
scotopic ERG data.sav
DataSet2
<none>
<none>
<none>
512
User-defined missing values for 
dependent variables are treated as 
missing.
Statistics are based on cases with no 
missing values for any dependent 
variable or factor used.
EXAMINE VARIABLES=Residual 
PearsonResidual
   /PLOT BOXPLOT STEMLEAF 
NPPLOT
   /COMPARE GROUPS
   /STATISTICS DESCRIPTIVES
   /CINTERVAL 95
   /MISSING LISTWISE
   /NOTOTAL.
00:00:02.50
00:00:02.24
[DataSet2] C:\Users\Public\Documents\PhD\ERG\Results\Z-CEM1376-7\progester
one scotopic ERG data.sav
Case Processing Summary
Cases
Valid Missing Total
N Percent N Percent N Percent
Raw Residual
Pearson Residual
496 96.9% 16 3.1% 512 100.0%
496 96.9% 16 3.1% 512 100.0%
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Descriptives
Statistic Std. Error
Raw Residual Mean
95% Confidence Interval 
for Mean
Lower Bound
Upper Bound
5% Trimmed Mean
Median
Variance
Std. Deviation
Minimum
Maximum
Range
Interquartile Range
Skewness
Kurtosis
Pearson Residual Mean
95% Confidence Interval 
for Mean
Lower Bound
Upper Bound
5% Trimmed Mean
Median
Variance
Std. Deviation
Minimum
Maximum
Range
Interquartile Range
Skewness
Kurtosis
.17798 2.018593
-3.78809
4.14404
-.22467
-.11241
2021.060
44.956205
-149.350
162.588
311.937
35.302
.114 .110
1.540 .219
.00318 .022900
-.04181
.04817
-.01134
-.01118
.260
.510000
-.981
2.503
3.484
.736
.522 .110
.570 .219
Tests of Normality
Kolmogorov-Smirnova Shapiro-Wilk
Statistic df Sig. Statistic df Sig.
Raw Residual
Pearson Residual
.115 496 .000 .957 496 .000
.069 496 .000 .979 496 .000
Lilliefors Significance Correctiona.
Raw Residual
Raw Residual Stem-and-Leaf Plot
 Frequency    Stem &  Leaf
    30.00 Extremes    (=<-71)
    12.00       -6 .  245&&&
    15.00       -5 .  02479&
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    28.00       -4 .  002333356779&
    18.00       -3 .  012357&
    14.00       -2 .  13458&
    35.00       -1 .  000111255666889&
    98.00       -0 .  0000001111111112222222223333334445555677788899
    96.00        0 .  00000000111111112222233333344445556667788999999
    36.00        1 .  0111224555777889&
    23.00        2 .  00134589&
    14.00        3 .  0257&
    19.00        4 .  167778&&
    16.00        5 .  34567&
     8.00        6 .  26&
    34.00 Extremes    (>=71)
 Stem width:    10.000
 Each leaf:       2 case(s)
 & denotes fractional leaves.
Observed Value
2001000-100-200
Ex
pe
ct
ed
 N
or
m
al
4
2
0
-2
-4
Normal Q-Q Plot of Raw Residual
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Observed Value
2001000-100-200
D
ev
 fr
om
 N
or
m
al
0.6
0.3
0.0
-0.3
-0.6
Detrended Normal Q-Q Plot of Raw Residual
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Raw Residual
200
100
0
-100
-200
191
189
319 240
317
285
124
287
160
126128
367
238 236
272
300 62
224
108
425
416
396
301
281492
255
366
158
368
283
496
Pearson Residual
Pearson Residual Stem-and-Leaf Plot
 Frequency    Stem &  Leaf
    21.00       -0 .  888888888888999999999
    32.00       -0 .  66666666666666667777777777777777
    70.00       -0 .  4444444444444444444444444444444444444444444444455555
555555555555555555
    68.00       -0 .  2222222222222222222222233333333333333333333333333333
3333333333333333
    59.00       -0 .  0000000000000000000000000000000000011111111111111111
1111111
    77.00        0 .  0000000000000000000000000000000000000000000000000001
1111111111111111111111111
    64.00        0 .  2222222222222222222222222222233333333333333333333333
333333333333
    47.00        0 .  44444444444444444444444455555555555555555555555
    22.00        0 .  6666666667777777777777
    23.00        0 .  88888888888888888999999
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     5.00        1 .  00111
     5.00        1 .  22233
     1.00        1 .  4
     2.00 Extremes    (>=1.5)
 Stem width:     1.000
 Each leaf:       1 case(s)
Observed Value
3210-1-2
Ex
pe
ct
ed
 N
or
m
al
6
4
2
0
-2
-4
Normal Q-Q Plot of Pearson Residual
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Observed Value
3210-1
D
ev
 fr
om
 N
or
m
al
2.5
2.0
1.5
1.0
0.5
0.0
-0.5
Detrended Normal Q-Q Plot of Pearson Residual
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Pearson Residual
3
2
1
0
-1
130
305
* Generalized Estimating Equations.
GENLIN awaveamplitudev BY timepointdays flashintensitymcd Treated1progesterone0vehicle EyeO
  /MODEL timepointdays flashintensitymcd Treated1progesterone0vehicle EyeOD1OS2 timepointday
    Treated1progesterone0vehicle*EyeOD1OS2 timepointdays*flashintensitymcd*Treated1progester
    timepointdays*flashintensitymcd*Treated1progesterone0vehicle*EyeOD1OS2 INTERCEPT=YES
 DISTRIBUTION=GAMMA LINK=LOG
  /CRITERIA METHOD=FISHER(1) SCALE=MLE MAXITERATIONS=100 MAXSTEPHALVING=5 PCONVERGE=1E-006(A
  /EMMEANS TABLES=flashintensitymcd*Treated1progesterone0vehicle SCALE=ORIGINAL
  /REPEATED SUBJECT=animal WITHINSUBJECT=Treated1progesterone0vehicle*EyeOD1OS2*timepointday
  /MISSING CLASSMISSING=EXCLUDE
  /PRINT CPS DESCRIPTIVES MODELINFO FIT SUMMARY.
Estimated Marginal Means 1: flashintensitymcd* Treated1progester
one0vehicle
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Estimates
flashintensitymcd
Treated1progesterone0ve
hicle Mean Std. Error
95% Wald Confidence Interval
Lower Upper
10 0
1
30 0
1
100 0
1
300 0
1
1000 0
1
3000 0
1
10000 0
1
25000 0
1
3.72 .476 2.90 4.78
4.64 .351 4.00 5.38
9.21 .763 7.83 10.83
9.91 .757 8.53 11.51
25.97 2.180 22.03 30.62
24.39 1.504 21.62 27.53
62.78 4.542 54.48 72.34
61.15 4.045 53.71 69.61
107.23 7.374 93.71 122.70
101.96 5.599 91.56 113.55
139.14 9.740 121.30 159.60
134.12 7.204 120.72 149.01
171.41 11.560 150.19 195.64
160.11 7.056 146.86 174.56
192.76 11.346 171.76 216.34
183.70 7.737 169.15 199.51
Estimated Marginal Means 2: flashintensitymcd* EyeOD1OS2
Estimates
flashintensitymcd EyeOD1OS2 Mean Std. Error
95% Wald Confidence Interval
Lower Upper
10 1
2
30 1
2
100 1
2
300 1
2
1000 1
2
3000 1
2
10000 1
2
25000 1
2
2.88 .416 2.17 3.82
5.99 .673 4.81 7.47
7.71 .664 6.51 9.13
11.84 1.414 9.36 14.96
21.02 1.575 18.15 24.35
30.14 2.288 25.98 34.98
52.96 3.736 46.12 60.81
72.48 4.987 63.34 82.94
92.34 5.871 81.52 104.59
118.40 7.990 103.74 135.15
120.55 7.506 106.70 136.20
154.80 9.543 137.18 174.68
141.58 8.733 125.45 159.77
193.86 11.019 173.42 216.70
163.36 9.303 146.11 182.65
216.76 10.417 197.28 238.17
Estimated Marginal Means 3: Treated1progesterone0vehicle* EyeO
D1OS2
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Estimates
Treated1progesterone0ve
hicle EyeOD1OS2 Mean Std. Error
95% Wald Confidence Interval
Lower Upper
0 1
2
1 1
2
38.37 4.176 31.00 47.49
59.70 6.920 47.56 74.92
41.39 3.403 35.23 48.63
55.36 3.370 49.14 62.38
Estimated Marginal Means 4: timepointdays* flashintensitymcd* Tre
ated1progesterone0vehicle
Estimates
timepointdays flashintensitymcd
Treated1progesterone0ve
hicle Mean Std. Error
95% Wald ...
Lower
7 10 0
1
30 0
1
100 0
1
300 0
1
1000 0
1
3000 0
1
10000 0
1
25000 0
1
14 10 0
1
30 0
1
100 0
1
300 0
1
1000 0
1
3000 0
1
10000 0
1
3.28 .607 2.28
5.08 .799 3.73
9.84 1.301 7.60
10.71 1.389 8.31
24.30 2.834 19.34
30.09 3.275 24.31
55.72 6.413 44.47
72.63 8.578 57.62
97.94 10.551 79.30
122.98 12.516 100.74
128.84 14.404 103.49
160.49 15.713 132.47
161.62 16.376 132.51
193.05 19.349 158.62
182.51 15.084 155.21
217.58 22.313 177.96
4.22 .819 2.89
4.24 .434 3.47
8.61 .861 7.08
9.17 1.525 6.62
27.76 2.974 22.50
19.78 2.962 14.75
70.72 6.531 59.01
51.48 8.866 36.73
117.40 11.084 97.57
84.54 13.421 61.93
150.27 13.828 125.47
112.08 16.415 84.11
181.80 16.505 152.17
132.80 15.885 105.05
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Estimates
timepointdays flashintensitymcd
Treated1progesterone0ve
hicle
95% Wald ...
Upper
7 10 0
1
30 0
1
100 0
1
300 0
1
1000 0
1
3000 0
1
10000 0
1
25000 0
1
14 10 0
1
30 0
1
100 0
1
300 0
1
1000 0
1
3000 0
1
10000 0
1
4.71
6.91
12.75
13.81
30.54
37.24
69.82
91.55
120.96
150.13
160.40
194.44
197.12
234.95
214.60
266.02
6.18
5.18
10.48
12.71
34.24
26.53
84.75
72.15
141.27
115.39
179.97
149.34
217.21
167.89
Estimates
timepointdays flashintensitymcd
Treated1progesterone0ve
hicle Mean Std. Error
95% Wald ...
Lower
25000 0
1
203.60 17.092 172.71
155.10 18.924 122.11
Estimates
timepointdays flashintensitymcd
Treated1progesterone0ve
hicle
95% Wald ...
Upper
25000 0
1
240.01
197.00
Page 29
Appendix 19, p30
Estimated Marginal Means 5: timepointdays* flashintensitymcd* Ey
eOD1OS2
Estimates
timepointdays flashintensitymcd EyeOD1OS2 Mean Std. Error
95% Wald ...
Lower
7 10 1
2
30 1
2
100 1
2
300 1
2
1000 1
2
3000 1
2
10000 1
2
25000 1
2
14 10 1
2
30 1
2
100 1
2
300 1
2
1000 1
2
3000 1
2
10000 1
2
25000 1
2
2.66 .466 1.89
6.25 1.343 4.10
8.71 1.060 6.86
12.10 2.022 8.72
21.98 2.527 17.55
33.26 4.350 25.74
55.79 5.835 45.45
72.54 7.983 58.47
98.61 9.166 82.19
122.15 12.695 99.64
128.20 10.775 108.73
161.29 16.413 132.13
153.51 13.128 129.82
203.24 18.613 169.85
174.19 14.334 148.25
227.97 20.232 191.57
3.12 .553 2.20
5.74 .944 4.16
6.82 .963 5.18
11.58 2.041 8.20
20.10 3.228 14.67
27.31 3.151 21.79
50.28 7.943 36.89
72.41 7.974 58.36
86.47 13.402 63.82
114.77 12.598 92.56
113.35 16.703 84.92
148.57 14.540 122.64
130.57 18.239 99.30
184.91 15.236 157.33
153.20 20.075 118.50
206.11 15.923 177.15
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Estimates
timepointdays flashintensitymcd EyeOD1OS2
95% Wald ...
Upper
7 10 1
2
30 1
2
100 1
2
300 1
2
1000 1
2
3000 1
2
10000 1
2
25000 1
2
14 10 1
2
30 1
2
100 1
2
300 1
2
1000 1
2
3000 1
2
10000 1
2
25000 1
2
3.75
9.52
11.06
16.79
27.54
42.98
68.48
90.01
118.31
149.75
151.16
196.90
181.52
243.20
204.68
271.28
4.41
7.93
9.00
16.36
27.53
34.24
68.52
89.86
117.17
142.32
151.31
179.99
171.69
217.32
198.06
239.81
Estimated Marginal Means 6: timepointdays* Treated1progesterone
0vehicle* EyeOD1OS2
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Estimates
timepointdays
Treated1progesterone0ve
hicle EyeOD1OS2 Mean Std. Error
95% Wald ...
Lower
7 0 1
2
1 1
2
14 0 1
2
1 1
2
36.14 3.035 30.66
55.56 9.409 39.86
48.72 7.860 35.51
64.66 7.577 51.39
40.73 9.434 25.87
64.15 7.604 50.85
35.17 5.623 25.71
47.40 8.423 33.46
Estimates
timepointdays
Treated1progesterone0ve
hicle EyeOD1OS2
95% Wald ...
Upper
7 0 1
2
1 1
2
14 0 1
2
1 1
2
42.61
77.43
66.84
81.36
64.14
80.92
48.11
67.15
Estimated Marginal Means 7: flashintensitymcd* Treated1progester
one0vehicle* EyeOD1OS2
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Estimates
flashintensitymcd
Treated1progesterone0ve
hicle EyeOD1OS2 Mean Std. Error
95% Wald ...
Lower
10 0 1
2
1 1
2
30 0 1
2
1 1
2
100 0 1
2
1 1
2
300 0 1
2
1 1
2
1000 0 1
2
1 1
2
3000 0 1
2
1 1
2
10000 0 1
2
1 1
2
25000 0 1
2
1 1
2
2.39 .596 1.47
5.79 1.110 3.98
3.47 .504 2.61
6.20 .725 4.93
7.02 .816 5.59
12.07 2.260 8.36
8.47 1.075 6.60
11.60 1.723 8.67
19.72 1.977 16.20
34.21 4.645 26.22
22.41 2.495 18.02
26.56 1.803 23.25
52.62 4.951 43.76
74.89 8.859 59.40
53.31 5.603 43.38
70.14 4.932 61.11
92.68 8.447 77.52
124.07 14.319 98.95
92.00 8.157 77.33
113.00 7.907 98.52
120.26 10.966 100.58
160.98 17.437 130.19
120.84 10.249 102.33
148.86 8.767 132.63
145.41 12.966 122.10
202.06 21.889 163.41
137.84 11.753 116.63
185.99 6.410 173.84
166.54 14.025 141.20
223.12 19.964 187.23
160.25 12.289 137.88
210.59 7.390 196.59
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Estimates
flashintensitymcd
Treated1progesterone0ve
hicle EyeOD1OS2
95% Wald ...
Upper
10 0 1
2
1 1
2
30 0 1
2
1 1
2
100 0 1
2
1 1
2
300 0 1
2
1 1
2
1000 0 1
2
1 1
2
3000 0 1
2
1 1
2
10000 0 1
2
1 1
2
25000 0 1
2
1 1
2
3.90
8.43
4.61
7.80
8.82
17.43
10.86
15.52
24.00
44.64
27.87
30.34
63.27
94.43
65.50
80.51
110.80
155.56
109.46
129.61
143.80
199.06
142.69
167.07
173.18
249.86
162.91
198.98
196.42
265.89
186.24
225.58
Estimated Marginal Means 8: timepointdays* flashintensitymcd* Tre
ated1progesterone0vehicle* EyeOD1OS2
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Estimates
timepointdays flashintensitymcd
Treated1progesterone0ve
hicle EyeOD1OS2 Mean Std. Error
7 10 0 1
2
1 1
2
30 0 1
2
1 1
2
100 0 1
2
1 1
2
300 0 1
2
1 1
2
1000 0 1
2
1 1
2
3000 0 1
2
1 1
2
10000 0 1
2
1 1
2
25000 0 1
2
1 1
2
14 10 0 1
2
1 1
2
30 0 1
2
1 1
2
100 0 1
2
1.75 .469
6.14 2.498
4.05 .911
6.36 .879
7.88 .920
12.30 3.065
9.64 2.058
11.90 2.651
18.35 2.856
32.19 7.041
26.34 4.458
34.38 4.929
49.39 5.643
62.88 10.654
63.02 11.042
83.70 11.756
90.46 8.712
106.04 17.682
107.49 17.092
140.71 17.462
115.50 11.202
143.72 23.410
142.30 19.537
181.01 22.087
139.50 12.077
187.24 28.090
168.93 24.919
220.61 23.182
160.03 11.481
208.15 28.875
189.61 28.086
249.68 27.645
3.26 1.021
5.46 1.226
2.97 .498
6.04 1.450
6.26 1.476
11.85 1.931
7.44 1.154
11.31 3.537
21.19 5.327
36.36 5.351
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Estimates
timepointdays flashintensitymcd
Treated1progesterone0ve
hicle EyeOD1OS2
95% Wald ...
Lower
7 10 0 1
2
1 1
2
30 0 1
2
1 1
2
100 0 1
2
1 1
2
300 0 1
2
1 1
2
1000 0 1
2
1 1
2
3000 0 1
2
1 1
2
10000 0 1
2
1 1
2
25000 0 1
2
1 1
2
14 10 0 1
2
1 1
2
30 0 1
2
1 1
2
100 0 1
2
1.03
2.76
2.61
4.85
6.26
7.55
6.34
7.69
13.53
20.96
18.90
25.95
39.48
45.11
44.71
63.56
74.90
76.47
78.71
110.33
95.51
104.45
108.73
142.51
117.73
139.54
126.51
179.55
139.03
158.60
141.84
200.97
1.77
3.52
2.14
3.77
3.95
8.61
5.49
6.13
12.94
27.25
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Estimates
timepointdays flashintensitymcd
Treated1progesterone0ve
hicle EyeOD1OS2
95% Wald ...
Upper
7 10 0 1
2
1 1
2
30 0 1
2
1 1
2
100 0 1
2
1 1
2
300 0 1
2
1 1
2
1000 0 1
2
1 1
2
3000 0 1
2
1 1
2
10000 0 1
2
1 1
2
25000 0 1
2
1 1
2
14 10 0 1
2
1 1
2
30 0 1
2
1 1
2
100 0 1
2
2.96
13.63
6.29
8.34
9.90
20.05
14.65
18.42
24.89
49.42
36.70
45.53
61.79
87.64
88.85
110.22
109.26
147.03
146.79
179.46
139.68
197.78
186.24
229.92
165.30
251.24
225.56
271.07
184.19
273.19
253.48
310.19
6.03
8.48
4.13
9.67
9.94
16.31
10.08
20.88
34.68
48.52
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Estimates
timepointdays flashintensitymcd
Treated1progesterone0ve
hicle EyeOD1OS2 Mean Std. Error
1 1
2
300 0 1
2
1 1
2
1000 0 1
2
1 1
2
3000 0 1
2
1 1
2
10000 0 1
2
1 1
2
25000 0 1
2
1 1
2
19.07 3.811
20.52 3.646
56.06 12.832
89.21 10.151
45.09 9.821
58.78 11.084
94.95 21.329
145.16 15.341
78.75 16.822
90.75 17.462
125.23 27.224
180.31 18.020
102.61 20.415
122.42 20.602
151.58 31.987
218.06 22.756
112.48 20.592
156.79 19.998
173.31 33.635
239.18 23.546
135.43 23.851
177.62 21.151
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Estimates
timepointdays flashintensitymcd
Treated1progesterone0ve
hicle EyeOD1OS2
95% Wald ...
Lower
1 1
2
300 0 1
2
1 1
2
1000 0 1
2
1 1
2
3000 0 1
2
1 1
2
10000 0 1
2
1 1
2
25000 0 1
2
1 1
2
12.89
14.48
35.80
71.38
29.42
40.62
61.14
118.01
51.81
62.24
81.78
148.24
69.47
88.02
100.23
177.73
78.57
122.11
118.48
197.20
95.90
140.65
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Estimates
timepointdays flashintensitymcd
Treated1progesterone0ve
hicle EyeOD1OS2
95% Wald ...
Upper
1 1
2
300 0 1
2
1 1
2
1000 0 1
2
1 1
2
3000 0 1
2
1 1
2
10000 0 1
2
1 1
2
25000 0 1
2
1 1
2
28.21
29.06
87.80
111.50
69.10
85.06
147.47
178.57
119.70
132.32
191.75
219.33
151.54
170.25
229.22
267.55
161.03
201.32
253.53
290.08
191.26
224.31
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